1549180	142	Satoh MS	Role of poly(ADP-ribose) formation in DNA repair.	Nature	1992	202
8358726	142	Kaufmann SH	Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis.	Cancer research	1993	272
10438458	142	Boulares AH	Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells.	The Journal of biological chemistry	1999	136
10728709	142	Gamet-Payrastre L	Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells.	Cancer research	2000	103
11069113	142	Smith S	Tankyrase promotes telomere elongation in human cells.	Current biology 	2000	95
11350913	142	Sunwoo JB	Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.	Clinical cancer research 	2001	96
12393461	142	Bharti AC	Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis.	Blood	2003	122
12821677	142	Ling YH	Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells.	The Journal of biological chemistry	2003	97
14514658	142	Singh AV	Sulforaphane induces caspase-mediated apoptosis in cultured PC-3 human prostate cancer cells and retards growth of PC-3 xenografts in vivo.	Carcinogenesis	2004	92
15077142	142	Cregan SP	Role of AIF in caspase-dependent and caspase-independent cell death.	Oncogene	2004	112
16728695	142	Catley L	Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.	Blood	2006	87
17016430	142	Chauhan D	A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma.	Oncogene	2007	59
17332279	142	Ratnam K	Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology.	Clinical cancer research 	2007	64
17339367	142	Pledgie-Tracy A	Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines.	Molecular cancer therapeutics	2007	70
17505006	142	Albert JM	Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models.	Clinical cancer research 	2007	77
17609380	142	Bey EA	An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.	Proceedings of the National Academy of Sciences of the United States of America	2007	65
18006697	142	Chauhan D	Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma.	Blood	2008	60
18055453	142	Langelier MF	A third zinc-binding domain of human poly(ADP-ribose) polymerase-1 coordinates DNA-dependent enzyme activation.	The Journal of biological chemistry	2008	51
18264088	142	Edwards SL	Resistance to therapy caused by intragenic deletion in BRCA2.	Nature	2008	209
18794155	142	Stan SD	Withaferin A causes FOXO3a- and Bim-dependent apoptosis and inhibits growth of human breast cancer cells in vivo.	Cancer research	2008	63
18795165	142	Pacurari M	Raw single-wall carbon nanotubes induce oxidative stress and activate MAPKs, AP-1, NF-kappaB, and Akt in normal and malignant human mesothelial cells.	Environmental health perspectives	2008	52
18980022	142	Anders C	Understanding and treating triple-negative breast cancer.	Oncology	2008	54
19047122	142	Plummer R	Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.	Clinical cancer research 	2008	96
19364967	142	Kummar S	Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.	Journal of clinical oncology 	2009	94
19509164	142	Ikeda H	The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo.	Clinical cancer research 	2009	48
19648052	142	Broxterman HJ	Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib.	Drug resistance updates 	2009	55
19762485	142	Kurtova AV	Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance.	Blood	2009	87
19901010	142	Gluz O	Triple-negative breast cancer--current status and future directions.	Annals of oncology 	2009	116
19996272	142	Carboni JM	BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR.	Molecular cancer therapeutics	2009	65
20049735	142	Mendes-Pereira AM	Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.	EMBO molecular medicine	2009	172
20056333	142	Abbotts R	Human AP endonuclease 1 (APE1): from mechanistic insights to druggable target in cancer.	Cancer treatment reviews	2010	56
20072652	142	Lin L	A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells.	Neoplasia	2010	52
20142589	142	Zarghooni M	Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets.	Journal of clinical oncology 	2010	90
20371688	142	Mukhopadhyay A	Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors.	Clinical cancer research 	2010	62
20406929	142	Fong PC	Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.	Journal of clinical oncology 	2010	202
20547991	142	Konstantinopoulos PA	Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.	Journal of clinical oncology 	2010	102
20551068	142	Gottipati P	Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells.	Cancer research	2010	57
20798217	142	Hastak K	Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin.	Cancer research	2010	45
20805366	142	Chauhan D	A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma.	Blood	2010	44
20858840	142	Anders CK	Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer.	Clinical cancer research 	2010	49
20944090	142	Dedes KJ	PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors.	Science translational medicine	2010	57
21205831	142	Yap TA	Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.	CA	2011	51
21208101	142	O'Shaughnessy J	Iniparib plus chemotherapy in metastatic triple-negative breast cancer.	The New England journal of medicine	2011	180
21278435	142	Hudis CA	Triple-negative breast cancer: an unmet medical need.	The oncologist	2011	163
21326243	142	Khan OA	A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours.	British journal of cancer	2011	36
21487248	142	Dedes KJ	Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.	Cell cycle	2011	52
21521830	142	Jelovac D	Recent progress in the diagnosis and treatment of ovarian cancer.	CA	2011	103
21590367	142	Samol J	Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study.	Investigational new drugs	2012	37
21706030	142	Johnson N	Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.	Nature medicine	2011	57
21709188	142	Norquist B	Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.	Journal of clinical oncology 	2011	85
21862407	142	Gelmon KA	Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.	The Lancet. Oncology	2011	225
21871443	142	Kim KY	Salinomycin-induced apoptosis of human prostate cancer cells due to accumulated reactive oxygen species and mitochondrial membrane depolarization.	Biochemical and biophysical research communications	2011	38
21908496	142	Rojo F	Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer.	Annals of oncology 	2012	38
22233320	142	Narwal M	Structural basis of selective inhibition of human tankyrases.	Journal of medicinal chemistry	2012	30
22330607	142	Kim A	Therapeutic strategies in epithelial ovarian cancer.	Journal of experimental and clinical cancer research 	2012	61
22343925	142	Wahlberg E	Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors.	Nature biotechnology	2012	99
22344029	142	Adamson B	A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response.	Nature cell biology	2012	108
22371451	142	Rajan A	A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.	Clinical cancer research 	2012	33
22388737	142	Ray Chaudhuri A	Topoisomerase I poisoning results in PARP-mediated replication fork reversal.	Nature structural and molecular biology	2012	107
22416035	142	Williamson CT	Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53.	EMBO molecular medicine	2012	40
22460902	142	Garnett MJ	Systematic identification of genomic markers of drug sensitivity in cancer cells.	Nature	2012	545
22582261	142	Langelier MF	Structural basis for DNA damage-dependent poly(ADP-ribosyl)ation by human PARP-1.	Science	2012	84
22641215	142	Tobin LA	Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias.	Oncogene	2013	27
22683995	142	Ali AAE	The zinc-finger domains of PARP1 cooperate to recognize DNA strand breaks.	Nature structural and molecular biology	2012	43
22711857	142	Alsop K	BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.	Journal of clinical oncology 	2012	148
22753495	142	Mao Z	Sirtuin 6 (SIRT6) rescues the decline of homologous recombination repair during replicative senescence.	Proceedings of the National Academy of Sciences of the United States of America	2012	38
22912389	142	Wang ZC	Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome.	Clinical cancer research 	2012	37
22961666	142	Byers LA	Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.	Cancer discovery	2012	67
22993403	142	Schiewer MJ	Dual roles of PARP-1 promote cancer growth and progression.	Cancer discovery	2012	62
23307860	142	Banerjee S	New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential.	Clinical cancer research 	2013	58
23319653	142	Robu M	Role of poly(ADP-ribose) polymerase-1 in the removal of UV-induced DNA lesions by nucleotide excision repair.	Proceedings of the National Academy of Sciences of the United States of America	2013	46
23370117	142	Curtin NJ	Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.	Molecular aspects of medicine	2013	64
23423489	142	Plummer R	A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.	Cancer chemotherapy and pharmacology	2013	30
23554447	142	Michels J	Cisplatin resistance associated with PARP hyperactivation.	Cancer research	2013	29
23656790	142	Bisso A	Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer.	Cell cycle	2013	30
23703322	142	Montero J	p53 regulates a non-apoptotic death induced by ROS.	Cell death and differentiation	2013	31
23744078	142	Young LC	Kdm4b histone demethylase is a DNA damage response protein and confers a survival advantage following γ-irradiation.	The Journal of biological chemistry	2013	32
23810467	142	Liu JF	A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.	European journal of cancer	2013	27
23881923	142	Shen Y	BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency.	Clinical cancer research 	2013	54
24037533	142	Michels J	Predictive biomarkers for cancer therapy with PARP inhibitors.	Oncogene	2014	21
24063698	142	Dent RA	Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer.	Breast cancer research 	2013	29
24077350	142	Cardnell RJ	Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer.	Clinical cancer research 	2013	47
24293652	142	Lan L	Novel method for site-specific induction of oxidative DNA damage reveals differences in recruitment of repair proteins to heterochromatin and euchromatin.	Nucleic acids research	2014	22
24435446	142	Fiskus W	Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells.	Molecular cancer therapeutics	2014	39
24607283	142	Liu JF	PARP inhibitors in ovarian cancer: current status and future promise.	Gynecologic oncology	2014	22
24650937	142	Murai J	Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.	The Journal of pharmacology and experimental therapeutics	2014	31
24726141	142	Piao L	The histone methyltransferase SMYD2 methylates PARP1 and promotes poly(ADP-ribosyl)ation activity in cancer cells.	Neoplasia	2014	25
24792170	142	Liu C	A fine-scale dissection of the DNA double-strand break repair machinery and its implications for breast cancer therapy.	Nucleic acids research	2014	22
24832602	142	Park EJ	β-Lapachone induces programmed necrosis through the RIP1-PARP-AIF-dependent pathway in human hepatocellular carcinoma SK-Hep1 cells.	Cell death and disease	2014	24
24912431	142	Cao Y	The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia.	Leukemia	2015	15
25026298	142	Ha K	Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.	Oncotarget	2014	23
25026313	142	Lupo B	Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited.	Biochimica et biophysica acta	2014	22
25286972	142	Sonnenblick A	An update on PARP inhibitors--moving to the adjuvant setting.	Nature reviews. Clinical oncology	2015	58
25341009	142	Lord CJ	Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors.	Annual review of medicine	2015	54
25422887	142	Gong Z	LOC401317, a p53-regulated long non-coding RNA, inhibits cell proliferation and induces apoptosis in the nasopharyngeal carcinoma cell line HNE2.	PloS one	2014	22
25533949	142	Sajish M	A human tRNA synthetase is a potent PARP1-activating effector target for resveratrol.	Nature	2015	22
25589624	142	Kummar S	Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer.	Clinical cancer research 	2015	20
25708226	142	Tangutoori S	PARP inhibitors: A new era of targeted therapy.	Maturitas	2015	26
25733714	142	Zellweger R	Rad51-mediated replication fork reversal is a global response to genotoxic treatments in human cells.	The Journal of cell biology	2015	70
25779564	142	Scott CL	Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.	Journal of clinical oncology 	2015	49
25818403	142	Coleman RL	A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.	Gynecologic oncology	2015	38
25869442	142	Ferguson LR	Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition.	Seminars in cancer biology	2015	22
25878361	142	Downward J	RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?	Clinical cancer research 	2015	21
26004083	142	Severson TM	BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential.	Molecular oncology	2015	18
26091343	142	Bai P	Biology of Poly(ADP-Ribose) Polymerases: The Factotums of Cell Maintenance.	Molecular cell	2015	21
26506418	142	Thorenoor N	Long non-coding RNA ZFAS1 interacts with CDK1 and is involved in p53-dependent cell cycle control and apoptosis in colorectal cancer.	Oncotarget	2016	23
26590714	142	O'Connor MJ	Targeting the DNA Damage Response in Cancer.	Molecular cell	2015	62
26779812	142	Du Y	Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.	Nature medicine	2016	13
27002934	142	Drew Y	Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.	British journal of cancer	2016	15
27376578	142	Adriaens C	p53 induces formation of NEAT1 lncRNA-containing paraspeckles that modulate replication stress response and chemosensitivity.	Nature medicine	2016	20
27406347	142	Rugo HS	Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.	The New England journal of medicine	2016	23
27908594	142	Swisher EM	Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.	The Lancet. Oncology	2017	18
233137	174	Aden DP	Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line.	Nature	1979	202
7544005	174	Thomson JA	Isolation of a primate embryonic stem cell line.	Proceedings of the National Academy of Sciences of the United States of America	1995	140
8594428	174	Mazzaferro V	Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.	The New England journal of medicine	1996	790
9731568	174	-	A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators.	Hepatology	1998	231
11156649	174	Bolondi L	Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis.	Gut	2001	103
11391528	174	Yao FY	Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.	Hepatology	2001	272
11394657	174	Trevisani F	Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status.	Journal of hepatology	2001	104
12029639	174	Hsu YS	Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.	Hepatology	2002	100
12547409	174	Imamura H	Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy.	Journal of hepatology	2003	187
12851874	174	Capurro M	Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma.	Gastroenterology	2003	134
15042359	174	Zhang BH	Randomized controlled trial of screening for hepatocellular carcinoma.	Journal of cancer research and clinical oncology	2004	201
15665226	174	Lencioni R	Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation.	Radiology	2005	112
16137783	174	Marrero JA	GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma.	Journal of hepatology	2005	87
16246200	174	Natsuizaka M	Clinical features of hepatocellular carcinoma with extrahepatic metastases.	Journal of gastroenterology and hepatology	2005	90
16282175	174	Malone FD	First-trimester or second-trimester screening, or both, for Down's syndrome.	The New England journal of medicine	2005	98
16542288	174	Colli A	Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review.	The American journal of gastroenterology	2006	66
16542289	174	Farinati F	Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither?	The American journal of gastroenterology	2006	68
16890600	174	Takayasu K	Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients.	Gastroenterology	2006	133
18069697	174	Forner A	Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.	Hepatology	2008	124
18182659	174	Chan HL	High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma.	Journal of clinical oncology 	2008	58
18350595	174	But DY	Natural history of hepatitis-related hepatocellular carcinoma.	World journal of gastroenterology	2008	66
18479363	174	Song W	Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma.	International journal of clinical practice	2008	53
18580463	174	Zheng SS	Liver transplantation for hepatocellular carcinoma: Hangzhou experiences.	Transplantation	2008	89
19042984	174	Sturgeon CM	National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.	Clinical chemistry	2008	92
19064965	174	Chan SL	New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy.	Journal of clinical oncology 	2009	56
19152426	174	Toso C	Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database.	Hepatology	2009	53
19223512	174	Goldman R	Detection of hepatocellular carcinoma using glycomic analysis.	Clinical cancer research 	2009	48
19302335	174	Nguyen VT	Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden.	Journal of viral hepatitis	2009	67
19362088	174	Marrero JA	Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.	Gastroenterology	2009	97
19392863	174	Singal A	Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis.	Alimentary pharmacology and therapeutics	2009	113
19454616	174	Wang M	Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma.	Cancer epidemiology, biomarkers and prevention 	2009	46
19731239	174	N'Kontchou G	Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis.	Hepatology	2009	55
19747749	174	Wu JC	Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma.	Journal of hepatology	2009	61
19766639	174	Salem R	Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes.	Gastroenterology	2010	158
19801927	174	Cherqui D	Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation.	Annals of surgery	2009	48
19805671	174	Riaz A	Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival.	Journal of clinical oncology 	2009	51
20057319	174	Sun HY	Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (&amp;lt; or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging.	Investigative radiology	2010	41
20066715	174	Carr BI	Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study.	Cancer	2010	44
20209641	174	Pomfret EA	Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States.	Liver transplantation 	2010	54
20339916	174	Malaguarnera G	Serum markers of hepatocellular carcinoma.	Digestive diseases and sciences	2010	49
20351325	174	Glazer ES	Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma.	Journal of clinical oncology 	2010	44
20578139	174	Davila JA	Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States.	Hepatology	2010	78
20683951	174	Asahina Y	Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection.	Hepatology	2010	40
20876776	174	Mao Y	Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma.	Gut	2010	52
21278583	174	Qu KZ	Circulating microRNAs as biomarkers for hepatocellular carcinoma.	Journal of clinical gastroenterology	2011	62
21294289	174	DuBay D	Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion.	Annals of surgery	2011	45
21618574	174	Sangro B	Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.	Hepatology	2011	109
21621346	174	Yoon SM	Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes.	International journal of radiation oncology, biology, physics	2012	60
22374994	174	Singal AG	Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis.	Cancer epidemiology, biomarkers and prevention 	2012	49
22414760	174	Personeni N	Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.	Journal of hepatology	2012	39
22750200	174	Duvoux C	Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria.	Gastroenterology	2012	57
22846859	174	Bertino G	Hepatocellualar carcinoma serum markers.	Seminars in oncology	2012	37
23041304	174	Cescon M	Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate.	Journal of hepatology	2013	26
23337478	174	Singal AG	Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail?	The American journal of gastroenterology	2013	34
23564522	174	Asahina Y	α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C.	Hepatology	2013	35
23874536	174	Zhong JH	Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization.	PloS one	2013	43
24002931	174	Flecken T	Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma.	Hepatology	2014	23
24096763	174	Zhong JH	Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma.	Annals of surgery	2014	69
24123097	174	Wong GL	On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir.	Hepatology	2014	23
24462733	174	El-Serag HB	A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis.	Gastroenterology	2014	23
24797281	174	Hameed B	Alpha-fetoprotein level &amp;gt; 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria.	Liver transplantation 	2014	26
24836552	174	Takeda H	Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan.	Liver international 	2015	17
24912628	174	Memeo R	Laparoscopic vs. open liver resection for hepatocellular carcinoma of cirrhotic liver: a case-control study.	World journal of surgery	2014	26
25271081	174	Hu B	Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma.	Clinical cancer research 	2014	29
25682869	174	Zhu M	Hepatitis B virus X protein induces expression of alpha-fetoprotein and activates PI3K/mTOR signaling pathway in liver cells.	Oncotarget	2015	19
25714016	174	Tang J	Circulation long non-coding RNAs act as biomarkers for predicting tumorigenesis and metastasis in hepatocellular carcinoma.	Oncotarget	2015	27
25804634	174	Xu X	Liver transplantation for hepatocellular carcinoma beyond the Milan criteria.	Gut	2016	17
25845839	174	Wen Y	Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma.	International journal of cancer	2015	20
26628466	174	Wahl DR	Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma.	Journal of clinical oncology 	2016	20
9301337	207	Marte BM	PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond.	Trends in biochemical sciences	1997	113
10200246	207	Cantley LC	New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway.	Proceedings of the National Academy of Sciences of the United States of America	1999	436
10203785	207	Maehama T	PTEN: a tumour suppressor that functions as a phospholipid phosphatase.	Trends in cell biology	1999	123
10576742	207	Zimmermann S	Phosphorylation and regulation of Raf by Akt (protein kinase B).	Science	1999	241
10753955	207	Hsu AL	The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2.	The Journal of biological chemistry	2000	93
10910062	207	Sekulić A	A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells.	Cancer research	2000	166
11357143	207	Blume-Jensen P	Oncogenic kinase signalling.	Nature	2001	728
11358816	207	Brognard J	Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation.	Cancer research	2001	199
11431323	207	Sonoda Y	Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma.	Cancer research	2001	86
11477064	207	Arico S	The tumor suppressor PTEN positively regulates macroautophagy by inhibiting the phosphatidylinositol 3-kinase/protein kinase B pathway.	The Journal of biological chemistry	2001	134
11948129	207	Malik SN	Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer.	Clinical cancer research 	2002	86
12039858	207	Humar R	Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling.	FASEB journal 	2002	84
12048182	207	Moelling K	Regulation of Raf-Akt Cross-talk.	The Journal of biological chemistry	2002	103
12094235	207	Vivanco I	The phosphatidylinositol 3-Kinase AKT pathway in human cancer.	Nature reviews. Cancer	2002	1352
12173037	207	Mitsiades CS	Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.	Oncogene	2002	104
12384559	207	Scotton CJ	Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer.	Cancer research	2002	115
12391322	207	Mitsiades N	Molecular sequelae of proteasome inhibition in human multiple myeloma cells.	Proceedings of the National Academy of Sciences of the United States of America	2002	153
12511591	207	West KA	Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells.	The Journal of clinical investigation	2003	163
12531180	207	West KA	Activation of the PI3K/Akt pathway and chemotherapeutic resistance.	Drug resistance updates 	2002	116
12702506	207	Xu Q	Survival of acute myeloid leukemia cells requires PI3 kinase activation.	Blood	2003	109
12727836	207	Grille SJ	The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines.	Cancer research	2003	152
12761494	207	Arlt A	Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death.	Oncogene	2003	117
12781366	207	Zhao JJ	Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase.	Cancer cell	2003	96
12897778	207	Matsunaga T	Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia.	Nature medicine	2003	133
12938083	207	Eng C	PTEN: one gene, many syndromes.	Human mutation	2003	184
14585353	207	Luo J	Targeting the PI3K-Akt pathway in human cancer: rationale and promise.	Cancer cell	2003	296
14612533	207	Christensen JG	A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.	Cancer research	2003	133
14695208	207	Burtrum D	A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.	Cancer research	2003	101
14737178	207	Steelman LS	JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis.	Leukemia	2004	125
15023346	207	Hanada M	Structure, regulation and function of PKB/AKT--a major therapeutic target.	Biochimica et biophysica acta	2004	157
15023437	207	Fresno Vara JA	PI3K/Akt signalling pathway and cancer.	Cancer treatment reviews	2004	281
15128949	207	Gao Y	Rational design and characterization of a Rac GTPase-specific small molecule inhibitor.	Proceedings of the National Academy of Sciences of the United States of America	2004	366
15143086	207	Chakravarti A	The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas.	Journal of clinical oncology 	2004	88
15156201	207	Majumder PK	mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways.	Nature medicine	2004	274
15208673	207	Altomare DA	AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth.	Oncogene	2004	109
15342917	207	Roux PP	Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.	Proceedings of the National Academy of Sciences of the United States of America	2004	221
15505410	207	Osaki M	PI3K-Akt pathway: its functions and alterations in human cancer.	Apoptosis 	2004	203
15533996	207	Manning BD	Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis.	The Journal of cell biology	2004	170
15585641	207	deGraffenried LA	Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.	Clinical cancer research 	2004	77
15657339	207	Lippman SM	Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT).	Journal of the National Cancer Institute	2005	75
15735123	207	Dai DL	Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases.	Journal of clinical oncology 	2005	74
15800333	207	Lefranc F	Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis.	Journal of clinical oncology 	2005	153
15833867	207	Takeuchi H	Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors.	Cancer research	2005	155
16023083	207	Shishodia S	Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma.	Biochemical pharmacology	2005	78
16096426	207	Morgensztern D	PI3K/Akt/mTOR pathway as a target for cancer therapy.	Anti-cancer drugs	2005	80
16103100	207	Graff JR	The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts.	Cancer research	2005	99
16200194	207	Amaravadi R	The survival kinases Akt and Pim as potential pharmacological targets.	The Journal of clinical investigation	2005	111
16288046	207	Guo F	Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin.	Cancer research	2005	68
16288292	207	Altomare DA	Perturbations of the AKT signaling pathway in human cancer.	Oncogene	2005	312
16299534	207	Arroyo JD	Involvement of PP2A in viral and cellular transformation.	Oncogene	2005	82
16324768	207	Tang JM	Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis.	Lung cancer	2006	84
16341064	207	Hennessy BT	Exploiting the PI3K/AKT pathway for cancer drug discovery.	Nature reviews. Drug discovery	2005	511
16397263	207	Schittenhelm MM	Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.	Cancer research	2006	92
16428510	207	Qian DZ	Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.	Clinical cancer research 	2006	71
16452206	207	O'Reilly KE	mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.	Cancer research	2006	763
16478915	207	Kakinuma T	Chemokines, chemokine receptors, and cancer metastasis.	Journal of leukocyte biology	2006	84
16532036	207	Mochizuki T	Inhibition of NADPH oxidase 4 activates apoptosis via the AKT/apoptosis signal-regulating kinase 1 pathway in pancreatic cancer PANC-1 cells.	Oncogene	2006	73
16537421	207	Wang G	Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor.	Proceedings of the National Academy of Sciences of the United States of America	2006	79
16537497	207	Liu H	Mechanism of Akt1 inhibition of breast cancer cell invasion reveals a protumorigenic role for TSC2.	Proceedings of the National Academy of Sciences of the United States of America	2006	64
16543232	207	Misra UK	Activation and cross-talk between Akt, NF-kappaB, and unfolded protein response signaling in 1-LN prostate cancer cells consequent to ligation of cell surface-associated GRP78.	The Journal of biological chemistry	2006	69
16613876	207	Motoshima H	AMPK and cell proliferation--AMPK as a therapeutic target for atherosclerosis and cancer.	The Journal of physiology	2006	120
16618740	207	Liu ZJ	Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression.	Cancer research	2006	82
16622124	207	Yaguchi S	Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor.	Journal of the National Cancer Institute	2006	66
16636132	207	Khakoo AY	Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma.	The Journal of experimental medicine	2006	181
16642045	207	Martelli AM	Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia.	Leukemia	2006	78
16715125	207	Wang X	Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation.	Oncogene	2006	71
16839745	207	Meng Q	Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway.	Cellular signalling	2006	60
16885382	207	Xu Y	Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins.	Cancer research	2006	97
16892082	207	Robey RB	Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt.	Oncogene	2006	124
17043657	207	Baril P	Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the beta4 integrin and the PI3k pathway.	Oncogene	2007	77
17047067	207	Cao C	Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells.	Cancer research	2006	93
17052453	207	Zhang HH	S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt.	Molecular cell	2006	99
17179228	207	Zeng Z	Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.	Blood	2007	117
17234779	207	Tabe Y	Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells.	Cancer research	2007	56
17234785	207	Opel D	Activation of Akt predicts poor outcome in neuroblastoma.	Cancer research	2007	61
17287275	207	Sadagopan S	Kaposi's sarcoma-associated herpesvirus induces sustained NF-kappaB activation during de novo infection of primary human dermal microvascular endothelial cells that is essential for viral gene expression.	Journal of virology	2007	73
17318262	207	Govindarajan B	Overexpression of Akt converts radial growth melanoma to vertical growth melanoma.	The Journal of clinical investigation	2007	86
17322919	207	Dillon RL	The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer.	Oncogene	2007	84
17353198	207	Ji Z	Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells.	The Journal of biological chemistry	2007	98
17395690	207	Aoki H	Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways.	Molecular pharmacology	2007	128
17404109	207	Puri N	c-Met is a potentially new therapeutic target for treatment of human melanoma.	Clinical cancer research 	2007	61
17452018	207	Dann SG	mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer.	Trends in molecular medicine	2007	161
17483336	207	Ao M	Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium.	Cancer research	2007	77
17551921	207	Shukla S	Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.	International journal of cancer	2007	73
17563753	207	Julien S	Activation of NF-kappaB by Akt upregulates Snail expression and induces epithelium mesenchyme transition.	Oncogene	2007	132
17611497	207	Carpten JD	A transforming mutation in the pleckstrin homology domain of AKT1 in cancer.	Nature	2007	373
17616691	207	Liu LZ	AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway.	Cancer research	2007	63
17627539	207	Vlodavsky I	Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate.	Current pharmaceutical design	2007	83
17646396	207	Lamouille S	Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway.	The Journal of cell biology	2007	159
17647198	207	Chong ZZ	The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury.	Histology and histopathology	2007	79
17786026	207	Shinojima N	Roles of the Akt/mTOR/p70S6K and ERK1/2 signaling pathways in curcumin-induced autophagy.	Autophagy	2007	72
17873377	207	Dreesen O	Signaling pathways in cancer and embryonic stem cells.	Stem cell reviews	2007	84
17878402	207	Tamburini J	Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.	Blood	2008	74
17918180	207	Fraser M	Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.	International journal of cancer	2008	50
17998146	207	Schmitz KJ	Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection.	Journal of hepatology	2008	60
18165616	207	Lefranc F	Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas.	The oncologist	2007	61
18166498	207	LoPiccolo J	Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.	Drug resistance updates 	2008	175
18245495	207	Hwang RF	Cancer-associated stromal fibroblasts promote pancreatic tumor progression.	Cancer research	2008	262
18281460	207	Hambardzumyan D	PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo.	Genes and development	2008	145
18288941	207	Tokunaga E	Deregulation of the Akt pathway in human cancer.	Current cancer drug targets	2008	54
18324353	207	Hatcher H	Curcumin: from ancient medicine to current clinical trials.	Cellular and molecular life sciences 	2008	230
18337767	207	Steelman LS	Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia.	Leukemia	2008	94
18339865	207	Yi T	Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling.	Cancer research	2008	51
18381444	207	Rhodes N	Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity.	Cancer research	2008	82
18414037	207	Palomero T	The role of the PTEN/AKT Pathway in NOTCH1-induced leukemia.	Cell cycle	2008	65
18425114	207	Al-Nedawi K	Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells.	Nature cell biology	2008	350
18473732	207	Carnero A	The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.	Current cancer drug targets	2008	139
18504432	207	Bleeker FE	AKT1(E17K) in human solid tumours.	Oncogene	2008	55
18511810	207	Paugh SW	A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia.	Blood	2008	80
18519641	207	Dan HC	Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK.	Genes and development	2008	141
18519702	207	Park CC	Beta1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts.	Cancer research	2008	65
18566586	207	Facchinetti V	The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C.	The EMBO journal	2008	191
18606717	207	Maira SM	Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.	Molecular cancer therapeutics	2008	363
18649363	207	Li W	Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma.	International journal of cancer	2008	86
18676830	207	Stemke-Hale K	An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.	Cancer research	2008	299
18701483	207	Schnell CR	Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging.	Cancer research	2008	60
18721898	207	Yap TA	Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises.	Current opinion in pharmacology	2008	138
18794129	207	Wang X	Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation.	Cancer research	2008	58
18794885	207	Garcia-Echeverria C	Drug discovery approaches targeting the PI3K/Akt pathway in cancer.	Oncogene	2008	120
18838554	207	Degtyarev M	Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents.	The Journal of cell biology	2008	147
18843284	207	Podar K	Bone marrow microenvironment and the identification of new targets for myeloma therapy.	Leukemia	2009	87
18931688	207	Wang S	The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway.	Oncogene	2008	50
18948577	207	Okawa Y	SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK.	Blood	2009	47
18955974	207	Franke TF	PI3K/Akt: getting it right matters.	Oncogene	2008	185
19010843	207	Hu-Lowe DD	Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.	Clinical cancer research 	2008	109
19033189	207	Wise DR	Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction.	Proceedings of the National Academy of Sciences of the United States of America	2008	504
19047305	207	Wolpin BM	Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer.	Journal of clinical oncology 	2009	76
19056420	207	Cheung YT	Effects of all-trans-retinoic acid on human SH-SY5Y neuroblastoma as in vitro model in neurotoxicity research.	Neurotoxicology	2009	66
19057672	207	Chen JL	The genomic analysis of lactic acidosis and acidosis response in human cancers.	PLoS genetics	2008	60
19066370	207	Lippman SM	Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).	JAMA	2009	470
19088048	207	Solit DB	Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.	Clinical cancer research 	2008	68
19110052	207	Chin YR	Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer.	Cellular signalling	2009	67
19130886	207	Robey RB	Is Akt the "Warburg kinase"?-Akt-energy metabolism interactions and oncogenesis.	Seminars in cancer biology	2009	130
19164214	207	Hildebrandt MA	Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy.	Journal of clinical oncology 	2009	51
19195051	207	Fabregat I	Dysregulation of apoptosis in hepatocellular carcinoma cells.	World journal of gastroenterology	2009	60
19216841	207	Gills JJ	Perifosine: update on a novel Akt inhibitor.	Current oncology reports	2009	62
19244107	207	Guo Z	A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth.	Cancer research	2009	256
19265662	207	Bleau AM	PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells.	Cell stem cell	2009	219
19270694	207	Lin HK	Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB.	Nature cell biology	2009	96
19270695	207	Gao D	Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APCCdh1-mediated Skp2 destruction.	Nature cell biology	2009	96
19275762	207	Morgan TM	Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway.	Current cancer drug targets	2009	73
19278961	207	Ma WW	Novel agents on the horizon for cancer therapy.	CA	2009	80
19298854	207	Sarkar FH	Cellular signaling perturbation by natural products.	Cellular signalling	2009	53
19303758	207	Bozulic L	PIKKing on PKB: regulation of PKB activity by phosphorylation.	Current opinion in cell biology	2009	67
19380449	207	Baselga J	Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.	Journal of clinical oncology 	2009	138
19411071	207	Junttila TT	Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.	Cancer cell	2009	221
19425170	207	Salazar M	Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells.	The Journal of clinical investigation	2009	166
19487299	207	Ricarte-Filho JC	Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.	Cancer research	2009	123
19487573	207	Huse JT	The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo.	Genes and development	2009	172
19491896	207	Shoji K	The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas.	British journal of cancer	2009	51
19556867	207	Di Vizio D	An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease and epithelial Akt activation.	Cell cycle	2009	60
19571822	207	Smalley KS	Understanding melanoma signaling networks as the basis for molecular targeted therapy.	The Journal of investigative dermatology	2010	40
19573808	207	Miao H	EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt.	Cancer cell	2009	110
19584280	207	Yu K	Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.	Cancer research	2009	115
19592505	207	Zong Y	ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells.	Proceedings of the National Academy of Sciences of the United States of America	2009	85
19595306	207	Jiang BH	PI3K/PTEN signaling in angiogenesis and tumorigenesis.	Advances in cancer research	2009	109
19597469	207	Dai J	Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells.	Oncogene	2009	52
19644473	207	Liu P	Targeting the phosphoinositide 3-kinase pathway in cancer.	Nature reviews. Drug discovery	2009	512
19773745	207	Zhong XS	Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication.	Molecular therapy 	2010	99
19808981	207	Golding SE	Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion.	Molecular cancer therapeutics	2009	83
19825827	207	Iliopoulos D	MicroRNAs differentially regulated by Akt isoforms control EMT and stem cell renewal in cancer cells.	Science signaling	2009	87
19917848	207	Missiaglia E	Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway.	Journal of clinical oncology 	2010	84
19920197	207	Fu L	Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy.	Cancer research	2009	49
19935711	207	Treins C	Rictor is a novel target of p70 S6 kinase-1.	Oncogene	2010	54
19996208	207	Davies MA	Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma.	Clinical cancer research 	2009	62
20051626	207	Ginestier C	CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts.	The Journal of clinical investigation	2010	205
20068177	207	Yu K	Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.	Cancer research	2010	56
20101214	207	Gustafson WC	Myc proteins as therapeutic targets.	Oncogene	2010	55
20117946	207	Krycer JR	The Akt-SREBP nexus: cell signaling meets lipid metabolism.	Trends in endocrinology and metabolism	2010	49
20133737	207	Ericson K	Genetic inactivation of AKT1, AKT2, and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation.	Proceedings of the National Academy of Sciences of the United States of America	2010	43
20182580	207	Liao Y	Physiological regulation of Akt activity and stability.	American journal of translational research	2010	96
20214616	207	Carnero A	The PKB/AKT pathway in cancer.	Current pharmaceutical design	2010	71
20299510	207	Bhatt AP	Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas.	Blood	2010	54
20384580	207	Ciuffreda L	The mTOR pathway: a new target in cancer therapy.	Current cancer drug targets	2010	48
20388782	207	Ali S	Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF.	Cancer research	2010	124
20437201	207	Grillari J	miR-17-92 cluster: ups and downs in cancer and aging.	Biogerontology	2010	42
20460539	207	Giovannetti E	MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.	Cancer research	2010	109
20563248	207	Molina JR	Invasive glioblastoma cells acquire stemness and increased Akt activation.	Neoplasia	2010	59
20571069	207	Hirai H	MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.	Molecular cancer therapeutics	2010	271
20622047	207	Zhang S	PI(3)king apart PTEN's role in cancer.	Clinical cancer research 	2010	73
20627085	207	Lipinski MM	A genome-wide siRNA screen reveals multiple mTORC1 independent signaling pathways regulating autophagy under normal nutritional conditions.	Developmental cell	2010	71
20639898	207	Whittaker S	The role of signaling pathways in the development and treatment of hepatocellular carcinoma.	Oncogene	2010	190
20671189	207	Goldstein AS	Identification of a cell of origin for human prostate cancer.	Science	2010	201
20671809	207	Martelli AM	The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.	Oncotarget	2010	67
20683952	207	Wang XQ	Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway.	Hepatology	2010	54
20694012	207	Niemeyer CM	Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia.	Nature genetics	2010	65
20830746	207	Wang N	Berberine induces autophagic cell death and mitochondrial apoptosis in liver cancer cells: the cellular mechanism.	Journal of cellular biochemistry	2010	48
20840586	207	Barash U	Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis.	The FEBS journal	2010	66
20876803	207	Chiarini F	Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia.	Cancer research	2010	52
20886116	207	Wu WI	Crystal structure of human AKT1 with an allosteric inhibitor reveals a new mode of kinase inhibition.	PloS one	2010	51
20940415	207	Pérez-Galán P	Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era.	Blood	2011	80
20972457	207	El Mjiyad N	Sugar-free approaches to cancer cell killing.	Oncogene	2011	54
21062993	207	Fan QW	Akt and autophagy cooperate to promote survival of drug-resistant glioma.	Science signaling	2010	103
21124782	207	Meng J	Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo.	PloS one	2010	51
21159657	207	Sablina AA	Identification of PP2A complexes and pathways involved in cell transformation.	Cancer research	2010	51
21205925	207	Chen KF	Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells.	The Journal of pharmacology and experimental therapeutics	2011	61
21216929	207	Janku F	PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.	Molecular cancer therapeutics	2011	127
21220598	207	Konopleva MY	Leukemia stem cells and microenvironment: biology and therapeutic targeting.	Journal of clinical oncology 	2011	107
21238503	207	Huang H	Regulation of FOXO protein stability via ubiquitination and proteasome degradation.	Biochimica et biophysica acta	2011	55
21278796	207	Garofalo C	Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling.	Oncogene	2011	57
21302297	207	McCubrey JA	Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.	Journal of cellular physiology	2011	52
21317449	207	Markman B	Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs.	Oncotarget	2010	115
21325072	207	Song L	Sphingosine kinase-1 enhances resistance to apoptosis through activation of PI3K/Akt/NF-κB pathway in human non-small cell lung cancer.	Clinical cancer research 	2011	49
21335088	207	Chumsri S	Aromatase, aromatase inhibitors, and breast cancer.	The Journal of steroid biochemistry and molecular biology	2011	44
21339740	207	Kim EK	Selective activation of Akt1 by mammalian target of rapamycin complex 2 regulates cancer cell migration, invasion, and metastasis.	Oncogene	2011	37
21343617	207	Chen CH	ER stress inhibits mTORC2 and Akt signaling through GSK-3β-mediated phosphorylation of rictor.	Science signaling	2011	46
21406469	207	Hernandez-Aya LF	Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer.	The oncologist	2011	37
21422497	207	Steelman LS	Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging.	Aging	2011	139
21464307	207	Xie X	IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct phosphorylation.	Proceedings of the National Academy of Sciences of the United States of America	2011	67
21475304	207	Vara D	Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy.	Cell death and differentiation	2011	45
21494257	207	Steelman LS	Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.	Leukemia	2011	56
21505451	207	Vincent EE	Akt phosphorylation on Thr308 but not on Ser473 correlates with Akt protein kinase activity in human non-small cell lung cancer.	British journal of cancer	2011	39
21538343	207	Zhu AX	Phase 1/2 study of everolimus in advanced hepatocellular carcinoma.	Cancer	2011	54
21568903	207	Raimondi C	Targeting PDK1 in cancer.	Current medicinal chemistry	2011	39
21587219	207	Janku F	Autophagy as a target for anticancer therapy.	Nature reviews. Clinical oncology	2011	171
21618573	207	You H	c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma.	Hepatology	2011	56
21622723	207	Maugeri-Saccà M	Cancer stem cells and chemosensitivity.	Clinical cancer research 	2011	42
21670080	207	Coloff JL	Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition.	Cancer research	2011	48
21752435	207	Behbakht K	Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.	Gynecologic oncology	2011	37
21757645	207	Dey-Guha I	Asymmetric cancer cell division regulated by AKT.	Proceedings of the National Academy of Sciences of the United States of America	2011	40
21788564	207	Oza AM	Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.	Journal of clinical oncology 	2011	55
21793738	207	Lindhurst MJ	A mosaic activating mutation in AKT1 associated with the Proteus syndrome.	The New England journal of medicine	2011	154
21878679	207	Chan JC	AKT promotes rRNA synthesis and cooperates with c-MYC to stimulate ribosome biogenesis in cancer.	Science signaling	2011	40
21884932	207	Sykes SM	AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias.	Cell	2011	76
21903249	207	Cho JA	Exosomes from ovarian cancer cells induce adipose tissue-derived mesenchymal stem cells to acquire the physical and functional characteristics of tumor-supporting myofibroblasts.	Gynecologic oncology	2011	45
21909130	207	Astle MV	AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy.	Oncogene	2012	40
21963805	207	Wang Z	Skp2: a novel potential therapeutic target for prostate cancer.	Biochimica et biophysica acta	2012	37
21974986	207	Otvos L Jr	Design and development of a peptide-based adiponectin receptor agonist for cancer treatment.	BMC biotechnology	2011	36
21975935	207	Yoo YA	Sonic hedgehog pathway promotes metastasis and lymphangiogenesis via activation of Akt, EMT, and MMP-9 pathway in gastric cancer.	Cancer research	2011	80
22025163	207	Yap TA	First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.	Journal of clinical oncology 	2011	160
22057914	207	Cheng Y	MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis.	Molecular cancer therapeutics	2012	38
22067563	207	Wakimoto H	Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells.	Neuro-oncology	2012	59
22116552	207	Rao E	The miRNA-17∼92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation.	Leukemia	2012	45
22156546	207	Venkatesh HS	Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma.	Neuro-oncology	2012	34
22194965	207	Atefi M	Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.	PloS one	2011	63
22200790	207	Hafsi S	Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review).	International journal of oncology	2012	40
22205714	207	Su F	Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.	Cancer research	2012	51
22234835	207	Fang Y	MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma.	Hepatology	2012	88
22239433	207	Bartholomeusz C	Targeting the PI3K signaling pathway in cancer therapy.	Expert opinion on therapeutic targets	2012	48
22248929	207	Garrett JT	Will PI3K pathway inhibitors be effective as single agents in patients with cancer?	Oncotarget	2011	35
22261800	207	Shimizu T	The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.	Clinical cancer research 	2012	110
22261810	207	Donahue TR	Integrative survival-based molecular profiling of human pancreatic cancer.	Clinical cancer research 	2012	37
22292935	207	Shi J	Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer.	BMC cancer	2012	38
22323820	207	Lee C	Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy.	Science translational medicine	2012	102
22328975	207	Hanrahan AJ	Genomic complexity and AKT dependence in serous ovarian cancer.	Cancer discovery	2012	32
22350330	207	Willems L	PI3K and mTOR signaling pathways in cancer: new data on targeted therapies.	Current oncology reports	2012	53
22392765	207	Hou J	Targeting Mnks for cancer therapy.	Oncotarget	2012	36
22402744	207	Weeraratne SD	Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma.	Acta neuropathologica	2012	53
22410781	207	Yu YH	MiR-520h-mediated FOXC2 regulation is critical for inhibition of lung cancer progression by resveratrol.	Oncogene	2013	29
22422409	207	Meric-Bernstam F	PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors.	Clinical cancer research 	2012	61
22471665	207	Sheppard K	Targeting PI3 kinase/AKT/mTOR signaling in cancer.	Critical reviews in oncogenesis	2012	65
22548703	207	Kirouac DC	Creating and analyzing pathway and protein interaction compendia for modelling signal transduction networks.	BMC systems biology	2012	30
22564882	207	Martelli AM	Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.	Oncotarget	2012	49
22579961	207	Bao B	The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness.	Biochimica et biophysica acta	2012	39
22585995	207	Xue G	Akt/PKB-mediated phosphorylation of Twist1 promotes tumor metastasis via mediating cross-talk between PI3K/Akt and TGF-β signaling axes.	Cancer discovery	2012	32
22846840	207	Salvesen HB	Markers for individualised therapy in endometrial carcinoma.	The Lancet. Oncology	2012	50
22875023	207	Ramaswamy B	Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway.	Cancer research	2012	55
22891270	207	Armstrong AJ	Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin.	Journal of clinical oncology 	2012	36
22898879	207	Wu K	Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development.	Hepatology	2012	43
23022474	207	Katoh M	Cancer genetics and genomics of human FOX family genes.	Cancer letters	2013	68
23082003	207	Slomovitz BM	The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.	Clinical cancer research 	2012	55
23112296	207	Wang RC	Akt-mediated regulation of autophagy and tumorigenesis through Beclin 1 phosphorylation.	Science	2012	146
23135998	207	Xu L	MicroRNA-7-regulated TLR9 signaling-enhanced growth and metastatic potential of human lung cancer cells by altering the phosphoinositide-3-kinase, regulatory subunit 3/Akt pathway.	Molecular biology of the cell	2013	26
23185040	207	Cai N	The microRNA-302-367 cluster suppresses the proliferation of cervical carcinoma cells through the novel target AKT1.	RNA	2013	27
23251084	207	Naujokat C	Salinomycin as a drug for targeting human cancer stem cells.	Journal of biomedicine and biotechnology	2012	54
23255107	207	Würth R	Metformin selectively affects human glioblastoma tumor-initiating cell viability: A role for metformin-induced inhibition of Akt.	Cell cycle	2013	52
23272133	207	Sheth S	Resveratrol reduces prostate cancer growth and metastasis by inhibiting the Akt/MicroRNA-21 pathway.	PloS one	2012	49
23287563	207	Lin J	Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models.	Clinical cancer research 	2013	34
23293329	207	Jankovic B	Clinical Review: Hashimoto's thyroiditis and papillary thyroid carcinoma: is there a correlation?	The Journal of clinical endocrinology and metabolism	2013	34
23355761	207	Xue G	PKB/Akt-dependent regulation of cell motility.	Journal of the National Cancer Institute	2013	44
23443307	207	Britten CD	PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types.	Cancer chemotherapy and pharmacology	2013	57
23444215	207	Catalanotti F	Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma.	Clinical cancer research 	2013	36
23456430	207	Bitting RL	Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.	Endocrine-related cancer	2013	56
23470275	207	O' Neill C	PI3-kinase/Akt/mTOR signaling: impaired on/off switches in aging, cognitive decline and Alzheimer's disease.	Experimental gerontology	2013	30
23493574	207	Chen YH	miRNA-93 inhibits GLUT4 and is overexpressed in adipose tissue of polycystic ovary syndrome patients and women with insulin resistance.	Diabetes	2013	31
23515290	207	Vo BT	TGF-β effects on prostate cancer cell migration and invasion are mediated by PGE2 through activation of PI3K/AKT/mTOR pathway.	Endocrinology	2013	34
23579241	207	Azijli K	Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family.	Cell death and differentiation	2013	31
23589885	207	Kucharzewska P	Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development.	Proceedings of the National Academy of Sciences of the United States of America	2013	132
23593475	207	Wu S	Microvesicles derived from human umbilical cord Wharton's jelly mesenchymal stem cells attenuate bladder tumor cell growth in vitro and in vivo.	PloS one	2013	27
23643661	207	Saini KS	Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.	Cancer treatment reviews	2013	62
23658859	207	Martini M	Targeting PI3K in Cancer: Any Good News?	Frontiers in oncology	2013	35
23684942	207	Lei Z	Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil.	Gastroenterology	2013	55
23778311	207	McCubrey JA	Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention.	Leukemia	2014	34
23840064	207	Pfeifer M	PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma.	Proceedings of the National Academy of Sciences of the United States of America	2013	35
23852728	207	Betz C	Feature Article: mTOR complex 2-Akt signaling at mitochondria-associated endoplasmic reticulum membranes (MAM) regulates mitochondrial physiology.	Proceedings of the National Academy of Sciences of the United States of America	2013	63
23897969	207	Iyer G	Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer.	Journal of clinical oncology 	2013	58
23911321	207	Chan CH	Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression.	Cell	2013	85
23958373	207	Akinleye A	Ibrutinib and novel BTK inhibitors in clinical development.	Journal of hematology and oncology	2013	49
24055012	207	Heavey S	Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC.	Cancer treatment reviews	2014	28
24065147	207	Niederst MJ	Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer.	Science signaling	2013	53
24082083	207	Kawamura K	Hippo signaling disruption and Akt stimulation of ovarian follicles for infertility treatment.	Proceedings of the National Academy of Sciences of the United States of America	2013	52
24096870	207	Liu PP	Metabolic regulation of cancer cell side population by glucose through activation of the Akt pathway.	Cell death and differentiation	2014	38
24166903	207	Shapiro GI	Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors.	Clinical cancer research 	2014	36
24194905	207	Chai ZT	MicroRNA-26a inhibits angiogenesis by down-regulating VEGFA through the PIK3C2α/Akt/HIF-1α pathway in hepatocellular carcinoma.	PloS one	2013	26
24242861	207	Rosenberg JE	A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma.	Investigational new drugs	2014	32
24265152	207	Shi H	A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.	Cancer discovery	2014	46
24270740	207	Cheng S	BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity.	Leukemia	2014	37
24280585	207	Li YC	Plumbagin induces apoptotic and autophagic cell death through inhibition of the PI3K/Akt/mTOR pathway in human non-small cell lung cancer cells.	Cancer letters	2014	31
24316259	207	Ho WE	Artemisinins: pharmacological actions beyond anti-malarial.	Pharmacology and therapeutics	2014	44
24333502	207	Polivka J Jr	Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.	Pharmacology and therapeutics	2014	71
24336570	207	Johnson BE	Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.	Science	2014	192
24373826	207	Mancuso C	Ferulic acid: pharmacological and toxicological aspects.	Food and chemical toxicology 	2014	20
24387695	207	Molife LR	Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.	Journal of hematology and oncology	2014	31
24393708	207	Francipane MG	mTOR pathway in colorectal cancer: an update.	Oncotarget	2014	30
24440717	207	Janku F	Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.	Cell reports	2014	50
24469833	207	Mathews Griner LA	High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells.	Proceedings of the National Academy of Sciences of the United States of America	2014	60
24481312	207	Fruman DA	PI3K and cancer: lessons, challenges and opportunities.	Nature reviews. Drug discovery	2014	254
24556063	207	Husseinzadeh N	mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: a critical review.	Gynecologic oncology	2014	23
24583800	207	Meyer SC	Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors.	Clinical cancer research 	2014	22
24606897	207	Yue S	Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness.	Cell metabolism	2014	66
24662831	207	Xiao L	Targeting Epstein-Barr virus oncoprotein LMP1-mediated glycolysis sensitizes nasopharyngeal carcinoma to radiation therapy.	Oncogene	2014	21
24705351	207	Zhai B	Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma.	Molecular cancer therapeutics	2014	36
24774538	207	Ciruelos Gil EM	Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.	Cancer treatment reviews	2014	34
24777052	207	Ocana A	Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis.	PloS one	2014	30
24831732	207	Li X	Curcumin modulates miR-19/PTEN/AKT/p53 axis to suppress bisphenol A-induced MCF-7 breast cancer cell proliferation.	Phytotherapy research 	2014	27
24838891	207	Chin YR	PTEN-deficient tumors depend on AKT2 for maintenance and survival.	Cancer discovery	2014	22
24861879	207	Shi Z	MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras.	Neuro-oncology	2014	27
24896186	207	Wang L	Novel somatic and germline mutations in intracranial germ cell tumours.	Nature	2014	26
24929024	207	Houédé N	Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: its potential use in the treatment of bladder cancers.	Pharmacology and therapeutics	2015	15
24946933	207	Zhang C	NOX4 promotes non-small cell lung cancer cell proliferation and metastasis through positive feedback regulation of PI3K/Akt signaling.	Oncotarget	2014	22
24980823	207	Wang L	MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma.	Oncotarget	2014	36
24998913	207	Lee JV	Akt-dependent metabolic reprogramming regulates tumor cell histone acetylation.	Cell metabolism	2014	64
25001183	207	Hu J	microRNA-128 plays a critical role in human non-small cell lung cancer tumourigenesis, angiogenesis and lymphangiogenesis by directly targeting vascular endothelial growth factor-C.	European journal of cancer	2014	23
25071141	207	Sabine VS	Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study.	Journal of clinical oncology 	2014	21
25115638	207	Manfredi GI	PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy.	Endocrine	2015	19
25146530	207	Lim HJ	Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.	Journal of cancer research and clinical oncology	2015	21
25151012	207	Toren P	Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models.	European urology	2015	28
25187230	207	Yu SH	miR-99a suppresses the metastasis of human non-small cell lung cancer cells by targeting AKT1 signaling pathway.	Journal of cellular biochemistry	2015	19
25202833	207	Hsueh AJ	Intraovarian control of early folliculogenesis.	Endocrine reviews	2015	21
25240910	207	Bauer TM	Targeting PI3 kinase in cancer.	Pharmacology and therapeutics	2015	21
25284585	207	Dillon LM	P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer.	Oncogene	2015	17
25370471	207	Sarker D	First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.	Clinical cancer research 	2015	38
25399420	207	Gao Y	The H19/let-7 double-negative feedback loop contributes to glucose metabolism in muscle cells.	Nucleic acids research	2014	34
25500057	207	Bedard PL	A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors.	Clinical cancer research 	2015	39
25503676	207	Wei JX	Vps4A functions as a tumor suppressor by regulating the secretion and uptake of exosomal microRNAs in human hepatoma cells.	Hepatology	2015	19
25541152	207	Musilova K	MicroRNAs in B-cell lymphomas: how a complex biology gets more complex.	Leukemia	2015	32
25556614	207	Cheaib B	The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges.	Chinese journal of cancer	2015	21
25590803	207	Choudhary GS	MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies.	Cell death and disease	2015	49
25600436	207	Frigault MJ	Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells.	Cancer immunology research	2015	25
25623055	207	Shu YJ	SPOCK1 as a potential cancer prognostic marker promotes the proliferation and metastasis of gallbladder cancer cells by activating the PI3K/AKT pathway.	Molecular cancer	2015	22
25654238	207	Zhu J	Associations of PI3KR1 and mTOR polymorphisms with esophageal squamous cell carcinoma risk and gene-environment interactions in Eastern Chinese populations.	Scientific reports	2015	18
25677064	207	Mabuchi S	The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.	Gynecologic oncology	2015	30
25689954	207	Courtnay R	Cancer metabolism and the Warburg effect: the role of HIF-1 and PI3K.	Molecular biology reports	2015	27
25704303	207	Zhang J	PI3K/Akt signaling in osteosarcoma.	Clinica chimica acta; international journal of clinical chemistry	2015	22
25749412	207	Warfel NA	PIM kinase (and Akt) biology and signaling in tumors.	Pharmacology and therapeutics	2015	22
25796440	207	Paw I	Mechanisms regulating glioma invasion.	Cancer letters	2015	31
25909227	207	Go H	MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.	Oncotarget	2015	16
25918701	207	Davis WJ	Nuclear PI3K signaling in cell growth and tumorigenesis.	Frontiers in cell and developmental biology	2015	16
25964336	207	Kuppusamy KT	Let-7 family of microRNA is required for maturation and adult-like metabolism in stem cell-derived cardiomyocytes.	Proceedings of the National Academy of Sciences of the United States of America	2015	28
26014291	207	Meric-Bernstam F	Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials.	Journal of clinical oncology 	2015	51
26124089	207	Caino MC	PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion.	Proceedings of the National Academy of Sciences of the United States of America	2015	28
26193287	207	Chen MC	Low Molecular Weight Fucoidan Inhibits Tumor Angiogenesis through Downregulation of HIF-1/VEGF Signaling under Hypoxia.	Marine drugs	2015	21
26299803	207	Cheng Z	A long noncoding RNA AB073614 promotes tumorigenesis and predicts poor prognosis in ovarian cancer.	Oncotarget	2015	26
26342236	207	Le Tourneau C	Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.	The Lancet. Oncology	2015	66
26364608	207	Coarfa C	Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer.	Oncogene	2016	16
26451606	207	Sharma N	PI3K/AKT/mTOR and sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth.	Oncotarget	2015	33
26473415	207	Mayer IA	The PI3K/AKT Pathway as a Target for Cancer Treatment.	Annual review of medicine	2016	38
26804739	207	Subramani R	Nimbolide inhibits pancreatic cancer growth and metastasis through ROS-mediated apoptosis and inhibition of epithelial-to-mesenchymal transition.	Scientific reports	2016	12
26826201	207	Abedalthagafi M	Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.	Neuro-oncology	2016	16
26832662	207	Lechman ER	miR-126 Regulates Distinct Self-Renewal Outcomes in Normal and Malignant Hematopoietic Stem Cells.	Cancer cell	2016	18
26947078	207	Chen F	Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma.	Cell reports	2016	24
27014910	207	Chen QY	miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.	Oncotarget	2016	14
27050099	207	Lee JK	N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells.	Cancer cell	2016	18
27061150	207	Kim H	Mango polyphenolics reduce inflammation in intestinal colitis-involvement of the miR-126/PI3K/AKT/mTOR axis in vitro and in vivo.	Molecular carcinogenesis	2017	5
27642729	207	Kaneda MM	PI3Kγ is a molecular switch that controls immune suppression.	Nature	2016	18
17920722	216	Patel M	ALDH1A1 and ALDH3A1 expression in lung cancers: correlation with histologic type and potential precursors.	Lung cancer	2008	55
18371393	216	Ginestier C	ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome.	Cell stem cell	2007	1089
18560594	216	Dylla SJ	Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy.	PloS one	2008	165
19276181	216	Jiang F	Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer.	Molecular cancer research 	2009	215
19329942	216	Chang B	ALDH1 expression correlates with favorable prognosis in ovarian cancers.	Modern pathology 	2009	46
19336570	216	Huang EH	Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis.	Cancer research	2009	319
19385968	216	Morimoto K	Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression.	Cancer science	2009	56
19450560	216	Chen YC	Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer.	Biochemical and biophysical research communications	2009	114
19509181	216	Tanei T	Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.	Clinical cancer research 	2009	135
19911270	216	Resetkova E	Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment.	Breast cancer research and treatment	2010	57
20010854	216	Li T	ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome.	Laboratory investigation; a journal of technical methods and pathology	2010	103
20028757	216	Charafe-Jauffret E	Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer.	Clinical cancer research 	2010	213
20142235	216	Su Y	Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer.	Cancer epidemiology, biomarkers and prevention 	2010	65
20228222	216	Neumeister V	In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis.	The American journal of pathology	2010	45
20422001	216	Deng S	Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers.	PloS one	2010	141
20889728	216	Landen CN Jr	Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer.	Molecular cancer therapeutics	2010	101
21103958	216	Ma I	The role of human aldehyde dehydrogenase in normal and cancer stem cells.	Stem cell reviews	2011	111
21118965	216	Sullivan JP	Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling.	Cancer research	2010	107
21552008	216	Marcato P	Aldehyde dehydrogenase: its role as a cancer stem cell marker comes down to the specific isoform.	Cell cycle	2011	123
22079344	216	Moreb JS	The enzymatic activity of human aldehyde dehydrogenases 1A2 and 2 (ALDH1A2 and ALDH2) is detected by Aldefluor, inhibited by diethylaminobenzaldehyde and has significant effects on cell proliferation and drug resistance.	Chemico-biological interactions	2012	45
22544865	216	Koppaka V	Aldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application.	Pharmacological reviews	2012	67
22887839	216	Luo Y	ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets.	Stem cells	2012	67
23467088	216	Flesken-Nikitin A	Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche.	Nature	2013	84
23548270	216	Yu CC	miR145 targets the SOX9/ADAM17 axis to inhibit tumor-initiating cells and IL-6-mediated paracrine effects in head and neck cancer.	Cancer research	2013	35
24142344	216	Charafe-Jauffret E	ALDH1-positive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program.	Cancer research	2013	30
24201124	216	Yang L	ALDH1A1 defines invasive cancer stem-like cells and predicts poor prognosis in patients with esophageal squamous cell carcinoma.	Modern pathology 	2014	23
24615157	216	Liu L	Triptolide reverses hypoxia-induced epithelial-mesenchymal transition and stem-like features in pancreatic cancer by NF-κB downregulation.	International journal of cancer	2014	22
24859412	216	Honjo S	Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer.	International journal of oncology	2014	21
25384215	216	Zhao D	NOTCH-induced aldehyde dehydrogenase 1A1 deacetylation promotes breast cancer stem cells.	The Journal of clinical investigation	2014	23
25670168	216	Cojoc M	Aldehyde Dehydrogenase Is Regulated by β-Catenin/TCF and Promotes Radioresistance in Prostate Cancer Progenitor Cells.	Cancer research	2015	25
26020648	216	Grosse-Wilde A	Stemness of the hybrid Epithelial/Mesenchymal State in Breast Cancer and Its Association with Poor Survival.	PloS one	2015	28
26783961	216	Tomita H	Aldehyde dehydrogenase 1A1 in stem cells and cancer.	Oncotarget	2016	32
17414097	238	Coffin CM	Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases.	The American journal of surgical pathology	2007	113
17519389	238	Amin HM	Pathobiology of ALK+ anaplastic large-cell lymphoma.	Blood	2007	60
18089725	238	Christensen JG	Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.	Molecular cancer therapeutics	2007	157
18385450	238	Savage KJ	ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project.	Blood	2008	118
18451166	238	McDermott U	Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.	Cancer research	2008	119
18594010	238	Koivunen JP	EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.	Clinical cancer research 	2008	213
18990089	238	Carén H	High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours.	The Biochemical journal	2008	61
19147828	238	Martelli MP	EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues.	The American journal of pathology	2009	78
19671850	238	Rodig SJ	Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.	Clinical cancer research 	2009	141
19737969	238	Lin E	Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers.	Molecular cancer research 	2009	79
20009909	238	Solomon B	ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer.	Journal of thoracic oncology 	2009	62
20418096	238	Sasaki T	The biology and treatment of EML4-ALK non-small cell lung cancer.	European journal of cancer	2010	101
20660290	238	Schmitz N	Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.	Blood	2010	47
20979469	238	Kwak EL	Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.	The New England journal of medicine	2010	1033
20979472	238	Butrynski JE	Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.	The New England journal of medicine	2010	140
20979473	238	Choi YL	EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.	The New England journal of medicine	2010	271
21030459	238	Sasaki T	The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.	Cancer research	2010	98
21156280	238	Gerber DE	ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time.	Cancer cell	2010	65
21258247	238	Paik JH	Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization.	Journal of thoracic oncology 	2011	68
21278610	238	Yi ES	Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH.	Journal of thoracic oncology 	2011	58
21288922	238	Shaw AT	Targeting anaplastic lymphoma kinase in lung cancer.	Clinical cancer research 	2011	48
21336183	238	Camidge DR	Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.	Journal of thoracic oncology 	2011	61
21502504	238	Katayama R	Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.	Proceedings of the National Academy of Sciences of the United States of America	2011	147
21575866	238	Sakamoto H	CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.	Cancer cell	2011	114
21596819	238	Murugan AK	Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene.	Cancer research	2011	42
21623265	238	Ou SH	Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.	Journal of thoracic oncology 	2011	96
21642865	238	Lee JO	Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer.	Journal of thoracic oncology 	2011	38
21933749	238	Shaw AT	Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.	The Lancet. Oncology	2011	199
22034911	238	Zhang S	Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen.	Chemical biology and drug design	2011	41
22071784	238	McLeer-Florin A	Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study.	Journal of thoracic oncology 	2012	40
22129856	238	Paik JH	Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma.	Lung cancer	2012	34
22473102	238	Camidge DR	Treating ALK-positive lung cancer--early successes and future challenges.	Nature reviews. Clinical oncology	2012	51
22585002	238	Carpenter EL	Targeting ALK in neuroblastoma--preclinical and clinical advancements.	Nature reviews. Clinical oncology	2012	35
22589483	238	Matthay KK	Promising therapeutic targets in neuroblastoma.	Clinical cancer research 	2012	41
22735679	238	Ilie M	ALK-gene rearrangement: a comparative analysis on circulating tumour cells and tumour tissue from patients with lung adenocarcinoma.	Annals of oncology 	2012	37
22851556	238	d'Amore F	Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.	Journal of clinical oncology 	2012	43
22954507	238	Camidge DR	Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.	The Lancet. Oncology	2012	250
23255319	238	Park JR	Children's Oncology Group's 2013 blueprint for research: neuroblastoma.	Pediatric blood and cancer	2013	44
23344087	238	Kim S	Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.	Journal of thoracic oncology 	2013	38
23401436	238	Shaw AT	ALK in lung cancer: past, present, and future.	Journal of clinical oncology 	2013	77
23533265	238	Sang J	Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer.	Cancer discovery	2013	69
23598171	238	Mossé YP	Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.	The Lancet. Oncology	2013	100
23639470	238	Seto T	CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.	The Lancet. Oncology	2013	117
23669222	238	Pailler E	Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer.	Journal of clinical oncology 	2013	57
23724913	238	Shaw AT	Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.	The New England journal of medicine	2013	584
23724914	238	Awad MM	Acquired resistance to crizotinib from a mutation in CD74-ROS1.	The New England journal of medicine	2013	53
23742252	238	Marsilje TH	Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials.	Journal of medicinal chemistry	2013	54
23904459	238	Ying J	Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma.	Annals of oncology 	2013	35
24060861	238	Hallberg B	Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology.	Nature reviews. Cancer	2013	82
24478318	238	Ou SH	Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.	Annals of oncology 	2014	35
24491302	238	Gambacorti Passerini C	Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients.	Journal of the National Cancer Institute	2014	34
24629636	238	Pan Y	ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.	Lung cancer	2014	45
24670165	238	Shaw AT	Ceritinib in ALK-rearranged non-small-cell lung cancer.	The New England journal of medicine	2014	252
24675041	238	Friboulet L	The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.	Cancer discovery	2014	128
24736079	238	Ignatius Ou SH	Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.	Journal of thoracic oncology 	2014	33
24789032	238	Lovly CM	Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies.	Clinical cancer research 	2014	24
24819116	238	Johnson TW	Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo4,3-h2,5,11-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations.	Journal of medicinal chemistry	2014	38
24875859	238	Lovly CM	Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions.	Cancer discovery	2014	30
24887559	238	Kodama T	Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance.	Cancer letters	2014	28
24894770	238	Parrilla Castellar ER	ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes.	Blood	2014	25
25153538	238	Gadgeel SM	Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.	The Lancet. Oncology	2014	103
25173427	238	Lovly CM	Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer.	Nature medicine	2014	51
25228534	238	Katayama R	Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.	Clinical cancer research 	2014	45
25264305	238	Shaw AT	Crizotinib in ROS1-rearranged non-small-cell lung cancer.	The New England journal of medicine	2014	165
25322323	238	Awad MM	ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.	Clinical advances in hematology and oncology 	2014	40
25470694	238	Solomon BJ	First-line crizotinib versus chemotherapy in ALK-positive lung cancer.	The New England journal of medicine	2014	306
25500544	238	Yoshihara K	The landscape and therapeutic relevance of cancer-associated transcript fusions.	Oncogene	2015	56
25526238	238	Gainor JF	Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib.	Journal of thoracic oncology 	2015	23
25721120	238	Pekar-Zlotin M	Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer.	The oncologist	2015	20
25724526	238	Gainor JF	Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib.	Clinical cancer research 	2015	25
26544515	238	Nilsson RJ	Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer.	Oncotarget	2016	14
26554404	238	Infarinato NR	The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.	Cancer discovery	2016	14
26598747	238	Ou SH	Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.	Journal of clinical oncology 	2016	61
26698910	238	Shaw AT	Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.	The New England journal of medicine	2016	42
26708155	238	Shaw AT	Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.	The Lancet. Oncology	2016	64
26829319	238	Zheng GX	Haplotyping germline and cancer genomes with high-throughput linked-read sequencing.	Nature biotechnology	2016	34
26916631	238	Marchetti A	ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm.	Journal of thoracic oncology 	2016	13
26973324	238	Kim DW	Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.	The Lancet. Oncology	2016	45
27432917	238	Crinò L	Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.	Journal of clinical oncology 	2016	21
27863201	238	Gadgeel SM	Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.	Journal of clinical oncology 	2016	10
15476283	308	Li L	Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis.	Cancer	2004	74
15940614	308	Huber V	Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape.	Gastroenterology	2005	95
16092118	308	Li L	Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis.	Cancer	2005	96
17431114	308	Liu TJ	Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo.	Molecular cancer therapeutics	2007	59
17909050	308	Phillips PA	Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70.	Cancer research	2007	80
18523067	308	Blankenberg FG	In vivo detection of apoptosis.	Journal of nuclear medicine 	2008	62
19236062	308	AshaRani PV	Cytotoxicity and genotoxicity of silver nanoparticles in human cells.	ACS nano	2009	263
20428844	308	Foldbjerg R	Cytotoxicity and genotoxicity of silver nanoparticles in the human lung cancer cell line, A549.	Archives of toxicology	2011	62
20440562	308	Schutters K	Phosphatidylserine targeting for diagnosis and treatment of human diseases.	Apoptosis 	2010	50
1707140	354	Catalona WJ	Measurement of prostate-specific antigen in serum as a screening test for prostate cancer.	The New England journal of medicine	1991	168
2442609	354	Stamey TA	Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.	The New England journal of medicine	1987	173
7512659	354	Catalona WJ	Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.	The Journal of urology	1994	140
9605647	354	Kattan MW	A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.	Journal of the National Cancer Institute	1998	177
9605898	354	Catalona WJ	Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.	JAMA	1998	117
9749478	354	D'Amico AV	Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.	JAMA	1998	546
10585584	354	Hsing AW	International trends and patterns of prostate cancer incidence and mortality.	International journal of cancer	2000	115
10984506	354	Mueller E	Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer.	Proceedings of the National Academy of Sciences of the United States of America	2000	94
11016644	354	Butler LM	Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.	Cancer research	2000	138
11189683	354	Gohagan JK	The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status.	Controlled clinical trials	2000	108
11189684	354	Prorok PC	Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.	Controlled clinical trials	2000	259
11238701	354	Hoffman RM	Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study.	Journal of the National Cancer Institute	2001	93
11294823	354	Yousef GM	The new human tissue kallikrein gene family: structure, function, and association to disease.	Endocrine reviews	2001	89
11317522	354	Korenchuk S	VCaP, a cell-based model system of human prostate cancer.	In vivo	2001	93
11744442	354	Partin AW	Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium.	Urology	2001	99
11792912	354	Hull GW	Cancer control with radical prostatectomy alone in 1,000 consecutive patients.	The Journal of urology	2002	98
12086878	354	Singh D	Gene expression correlates of clinical prostate cancer behavior.	Cancer cell	2002	388
12438256	354	Tepper CG	Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line.	Cancer research	2002	83
12544300	354	Han M	Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.	The Journal of urology	2003	125
12627518	354	Swan J	Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey.	Cancer	2003	202
12636464	354	Sirovich BE	Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence?	JAMA	2003	86
12699469	354	Duffield-Lillico AJ	Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial.	BJU international	2003	108
12813170	354	Draisma G	Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.	Journal of the National Cancer Institute	2003	161
14581419	354	Hanks GE	Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.	Journal of clinical oncology 	2003	118
14691120	354	Amling CL	Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy.	Journal of clinical oncology 	2004	83
14706503	354	Crawford ED	Epidemiology of prostate cancer.	Urology	2003	89
15020604	354	Small EJ	Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).	Journal of clinical oncology 	2004	109
15067324	354	Glinsky GV	Gene expression profiling predicts clinical outcome of prostate cancer.	The Journal of clinical investigation	2004	136
15126525	354	Wang C	Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.	The Journal of clinical endocrinology and metabolism	2004	79
15163773	354	Thompson IM	Prevalence of prostate cancer among men with a prostate-specific antigen level &amp;lt; or =4.0 ng per milliliter.	The New England journal of medicine	2004	383
15169797	354	Papandreou CN	Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.	Journal of clinical oncology 	2004	103
15169800	354	Cooperberg MR	The changing face of low-risk prostate cancer: trends in clinical presentation and primary management.	Journal of clinical oncology 	2004	103
15247353	354	D'Amico AV	Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.	The New England journal of medicine	2004	113
15310996	354	Roehl KA	Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results.	The Journal of urology	2004	123
15470213	354	Tannock IF	Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.	The New England journal of medicine	2004	945
15470214	354	Petrylak DP	Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.	The New England journal of medicine	2004	667
15867235	354	Gulley JL	Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.	Clinical cancer research 	2005	110
15988529	354	Seligson DB	Global histone modification patterns predict risk of prostate cancer recurrence.	Nature	2005	260
15998892	354	Thompson IM	Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.	JAMA	2005	123
16014598	354	Sharifi N	Androgen deprivation therapy for prostate cancer.	JAMA	2005	192
16046649	354	Freedland SJ	Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.	JAMA	2005	217
16160131	354	Zietman AL	Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.	JAMA	2005	168
16177248	354	Wang X	Autoantibody signatures in prostate cancer.	The New England journal of medicine	2005	150
16192588	354	Stephenson AJ	Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy.	Journal of clinical oncology 	2005	108
16314649	354	Bellizzi KM	Health behaviors of cancer survivors: examining opportunities for cancer control intervention.	Journal of clinical oncology 	2005	148
16622122	354	Thompson IM	Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial.	Journal of the National Cancer Institute	2006	193
16627561	354	Groskopf J	APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer.	Clinical chemistry	2006	76
16705126	354	Stephenson AJ	Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy.	Journal of the National Cancer Institute	2006	93
16798415	354	Roach M 3rd	Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.	International journal of radiation oncology, biology, physics	2006	291
16818701	354	Pantuck AJ	Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer.	Clinical cancer research 	2006	66
16921049	354	Stephenson AJ	Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition.	Journal of clinical oncology 	2006	84
16921050	354	Braga-Basaria M	Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.	Journal of clinical oncology 	2006	96
16921051	354	Hussain M	Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).	Journal of clinical oncology 	2006	70
16952647	354	Zelefsky MJ	Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer.	The Journal of urology	2006	71
17077354	354	Carter HB	Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability.	Journal of the National Cancer Institute	2006	67
17105796	354	Walter LC	PSA screening among elderly men with limited life expectancies.	JAMA	2006	80
17179483	354	Platz EA	Statin drugs and risk of advanced prostate cancer.	Journal of the National Cancer Institute	2006	100
17211863	354	Wright ME	Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality.	Cancer	2007	74
17222629	354	Cookson MS	Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes.	The Journal of urology	2007	101
17382159	354	Marks LS	PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.	Urology	2007	67
17392247	354	Hricak H	Imaging prostate cancer: a multidisciplinary perspective.	Radiology	2007	88
17404365	354	Loblaw DA	Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.	Journal of clinical oncology 	2007	98
17478439	354	Freedland SJ	Obesity and prostate cancer: making sense out of apparently conflicting data.	Epidemiologic reviews	2007	60
17531401	354	Lawton CA	An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions.	International journal of radiation oncology, biology, physics	2007	67
17572194	354	Makarov DV	Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005.	Urology	2007	72
17644125	354	Cooperberg MR	Contemporary trends in low risk prostate cancer: risk assessment and treatment.	The Journal of urology	2007	91
17652279	354	Vickers AJ	The surgical learning curve for prostate cancer control after radical prostatectomy.	Journal of the National Cancer Institute	2007	72
17785564	354	Hessels D	Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer.	Clinical cancer research 	2007	77
17886253	354	Carducci MA	A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.	Cancer	2007	70
17920184	354	Heidenreich A	EAU guidelines on prostate cancer.	European urology	2008	135
17936806	354	Carter HB	Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience.	The Journal of urology	2007	63
18029831	354	Bañez LL	Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer.	JAMA	2007	73
18036719	354	Nickel JC	The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial.	European urology	2008	72
18056182	354	Danila DC	Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer.	Clinical cancer research 	2007	153
18172272	354	Dahut WL	A phase II clinical trial of sorafenib in androgen-independent prostate cancer.	Clinical cancer research 	2008	56
18182665	354	Berthold DR	Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.	Journal of clinical oncology 	2008	184
18199855	354	Zheng SL	Cumulative association of five genetic variants with prostate cancer.	The New England journal of medicine	2008	221
18245462	354	Laxman B	A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer.	Cancer research	2008	103
18252677	354	Wilt TJ	Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.	Annals of internal medicine	2008	124
18295257	354	Deras IL	PCA3: a molecular urine assay for predicting prostate biopsy outcome.	The Journal of urology	2008	68
18306379	354	Dall'Era MA	Active surveillance for early-stage prostate cancer: review of the current literature.	Cancer	2008	59
18309951	354	Scher HI	Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.	Journal of clinical oncology 	2008	394
18354103	354	Sanda MG	Quality of life and satisfaction with outcome among prostate-cancer survivors.	The New England journal of medicine	2008	361
18413638	354	Horwitz EM	Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer.	Journal of clinical oncology 	2008	115
18486743	354	Damber JE	Prostate cancer.	Lancet	2008	106
18611265	354	Vickers AJ	A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden.	BMC medicine	2008	53
18628467	354	Madan RA	Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy.	Clinical cancer research 	2008	50
18648226	354	Biki B	Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis.	Anesthesiology	2008	74
18678846	354	Lin K	Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force.	Annals of internal medicine	2008	53
18755555	354	King CR	Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.	International journal of radiation oncology, biology, physics	2009	57
18785254	354	Nelson JB	Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer.	Cancer	2008	58
18805628	354	van den Bergh RC	Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly.	European urology	2009	50
18824702	354	Tolcher AW	Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.	Journal of clinical oncology 	2008	59
18829513	354	de Bono JS	Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.	Clinical cancer research 	2008	409
18981012	354	Vidal L	A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer.	Clinical cancer research 	2008	74
19035858	354	Klotz L	The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.	BJU international	2008	70
19064985	354	Segal RJ	Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer.	Journal of clinical oncology 	2009	68
19101947	354	Baade PD	International epidemiology of prostate cancer: geographical distribution and secular trends.	Molecular nutrition and food research	2009	87
19213602	354	Scher HI	Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data.	The Lancet. Oncology	2009	138
19216571	354	Mani V	Ultrasensitive immunosensor for cancer biomarker proteins using gold nanoparticle film electrodes and multienzyme-particle amplification.	ACS nano	2009	52
19297565	354	Andriole GL	Mortality results from a randomized prostate-cancer screening trial.	The New England journal of medicine	2009	552
19297566	354	Schröder FH	Screening and prostate-cancer mortality in a randomized European study.	The New England journal of medicine	2009	729
19359544	354	Tran C	Development of a second-generation antiandrogen for treatment of advanced prostate cancer.	Science	2009	438
19409690	354	Tomlins SA	ETS gene fusions in prostate cancer: from discovery to daily clinical practice.	European urology	2009	98
19434657	354	Kader AK	Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients.	The Prostate	2009	45
19509351	354	Cooperberg MR	Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis.	Journal of the National Cancer Institute	2009	57
19548854	354	Madan RA	Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.	Expert opinion on investigational drugs	2009	61
19636023	354	Stephenson AJ	Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era.	Journal of clinical oncology 	2009	79
19720969	354	Welch HG	Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.	Journal of the National Cancer Institute	2009	121
19781717	354	Greene KL	Prostate specific antigen best practice statement: 2009 update.	The Journal of urology	2009	88
19841273	354	Thaxton CS	Nanoparticle-based bio-barcode assay redefines "undetectable" PSA and biochemical recurrence after radical prostatectomy.	Proceedings of the National Academy of Sciences of the United States of America	2009	53
19917860	354	Klotz L	Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer.	Journal of clinical oncology 	2010	192
19920114	354	Yu EY	Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer.	Clinical cancer research 	2009	65
20006859	354	Hambrock T	Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen.	The Journal of urology	2010	56
20006878	354	Epstein JI	An update of the Gleason grading system.	The Journal of urology	2010	91
20047800	354	Arcangeli G	A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer.	International journal of radiation oncology, biology, physics	2010	44
20103546	354	Lawrence MG	Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus.	Endocrine reviews	2010	46
20117878	354	Jentzmik F	Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours.	European urology	2010	44
20159826	354	Zelefsky MJ	Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix.	Journal of clinical oncology 	2010	50
20233430	354	Sboner A	Molecular sampling of prostate cancer: a dilemma for predicting disease progression.	BMC medical genomics	2010	74
20424012	354	Stott SL	Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer.	Science translational medicine	2010	148
20598634	354	Hugosson J	Mortality results from the Göteborg randomised population-based prostate-cancer screening trial.	The Lancet. Oncology	2010	173
20733135	354	Chi KN	Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.	Journal of clinical oncology 	2010	55
20807808	354	Zhu ML	Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer.	Cancer research	2010	79
20843935	354	Vickers AJ	Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.	BMJ	2010	52
20934277	354	Yeoh EE	Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial.	International journal of radiation oncology, biology, physics	2011	42
21044246	354	Nonomura N	Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer.	BJU international	2011	39
21047585	354	Bray F	Prostate cancer incidence and mortality trends in 37 European countries: an overview.	European journal of cancer	2010	53
21115873	354	Cooperberg MR	Outcomes of active surveillance for men with intermediate-risk prostate cancer.	Journal of clinical oncology 	2011	48
21212412	354	Sun D	miR-99 family of MicroRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation.	Cancer research	2011	82
21295399	354	Aly M	Polygenic risk score improves prostate cancer risk prediction: results from the Stockholm-1 cohort study.	European urology	2011	43
21300474	354	King CR	Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer.	International journal of radiation oncology, biology, physics	2012	79
21315502	354	Mottet N	EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.	European urology	2011	103
21353695	354	Fizazi K	Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.	Lancet	2011	288
21419439	354	Catalona WJ	A multicenter study of -2pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range.	The Journal of urology	2011	64
21425143	354	Alicikus ZA	Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer.	Cancer	2011	47
21426475	354	Haffner J	Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection.	BJU international	2011	54
21432867	354	Tai S	PC3 is a cell line characteristic of prostatic small cell carcinoma.	The Prostate	2011	45
21436259	354	Lamont KR	Minireview: Alternative activation pathways for the androgen receptor in prostate cancer.	Molecular endocrinology	2011	48
21537045	354	Hendrickson WK	Vitamin D receptor protein expression in tumor tissue and prostate cancer progression.	Journal of clinical oncology 	2011	37
21612468	354	de Bono JS	Abiraterone and increased survival in metastatic prostate cancer.	The New England journal of medicine	2011	760
21632234	354	Chikkaveeraiah BV	Microfluidic electrochemical immunoarray for ultrasensitive detection of two cancer biomarker proteins in serum.	Biosensors and bioelectronics	2011	35
21647869	354	Cooperberg MR	The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy.	Cancer	2011	49
21679984	354	Ahmed HU	Characterizing clinically significant prostate cancer using template prostate mapping biopsy.	The Journal of urology	2011	36
21693743	354	Kenfield SA	Smoking and prostate cancer survival and recurrence.	JAMA	2011	56
21777360	354	Antonarakis ES	The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up.	BJU international	2012	46
21825257	354	Cooperberg MR	Active surveillance for prostate cancer: progress and promise.	Journal of clinical oncology 	2011	62
21849184	354	Pinto PA	Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging.	The Journal of urology	2011	86
21859898	354	Tolcher AW	A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer.	Annals of oncology 	2012	35
21859988	354	Scher HI	End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice.	Journal of clinical oncology 	2011	41
21931019	354	Pili R	Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.	Journal of clinical oncology 	2011	45
21934053	354	Alemozaffar M	Prediction of erectile function following treatment for prostate cancer.	JAMA	2011	42
21976132	354	Araujo JC	Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study.	Cancer	2012	53
22056152	354	Warde P	Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.	Lancet	2011	82
22093187	354	Smith MR	Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial.	Lancet	2012	149
22099611	354	Armstrong AJ	Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer.	European urology	2012	43
22129890	354	Fizazi K	Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.	European journal of cancer	2012	36
22169079	354	Boorjian SA	A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes.	European urology	2012	31
22170628	354	McBride SM	Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial.	Cancer	2012	54
22228146	354	Andriole GL	Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.	Journal of the National Cancer Institute	2012	201
22239226	354	Grimm P	Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group.	BJU international	2012	43
22325447	354	Hoeks CM	Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers.	European urology	2012	37
22330997	354	Zelefsky MJ	Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer.	International journal of radiation oncology, biology, physics	2012	58
22336380	354	Epstein JI	Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades.	European urology	2012	70
22361632	354	Cuzick J	Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort.	British journal of cancer	2012	62
22417251	354	Schröder FH	Prostate-cancer mortality at 11 years of follow-up.	The New England journal of medicine	2012	252
22454414	354	Kelly WK	Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.	Journal of clinical oncology 	2012	134
22476558	354	Brawley OW	Prostate cancer epidemiology in the United States.	World journal of urology	2012	60
22512844	354	Ahmed HU	Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study.	The Lancet. Oncology	2012	49
22537541	354	Arcangeli S	Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer.	International journal of radiation oncology, biology, physics	2012	34
22561842	354	Van Hemelrijck M	Cohort Profile: the National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0.	International journal of epidemiology	2013	28
22704366	354	Schröder FH	Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC).	European urology	2012	37
22801674	354	Moyer VA	Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.	Annals of internal medicine	2012	396
22802323	354	Basch E	Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion.	Journal of clinical oncology 	2012	32
22808955	354	Wilt TJ	Radical prostatectomy versus observation for localized prostate cancer.	The New England journal of medicine	2012	272
22894553	354	Scher HI	Increased survival with enzalutamide in prostate cancer after chemotherapy.	The New England journal of medicine	2012	621
22894572	354	Heijnsdijk EA	Quality-of-life effects of prostate-specific antigen screening.	The New England journal of medicine	2012	58
22931259	354	Crook JM	Intermittent androgen suppression for rising PSA level after radiotherapy.	The New England journal of medicine	2012	53
22998901	354	Crawford ED	Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases.	The Journal of urology	2012	31
23017866	354	Vargas HA	Magnetic resonance imaging for predicting prostate biopsy findings in patients considered for active surveillance of clinically low risk prostate cancer.	The Journal of urology	2012	35
23063807	354	Kasivisvanathan V	Transperineal magnetic resonance image targeted prostate biopsy versus transperineal template prostate biopsy in the detection of clinically significant prostate cancer.	The Journal of urology	2013	28
23083875	354	Vourganti S	Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies.	The Journal of urology	2012	50
23158413	354	Sonn GA	Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion device.	The Journal of urology	2013	49
23159452	354	Bul M	Active surveillance for low-risk prostate cancer worldwide: the PRIAS study.	European urology	2013	61
23228172	354	Ryan CJ	Abiraterone in metastatic prostate cancer without previous chemotherapy.	The New England journal of medicine	2013	332
23306100	354	Gravis G	Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.	The Lancet. Oncology	2013	39
23375961	354	Lazzeri M	Serum isoform -2proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study.	European urology	2013	35
23381039	354	Gulati R	Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.	Annals of internal medicine	2013	28
23395803	354	Pastuszak AW	Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy.	The Journal of urology	2013	31
23440794	354	Ilic D	Screening for prostate cancer.	The Cochrane database of systematic reviews	2013	70
23486334	354	Evangelista L	Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis.	Clinical nuclear medicine	2013	28
23523537	354	Sonn GA	Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen.	European urology	2014	52
23567643	354	Qaseem A	Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians.	Annals of internal medicine	2013	39
23569308	354	Fizazi K	Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.	Journal of clinical oncology 	2013	41
23582482	354	Schellhammer PF	Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial.	Urology	2013	34
23687298	354	Lin TH	Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.	The Journal of biological chemistry	2013	31
23708103	354	Velonas VM	Current status of biomarkers for prostate cancer.	International journal of molecular sciences	2013	30
23727310	354	Rais-Bahrami S	Utility of multiparametric magnetic resonance imaging suspicion levels for detecting prostate cancer.	The Journal of urology	2013	37
23764502	354	Leymarie N	Interlaboratory study on differential analysis of protein glycosylation by mass spectrometry: the ABRF glycoprotein research multi-institutional study 2012.	Molecular and cellular proteomics 	2013	29
23770138	354	Karnes RJ	Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population.	The Journal of urology	2013	61
23849416	354	Schrader AJ	Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone.	European urology	2014	56
23856038	354	Heidenreich A	Early detection of prostate cancer: European Association of Urology recommendation.	European urology	2013	28
23873756	354	Murphy DR	Electronic health record-based triggers to detect potential delays in cancer diagnosis.	BMJ quality and safety	2014	22
24002508	354	Rathkopf DE	Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.	Journal of clinical oncology 	2013	36
24166498	354	Formosa A	MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells.	Oncogene	2014	63
24177197	354	Dijkstra S	Clinical use of novel urine and blood based prostate cancer biomarkers: a review.	Clinical biochemistry	2014	25
24210085	354	Trump DL	Commentary on "Abiraterone in metastatic prostate cancer without previous chemotherapy." Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators, Genitourinary Medical Oncology Program, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA. N Engl J Med 2013;368(2):138-48 Epub 2012 Dec 10; N Engl J Med 2013;368(6):584.	Urologic oncology	2013	55
24321502	354	Heidenreich A	EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.	European urology	2014	165
24333515	354	Rastinehad AR	Improving detection of clinically significant prostate cancer: magnetic resonance imaging/transrectal ultrasound fusion guided prostate biopsy.	The Journal of urology	2014	31
24382803	354	Badrising S	Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment.	Cancer	2014	25
24439788	354	Loeb S	Overdiagnosis and overtreatment of prostate cancer.	European urology	2014	59
24449231	354	Halabi S	Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.	Journal of clinical oncology 	2014	42
24463248	354	Zu K	Dietary lycopene, angiogenesis, and prostate cancer: a prospective study in the prostate-specific antigen era.	Journal of the National Cancer Institute	2014	26
24478320	354	Sternberg CN	Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial.	Annals of oncology 	2014	28
24484606	354	Bancroft EK	Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.	European urology	2014	26
24518762	354	Thompson JE	Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study.	The Journal of urology	2014	27
24643604	354	Hayes JH	Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence.	JAMA	2014	38
24666839	354	Pokorny MR	Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies.	European urology	2014	56
24714754	354	Lin HM	Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer.	British journal of cancer	2014	28
24727321	354	Beltran H	Aggressive variants of castration-resistant prostate cancer.	Clinical cancer research 	2014	47
24748218	354	Gurel B	Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial.	Cancer epidemiology, biomarkers and prevention 	2014	40
24778277	354	Gulley JL	Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer.	Cancer immunology research	2014	30
24836057	354	Klein EA	A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.	European urology	2014	68
24881730	354	Beer TM	Enzalutamide in metastatic prostate cancer before chemotherapy.	The New England journal of medicine	2014	244
25018038	354	Azad AA	Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.	European urology	2015	21
25023249	354	Lansdorp-Vogelaar I	Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits.	Annals of internal medicine	2014	22
25024180	354	Hieronymus H	Copy number alteration burden predicts prostate cancer relapse.	Proceedings of the National Academy of Sciences of the United States of America	2014	44
25035207	354	Den RB	Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy.	International journal of radiation oncology, biology, physics	2014	32
25085000	354	Idorn M	Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer.	Cancer immunology, immunotherapy 	2014	23
25108889	354	Schröder FH	Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.	Lancet	2014	114
25159890	354	Womble PR	Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer.	European urology	2015	29
25281467	354	Cuzick J	Prevention and early detection of prostate cancer.	The Lancet. Oncology	2014	44
25301760	354	James ND	Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).	European urology	2015	30
25385735	354	Wei JT	Can urinary PCA3 supplement PSA in the early detection of prostate cancer?	Journal of clinical oncology 	2014	36
25454615	354	Parekh DJ	A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer.	European urology	2015	28
25457014	354	Loeb S	Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification.	European urology	2015	18
25463993	354	Loeb S	The prostate health index selectively identifies clinically significant prostate cancer.	The Journal of urology	2015	18
25466945	354	Klein EA	A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.	European urology	2015	28
25484141	354	van Soest RJ	Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.	European urology	2015	17
25505238	354	Heijnsdijk EA	Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.	Journal of the National Cancer Institute	2015	19
25512465	354	Klotz L	Long-term follow-up of a large active surveillance cohort of patients with prostate cancer.	Journal of clinical oncology 	2015	69
25521481	354	Kachakova D	Combinations of serum prostate-specific antigen and plasma expression levels of let-7c, miR-30c, miR-141, and miR-375 as potential better diagnostic biomarkers for prostate cancer.	DNA and cell biology	2015	18
25538172	354	Lorente D	Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use.	Annals of oncology 	2015	26
25568070	354	Schweizer MT	Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study.	Science translational medicine	2015	27
25613154	354	Gratzke C	EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction.	European urology	2015	34
25624429	354	Fizazi K	Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5.	Journal of clinical oncology 	2015	22
25626035	354	Siddiqui MM	Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.	JAMA	2015	86
25656808	354	Fütterer JJ	Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature.	European urology	2015	44
25667284	354	Den RB	Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy.	Journal of clinical oncology 	2015	26
25682340	354	Stattin P	Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.	European urology	2015	19
25691677	354	Mason MD	Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer.	Journal of clinical oncology 	2015	21
25964175	354	Tomlins SA	Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.	European urology	2015	20
26181238	354	Antonarakis ES	Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.	JAMA oncology	2015	59
26188394	354	Onstenk W	Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells.	European urology	2015	27
26244877	354	Sweeney CJ	Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.	The New England journal of medicine	2015	100
26324359	354	Tosoian JJ	Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer.	Journal of clinical oncology 	2015	20
26537258	354	Romanel A	Plasma AR and abiraterone-resistant prostate cancer.	Science translational medicine	2015	37
26575061	354	Jemal A	Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations.	JAMA	2015	30
26719232	354	James ND	Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.	Lancet	2016	60
26790878	354	Saini S	PSA and beyond: alternative prostate cancer biomarkers.	Cellular oncology	2016	10
26811535	354	Penson DF	Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.	Journal of clinical oncology 	2016	15
26992225	354	Koppers-Lalic D	Non‑invasive prostate cancer detection by measuring miRNA variants (isomiRs) in urine extracellular vesicles.	Oncotarget	2016	11
27032035	354	McKiernan J	A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy.	JAMA oncology	2016	16
27262168	354	Scher HI	Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.	JAMA oncology	2016	34
27400947	354	Smith M	Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.	Journal of clinical oncology 	2016	10
28034081	354	Beer TM	Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.	Journal of clinical oncology 	2017	7
2260966	367	Veldscholte J	A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens.	Biochemical and biophysical research communications	1990	150
7795646	367	Visakorpi T	In vivo amplification of the androgen receptor gene and progression of human prostate cancer.	Nature genetics	1995	280
9000575	367	Koivisto P	Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer.	Cancer research	1997	132
10318905	367	Yeh S	From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells.	Proceedings of the National Academy of Sciences of the United States of America	1999	111
10363963	367	Taplin ME	Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.	Cancer research	1999	113
10835690	367	Zhao XY	Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor.	Nature medicine	2000	92
11032808	367	Migliaccio A	Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation.	The EMBO journal	2000	148
11751884	367	Ueda T	Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways.	The Journal of biological chemistry	2002	84
12888829	367	Edwards J	Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer.	British journal of cancer	2003	78
14695335	367	Holzbeierlein J	Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance.	The American journal of pathology	2004	162
15389811	367	Miyamoto H	Androgen deprivation therapy for prostate cancer: current status and future prospects.	The Prostate	2004	77
15808953	367	Sim HG	Changing demography of prostate cancer in Asia.	European journal of cancer	2005	71
15833816	367	Bohl CE	Structural basis for antagonism and resistance of bicalutamide in prostate cancer.	Proceedings of the National Academy of Sciences of the United States of America	2005	70
16000557	367	Titus MA	Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer.	Clinical cancer research 	2005	134
16322242	367	Collins AT	Prospective identification of tumorigenic prostate cancer stem cells.	Cancer research	2005	698
16751763	367	Morfini G	JNK mediates pathogenic effects of polyglutamine-expanded androgen receptor on fast axonal transport.	Nature neuroscience	2006	76
17045208	367	Guo Z	Regulation of androgen receptor activity by tyrosine phosphorylation.	Cancer cell	2006	142
17409422	367	Miki J	Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens.	Cancer research	2007	101
17510410	367	Gu G	Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo.	Cancer research	2007	105
17699749	367	Bolton EC	Cell- and gene-specific regulation of primary target genes by the androgen receptor.	Genes and development	2007	129
18319300	367	Cutress ML	Structural basis for the nuclear import of the human androgen receptor.	Journal of cell science	2008	53
18539965	367	Maitland NJ	Prostate cancer stem cells: a new target for therapy.	Journal of clinical oncology 	2008	80
18593950	367	Dehm SM	Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance.	Cancer research	2008	248
18676866	367	Locke JA	Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.	Cancer research	2008	215
18838208	367	Morgentaler A	Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth.	European urology	2009	59
18997859	367	Jia L	Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity.	PloS one	2008	68
19074586	367	Vandenberg LN	Bisphenol-A and the great divide: a review of controversies in the field of endocrine disruption.	Endocrine reviews	2009	211
19111796	367	Yuan X	Mechanisms mediating androgen receptor reactivation after castration.	Urologic oncology	2009	82
19118031	367	Snoek R	In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors.	Clinical cancer research 	2009	52
19198621	367	Harris WP	Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion.	Nature clinical practice. Urology	2009	127
19276271	367	Leversha MA	Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer.	Clinical cancer research 	2009	60
19289629	367	Mendiratta P	Genomic strategy for targeting therapy in castration-resistant prostate cancer.	Journal of clinical oncology 	2009	46
19366804	367	Steinkamp MP	Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy.	Cancer research	2009	60
19668381	367	Lin B	Integrated expression profiling and ChIP-seq analyses of the growth inhibition response program of the androgen receptor.	PloS one	2009	46
20127405	367	Castellano I	Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers.	Breast cancer research and treatment	2010	44
20398925	367	Scher HI	Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.	Lancet	2010	268
20440270	367	Niu Y	Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails.	Oncogene	2010	45
20570726	367	Tonelli F	FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells.	Cellular signalling	2010	58
20644256	367	Sun S	Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.	The Journal of clinical investigation	2010	231
20731602	367	Dodson S	Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies.	Annual review of medicine	2011	47
20823238	367	Watson PA	Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.	Proceedings of the National Academy of Sciences of the United States of America	2010	204
20844012	367	Shen MM	Molecular genetics of prostate cancer: new prospects for old challenges.	Genes and development	2010	243
20859283	367	Seruga B	Drug resistance in metastatic castration-resistant prostate cancer.	Nature reviews. Clinical oncology	2011	61
21099110	367	Sharma A	The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression.	The Journal of clinical investigation	2010	103
21135112	367	Cai H	Invasive prostate carcinoma driven by c-Src and androgen receptor synergy.	Cancer research	2011	43
21177307	367	Siddiqui IA	Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer.	FASEB journal 	2011	39
21248069	367	Li Y	Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression.	Cancer research	2011	72
21264529	367	He J	Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray.	Medical oncology	2012	37
21303972	367	Mohler JL	Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer.	Cancer research	2011	42
21310761	367	Park S	Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers.	Annals of oncology 	2011	38
21325075	367	Hu R	Androgen receptor expression and breast cancer survival in postmenopausal women.	Clinical cancer research 	2011	77
21446008	367	Hu R	A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities.	The Prostate	2011	76
21552212	367	Collins LC	Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study.	Modern pathology 	2011	39
21552559	367	Hörnberg E	Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival.	PloS one	2011	122
21633166	367	Lehmann BD	Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.	The Journal of clinical investigation	2011	769
21680543	367	Massard C	Targeting continued androgen receptor signaling in prostate cancer.	Clinical cancer research 	2011	40
21799031	367	Darshan MS	Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer.	Cancer research	2011	109
21820033	367	Gioeli D	Post-translational modification of the androgen receptor.	Molecular and cellular endocrinology	2012	41
21837479	367	Loibl S	Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy.	Breast cancer research and treatment	2011	36
21859989	367	Ryan CJ	Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically.	Journal of clinical oncology 	2011	75
22064655	367	Huang WC	Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells.	Molecular cancer research 	2012	46
22083957	367	Tan PY	Integration of regulatory networks by NKX3-1 promotes androgen-dependent prostate cancer survival.	Molecular and cellular biology	2012	50
22108827	367	Sun Y	Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy.	Cancer research	2012	86
22114732	367	Zhang X	Androgen receptor variants occur frequently in castration resistant prostate cancer metastases.	PloS one	2011	95
22128178	367	Nadiminty N	MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells.	The Journal of biological chemistry	2012	59
22131877	367	Lonigro RJ	Detection of somatic copy number alterations in cancer using targeted exome capture sequencing.	Neoplasia	2011	42
22184395	367	Efstathiou E	Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone.	Journal of clinical oncology 	2012	59
22266222	367	Clegg NJ	ARN-509: a novel antiandrogen for prostate cancer treatment.	Cancer research	2012	95
22266865	367	Li Y	AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression.	Oncogene	2012	67
22334387	367	Gottlieb B	The androgen receptor gene mutations database: 2012 update.	Human mutation	2012	64
22355276	367	Yamashita S	ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors.	Neoplasia	2012	38
22831834	367	Lee SO	New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells.	Journal of molecular cell biology	2013	31
23069658	367	Shi XB	Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells.	Oncogene	2013	47
23093251	367	Miyamoto DT	Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer.	Cancer discovery	2012	72
23117885	367	Li Y	Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.	Cancer research	2013	172
23157556	367	Matsumoto T	The androgen receptor in health and disease.	Annual review of physiology	2013	39
23260764	367	Sharma NL	The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man.	Cancer cell	2013	108
23518348	367	Qi J	The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity.	Cancer cell	2013	44
23576708	367	Loriot Y	Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).	Annals of oncology 	2013	62
23580326	367	Balbas MD	Overcoming mutation-based resistance to antiandrogens with rational drug design.	eLife	2013	81
23589550	367	Roychowdhury S	Advancing precision medicine for prostate cancer through genomics.	Journal of clinical oncology 	2013	27
23704919	367	Gao L	Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation.	PloS one	2013	31
23752182	367	Karantanos T	Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches.	Oncogene	2013	117
23779130	367	Joseph JD	A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.	Cancer discovery	2013	104
23811619	367	Logothetis CJ	Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer.	Cancer discovery	2013	26
23842682	367	Korpal M	An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).	Cancer discovery	2013	103
23859952	367	Shafi AA	Androgen receptors in hormone-dependent and castration-resistant prostate cancer.	Pharmacology and therapeutics	2013	42
23982944	367	Izumi K	Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation.	EMBO molecular medicine	2013	35
24037531	367	Mishra S	Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor II (TGFBR2) expression in prostate cancer.	Oncogene	2014	26
24046116	367	McGhan LJ	Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype.	Annals of surgical oncology	2014	24
24101480	367	Nyquist MD	TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer.	Proceedings of the National Academy of Sciences of the United States of America	2013	33
24177177	367	Schroeder A	Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling.	Cancer research	2014	31
24200698	367	van Soest RJ	Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.	European journal of cancer	2013	36
24508459	367	An J	Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants.	Cell reports	2014	42
24659820	367	Marín-Aguilera M	Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer.	Molecular cancer therapeutics	2014	25
24740322	367	Liu C	Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.	Clinical cancer research 	2014	50
24837363	367	Ferraldeschi R	Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects.	Oncogene	2015	31
24840076	367	Wong YN	Evolution of androgen receptor targeted therapy for advanced prostate cancer.	Nature reviews. Clinical oncology	2014	27
24909511	367	Tan MH	Androgen receptor: structure, role in prostate cancer and drug discovery.	Acta pharmacologica Sinica	2015	30
25145503	367	Choi JE	Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.	Annals of surgical oncology	2015	21
25184630	367	Antonarakis ES	AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.	The New England journal of medicine	2014	256
25232177	367	Carreira S	Tumor clone dynamics in lethal prostate cancer.	Science translational medicine	2014	68
25274033	367	Geng C	Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer.	Cancer research	2014	23
25307492	367	Kong D	Androgen receptor splice variants contribute to prostate cancer aggressiveness through induction of EMT and expression of stem cell marker genes.	The Prostate	2015	21
25634993	367	Yamamoto Y	Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth.	Clinical cancer research 	2015	21
25691773	367	de Leeuw R	Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.	Clinical cancer research 	2015	17
25712683	367	Azad AA	Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.	Clinical cancer research 	2015	51
25830880	367	Gundem G	The evolutionary history of lethal metastatic prostate cancer.	Nature	2015	108
25887482	367	Jézéquel P	Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response.	Breast cancer research 	2015	19
26117829	367	Nakazawa M	Serial blood-based analysis of AR-V7 in men with advanced prostate cancer.	Annals of oncology 	2015	30
26160840	367	Zhang G	Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents.	Oncotarget	2015	18
26196735	367	Crawford ED	Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.	The Journal of urology	2015	19
26563462	367	Watson PA	Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer.	Nature reviews. Cancer	2015	64
26774508	367	Shore ND	Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study.	The Lancet. Oncology	2016	15
26855148	367	Beltran H	Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.	Nature medicine	2016	57
27184417	367	Bianchini G	Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.	Nature reviews. Clinical oncology	2016	42
28059768	367	Mu P	SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.	Science	2017	14
7792600	472	Savitsky K	A single ataxia telangiectasia gene with a product similar to PI-3 kinase.	Science	1995	475
9427750	472	Cliby WA	Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints.	The EMBO journal	1998	160
9843217	472	Khanna KK	ATM associates with and phosphorylates p53: mapping the region of interaction.	Nature genetics	1998	124
11242102	472	Khanna KK	DNA double-strand breaks: signaling, repair and the cancer connection.	Nature genetics	2001	495
11248557	472	Durocher D	DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme?	Current opinion in cell biology	2001	120
12919958	472	Yang J	ATM, ATR and DNA-PK: initiators of the cellular genotoxic stress responses.	Carcinogenesis	2003	79
14744762	472	Kühne M	A double-strand break repair defect in ATM-deficient cells contributes to radiosensitivity.	Cancer research	2004	86
15928302	472	Thompson D	Cancer risks and mortality in heterozygous ATM mutation carriers.	Journal of the National Cancer Institute	2005	85
16523492	472	Zou Y	Functions of human replication protein A (RPA): from DNA replication to DNA damage and stress responses.	Journal of cellular physiology	2006	108
17968022	472	Austen B	Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion.	Journal of clinical oncology 	2007	59
18794134	472	Rainey MD	Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation.	Cancer research	2008	57
20080624	472	Hu H	ATM is down-regulated by N-Myc-regulated microRNA-421.	Proceedings of the National Academy of Sciences of the United States of America	2010	76
20580718	472	Derheimer FA	Multiple roles of ATM in monitoring and maintaining DNA integrity.	FEBS letters	2010	80
20615625	472	Sanli T	Ionizing radiation activates AMP-activated kinase (AMPK): a target for radiosensitization of human cancer cells.	International journal of radiation oncology, biology, physics	2010	50
21139141	472	Bensimon A	ATM-dependent and -independent dynamics of the nuclear phosphoproteome after DNA damage.	Science signaling	2010	87
21187855	472	Miyamoto S	Nuclear initiated NF-κB signaling: NEMO and ATM take center stage.	Cell research	2011	63
21490603	472	Reaper PM	Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR.	Nature chemical biology	2011	136
22374981	472	Brennan K	Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk.	Cancer research	2012	45
22585167	472	Roberts NJ	ATM mutations in patients with hereditary pancreatic cancer.	Cancer discovery	2012	93
22740399	472	Gillespie KA	Human papillomaviruses recruit cellular DNA repair and homologous recombination factors to viral replication centers.	Journal of virology	2012	60
23440242	472	Ambrose M	Pathogenesis of ataxia-telangiectasia: the next generation of ATM functions.	Blood	2013	33
23532176	472	Stracker TH	The ATM signaling network in development and disease.	Frontiers in genetics	2013	32
23620409	472	Biddlestone-Thorpe L	ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation.	Clinical cancer research 	2013	32
23851489	472	Velimezi G	Functional interplay between the DNA-damage-response kinase ATM and ARF tumour suppressor protein in human cancer.	Nature cell biology	2013	39
23851492	472	Cremona CA	ATM signalling and cancer.	Oncogene	2014	36
26282658	472	Bang YJ	Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer.	Journal of clinical oncology 	2015	40
28096526	472	Maciejowski J	Telomeres in cancer: tumour suppression and genome instability.	Nature reviews. Molecular cell biology	2017	9
7907678	672	Ford D	Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.	Lancet	1994	261
9145676	672	Struewing JP	The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.	The New England journal of medicine	1997	316
9443863	672	Parmigiani G	Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2.	American journal of human genetics	1998	141
9701363	672	Lakhani SR	Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations.	Journal of the National Cancer Institute	1998	119
9839517	672	Risch HA	Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone.	Journal of the National Cancer Institute	1998	138
9988281	672	Wilson CA	Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas.	Nature genetics	1999	101
10359546	672	Peto J	Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer.	Journal of the National Cancer Institute	1999	148
10635334	672	Scully R	Genetic analysis of BRCA1 function in a defined tumor cell line.	Molecular cell	1999	112
10883018	672	Holschneider CH	Ovarian cancer: epidemiology, biology, and prognostic factors.	Seminars in surgical oncology	2000	105
11179017	672	Risch HA	Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.	American journal of human genetics	2001	166
11207349	672	Hedenfalk I	Gene-expression profiles in hereditary breast cancer.	The New England journal of medicine	2001	260
11257103	672	Welcsh PL	BRCA1 and BRCA2 and the genetics of breast and ovarian cancer.	Human molecular genetics	2001	114
11320250	672	Ruffner H	Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity.	Proceedings of the National Academy of Sciences of the United States of America	2001	96
11463009	672	Meijers-Heijboer H	Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.	The New England journal of medicine	2001	91
11516927	672	Dronkert ML	Repair of DNA interstrand cross-links.	Mutation research	2001	167
11710890	672	King MC	Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.	JAMA	2001	91
11823860	672	van 't Veer LJ	Gene expression profiling predicts clinical outcome of breast cancer.	Nature	2002	2130
11857015	672	Antoniou AC	A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes.	British journal of cancer	2002	106
12023992	672	Kauff ND	Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.	The New England journal of medicine	2002	167
12023993	672	Rebbeck TR	Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.	The New England journal of medicine	2002	204
12162889	672	Radmacher MD	A paradigm for class prediction using gene expression profiles.	Journal of computational biology 	2002	82
12237281	672	Thompson D	Cancer Incidence in BRCA1 mutation carriers.	Journal of the National Cancer Institute	2002	206
12483514	672	Jasin M	Homologous repair of DNA damage and tumorigenesis: the BRCA connection.	Oncogene	2002	94
12677558	672	Antoniou A	Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.	American journal of human genetics	2003	579
12712470	672	Cass I	Improved survival in women with BRCA-associated ovarian carcinoma.	Cancer	2003	113
14576434	672	King MC	Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.	Science	2003	394
14981104	672	Rebbeck TR	Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.	Journal of clinical oncology 	2004	146
15041722	672	Foulkes WD	Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type.	Clinical cancer research 	2004	76
15057881	672	Tyrer J	A breast cancer prediction model incorporating familial and personal risk factors.	Statistics in medicine	2004	149
15197194	672	Metcalfe K	Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.	Journal of clinical oncology 	2004	111
15367553	672	Warner E	Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.	JAMA	2004	146
15547178	672	Kennedy RD	The role of BRCA1 in the cellular response to chemotherapy.	Journal of the National Cancer Institute	2004	85
15784178	672	Dumitrescu RG	Understanding breast cancer risk -- where do we stand in 2005?	Journal of cellular and molecular medicine	2005	81
15910949	672	Leach MO	Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS).	Lancet	2005	156
16014699	672	Tavtigian SV	Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral.	Journal of medical genetics	2006	168
16137750	672	Finch A	Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers.	Gynecologic oncology	2006	73
16144895	672	Nelson HD	Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force.	Annals of internal medicine	2005	84
16234515	672	Eisen A	Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.	Journal of clinical oncology 	2005	79
16284991	672	Pal T	BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.	Cancer	2005	156
16293877	672	Kuhl CK	Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer.	Journal of clinical oncology 	2005	116
16357213	672	Kennedy RD	The Fanconi Anemia/BRCA pathway: new faces in the crowd.	Genes and development	2005	154
16397213	672	Elstrodt F	BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.	Cancer research	2006	68
16434898	672	Medeiros F	The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome.	The American journal of surgical pathology	2006	135
16484695	672	Chen S	Characterization of BRCA1 and BRCA2 mutations in a large United States sample.	Journal of clinical oncology 	2006	70
16488803	672	Fentiman IS	Male breast cancer.	Lancet	2006	77
16522644	672	Mathe E	Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods.	Nucleic acids research	2006	81
16522651	672	Deng CX	BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution.	Nucleic acids research	2006	120
16835424	672	Finch A	Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.	JAMA	2006	93
16912212	672	Malone KE	Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years.	Cancer research	2006	64
17117391	672	Lee Y	A candidate precursor to serous carcinoma that originates in the distal fallopian tube.	The Journal of pathology	2007	198
17218844	672	Crum CP	The distal fallopian tube: a new model for pelvic serous carcinogenesis.	Current opinion in obstetrics and gynecology	2007	114
17416853	672	Chen S	Meta-analysis of BRCA1 and BRCA2 penetrance.	Journal of clinical oncology 	2007	280
17456833	672	Crum CP	Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer.	Clinical medicine and research	2007	64
17525342	672	Kim H	Ubiquitin-binding protein RAP80 mediates BRCA1-dependent DNA damage response.	Science	2007	215
17761984	672	Callahan MJ	Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction.	Journal of clinical oncology 	2007	100
17924331	672	Easton DF	A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes.	American journal of human genetics	2007	131
18034184	672	Fackenthal JD	Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations.	Nature reviews. Cancer	2007	108
18159056	672	John EM	Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups.	JAMA	2007	104
18182601	672	Begg CB	Variation of breast cancer risk among BRCA1/2 carriers.	JAMA	2008	82
18268356	672	Kauff ND	Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.	Journal of clinical oncology 	2008	92
18342932	672	Folkins AK	A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations.	Gynecologic oncology	2008	62
18349832	672	Antoniou AC	The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions.	British journal of cancer	2008	99
18458280	672	Warner E	Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer.	Annals of internal medicine	2008	79
18573080	672	Uversky VN	Intrinsically disordered proteins in human diseases: introducing the D2 concept.	Annual review of biophysics	2008	252
18649131	672	Byrski T	Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients.	Breast cancer research and treatment	2009	72
18779615	672	Atchley DP	Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.	Journal of clinical oncology 	2008	107
18955455	672	Tan DS	"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.	Journal of clinical oncology 	2008	101
19060844	672	Clarke B	Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss.	Modern pathology 	2009	60
19141781	672	Rebbeck TR	Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.	Journal of the National Cancer Institute	2009	128
19241424	672	Hall MJ	BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer.	Cancer	2009	70
19298662	672	Young SR	The prevalence of BRCA1 mutations among young women with triple-negative breast cancer.	BMC cancer	2009	55
19369211	672	Sy SM	PALB2 is an integral component of the BRCA complex required for homologous recombination repair.	Proceedings of the National Academy of Sciences of the United States of America	2009	132
19460581	672	Anders CK	Breast cancer before age 40 years.	Seminars in oncology	2009	85
19491823	672	Poley JW	The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer.	The American journal of gastroenterology	2009	64
19553641	672	Fong PC	Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.	The New England journal of medicine	2009	840
19636370	672	Brown PO	The preclinical natural history of serous ovarian cancer: defining the target for early detection.	PLoS medicine	2009	57
19648928	672	Lim E	Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers.	Nature medicine	2009	454
19841585	672	Kurian AW	BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications.	Current opinion in obstetrics and gynecology	2010	41
19858402	672	Graeser MK	Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.	Journal of clinical oncology 	2009	52
19996028	672	Oktay K	Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks.	Journal of clinical oncology 	2010	57
20008645	672	Byrski T	Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy.	Journal of clinical oncology 	2010	108
20016594	672	Morris JR	The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress.	Nature	2009	163
20177395	672	Moynahan ME	Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis.	Nature reviews. Molecular cell biology	2010	267
20368571	672	Malone KE	Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2.	Journal of clinical oncology 	2010	46
20400477	672	O'Donovan PJ	BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair.	Carcinogenesis	2010	70
20427433	672	Amir E	Assessing women at high risk of breast cancer: a review of risk assessment models.	Journal of the National Cancer Institute	2010	89
20606085	672	Hennessy BT	Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.	Journal of clinical oncology 	2010	67
20609467	672	Tutt A	Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.	Lancet	2010	389
20609468	672	Audeh MW	Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.	Lancet	2010	309
20616022	672	Walsh T	Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing.	Proceedings of the National Academy of Sciences of the United States of America	2010	126
20810374	672	Domchek SM	Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.	JAMA	2010	187
21135251	672	Villarroel MC	Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.	Molecular cancer therapeutics	2011	65
21146769	672	Bellcross CA	Awareness and utilization of BRCA1/2 testing among U.S. primary care physicians.	American journal of preventive medicine	2011	38
21228333	672	Vencken PM	Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients.	Annals of oncology 	2011	38
21233401	672	Gonzalez-Angulo AM	Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer.	Clinical cancer research 	2011	109
21324516	672	Zhang S	Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer.	Gynecologic oncology	2011	52
21358336	672	Levy DE	Underutilization of BRCA1/2 testing to guide breast cancer treatment: black and Hispanic women particularly at risk.	Genetics in medicine 	2011	55
21464413	672	King TA	Clinical management factors contribute to the decision for contralateral prophylactic mastectomy.	Journal of clinical oncology 	2011	48
21505135	672	Link DC	Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML.	JAMA	2011	59
21717445	672	Schwartz MD	Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance.	Cancer	2012	31
21727289	672	Schousboe JT	Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness.	Annals of internal medicine	2011	62
21987798	672	Konishi H	Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells.	Proceedings of the National Academy of Sciences of the United States of America	2011	47
21990146	672	Spurdle AB	ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes.	Human mutation	2012	45
21990299	672	Yang D	Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.	JAMA	2011	104
22193408	672	Roy R	BRCA1 and BRCA2: different roles in a common pathway of genome protection.	Nature reviews. Cancer	2011	216
22203755	672	Kaye SB	Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.	Journal of clinical oncology 	2012	94
22314128	672	Krepischi AC	Germline DNA copy number variation in familial and early-onset breast cancer.	Breast cancer research 	2012	31
22452356	672	Ledermann J	Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.	The New England journal of medicine	2012	200
22516946	672	Leongamornlert D	Germline BRCA1 mutations increase prostate cancer risk.	British journal of cancer	2012	30
22576213	672	Birkbak NJ	Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents.	Cancer discovery	2012	44
22614657	672	Hartman AR	Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer.	Cancer	2012	37
22915752	672	Ibrahim YH	PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.	Cancer discovery	2012	104
22933060	672	Popova T	Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation.	Cancer research	2012	57
23099806	672	Iqbal J	The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers.	British journal of cancer	2012	33
23233716	672	Weitzel JN	Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network.	Journal of clinical oncology 	2013	33
23257159	672	McLaughlin JR	Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2.	Journal of the National Cancer Institute	2013	26
23257362	672	Verhaak RG	Prognostically relevant gene signatures of high-grade serous ovarian carcinoma.	The Journal of clinical investigation	2013	106
23269703	672	Domchek SM	Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer.	Cancer discovery	2013	29
23377543	672	Tang J	Acetylation limits 53BP1 association with damaged chromatin to promote homologous recombination.	Nature structural and molecular biology	2013	123
23409019	672	Gracia-Aznarez FJ	Whole exome sequencing suggests much of non-BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles.	PloS one	2013	27
23558900	672	Lips EH	Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers.	British journal of cancer	2013	33
23569316	672	Castro E	Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.	Journal of clinical oncology 	2013	59
23628597	672	Mavaddat N	Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.	Journal of the National Cancer Institute	2013	94
23810788	672	Sandhu SK	The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.	The Lancet. Oncology	2013	84
23918944	672	Phillips KA	Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.	Journal of clinical oncology 	2013	27
23942203	672	Tarabeux J	Streamlined ion torrent PGM-based diagnostics: BRCA1 and BRCA2 genes as a model.	European journal of human genetics 	2014	21
24042365	672	Rosenberg SM	Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey.	Annals of internal medicine	2013	27
24140203	672	Widschwendter M	The sex hormone system in carriers of BRCA1/2 mutations: a case-control study.	The Lancet. Oncology	2013	25
24218601	672	Etemadmoghadam D	Synthetic lethality between CCNE1 amplification and loss of BRCA1.	Proceedings of the National Academy of Sciences of the United States of America	2013	31
24225019	672	Lee JM	PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.	Annals of oncology 	2014	55
24292448	672	Phelan CM	Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study.	British journal of cancer	2014	23
24346285	672	Lee AJ	BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface.	British journal of cancer	2014	21
24366376	672	Moyer VA	Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement.	Annals of internal medicine	2014	57
24366442	672	Nelson HD	Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation.	Annals of internal medicine	2014	33
24449235	672	Schwartz MD	Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer.	Journal of clinical oncology 	2014	24
24478461	672	Laddha SV	Mutational landscape of the essential autophagy gene BECN1 in human cancers.	Molecular cancer research 	2014	37
24519767	672	Metcalfe K	Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis.	BMJ	2014	23
24567435	672	Finch AP	Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation.	Journal of clinical oncology 	2014	57
24618965	672	Dewey FE	Clinical interpretation and implications of whole-genome sequencing.	JAMA	2014	118
24675953	672	Couch FJ	Two decades after BRCA: setting paradigms in personalized cancer care and prevention.	Science	2014	57
24675954	672	Venkitaraman AR	Cancer suppression by the chromosome custodians, BRCA1 and BRCA2.	Science	2014	31
24824314	672	Friebel TM	Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis.	Journal of the National Cancer Institute	2014	23
24947112	672	Heemskerk-Gerritsen BA	Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis.	International journal of cancer	2015	16
25072261	672	Golan T	Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers.	British journal of cancer	2014	24
25224030	672	Mersch J	Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian.	Cancer	2015	25
25348513	672	Zhong Q	Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.	Clinical cancer research 	2015	19
25366685	672	Kaufman B	Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.	Journal of clinical oncology 	2015	144
25398451	672	Candido-dos-Reis FJ	Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer.	Clinical cancer research 	2015	16
25454609	672	Castro E	Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer.	European urology	2015	16
25481791	672	Oza AM	Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.	The Lancet. Oncology	2015	70
25673085	672	Dietze EC	Triple-negative breast cancer in African-American women: disparities versus biology.	Nature reviews. Cancer	2015	28
25800746	672	Wang P	Identification of lncRNA-associated competing triplets reveals global patterns and prognostic markers for cancer.	Nucleic acids research	2015	28
26187614	672	Kim G	FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy.	Clinical cancer research 	2015	35
26426480	672	Armstrong J	Utilization and Outcomes of BRCA Genetic Testing and Counseling in a National Commercially Insured Population: The ABOUT Study.	JAMA oncology	2015	15
26757170	672	Siu AL	Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement.	Annals of internal medicine	2016	42
26774285	672	Tkáč J	HELB Is a Feedback Inhibitor of DNA End Resection.	Molecular cell	2016	13
12068308	673	Davies H	Mutations of the BRAF gene in human cancer.	Nature	2002	2004
12198537	673	Rajagopalan H	Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status.	Nature	2002	276
12460918	673	Brose MS	BRAF and RAS mutations in human lung cancer and melanoma.	Cancer research	2002	256
12697856	673	Cohen Y	BRAF mutation in papillary thyroid carcinoma.	Journal of the National Cancer Institute	2003	149
12970315	673	Namba H	Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers.	The Journal of clinical endocrinology and metabolism	2003	78
14500344	673	Hingorani SR	Suppression of BRAF(V599E) in human melanoma abrogates transformation.	Cancer research	2003	105
14679157	673	Maldonado JL	Determinants of BRAF mutations in primary melanomas.	Journal of the National Cancer Institute	2003	104
15488754	673	Garnett MJ	Guilty as charged: B-RAF is a human oncogene.	Cancer cell	2004	156
16079850	673	Michaloglou C	BRAFE600-associated senescence-like cell cycle arrest of human naevi.	Nature	2005	551
16174717	673	Xing M	BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.	The Journal of clinical endocrinology and metabolism	2005	147
16804544	673	Weisenberger DJ	CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer.	Nature genetics	2006	534
17148775	673	Samowitz WS	Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer.	Journal of the National Cancer Institute	2006	105
17717450	673	Kebebew E	The prevalence and prognostic value of BRAF mutation in thyroid cancer.	Annals of surgery	2007	69
17724477	673	Michaloglou C	BRAF(E600) in benign and malignant human tumours.	Oncogene	2008	71
17785355	673	Lupi C	Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma.	The Journal of clinical endocrinology and metabolism	2007	60
17940185	673	Xing M	BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.	Endocrine reviews	2007	186
18287029	673	Tsai J	Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.	Proceedings of the National Academy of Sciences of the United States of America	2008	331
18310287	673	Frasca F	BRAF(V600E) mutation and the biology of papillary thyroid cancer.	Endocrine-related cancer	2008	54
18398503	673	Pfister S	BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas.	The Journal of clinical investigation	2008	112
18519771	673	French AJ	Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer.	Clinical cancer research 	2008	71
18532874	673	Viros A	Improving melanoma classification by integrating genetic and morphologic features.	PLoS medicine	2008	59
18559533	673	Montagut C	Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.	Cancer research	2008	145
18682506	673	Elisei R	BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.	The Journal of clinical endocrinology and metabolism	2008	92
18832519	673	Ogino S	CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.	Gut	2009	259
19255327	673	Kloos RT	Phase II trial of sorafenib in metastatic thyroid cancer.	Journal of clinical oncology 	2009	123
19276360	673	Hoeflich KP	Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.	Cancer research	2009	50
19414674	673	Xing M	BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer.	Journal of clinical oncology 	2009	47
19861538	673	Riesco-Eizaguirre G	The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.	Cancer research	2009	48
19883729	673	Xing M	Prognostic utility of BRAF mutation in papillary thyroid cancer.	Molecular and cellular endocrinology	2010	41
19924296	673	MacConaill LE	Profiling critical cancer gene mutations in clinical tumor samples.	PloS one	2009	145
20008640	673	Roth AD	Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.	Journal of clinical oncology 	2010	282
20450891	673	Inamdar GS	Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail.	Biochemical pharmacology	2010	41
20472680	673	Pratilas CA	Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response.	Clinical cancer research 	2010	51
20519626	673	Badalian-Very G	Recurrent BRAF mutations in Langerhans cell histiocytosis.	Blood	2010	108
20551065	673	Yang H	RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.	Cancer research	2010	102
20587792	673	Limsui D	Cigarette smoking and colorectal cancer risk by molecularly defined subtypes.	Journal of the National Cancer Institute	2010	88
20630094	673	Rubinstein JC	Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.	Journal of translational medicine	2010	60
20635392	673	Tie J	Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation.	International journal of cancer	2011	39
20818844	673	Flaherty KT	Inhibition of mutated, activated BRAF in metastatic melanoma.	The New England journal of medicine	2010	938
20823850	673	Bollag G	Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.	Nature	2010	428
20959481	673	Gopal YN	Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.	Cancer research	2010	96
21139585	673	Arkenau HT	Targeting BRAF for patients with melanoma.	British journal of cancer	2011	36
21169256	673	Comin-Anduix B	The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations.	Clinical cancer research 	2010	50
21274720	673	Schindler G	Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma.	Acta neuropathologica	2011	134
21285991	673	Yokota T	BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer.	British journal of cancer	2011	79
21343559	673	Long GV	Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.	Journal of clinical oncology 	2011	163
21430775	673	Chapman MA	Initial genome sequencing and analysis of multiple myeloma.	Nature	2011	414
21456008	673	Tran B	Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer.	Cancer	2011	92
21479234	673	Dias-Santagata D	BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications.	PloS one	2011	57
21639808	673	Chapman PB	Improved survival with vemurafenib in melanoma with BRAF V600E mutation.	The New England journal of medicine	2011	1498
21663470	673	Tiacci E	BRAF mutations in hairy-cell leukemia.	The New England journal of medicine	2011	157
21768580	673	Ladabaum U	Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis.	Annals of internal medicine	2011	71
21825258	673	Marchetti A	Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations.	Journal of clinical oncology 	2011	84
21882184	673	Kim TH	The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.	Cancer	2012	60
22012135	673	Capper D	Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases.	Acta neuropathologica	2012	40
22038996	673	Nicolaides TP	Targeted therapy for BRAFV600E malignant astrocytoma.	Clinical cancer research 	2011	51
22105174	673	Chakravarty D	Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.	The Journal of clinical investigation	2011	59
22147942	673	Ogino S	Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.	Clinical cancer research 	2012	80
22180495	673	Yang H	Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.	Cancer research	2012	54
22217739	673	Nikolaou VA	Melanoma: new insights and new therapies.	The Journal of investigative dermatology	2012	44
22228154	673	Kalady MF	BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis.	Diseases of the colon and rectum	2012	38
22235286	673	Yancovitz M	Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma.	PloS one	2012	59
22239440	673	Santarpia L	Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy.	Expert opinion on therapeutic targets	2012	108
22306669	673	Halait H	Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma.	Diagnostic molecular pathology 	2012	35
22332713	673	Anderson S	Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma.	Archives of pathology and laboratory medicine	2012	37
22355009	673	Hong DS	BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency.	Clinical cancer research 	2012	36
22356324	673	Sosman JA	Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.	The New England journal of medicine	2012	474
22385436	673	Finn L	Therapy for metastatic melanoma: the past, present, and future.	BMC medicine	2012	44
22393095	673	Popovici V	Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer.	Journal of clinical oncology 	2012	47
22395615	673	Shi H	Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance.	Nature communications	2012	160
22453018	673	Wu R	Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.	Cancer journal	2012	39
22454415	673	McArthur GA	Marked, homogeneous, and early 18Ffluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma.	Journal of clinical oncology 	2012	33
22508706	673	Guerra A	A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome.	The Journal of clinical endocrinology and metabolism	2012	30
22535154	673	Menzies AM	Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma.	Clinical cancer research 	2012	64
22549727	673	Vredeveld LC	Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.	Genes and development	2012	80
22608338	673	Falchook GS	Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.	Lancet	2012	179
22640478	673	Ascierto PA	Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use.	Journal of translational medicine	2012	30
22649091	673	Sen B	Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.	Science translational medicine	2012	34
22743296	673	Gautschi O	A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib.	Journal of thoracic oncology 	2012	37
22798288	673	Dahlman KB	BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.	Cancer discovery	2012	49
22850568	673	Khalili JS	Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma.	Clinical cancer research 	2012	59
22899730	673	Phipps AI	BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics.	Cancer epidemiology, biomarkers and prevention 	2012	40
22930283	673	Grisham RN	BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer.	Cancer	2013	27
22932786	673	Tufano RP	BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis.	Medicine	2012	46
22941165	673	Howell GM	BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer.	Annals of surgical oncology	2013	27
22972589	673	Patel SP	Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.	Cancer	2013	28
23026937	673	Long GV	Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.	The American journal of surgical pathology	2013	46
23055546	673	Li C	BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis.	The Journal of clinical endocrinology and metabolism	2012	36
23066120	673	Elisei R	The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study.	The Journal of clinical endocrinology and metabolism	2012	34
23273605	673	Greaves WO	Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma.	The Journal of molecular diagnostics 	2013	37
23290787	673	Sullivan RJ	Resistance to BRAF-targeted therapy in melanoma.	European journal of cancer	2013	74
23307859	673	Frederick DT	BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.	Clinical cancer research 	2013	152
23352452	673	Freeman AK	Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling.	Molecular cell	2013	39
23416974	673	Kwong LN	Targeted therapy for melanoma: rational combinatorial approaches.	Oncogene	2014	23
23442159	673	Chappé C	Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF(V600E) mutation and expression.	Brain pathology	2013	26
23533272	673	Sievert AJ	Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas.	Proceedings of the National Academy of Sciences of the United States of America	2013	52
23569304	673	Trunzer K	Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.	Journal of clinical oncology 	2013	83
23571588	673	Xing M	Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.	JAMA	2013	123
23612012	673	Andrulis M	Targeting the BRAF V600E mutation in multiple myeloma.	Cancer discovery	2013	35
23735514	673	Robert C	Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.	The Lancet. Oncology	2013	36
23800934	673	Nishihara R	Aspirin use and risk of colorectal cancer according to BRAF mutation status.	JAMA	2013	48
23833299	673	Nathanson KL	Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436).	Clinical cancer research 	2013	36
23852808	673	Roepman P	Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition.	International journal of cancer	2014	47
23856246	673	Abaan OD	The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.	Cancer research	2013	80
23878352	673	Lochhead P	Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication.	Journal of the National Cancer Institute	2013	81
23890088	673	Botton T	Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.	Pigment cell and melanoma research	2013	28
23903755	673	Corcoran RB	TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma.	Science translational medicine	2013	49
23918947	673	Ascierto PA	Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.	Journal of clinical oncology 	2013	60
24291778	673	Bucheit AD	Emerging insights into resistance to BRAF inhibitors in melanoma.	Biochemical pharmacology	2014	29
24295639	673	Dummer R	Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.	European journal of cancer	2014	36
24345920	673	Hutchinson KE	BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.	Clinical cancer research 	2013	33
24410877	673	Ihle MA	Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations.	BMC cancer	2014	46
24463458	673	Rizos H	BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.	Clinical cancer research 	2014	63
24508103	673	McArthur GA	Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.	The Lancet. Oncology	2014	119
24582505	673	Larkin J	Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.	The Lancet. Oncology	2014	28
24617711	673	Liu X	TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.	The Journal of clinical endocrinology and metabolism	2014	41
24638167	673	Berres ML	BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups.	The Journal of experimental medicine	2014	42
24725538	673	Robinson GW	Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy.	BMC cancer	2014	24
24737664	673	Yaeger R	BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer.	Cancer	2014	29
24768112	673	Brose MS	Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.	Lancet	2014	112
24958825	673	Hu-Lieskovan S	Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges.	Journal of clinical oncology 	2014	41
24991839	673	Rangwala R	Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma.	Autophagy	2014	63
25024077	673	Xing M	BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.	Journal of clinical oncology 	2014	57
25139339	673	Venderbosch S	Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.	Clinical cancer research 	2014	23
25157892	673	Kankotia S	Dichloroacetate and cancer: new home for an orphan drug?	Biochimica et biophysica acta	2014	33
25202140	673	Chakraborty R	Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.	Blood	2014	35
25332244	673	Xing M	Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.	Journal of clinical oncology 	2015	48
25344914	673	Spagnolo F	Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma.	Oncotarget	2014	28
25353071	673	Dadu R	Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience.	The Journal of clinical endocrinology and metabolism	2015	17
25411185	673	Sanmamed MF	Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors.	Clinical chemistry	2015	23
25494202	673	Konermann S	Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex.	Nature	2015	229
25617424	673	Wang T	BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth.	Clinical cancer research 	2015	15
25713148	673	Loupakis F	Primary tumor location as a prognostic factor in metastatic colorectal cancer.	Journal of the National Cancer Institute	2015	27
25891304	673	Postow MA	Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.	The New England journal of medicine	2015	330
25918280	673	Fakih MG	Metastatic colorectal cancer: current state and future directions.	Journal of clinical oncology 	2015	33
26037941	673	Long GV	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.	Lancet	2015	84
26038390	673	Campbell PT	Association between body mass index and mortality for colorectal cancer survivors: overall and by tumor molecular phenotype.	Cancer epidemiology, biomarkers and prevention 	2015	16
26181250	673	Larkin J	Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.	JAMA oncology	2015	25
26287849	673	Hyman DM	Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.	The New England journal of medicine	2015	128
26338525	673	Cremolini C	FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.	The Lancet. Oncology	2015	39
26527776	673	André T	Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.	Journal of clinical oncology 	2015	20
26715644	673	Girotti MR	Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma.	Cancer discovery	2016	16
26733501	673	Liu R	TERT promoter mutations in thyroid cancer.	Endocrine-related cancer	2016	13
26811525	673	Long GV	Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.	Journal of clinical oncology 	2016	21
27022117	673	Stadler ZK	Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels.	Journal of clinical oncology 	2016	18
27070934	673	Chan JC	The Lymphocyte-to-Monocyte Ratio is a Superior Predictor of Overall Survival in Comparison to Established Biomarkers of Resectable Colorectal Cancer.	Annals of surgery	2017	13
27080216	673	Planchard D	Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.	The Lancet. Oncology	2016	18
10545506	1000	Nieman MT	N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression.	The Journal of cell biology	1999	175
12414534	1000	Rosivatz E	Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer.	The American journal of pathology	2002	133
12547715	1000	Hirakawa S	Identification of vascular lineage-specific genes by transcriptional profiling of isolated blood vascular and lymphatic endothelial cells.	The American journal of pathology	2003	110
15970553	1000	Meier F	The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma.	Frontiers in bioscience 	2005	76
16397214	1000	Yang AD	Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells.	Cancer research	2006	70
17409456	1000	Alonso SR	A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis.	Cancer research	2007	79
17458507	1000	Sullivan R	Hypoxia-driven selection of the metastatic phenotype.	Cancer metastasis reviews	2007	106
17987116	1000	Rosell R	BRCA1: a novel prognostic factor in resected non-small-cell lung cancer.	PloS one	2007	65
18056176	1000	Gravdal K	A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer.	Clinical cancer research 	2007	115
18056451	1000	Eastham AM	Epithelial-mesenchymal transition events during human embryonic stem cell differentiation.	Cancer research	2007	75
18362184	1000	Shintani Y	Collagen I-mediated up-regulation of N-cadherin requires cooperative signals from integrins and discoidin domain receptor 1.	The Journal of cell biology	2008	64
18381457	1000	Graham TR	Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells.	Cancer research	2008	119
20808935	1000	Klopp AH	Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells.	PloS one	2010	50
21125666	1000	Castilla MÁ	Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma.	The Journal of pathology	2011	53
21356352	1000	Hou JM	Circulating tumor cells as a window on metastasis biology in lung cancer.	The American journal of pathology	2011	96
21618587	1000	Latifi A	Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile.	Journal of cellular biochemistry	2011	63
21665936	1000	Armstrong AJ	Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers.	Molecular cancer research 	2011	158
22402125	1000	Ru P	miRNA-29b suppresses prostate cancer metastasis by regulating epithelial-mesenchymal transition signaling.	Molecular cancer therapeutics	2012	59
22844540	1000	Balasubramanian P	Multiparameter analysis, including EMT markers, on negatively enriched blood samples from patients with squamous cell carcinoma of the head and neck.	PloS one	2012	32
23299311	1000	Zhang B	Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling.	Blood	2013	59
23469181	1000	Wang P	Identification and characterization of cells with cancer stem cell properties in human primary lung cancer cell lines.	PloS one	2013	32
23686305	1000	Davis FM	Induction of epithelial-mesenchymal transition (EMT) in breast cancer cells is calcium signal dependent.	Oncogene	2014	42
23947765	1000	Gomez-Casal R	Non-small cell lung cancer cells survived ionizing radiation treatment display cancer stem cell and epithelial-mesenchymal transition phenotypes.	Molecular cancer	2013	41
24013226	1000	Zhang JP	MicroRNA-148a suppresses the epithelial-mesenchymal transition and metastasis of hepatoma cells by targeting Met/Snail signaling.	Oncogene	2014	48
24085799	1000	Li LZ	miR-720 inhibits tumor invasion and migration in breast cancer by targeting TWIST1.	Carcinogenesis	2014	25
24201814	1000	Huang RY	An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530).	Cell death and disease	2013	55
24325753	1000	Bocca C	Expression of Cox-2 in human breast cancer cells as a critical determinant of epithelial-to-mesenchymal transition and invasiveness.	Expert opinion on therapeutic targets	2014	25
24704494	1000	Medyouf H	Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit.	Cell stem cell	2014	51
25056574	1000	Zhao Z	Nestin positively regulates the Wnt/β-catenin pathway and the proliferation, survival and invasiveness of breast cancer stem cells.	Breast cancer research 	2014	26
25069777	1000	Sareen D	Differentiation of human limbal-derived induced pluripotent stem cells into limbal-like epithelium.	Stem cells translational medicine	2014	23
25301732	1000	Wang D	Oct-4 and Nanog promote the epithelial-mesenchymal transition of breast cancer stem cells and are associated with poor prognosis in breast cancer patients.	Oncotarget	2014	35
25600338	1000	Wang H	The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells.	Cancer cell	2015	37
25728352	1000	Islam SS	Sonic hedgehog (Shh) signaling promotes tumorigenicity and stemness via activation of epithelial-to-mesenchymal transition (EMT) in bladder cancer.	Molecular carcinogenesis	2016	13
25792811	1000	Niu NK	Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.	Drug design, development and therapy	2015	17
25797269	1000	Kim HS	MicroRNA-31 functions as a tumor suppressor by regulating cell cycle and epithelial-mesenchymal transition regulatory proteins in liver cancer.	Oncotarget	2015	24
25863539	1000	Wu Y	The long non-coding RNA HNF1A-AS1 regulates proliferation and metastasis in lung adenocarcinoma.	Oncotarget	2015	30
25945841	1000	Huang N	MiR-338-3p inhibits epithelial-mesenchymal transition in gastric cancer cells by targeting ZEB2 and MACC1/Met/Akt signaling.	Oncotarget	2015	22
26069251	1000	Mudduluru G	A Systematic Approach to Defining the microRNA Landscape in Metastasis.	Cancer research	2015	15
26487301	1000	Yue B	LncRNA-ATB mediated E-cadherin repression promotes the progression of colon cancer and predicts poor prognosis.	Journal of gastroenterology and hepatology	2016	12
26668317	1000	Noy PJ	TspanC8 Tetraspanins and A Disintegrin and Metalloprotease 10 (ADAM10) Interact via Their Extracellular Regions: EVIDENCE FOR DISTINCT BINDING MECHANISMS FOR DIFFERENT TspanC8 PROTEINS.	The Journal of biological chemistry	2016	10
27629879	1000	Lu M	The high expression of long non-coding RNA PANDAR indicates a poor prognosis for colorectal cancer and promotes metastasis by EMT pathway.	Journal of cancer research and clinical oncology	2017	7
1388288	1017	Koff A	Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle.	Science	1992	232
1398067	1017	Lees E	Cyclin E/cdk2 and cyclin A/cdk2 kinases associate with p107 and E2F in a temporally distinct manner.	Genes and development	1992	133
1833068	1017	Koff A	Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family.	Cell	1991	148
7630397	1017	Jeffrey PD	Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex.	Nature	1995	328
7649471	1017	Reynisdóttir I	Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta.	Genes and development	1995	195
7739542	1017	Ohtsubo M	Human cyclin E, a nuclear protein essential for the G1-to-S phase transition.	Molecular and cellular biology	1995	255
8266103	1017	van den Heuvel S	Distinct roles for cyclin-dependent kinases in cell cycle control.	Science	1993	305
8684460	1017	Russo AA	Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex.	Nature	1996	233
9030781	1017	Meijer L	Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.	European journal of biochemistry	1997	307
9192874	1017	Lukas J	Cyclin E-induced S phase without activation of the pRb/E2F pathway.	Genes and development	1997	105
10201372	1017	Tetsu O	Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells.	Nature	1999	920
10323868	1017	Montagnoli A	Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation.	Genes and development	1999	151
10499591	1017	Spruck CH	Deregulated cyclin E induces chromosome instability.	Nature	1999	188
10648628	1017	Dickson MA	Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics.	Molecular and cellular biology	2000	241
10919634	1017	Sherr CJ	The Pezcoller lecture: cancer cell cycles revisited.	Cancer research	2000	213
10995386	1017	Zhao J	NPAT links cyclin E-Cdk2 to the regulation of replication-dependent histone gene transcription.	Genes and development	2000	118
11850621	1017	Falck J	The DNA damage-dependent intra-S phase checkpoint is regulated by parallel pathways.	Nature genetics	2002	100
12718885	1017	Vaziri C	A p53-dependent checkpoint pathway prevents rereplication.	Molecular cell	2003	135
12840228	1017	Davie JR	Inhibition of histone deacetylase activity by butyrate.	The Journal of nutrition	2003	197
15126355	1017	Stephen RL	Activation of peroxisome proliferator-activated receptor delta stimulates the proliferation of human breast and prostate cancer cell lines.	Cancer research	2004	70
15173011	1017	Nahta R	P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells.	Cancer research	2004	79
16082211	1017	Aggarwal BB	Molecular targets and anticancer potential of indole-3-carbinol and its derivatives.	Cell cycle	2005	101
16236519	1017	Malumbres M	Mammalian cyclin-dependent kinases.	Trends in biochemical sciences	2005	249
16505103	1017	Mantena SK	Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells.	Molecular cancer therapeutics	2006	65
16546962	1017	Wang Z	Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells.	Molecular cancer therapeutics	2006	100
16603719	1017	Shapiro GI	Cyclin-dependent kinase pathways as targets for cancer treatment.	Journal of clinical oncology 	2006	190
18627125	1017	Galea CA	Regulation of cell division by intrinsically unstructured proteins: intrinsic flexibility, modularity, and signaling conduits.	Biochemistry	2008	55
19234140	1017	Chen R	Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.	Blood	2009	46
19738602	1017	Takeshita F	Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes.	Molecular therapy 	2010	124
19915147	1017	Bogunovic D	Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival.	Proceedings of the National Academy of Sciences of the United States of America	2009	87
20479412	1017	Tong WG	Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma.	Journal of clinical oncology 	2010	43
20630104	1017	Sasaki K	Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells.	BMC cancer	2010	68
21062975	1017	Lin SL	MicroRNA miR-302 inhibits the tumorigenecity of human pluripotent stem cells by coordinate suppression of the CDK2 and CDK4/6 cell cycle pathways.	Cancer research	2010	50
21321214	1017	Scaltriti M	Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients.	Proceedings of the National Academy of Sciences of the United States of America	2011	79
23204228	1017	Cai J	miR-186 downregulation correlates with poor survival in lung adenocarcinoma, where it interferes with cell-cycle regulation.	Cancer research	2013	31
24444383	1017	Kang J	Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.	BMC cancer	2014	26
25395429	1017	Kumar SK	Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma.	Blood	2015	30
25535366	1017	Baratta MG	An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma.	Proceedings of the National Academy of Sciences of the United States of America	2015	28
25633797	1017	Asghar U	The history and future of targeting cyclin-dependent kinases in cancer therapy.	Nature reviews. Drug discovery	2015	110
26824338	1017	Zakraoui O	Lebein, a snake venom disintegrin, suppresses human colon cancer cells proliferation and tumor-induced angiogenesis through cell cycle arrest, apoptosis induction and inhibition of VEGF expression.	Molecular carcinogenesis	2017	5
26861625	1017	Du WW	Foxo3 circular RNA retards cell cycle progression via forming ternary complexes with p21 and CDK2.	Nucleic acids research	2016	38
7652577	1019	Wölfel T	A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma.	Science	1995	179
7777060	1019	Lukas J	Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16.	Nature	1995	182
8114739	1019	Meyerson M	Identification of G1 kinase activity for cdk6, a novel cyclin D partner.	Molecular and cellular biology	1994	186
8152487	1019	Nobori T	Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers.	Nature	1994	206
9242437	1019	Schutte M	Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas.	Cancer research	1997	136
11426655	1019	Hidalgo M	The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.	Oncogene	2000	109
11960696	1019	Ortega S	Cyclin D-dependent kinases, INK4 inhibitors and cancer.	Biochimica et biophysica acta	2002	156
11983916	1019	Menssen A	Characterization of the c-MYC-regulated transcriptome by SAGE: identification and analysis of c-MYC target genes.	Proceedings of the National Academy of Sciences of the United States of America	2002	123
15604268	1019	Ramirez RD	Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins.	Cancer research	2004	234
15961763	1019	Banerji U	Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies.	Journal of clinical oncology 	2005	123
16413469	1019	Yu Q	Requirement for CDK4 kinase function in breast cancer.	Cancer cell	2006	84
16489012	1019	Sato M	Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells.	Cancer research	2006	122
16860662	1019	Sharp S	Inhibitors of the HSP90 molecular chaperone: current status.	Advances in cancer research	2006	82
16972248	1019	Becker KA	Self-renewal of human embryonic stem cells is supported by a shortened G1 cell cycle phase.	Journal of cellular physiology	2006	137
17023580	1019	Rodriguez PC	L-arginine availability regulates T-lymphocyte cell-cycle progression.	Blood	2007	144
17047042	1019	Goldstein AM	High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL.	Cancer research	2006	74
17259553	1019	Powers MV	Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.	Endocrine-related cancer	2006	78
18006822	1019	Ovcharenko D	Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL-induced apoptosis pathway.	Cancer research	2007	68
18790768	1019	Smalley KS	Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas.	Molecular cancer therapeutics	2008	64
19001083	1019	Joshi I	Notch signaling mediates G1/S cell-cycle progression in T cells via cyclin D3 and its dependent kinases.	Blood	2009	53
19091943	1019	Luo B	Highly parallel identification of essential genes in cancer cells.	Proceedings of the National Academy of Sciences of the United States of America	2008	202
19415697	1019	Kim JK	Nuclear cyclin D1: an oncogenic driver in human cancer.	Journal of cellular physiology	2009	108
19609742	1019	Rao SK	A survey of glioblastoma genomic amplifications and deletions.	Journal of neuro-oncology	2010	46
19874578	1019	Finn RS	PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.	Breast cancer research 	2009	194
20080666	1019	Kim H	Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship.	Proceedings of the National Academy of Sciences of the United States of America	2010	79
20179208	1019	Zhong Z	Cyclin D1/cyclin-dependent kinase 4 interacts with filamin A and affects the migration and invasion potential of breast cancer cells.	Cancer research	2010	45
20440268	1019	Liu F	Epigenomic alterations and gene expression profiles in respiratory epithelia exposed to cigarette smoke condensate.	Oncogene	2010	83
20577054	1019	Johnson SM	Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition.	The Journal of clinical investigation	2010	62
20951943	1019	Aggarwal P	Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase.	Cancer cell	2010	66
21200143	1019	Wang C	Reviewing once more the c-myc and Ras collaboration: converging at the cyclin D1-CDK4 complex and challenging basic concepts of cancer biology.	Cell cycle	2011	41
21278242	1019	Pacey S	A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors.	Clinical cancer research 	2011	52
21412932	1019	Birnbaum DJ	Genome profiling of pancreatic adenocarcinoma.	Genes, chromosomes and cancer	2011	43
21502498	1019	Karst AM	Modeling high-grade serous ovarian carcinogenesis from the fallopian tube.	Proceedings of the National Academy of Sciences of the United States of America	2011	83
21552124	1019	Crago AM	Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma.	Current opinion in oncology	2011	56
21734724	1019	Musgrove EA	Cyclin D as a therapeutic target in cancer.	Nature reviews. Cancer	2011	268
22222629	1019	Kato K	The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo.	Molecular cancer therapeutics	2012	53
22383795	1019	Leonard JP	Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.	Blood	2012	66
22711607	1019	Cen L	p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.	Neuro-oncology	2012	34
22767154	1019	Dean JL	Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors.	Cell cycle	2012	44
23079656	1019	Sawai CM	Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia.	Cancer cell	2012	38
23449933	1019	Sato M	Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations.	Molecular cancer research 	2013	52
23569312	1019	Dickson MA	Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.	Journal of clinical oncology 	2013	75
23604310	1019	Eswaran J	RNA sequencing of cancer reveals novel splicing alterations.	Scientific reports	2013	58
23644662	1019	Choi YJ	Signaling through cyclin D-dependent kinases.	Oncogene	2014	36
24045179	1019	Rader J	Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma.	Clinical cancer research 	2013	51
24387133	1019	Casimiro MC	Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present.	Expert opinion on investigational drugs	2014	28
24495407	1019	Young RJ	Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.	Pigment cell and melanoma research	2014	25
24604117	1019	Liu G	MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer.	The Journal of pathology	2014	25
24795392	1019	Dickson MA	Molecular pathways: CDK4 inhibitors for cancer therapy.	Clinical cancer research 	2014	43
24919854	1019	Gelbert LM	Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine.	Investigational new drugs	2014	40
24931142	1019	Janku F	Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing.	Oncotarget	2014	23
25002028	1019	Vora SR	CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.	Cancer cell	2014	50
25053825	1019	Fiskus W	BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD.	Molecular cancer therapeutics	2014	35
25082755	1019	Chiron D	Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.	Cancer discovery	2014	33
25206307	1019	Hosford SR	Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.	Pharmacogenomics and personalized medicine	2014	22
25498841	1019	Carneiro BA	Emerging therapeutic targets in bladder cancer.	Cancer treatment reviews	2015	16
25501126	1019	DeMichele A	CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment.	Clinical cancer research 	2015	42
25524798	1019	Finn RS	The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.	The Lancet. Oncology	2015	183
25609060	1019	Di Stefano AL	Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.	Clinical cancer research 	2015	19
25803170	1019	Kovatcheva M	MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition.	Oncotarget	2015	16
26030518	1019	Turner NC	Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.	The New England journal of medicine	2015	140
26324739	1019	Beaver JA	FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer.	Clinical cancer research 	2015	24
26658964	1019	Sherr CJ	Targeting CDK4 and CDK6: From Discovery to Therapy.	Cancer discovery	2016	40
26833129	1019	Bouillez A	Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas.	Cancer research	2016	14
26923330	1019	Johnson J	Targeting the RB-E2F pathway in breast cancer.	Oncogene	2016	13
26947331	1019	Cristofanilli M	Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.	The Lancet. Oncology	2016	40
27217383	1019	Patnaik A	Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.	Cancer discovery	2016	21
27717303	1019	Hortobagyi GN	Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.	The New England journal of medicine	2016	25
27849562	1019	Bollard J	Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma.	Gut	2017	6
7585571	1026	Waldman T	p21 is necessary for the p53-mediated G1 arrest in human cancer cells.	Cancer research	1995	282
7729684	1026	Matsuoka S	p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene.	Genes and development	1995	190
7958916	1026	Di Leonardo A	DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts.	Genes and development	1994	207
8118801	1026	el-Deiry WS	WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis.	Cancer research	1994	376
8649519	1026	Waldman T	Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21.	Nature	1996	132
8843196	1026	Chen X	p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells.	Genes and development	1996	154
9296497	1026	Somasundaram K	Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1.	Nature	1997	106
9736735	1026	Yu ZK	Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21(CIP1/WAF1) and cyclin D proteins.	Proceedings of the National Academy of Sciences of the United States of America	1998	134
10200307	1026	Saito A	A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.	Proceedings of the National Academy of Sciences of the United States of America	1999	107
10430607	1026	Bunz F	Disruption of p53 in human cancer cells alters the responses to therapeutic agents.	The Journal of clinical investigation	1999	247
10760295	1026	Chang BD	Effects of p21Waf1/Cip1/Sdi1 on cellular gene expression: implications for carcinogenesis, senescence, and age-related diseases.	Proceedings of the National Academy of Sciences of the United States of America	2000	95
10954755	1026	Richon VM	Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.	Proceedings of the National Academy of Sciences of the United States of America	2000	239
11159180	1026	Specht K	Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue.	The American journal of pathology	2001	91
11309634	1026	Watanabe T	Molecular predictors of survival after adjuvant chemotherapy for colon cancer.	The New England journal of medicine	2001	174
11517191	1026	Lazennec G	ER beta inhibits proliferation and invasion of breast cancer cells.	Endocrinology	2001	94
11745677	1026	Piek JM	Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer.	The Journal of pathology	2001	132
11880176	1026	Roninson IB	Oncogenic functions of tumour suppressor p21(Waf1/Cip1/Sdi1): association with cell senescence and tumour-promoting activities of stromal fibroblasts.	Cancer letters	2002	86
12773551	1026	Zhu WG	Methylation of adjacent CpG sites affects Sp1/Sp3 binding and activity in the p21(Cip1) promoter.	Molecular and cellular biology	2003	77
12839953	1026	Rosato RR	The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1.	Cancer research	2003	105
12851486	1026	Liang J	Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression.	Cell cycle	2003	219
14617782	1026	Kondapaka SB	Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation.	Molecular cancer therapeutics	2003	100
15173093	1026	Pei XY	Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.	Clinical cancer research 	2004	92
15313918	1026	Myzak MC	A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase.	Cancer research	2004	134
15517885	1026	Aggarwal BB	Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies.	Anticancer research	2004	196
15617686	1026	Clarke RB	A putative human breast stem cell population is enriched for steroid receptor-positive cells.	Developmental biology	2005	87
16280330	1026	Myzak MC	Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells.	Carcinogenesis	2006	84
16434701	1026	Saramäki A	Regulation of the human p21(waf1/cip1) gene promoter via multiple binding sites for p53 and the vitamin D3 receptor.	Nucleic acids research	2006	77
16854453	1026	McCubrey JA	Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.	Advances in enzyme regulation	2006	155
17172425	1026	Kuo PL	Plumbagin induces G2-M arrest and autophagy by inhibiting the AKT/mammalian target of rapamycin pathway in breast cancer cells.	Molecular cancer therapeutics	2006	64
17332326	1026	Li M	Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway.	Cancer research	2007	67
17412634	1026	Ocker M	Histone deacetylase inhibitors: signalling towards p21cip1/waf1.	The international journal of biochemistry and cell biology	2007	91
17417771	1026	Kumagai T	Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells.	International journal of cancer	2007	57
18171934	1026	Langley B	Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21(waf1/cip1) in cell cycle-independent neuroprotection.	The Journal of neuroscience 	2008	61
18413741	1026	Majid S	Genistein induces the p21WAF1/CIP1 and p16INK4a tumor suppressor genes in prostate cancer cells by epigenetic mechanisms involving active chromatin modification.	Cancer research	2008	54
18440854	1026	Jiang BH	Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment.	Drug resistance updates 	2008	66
18467589	1026	Hume AJ	Phosphorylation of retinoblastoma protein by viral protein with cyclin-dependent kinase function.	Science	2008	88
18590585	1026	Abukhdeir AM	P21 and p27: roles in carcinogenesis and drug resistance.	Expert reviews in molecular medicine	2008	92
19010882	1026	Godlewski J	Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal.	Cancer research	2008	229
19141585	1026	Agarwal SK	Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states.	The Journal of clinical endocrinology and metabolism	2009	48
19440038	1026	Liu B	Metformin induces unique biological and molecular responses in triple negative breast cancer cells.	Cell cycle	2009	116
19440234	1026	Abbas T	p21 in cancer: intricate networks and multiple activities.	Nature reviews. Cancer	2009	498
19671864	1026	Badros A	Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma.	Clinical cancer research 	2009	67
19738071	1026	Escoubet-Lozach L	Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism.	Cancer research	2009	50
19773443	1026	Garbe JC	Molecular distinctions between stasis and telomere attrition senescence barriers shown by long-term culture of normal human mammary epithelial cells.	Cancer research	2009	69
19858489	1026	Liu M	p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo.	Proceedings of the National Academy of Sciences of the United States of America	2009	65
19861444	1026	Chung CH	Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications.	Clinical cancer research 	2009	92
20020197	1026	Györffy B	An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients.	Breast cancer research and treatment	2010	435
20444885	1026	Kim AY	Adiponectin represses colon cancer cell proliferation via AdipoR1- and -R2-mediated AMPK activation.	Molecular endocrinology	2010	49
20507599	1026	Baba Y	Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors.	Molecular cancer	2010	50
20851997	1026	Hong L	The miR-17-92 cluster of microRNAs confers tumorigenicity by inhibiting oncogene-induced senescence.	Cancer research	2010	55
20858478	1026	Vidya Priyadarsini R	The flavonoid quercetin induces cell cycle arrest and mitochondria-mediated apoptosis in human cervical cancer (HeLa) cells through p53 induction and NF-κB inhibition.	European journal of pharmacology	2010	46
21209038	1026	Nandakumar V	(-)-Epigallocatechin-3-gallate reactivates silenced tumor suppressor genes, Cip1/p21 and p16INK4a, by reducing DNA methylation and increasing histones acetylation in human skin cancer cells.	Carcinogenesis	2011	64
21258631	1026	Meeran SM	Epigenetic targets of bioactive dietary components for cancer prevention and therapy.	Clinical epigenetics	2010	56
21331045	1026	Elyada E	CKIα ablation highlights a critical role for p53 in invasiveness control.	Nature	2011	56
21383005	1026	Fan T	EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression.	Molecular cancer research 	2011	46
21703415	1026	Cesselli D	Effects of age and heart failure on human cardiac stem cell function.	The American journal of pathology	2011	54
21747117	1026	Mazumdar T	Blocking Hedgehog survival signaling at the level of the GLI genes induces DNA damage and extensive cell death in human colon carcinoma cells.	Cancer research	2011	43
22108298	1026	Piotrowska H	Biological activity of piceatannol: leaving the shadow of resveratrol.	Mutation research	2012	41
22154077	1026	Starostina NG	Multiple degradation pathways regulate versatile CIP/KIP CDK inhibitors.	Trends in cell biology	2012	47
22249270	1026	Yi C	MiR-663, a microRNA targeting p21(WAF1/CIP1), promotes the proliferation and tumorigenesis of nasopharyngeal carcinoma.	Oncogene	2012	50
22287560	1026	Baraniskin A	MiR-30a-5p suppresses tumor growth in colon carcinoma by targeting DTL.	Carcinogenesis	2012	46
22580610	1026	Yin D	miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme.	Oncogene	2013	27
22684298	1026	Capparelli C	Autophagy and senescence in cancer-associated fibroblasts metabolically supports tumor growth and metastasis via glycolysis and ketone production.	Cell cycle	2012	54
22773548	1026	Chen HP	Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies.	Gut	2013	59
22895844	1026	Chiba M	Exosomes secreted from human colorectal cancer cell lines contain mRNAs, microRNAs and natural antisense RNAs, that can transfer into the human hepatoma HepG2 and lung cancer A549 cell lines.	Oncology reports	2012	46
22935696	1026	Capparelli C	CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts, "fueling" tumor growth via paracrine interactions, without an increase in neo-angiogenesis.	Cell cycle	2012	41
23074173	1026	Lui GY	The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.	Molecular pharmacology	2013	26
23632475	1026	Storozhuk Y	Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK.	British journal of cancer	2013	49
23723074	1026	Dong Y	Tumor suppressor functions of miR-133a in colorectal cancer.	Molecular cancer research 	2013	27
23770676	1026	Acosta JC	A complex secretory program orchestrated by the inflammasome controls paracrine senescence.	Nature cell biology	2013	141
23950209	1026	Segura MF	BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy.	Cancer research	2013	41
24027026	1026	Irshad S	A molecular signature predictive of indolent prostate cancer.	Science translational medicine	2013	32
24100703	1026	Sanli T	AMP-activated protein kinase (AMPK) beyond metabolism: a novel genomic stress sensor participating in the DNA damage response pathway.	Cancer biology and therapy	2014	37
24122720	1026	Wang D	MicroRNA-124 controls the proliferative, migratory, and inflammatory phenotype of pulmonary vascular fibroblasts.	Circulation research	2014	37
24699304	1026	Fiskus W	Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells.	Leukemia	2014	34
24991835	1026	Mahalingam D	Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors.	Autophagy	2014	63
25633810	1026	Ohta K	MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A.	Oncotarget	2015	26
25728677	1026	Xu TP	SP1-induced upregulation of the long noncoding RNA TINCR regulates cell proliferation and apoptosis by affecting KLF2 mRNA stability in gastric cancer.	Oncogene	2015	43
25813522	1026	Léveillé N	Genome-wide profiling of p53-regulated enhancer RNAs uncovers a subset of enhancers controlled by a lncRNA.	Nature communications	2015	30
26913601	1026	Zhang E	Increased expression of long noncoding RNA TUG1 predicts a poor prognosis of gastric cancer and regulates cell proliferation by epigenetically silencing of p57.	Cell death and disease	2016	17
27323328	1026	Galanos P	Chronic p53-independent p21 expression causes genomic instability by deregulating replication licensing.	Nature cell biology	2016	18
8033212	1027	Polyak K	Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals.	Cell	1994	385
9018243	1027	Porter PL	Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients.	Nature medicine	1997	135
9018244	1027	Catzavelos C	Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer.	Nature medicine	1997	114
10213503	1027	Huang SM	Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck.	Cancer research	1999	109
10482195	1027	Sliwkowski MX	Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).	Seminars in oncology	1999	113
11073822	1027	Ouyang H	Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype.	The American journal of pathology	2000	102
11278274	1027	Nam S	Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo.	The Journal of biological chemistry	2001	109
11593406	1027	Hideshima T	Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma.	Oncogene	2001	90
12244301	1027	Shin I	PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization.	Nature medicine	2002	195
12244303	1027	Viglietto G	Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer.	Nature medicine	2002	153
12773099	1027	Sharpe RM	Proliferation and functional maturation of Sertoli cells, and their relevance to disorders of testis function in adulthood.	Reproduction	2003	154
15652749	1027	Baldassarre G	p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion.	Cancer cell	2005	84
17030811	1027	Pellegata NS	Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans.	Proceedings of the National Academy of Sciences of the United States of America	2006	91
17237771	1027	Liang J	The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis.	Nature cell biology	2007	277
17721077	1027	Gillies JK	Regulation of p27Kip1 by miRNA 221/222 in glioblastoma.	Cell cycle	2007	64
17914108	1027	Visone R	MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle.	Endocrine-related cancer	2007	123
18246122	1027	Garofalo M	MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer.	Oncogene	2008	95
18305219	1027	Chen Q	Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy.	Blood	2008	72
18354415	1027	Chu IM	The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy.	Nature reviews. Cancer	2008	278
18559508	1027	Wei D	Kruppel-like factor 4 induces p27Kip1 expression in and suppresses the growth and metastasis of human pancreatic cancer cells.	Cancer research	2008	54
18691549	1027	Majumder PK	A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression.	Cancer cell	2008	67
18708351	1027	Miller TE	MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1.	The Journal of biological chemistry	2008	240
19221487	1027	Wang X	MicroRNAs181 regulate the expression of p27Kip1 in human myeloid leukemia cells induced to differentiate by 1,25-dihydroxyvitamin D3.	Cell cycle	2009	52
19221498	1027	Alimova IN	Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro.	Cell cycle	2009	126
21245089	1027	Gilmartin AG	GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition.	Clinical cancer research 	2011	130
21523318	1027	Yamaguchi T	Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo.	International journal of oncology	2011	43
21683433	1027	Ceccarelli DF	An allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzyme.	Cell	2011	60
21750219	1027	Yuan J	PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.	Molecular cancer therapeutics	2011	46
22277193	1027	Gyorffy B	Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients.	Endocrine-related cancer	2012	118
23479461	1027	Di Martino MT	In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma.	Oncotarget	2013	43
23933118	1027	Thakker RV	Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4).	Molecular and cellular endocrinology	2014	37
24423924	1027	Hou T	MicroRNA-196a promotes cervical cancer proliferation through the regulation of FOXO1 and p27Kip1.	British journal of cancer	2014	23
24457952	1027	Huang J	Long non-coding RNA UCA1 promotes breast tumor growth by suppression of p27 (Kip1).	Cell death and disease	2014	71
25151966	1027	Fernandez S	miR-340 inhibits tumor cell proliferation and induces apoptosis by targeting multiple negative regulators of p27 in non-small cell lung cancer.	Oncogene	2015	29
26551667	1027	da Silva Almeida AC	The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome.	Nature genetics	2015	27
27591936	1027	Pan J	Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells.	Cancer letters	2016	13
7553621	1029	Herman JG	Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers.	Cancer research	1995	241
7585152	1029	Merlo A	5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers.	Nature medicine	1995	274
8153634	1029	Kamb A	A cell cycle regulator potentially involved in genesis of many tumor types.	Science	1994	337
8622687	1029	Hara E	Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence.	Molecular and cellular biology	1996	126
8790415	1029	Herman JG	Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.	Proceedings of the National Academy of Sciences of the United States of America	1996	1046
8939849	1029	Sherr CJ	Cancer cell cycles.	Science	1996	911
9135016	1029	Rozenblum E	Tumor-suppressive pathways in pancreatic carcinoma.	Cancer research	1997	154
9724636	1029	Stott FJ	The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2.	The EMBO journal	1998	262
9751761	1029	Belinsky SA	Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis.	Proceedings of the National Academy of Sciences of the United States of America	1998	140
9765203	1029	Lin AW	Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling.	Genes and development	1998	245
9776413	1029	Cairncross JG	Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.	Journal of the National Cancer Institute	1998	181
9817205	1029	Kiyono T	Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells.	Nature	1998	275
9892187	1029	Esteller M	Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients.	Cancer research	1999	133
10072356	1029	Sharpless NE	The INK4A/ARF locus and its two gene products.	Current opinion in genetics and development	1999	107
10319873	1029	Barrett MT	Evolution of neoplastic cell lineages in Barrett oesophagus.	Nature genetics	1999	97
10416987	1029	Ishii N	Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines.	Brain pathology	1999	155
10541553	1029	Schmitt CA	INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53.	Genes and development	1999	135
10801130	1029	Rhee I	CpG methylation is maintained in human cancer cells lacking DNMT1.	Nature	2000	93
10811111	1029	Esteller M	Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis.	Cancer research	2000	93
11016622	1029	Eads CA	Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma.	Cancer research	2000	100
11085511	1029	Palmisano WA	Predicting lung cancer by detecting aberrant promoter methylation in sputum.	Cancer research	2000	137
11196170	1029	Zöchbauer-Müller S	Aberrant promoter methylation of multiple genes in non-small cell lung cancers.	Cancer research	2001	104
11291057	1029	Klaes R	Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri.	International journal of cancer	2001	132
11309270	1029	Esteller M	A gene hypermethylation profile of human cancer.	Cancer research	2001	379
11309301	1029	Eads CA	Epigenetic patterns in the progression of esophageal adenocarcinoma.	Cancer research	2001	136
11325821	1029	Issa JP	Accelerated age-related CpG island methylation in ulcerative colitis.	Cancer research	2001	129
11355949	1029	Vonlanthen S	The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression.	British journal of cancer	2001	90
11544531	1029	Sharpless NE	Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis.	Nature	2001	231
11584300	1029	Sherr CJ	The INK4a/ARF network in tumour suppression.	Nature reviews. Molecular cell biology	2001	204
11748635	1029	Esteller M	Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours.	The Journal of pathology	2002	117
12438235	1029	Nguyen CT	Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine.	Cancer research	2002	103
12573439	1029	Lowe SW	Tumor suppression by Ink4a-Arf: progress and puzzles.	Current opinion in genetics and development	2003	207
12618505	1029	Cheng JC	Inhibition of DNA methylation and reactivation of silenced genes by zebularine.	Journal of the National Cancer Institute	2003	90
12620412	1029	Rosenwald A	The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma.	Cancer cell	2003	152
12692724	1029	Sipos B	A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform.	Virchows Archiv 	2003	84
12789288	1029	Wu H	PTEN signaling pathways in melanoma.	Oncogene	2003	86
12810640	1029	van Engeland M	Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer.	Cancer research	2003	76
12937151	1029	Yang B	Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma.	The American journal of pathology	2003	87
14507645	1029	Lee S	Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis.	The American journal of pathology	2003	79
14633667	1029	Fang MZ	Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines.	Cancer research	2003	205
14722605	1029	Sharpless NE	Telomeres, stem cells, senescence, and cancer.	The Journal of clinical investigation	2004	112
14729608	1029	Ginos MA	Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck.	Cancer research	2004	99
15026333	1029	Yegnasubramanian S	Hypermethylation of CpG islands in primary and metastatic human prostate cancer.	Cancer research	2004	128
15082532	1029	Kalinichenko VV	Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor.	Genes and development	2004	137
15466178	1029	Ohgaki H	Genetic pathways to glioblastoma: a population-based study.	Cancer research	2004	282
15471900	1029	Shay JW	Senescence and immortalization: role of telomeres and telomerase.	Carcinogenesis	2005	145
15520862	1029	Krishnamurthy J	Ink4a/Arf expression is a biomarker of aging.	The Journal of clinical investigation	2004	364
15822191	1029	Esteller M	Aberrant DNA methylation as a cancer-inducing mechanism.	Annual review of pharmacology and toxicology	2005	96
15824739	1029	Schulmann K	Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk.	Oncogene	2005	66
15899794	1029	Rich JN	Gene expression profiling and genetic markers in glioblastoma survival.	Cancer research	2005	78
15930332	1029	Singhal S	Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review.	Clinical cancer research 	2005	66
15977639	1029	Ohgaki H	Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.	Journal of neuropathology and experimental neurology	2005	237
16054941	1029	Robinson BW	Malignant mesothelioma.	Lancet	2005	126
16115905	1029	Begum S	Tissue distribution of human papillomavirus 16 DNA integration in patients with tonsillar carcinoma.	Clinical cancer research 	2005	66
16203797	1029	Fang MZ	Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy.	Clinical cancer research 	2005	83
16251483	1029	Chanda S	DNA hypermethylation of promoter of gene p53 and p16 in arsenic-exposed people with and without malignancy.	Toxicological sciences 	2006	67
16401683	1029	Weinberger PM	Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis.	Journal of clinical oncology 	2006	171
16424060	1029	Matsubayashi H	DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease.	Cancer research	2006	62
16572177	1029	Gonzalez S	Oncogenic activity of Cdc6 through repression of the INK4/ARF locus.	Nature	2006	66
16778197	1029	Song LB	Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells.	Cancer research	2006	121
16799619	1029	Laurent-Puig P	Genetics of hepatocellular tumors.	Oncogene	2006	82
16849682	1029	Hoque MO	Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection.	Journal of the National Cancer Institute	2006	67
16880792	1029	Gray-Schopfer VC	Cellular senescence in naevi and immortalisation in melanoma: a role for p16?	British journal of cancer	2006	101
16901784	1029	Narita M	A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation.	Cell	2006	185
16905682	1029	Goldstein AM	Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents.	Journal of medical genetics	2007	75
16921403	1029	Gil J	Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all.	Nature reviews. Molecular cell biology	2006	250
16964246	1029	Denoyelle C	Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway.	Nature cell biology	2006	97
17055429	1029	Kim WY	The regulation of INK4/ARF in cancer and aging.	Cell	2006	292
17088437	1029	Ikediobi ON	Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.	Molecular cancer therapeutics	2006	152
17139617	1029	Cho NY	Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features.	The Journal of pathology	2007	63
17179101	1029	Licitra L	High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma.	Journal of clinical oncology 	2006	138
17236202	1029	Reimers N	Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer.	International journal of cancer	2007	90
17326708	1029	Galipeau PC	NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma.	PLoS medicine	2007	87
17334996	1029	Jönsson G	High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization.	Genes, chromosomes and cancer	2007	64
17456751	1029	Ohgaki H	Genetic pathways to primary and secondary glioblastoma.	The American journal of pathology	2007	299
17654117	1029	Cánepa ET	INK4 proteins, a family of mammalian CDK inhibitors with novel biological functions.	IUBMB life	2007	64
17680565	1029	Smeets SJ	A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen.	International journal of cancer	2007	117
17717515	1029	Sharpless NE	How stem cells age and why this makes us grow old.	Nature reviews. Molecular cell biology	2007	260
17890455	1029	Kawamata N	Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray.	Blood	2008	57
17947473	1029	Shen L	Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy.	Clinical cancer research 	2007	56
18039136	1029	Maitra A	Pancreatic cancer.	Annual review of pathology	2008	210
18161048	1029	Nishida N	Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma.	Hepatology	2008	74
18265945	1029	Lu X	The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways.	Cancer metastasis reviews	2008	75
18305067	1029	Leedham SJ	Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett's oesophagus.	Gut	2008	56
18324472	1029	Lund MJ	Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA.	Breast cancer research and treatment	2009	108
18332116	1029	Kia SK	SWI/SNF mediates polycomb eviction and epigenetic reprogramming of the INK4b-ARF-INK4a locus.	Molecular and cellular biology	2008	83
18353141	1029	Bennett DC	How to make a melanoma: what do we know of the primary clonal events?	Pigment cell and melanoma research	2008	54
18360824	1029	Hafkamp HC	Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas.	International journal of cancer	2008	70
18394558	1029	Wiedemeyer R	Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development.	Cancer cell	2008	59
18474878	1029	Kumar B	EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer.	Journal of clinical oncology 	2008	169
18555778	1029	Kuilman T	Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network.	Cell	2008	419
18688285	1029	Hacein-Bey-Abina S	Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1.	The Journal of clinical investigation	2008	456
18688286	1029	Howe SJ	Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients.	The Journal of clinical investigation	2008	321
18806226	1029	Dumont N	Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers.	Proceedings of the National Academy of Sciences of the United States of America	2008	80
18843198	1029	Bueno MJ	Control of cell proliferation pathways by microRNAs.	Cell cycle	2008	93
18922929	1029	Barault L	Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases.	Cancer research	2008	106
18957520	1029	Szarewski A	Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears.	Cancer epidemiology, biomarkers and prevention 	2008	55
19074898	1029	Solomon DA	Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma.	Cancer research	2008	50
19289615	1029	Lassen P	Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck.	Journal of clinical oncology 	2009	102
19427557	1029	Kong CS	The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas.	International journal of radiation oncology, biology, physics	2009	61
19450526	1029	Witcher M	Epigenetic silencing of the p16(INK4a) tumor suppressor is associated with loss of CTCF binding and a chromatin boundary.	Molecular cell	2009	85
19451217	1029	Agger K	The H3K27me3 demethylase JMJD3 contributes to the activation of the INK4A-ARF locus in response to oncogene- and stress-induced senescence.	Genes and development	2009	137
19470766	1029	Beroukhim R	Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney.	Cancer research	2009	119
19509227	1029	Novak P	Stepwise DNA methylation changes are linked to escape from defined proliferation barriers and mammary epithelial cell immortalization.	Cancer research	2009	56
19593635	1029	Hollestelle A	Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.	Breast cancer research and treatment	2010	83
19638619	1029	Fiskus W	Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.	Blood	2009	107
19668188	1029	Li H	The Ink4/Arf locus is a barrier for iPS cell reprogramming.	Nature	2009	353
19718709	1029	Mohseny AB	Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2.	The Journal of pathology	2009	71
19787792	1029	Ottaviano L	Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort.	Genes, chromosomes and cancer	2010	48
19825961	1029	Ogino S	Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype.	Clinical cancer research 	2009	92
19853898	1029	D'Angelo E	Uterine sarcomas: a review.	Gynecologic oncology	2010	101
19884544	1029	Shi W	Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma.	Journal of clinical oncology 	2009	58
19966864	1029	Worthley DL	DNA methylation within the normal colorectal mucosa is associated with pathway-specific predisposition to cancer.	Oncogene	2010	42
20060892	1029	Shaulian E	AP-1--The Jun proteins: Oncogenes or tumor suppressors in disguise?	Cellular signalling	2010	98
20068183	1029	Schiffman JD	Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas.	Cancer research	2010	86
20145169	1029	Knudsen ES	Targeting the RB-pathway in cancer therapy.	Clinical cancer research 	2010	48
20146264	1029	Braconi C	MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes.	Hepatology	2010	106
20186832	1029	Singhi AD	Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience.	Cancer	2010	84
20423306	1029	Li Y	Impact on DNA methylation in cancer prevention and therapy by bioactive dietary components.	Current medicinal chemistry	2010	49
20427430	1029	Kerlikowske K	Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.	Journal of the National Cancer Institute	2010	81
20445578	1029	Kuiper RP	IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL.	Leukemia	2010	57
20460471	1029	Jönsson G	Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome.	Clinical cancer research 	2010	58
20522802	1029	Kajstura J	Cardiomyogenesis in the adult human heart.	Circulation research	2010	101
20549699	1029	Ozenne P	The ARF tumor suppressor: structure, functions and status in cancer.	International journal of cancer	2010	44
20587061	1029	Dayyani F	Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC).	Head and neck oncology	2010	74
20596971	1029	Chernock RD	HPV-related nonkeratinizing squamous cell carcinoma of the oropharynx: utility of microscopic features in predicting patient outcome.	Head and neck pathology	2009	47
20876795	1029	Verna EC	Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics.	Clinical cancer research 	2010	60
21129377	1029	Vasen HF	Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation.	Gastroenterology	2011	39
21145824	1029	Um TH	Aberrant CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B virus-related human multistep hepatocarcinogenesis.	Journal of hepatology	2011	41
21278246	1029	Konecny GE	Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer.	Clinical cancer research 	2011	51
21294121	1029	Marsh D	Stromal features are predictive of disease mortality in oral cancer patients.	The Journal of pathology	2011	47
21336312	1029	Di Micco R	Interplay between oncogene-induced DNA damage response and heterochromatin in senescence and cancer.	Nature cell biology	2011	92
21509761	1029	Ahn JB	DNA methylation predicts recurrence from resected stage III proximal colon cancer.	Cancer	2011	47
21559395	1029	von Levetzow C	Modeling initiation of Ewing sarcoma in human neural crest cells.	PloS one	2011	50
21613826	1029	Sartor MA	Genome-wide methylation and expression differences in HPV(+) and HPV(-) squamous cell carcinoma cell lines are consistent with divergent mechanisms of carcinogenesis.	Epigenetics	2011	48
21619050	1029	Li J	Regulatory mechanisms of tumor suppressor P16(INK4A) and their relevance to cancer.	Biochemistry	2011	38
21636552	1029	Raabe EH	BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model.	Clinical cancer research 	2011	42
21836494	1029	Ukpo OC	High-risk human papillomavirus E6/E7 mRNA detection by a novel in situ hybridization assay strongly correlates with p16 expression and patient outcomes in oropharyngeal squamous cell carcinoma.	The American journal of surgical pathology	2011	50
21837480	1029	Cho YH	Prognostic significance of gene-specific promoter hypermethylation in breast cancer patients.	Breast cancer research and treatment	2012	33
21880712	1029	Coppé JP	Tumor suppressor and aging biomarker p16(INK4a) induces cellular senescence without the associated inflammatory secretory phenotype.	The Journal of biological chemistry	2011	75
21921043	1029	Hogan LE	Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies.	Blood	2011	47
21952072	1029	Beltran AS	Generation of tumor-initiating cells by exogenous delivery of OCT4 transcription factor.	Breast cancer research 	2011	37
21969383	1029	Schache AG	Evaluation of human papilloma virus diagnostic testing in oropharyngeal squamous cell carcinoma: sensitivity, specificity, and prognostic discrimination.	Clinical cancer research 	2011	47
22037160	1029	Larsson LG	Oncogene- and tumor suppressor gene-mediated suppression of cellular senescence.	Seminars in cancer biology	2011	45
22065079	1029	Carbone M	Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma.	Clinical cancer research 	2012	46
22067401	1029	Oberholzer PA	RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.	Journal of clinical oncology 	2012	79
22084097	1029	Nagai H	Diameter and rigidity of multiwalled carbon nanotubes are critical factors in mesothelial injury and carcinogenesis.	Proceedings of the National Academy of Sciences of the United States of America	2011	89
22180304	1029	El-Naggar AK	p16 expression as a surrogate marker for HPV-related oropharyngeal carcinoma: a guide for interpretative relevance and consistency.	Head and neck	2012	38
22251937	1029	Yachida S	Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors.	The American journal of surgical pathology	2012	39
22256804	1029	Su F	RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.	The New England journal of medicine	2012	200
22385920	1029	Ang KK	Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma.	Seminars in radiation oncology	2012	41
22407776	1029	Nishida N	Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma.	Hepatology	2012	37
22422852	1029	Szarewski A	Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study.	Journal of clinical microbiology	2012	31
22565003	1029	Gillison ML	Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer.	Journal of clinical oncology 	2012	73
22782226	1029	Lewis JS Jr	p16 Immunohistochemistry as a standalone test for risk stratification in oropharyngeal squamous cell carcinoma.	Head and neck pathology	2012	35
22782230	1029	Isayeva T	Human papillomavirus in non-oropharyngeal head and neck cancers: a systematic literature review.	Head and neck pathology	2012	31
22833868	1029	Rothenberg SM	The molecular pathogenesis of head and neck squamous cell carcinoma.	The Journal of clinical investigation	2012	72
22888763	1029	Jeck WR	Review: a meta-analysis of GWAS and age-associated diseases.	Aging cell	2012	37
22949073	1029	Rietbergen MM	Increasing prevalence rates of HPV attributable oropharyngeal squamous cell carcinomas in the Netherlands as assessed by a validated test algorithm.	International journal of cancer	2013	25
22975375	1029	Navas C	EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma.	Cancer cell	2012	91
22991304	1029	Liang C	Biomarkers of HPV in head and neck squamous cell carcinoma.	Cancer research	2012	38
22991414	1029	Yachida S	Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors.	Clinical cancer research 	2012	35
23095507	1029	Bishop JA	Human papillomavirus-related carcinomas of the sinonasal tract.	The American journal of surgical pathology	2013	28
23135763	1029	Canto MI	International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer.	Gut	2013	87
23318426	1029	Nishi M	Induction of cells with cancer stem cell properties from nontumorigenic human mammary epithelial cells by defined reprogramming factors.	Oncogene	2014	25
23373539	1029	Etchin J	KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.	British journal of haematology	2013	63
23412337	1029	Sottoriva A	Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics.	Proceedings of the National Academy of Sciences of the United States of America	2013	266
23459718	1029	Hui AB	Potentially prognostic miRNAs in HPV-associated oropharyngeal carcinoma.	Clinical cancer research 	2013	27
23460709	1029	Martins RG	Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial.	Journal of clinical oncology 	2013	26
23470568	1029	Oshima M	Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.	Annals of surgery	2013	42
23487770	1029	Roy S	Rare somatic cells from human breast tissue exhibit extensive lineage plasticity.	Proceedings of the National Academy of Sciences of the United States of America	2013	33
23585871	1029	Amir S	Oncomir miR-125b suppresses p14(ARF) to modulate p53-dependent and p53-independent apoptosis in prostate cancer.	PloS one	2013	29
23601657	1029	Riaz M	miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.	Breast cancer research 	2013	38
23602369	1029	Rieckmann T	HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity.	Radiotherapy and oncology 	2013	41
23663786	1029	Yang L	Diverse mechanisms of somatic structural variations in human cancer genomes.	Cell	2013	74
23677068	1029	Sekido Y	Molecular pathogenesis of malignant mesothelioma.	Carcinogenesis	2013	32
23680149	1029	Gargiulo G	In vivo RNAi screen for BMI1 targets identifies TGF-β/BMP-ER stress pathways as key regulators of neural- and malignant glioma-stem cell homeostasis.	Cancer cell	2013	41
23746666	1029	Vermorken JB	Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.	The Lancet. Oncology	2013	56
23751258	1029	Pathai S	Accelerated biological ageing in HIV-infected individuals in South Africa: a case-control study.	AIDS	2013	28
23887298	1029	Ross JS	Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy.	Modern pathology 	2014	36
23907151	1029	Kanagal-Shamanna R	Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics.	Modern pathology 	2014	32
24127483	1029	Fabbri G	Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome.	The Journal of experimental medicine	2013	26
24177760	1029	Walline HM	High-risk human papillomavirus detection in oropharyngeal, nasopharyngeal, and oral cavity cancers: comparison of multiple methods.	JAMA otolaryngology-- head and neck surgery	2013	29
24425785	1029	Li H	Genomic analysis of head and neck squamous cell carcinoma cell lines and human tumors: a rational approach to preclinical model selection.	Molecular cancer research 	2014	21
24449267	1029	Salama R	Cellular senescence and its effector programs.	Genes and development	2014	120
24484372	1029	Hong Y	Melatonin treatment induces interplay of apoptosis, autophagy, and senescence in human colorectal cancer cells.	Journal of pineal research	2014	21
24522534	1029	Sousa-Victor P	Geriatric muscle stem cells switch reversible quiescence into senescence.	Nature	2014	126
24623306	1029	Serra RW	A KRAS-directed transcriptional silencing pathway that mediates the CpG island methylator phenotype.	eLife	2014	24
24681605	1029	Sanoff HK	Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer.	Journal of the National Cancer Institute	2014	31
24728135	1029	Piunti A	Polycomb proteins control proliferation and transformation independently of cell cycle checkpoints by regulating DNA replication.	Nature communications	2014	24
24732595	1029	Yan H	piRNA-823 contributes to tumorigenesis by regulating de novo DNA methylation and angiogenesis in multiple myeloma.	Leukemia	2015	20
24733792	1029	Kurian AW	Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment.	Journal of clinical oncology 	2014	68
24798001	1029	Ahn SM	Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification.	Hepatology	2014	45
24811890	1029	Wheler JJ	Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms.	Oncotarget	2014	22
24817381	1029	Alemany L	Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide.	International journal of cancer	2015	33
24818748	1029	Xu Y	Emerging roles of the p38 MAPK and PI3K/AKT/mTOR pathways in oncogene-induced senescence.	Trends in biochemical sciences	2014	29
24821878	1029	Serup-Hansen E	Human papillomavirus genotyping and p16 expression as prognostic factors for patients with American Joint Committee on Cancer stages I to III carcinoma of the anal canal.	Journal of clinical oncology 	2014	24
24910096	1029	Johmura Y	Necessary and sufficient role for a mitosis skip in senescence induction.	Molecular cell	2014	32
24957142	1029	Moorman AV	A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia.	Blood	2014	24
24958820	1029	Fakhry C	Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma.	Journal of clinical oncology 	2014	31
25009010	1029	De Mattos-Arruda L	Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.	Annals of oncology 	2014	47
25010205	1029	Brohl AS	The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation.	PLoS genetics	2014	53
25092538	1029	Kim PH	Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder.	European urology	2015	19
25154822	1029	Ang KK	Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.	Journal of clinical oncology 	2014	101
25223734	1029	Tirode F	Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations.	Cancer discovery	2014	57
25267748	1029	Chung CH	p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma.	Journal of clinical oncology 	2014	44
25366680	1029	Nguyen-Tan PF	Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity.	Journal of clinical oncology 	2014	25
25479140	1029	Grant RC	Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer.	Gastroenterology	2015	23
25503501	1029	Maxwell KN	Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer.	Genetics in medicine 	2015	24
25536104	1029	Churi CR	Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.	PloS one	2014	40
25584893	1029	Damsky W	mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation.	Cancer cell	2015	15
25589618	1029	Li YY	Genomic analysis of metastatic cutaneous squamous cell carcinoma.	Clinical cancer research 	2015	17
25712460	1029	Chung CH	Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing.	Annals of oncology 	2015	17
25754026	1029	Huang T	Meta-analyses of gene methylation and smoking behavior in non-small cell lung cancer patients.	Scientific reports	2015	18
25822088	1029	Schulze K	Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.	Nature genetics	2015	104
25890171	1029	Kong R	Long noncoding RNA PVT1 indicates a poor prognosis of gastric cancer and promotes cell proliferation through epigenetically regulating p15 and p16.	Molecular cancer	2015	26
25908244	1029	Montes M	The lncRNA MIR31HG regulates p16(INK4A) expression to modulate senescence.	Nature communications	2015	25
26024833	1029	Fu WM	Hotair mediates hepatocarcinogenesis through suppressing miRNA-218 expression and activating P14 and P16 signaling.	Journal of hepatology	2015	24
26099527	1029	Zucman-Rossi J	Genetic Landscape and Biomarkers of Hepatocellular Carcinoma.	Gastroenterology	2015	47
26192918	1029	Stachler MD	Paired exome analysis of Barrett's esophagus and adenocarcinoma.	Nature genetics	2015	30
26536169	1029	Cancer Genome Atlas Research Network.	Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma.	The New England journal of medicine	2016	69
26551670	1029	Wang L	Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes.	Nature genetics	2015	24
26658419	1029	Roberts NJ	Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer.	Cancer discovery	2016	14
26762611	1029	Alemany L	Role of Human Papillomavirus in Penile Carcinomas Worldwide.	European urology	2016	16
26823521	1029	Castellsagué X	HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients.	Journal of the National Cancer Institute	2016	27
26830752	1029	Kamisawa T	Pancreatic cancer.	Lancet	2016	47
26873401	1029	Sawada G	Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population.	Gastroenterology	2016	17
26950362	1029	Helman A	p16(Ink4a)-induced senescence of pancreatic beta cells enhances insulin secretion.	Nature medicine	2016	19
27007578	1029	Mehanna H	PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer.	The New England journal of medicine	2016	15
27114589	1029	Vasen H	Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers.	Journal of clinical oncology 	2016	16
27213815	1029	Dauch D	A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer.	Nature medicine	2016	15
7553870	1050	Martínez-Balbás MA	Displacement of sequence-specific transcription factors from mitotic chromatin.	Cell	1995	138
11242107	1050	Pabst T	Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.	Nature genetics	2001	172
11283671	1050	Pabst T	AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.	Nature medicine	2001	99
14726504	1050	Fröhling S	CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations.	Journal of clinical oncology 	2004	80
14982876	1050	Calabretta B	The biology of CML blast crisis.	Blood	2004	112
15084694	1050	Valk PJ	Prognostically useful gene-expression profiles in acute myeloid leukemia.	The New England journal of medicine	2004	309
15831231	1050	Brat DJ	The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis.	Neuro-oncology	2005	147
15870183	1050	Tallman MS	Drug therapy for acute myeloid leukemia.	Blood	2005	136
16051734	1050	Döhner K	Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.	Blood	2005	140
16076867	1050	Schnittger S	Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.	Blood	2005	106
16109776	1050	Verhaak RG	Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.	Blood	2005	94
16446383	1050	Radomska HS	Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations.	The Journal of experimental medicine	2006	63
16960150	1050	Mrózek K	Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?	Blood	2007	122
17260024	1050	Garzon R	MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia.	Oncogene	2007	107
17925434	1050	Kendall J	Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer.	Proceedings of the National Academy of Sciences of the United States of America	2007	91
18288131	1050	Renneville A	Cooperating gene mutations in acute myeloid leukemia: a review of the literature.	Leukemia	2008	62
18326822	1050	Pinto JP	Erythropoietin mediates hepcidin expression in hepatocytes through EPOR signaling and regulation of C/EBPalpha.	Blood	2008	63
18337557	1050	Jongen-Lavrencic M	MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia.	Blood	2008	128
18450602	1050	Schlenk RF	Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.	The New England journal of medicine	2008	304
18559874	1050	Paschka P	Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.	Journal of clinical oncology 	2008	60
18809607	1050	Marcucci G	Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.	Journal of clinical oncology 	2008	108
18818206	1050	Nasser MW	Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1.	The Journal of biological chemistry	2008	130
18838472	1050	Verhaak RG	Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling.	Haematologica	2009	86
19075268	1050	Koschmieder S	Dysregulation of the C/EBPalpha differentiation pathway in human cancer.	Journal of clinical oncology 	2009	45
20038735	1050	Dufour A	Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.	Journal of clinical oncology 	2010	45
20060365	1050	Figueroa ME	DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia.	Cancer cell	2010	202
20110263	1050	van der Meer DL	Profiling of promoter occupancy by PPARalpha in human hepatoma cells via ChIP-chip analysis.	Nucleic acids research	2010	41
20368538	1050	Wagner K	Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.	Journal of clinical oncology 	2010	55
20889924	1050	Pulikkan JA	C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations.	Blood	2010	45
21038412	1050	Zeng C	A novel GSK-3 beta-C/EBP alpha-miR-122-insulin-like growth factor 1 receptor regulatory circuitry in human hepatocellular carcinoma.	Hepatology	2010	41
21177436	1050	Taskesen E	Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity.	Blood	2011	47
21220605	1050	Burnett A	Therapeutic advances in acute myeloid leukemia.	Journal of clinical oncology 	2011	128
21383193	1050	Jan M	Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker.	Proceedings of the National Academy of Sciences of the United States of America	2011	49
21881046	1050	Shen Y	Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia.	Blood	2011	63
22180162	1050	Estey EH	Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management.	American journal of hematology	2012	36
22417203	1050	Patel JP	Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.	The New England journal of medicine	2012	352
22987078	1050	Mrózek K	Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia.	Journal of clinical oncology 	2012	75
23526416	1050	Estey EH	Acute myeloid leukemia: 2013 update on risk-stratification and management.	American journal of hematology	2013	65
23665916	1050	Grøntved L	C/EBP maintains chromatin accessibility in liver and facilitates glucocorticoid receptor recruitment to steroid response elements.	The EMBO journal	2013	40
23769673	1050	Wang J	TRIB2 acts downstream of Wnt/TCF in liver cancer cells to regulate YAP and C/EBPα function.	Molecular cell	2013	33
24183681	1050	Zhang H	Sox4 is a key oncogenic target in C/EBPα mutant acute myeloid leukemia.	Cancer cell	2013	31
24487413	1050	Kihara R	Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients.	Leukemia	2014	34
25079101	1050	Meyer SC	Translational implications of somatic genomics in acute myeloid leukaemia.	The Lancet. Oncology	2014	21
25303533	1050	Chen JC	Identification of causal genetic drivers of human disease through systems-level analysis of regulatory networks.	Cell	2014	42
25512507	1050	Garzon R	Expression and prognostic impact of lncRNAs in acute myeloid leukemia.	Proceedings of the National Academy of Sciences of the United States of America	2014	35
7740812	1084	Scheele J	Resection of colorectal liver metastases.	World journal of surgery	1995	197
8608500	1084	Nordlinger B	Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie.	Cancer	1996	222
10202129	1084	Hammarström S	The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues.	Seminars in cancer biology	1999	215
11274010	1084	Duffy MJ	Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?	Clinical chemistry	2001	94
12685552	1084	Terada T	Minute mixed ductal-endocrine carcinoma of the pancreas with predominant intraductal growth.	Pathology international	2002	96
15131794	1084	Brugge WR	Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study.	Gastroenterology	2004	170
15613691	1084	Marshall JL	Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.	Journal of clinical oncology 	2005	83
15849507	1084	Pawlik TM	Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases.	Annals of surgery	2005	169
17060676	1084	Locker GY	ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.	Journal of clinical oncology 	2006	270
18362931	1084	Dai S	Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer.	Molecular therapy 	2008	93
18519811	1084	Morse MA	Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines.	Blood	2008	101
18665430	1084	Kaushal S	Fluorophore-conjugated anti-CEA antibody for the intraoperative imaging of pancreatic and colorectal cancer.	Journal of gastrointestinal surgery 	2008	62
18818422	1084	Abd Hamid UM	A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression.	Glycobiology	2008	59
19152896	1084	Khalid A	Pancreatic cyst fluid DNA analysis in evaluating pancreatic cysts: a report of the PANDA study.	Gastrointestinal endoscopy	2009	78
20103634	1084	Galanis E	Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.	Cancer research	2010	98
21189474	1084	Rittig SM	Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients.	Molecular therapy 	2011	36
21325298	1084	Brand RE	Serum biomarker panels for the detection of pancreatic cancer.	Clinical cancer research 	2011	65
21422427	1084	Iinuma H	Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.	Journal of clinical oncology 	2011	78
21606835	1084	Hartwig W	Pancreatic cancer surgery in the new millennium: better prediction of outcome.	Annals of surgery	2011	63
21775920	1084	Cizginer S	Cyst fluid carcinoembryonic antigen is an accurate diagnostic marker of pancreatic mucinous cysts.	Pancreas	2011	42
22986452	1084	Yao Y	Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy.	Cancer immunology, immunotherapy 	2013	43
23307251	1084	He W	Initial neutrophil lymphocyte ratio is superior to platelet lymphocyte ratio as an adverse prognostic and predictive factor in metastatic colorectal cancer.	Medical oncology	2013	40
23315099	1084	Haas M	Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy.	Journal of cancer research and clinical oncology	2013	29
23331006	1084	Poruk KE	The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates.	Current molecular medicine	2013	26
23572188	1084	Shimada H	Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association.	Gastric cancer 	2014	32
23649003	1084	Aparicio AM	Platinum-based chemotherapy for variant castrate-resistant prostate cancer.	Clinical cancer research 	2013	38
23657083	1084	Morse MA	A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer.	Annals of surgery	2013	30
23672279	1084	He CZ	Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer.	BMC gastroenterology	2013	29
24249594	1084	Metildi CA	Fluorescently labeled chimeric anti-CEA antibody improves detection and resection of human colon cancer in a patient-derived orthotopic xenograft (PDOX) nude mouse model.	Journal of surgical oncology	2014	42
24373959	1084	Hiroshima Y	Hand-held high-resolution fluorescence imaging system for fluorescence-guided surgery of patient and cell-line pancreatic tumors growing orthotopically in nude mice.	The Journal of surgical research	2014	33
24430319	1084	Primrose JN	Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial.	JAMA	2014	39
24494971	1084	Hiroshima Y	Successful fluorescence-guided surgery on human colon cancer patient-derived orthotopic xenograft mouse models using a fluorophore-conjugated anti-CEA antibody and a portable imaging system.	Journal of laparoendoscopic and advanced surgical techniques. Part A	2014	37
24709885	1084	Wang J	Identification of a circulating microRNA signature for colorectal cancer detection.	PloS one	2014	35
25087904	1084	Isik A	Importance of metastatic lymph node ratio in non-metastatic, lymph node-invaded colon cancer: a clinical trial.	Medical science monitor 	2014	44
25273947	1084	Liu L	A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer.	International journal of cancer	2015	19
25851626	1084	Tie J	Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer.	Annals of oncology 	2015	38
26861458	1084	Bacac M	A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors.	Clinical cancer research 	2016	13
10859164	1111	Liu Q	Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint.	Genes and development	2000	509
11333986	1111	Bulavin DV	Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase.	Nature	2001	124
11481475	1111	Nghiem P	ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation.	Proceedings of the National Academy of Sciences of the United States of America	2001	102
12676583	1111	Sørensen CS	Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A.	Cancer cell	2003	144
12781359	1111	Bartek J	Chk1 and Chk2 kinases in checkpoint control and cancer.	Cancer cell	2003	347
14608368	1111	d'Adda di Fagagna F	A DNA damage checkpoint response in telomere-initiated senescence.	Nature	2003	634
15159417	1111	Melixetian M	Loss of Geminin induces rereplication in the presence of functional p53.	The Journal of cell biology	2004	101
15189136	1111	Sancar A	Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints.	Annual review of biochemistry	2004	775
15311285	1111	Krämer A	Centrosome-associated Chk1 prevents premature activation of cyclin-B-Cdk1 kinase.	Nature cell biology	2004	96
15665856	1111	Sørensen CS	The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair.	Nature cell biology	2005	209
15831461	1111	Syljuåsen RG	Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage.	Molecular and cellular biology	2005	178
15995699	1111	Gasser S	The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor.	Nature	2005	342
17051156	1111	Bao S	Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.	Nature	2006	1463
17485253	1111	Kaina B	MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents.	DNA repair	2007	131
17515603	1111	Seiler JA	The intra-S-phase checkpoint affects both DNA replication initiation and elongation: single-cell and -DNA fiber analyses.	Molecular and cellular biology	2007	96
17991895	1111	Palii SS	DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B.	Molecular and cellular biology	2008	92
18790776	1111	Zabludoff SD	AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies.	Molecular cancer therapeutics	2008	129
19091954	1111	Wilsker D	Essential function of Chk1 can be uncoupled from DNA damage checkpoint and replication control.	Proceedings of the National Academy of Sciences of the United States of America	2008	53
19716789	1111	Zhang YW	The F box protein Fbx6 regulates Chk1 stability and cellular sensitivity to replication stress.	Molecular cell	2009	61
19808869	1111	Bolderson E	Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair.	Clinical cancer research 	2009	64
20233881	1111	Mitchell JB	In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762.	Clinical cancer research 	2010	46
20371347	1111	Davoli T	Persistent telomere damage induces bypass of mitosis and tetraploidy.	Cell	2010	92
20501833	1111	Morgan MA	Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.	Cancer research	2010	95
20581868	1111	Bartkova J	Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signalling in human gliomas.	Oncogene	2010	53
21087899	1111	Ma CX	Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics.	Trends in molecular medicine	2011	92
21321066	1111	Guzi TJ	Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening.	Molecular cancer therapeutics	2011	51
21458083	1111	Garrett MD	Anticancer therapy with checkpoint inhibitors: what, where and when?	Trends in pharmacological sciences	2011	58
21818590	1111	Croker AK	Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44⁺ human breast cancer cells.	Breast cancer research and treatment	2012	57
21937510	1111	Sørensen CS	Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication.	Nucleic acids research	2012	72
22117197	1111	Bartucci M	Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy.	Cell death and differentiation	2012	34
22446188	1111	Ma CX	Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.	The Journal of clinical investigation	2012	50
22713237	1111	Carrassa L	Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.	Cell cycle	2012	35
22825331	1111	Prevo R	The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy.	Cancer biology and therapy	2012	53
23135916	1111	Russell MR	Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma.	Cancer research	2013	31
23222511	1111	Fokas E	Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation.	Cell death and disease	2012	48
23242585	1111	Ma CX	A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.	Breast cancer research and treatment	2013	27
23593991	1111	Thompson R	The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design.	British journal of clinical pharmacology	2013	31
24140082	1111	McNeely S	CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy.	Pharmacology and therapeutics	2014	37
24448638	1111	Sausville E	Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors.	Cancer chemotherapy and pharmacology	2014	28
25010037	1111	Hall AB	Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970.	Oncotarget	2014	24
25605849	1111	Daud AI	Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.	Journal of clinical oncology 	2015	28
25840419	1111	Liu B	MiR-195 suppresses non-small cell lung cancer by targeting CHEK1.	Oncotarget	2015	16
25931285	1111	Khanna A	DNA damage in cancer therapeutics: a boon or a curse?	Cancer research	2015	17
12874759	1113	Roudier MP	Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone.	Human pathology	2003	88
16253899	1113	Oberg K	Endocrine tumours of the pancreas.	Best practice and research. Clinical gastroenterology	2005	69
16421420	1113	Kulke MH	Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.	Journal of clinical oncology 	2006	80
17505000	1113	Ekeblad S	Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors.	Clinical cancer research 	2007	62
18261235	1113	Immervoll H	Expression of the "stem cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas.	BMC cancer	2008	59
18603570	1113	Pape UF	Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours.	Endocrine-related cancer	2008	53
18703061	1113	Metz DC	Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors.	Gastroenterology	2008	103
19933912	1113	Yao JC	Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.	Journal of clinical oncology 	2010	110
20159983	1113	Sobczak K	Structural diversity of triplet repeat RNAs.	The Journal of biological chemistry	2010	41
20664475	1113	Chen H	The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer.	Pancreas	2010	53
21803805	1113	Cibulskis K	ContEst: estimating cross-contamination of human samples in next-generation sequencing data.	Bioinformatics	2011	46
23845449	1113	Vélayoudom-Céphise FL	Are G3 ENETS neuroendocrine neoplasms heterogeneous?	Endocrine-related cancer	2013	26
25646366	1113	Caplin ME	Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids.	Annals of oncology 	2015	21
16106023	1302	Mukohara T	Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.	Journal of the National Cancer Institute	2005	85
20007781	1302	Brachmann SM	Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells.	Proceedings of the National Academy of Sciences of the United States of America	2009	105
20060649	1302	Bosch A	Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research.	Cancer treatment reviews	2010	55
20802015	1302	Graeser M	A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer.	Clinical cancer research 	2010	55
21701688	1302	Lee ZW	The slow-releasing hydrogen sulfide donor, GYY4137, exhibits novel anti-cancer effects in vitro and in vivo.	PloS one	2011	50
21795476	1302	Kummar S	Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.	Cancer research	2011	75
22307137	1302	Kummar S	A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas.	Clinical cancer research 	2012	52
23259582	1302	Pommier Y	Drugging topoisomerases: lessons and challenges.	ACS chemical biology	2013	119
24270682	1302	Bouwman P	Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?	Clinical cancer research 	2014	40
25512557	1302	Wang J	PTIP associates with Artemis to dictate DNA repair pathway choice.	Genes and development	2014	21
26196320	1302	Kwegyir-Afful AK	Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo.	Oncotarget	2015	23
27056384	1302	Shang C	Silence of long noncoding RNA UCA1 inhibits malignant proliferation and chemotherapy resistance to adriamycin in gastric cancer.	Cancer chemotherapy and pharmacology	2016	15
6407019	1351	Edgell CJ	Permanent cell line expressing human factor VIII-related antigen established by hybridization.	Proceedings of the National Academy of Sciences of the United States of America	1983	311
7977430	1351	Mazzaferri EL	Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.	The American journal of medicine	1994	236
10387937	1351	Socié G	Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry.	The New England journal of medicine	1999	104
12782577	1351	Choe G	Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo.	Cancer research	2003	105
12885809	1351	Le Voyer TE	Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089.	Journal of clinical oncology 	2003	153
15317891	1351	Cristofanilli M	Circulating tumor cells, disease progression, and survival in metastatic breast cancer.	The New England journal of medicine	2004	839
15647578	1351	Shahinian VB	Risk of fracture after androgen deprivation for prostate cancer.	The New England journal of medicine	2005	239
15685166	1351	Nakamura T	Rescue and propagation of fully retargeted oncolytic measles viruses.	Nature biotechnology	2005	91
15814556	1351	Gui J	Penalized Cox regression analysis in the high-dimensional and low-sample size settings, with applications to microarray gene expression data.	Bioinformatics	2005	70
16790697	1351	Winer RL	Condom use and the risk of genital human papillomavirus infection in young women.	The New England journal of medicine	2006	105
17179478	1351	Chlebowski RT	Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study.	Journal of the National Cancer Institute	2006	163
17349844	1351	Shah SA	Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes.	Surgery	2007	66
17522398	1351	Chan AT	Aspirin and the risk of colorectal cancer in relation to the expression of COX-2.	The New England journal of medicine	2007	228
17640394	1351	Howe LR	Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer.	Breast cancer research 	2007	81
17850917	1351	Zhang X	A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model.	Computer methods and programs in biomedicine	2007	58
17928595	1351	Ford I	Long-term follow-up of the West of Scotland Coronary Prevention Study.	The New England journal of medicine	2007	71
18329481	1351	Flores RM	Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.	The Journal of thoracic and cardiovascular surgery	2008	72
18936567	1351	Peyre CG	The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection.	Annals of surgery	2008	62
19012918	1351	Huang WC	Partial nephrectomy versus radical nephrectomy in patients with small renal tumors--is there a difference in mortality and cardiovascular outcomes?	The Journal of urology	2009	108
19033573	1351	Benedetti Panici P	Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.	Journal of the National Cancer Institute	2008	134
19088353	1351	Barone BB	Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis.	JAMA	2008	156
19225398	1351	Steinmetz J	Long-term consequences of postoperative cognitive dysfunction.	Anesthesiology	2009	112
20219352	1351	Zhi F	The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma.	European journal of cancer	2010	56
20798312	1351	Liu H	Atomic structure of human adenovirus by cryo-EM reveals interactions among protein networks.	Science	2010	125
21203579	1351	Gijsen M	HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer.	PLoS biology	2010	44
21468044	1351	Couto E	Mediterranean dietary pattern and cancer risk in the EPIC cohort.	British journal of cancer	2011	38
21523717	1351	Daskivich TJ	Overtreatment of men with low-risk prostate cancer and significant comorbidity.	Cancer	2011	38
22465831	1351	Sadeghi N	Metformin use is associated with better survival of diabetic patients with pancreatic cancer.	Clinical cancer research 	2012	75
22552668	1351	Bozic KJ	Patient-related risk factors for periprosthetic joint infection and postoperative mortality following total hip arthroplasty in Medicare patients.	The Journal of bone and joint surgery. American volume	2012	39
23426947	1351	McIntosh J	Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant.	Blood	2013	48
23446902	1351	Schöttker B	Strong associations of 25-hydroxyvitamin D concentrations with all-cause, cardiovascular, cancer, and respiratory disease mortality in a large cohort study.	The American journal of clinical nutrition	2013	45
23555212	1351	Zhang W	Network-based survival analysis reveals subnetwork signatures for predicting outcomes of ovarian cancer treatment.	PLoS computational biology	2013	33
23897954	1351	Metzger-Filho O	Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX.	Journal of clinical oncology 	2013	40
24062405	1351	Aizer AA	Marital status and survival in patients with cancer.	Journal of clinical oncology 	2013	86
24693890	1351	Corley DA	Adenoma detection rate and risk of colorectal cancer and death.	The New England journal of medicine	2014	107
25663689	1351	Hur K	Identification of a metastasis-specific MicroRNA signature in human colorectal cancer.	Journal of the National Cancer Institute	2015	34
25671255	1351	Carter BD	Smoking and mortality--beyond established causes.	The New England journal of medicine	2015	72
26288820	1351	Hou L	Blood Telomere Length Attrition and Cancer Development in the Normative Aging Study Cohort.	EBioMedicine	2015	20
26527675	1351	Kollman C	The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy.	Blood	2016	14
10581258	1432	Bulavin DV	Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation.	The EMBO journal	1999	137
10880336	1432	Pyne S	Sphingosine 1-phosphate signalling in mammalian cells.	The Biochemical journal	2000	129
10987301	1432	Sodhi A	The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha.	Cancer research	2000	125
11506818	1432	Surh YJ	Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation.	Mutation research	2001	183
12185362	1432	Weijzen S	Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells.	Nature medicine	2002	143
12509443	1432	Frevel MA	p38 Mitogen-activated protein kinase-dependent and -independent signaling of mRNA stability of AU-rich element-containing transcripts.	Molecular and cellular biology	2003	91
14634666	1432	Uhlik MT	Rac-MEKK3-MKK3 scaffolding for p38 MAPK activation during hyperosmotic shock.	Nature cell biology	2003	124
15184882	1432	Xiao D	Diallyl trisulfide-induced apoptosis in human prostate cancer cells involves c-Jun N-terminal kinase and extracellular-signal regulated kinase-mediated phosphorylation of Bcl-2.	Oncogene	2004	73
15279797	1432	Stojic L	Mismatch repair and DNA damage signalling.	DNA repair	2004	105
15629715	1432	Manke IA	MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation.	Molecular cell	2005	122
15667933	1432	Tsuda M	Neuropathic pain and spinal microglia: a big problem from molecules in "small" glia.	Trends in neurosciences	2005	183
15753463	1432	Gutierrez MC	Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.	Journal of clinical oncology 	2005	122
16046538	1432	Carter TA	Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.	Proceedings of the National Academy of Sciences of the United States of America	2005	116
16198162	1432	Kaminska B	MAPK signalling pathways as molecular targets for anti-inflammatory therapy--from molecular mechanisms to therapeutic benefits.	Biochimica et biophysica acta	2005	142
16452201	1432	Zetser A	Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation.	Cancer research	2006	80
16799564	1432	Androutsellis-Theotokis A	Notch signalling regulates stem cell numbers in vitro and in vivo.	Nature	2006	260
16901744	1432	Ilan N	Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis.	The international journal of biochemistry and cell biology	2006	153
17481747	1432	Cuenda A	p38 MAP-kinases pathway regulation, function and role in human diseases.	Biochimica et biophysica acta	2007	249
17656116	1432	Peng G	Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway.	Immunity	2007	95
17906618	1432	Plun-Favreau H	The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1.	Nature cell biology	2007	145
18339885	1432	Lakshman M	Dietary genistein inhibits metastasis of human prostate cancer in mice.	Cancer research	2008	57
18793712	1432	Miller AH	Norman Cousins Lecture. Mechanisms of cytokine-induced behavioral changes: psychoneuroimmunology at the translational interface.	Brain, behavior, and immunity	2009	50
19617536	1432	Markovic DS	Gliomas induce and exploit microglial MT1-MMP expression for tumor expansion.	Proceedings of the National Academy of Sciences of the United States of America	2009	68
19654295	1432	Yodkeeree S	Zerumbone enhances TRAIL-induced apoptosis through the induction of death receptors in human colon cancer cells: Evidence for an essential role of reactive oxygen species.	Cancer research	2009	45
19662154	1432	Samaga R	The logic of EGFR/ErbB signaling: theoretical properties and analysis of high-throughput data.	PLoS computational biology	2009	61
19893488	1432	Webber JL	Coordinated regulation of autophagy by p38alpha MAPK through mAtg9 and p38IP.	The EMBO journal	2010	74
20802523	1432	Wendt MK	Transforming growth factor-β-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression.	Oncogene	2010	75
21306997	1432	Sunaga N	Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.	Molecular cancer therapeutics	2011	54
21931870	1432	Ivanov AV	Hepatitis C virus proteins activate NRF2/ARE pathway by distinct ROS-dependent and independent mechanisms in HUH7 cells.	PloS one	2011	38
22254000	1432	Vauzour D	Polyphenols and human health: prevention of disease and mechanisms of action.	Nutrients	2010	61
22696230	1432	Chung LY	Galectin-1 promotes lung cancer progression and chemoresistance by upregulating p38 MAPK, ERK, and cyclooxygenase-2.	Clinical cancer research 	2012	35
23272696	1432	Wu J	Mechanism and in vitro pharmacology of TAK1 inhibition by (5Z)-7-Oxozeaenol.	ACS chemical biology	2013	26
24185179	1432	Sato A	Pivotal role for ROS activation of p38 MAPK in the control of differentiation and tumor-initiating capacity of glioma-initiating cells.	Stem cell research	2014	21
24465942	1432	Ahn HJ	Targeting cancer cells with reactive oxygen and nitrogen species generated by atmospheric-pressure air plasma.	PloS one	2014	36
25083993	1432	Henson SM	p38 signaling inhibits mTORC1-independent autophagy in senescent human CD8⁺ T cells.	The Journal of clinical investigation	2014	34
25110412	1432	Grossi V	p38α MAPK pathway: a key factor in colorectal cancer therapy and chemoresistance.	World journal of gastroenterology	2014	21
25361077	1432	Corazzari M	Oncogenic BRAF induces chronic ER stress condition resulting in increased basal autophagy and apoptotic resistance of cutaneous melanoma.	Cell death and differentiation	2015	19
25374165	1432	Lei YY	Mitogen-activated protein kinase signal transduction in solid tumors.	Asian Pacific journal of cancer prevention 	2014	20
25595279	1432	Gonzalez-Villasana V	Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer.	Clinical cancer research 	2015	16
26483953	1432	Ichihara M	Beneficial biological effects and the underlying mechanisms of molecular hydrogen - comprehensive review of 321 original articles.	Medical gas research	2015	18
26601950	1432	Purushothaman A	Fibronectin on the Surface of Myeloma Cell-derived Exosomes Mediates Exosome-Cell Interactions.	The Journal of biological chemistry	2016	17
27135739	1432	Fukawa T	Excessive fatty acid oxidation induces muscle atrophy in cancer cachexia.	Nature medicine	2016	15
8006603	1437	Romani N	Proliferating dendritic cell progenitors in human blood.	The Journal of experimental medicine	1994	266
8274730	1437	Tilg H	Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55.	Blood	1994	127
9500607	1437	Nestle FO	Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.	Nature medicine	1998	310
9712065	1437	Luft T	Type I IFNs enhance the terminal differentiation of dendritic cells.	Journal of immunology	1998	123
10389921	1437	Chen Z	Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer.	Clinical cancer research 	1999	112
10866317	1437	Mach N	Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand.	Cancer research	2000	115
12473579	1437	Giaccone G	A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.	Clinical cancer research 	2002	124
15289501	1437	Thomas AM	Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients.	The Journal of experimental medicine	2004	104
15871677	1437	Hughes MS	Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions.	Human gene therapy	2005	77
16204061	1437	Queen MM	Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression.	Cancer research	2005	73
17116643	1437	Parmiani G	Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients.	Annals of oncology 	2007	65
17121894	1437	Hu JC	A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.	Clinical cancer research 	2006	109
17236223	1437	Keefe DM	Updated clinical practice guidelines for the prevention and treatment of mucositis.	Cancer	2007	92
17261184	1437	Chavey C	Oestrogen receptor negative breast cancers exhibit high cytokine content.	Breast cancer research 	2007	80
17284714	1437	Hershman D	Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.	Journal of the National Cancer Institute	2007	70
17492620	1437	Dubsky P	IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL.	European journal of immunology	2007	57
17577033	1437	Filipazzi P	Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.	Journal of clinical oncology 	2007	230
17606721	1437	Small EJ	Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer.	Clinical cancer research 	2007	63
17965776	1437	Thorne SH	Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963.	The Journal of clinical investigation	2007	65
18287062	1437	Hodi FS	Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.	Proceedings of the National Academy of Sciences of the United States of America	2008	171
18316569	1437	Laheru D	Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation.	Clinical cancer research 	2008	95
18495536	1437	Park BH	Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.	The Lancet. Oncology	2008	135
18535155	1437	Banas A	IFATS collection: in vivo therapeutic potential of human adipose tissue mesenchymal stem cells after transplantation into mice with liver injury.	Stem cells	2008	58
18628758	1437	Liu TC	The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma.	Molecular therapy 	2008	62
18646045	1437	Higano CS	Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer.	Cancer	2008	55
19201905	1437	Motohashi S	A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer.	Journal of immunology	2009	54
19228745	1437	Kirkwood JM	Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696.	Clinical cancer research 	2009	48
19308771	1437	Berg M	Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells.	Cytotherapy	2009	72
19609242	1437	Weide B	Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients.	Journal of immunotherapy	2009	45
19636017	1437	McNeel DG	Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer.	Journal of clinical oncology 	2009	74
19805669	1437	Emens LA	Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation.	Journal of clinical oncology 	2009	69
19890632	1437	Gulley JL	Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.	Cancer immunology, immunotherapy 	2010	109
19903780	1437	Slingluff CL Jr	Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial.	Clinical cancer research 	2009	62
19915919	1437	Kaufman HL	Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma.	Annals of surgical oncology	2010	118
20145120	1437	Holland SJ	R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.	Cancer research	2010	111
20179677	1437	Morgan RA	Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.	Molecular therapy 	2010	397
20386463	1437	Correale P	Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy.	Journal of immunotherapy	2010	60
20484030	1437	Cerullo V	Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients.	Cancer research	2010	69
20484626	1437	Emmanouilidou E	Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival.	The Journal of neuroscience 	2010	237
20528232	1437	Kaufman HL	OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma.	Future oncology	2010	56
20664527	1437	Koski A	Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.	Molecular therapy 	2010	69
20879881	1437	Yu AL	Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.	The New England journal of medicine	2010	283
21030562	1437	Rosenblatt J	Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma.	Blood	2011	44
21217520	1437	Lutz E	A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation.	Annals of surgery	2011	94
21315783	1437	Finke J	MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.	International immunopharmacology	2011	64
21630267	1437	Pesonen S	Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors.	International journal of cancer	2012	32
21632504	1437	Schuster SJ	Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.	Journal of clinical oncology 	2011	78
21734236	1437	Solito S	A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells.	Blood	2011	77
21772252	1437	Hwang TH	A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma.	Molecular therapy 	2011	42
21989902	1437	Mittendorf EA	Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.	Cancer	2012	34
23075808	1437	Gleason MK	Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production.	Molecular cancer therapeutics	2012	38
23088985	1437	Burke JM	A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer.	The Journal of urology	2012	38
23393196	1437	Breitbach CJ	Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans.	Cancer research	2013	40
23493351	1437	Kanerva A	Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus.	Clinical cancer research 	2013	42
23677592	1437	Kim MK	Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans.	Science translational medicine	2013	36
23924790	1437	Le DT	Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer.	Journal of immunotherapy	2013	92
24020520	1437	Bartlett DL	Oncolytic viruses as therapeutic cancer vaccines.	Molecular cancer	2013	66
24458546	1437	Helm O	Tumor-associated macrophages exhibit pro- and anti-inflammatory properties by which they impact on pancreatic tumorigenesis.	International journal of cancer	2014	25
24520093	1437	Rapoport AP	Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells.	Clinical cancer research 	2014	27
24816404	1437	Wu P	γδT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer.	Immunity	2014	60
24823638	1437	Su S	A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis.	Cancer cell	2014	85
24907636	1437	Mittendorf EA	Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients.	Annals of oncology 	2014	28
24942756	1437	Lutz ER	Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation.	Cancer immunology research	2014	63
24954781	1437	Middleton G	Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.	The Lancet. Oncology	2014	45
25369488	1437	Hodi FS	Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.	JAMA	2014	51
25714011	1437	Hemminki O	Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy.	Oncotarget	2015	21
26014293	1437	Andtbacka RH	Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.	Journal of clinical oncology 	2015	197
26095785	1437	Golden EB	Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial.	The Lancet. Oncology	2015	50
26554728	1437	De Mattos-Arruda L	Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma.	Nature communications	2015	20
26719429	1437	Kohlhapp FJ	Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy.	Clinical cancer research 	2016	11
27374224	1437	Singhal S	Origin and Role of a Subset of Tumor-Associated Neutrophils with Antigen-Presenting Cell Features in Early-Stage Human Lung Cancer.	Cancer cell	2016	13
10477735	1440	Holyoake T	Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia.	Blood	1999	100
11172139	1440	Bensinger WI	Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers.	The New England journal of medicine	2001	99
11756187	1440	Graham SM	Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.	Blood	2002	262
12791654	1440	Maris MB	HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies.	Blood	2003	79
15753458	1440	Aversa F	Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse.	Journal of clinical oncology 	2005	119
15824174	1440	Gorelik E	Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer.	Cancer epidemiology, biomarkers and prevention 	2005	82
16497969	1440	Rosenberg PS	The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy.	Blood	2006	72
16682719	1440	Smith TJ	2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.	Journal of clinical oncology 	2006	254
16750358	1440	Aapro MS	EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.	European journal of cancer	2006	72
17227995	1440	Lewis IJ	Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup.	Journal of the National Cancer Institute	2007	57
17330101	1440	Jiang X	Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies.	Leukemia	2007	80
17655751	1440	Cohen PR	Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis.	Orphanet journal of rare diseases	2007	76
17942672	1440	Ebos JM	Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy.	Proceedings of the National Academy of Sciences of the United States of America	2007	112
18426988	1440	Devine SM	Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction.	Blood	2008	72
18728788	1440	Levina V	Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties.	PloS one	2008	127
19161986	1440	De Clercq E	The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil).	Biochemical pharmacology	2009	55
19363221	1440	DiPersio JF	Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.	Blood	2009	104
19720922	1440	DiPersio JF	Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.	Journal of clinical oncology 	2009	97
20160717	1440	Saito Y	Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML.	Nature biotechnology	2010	85
20599449	1440	Essers MA	Targeting leukemic stem cells by breaking their dormancy.	Molecular oncology	2010	46
21095116	1440	Aapro MS	2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.	European journal of cancer	2011	120
21121833	1440	Martín M	Adjuvant docetaxel for high-risk, node-negative breast cancer.	The New England journal of medicine	2010	42
21172891	1440	Burnett AK	Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.	Journal of clinical oncology 	2011	103
21430413	1440	Adcock IM	Chronic obstructive pulmonary disease and lung cancer: new molecular insights.	Respiration; international review of thoracic diseases	2011	48
21480223	1440	Eruslanov E	Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer.	International journal of cancer	2012	32
21491378	1440	Worthington HV	Interventions for preventing oral mucositis for patients with cancer receiving treatment.	The Cochrane database of systematic reviews	2011	37
21636707	1440	Raychaudhuri B	Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma.	Neuro-oncology	2011	85
21886173	1440	Rettig MP	Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4.	Leukemia	2012	46
21907922	1440	Granot Z	Tumor entrained neutrophils inhibit seeding in the premetastatic lung.	Cancer cell	2011	105
22516264	1440	Zhang B	Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia.	Cancer cell	2012	76
22828446	1440	Mougiakakos D	Immunosuppressive CD14+HLA-DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation.	Leukemia	2013	27
23165479	1440	Di Bartolomeo P	Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies.	Blood	2013	33
23615461	1440	Cunningham D	Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.	Lancet	2013	30
24469032	1440	Hansen MT	A link between inflammation and metastasis: serum amyloid A1 and A3 induce metastasis, and are targets of metastasis-inducing S100A4.	Oncogene	2015	19
25131807	1440	Bendall LJ	G-CSF: From granulopoietic stimulant to bone marrow stem cell mobilizing agent.	Cytokine and growth factor reviews	2014	32
11390437	1493	Dieckmann D	Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood.	The Journal of experimental medicine	2001	209
11895781	1493	Steinbrink K	CD4(+) and CD8(+) anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity.	Blood	2002	81
11970966	1493	Woo EY	Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation.	Journal of immunology	2002	140
12193750	1493	Liyanage UK	Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma.	Journal of immunology	2002	314
12576425	1493	Wolf AM	Increase of regulatory T cells in the peripheral blood of cancer patients.	Clinical cancer research 	2003	159
12826605	1493	Phan GQ	Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.	Proceedings of the National Academy of Sciences of the United States of America	2003	320
14604957	1493	Marshall NA	Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma.	Blood	2004	90
15613700	1493	Sanderson K	Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma.	Journal of clinical oncology 	2005	85
15785759	1493	von Boehmer H	Mechanisms of suppression by suppressor T cells.	Nature immunology	2005	230
15914560	1493	Beyer M	Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine.	Blood	2005	103
15932517	1493	Gregg R	The number of human peripheral blood CD4+ CD25high regulatory T cells increases with age.	Clinical and experimental immunology	2005	84
16087944	1493	Attia P	Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.	Journal of clinical oncology 	2005	192
16204013	1493	Ribas A	Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.	Journal of clinical oncology 	2005	101
16224277	1493	Blansfield JA	Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer.	Journal of immunotherapy	2005	71
16283570	1493	Maker AV	Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.	Annals of surgical oncology	2005	106
16301685	1493	Maker AV	Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade.	Journal of immunology	2005	75
16328385	1493	Kono K	CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers.	Cancer immunology, immunotherapy 	2006	63
16464564	1493	Peggs KS	Principles and use of anti-CTLA4 antibody in human cancer immunotherapy.	Current opinion in immunology	2006	97
16505437	1493	Cesana GC	Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma.	Journal of clinical oncology 	2006	66
16710025	1493	Beck KE	Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.	Journal of clinical oncology 	2006	116
16723631	1493	El Andaloussi A	An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme.	Neuro-oncology	2006	75
17293384	1493	Czerniecki BJ	Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion.	Cancer research	2007	79
17363537	1493	Small EJ	A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer.	Clinical cancer research 	2007	102
17606437	1493	Prevosto C	Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction.	Haematologica	2007	83
17673617	1493	Weber J	Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.	The oncologist	2007	65
17982122	1493	Downey SG	Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.	Clinical cancer research 	2007	99
18000991	1493	O'Day SJ	Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies.	Cancer	2007	57
18519750	1493	Sfanos KS	Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing.	Clinical cancer research 	2008	119
18523152	1493	Kavanagh B	CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion.	Blood	2008	59
18818309	1493	Liakou CI	CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients.	Proceedings of the National Academy of Sciences of the United States of America	2008	103
18974373	1493	Bashey A	CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation.	Blood	2009	59
19009291	1493	Galustian C	The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells.	Cancer immunology, immunotherapy 	2009	78
19074257	1493	Yuan J	CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit.	Proceedings of the National Academy of Sciences of the United States of America	2008	111
19139427	1493	Camacho LH	Phase I/II trial of tremelimumab in patients with metastatic melanoma.	Journal of clinical oncology 	2009	67
19147575	1493	Fong L	Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.	Cancer research	2009	83
19198837	1493	Weber J	Ipilimumab: controversies in its development, utility and autoimmune adverse events.	Cancer immunology, immunotherapy 	2009	59
19202079	1493	Chen H	Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues.	Proceedings of the National Academy of Sciences of the United States of America	2009	48
19338264	1493	Oble DA	Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma.	Cancer immunity	2009	53
19789309	1493	Ribas A	Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma.	Clinical cancer research 	2009	53
19808874	1493	Ansell SM	Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.	Clinical cancer research 	2009	59
20038811	1493	Derré L	BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination.	The Journal of clinical investigation	2010	67
20220088	1493	Allen CE	Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells.	Journal of immunology	2010	43
20460488	1493	Carthon BC	Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.	Clinical cancer research 	2010	91
20479064	1493	Vonderheide RH	Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells.	Clinical cancer research 	2010	46
20498386	1493	Chung KY	Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer.	Journal of clinical oncology 	2010	45
21074063	1493	Callahan MK	Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy.	Seminars in oncology	2010	59
21074065	1493	Di Giacomo AM	The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications.	Seminars in oncology	2010	52
21074069	1493	Hoos A	Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.	Seminars in oncology	2010	60
21900389	1493	Lipson EJ	Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma.	Clinical cancer research 	2011	79
21933959	1493	Yuan J	Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab.	Proceedings of the National Academy of Sciences of the United States of America	2011	90
22071969	1493	Dias JD	Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4.	Gene therapy	2012	34
22146893	1493	Ji RR	An immune-active tumor microenvironment favors clinical response to ipilimumab.	Cancer immunology, immunotherapy 	2012	127
22193102	1493	Mellman I	Cancer immunotherapy comes of age.	Nature	2011	489
22271879	1493	Prieto PA	CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma.	Clinical cancer research 	2012	140
22326924	1493	Madan RA	Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.	The Lancet. Oncology	2012	92
22397654	1493	Postow MA	Immunologic correlates of the abscopal effect in a patient with melanoma.	The New England journal of medicine	2012	313
22554099	1493	Ascierto PA	The role of BRAF V600 mutation in melanoma.	Journal of translational medicine	2012	56
22585562	1493	Schuler PJ	Phenotypic and functional characteristics of CD4+ CD39+ FOXP3+ and CD4+ CD39+ FOXP3neg T-cell subsets in cancer patients.	European journal of immunology	2012	33
22858559	1493	Reck M	Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial.	Annals of oncology 	2013	84
22878899	1493	Santegoets SJ	T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment.	Cancer immunology, immunotherapy 	2013	29
22981501	1493	Garbe C	Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline--Update 2012.	European journal of cancer	2012	35
23028051	1493	Corrales L	Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression.	Journal of immunology	2012	36
23160205	1493	Pardoll DM	Immunology beats cancer: a blueprint for successful translation.	Nature immunology	2012	36
23341990	1493	Voskens CJ	The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network.	PloS one	2013	45
23356291	1493	Whiteside TL	Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes).	Biochemical Society transactions	2013	55
23452415	1493	Ascierto PA	The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment.	Journal of translational medicine	2013	33
23460531	1493	Melero I	Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination.	Clinical cancer research 	2013	46
23460532	1493	Ascierto PA	Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types.	Clinical cancer research 	2013	44
23460535	1493	Melero I	Agonist antibodies to TNFR molecules that costimulate T and NK cells.	Clinical cancer research 	2013	35
23466307	1493	Sangro B	A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.	Journal of hepatology	2013	80
23535954	1493	Slovin SF	Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.	Annals of oncology 	2013	102
23580578	1493	Aerts JG	Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer.	Cancer research	2013	27
23667165	1493	Callahan MK	At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.	Journal of leukocyte biology	2013	75
23690483	1493	Besser MJ	Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies.	Clinical cancer research 	2013	42
23724867	1493	Wolchok JD	Nivolumab plus ipilimumab in advanced melanoma.	The New England journal of medicine	2013	793
23772560	1493	Wolchok JD	Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.	Annals of the New York Academy of Sciences	2013	55
23913718	1493	Luke JJ	Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.	Cancer	2013	33
23960017	1493	Han Y	Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma.	Hepatology	2014	26
24035405	1493	Calabrò L	Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.	The Lancet. Oncology	2013	42
24045166	1493	Kmiecik J	Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level.	Journal of neuroimmunology	2013	32
24054424	1493	Eggermont AM	Cutaneous melanoma.	Lancet	2014	64
24089443	1493	Ott PA	CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.	Clinical cancer research 	2013	106
24161671	1493	Kyi C	Checkpoint blocking antibodies in cancer immunotherapy.	FEBS letters	2014	52
24169351	1493	Jie HB	Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients.	British journal of cancer	2013	46
24277834	1493	Feig C	Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.	Proceedings of the National Academy of Sciences of the United States of America	2013	124
24357148	1493	Meyer C	Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab.	Cancer immunology, immunotherapy 	2014	54
24388175	1493	Rong Z	An effective approach to prevent immune rejection of human ESC-derived allografts.	Cell stem cell	2014	25
24445516	1493	Gangadhar TC	Mitigating the toxic effects of anticancer immunotherapy.	Nature reviews. Clinical oncology	2014	32
24485523	1493	Perez-Gracia JL	Orchestrating immune check-point blockade for cancer immunotherapy in combinations.	Current opinion in immunology	2014	27
24514956	1493	Jochems C	A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates.	Cancer immunology, immunotherapy 	2014	23
24563870	1493	Golden EB	An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer.	Cancer immunology research	2013	85
24583799	1493	Robert L	CTLA4 blockade broadens the peripheral T-cell receptor repertoire.	Clinical cancer research 	2014	44
24610577	1493	Ryder M	Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution.	Endocrine-related cancer	2014	30
24777852	1493	Ng Tang D	Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy.	Cancer immunology research	2013	33
24795351	1493	Anderson AC	Tim-3: an emerging target in the cancer immunotherapy landscape.	Cancer immunology research	2014	30
24860567	1493	Corthay A	Does the immune system naturally protect against cancer?	Frontiers in immunology	2014	29
24871131	1493	Cha E	Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients.	Science translational medicine	2014	57
25211661	1493	Naidoo J	Immune modulation for cancer therapy.	British journal of cancer	2014	33
25213377	1493	Kuehn HS	Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4.	Science	2014	83
25232180	1493	Kvistborg P	Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.	Science translational medicine	2014	57
25323844	1493	Philips GK	Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.	International immunology	2015	46
25409260	1493	Snyder A	Genetic basis for clinical response to CTLA-4 blockade in melanoma.	The New England journal of medicine	2014	455
25415283	1493	Soares KC	PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors.	Journal of immunotherapy	2015	49
25428504	1493	Herbst RS	Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.	Nature	2014	530
25524312	1493	Gibney GT	Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma.	Clinical cancer research 	2015	25
25583297	1493	Zamarin D	Immune checkpoint modulation: rational design of combination strategies.	Pharmacology and therapeutics	2015	24
25589619	1493	Liu L	The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4.	Clinical cancer research 	2015	31
25621841	1493	Shin DS	The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?	Current opinion in immunology	2015	63
25672397	1493	Beavis PA	Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses.	Cancer immunology research	2015	16
25682878	1493	Luke JJ	PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma.	Oncotarget	2015	22
25733707	1493	Anagnostou VK	Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer.	Clinical cancer research 	2015	32
25795410	1493	Weber JS	Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.	The Lancet. Oncology	2015	227
25823918	1493	Mahoney KM	The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.	Clinical therapeutics	2015	55
25824720	1493	Carosella ED	A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.	European urology	2015	24
25918390	1493	Romano E	Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients.	Proceedings of the National Academy of Sciences of the United States of America	2015	38
25965355	1493	Baksh K	Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinations.	Seminars in oncology	2015	17
25979932	1493	Soria JC	Immune checkpoint modulation for non-small cell lung cancer.	Clinical cancer research 	2015	16
25993145	1493	Postow MA	Managing immune checkpoint-blocking antibody side effects.	American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting	2015	32
26027431	1493	Larkin J	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.	The New England journal of medicine	2015	521
26171394	1493	Niezgoda A	Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy.	BioMed research international	2015	24
26205340	1493	Melero I	Evolving synergistic combinations of targeted immunotherapies to combat cancer.	Nature reviews. Cancer	2015	69
26258847	1493	Ungewickell A	Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2.	Nature genetics	2015	27
26323609	1493	Nduom EK	PD-L1 expression and prognostic impact in glioblastoma.	Neuro-oncology	2016	30
26325034	1493	Buchbinder E	Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade.	The Journal of clinical investigation	2015	20
26337719	1493	Bertrand A	Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis.	BMC medicine	2015	25
26359337	1493	Van Allen EM	Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.	Science	2015	151
26420858	1493	Mak MP	A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.	Clinical cancer research 	2016	24
26451318	1493	Chandra RA	A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab.	Oncoimmunology	2015	17
26558876	1493	Buchbinder EI	CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition.	American journal of clinical oncology	2016	32
26707829	1493	Ugurel S	Survival of patients with advanced metastatic melanoma: The impact of novel therapies.	European journal of cancer	2016	11
26715621	1493	Champiat S	Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper.	Annals of oncology 	2016	19
26765102	1493	Michot JM	Immune-related adverse events with immune checkpoint blockade: a comprehensive review.	European journal of cancer	2016	41
26837003	1493	Dubin K	Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis.	Nature communications	2016	12
26850630	1493	Redman JM	Advances in immunotherapy for melanoma.	BMC medicine	2016	11
26858122	1493	Antonia S	Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.	The Lancet. Oncology	2016	41
26940869	1493	McGranahan N	Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.	Science	2016	126
26972336	1493	Webb JR	PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.	Gynecologic oncology	2016	17
27084739	1493	Zarour HM	Reversing T-cell Dysfunction and Exhaustion in Cancer.	Clinical cancer research 	2016	15
27141885	1493	Boutros C	Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.	Nature reviews. Clinical oncology	2016	15
27192569	1493	Attanasio J	Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease.	Immunity	2016	11
27216414	1493	Hughes PE	Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer.	Trends in immunology	2016	14
27256570	1493	Vilgelm AE	Combinatorial approach to cancer immunotherapy: strength in numbers.	Journal of leukocyte biology	2016	11
27332730	1493	Pitt JM	Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors.	Immunity	2016	18
27410923	1493	Davids MS	Ipilimumab for Patients with Relapse after Allogeneic Transplantation.	The New England journal of medicine	2016	23
27622997	1493	Hodi FS	Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.	The Lancet. Oncology	2016	31
27828943	1493	De Henau O	Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.	Nature	2016	12
27951441	1493	O'Donnell JS	Resistance to PD1/PDL1 checkpoint inhibition.	Cancer treatment reviews	2017	6
28052254	1493	Charoentong P	Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade.	Cell reports	2017	8
28102259	1493	Chen DS	Elements of cancer immunity and the cancer-immune set point.	Nature	2017	15
9294210	1499	Ilyas M	Beta-catenin mutations in cell lines established from human colorectal cancers.	Proceedings of the National Academy of Sciences of the United States of America	1997	118
9601641	1499	Hart MJ	Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta.	Current biology 	1998	201
9990071	1499	Mann B	Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas.	Proceedings of the National Academy of Sciences of the United States of America	1999	180
10023660	1499	Latres E	The human F box protein beta-Trcp associates with the Cul1/Skp1 complex and regulates the stability of beta-catenin.	Oncogene	1999	124
10092233	1499	Seeling JM	Regulation of beta-catenin signaling by the B56 subunit of protein phosphatase 2A.	Science	1999	108
10192393	1499	Chan EF	A common human skin tumour is caused by activating mutations in beta-catenin.	Nature genetics	1999	126
10514384	1499	Brabletz T	beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer.	The American journal of pathology	1999	138
10630639	1499	Miller JR	Mechanism and function of signal transduction by the Wnt/beta-catenin and Wnt/Ca2+ pathways.	Oncogene	1999	124
10759547	1499	Lin SY	Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression.	Proceedings of the National Academy of Sciences of the United States of America	2000	203
10987273	1499	Truica CI	Beta-catenin affects androgen receptor transcriptional activity and ligand specificity.	Cancer research	2000	102
11381089	1499	Gottardi CJ	E-cadherin suppresses cellular transformation by inhibiting beta-catenin signaling in an adhesion-independent manner.	The Journal of cell biology	2001	150
11433302	1499	Bafico A	Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow.	Nature cell biology	2001	175
11532957	1499	Barker N	The chromatin remodelling factor Brg-1 interacts with beta-catenin to promote target gene activation.	The EMBO journal	2001	113
11533658	1499	Ryo A	Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC.	Nature cell biology	2001	131
11752446	1499	Yan D	Elevated expression of axin2 and hnkd mRNA provides evidence that Wnt/beta -catenin signaling is activated in human colon tumors.	Proceedings of the National Academy of Sciences of the United States of America	2001	116
11895924	1499	Joe AK	Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines.	Clinical cancer research 	2002	84
11940574	1499	Leung JY	Activation of AXIN2 expression by beta-catenin-T cell factor. A feedback repressor pathway regulating Wnt signaling.	The Journal of biological chemistry	2002	119
12045208	1499	Albuquerque C	The 'just-right' signaling model: APC somatic mutations are selected based on a specific level of activation of the beta-catenin signaling cascade.	Human molecular genetics	2002	98
12086864	1499	Weeraratna AT	Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma.	Cancer cell	2002	231
12398896	1499	Deng J	beta-catenin interacts with and inhibits NF-kappa B in human colon and breast cancer.	Cancer cell	2002	91
12592400	1499	Fujimuro M	A novel viral mechanism for dysregulation of beta-catenin in Kaposi's sarcoma-associated herpesvirus latency.	Nature medicine	2003	126
12750294	1499	Gilles C	Transactivation of vimentin by beta-catenin in human breast cancer cells.	Cancer research	2003	84
12820959	1499	Wu G	Structure of a beta-TrCP1-Skp1-beta-catenin complex: destruction motif binding and lysine specificity of the SCF(beta-TrCP1) ubiquitin ligase.	Molecular cell	2003	214
12841864	1499	Hirohashi S	Cell adhesion system and human cancer morphogenesis.	Cancer science	2003	82
14562050	1499	Uematsu K	Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression.	Oncogene	2003	80
14623871	1499	Conacci-Sorrell M	Autoregulation of E-cadherin expression by cadherin-cadherin interactions: the roles of beta-catenin signaling, Slug, and MAPK.	The Journal of cell biology	2003	120
14706341	1499	Lu Z	Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion.	Cancer cell	2003	169
14739782	1499	Howe LR	Wnt signaling and breast cancer.	Cancer biology and therapy	2004	90
15072585	1499	Sugimura T	Heterocyclic amines: Mutagens/carcinogens produced during cooking of meat and fish.	Cancer science	2004	109
15208662	1499	You L	Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells.	Oncogene	2004	73
15300008	1499	Brennan KR	Wnt proteins in mammary development and cancer.	Journal of mammary gland biology and neoplasia	2004	79
15316903	1499	Chen G	Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications.	Cancer	2004	73
15480989	1499	Merle P	Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma.	Gastroenterology	2004	72
15542433	1499	Bafico A	An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells.	Cancer cell	2004	119
15592430	1499	Chamorro MN	FGF-20 and DKK1 are transcriptional targets of beta-catenin and FGF-20 is implicated in cancer and development.	The EMBO journal	2005	85
15690474	1499	Sirica AE	Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy.	Hepatology	2005	97
15761464	1499	Bell DA	Origins and molecular pathology of ovarian cancer.	Modern pathology 	2005	100
15778706	1499	van Es JH	Wnt signalling induces maturation of Paneth cells in intestinal crypts.	Nature cell biology	2005	174
15925592	1499	Pinto D	Wnt control of stem cells and differentiation in the intestinal epithelium.	Experimental cell research	2005	79
15973414	1499	Batlle E	EphB receptor activity suppresses colorectal cancer progression.	Nature	2005	110
16023783	1499	Verras M	Roles and regulation of Wnt signaling and beta-catenin in prostate cancer.	Cancer letters	2006	72
16039586	1499	Ding Q	Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin.	Molecular cell	2005	175
16230409	1499	Thomson S	Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition.	Cancer research	2005	193
16239965	1499	Balint K	Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression.	The Journal of clinical investigation	2005	94
16258095	1499	Ellison DW	beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee.	Journal of clinical oncology 	2005	68
16288032	1499	Huang L	MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin.	Cancer research	2005	99
16357527	1499	Kim KA	R-Spondin proteins: a novel link to beta-catenin activation.	Cell cycle	2006	72
16377174	1499	Brembeck FH	Balancing cell adhesion and Wnt signaling, the key role of beta-catenin.	Current opinion in genetics and development	2006	184
16449977	1499	Patrawala L	Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells.	Oncogene	2006	284
16477019	1499	Radich JP	Gene expression changes associated with progression and response in chronic myeloid leukemia.	Proceedings of the National Academy of Sciences of the United States of America	2006	129
16630820	1499	Mosimann C	Parafibromin/Hyrax activates Wnt/Wg target gene transcription by direct association with beta-catenin/Armadillo.	Cell	2006	94
16713950	1499	Städeli R	Transcription under the control of nuclear Arm/beta-catenin.	Current biology 	2006	68
16756720	1499	Zeng G	Aberrant Wnt/beta-catenin signaling in pancreatic adenocarcinoma.	Neoplasia	2006	75
16799620	1499	Breuhahn K	Dysregulation of growth factor signaling in human hepatocellular carcinoma.	Oncogene	2006	99
16799625	1499	Levrero M	Viral hepatitis and liver cancer: the case of hepatitis C.	Oncogene	2006	107
16857785	1499	Yang AD	Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines.	Clinical cancer research 	2006	132
16964294	1499	Zucman-Rossi J	Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas.	Oncogene	2007	59
17079465	1499	Kurayoshi M	Expression of Wnt-5a is correlated with aggressiveness of gastric cancer by stimulating cell migration and invasion.	Cancer research	2006	122
17145894	1499	Wang Y	Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice.	Cancer research	2006	66
17187432	1499	Boyault S	Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets.	Hepatology	2007	191
17208432	1499	Polakis P	The many ways of Wnt in cancer.	Current opinion in genetics and development	2007	269
17287208	1499	Fang D	Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity.	The Journal of biological chemistry	2007	220
17295177	1499	Villanueva A	Genomics and signaling pathways in hepatocellular carcinoma.	Seminars in liver disease	2007	150
17371942	1499	Giuliani N	The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients.	Blood	2007	56
17452641	1499	Sukhdeo K	Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma.	Proceedings of the National Academy of Sciences of the United States of America	2007	60
17464972	1499	Thompson MD	WNT/beta-catenin signaling in liver health and disease.	Hepatology	2007	126
17638895	1499	Vignjevic D	Fascin, a novel target of beta-catenin-TCF signaling, is expressed at the invasive front of human colon cancer.	Cancer research	2007	73
17785413	1499	Tward AD	Distinct pathways of genomic progression to benign and malignant tumors of the liver.	Proceedings of the National Academy of Sciences of the United States of America	2007	64
17854061	1499	Gavert N	beta-Catenin signaling in biological control and cancer.	Journal of cellular biochemistry	2007	59
17909916	1499	Shah AN	Development and characterization of gemcitabine-resistant pancreatic tumor cells.	Annals of surgical oncology	2007	149
17979879	1499	Mimeault M	Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers.	Journal of cellular and molecular medicine	2007	59
18006828	1499	Yamashita T	Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma.	Cancer research	2007	113
18339531	1499	Huang H	Wnt/beta-catenin signaling: new (and old) players and new insights.	Current opinion in cell biology	2008	149
18339862	1499	Li H	PC3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells.	Cancer research	2008	76
18364678	1499	Qiao L	Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model.	Cell research	2008	76
18381440	1499	Sawada K	Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target.	Cancer research	2008	104
18385740	1499	Malanchi I	Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling.	Nature	2008	169
18455124	1499	Petrova TV	Transcription factor PROX1 induces colon cancer progression by promoting the transition from benign to highly dysplastic phenotype.	Cancer cell	2008	55
18519688	1499	Yang W	Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells.	Cancer research	2008	101
18555664	1499	Jin T	Wnt and beyond Wnt: multiple mechanisms control the transcriptional property of beta-catenin.	Cellular signalling	2008	72
18577996	1499	Bengochea A	Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma.	British journal of cancer	2008	53
18667462	1499	Sumi T	Defining early lineage specification of human embryonic stem cells by the orchestrated balance of canonical Wnt/beta-catenin, Activin/Nodal and BMP signaling.	Development	2008	94
18679417	1499	Chang YM	Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530.	Oncogene	2008	55
18718806	1499	Sabbah M	Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers.	Drug resistance updates 	2008	98
18769486	1499	Kool M	Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features.	PloS one	2008	203
18791199	1499	Cannito S	Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells.	Carcinogenesis	2008	87
18805044	1499	Molinolo AA	Dysregulated molecular networks in head and neck carcinogenesis.	Oral oncology	2009	98
18832571	1499	Lazar AJ	Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors.	The American journal of pathology	2008	55
18949017	1499	Pu P	Downregulation of Wnt2 and beta-catenin by siRNA suppresses malignant glioma cell growth.	Cancer gene therapy	2009	58
18987168	1499	Smallridge RC	Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.	Endocrine-related cancer	2009	84
19001663	1499	Major MB	New regulators of Wnt/beta-catenin signaling revealed by integrative molecular screening.	Science signaling	2008	55
19037088	1499	Suh Y	A plant flavonoid fisetin induces apoptosis in colon cancer cells by inhibition of COX2 and Wnt/EGFR/NF-kappaB-signaling pathways.	Carcinogenesis	2009	48
19047049	1499	Bourguignon LY	Hyaluronan-mediated CD44 interaction with p300 and SIRT1 regulates beta-catenin signaling and NFkappaB-specific transcription activity leading to MDR1 and Bcl-xL gene expression and chemoresistance in breast tumor cells.	The Journal of biological chemistry	2009	47
19060929	1499	Dar AA	The aurora kinase A regulates GSK-3beta in gastric cancer cells.	Oncogene	2009	45
19061838	1499	Cairo S	Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer.	Cancer cell	2008	56
19078924	1499	Bansal N	The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies.	Cancer control 	2009	64
19144919	1499	Chien AJ	Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model.	Proceedings of the National Academy of Sciences of the United States of America	2009	106
19197950	1499	Fattet S	Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics.	The Journal of pathology	2009	50
19252499	1499	Zhang Y	Inhibition of Wnt signaling by Dishevelled PDZ peptides.	Nature chemical biology	2009	48
19365403	1499	Bisson I	WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics.	Cell research	2009	89
19492080	1499	Korkaya H	Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling.	PLoS biology	2009	184
19493674	1499	Spencer L	The effect of omega-3 FAs on tumour angiogenesis and their therapeutic potential.	European journal of cancer	2009	47
19585623	1499	Bioulac-Sage P	Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience.	Hepatology	2009	54
19603030	1499	McDonald SL	The opposing roles of Wnt-5a in cancer.	British journal of cancer	2009	81
19619488	1499	MacDonald BT	Wnt/beta-catenin signaling: components, mechanisms, and diseases.	Developmental cell	2009	1104
19633433	1499	Ying Y	Epigenetic disruption of the WNT/beta-catenin signaling pathway in human cancers.	Epigenetics	2009	55
19666525	1499	Chan KS	Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells.	Proceedings of the National Academy of Sciences of the United States of America	2009	149
19703993	1499	Saydam O	Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway.	Molecular and cellular biology	2009	83
19723656	1499	Hoshida Y	Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma.	Cancer research	2009	176
19797115	1499	Dennler S	Cloning of the human GLI2 Promoter: transcriptional activation by transforming growth factor-beta via SMAD3/beta-catenin cooperation.	The Journal of biological chemistry	2009	48
19798449	1499	Ooi CH	Oncogenic pathway combinations predict clinical prognosis in gastric cancer.	PLoS genetics	2009	66
19852728	1499	van Zijl F	Epithelial-mesenchymal transition in hepatocellular carcinoma.	Future oncology	2009	78
19882675	1499	Cai Y	Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma.	The Journal of pathology	2010	42
19915524	1499	Liu LK	Upregulation of vimentin and aberrant expression of E-cadherin/beta-catenin complex in oral squamous cell carcinomas: correlation with the clinicopathological features and patient outcome.	Modern pathology 	2010	47
20018914	1499	Ghosh AK	Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression.	Blood	2010	61
20227366	1499	Tauriello DV	Loss of the tumor suppressor CYLD enhances Wnt/beta-catenin signaling through K63-linked ubiquitination of Dvl.	Molecular cell	2010	46
20227497	1499	Haussler MR	The nuclear vitamin D receptor controls the expression of genes encoding factors which feed the "Fountain of Youth" to mediate healthful aging.	The Journal of steroid biochemistry and molecular biology	2010	47
20348907	1499	Zhang L	Chemoprevention of colorectal cancer by targeting APC-deficient cells for apoptosis.	Nature	2010	41
20395444	1499	Khramtsov AI	Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome.	The American journal of pathology	2010	108
20460455	1499	Bottomly D	Identification of {beta}-catenin binding regions in colon cancer cells using ChIP-Seq.	Nucleic acids research	2010	67
20603725	1499	Lucero OM	A re-evaluation of the "oncogenic" nature of Wnt/beta-catenin signaling in melanoma and other cancers.	Current oncology reports	2010	44
20610629	1499	Gu Y	GlcNAcylation plays an essential role in breast cancer metastasis.	Cancer research	2010	44
20691072	1499	Kanwar SS	The Wnt/beta-catenin pathway regulates growth and maintenance of colonospheres.	Molecular cancer	2010	86
20716670	1499	Mimeault M	Frequent deregulations in the hedgehog signaling network and cross-talks with the epidermal growth factor receptor pathway involved in cancer progression and targeted therapies.	Pharmacological reviews	2010	42
20921458	1499	Ellison DW	Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables.	Journal of clinical oncology 	2011	63
20978119	1499	He BC	Tetrandrine inhibits Wnt/β-catenin signaling and suppresses tumor growth of human colorectal cancer.	Molecular pharmacology	2011	43
21156284	1499	Yeung J	β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells.	Cancer cell	2010	66
21199802	1499	Waaler J	Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth.	Cancer research	2011	35
21245303	1499	Fiedler M	Dishevelled interacts with the DIX domain polymerization interface of Axin to interfere with its function in down-regulating β-catenin.	Proceedings of the National Academy of Sciences of the United States of America	2011	48
21324318	1499	Toffanin S	MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.	Gastroenterology	2011	53
21346776	1499	Syed DN	Inhibition of human melanoma cell growth by the dietary flavonoid fisetin is associated with disruption of Wnt/β-catenin signaling and decreased Mitf levels.	The Journal of investigative dermatology	2011	39
21386792	1499	Fassnacht M	Adrenocortical carcinoma: a clinician's update.	Nature reviews. Endocrinology	2011	49
21393571	1499	Gonsalves FC	An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway.	Proceedings of the National Academy of Sciences of the United States of America	2011	78
21518267	1499	Kikuchi A	Wnt5a: its signalling, functions and implication in diseases.	Acta physiologica	2012	83
21521850	1499	Morikawa T	Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer.	JAMA	2011	78
21531761	1499	Osada T	Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations.	Cancer research	2011	54
21636786	1499	Gaston-Massuet C	Increased Wingless (Wnt) signaling in pituitary progenitor/stem cells gives rise to pituitary tumors in mice and humans.	Proceedings of the National Academy of Sciences of the United States of America	2011	41
21704588	1499	Froeling FE	Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-β-catenin signaling to slow tumor progression.	Gastroenterology	2011	57
21788521	1499	Lu D	Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells.	Proceedings of the National Academy of Sciences of the United States of America	2011	84
21898546	1499	King TD	The Wnt/β-catenin signaling pathway: a potential therapeutic target in the treatment of triple negative breast cancer.	Journal of cellular biochemistry	2012	52
21966251	1499	Nishida N	Genetic and epigenetic signatures in human hepatocellular carcinoma: a systematic review.	Current genomics	2011	40
22007144	1499	Tian X	E-cadherin/β-catenin complex and the epithelial barrier.	Journal of biomedicine and biotechnology	2011	56
22020335	1499	Zhou AD	β-Catenin/LEF1 transactivates the microRNA-371-373 cluster that modulates the Wnt/β-catenin-signaling pathway.	Oncogene	2012	37
22056988	1499	Yang W	Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation.	Nature	2011	210
22071650	1499	Sequist LV	Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice.	Annals of oncology 	2011	92
22080605	1499	Sánchez-Tilló E	β-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness.	Proceedings of the National Academy of Sciences of the United States of America	2011	96
22083670	1499	Kim Y	Wnt activation is implicated in glioblastoma radioresistance.	Laboratory investigation; a journal of technical methods and pathology	2012	42
22115830	1499	Freeman TJ	Smad4-mediated signaling inhibits intestinal neoplasia by inhibiting expression of β-catenin.	Gastroenterology	2012	39
22142829	1499	Shukla N	Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.	Clinical cancer research 	2012	62
22158988	1499	Wu J	Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways.	Proceedings of the National Academy of Sciences of the United States of America	2011	120
22234612	1499	Biechele TL	Wnt/β-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma.	Science signaling	2012	50
22430211	1499	Yeramian A	Endometrial carcinoma: molecular alterations involved in tumor development and progression.	Oncogene	2013	26
22459349	1499	Moncharmont C	Targeting a cornerstone of radiation resistance: cancer stem cell.	Cancer letters	2012	38
22459450	1499	Sun JY	MicroRNA-320a suppresses human colon cancer cell proliferation by directly targeting β-catenin.	Biochemical and biophysical research communications	2012	45
22484120	1499	Zhang J	MicroRNA-26a promotes cholangiocarcinoma growth by activating β-catenin.	Gastroenterology	2012	47
22494971	1499	Jeong WJ	Ras stabilization through aberrant activation of Wnt/β-catenin signaling promotes intestinal tumorigenesis.	Science signaling	2012	32
22536370	1499	Lovly CM	Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.	PloS one	2012	49
22538770	1499	Santarpia L	Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.	Breast cancer research and treatment	2012	35
22580612	1499	Kufe DW	MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches.	Oncogene	2013	82
22610277	1499	Tenbaum SP	β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer.	Nature medicine	2012	82
22610915	1499	Zhang Y	Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling.	Hepatology	2012	74
22653804	1499	McConechy MK	Use of mutation profiles to refine the classification of endometrial carcinomas.	The Journal of pathology	2012	45
22704062	1499	Chaw SY	Epithelial to mesenchymal transition (EMT) biomarkers--E-cadherin, beta-catenin, APC and Vimentin--in oral squamous cell carcinogenesis and transformation.	Oral oncology	2012	39
22723415	1499	Hoffmeyer K	Wnt/β-catenin signaling regulates telomerase in stem cells and cancer cells.	Science	2012	126
22738915	1499	Casás-Selves M	Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition.	Cancer research	2012	33
22820256	1499	Pugh TJ	Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations.	Nature	2012	203
22851508	1499	Ibrahim EE	Embryonic NANOG activity defines colorectal cancer stem cells and modulates through AP1- and TCF-dependent mechanisms.	Stem cells	2012	35
22914623	1499	Takada K	Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling.	Science translational medicine	2012	48
22924465	1499	Maiese K	Targeting disease through novel pathways of apoptosis and autophagy.	Expert opinion on therapeutic targets	2012	45
22975805	1499	Seo JS	The transcriptional landscape and mutational profile of lung adenocarcinoma.	Genome research	2012	139
23034650	1499	Grivennikov SI	Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth.	Nature	2012	215
23139209	1499	Gong A	FoxM1 and Wnt/β-catenin signaling in glioma stem cells.	Cancer research	2012	34
23178882	1499	Youssef KK	Adult interfollicular tumour-initiating cells are reprogrammed into an embryonic hair follicle progenitor-like fate during basal cell carcinoma initiation.	Nature cell biology	2012	32
23188675	1499	Hsieh IS	MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway.	Carcinogenesis	2013	66
23291185	1499	Ma Y	Inhibition of the Wnt-β-catenin and Notch signaling pathways sensitizes osteosarcoma cells to chemotherapy.	Biochemical and biophysical research communications	2013	26
23300485	1499	Francis JC	β-catenin is required for prostate development and cooperates with Pten loss to drive invasive carcinoma.	PLoS genetics	2013	28
23303697	1499	Shehzad A	Molecular mechanisms of curcumin action: signal transduction.	BioFactors	2013	42
23303705	1499	Shehzad A	Curcumin in various cancers.	BioFactors	2013	32
23307470	1499	Wend P	WNT10B/β-catenin signalling induces HMGA2 and proliferation in metastatic triple-negative breast cancer.	EMBO molecular medicine	2013	36
23325582	1499	Peeters M	Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer.	Clinical cancer research 	2013	56
23333633	1499	Chiang CH	Up-regulation of miR-182 by β-catenin in breast cancer increases tumorigenicity and invasiveness by targeting the matrix metalloproteinase inhibitor RECK.	Biochimica et biophysica acta	2013	33
23337059	1499	Wangefjord S	Associations of beta-catenin alterations and MSI screening status with expression of key cell cycle regulating proteins and survival from colorectal cancer.	Diagnostic pathology	2013	27
23343194	1499	Kim W	Wnt/β-catenin signalling: from plasma membrane to nucleus.	The Biochemical journal	2013	56
23359139	1499	Kadaba R	Imbalance of desmoplastic stromal cell numbers drives aggressive cancer processes.	The Journal of pathology	2013	28
23454242	1499	Seshacharyulu P	Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer.	Cancer letters	2013	58
23463346	1499	Beyoğlu D	Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification.	Hepatology	2013	37
23539445	1499	Xu C	β-Catenin/POU5F1/SOX2 transcription factor complex mediates IGF-I receptor signaling and predicts poor prognosis in lung adenocarcinoma.	Cancer research	2013	28
23636398	1499	Cancer Genome Atlas Research Network.	Integrated genomic characterization of endometrial carcinoma.	Nature	2013	552
23765252	1499	McConechy MK	Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles.	Modern pathology 	2014	25
23780408	1499	Bashashati A	Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling.	The Journal of pathology	2013	80
23788652	1499	Kan Z	Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma.	Genome research	2013	95
23887712	1499	Nault JC	High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.	Nature communications	2013	82
23941831	1499	Rogler G	Chronic ulcerative colitis and colorectal cancer.	Cancer letters	2014	33
23945276	1499	Pegoraro S	HMGA1 promotes metastatic processes in basal-like breast cancer regulating EMT and stemness.	Oncotarget	2013	33
23979959	1499	Nikiforova MN	Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer.	The Journal of clinical endocrinology and metabolism	2013	52
23999433	1499	Neviani P	PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.	The Journal of clinical investigation	2013	54
24054872	1499	Rajan P	Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy.	European urology	2014	28
24087794	1499	Berthon A	WNT/β-catenin signalling is activated in aldosterone-producing adenomas and controls aldosterone production.	Human molecular genetics	2014	23
24125749	1499	Arend RC	The Wnt/β-catenin pathway in ovarian cancer: a review.	Gynecologic oncology	2013	52
24209998	1499	Dey N	Wnt signaling in triple negative breast cancer is associated with metastasis.	BMC cancer	2013	29
24244343	1499	Ji Q	Resveratrol inhibits invasion and metastasis of colorectal cancer cells via MALAT1 mediated Wnt/β-catenin signal pathway.	PloS one	2013	49
24282295	1499	Stoyanova T	Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells.	Proceedings of the National Academy of Sciences of the United States of America	2013	40
24309006	1499	Stewart DJ	Wnt signaling pathway in non-small cell lung cancer.	Journal of the National Cancer Institute	2014	80
24335145	1499	Tang X	Glycogen synthase kinase 3 beta inhibits microRNA-183-96-182 cluster via the β-Catenin/TCF/LEF-1 pathway in gastric cancer cells.	Nucleic acids research	2014	21
24347249	1499	Ramteke A	Exosomes secreted under hypoxia enhance invasiveness and stemness of prostate cancer cells by targeting adherens junction molecules.	Molecular carcinogenesis	2015	29
24413733	1499	Brastianos PK	Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas.	Nature genetics	2014	36
24429522	1499	Kode A	Leukaemogenesis induced by an activating β-catenin mutation in osteoblasts.	Nature	2014	80
24436047	1499	Shern JF	Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.	Cancer discovery	2014	82
24582836	1499	Lau CC	Viral-human chimeric transcript predisposes risk to liver cancer development and progression.	Cancer cell	2014	43
24589894	1499	Llovet JM	Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design.	Clinical cancer research 	2014	61
24706870	1499	Chen EY	Glycogen synthase kinase 3 inhibitors induce the canonical WNT/β-catenin pathway to suppress growth and self-renewal in embryonal rhabdomyosarcoma.	Proceedings of the National Academy of Sciences of the United States of America	2014	26
24735922	1499	Pilati C	Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation.	Cancer cell	2014	28
24736023	1499	Arend RC	Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer.	Gynecologic oncology	2014	32
24837480	1499	Tao J	Activation of β-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice.	Gastroenterology	2014	34
24859161	1499	Li L	Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and β-catenin signaling in pancreatic ductal adenocarcinoma cells.	Gastroenterology	2014	27
24931005	1499	McCubrey JA	GSK-3 as potential target for therapeutic intervention in cancer.	Oncotarget	2014	71
24975608	1499	Saretzki G	Extra-telomeric functions of human telomerase: cancer, mitochondria and oxidative stress.	Current pharmaceutical design	2014	21
25123931	1499	Wroblewski LE	Helicobacter pylori targets cancer-associated apical-junctional constituents in gastroids and gastric epithelial cells.	Gut	2015	23
25248380	1499	Friemel J	Intratumor heterogeneity in hepatocellular carcinoma.	Clinical cancer research 	2015	28
25371073	1499	Tang Q	MicroRNA-93 suppress colorectal cancer development via Wnt/β-catenin pathway downregulating.	Tumour biology 	2015	20
25444902	1499	Zhang J	EZH2 is a negative prognostic factor and exhibits pro-oncogenic activity in glioblastoma.	Cancer letters	2015	18
25490274	1499	Juhlin CC	Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma.	The Journal of clinical endocrinology and metabolism	2015	17
25500543	1499	Lemieux E	Oncogenic KRAS signalling promotes the Wnt/β-catenin pathway through LRP6 in colorectal cancer.	Oncogene	2015	27
25501033	1499	Penna E	miR-214 as a key hub that controls cancer networks: small player, multiple functions.	The Journal of investigative dermatology	2015	20
25600645	1499	Hirata H	Long Noncoding RNA MALAT1 Promotes Aggressive Renal Cell Carcinoma through Ezh2 and Interacts with miR-205.	Cancer research	2015	81
25608619	1499	Zhang Z	microRNA-146a inhibits cancer metastasis by downregulating VEGF through dual pathways in hepatocellular carcinoma.	Molecular cancer	2015	18
25624430	1499	Slomovitz BM	Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.	Journal of clinical oncology 	2015	17
25720322	1499	Stelloo E	Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative.	Modern pathology 	2015	16
25813403	1499	Leung WK	Wnt/β-Catenin activates MiR-183/96/182 expression in hepatocellular carcinoma that promotes cell invasion.	Cancer letters	2015	23
25820276	1499	Bol GM	Targeting DDX3 with a small molecule inhibitor for lung cancer therapy.	EMBO molecular medicine	2015	22
25871400	1499	Zhou Y	Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the β-catenin/TCF complex association via FOXO3a activation.	Oncotarget	2015	18
25901018	1499	Madan B	Targeting Wnts at the source--new mechanisms, new biomarkers, new drugs.	Molecular cancer therapeutics	2015	18
26025765	1499	Ghahhari NM	Interplay between microRNAs and WNT/β-catenin signalling pathway regulates epithelial-mesenchymal transition in cancer.	European journal of cancer	2015	19
26202299	1499	Jang GB	Blockade of Wnt/β-catenin signaling suppresses breast cancer metastasis by inhibiting CSC-like phenotype.	Scientific reports	2015	25
26364599	1499	Zhou L	Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.	Oncogene	2016	25
26684358	1499	Zheng H	MicroRNA-1225-5p inhibits proliferation and metastasis of gastric carcinoma through repressing insulin receptor substrate-1 and activation of β-catenin signaling.	Oncotarget	2016	13
26811628	1499	Vilchez V	Targeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment.	World journal of gastroenterology	2016	13
26907633	1499	Tagde A	MUC1-C drives MYC in multiple myeloma.	Blood	2016	12
27042933	1499	Kaur A	sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance.	Nature	2016	27
7680764	1649	Fisher RI	Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.	The New England journal of medicine	1993	164
8510758	1649	Crozat A	Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma.	Nature	1993	187
11807147	1649	Coiffier B	CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.	The New England journal of medicine	2002	604
15322075	1649	Yamaguchi H	CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells.	The Journal of biological chemistry	2004	175
15591112	1649	Dreyling M	Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network.	Blood	2005	73
15668467	1649	Lenz G	Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).	Journal of clinical oncology 	2005	84
15867204	1649	Feugier P	Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.	Journal of clinical oncology 	2005	204
15955905	1649	Sehn LH	Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.	Journal of clinical oncology 	2005	135
16123223	1649	Hiddemann W	Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.	Blood	2005	160
16230674	1649	Fisher RI	New treatment options have changed the survival of patients with follicular lymphoma.	Journal of clinical oncology 	2005	68
16357160	1649	Nawrocki ST	Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells.	Cancer research	2005	79
16754935	1649	Habermann TM	Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.	Journal of clinical oncology 	2006	218
16873669	1649	van Oers MH	Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.	Blood	2006	83
17105812	1649	Sehn LH	The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.	Blood	2007	160
17308121	1649	Meister S	Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.	Cancer research	2007	86
17586092	1649	Grosso F	Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.	The Lancet. Oncology	2007	83
17942911	1649	Pyrko P	The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas.	Cancer research	2007	116
18226581	1649	Pfreundschuh M	Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).	The Lancet. Oncology	2008	138
18544678	1649	Rimsza LM	Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP.	Blood	2008	50
18625886	1649	Geisler CH	Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group.	Blood	2008	86
19038878	1649	Lenz G	Stromal gene signatures in large-B-cell lymphomas.	The New England journal of medicine	2008	321
19075267	1649	Yeo W	Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.	Journal of clinical oncology 	2009	95
19420259	1649	Di Nardo A	Tuberous sclerosis complex activity is required to control neuronal stress responses in an mTOR-dependent manner.	The Journal of neuroscience 	2009	60
19704118	1649	Savage KJ	MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.	Blood	2009	105
19723703	1649	Senkal CE	Antiapoptotic roles of ceramide-synthase-6-generated C16-ceramide via selective regulation of the ATF6/CHOP arm of ER-stress-response pathways.	FASEB journal 	2010	79
20385988	1649	Ziepert M	Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.	Journal of clinical oncology 	2010	67
20439641	1649	van Oers MH	Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study.	Journal of clinical oncology 	2010	43
20548096	1649	Coiffier B	Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.	Blood	2010	151
20616807	1649	Kang YJ	The TSC1 and TSC2 tumor suppressors are required for proper ER stress response and protect cells from ER stress-induced apoptosis.	Cell death and differentiation	2011	39
21030533	1649	Flowers CR	Improving outcomes for patients with diffuse large B-cell lymphoma.	CA	2010	47
21135273	1649	Meyer PN	Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab.	Journal of clinical oncology 	2011	73
21189393	1649	Ruan J	Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.	Journal of clinical oncology 	2011	54
22337718	1649	Müller C	The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL.	Blood	2012	34
22437443	1649	Visco C	Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.	Leukemia	2012	68
22718839	1649	Delarue R	CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte.	Blood	2013	40
22873532	1649	Kluin-Nelemans HC	Treatment of older patients with mantle-cell lymphoma.	The New England journal of medicine	2012	52
22911837	1649	Li ZM	Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP.	PloS one	2012	32
23375551	1649	Martelli M	Diffuse large B-cell lymphoma.	Critical reviews in oncology/hematology	2013	42
23530110	1649	Federico M	R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi.	Journal of clinical oncology 	2013	28
23578722	1649	Delarue R	Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.	The Lancet. Oncology	2013	26
23670030	1649	Li T	Salinomycin induces cell death with autophagy through activation of endoplasmic reticulum stress in human cancer cells.	Autophagy	2013	28
24171516	1649	Stiff PJ	Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma.	The New England journal of medicine	2013	27
24336156	1649	Tzankov A	Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.	Modern pathology 	2014	23
24506200	1649	Perry AM	MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab.	British journal of haematology	2014	25
24591201	1649	Flinn IW	Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.	Blood	2014	39
24732592	1649	Rossille D	High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial.	Leukemia	2014	32
24943107	1649	Oki Y	Double hit lymphoma: the MD Anderson Cancer Center clinical experience.	British journal of haematology	2014	26
25042202	1649	Younes A	Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.	The Lancet. Oncology	2014	41
25499448	1649	Sehn LH	Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity.	Blood	2015	36
25738670	1649	Robak T	Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.	The New England journal of medicine	2015	30
25867072	1649	He K	mTOR inhibitors induce apoptosis in colon cancer cells via CHOP-dependent DR5 induction on 4E-BP1 dephosphorylation.	Oncogene	2016	13
25980682	1649	Kim B	Curcumin induces ER stress-mediated apoptosis through selective generation of reactive oxygen species in cervical cancer cells.	Molecular carcinogenesis	2016	12
26124482	1649	Casulo C	Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.	Journal of clinical oncology 	2015	20
26240231	1649	Scott DW	Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies.	Journal of clinical oncology 	2015	19
10325416	1786	Robertson KD	The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors.	Nucleic acids research	1999	196
10888886	1786	Robertson KD	DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters.	Nature genetics	2000	227
11585728	1786	Yang X	Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells.	Cancer research	2001	103
11932749	1786	Rhee I	DNMT1 and DNMT3b cooperate to silence genes in human cancer cells.	Nature	2002	332
12438232	1786	Cui H	Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2.	Cancer research	2002	116
12496760	1786	Robert MF	DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells.	Nature genetics	2003	140
16230360	1786	Lee BH	Procainamide is a specific inhibitor of DNA methyltransferase 1.	The Journal of biological chemistry	2005	69
16963560	1786	Egger G	Identification of DNMT1 (DNA methyltransferase 1) hypomorphs in somatic knockouts suggests an essential role for DNMT1 in cell survival.	Proceedings of the National Academy of Sciences of the United States of America	2006	67
17107663	1786	Reichard JF	Long term low-dose arsenic exposure induces loss of DNA methylation.	Biochemical and biophysical research communications	2007	60
17283125	1786	Valinluck V	Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltransferase DNMT1.	Cancer research	2007	158
17308078	1786	Brueckner B	The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function.	Cancer research	2007	103
17322882	1786	Chen T	Complete inactivation of DNMT1 leads to mitotic catastrophe in human cancer cells.	Nature genetics	2007	93
17408664	1786	Park IY	Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein.	Gastroenterology	2007	69
17934516	1786	Achour M	The interaction of the SRA domain of ICBP90 with a novel domain of DNMT1 is involved in the regulation of VEGF gene expression.	Oncogene	2008	53
18179966	1786	Griffiths EA	DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.	Seminars in hematology	2008	55
18505931	1786	Zhou Q	Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells.	Molecular cancer research 	2008	55
19358274	1786	Li Y	Genistein depletes telomerase activity through cross-talk between genetic and epigenetic mechanisms.	International journal of cancer	2009	51
19620278	1786	Jeong S	Selective anchoring of DNA methyltransferases 3A and 3B to nucleosomes containing methylated DNA.	Molecular and cellular biology	2009	76
19730874	1786	Schaefer M	Solving the Dnmt2 enigma.	Chromosoma	2010	48
19789556	1786	Jones PA	Rethinking how DNA methylation patterns are maintained.	Nature reviews. Genetics	2009	180
19891661	1786	Kanai Y	Genome-wide DNA methylation profiles in precancerous conditions and cancers.	Cancer science	2010	44
20093774	1786	Lin RK	The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation and tumor suppressor gene hypermethylation in mice and lung cancer patients.	The Journal of clinical investigation	2010	58
20126405	1786	Hollenbach PW	A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines.	PloS one	2010	69
20570896	1786	Lin RK	Dysregulation of p53/Sp1 control leads to DNA methyltransferase-1 overexpression in lung cancer.	Cancer research	2010	45
20613874	1786	Hervouet E	Disruption of Dnmt1/PCNA/UHRF1 interactions promotes tumorigenesis from human and mice glial cells.	PloS one	2010	43
21163962	1786	Song J	Structure of DNMT1-DNA complex reveals a role for autoinhibition in maintenance DNA methylation.	Science	2011	86
21321201	1786	Shock LS	DNA methyltransferase 1, cytosine methylation, and cytosine hydroxymethylation in mammalian mitochondria.	Proceedings of the National Academy of Sciences of the United States of America	2011	102
21526191	1786	Hahn MA	Relationship between gene body DNA methylation and intragenic H3K9me3 and H3K36me3 chromatin marks.	PloS one	2011	42
22391571	1786	Kalvik TV	Protein N-terminal acetyltransferases in cancer.	Oncogene	2013	31
22956494	1786	Jin B	DNA methyltransferases, DNA damage repair, and cancer.	Advances in experimental medicine and biology	2013	57
22967704	1786	Gros C	DNA methylation inhibitors in cancer: recent and future approaches.	Biochimie	2012	40
23177624	1786	Jin B	Linking DNA methyltransferases to epigenetic marks and nucleosome structure genome-wide in human tumor cells.	Cell reports	2012	38
23955273	1786	Clozel T	Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.	Cancer discovery	2013	30
24077826	1786	Turcan S	Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.	Oncotarget	2013	39
24270890	1786	Cruickshanks HA	Senescent cells harbour features of the cancer epigenome.	Nature cell biology	2013	53
24535937	1786	Odunsi K	Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer.	Cancer immunology research	2014	23
25319390	1786	Tang H	miR-185 suppresses tumor proliferation by directly targeting E2F6 and DNMT1 and indirectly upregulating BRCA1 in triple-negative breast cancer.	Molecular cancer therapeutics	2014	23
25595591	1786	Ning X	DNMT1 and EZH2 mediated methylation silences the microRNA-200b/a/429 gene and promotes tumor progression.	Cancer letters	2015	19
25598321	1786	Zhao S	β-elemene inhibited expression of DNA methyltransferase 1 through activation of ERK1/2 and AMPKα signalling pathways in human lung cancer cells: the role of Sp1.	Journal of cellular and molecular medicine	2015	22
25641194	1786	Zhuo H	The aberrant expression of MEG3 regulated by UHRF1 predicts the prognosis of hepatocellular carcinoma.	Molecular carcinogenesis	2016	24
25942534	1786	Hamidi T	Genetic alterations of DNA methylation machinery in human diseases.	Epigenomics	2015	27
26503055	1786	Peng D	Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy.	Nature	2015	49
8405995	1869	Helin K	Heterodimerization of the transcription factors E2F-1 and DP-1 leads to cooperative trans-activation.	Genes and development	1993	146
8413249	1869	Helin K	Inhibition of E2F-1 transactivation by direct binding of the retinoblastoma protein.	Molecular and cellular biology	1993	134
11034215	1869	Irwin M	Role for the p53 homologue p73 in E2F-1-induced apoptosis.	Nature	2000	153
15169882	1869	Louie MC	ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance.	Molecular and cellular biology	2004	99
16096373	1869	Mendell JT	MicroRNAs: critical regulators of development, cellular physiology and malignancy.	Cell cycle	2005	113
16299810	1869	Hanada N	Co-regulation of B-Myb expression by E2F1 and EGF receptor.	Molecular carcinogenesis	2006	62
16601104	1869	Dasgupta P	Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin.	Proceedings of the National Academy of Sciences of the United States of America	2006	82
16862215	1869	Dasgupta P	Nicotine induces cell proliferation by beta-arrestin-mediated activation of Src and Rb-Raf-1 pathways.	The Journal of clinical investigation	2006	95
16892051	1869	Wang C	Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage.	Nature cell biology	2006	125
17135268	1869	Woods K	Direct regulation of an oncogenic micro-RNA cluster by E2F transcription factors.	The Journal of biological chemistry	2007	179
17894887	1869	Cho WC	OncomiRs: the discovery and progress of microRNAs in cancers.	Molecular cancer	2007	195
18042711	1869	Nikiforov MA	Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition.	Proceedings of the National Academy of Sciences of the United States of America	2007	71
18328430	1869	Petrocca F	E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer.	Cancer cell	2008	299
18607389	1869	Monzo M	Overlapping expression of microRNAs in human embryonic colon and colorectal cancer.	Cell research	2008	57
18644991	1869	Yi T	Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways.	Molecular cancer therapeutics	2008	52
19034270	1869	Brosh R	p53-Repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation.	Molecular systems biology	2008	63
19861459	1869	Dang CV	MYC-induced cancer cell energy metabolism and therapeutic opportunities.	Clinical cancer research 	2009	207
20421545	1869	Lee JS	Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors.	Journal of clinical oncology 	2010	58
21454377	1869	Ofir M	MiR-15 and miR-16 are direct transcriptional targets of E2F1 that limit E2F-induced proliferation by targeting cyclin E.	Molecular cancer research 	2011	59
21857159	1869	Lizé M	MicroRNA-449 in cell fate determination.	Cell cycle	2011	40
22241525	1869	Kanaan Z	Differential microRNA expression tracks neoplastic progression in inflammatory bowel disease-associated colorectal cancer.	Human mutation	2012	33
22349817	1869	Gulzar ZG	Increased expression of NuSAP in recurrent prostate cancer is mediated by E2F1.	Oncogene	2013	28
23306062	1869	Laine A	Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1.	Cancer discovery	2013	29
23868977	1869	Wu Q	MiR-19b/20a/92a regulates the self-renewal and proliferation of gastric cancer stem cells.	Journal of cell science	2013	27
24357161	1869	Shi X	A critical role for the long non-coding RNA GAS5 in proliferation and apoptosis in non-small-cell lung cancer.	Molecular carcinogenesis	2015	48
24362522	1869	Andrechek ER	HER2/Neu tumorigenesis and metastasis is regulated by E2F activator transcription factors.	Oncogene	2015	16
26051178	1869	Vardabasso C	Histone Variant H2A.Z.2 Mediates Proliferation and Drug Sensitivity of Malignant Melanoma.	Molecular cell	2015	21
26540633	1869	Lu Z	Long non-coding RNA HULC promotes tumor angiogenesis in liver cancer by up-regulating sphingosine kinase 1 (SPHK1).	Oncotarget	2016	20
26928463	1869	Kumar A	Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer.	Nature medicine	2016	25
6602130	1950	Assoian RK	Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization.	The Journal of biological chemistry	1983	234
11457733	1950	Jiang BH	Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1.	Cell growth and differentiation 	2001	108
15632317	1950	Simard J	Molecular biology of the 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family.	Endocrine reviews	2005	80
15802268	1950	Phillips RJ	Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha.	The Journal of biological chemistry	2005	93
17016520	1950	Wolf-Yadlin A	Effects of HER2 overexpression on cell signaling networks governing proliferation and migration.	Molecular systems biology	2006	91
17121914	1950	Buck E	Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors.	Molecular cancer therapeutics	2006	67
17477732	1950	Adams KE	Comparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer.	Journal of biomedical optics	2007	86
18167406	1950	Tanabe KK	Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis.	JAMA	2008	59
18291115	1950	Lafky JM	Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer.	Biochimica et biophysica acta	2008	73
18292095	1950	Soeda A	Epidermal growth factor plays a crucial role in mitogenic regulation of human brain tumor stem cells.	The Journal of biological chemistry	2008	56
18379349	1950	Beau-Faller M	MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort.	Journal of thoracic oncology 	2008	60
19343194	1950	Aldridge BB	Fuzzy logic analysis of kinase pathway crosstalk in TNF/EGF/insulin-induced signaling.	PLoS computational biology	2009	50
19484147	1950	Neiva KG	Cross talk initiated by endothelial cells enhances migration and inhibits anoikis of squamous cell carcinoma cells through STAT3/Akt/ERK signaling.	Neoplasia	2009	50
21440548	1950	Abu Dayyeh BK	A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma.	Gastroenterology	2011	41
25143389	1950	Nair V	Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) transcription factors.	The Journal of biological chemistry	2014	23
25175731	1950	Yang J	Site-specific mapping and quantification of protein S-sulphenylation in cells.	Nature communications	2014	37
25688736	1950	Chen ZY	Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer.	British journal of cancer	2015	17
25924068	1950	Drost J	Sequential cancer mutations in cultured human intestinal stem cells.	Nature	2015	71
1557402	1956	Wong AJ	Structural alterations of the epidermal growth factor receptor gene in human gliomas.	Proceedings of the National Academy of Sciences of the United States of America	1992	188
2981413	1956	Libermann TA	Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin.	Nature	1985	263
3477813	1956	Wong AJ	Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification.	Proceedings of the National Academy of Sciences of the United States of America	1987	173
3798106	1956	Slamon DJ	Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.	Science	1987	1881
6157683	1956	Ushiro H	Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes.	The Journal of biological chemistry	1980	190
6320011	1956	Downward J	Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences.	Nature	1984	417
6328312	1956	Ullrich A	Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells.	Nature	1984	491
7585629	1956	Moscatello DK	Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors.	Cancer research	1995	118
8339264	1956	Grandis JR	Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer.	Cancer research	1993	154
9006938	1956	Huang HS	The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling.	The Journal of biological chemistry	1997	162
9041202	1956	Relf M	Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis.	Cancer research	1997	128
9403702	1956	Petit AM	Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.	The American journal of pathology	1997	115
9625170	1956	Rubin Grandis J	Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival.	Journal of the National Cancer Institute	1998	198
9815926	1956	Goldstein NI	Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model.	Clinical cancer research 	1995	117
9831867	1956	Ross JS	The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.	Stem cells	1998	109
10075741	1956	Biscardi JS	c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function.	The Journal of biological chemistry	1999	174
10722725	1956	Jo M	Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells.	The Journal of biological chemistry	2000	104
10728703	1956	Frederick L	Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.	Cancer research	2000	153
10760290	1956	Grandis JR	Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo.	Proceedings of the National Academy of Sciences of the United States of America	2000	149
10815932	1956	Ciardiello F	Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.	Clinical cancer research 	2000	107
10873065	1956	Huang SM	Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis.	Clinical cancer research 	2000	98
11156248	1956	Sirotnak FM	Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.	Clinical cancer research 	2000	94
11156523	1956	Harari D	Molecular mechanisms underlying ErbB2/HER2 action in breast cancer.	Oncogene	2000	118
11283316	1956	Wechsler-Reya R	The developmental biology of brain tumors.	Annual review of neuroscience	2001	101
11420660	1956	Garcia R	Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells.	Oncogene	2001	164
11426640	1956	Mendelsohn J	The EGF receptor family as targets for cancer therapy.	Oncogene	2000	206
11431346	1956	Viloria-Petit A	Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.	Cancer research	2001	110
11504770	1956	Smith JS	PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme.	Journal of the National Cancer Institute	2001	100
11585753	1956	Moasser MM	The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.	Cancer research	2001	87
11595683	1956	Ciardiello F	A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.	Clinical cancer research 	2001	135
11597398	1956	Yarden Y	The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities.	European journal of cancer	2001	296
11597399	1956	Nicholson RI	EGFR and cancer prognosis.	European journal of cancer	2001	363
11897506	1956	Filardo EJ	Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer.	The Journal of steroid biochemistry and molecular biology	2002	91
11948098	1956	Buettner R	Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention.	Clinical cancer research 	2002	265
12124174	1956	Liu D	EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma.	Cancer cell	2002	103
12183421	1956	Wedge SR	ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.	Cancer research	2002	158
12214266	1956	Xia W	Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.	Oncogene	2002	161
12359858	1956	Wang F	Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts.	Journal of the National Cancer Institute	2002	111
12384534	1956	Wakeling AE	ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.	Cancer research	2002	132
12429632	1956	Di Lorenzo G	Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer.	Clinical cancer research 	2002	88
12435727	1956	Andl CD	Epidermal growth factor receptor mediates increased cell proliferation, migration, and aggregation in esophageal keratinocytes in vitro and in vivo.	The Journal of biological chemistry	2003	90
12499279	1956	Ang KK	Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma.	Cancer research	2002	224
12648469	1956	Holbro T	The ErbB receptors and their role in cancer progression.	Experimental cell research	2003	151
12717449	1956	Smith LL	Telomerase modulates expression of growth-controlling genes and enhances cell proliferation.	Nature cell biology	2003	107
12743152	1956	Cohen EE	Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.	Journal of clinical oncology 	2003	98
12824187	1956	Buchanan FG	Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor.	The Journal of biological chemistry	2003	104
12845624	1956	Witton CJ	Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.	The Journal of pathology	2003	129
12860957	1956	Mendelsohn J	Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.	Journal of clinical oncology 	2003	184
12953099	1956	Hirsch FR	Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.	Journal of clinical oncology 	2003	238
14570950	1956	Kris MG	Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.	JAMA	2003	389
14583498	1956	Shinojima N	Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.	Cancer research	2003	158
14638850	1956	Rich JN	Phase II trial of gefitinib in recurrent glioblastoma.	Journal of clinical oncology 	2004	122
14641026	1956	Fischer OM	EGFR signal transactivation in cancer cells.	Biochemical Society transactions	2003	95
14701768	1956	Soulieres D	Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.	Journal of clinical oncology 	2004	145
14744244	1956	Holbro T	ErbB receptors: directing key signaling networks throughout life.	Annual review of pharmacology and toxicology	2004	147
14769856	1956	Liu H	Polarity and proliferation are controlled by distinct signaling pathways downstream of PI3-kinase in breast epithelial tumor cells.	The Journal of cell biology	2004	93
14993230	1956	Saltz LB	Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.	Journal of clinical oncology 	2004	287
15057284	1956	Qian X	E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases.	The EMBO journal	2004	106
15059883	1956	Nahta R	The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.	Cancer research	2004	112
15084238	1956	Arpino G	Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome.	Breast cancer research 	2004	105
15118073	1956	Lynch TJ	Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.	The New England journal of medicine	2004	2246
15118125	1956	Paez JG	EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.	Science	2004	1965
15158434	1956	Roskoski R Jr	The ErbB/HER receptor protein-tyrosine kinases and cancer.	Biochemical and biophysical research communications	2004	70
15226328	1956	Xiong HQ	Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial.	Journal of clinical oncology 	2004	91
15269313	1956	Cunningham D	Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.	The New England journal of medicine	2004	891
15310767	1956	Pérez-Soler R	Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.	Journal of clinical oncology 	2004	151
15328174	1956	Nielsen TO	Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.	Clinical cancer research 	2004	595
15329413	1956	Pao W	EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.	Proceedings of the National Academy of Sciences of the United States of America	2004	999
15345710	1956	Laederich MB	The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases.	The Journal of biological chemistry	2004	75
15492241	1956	Tracy S	Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.	Cancer research	2004	86
15598946	1956	Spano JP	Impact of EGFR expression on colorectal cancer patient prognosis and survival.	Annals of oncology 	2005	70
15623594	1956	Huang SF	High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.	Clinical cancer research 	2004	78
15665299	1956	Amann J	Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer.	Cancer research	2005	98
15665312	1956	Lo HW	Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer.	Cancer research	2005	92
15677699	1956	Chung KY	Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.	Journal of clinical oncology 	2005	200
15681531	1956	Marchetti A	EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.	Journal of clinical oncology 	2005	149
15684311	1956	Spector NL	Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.	Journal of clinical oncology 	2005	82
15709185	1956	Tokumo M	The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers.	Clinical cancer research 	2005	94
15710947	1956	Han SW	Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.	Journal of clinical oncology 	2005	135
15728811	1956	Kobayashi S	EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.	The New England journal of medicine	2005	832
15731348	1956	Engelman JA	ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.	Proceedings of the National Academy of Sciences of the United States of America	2005	148
15735034	1956	Stabile LP	Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.	Cancer research	2005	82
15737014	1956	Pao W	Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.	PLoS medicine	2005	871
15738541	1956	Mitsudomi T	Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.	Journal of clinical oncology 	2005	175
15741570	1956	Shigematsu H	Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.	Journal of the National Cancer Institute	2005	439
15746047	1956	Heimberger AB	Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients.	Clinical cancer research 	2005	134
15753357	1956	Shigematsu H	Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.	Cancer research	2005	142
15753462	1956	Herbst RS	Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.	Journal of clinical oncology 	2005	86
15767641	1956	Pao W	Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.	Journal of clinical oncology 	2005	94
15814656	1956	Shimizu M	(-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells.	Clinical cancer research 	2005	65
15833866	1956	Chinnaiyan P	Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).	Cancer research	2005	84
15863375	1956	Moroni M	Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.	The Lancet. Oncology	2005	197
15864276	1956	Hynes NE	ERBB receptors and cancer: the complexity of targeted inhibitors.	Nature reviews. Cancer	2005	833
15870435	1956	Cappuzzo F	Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.	Journal of the National Cancer Institute	2005	311
15886310	1956	Jänne PA	Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology.	Journal of clinical oncology 	2005	82
15920544	1956	Bhargava R	EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations.	Modern pathology 	2005	76
15939921	1956	Baselga J	Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.	Journal of clinical oncology 	2005	77
15955900	1956	Burris HA 3rd	Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.	Journal of clinical oncology 	2005	123
15956649	1956	Haas-Kogan DA	Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.	Journal of the National Cancer Institute	2005	132
15994331	1956	Clayton AH	Ligand-induced dimer-tetramer transition during the activation of the cell surface epidermal growth factor receptor-A multidimensional microscopy analysis.	The Journal of biological chemistry	2005	82
15994928	1956	Zhao X	Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis.	Cancer research	2005	120
15998907	1956	Takano T	Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer.	Journal of clinical oncology 	2005	139
16014882	1956	Shepherd FA	Erlotinib in previously treated non-small-cell lung cancer.	The New England journal of medicine	2005	1010
16014883	1956	Tsao MS	Erlotinib in lung cancer - molecular and clinical predictors of outcome.	The New England journal of medicine	2005	312
16020518	1956	Means AL	Pancreatic epithelial plasticity mediated by acinar cell transdifferentiation and generation of nestin-positive intermediates.	Development	2005	106
16033833	1956	Lakhani SR	Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype.	Clinical cancer research 	2005	149
16043828	1956	Eberhard DA	Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.	Journal of clinical oncology 	2005	344
16043829	1956	Herbst RS	TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2005	275
16051952	1956	Cappuzzo F	Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.	Journal of clinical oncology 	2005	69
16051966	1956	Peréz-Soler R	Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?	Journal of clinical oncology 	2005	70
16061871	1956	Schilder RJ	Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study.	Clinical cancer research 	2005	66
16105816	1956	Nagai Y	Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp.	Cancer research	2005	91
16115926	1956	Psyrri A	Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis.	Clinical cancer research 	2005	90
16145046	1956	Arpino G	Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.	Journal of the National Cancer Institute	2005	100
16161046	1956	Hanawa M	EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus.	International journal of cancer	2006	67
16170173	1956	Philip PA	Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.	Journal of clinical oncology 	2005	94
16204011	1956	Bell DW	Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.	Journal of clinical oncology 	2005	119
16230383	1956	Baird K	Gene expression profiling of human sarcomas: insights into sarcoma biology.	Cancer research	2005	85
16231326	1956	Shigematsu H	Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers.	International journal of cancer	2006	139
16261406	1956	Lo HW	EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization.	Breast cancer research and treatment	2006	63
16282176	1956	Mellinghoff IK	Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.	The New England journal of medicine	2005	399
16314626	1956	Burtness B	Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.	Journal of clinical oncology 	2005	166
16322287	1956	Haura EB	Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.	Clinical cancer research 	2005	70
16333527	1956	Hiscox S	Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells.	Breast cancer research and treatment	2006	64
16361555	1956	Yauch RL	Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients.	Clinical cancer research 	2005	161
16377102	1956	Normanno N	Epidermal growth factor receptor (EGFR) signaling in cancer.	Gene	2006	350
16397019	1956	Diaz N	Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression.	Clinical cancer research 	2006	78
16424029	1956	Witta SE	Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.	Cancer research	2006	137
16434982	1956	Lo HW	Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival.	British journal of cancer	2006	86
16452222	1956	Konecny GE	Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.	Cancer research	2006	213
16467097	1956	Riely GJ	Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.	Clinical cancer research 	2006	173
16467544	1956	Bonner JA	Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.	The New England journal of medicine	2006	811
16533778	1956	Rodríguez-Pinilla SM	Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas.	Clinical cancer research 	2006	68
16533793	1956	Tam IY	Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features.	Clinical cancer research 	2006	112
16540667	1956	Alvarez JV	Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor.	Cancer research	2006	61
16549822	1956	Takeuchi T	Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors.	Journal of clinical oncology 	2006	64
16552725	1956	Lo HW	Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin beta1 and CRM1.	Journal of cellular biochemistry	2006	84
16565089	1956	Bourguignon LY	Hyaluronan-CD44 interaction with leukemia-associated RhoGEF and epidermal growth factor receptor promotes Rho/Ras co-activation, phospholipase C epsilon-Ca2+ signaling, and cytoskeleton modification in head and neck squamous cell carcinoma cells.	The Journal of biological chemistry	2006	74
16565487	1956	Li YC	Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents.	The American journal of pathology	2006	96
16585219	1956	Creighton CJ	Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors.	Cancer research	2006	83
16730237	1956	Ji H	The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.	Cancer cell	2006	125
16740687	1956	Song L	Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival.	Cancer research	2006	73
16757721	1956	Carey LA	Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.	JAMA	2006	957
16763281	1956	Kalyankrishna S	Epidermal growth factor receptor biology in head and neck cancer.	Journal of clinical oncology 	2006	160
16785471	1956	Inoue A	Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.	Journal of clinical oncology 	2006	116
16809731	1956	Philip PA	Phase II study of erlotinib in patients with advanced biliary cancer.	Journal of clinical oncology 	2006	70
16829981	1956	Citri A	EGF-ERBB signalling: towards the systems level.	Nature reviews. Molecular cell biology	2006	536
16837691	1956	Zakowski MF	EGFR mutations in small-cell lung cancers in patients who have never smoked.	The New England journal of medicine	2006	65
16847054	1956	Peng XH	Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression.	The Journal of biological chemistry	2006	66
16890793	1956	Mendelsohn J	Epidermal growth factor receptor targeting in cancer.	Seminars in oncology	2006	150
16912159	1956	Wang MY	Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells.	Cancer research	2006	96
16931954	1956	Hicks DG	Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR.	The American journal of surgical pathology	2006	68
16938528	1956	Kim MJ	Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.	Human pathology	2006	82
16980606	1956	Ceppi P	ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine.	Annals of oncology 	2006	63
17020982	1956	Kosaka T	Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.	Clinical cancer research 	2006	131
17030071	1956	Malhi H	Cholangiocarcinoma: modern advances in understanding a deadly old disease.	Journal of hepatology	2006	65
17047074	1956	Morgillo F	Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.	Cancer research	2006	101
17047648	1956	Asahina H	A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.	British journal of cancer	2006	67
17050875	1956	Lenz HJ	Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.	Journal of clinical oncology 	2006	90
17050876	1956	Dragovich T	Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.	Journal of clinical oncology 	2006	75
17075123	1956	Hirsch FR	Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2006	145
17085664	1956	Balak MN	Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.	Clinical cancer research 	2006	195
17115032	1956	Wang SC	Tyrosine phosphorylation controls PCNA function through protein stability.	Nature cell biology	2006	102
17126425	1956	McCubrey JA	Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.	Biochimica et biophysica acta	2007	423
17146782	1956	Rakha EA	Prognostic markers in triple-negative breast cancer.	Cancer	2007	262
17189394	1956	Riely GJ	Update on epidermal growth factor receptor mutations in non-small cell lung cancer.	Clinical cancer research 	2006	99
17189395	1956	Ono M	Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs.	Clinical cancer research 	2006	79
17192538	1956	Geyer CE	Lapatinib plus capecitabine for HER2-positive advanced breast cancer.	The New England journal of medicine	2006	587
17206155	1956	Sergina NV	Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.	Nature	2007	280
17218988	1956	Kenny PA	Targeting TACE-dependent EGFR ligand shedding in breast cancer.	The Journal of clinical investigation	2007	72
17228019	1956	Jackman DM	Phase II clinical trial of chemotherapy-naive patients &amp;gt; or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer.	Journal of clinical oncology 	2007	82
17251932	1956	Ventura A	Restoration of p53 function leads to tumour regression in vivo.	Nature	2007	502
17283074	1956	Hsu SC	Characterization of a novel tripartite nuclear localization sequence in the EGFR family.	The Journal of biological chemistry	2007	83
17290066	1956	Subramanian J	Lung cancer in never smokers: a review.	Journal of clinical oncology 	2007	141
17290067	1956	Sequist LV	Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.	Journal of clinical oncology 	2007	144
17308052	1956	Buck E	Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition.	Molecular cancer therapeutics	2007	70
17308062	1956	Nahta R	Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.	Molecular cancer therapeutics	2007	67
17314037	1956	Bublil EM	The EGF receptor family: spearheading a merger of signaling and therapeutics.	Current opinion in cell biology	2007	113
17317677	1956	Hirsch FR	Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.	Annals of oncology 	2007	69
17332301	1956	Kurai J	Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines.	Clinical cancer research 	2007	86
17332364	1956	Mulloy R	Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib.	Cancer research	2007	62
17360479	1956	Scott AM	A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors.	Proceedings of the National Academy of Sciences of the United States of America	2007	59
17363584	1956	Benvenuti S	Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.	Cancer research	2007	207
17372238	1956	Yang XR	Differences in risk factors for breast cancer molecular subtypes in a population-based study.	Cancer epidemiology, biomarkers and prevention 	2007	153
17403429	1956	Smith HO	GPR30: a novel indicator of poor survival for endometrial carcinoma.	American journal of obstetrics and gynecology	2007	74
17404082	1956	Shaffer DR	Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer.	Clinical cancer research 	2007	98
17409807	1956	Sato M	A translational view of the molecular pathogenesis of lung cancer.	Journal of thoracic oncology 	2007	79
17440163	1956	Farnie G	Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways.	Journal of the National Cancer Institute	2007	98
17452677	1956	Moore MJ	Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.	Journal of clinical oncology 	2007	820
17470858	1956	Van Cutsem E	Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.	Journal of clinical oncology 	2007	381
17473213	1956	Morgillo F	Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib.	Clinical cancer research 	2007	80
17473659	1956	Wu YL	Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China.	Journal of thoracic oncology 	2007	58
17474783	1956	Huang X	Cancer cells assemble and align gold nanorods conjugated to antibodies to produce highly enhanced, sharp, and polarized surface Raman spectra: a potential cancer diagnostic marker.	Nano letters	2007	58
17483330	1956	Palmieri D	Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain.	Cancer research	2007	101
17496923	1956	Roberts PJ	Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.	Oncogene	2007	633
17504988	1956	Massarelli E	KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.	Clinical cancer research 	2007	154
17538160	1956	Temam S	Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer.	Journal of clinical oncology 	2007	89
17538161	1956	Vermorken JB	Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.	Journal of clinical oncology 	2007	158
17551144	1956	Taguchi F	Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.	Journal of the National Cancer Institute	2007	68
17606725	1956	Wacker B	Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies.	Clinical cancer research 	2007	84
17620423	1956	Omuro AM	Lessons learned in the development of targeted therapy for malignant gliomas.	Molecular cancer therapeutics	2007	59
17623837	1956	Thomas MB	Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma.	Cancer	2007	69
17646646	1956	Huang PH	Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma.	Proceedings of the National Academy of Sciences of the United States of America	2007	147
17663798	1956	Hoadley KA	EGFR associated expression profiles vary with breast tumor subtype.	BMC genomics	2007	101
17664471	1956	Khambata-Ford S	Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.	Journal of clinical oncology 	2007	291
17664472	1956	Sartore-Bianchi A	Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab.	Journal of clinical oncology 	2007	82
17667926	1956	Hsieh AC	Targeting HER proteins in cancer therapy and the role of the non-target HER3.	British journal of cancer	2007	80
17670948	1956	Franovic A	Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer.	Proceedings of the National Academy of Sciences of the United States of America	2007	68
17679728	1956	Smith IE	A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer.	Journal of clinical oncology 	2007	57
17699871	1956	Ritter CA	Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network.	Clinical cancer research 	2007	166
17785346	1956	Krex D	Long-term survival with glioblastoma multiforme.	Brain 	2007	171
17785546	1956	Molinolo AA	Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative.	Clinical cancer research 	2007	70
17785570	1956	Riely GJ	Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.	Clinical cancer research 	2007	93
17827454	1956	Harari PM	Biology of interactions: antiepidermal growth factor receptor agents.	Journal of clinical oncology 	2007	56
17888036	1956	Mitsudomi T	Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer.	Cancer science	2007	121
17894407	1956	De Luca A	The role of the EGFR signaling in tumor microenvironment.	Journal of cellular physiology	2008	89
17896140	1956	Lieto E	Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients.	Annals of surgical oncology	2008	52
17922188	1956	Tan DS	Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients.	Breast cancer research and treatment	2008	60
17947225	1956	Rosell R	Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.	Annals of oncology 	2008	60
17974556	1956	Cappuzzo F	EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients.	Annals of oncology 	2008	66
17974918	1956	Okawa T	The functional interplay between EGFR overexpression, hTERT activation, and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion, and differentiation.	Genes and development	2007	65
18003960	1956	Jonker DJ	Cetuximab for the treatment of colorectal cancer.	The New England journal of medicine	2007	366
18024868	1956	Tabernero J	Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.	Journal of clinical oncology 	2007	63
18026190	1956	Eskens FA	A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours.	British journal of cancer	2008	56
18060032	1956	Gao SP	Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas.	The Journal of clinical investigation	2007	193
18083107	1956	Rikova K	Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.	Cell	2007	600
18087285	1956	Yoshikawa D	Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma.	British journal of cancer	2008	79
18093943	1956	Bean J	MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.	Proceedings of the National Academy of Sciences of the United States of America	2007	446
18188694	1956	Cameron D	A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.	Breast cancer research and treatment	2008	143
18211286	1956	Vazquez-Martin A	Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells.	Cell proliferation	2008	54
18236164	1956	Barr S	Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions.	Clinical and experimental metastasis	2008	70
18259690	1956	Wieduwilt MJ	The epidermal growth factor receptor family: biology driving targeted therapeutics.	Cellular and molecular life sciences 	2008	66
18272912	1956	Tol J	A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.	Annals of oncology 	2008	56
18281673	1956	Eberhard DA	Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.	Journal of clinical oncology 	2008	67
18283321	1956	Tamura K	Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403).	British journal of cancer	2008	54
18297114	1956	Wheeler DL	Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members.	Oncogene	2008	159
18303429	1956	Marks JL	Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma.	Journal of thoracic oncology 	2008	71
18304967	1956	Weiss GJ	EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines.	Annals of oncology 	2008	74
18316557	1956	Cheang MC	Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.	Clinical cancer research 	2008	299
18325048	1956	Taniguchi K	Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib.	Cancer science	2008	61
18339877	1956	Jhawer M	PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.	Cancer research	2008	130
18349398	1956	Miller VA	Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.	Journal of clinical oncology 	2008	66
18362333	1956	Diehn M	Identification of noninvasive imaging surrogates for brain tumor gene-expression modules.	Proceedings of the National Academy of Sciences of the United States of America	2008	85
18375904	1956	Kumar A	Structure and clinical relevance of the epidermal growth factor receptor in human cancer.	Journal of clinical oncology 	2008	58
18380996	1956	Marur S	Head and neck cancer: changing epidemiology, diagnosis, and treatment.	Mayo Clinic proceedings	2008	84
18381447	1956	Fuchs BC	Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells.	Cancer research	2008	86
18390971	1956	Sobrero AF	EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.	Journal of clinical oncology 	2008	168
18391747	1956	Motoi N	Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis.	The American journal of surgical pathology	2008	77
18397279	1956	Kim MA	EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number.	Histopathology	2008	67
18403491	1956	Sampson JH	Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors.	Neuro-oncology	2008	54
18408761	1956	Li D	BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.	Oncogene	2008	267
18413800	1956	Godin-Heymann N	The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.	Molecular cancer therapeutics	2008	58
18421051	1956	Lin NU	Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.	Journal of clinical oncology 	2008	97
18437168	1956	Ladanyi M	Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond.	Modern pathology 	2008	71
18452692	1956	Molina JR	Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.	Mayo Clinic proceedings	2008	357
18458038	1956	Sequist LV	First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.	Journal of clinical oncology 	2008	233
18486742	1956	Argiris A	Head and neck cancer.	Lancet	2008	285
18509184	1956	Yang CH	Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.	Journal of clinical oncology 	2008	56
18565887	1956	Murat A	Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma.	Journal of clinical oncology 	2008	213
18596266	1956	Maheswaran S	Detection of mutations in EGFR in circulating lung-cancer cells.	The New England journal of medicine	2008	402
18604200	1956	Kolev V	EGFR signalling as a negative regulator of Notch1 gene transcription and function in proliferating keratinocytes and cancer.	Nature cell biology	2008	67
18612148	1956	Anders CK	Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression.	Journal of clinical oncology 	2008	140
18612151	1956	Hirsch FR	Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy.	Journal of clinical oncology 	2008	65
18626007	1956	Zhu CQ	Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.	Journal of clinical oncology 	2008	160
18632642	1956	Lee-Hoeflich ST	A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.	Cancer research	2008	168
18676761	1956	Wu JY	Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response.	Clinical cancer research 	2008	71
18681955	1956	Tamimi RM	Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer.	Breast cancer research 	2008	84
18782861	1956	Tao RH	All EGF(ErbB) receptors have preformed homo- and heterodimeric structures in living cells.	Journal of cell science	2008	69
18794099	1956	Personeni N	Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study.	Clinical cancer research 	2008	51
18802721	1956	van Krieken JH	KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.	Virchows Archiv 	2008	73
18821591	1956	Llovet JM	Molecular targeted therapies in hepatocellular carcinoma.	Hepatology	2008	267
18829483	1956	Lo HW	Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators.	Clinical cancer research 	2008	65
18836087	1956	Cappuzzo F	MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.	Annals of oncology 	2009	80
18839307	1956	Viale G	Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity.	Breast cancer research and treatment	2009	51
18922904	1956	Buck E	Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.	Cancer research	2008	82
18927285	1956	Fichtner I	Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.	Clinical cancer research 	2008	85
18936474	1956	Heymach JV	Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.	Journal of clinical oncology 	2008	56
18948947	1956	Ding L	Somatic mutations affect key pathways in lung adenocarcinoma.	Nature	2008	865
18955445	1956	Brown PD	Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.	Journal of clinical oncology 	2008	61
18955454	1956	Di Leo A	Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.	Journal of clinical oncology 	2008	92
18978815	1956	Pickl M	Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab.	Oncogene	2009	84
18981003	1956	Costa DB	Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.	Clinical cancer research 	2008	54
19010870	1956	Bean J	Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.	Clinical cancer research 	2008	77
19010912	1956	Pratilas CA	Genetic predictors of MEK dependence in non-small cell lung cancer.	Cancer research	2008	83
19010923	1956	Yano S	Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.	Cancer research	2008	169
19027483	1956	Kim ES	Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.	Lancet	2008	258
19047149	1956	Saxena NK	Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor.	Cancer research	2008	65
19058255	1956	Xia W	Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer.	Molecular carcinogenesis	2009	67
19060928	1956	Scaltriti M	Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity.	Oncogene	2009	103
19073608	1956	Webster RJ	Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7.	The Journal of biological chemistry	2009	138
19075262	1956	Prados MD	Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.	Journal of clinical oncology 	2009	88
19088172	1956	Gow CH	Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer.	Annals of oncology 	2009	47
19089838	1956	Yang L	Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging.	Small	2009	87
19091906	1956	Aerts HJ	Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET.	Journal of nuclear medicine 	2009	53
19096300	1956	Onozato R	Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.	Journal of thoracic oncology 	2009	61
19109410	1956	Graner MW	Proteomic and immunologic analyses of brain tumor exosomes.	FASEB journal 	2009	101
19114685	1956	Hecht JR	A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.	Journal of clinical oncology 	2009	180
19117999	1956	Huang F	The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors.	Cancer research	2009	63
19118495	1956	Sahin O	Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance.	BMC systems biology	2009	52
19147502	1956	Griffero F	Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors.	The Journal of biological chemistry	2009	49
19150933	1956	Corkery B	Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.	Annals of oncology 	2009	66
19169683	1956	Ramanathan RK	A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer.	Cancer chemotherapy and pharmacology	2009	59
19170230	1956	Wong DW	The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.	Cancer	2009	157
19176518	1956	Fan QW	EGFR signals to mTOR through PKC and independently of Akt in glioma.	Science signaling	2009	60
19188670	1956	Allegra CJ	American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.	Journal of clinical oncology 	2009	311
19201650	1956	Cohen EE	Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.	The Lancet. Oncology	2009	52
19204207	1956	van den Bent MJ	Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.	Journal of clinical oncology 	2009	110
19217204	1956	Montagut C	Targeting the RAF-MEK-ERK pathway in cancer therapy.	Cancer letters	2009	108
19224850	1956	Inoue A	First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy.	Journal of clinical oncology 	2009	84
19228746	1956	Lin NU	Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.	Clinical cancer research 	2009	105
19234131	1956	Al-Nedawi K	Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR.	Proceedings of the National Academy of Sciences of the United States of America	2009	141
19234440	1956	Inamura K	EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.	Modern pathology 	2009	103
19238632	1956	Tang Z	Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer.	British journal of cancer	2008	57
19255323	1956	Cappuzzo F	Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients.	Journal of clinical oncology 	2009	114
19276259	1956	Yung TK	Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients.	Clinical cancer research 	2009	99
19276389	1956	Narayan M	Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells.	Cancer research	2009	69
19276677	1956	Wheeler DL	Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab.	Cancer biology and therapy	2009	55
19289630	1956	Stewart JS	Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck corrected.	Journal of clinical oncology 	2009	57
19296866	1956	Johnson LN	Protein kinase inhibitors: contributions from structure to clinical compounds.	Quarterly reviews of biophysics	2009	58
19319529	1956	López-Albaitero A	Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells.	Cancer immunology, immunotherapy 	2009	54
19332730	1956	Natale RB	Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study.	Journal of clinical oncology 	2009	51
19346299	1956	Ross JS	The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.	The oncologist	2009	199
19351754	1956	Kuang Y	Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer.	Clinical cancer research 	2009	65
19366827	1956	Yu J	Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer.	Clinical cancer research 	2009	54
19410716	1956	Pirker R	Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.	Lancet	2009	294
19412429	1956	Pillay V	The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.	Neoplasia	2009	48
19414683	1956	Bai H	Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.	Journal of clinical oncology 	2009	84
19421193	1956	Bos PD	Genes that mediate breast cancer metastasis to the brain.	Nature	2009	433
19421880	1956	Dembinski JL	Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma.	Clinical and experimental metastasis	2009	60
19447865	1956	Naumov GN	Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.	Clinical cancer research 	2009	55
19480968	1956	Kuremsky JG	Biomarkers for response to neoadjuvant chemoradiation for rectal cancer.	International journal of radiation oncology, biology, physics	2009	56
19483740	1956	Linardou H	Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.	Nature reviews. Clinical oncology	2009	57
19490536	1956	Stuffers S	Multivesicular endosome biogenesis in the absence of ESCRTs.	Traffic	2009	58
19536107	1956	Baselga J	Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.	Nature reviews. Cancer	2009	312
19536109	1956	Walther A	Genetic prognostic and predictive markers in colorectal cancer.	Nature reviews. Cancer	2009	170
19544433	1956	Kelly JJ	Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens.	Stem cells	2009	62
19584155	1956	Schmid K	EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.	Clinical cancer research 	2009	66
19596646	1956	Anders CK	Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer.	Clinical breast cancer	2009	104
19597023	1956	Mandrekar SJ	Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.	Journal of clinical oncology 	2009	74
19625624	1956	Guo D	The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis.	Proceedings of the National Academy of Sciences of the United States of America	2009	81
19632948	1956	Nguyen KS	Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.	Clinical lung cancer	2009	108
19636327	1956	Normanno N	Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.	Nature reviews. Clinical oncology	2009	107
19667264	1956	Shaw AT	Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.	Journal of clinical oncology 	2009	383
19671762	1956	Liu TJ	NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas.	Molecular cancer therapeutics	2009	89
19671843	1956	Jackman DM	Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.	Clinical cancer research 	2009	111
19680293	1956	Gazdar AF	Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.	Oncogene	2009	163
19680294	1956	Hirsch FR	Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer.	Oncogene	2009	56
19689244	1956	Hartmann JT	Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects.	Current drug metabolism	2009	56
19690143	1956	Lu KV	Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients.	Cancer research	2009	55
19692680	1956	Mok TS	Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.	The New England journal of medicine	2009	1545
19692684	1956	Rosell R	Screening for epidermal growth factor receptor mutations in lung cancer.	The New England journal of medicine	2009	452
19706799	1956	Desbois-Mouthon C	Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.	Clinical cancer research 	2009	57
19720911	1956	Millar EK	Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel.	Journal of clinical oncology 	2009	60
19723643	1956	Krishnaswamy S	Ethnic differences and functional analysis of MET mutations in lung cancer.	Clinical cancer research 	2009	55
19738203	1956	Huang PH	Oncogenic EGFR signaling networks in glioma.	Science signaling	2009	92
19775602	1956	Dawson SJ	Triple negative breast cancers: clinical and prognostic implications.	European journal of cancer	2009	55
19786658	1956	Johnston S	Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.	Journal of clinical oncology 	2009	191
19787002	1956	Kim LC	Src kinases as therapeutic targets for cancer.	Nature reviews. Clinical oncology	2009	214
19806185	1956	Sartore-Bianchi A	Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer.	PloS one	2009	85
19825799	1956	Sampson JH	An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme.	Molecular cancer therapeutics	2009	75
19840943	1956	Demory ML	Epidermal growth factor receptor translocation to the mitochondria: regulation and effect.	The Journal of biological chemistry	2009	48
19852961	1956	Goetz M	In vivo molecular imaging of colorectal cancer with confocal endomicroscopy by targeting epidermal growth factor receptor.	Gastroenterology	2010	59
19861462	1956	Wang SC	Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors.	Clinical cancer research 	2009	63
19884552	1956	Spector NL	Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.	Journal of clinical oncology 	2009	110
19884556	1956	Laurent-Puig P	Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.	Journal of clinical oncology 	2009	189
19914732	1956	Dempke WC	Targeted therapies for non-small cell lung cancer.	Lung cancer	2010	44
19917871	1956	Azzoli CG	American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer.	Journal of clinical oncology 	2009	139
19920198	1956	Gravendeel LA	Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology.	Cancer research	2009	128
19934333	1956	Scheuer W	Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.	Cancer research	2009	118
19942479	1956	Folprecht G	Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.	The Lancet. Oncology	2010	131
19949011	1956	Jackman D	Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.	Journal of clinical oncology 	2010	156
19949019	1956	Hanrahan EO	Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.	Journal of clinical oncology 	2010	52
19960228	1956	Peereboom DM	Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.	Journal of neuro-oncology	2010	57
20012924	1956	McConkey DJ	Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer.	Cancer metastasis reviews	2009	81
20022809	1956	Mitsudomi T	Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.	The Lancet. Oncology	2010	783
20027191	1956	Esteva FJ	Molecular predictors of response to trastuzumab and lapatinib in breast cancer.	Nature reviews. Clinical oncology	2010	48
20028749	1956	Dahabreh IJ	Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer.	Clinical cancer research 	2010	44
20038723	1956	Douillard JY	Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.	Journal of clinical oncology 	2010	141
20048743	1956	Zhou X	Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status.	Laboratory investigation; a journal of technical methods and pathology	2010	94
20049729	1956	Watt FM	Epidermal stem cell diversity and quiescence.	EMBO molecular medicine	2009	69
20064507	1956	Kruser TJ	Mechanisms of resistance to HER family targeting antibodies.	Experimental cell research	2010	50
20065189	1956	Wells SA Jr	Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.	Journal of clinical oncology 	2010	95
20082448	1956	Rimawi MF	Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes.	Cancer	2010	45
20100958	1956	Khambata-Ford S	Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2010	63
20100961	1956	Bardelli A	Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.	Journal of clinical oncology 	2010	160
20100966	1956	Lynch TJ	Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.	Journal of clinical oncology 	2010	103
20103678	1956	Baldus SE	Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.	Clinical cancer research 	2010	109
20108024	1956	Suda K	Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation.	Cancer metastasis reviews	2010	44
20113523	1956	Ren Y	MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol.	BMC cancer	2010	47
20124471	1956	McDermott U	Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency.	Cancer research	2010	51
20129249	1956	Turke AB	Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.	Cancer cell	2010	279
20130423	1956	Lurje G	EGFR signaling and drug discovery.	Oncology	2009	103
20142592	1956	Haura EB	Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2010	57
20142600	1956	Lacouture ME	Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer.	Journal of clinical oncology 	2010	59
20146086	1956	Clarke JL	High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer.	Journal of neuro-oncology	2010	50
20150372	1956	Raizer JJ	A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.	Neuro-oncology	2010	56
20179223	1956	Campbell MR	HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy.	Clinical cancer research 	2010	55
20183914	1956	Takahashi T	Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.	Annals of surgical oncology	2010	80
20194857	1956	Voduc KD	Breast cancer subtypes and the risk of local and regional relapse.	Journal of clinical oncology 	2010	212
20332324	1956	Johnston SR	New strategies in estrogen receptor-positive breast cancer.	Clinical cancer research 	2010	61
20351699	1956	Harris TJ	The molecular pathology of cancer.	Nature reviews. Clinical oncology	2010	57
20399983	1956	Tol J	Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.	Clinical therapeutics	2010	50
20431034	1956	Tsiatis AC	Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications.	The Journal of molecular diagnostics 	2010	105
20479403	1956	Sequist LV	Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.	Journal of clinical oncology 	2010	96
20493771	1956	Cappuzzo F	Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.	The Lancet. Oncology	2010	278
20501798	1956	O'Brien NA	Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.	Molecular cancer therapeutics	2010	83
20508278	1956	Ghosh N	COX-2 as a target for cancer chemotherapy.	Pharmacological reports 	2010	54
20515495	1956	Krakstad C	Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics.	Molecular cancer	2010	65
20520800	1956	Blows FM	Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies.	PLoS medicine	2010	185
20530271	1956	Lubner SJ	Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.	Journal of clinical oncology 	2010	55
20530283	1956	Alvarez RH	Emerging targeted therapies for breast cancer.	Journal of clinical oncology 	2010	41
20551942	1956	Wheeler DL	Understanding resistance to EGFR inhibitors-impact on future treatment strategies.	Nature reviews. Clinical oncology	2010	173
20551945	1956	Janku F	Targeted therapy in non-small-cell lung cancer--is it becoming a reality?	Nature reviews. Clinical oncology	2010	61
20562913	1956	Gan Y	Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells.	Oncogene	2010	73
20570559	1956	Herbst RS	Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.	The Lancet. Oncology	2010	99
20573926	1956	Maemondo M	Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.	The New England journal of medicine	2010	979
20595147	1956	Porta R	Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation.	The European respiratory journal	2011	60
20621056	1956	Curtis SJ	Primary tumor genotype is an important determinant in identification of lung cancer propagating cells.	Cell stem cell	2010	50
20624322	1956	Zhang X	Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.	Molecular cancer	2010	79
20627894	1956	Eichler AF	EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer.	Neuro-oncology	2010	48
20647323	1956	Hadjipanayis CG	EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma.	Cancer research	2010	82
20716591	1956	Sathornsumetee S	Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.	Neuro-oncology	2010	48
20736298	1956	Cameron D	Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial.	The oncologist	2010	49
20736484	1956	Moritz A	Akt-RSK-S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases.	Science signaling	2010	100
20798686	1956	Li QQ	Involvement of NF-κB/miR-448 regulatory feedback loop in chemotherapy-induced epithelial-mesenchymal transition of breast cancer cells.	Cell death and differentiation	2011	40
20824720	1956	da Cunha Santos G	Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.	Cancer	2010	42
20838621	1956	Punnoose EA	Molecular biomarker analyses using circulating tumor cells.	PloS one	2010	78
20855820	1956	Johnson FM	Phase II study of dasatinib in patients with advanced non-small-cell lung cancer.	Journal of clinical oncology 	2010	53
20855837	1956	Sun Y	Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.	Journal of clinical oncology 	2010	93
20858720	1956	Mazzoleni S	Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis.	Cancer research	2010	65
20861192	1956	Hochgräfe F	Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.	Cancer research	2010	56
20864632	1956	Attolini CS	A mathematical framework to determine the temporal sequence of somatic genetic events in cancer.	Proceedings of the National Academy of Sciences of the United States of America	2010	47
20871269	1956	Pirker R	Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop.	Journal of thoracic oncology 	2010	57
20874002	1956	Katakowski M	MiR-146b-5p suppresses EGFR expression and reduces in vitro migration and invasion of glioma.	Cancer investigation	2010	47
20887192	1956	da Cunha Santos G	EGFR mutations and lung cancer.	Annual review of pathology	2011	65
20887199	1956	Osborne CK	Mechanisms of endocrine resistance in breast cancer.	Annual review of medicine	2011	214
20921459	1956	Sampson JH	Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.	Journal of clinical oncology 	2010	184
20921461	1956	Roberts PJ	Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?	Journal of clinical oncology 	2010	77
20921462	1956	Peeters M	Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.	Journal of clinical oncology 	2010	181
20921465	1956	Douillard JY	Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.	Journal of clinical oncology 	2010	342
20940188	1956	Sequist LV	Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.	Journal of clinical oncology 	2010	100
20943624	1956	Vermorken JB	Optimal treatment for recurrent/metastatic head and neck cancer.	Annals of oncology 	2010	51
20966921	1956	Pao W	Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer.	Nature reviews. Cancer	2010	237
21030498	1956	Heon S	Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.	Clinical cancer research 	2010	44
21048039	1956	Licitra L	Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.	Annals of oncology 	2011	54
21062932	1956	Camidge DR	Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.	Clinical cancer research 	2010	75
21062933	1956	Suda K	Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer.	Clinical cancer research 	2010	47
21081655	1956	John T	The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer.	Clinical cancer research 	2011	38
21135146	1956	Oxnard GR	Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation.	Clinical cancer research 	2011	102
21160078	1956	Weiss J	Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.	Science translational medicine	2010	191
21160525	1956	Leemans CR	The molecular biology of head and neck cancer.	Nature reviews. Cancer	2011	466
21161370	1956	Pal SK	Triple negative breast cancer: unmet medical needs.	Breast cancer research and treatment	2011	74
21163703	1956	De Roock W	KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.	The Lancet. Oncology	2011	125
21165163	1956	Zhang Z	EGFR-mutated lung cancer: a paradigm of molecular oncology.	Oncotarget	2010	53
21168239	1956	Chung JH	Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs.	Lung cancer	2011	39
21200037	1956	Dahabreh IJ	Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer.	Annals of internal medicine	2011	47
21220471	1956	Jänne PA	Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors.	Clinical cancer research 	2011	39
21220474	1956	Donev IS	Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.	Clinical cancer research 	2011	37
21220480	1956	Osborne CK	Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study.	Clinical cancer research 	2011	52
21233402	1956	Rosell R	Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.	Clinical cancer research 	2011	78
21252999	1956	Avraham R	Feedback regulation of EGFR signalling: decision making by early and delayed loops.	Nature reviews. Molecular cell biology	2011	180
21253578	1956	Gu TL	Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma.	PloS one	2011	89
21258250	1956	Ludovini V	Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.	Journal of thoracic oncology 	2011	44
21258415	1956	Normant E	The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.	Oncogene	2011	46
21266349	1956	Liccardi G	EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment.	Cancer research	2011	65
21266357	1956	Qi J	Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors.	Cancer research	2011	49
21273060	1956	Krumbach R	Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance.	European journal of cancer	2011	39
21277552	1956	Pao W	New driver mutations in non-small-cell lung cancer.	The Lancet. Oncology	2011	244
21282537	1956	de Boer RH	Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.	Journal of clinical oncology 	2011	61
21282542	1956	Natale RB	Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.	Journal of clinical oncology 	2011	65
21289483	1956	Cho WC	MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1.	RNA biology	2011	53
21293176	1956	Brand TM	Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab.	Cancer biology and therapy	2011	40
21303969	1956	Ramalingam SS	Lung cancer: New biological insights and recent therapeutic advances.	CA	2011	87
21324925	1956	Ghosh R	Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers.	Cancer research	2011	50
21377930	1956	Machiels JP	Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial.	The Lancet. Oncology	2011	36
21407195	1956	Maretzky T	Migration of growth factor-stimulated epithelial and endothelial cells depends on EGFR transactivation by ADAM17.	Nature communications	2011	38
21408138	1956	van Eijk R	Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR.	PloS one	2011	43
21412767	1956	Zhang Y	Potential mechanism of interleukin-8 production from lung cancer cells: an involvement of EGF-EGFR-PI3K-Akt-Erk pathway.	Journal of cellular physiology	2012	34
21422426	1956	Zander T	Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using (18)Ffluorodeoxyglucose and (18)Ffluorothymidine positron emission tomography.	Journal of clinical oncology 	2011	37
21430269	1956	Sequist LV	Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.	Science translational medicine	2011	619
21430781	1956	Bivona TG	FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR.	Nature	2011	99
21468131	1956	Okines A	Targeting the human EGFR family in esophagogastric cancer.	Nature reviews. Clinical oncology	2011	43
21471286	1956	Hegi ME	Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib--a phase II trial.	Molecular cancer therapeutics	2011	35
21482987	1956	D'Angelo SP	Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas.	Journal of clinical oncology 	2011	59
21482992	1956	Keedy VL	American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.	Journal of clinical oncology 	2011	117
21483012	1956	Paik PK	Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.	Journal of clinical oncology 	2011	115
21502544	1956	Van Cutsem E	Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.	Journal of clinical oncology 	2011	350
21531810	1956	Wu JY	Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.	Clinical cancer research 	2011	85
21555682	1956	Blumenschein GR Jr	Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324.	Journal of clinical oncology 	2011	46
21576636	1956	Spigel DR	Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.	Journal of clinical oncology 	2011	40
21597390	1956	Suda K	Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.	Journal of thoracic oncology 	2011	69
21630130	1956	Lacouture ME	Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.	Supportive care in cancer 	2011	37
21641636	1956	Maughan TS	Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.	Lancet	2011	199
21646616	1956	Price TJ	Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer.	Journal of clinical oncology 	2011	58
21653320	1956	Wang X	A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells.	Blood	2011	95
21655094	1956	Han W	EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells.	PloS one	2011	61
21687663	1956	Li N	Inhibition of cell proliferation by an anti-EGFR aptamer.	PloS one	2011	41
21690342	1956	Jin K	The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway.	Proceedings of the National Academy of Sciences of the United States of America	2012	30
21720997	1956	Kim HR	Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.	Cancer	2012	33
21730270	1956	Yatabe Y	Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma.	Journal of clinical oncology 	2011	46
21734175	1956	Chmielecki J	Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling.	Science translational medicine	2011	156
21764376	1956	Yasuda H	EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.	The Lancet. Oncology	2012	79
21768463	1956	Sequist LV	Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.	Journal of clinical oncology 	2011	120
21775534	1956	Oxnard GR	New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer.	Clinical cancer research 	2011	83
21782507	1956	O'Byrne KJ	Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.	The Lancet. Oncology	2011	55
21783417	1956	Zhou C	Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.	The Lancet. Oncology	2011	709
21788562	1956	Zhou Q	Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer.	Journal of clinical oncology 	2011	61
21791641	1956	Sasaki T	A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.	Cancer research	2011	157
21830014	1956	Tamimi RM	Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer.	Breast cancer research and treatment	2012	47
21849857	1956	Janku F	Novel therapeutic targets in non-small cell lung cancer.	Journal of thoracic oncology 	2011	38
21856766	1956	Chaft JE	Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.	Clinical cancer research 	2011	90
21862980	1956	Mok TS	Personalized medicine in lung cancer: what we need to know.	Nature reviews. Clinical oncology	2011	40
21865399	1956	Grommes C	"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.	Neuro-oncology	2011	57
21886163	1956	Breitbach CJ	Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.	Nature	2011	138
21893191	1956	Wertheimer E	Rac signaling in breast cancer: a tale of GEFs and GAPs.	Cellular signalling	2012	62
21900593	1956	Yonesaka K	Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab.	Science translational medicine	2011	134
21900837	1956	Goto K	Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer.	Journal of thoracic oncology 	2012	51
21909139	1956	Yue P	Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells.	Oncogene	2012	36
21914172	1956	Sihto H	Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study.	Breast cancer research 	2011	40
21926387	1956	Travis WD	International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary.	Proceedings of the American Thoracic Society	2011	71
21969500	1956	Brugger W	Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2011	68
21976538	1956	Taniguchi K	Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas.	Clinical cancer research 	2011	75
21990576	1956	Terwisscha van Scheltinga AG	Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies.	Journal of nuclear medicine 	2011	51
22003071	1956	LoRusso PM	Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer.	Clinical cancer research 	2011	65
22025148	1956	Lai A	Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.	Journal of clinical oncology 	2011	91
22025157	1956	Ramalingam SS	Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer.	Journal of clinical oncology 	2011	59
22042947	1956	Lennerz JK	MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.	Journal of clinical oncology 	2011	116
22052230	1956	Yano S	Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.	Journal of thoracic oncology 	2011	47
22054879	1956	Travis WD	Pathology of lung cancer.	Clinics in chest medicine	2011	59
22056021	1956	Pirker R	EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.	The Lancet. Oncology	2012	132
22065080	1956	Koul D	Antitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells.	Clinical cancer research 	2012	44
22080568	1956	Okayama H	Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas.	Cancer research	2012	124
22112968	1956	He X	Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer.	Annals of oncology 	2012	49
22119437	1956	Soria JC	EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects.	Cancer treatment reviews	2012	35
22127113	1956	Brand TM	The nuclear epidermal growth factor receptor signaling network and its role in cancer.	Discovery medicine	2011	51
22135231	1956	Chaft JE	Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.	Molecular cancer therapeutics	2012	55
22137795	1956	Snuderl M	Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma.	Cancer cell	2011	184
22139077	1956	Bonavia R	EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway.	Oncogene	2012	52
22140546	1956	Li C	Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers.	PloS one	2011	54
22144946	1956	Karar J	PI3K/AKT/mTOR Pathway in Angiogenesis.	Frontiers in molecular neuroscience	2011	107
22162641	1956	Ou SH	Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond.	Drug design, development and therapy	2011	37
22173704	1956	Krebs MG	Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches.	Journal of thoracic oncology 	2012	101
22178589	1956	Andersen JB	Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.	Gastroenterology	2012	76
22186794	1956	Parato KA	The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.	Molecular therapy 	2012	47
22189713	1956	Deng XS	Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers.	Cell cycle	2012	48
22191652	1956	Zhang Y	PET tracers based on Zirconium-89.	Current radiopharmaceuticals	2011	40
22194472	1956	Ju YS	A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.	Genome research	2012	122
22207554	1956	Park S	High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients.	Histology and histopathology	2012	35
22209049	1956	O'Flaherty JD	Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer.	Lung cancer	2012	44
22215752	1956	Su KY	Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.	Journal of clinical oncology 	2012	111
22228640	1956	Rekhtman N	Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.	Clinical cancer research 	2012	73
22228822	1956	Kim Y	The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor.	Molecular cancer therapeutics	2012	34
22235099	1956	Doebele RC	Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.	Clinical cancer research 	2012	213
22237264	1956	Sun PL	High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.	Journal of thoracic oncology 	2012	34
22239438	1956	Seshacharyulu P	Targeting the EGFR signaling pathway in cancer therapy.	Expert opinion on therapeutic targets	2012	73
22261334	1956	Han W	Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations.	Cancer letters	2012	64
22270724	1956	Montagut C	Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.	Nature medicine	2012	100
22277784	1956	Katayama R	Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.	Science translational medicine	2012	268
22281684	1956	Prahallad A	Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.	Nature	2012	392
22282022	1956	Doebele RC	Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer.	Cancer	2012	48
22282308	1956	Cheng L	Molecular pathology of lung cancer: key to personalized medicine.	Modern pathology 	2012	41
22285168	1956	Rosell R	Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.	The Lancet. Oncology	2012	876
22305568	1956	Spike BT	A mammary stem cell population identified and characterized in late embryogenesis reveals similarities to human breast cancer.	Cell stem cell	2012	56
22315472	1956	Deng N	A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets.	Gut	2012	127
22317764	1956	Zhang Y	Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.	Clinical cancer research 	2012	46
22370318	1956	Lee JS	Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).	Journal of clinical oncology 	2012	70
22407829	1956	Perez-Moreno P	Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities.	Clinical cancer research 	2012	48
22414764	1956	Blivet-Van Eggelpoël MJ	Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells.	Journal of hepatology	2012	37
22418026	1956	Oliveira S	Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody.	Molecular imaging	2012	34
22418700	1956	Lin NU	A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.	Breast cancer research and treatment	2012	44
22440336	1956	Scagliotti GV	Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer.	Clinical lung cancer	2012	44
22448344	1956	Corcoran RB	EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.	Cancer discovery	2012	179
22452803	1956	Fokas E	NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity.	Radiation oncology	2012	30
22452895	1956	Yang JC	Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.	The Lancet. Oncology	2012	76
22452896	1956	Miller VA	Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.	The Lancet. Oncology	2012	210
22454081	1956	Gallardo A	Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas.	British journal of cancer	2012	55
22464348	1956	Couraud S	Lung cancer in never smokers--a review.	European journal of cancer	2012	51
22492982	1956	Punnoose EA	Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.	Clinical cancer research 	2012	75
22505743	1956	Navani N	Suitability of endobronchial ultrasound-guided transbronchial needle aspiration specimens for subtyping and genotyping of non-small cell lung cancer: a multicenter study of 774 patients.	American journal of respiratory and critical care medicine	2012	53
22508830	1956	Witta SE	Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy.	Journal of clinical oncology 	2012	50
22520625	1956	Wang YN	Nuclear functions and subcellular trafficking mechanisms of the epidermal growth factor receptor family.	Cell and bioscience	2012	32
22535374	1956	De Boeck A	Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling.	Gut	2013	34
22541616	1956	Saintigny P	Recent advances in non-small cell lung cancer biology and clinical management.	Discovery medicine	2012	33
22547605	1956	Jänne PA	Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial.	Journal of clinical oncology 	2012	75
22552284	1956	Turke AB	MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors.	Cancer research	2012	72
22564989	1956	Scagliotti GV	Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial.	Journal of clinical oncology 	2012	50
22579283	1956	Lee MJ	Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks.	Cell	2012	180
22588883	1956	Vivanco I	Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.	Cancer discovery	2012	73
22590557	1956	Wilkerson MD	Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation.	PloS one	2012	45
22591372	1956	Gorges TM	Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.	BMC cancer	2012	110
22605616	1956	Goldman JW	Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib.	Cancer	2012	35
22611028	1956	Roselli M	Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer.	Clinical cancer research 	2012	36
22649089	1956	Forshew T	Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA.	Science translational medicine	2012	209
22658319	1956	Hurvitz SA	Current approaches and future directions in the treatment of HER2-positive breast cancer.	Cancer treatment reviews	2013	29
22673630	1956	Chen ZY	EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas.	The oncologist	2012	36
22677429	1956	Park SJ	Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.	Lung cancer	2012	50
22722830	1956	Misale S	Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.	Nature	2012	333
22722843	1956	Diaz LA Jr	The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.	Nature	2012	379
22751098	1956	Zhang Z	Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.	Nature genetics	2012	263
22753918	1956	Ramalingam SS	Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.	Journal of clinical oncology 	2012	63
22764208	1956	Issadore D	Ultrasensitive clinical enumeration of rare cells ex vivo using a micro-hall detector.	Science translational medicine	2012	55
22768234	1956	An SJ	Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status.	PloS one	2012	50
22773810	1956	Ohashi K	Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.	Proceedings of the National Academy of Sciences of the United States of America	2012	121
22778317	1956	Gridelli C	First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial.	Journal of clinical oncology 	2012	54
22780919	1956	Morgan RA	Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma.	Human gene therapy	2012	71
22785351	1956	Yarden Y	The ERBB network: at last, cancer therapy meets systems biology.	Nature reviews. Cancer	2012	143
22797485	1956	Zhao X	Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients.	Respiration; international review of thoracic diseases	2013	30
22806307	1956	Togashi Y	Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer.	Cancer chemotherapy and pharmacology	2012	34
22810899	1956	Johnson ML	Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.	Cancer	2013	32
22826274	1956	Bai H	Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer.	Journal of clinical oncology 	2012	60
22843788	1956	Tanizaki J	Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer.	Clinical cancer research 	2012	46
22847020	1956	Phuphanich S	Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma.	Cancer immunology, immunotherapy 	2013	68
22864381	1956	Komurov K	The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells.	Molecular systems biology	2012	32
22888144	1956	Solca F	Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker.	The Journal of pharmacology and experimental therapeutics	2012	95
22891331	1956	Fenton TR	Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.	Proceedings of the National Academy of Sciences of the United States of America	2012	32
22898037	1956	Argiris A	Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck.	Annals of oncology 	2013	34
22898678	1956	Leboulleux S	Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.	The Lancet. Oncology	2012	56
22949147	1956	Van Cutsem E	Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.	Journal of clinical oncology 	2012	183
22956860	1956	Creighton CJ	The molecular profile of luminal B breast cancer.	Biologics 	2012	45
22961667	1956	Ercan D	Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.	Cancer discovery	2012	77
22964225	1956	Johnson H	Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts.	Molecular and cellular proteomics 	2012	30
22967997	1956	Inoue A	Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002).	Annals of oncology 	2013	73
22977193	1956	Terashima M	Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer.	Clinical cancer research 	2012	59
23000897	1956	Cancer Genome Atlas Network.	Comprehensive molecular portraits of human breast tumours.	Nature	2012	2327
23012302	1956	André F	Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents.	Annals of oncology 	2012	58
23014527	1956	Dogan S	Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers.	Clinical cancer research 	2012	74
23021375	1956	Berg M	EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy.	Discovery medicine	2012	32
23045285	1956	Gusenbauer S	HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors.	Oncogene	2013	35
23052255	1956	Suehara Y	Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.	Clinical cancer research 	2012	35
23070115	1956	Uchida H	Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus.	Molecular therapy 	2013	26
23073759	1956	Masuda H	Role of epidermal growth factor receptor in breast cancer.	Breast cancer research and treatment	2012	81
23079155	1956	Yang JJ	Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer.	Lung cancer	2013	33
23084121	1956	Nielsen DL	Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.	Breast	2013	26
23103856	1956	Young A	Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling.	Cancer discovery	2013	48
23123196	1956	Yang W	EGFR-induced and PKCε monoubiquitylation-dependent NF-κB activation upregulates PKM2 expression and promotes tumorigenesis.	Molecular cell	2012	55
23129122	1956	Wu YL	Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803).	Annals of oncology 	2013	36
23136247	1956	Gasch C	Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer.	Clinical chemistry	2013	55
23149820	1956	Singh JK	Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms.	Clinical cancer research 	2013	49
23154552	1956	Weickhardt AJ	Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.	Journal of thoracic oncology 	2012	80
23154553	1956	D'Angelo SP	Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.	Journal of thoracic oncology 	2012	36
23172311	1956	Huang S	Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation.	Cancer research	2013	34
23172555	1956	Ellison G	EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples.	Journal of clinical pathology	2013	49
23221996	1956	Ocana A	HER3 overexpression and survival in solid tumors: a meta-analysis.	Journal of the National Cancer Institute	2013	48
23233388	1956	Mostert B	KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue.	International journal of cancer	2013	30
23242438	1956	Yoshizawa A	Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients.	Journal of thoracic oncology 	2013	67
23242808	1956	Girotti MR	Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.	Cancer discovery	2013	99
23265711	1956	Licitra L	Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies.	European journal of cancer	2013	27
23280481	1956	Chen CL	Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer.	The Prostate	2013	44
23319610	1956	Ferraro DA	Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR.	Proceedings of the National Academy of Sciences of the United States of America	2013	26
23332287	1956	Gadgeel SM	Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.	Clinical lung cancer	2013	29
23333074	1956	Zaiss DM	Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor.	Immunity	2013	49
23341526	1956	Welsh JW	Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.	Journal of clinical oncology 	2013	71
23341890	1956	Li Y	Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer.	PloS one	2013	41
23344264	1956	Yeh P	DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.	Clinical cancer research 	2013	35
23358903	1956	Bayraktar S	Molecularly targeted therapies for metastatic triple-negative breast cancer.	Breast cancer research and treatment	2013	31
23361103	1956	Gonzalez de Castro D	Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance.	Clinical pharmacology and therapeutics	2013	47
23362162	1956	Tuononen K	Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS.	Genes, chromosomes and cancer	2013	34
23370315	1956	Hirsch FR	Epidermal growth factor receptor inhibition in lung cancer: status 2012.	Journal of thoracic oncology 	2013	26
23375249	1956	Heinemann V	Targeted therapy in metastatic colorectal cancer -- an example of personalised medicine in action.	Cancer treatment reviews	2013	28
23383079	1956	Liu HB	Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis.	PloS one	2013	25
23391413	1956	Voss JS	Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions.	Human pathology	2013	38
23401433	1956	Li T	Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies.	Journal of clinical oncology 	2013	86
23401440	1956	Roberts PJ	KRAS mutation: should we test for it, and does it matter?	Journal of clinical oncology 	2013	54
23401443	1956	Travis WD	New pathologic classification of lung cancer: relevance for clinical practice and clinical trials.	Journal of clinical oncology 	2013	68
23401448	1956	Mok T	Treating patients with EGFR-sensitizing mutations: first line or second line--is there a difference?	Journal of clinical oncology 	2013	27
23401451	1956	Ohashi K	Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.	Journal of clinical oncology 	2013	103
23401452	1956	Laurie SA	Role of epidermal growth factor receptor inhibitors in epidermal growth factor receptor wild-type non-small-cell lung cancer.	Journal of clinical oncology 	2013	29
23404247	1956	Valtorta E	KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy.	International journal of cancer	2013	34
23407558	1956	Yu HA	Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors.	Journal of thoracic oncology 	2013	48
23542173	1956	Yamaguchi H	Signaling cross-talk in the resistance to HER family receptor targeted therapy.	Oncogene	2014	27
23547110	1956	Drier Y	Pathway-based personalized analysis of cancer.	Proceedings of the National Academy of Sciences of the United States of America	2013	39
23551194	1956	Lindeman NI	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.	Archives of pathology and laboratory medicine	2013	68
23552377	1956	Lindeman NI	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.	Journal of thoracic oncology 	2013	124
23553849	1956	Socinski MA	A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.	Clinical cancer research 	2013	70
23555746	1956	Luca AC	Impact of the 3D microenvironment on phenotype, gene expression, and EGFR inhibition of colorectal cancer cell lines.	PloS one	2013	36
23562183	1956	Lindeman NI	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.	The Journal of molecular diagnostics 	2013	60
23563269	1956	Murtaza M	Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA.	Nature	2013	259
23576557	1956	Keysar SB	Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer.	Cancer research	2013	26
23584089	1956	Sadanandam A	A colorectal cancer classification system that associates cellular phenotype and responses to therapy.	Nature medicine	2013	186
23584090	1956	De Sousa E Melo F	Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions.	Nature medicine	2013	132
23589544	1956	Buettner R	Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment.	Journal of clinical oncology 	2013	33
23594426	1956	Lee CK	Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.	Journal of the National Cancer Institute	2013	98
23607916	1956	Keysar SB	A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins.	Molecular oncology	2013	32
23633480	1956	Chettouh H	Mitogenic insulin receptor-A is overexpressed in human hepatocellular carcinoma due to EGFR-mediated dysregulation of RNA splicing factors.	Cancer research	2013	32
23636329	1956	Shen J	EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2.	Nature	2013	100
23645635	1956	Rizvi I	Flow induces epithelial-mesenchymal transition, cellular heterogeneity and biomarker modulation in 3D ovarian cancer nodules.	Proceedings of the National Academy of Sciences of the United States of America	2013	32
23653350	1956	Balanis N	Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway.	The Journal of biological chemistry	2013	29
23676460	1956	Banck MS	The genomic landscape of small intestine neuroendocrine tumors.	The Journal of clinical investigation	2013	36
23707073	1956	Babic I	EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer.	Cell metabolism	2013	30
23723294	1956	Dearden S	Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap).	Annals of oncology 	2013	58
23729361	1956	Gainor JF	ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.	Clinical cancer research 	2013	85
23729478	1956	Bardelli A	Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.	Cancer discovery	2013	126
23733761	1956	Baselga J	Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer.	Journal of clinical oncology 	2013	66
23768755	1956	Roengvoraphoj M	Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.	Cancer treatment reviews	2013	25
23777544	1956	Gan HK	The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered.	The FEBS journal	2013	46
23814043	1956	Gainor JF	Novel targets in non-small cell lung cancer: ROS1 and RET fusions.	The oncologist	2013	35
23816960	1956	Sequist LV	Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.	Journal of clinical oncology 	2013	383
23816963	1956	Katakami N	LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.	Journal of clinical oncology 	2013	63
23816967	1956	Yang JC	Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.	Journal of clinical oncology 	2013	49
23829935	1956	Remon J	Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins.	Cancer treatment reviews	2014	22
23830194	1956	Brand TM	Nuclear EGFR as a molecular target in cancer.	Radiotherapy and oncology 	2013	38
23833300	1956	Cardarella S	Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.	Clinical cancer research 	2013	34
23852704	1956	Duffy MJ	Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update.	International journal of cancer	2014	26
23872583	1956	Kanda R	Erlotinib resistance in lung cancer cells mediated by integrin β1/Src/Akt-driven bypass signaling.	Cancer research	2013	28
23883922	1956	Garassino MC	Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.	The Lancet. Oncology	2013	116
23888061	1956	Liu X	The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies.	Journal of clinical pathology	2013	29
23891509	1956	Tsuta K	The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations.	Lung cancer	2013	35
23894143	1956	Li R	Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer.	Molecular cancer therapeutics	2013	32
23931927	1956	Gridelli C	ALK inhibitors in the treatment of advanced NSCLC.	Cancer treatment reviews	2014	34
23948351	1956	Shi Y	Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.	The Lancet. Oncology	2013	73
23953842	1956	Yewale C	Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.	Biomaterials	2013	44
23972815	1956	Rosell R	Genetics and biomarkers in personalisation of lung cancer treatment.	Lancet	2013	60
23980091	1956	Goss GD	Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.	Journal of clinical oncology 	2013	40
24021541	1956	Iuchi T	Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma.	Lung cancer	2013	31
24026012	1956	Giles KM	Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib.	Molecular cancer therapeutics	2013	29
24034250	1956	Wei Y	EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance.	Cell	2013	104
24044505	1956	Xia W	An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.	Breast cancer research 	2013	31
24065731	1956	Walter AO	Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.	Cancer discovery	2013	122
24072220	1956	Goldberg SB	Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors.	The oncologist	2013	37
24098024	1956	Pichler M	miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor.	Journal of clinical pathology	2014	26
24101047	1956	Gainor JF	Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer.	Journal of clinical oncology 	2013	67
24101053	1956	Spigel DR	Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.	Journal of clinical oncology 	2013	93
24105277	1956	Hata A	Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations.	Cancer	2013	38
24122263	1956	Cummings MC	Metastatic progression of breast cancer: insights from 50 years of autopsies.	The Journal of pathology	2014	25
24122793	1956	Troiani T	Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells.	Clinical cancer research 	2013	36
24141978	1956	Zhang L	A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy.	Scientific reports	2013	28
24165158	1956	Rho JK	MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.	Cancer research	2014	29
24174329	1956	Clinical Lung Cancer Genome Project (CLCGP).	A genomics-based classification of human lung tumors.	Science translational medicine	2013	74
24199682	1956	Yamaguchi N	Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer.	Lung cancer	2014	23
24199791	1956	Ahmad A	Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs.	Journal of hematology and oncology	2013	29
24202392	1956	Chong CR	The quest to overcome resistance to EGFR-targeted therapies in cancer.	Nature medicine	2013	168
24236184	1956	Scarpa A	Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel.	PloS one	2013	28
24248375	1956	Drake JM	Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets.	Proceedings of the National Academy of Sciences of the United States of America	2013	28
24263064	1956	Douillard JY	First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study.	British journal of cancer	2014	33
24269963	1956	Roskoski R Jr	The ErbB/HER family of protein-tyrosine kinases and cancer.	Pharmacological research	2014	122
24285021	1956	Beau-Faller M	Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network.	Annals of oncology 	2014	26
24310612	1956	Nathanson DA	Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA.	Science	2014	70
24335959	1956	Huang WC	miRNA-491-5p and GIT1 serve as modulators and biomarkers for oral squamous cell carcinoma invasion and metastasis.	Cancer research	2014	31
24353160	1956	Yasuda H	Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.	Science translational medicine	2013	45
24366937	1956	Vergote IB	Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study.	Journal of clinical oncology 	2014	23
24378644	1956	Siegelin MD	Epidermal growth factor receptor mutations in lung adenocarcinoma.	Laboratory investigation; a journal of technical methods and pathology	2014	40
24384534	1956	Maroun CR	The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance.	Pharmacology and therapeutics	2014	31
24390343	1956	Scafidi J	Intranasal epidermal growth factor treatment rescues neonatal brain injury.	Nature	2014	43
24406864	1956	Park HS	High EGFR gene copy number predicts poor outcome in triple-negative breast cancer.	Modern pathology 	2014	33
24419411	1956	Shi Y	A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER).	Journal of thoracic oncology 	2014	113
24425048	1956	Kim J	microRNA-148a is a prognostic oncomiR that targets MIG6 and BIM to regulate EGFR and apoptosis in glioblastoma.	Cancer research	2014	25
24429876	1956	Oxnard GR	Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA.	Clinical cancer research 	2014	111
24439929	1956	Wu YL	Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.	The Lancet. Oncology	2014	223
24443522	1956	Yang JJ	Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation.	Clinical cancer research 	2014	29
24448239	1956	Luraghi P	MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors.	Cancer research	2014	23
24458568	1956	Suda K	The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor.	International journal of cancer	2014	22
24470557	1956	Wen PY	Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.	Neuro-oncology	2014	23
24478319	1956	Yu HA	Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing.	Annals of oncology 	2014	23
24501009	1956	Reckamp KL	A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.	Cancer	2014	23
24508104	1956	André F	Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER).	The Lancet. Oncology	2014	55
24513263	1956	Vanderlaan PA	Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer.	Lung cancer	2014	20
24533047	1956	Liang W	Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.	PloS one	2014	21
24550739	1956	Borad MJ	Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.	PLoS genetics	2014	55
24553385	1956	Bettegowda C	Detection of circulating tumor DNA in early- and late-stage human malignancies.	Science translational medicine	2014	385
24553387	1956	Misale S	Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer.	Science translational medicine	2014	58
24621885	1956	Zhang Y	MicroRNA-608 and microRNA-34a regulate chordoma malignancy by targeting EGFR, Bcl-xL and MET.	PloS one	2014	21
24626858	1956	Nagatsuma AK	Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma.	Gastric cancer 	2015	24
24632568	1956	Gasparini P	microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers.	Oncotarget	2014	46
24644001	1956	Li L	Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.	Clinical cancer research 	2014	43
24656976	1956	Yan M	HER2 aberrations in cancer: implications for therapy.	Cancer treatment reviews	2014	40
24666267	1956	Therkildsen C	The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.	Acta oncologica	2014	56
24670642	1956	Sun C	Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.	Nature	2014	139
24677197	1956	Fuchs BC	Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma.	Hepatology	2014	60
24685132	1956	Sun C	Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.	Cell reports	2014	43
24687833	1956	Schwartzberg LS	PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.	Journal of clinical oncology 	2014	99
24687921	1956	Koeppen H	Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit.	Clinical cancer research 	2014	26
24715074	1956	Lee JK	Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.	JAMA	2014	27
24739896	1956	Price TJ	Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study.	The Lancet. Oncology	2014	49
24743704	1956	Li S	Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.	British journal of cancer	2014	25
24747441	1956	Seguin L	An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.	Nature cell biology	2014	58
24773774	1956	Weber B	Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays.	BMC cancer	2014	25
24816687	1956	Zhou X	MicroRNA-7 inhibits tumor metastasis and reverses epithelial-mesenchymal transition through AKT/ERK1/2 inactivation by targeting EGFR in epithelial ovarian cancer.	PloS one	2014	24
24831979	1956	Gregorc V	Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial.	The Lancet. Oncology	2014	39
24841974	1956	Kawaguchi T	Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA).	Journal of clinical oncology 	2014	53
24846037	1956	Kris MG	Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.	JAMA	2014	182
24857062	1956	Abrams J	National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.	American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting	2014	32
24857124	1956	Gerber DE	Management and future directions in non-small cell lung cancer with known activating mutations.	American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting	2014	23
24863259	1956	Fumarola C	Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer.	Biochemical pharmacology	2014	42
24867380	1956	Liu S	Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms.	Cancer treatment reviews	2014	28
24868098	1956	Khozin S	U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.	The oncologist	2014	20
24886126	1956	Ma J	Targeting of erbB3 receptor to overcome resistance in cancer treatment.	Molecular cancer	2014	28
24893891	1956	Cross DA	AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.	Cancer discovery	2014	170
24895374	1956	Rohan TE	Tumor microenvironment of metastasis and risk of distant metastasis of breast cancer.	Journal of the National Cancer Institute	2014	33
24919569	1956	Van Cutsem E	Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer.	Clinical cancer research 	2014	22
24919575	1956	Yoshida T	Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.	Clinical cancer research 	2014	20
24928832	1956	Seiwert TY	A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck.	Annals of oncology 	2014	21
24939055	1956	Qu Y	Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.	Journal of experimental and clinical cancer research 	2014	22
24981256	1956	Camidge DR	Acquired resistance to TKIs in solid tumours: learning from lung cancer.	Nature reviews. Clinical oncology	2014	107
24986882	1956	Grusch M	Spatio-temporally precise activation of engineered receptor tyrosine kinases by light.	The EMBO journal	2014	29
25009014	1956	Azuma K	Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer.	Annals of oncology 	2014	66
25009231	1956	Rebouissou S	EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype.	Science translational medicine	2014	33
25013125	1956	Couraud S	Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002.	Clinical cancer research 	2014	40
25031274	1956	Lee SM	Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases.	Journal of the National Cancer Institute	2014	22
25057166	1956	Missiaglia E	Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features.	Annals of oncology 	2014	38
25074459	1956	Janjigian YY	Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.	Cancer discovery	2014	69
25079552	1956	Cancer Genome Atlas Research Network.	Comprehensive molecular profiling of lung adenocarcinoma.	Nature	2014	567
25080476	1956	Müller C	Hematogenous dissemination of glioblastoma multiforme.	Science translational medicine	2014	27
25091798	1956	Masterson L	De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis of current clinical trials.	European journal of cancer	2014	30
25103305	1956	Sorensen BS	Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib.	Cancer	2014	32
25115304	1956	Sorich MJ	Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.	Annals of oncology 	2015	68
25122430	1956	Douillard JY	Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status.	Journal of thoracic oncology 	2014	62
25125659	1956	Wilson C	AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs.	Cancer research	2014	22
25136066	1956	Brand TM	AXL mediates resistance to cetuximab therapy.	Cancer research	2014	27
25137181	1956	Marchetti A	Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment.	PloS one	2014	33
25150284	1956	Labussière M	Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.	Neurology	2014	29
25164765	1956	Brannon AR	Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions.	Genome biology	2014	54
25175099	1956	Seto T	Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.	The Lancet. Oncology	2014	67
25185971	1956	Satoh T	Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer.	Gastric cancer 	2015	20
25193862	1956	Wilson C	Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition.	Oncotarget	2014	28
25222496	1956	Zhang Y	Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis.	PloS one	2014	27
25247337	1956	Hoffknecht P	Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease.	Journal of thoracic oncology 	2015	25
25248381	1956	Laurent-Puig P	Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy.	Clinical cancer research 	2015	30
25271963	1956	Finlay MR	Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor.	Journal of medicinal chemistry	2014	27
25293556	1956	Misale S	Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution.	Cancer discovery	2014	48
25311215	1956	Leighl NB	Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline.	Journal of clinical oncology 	2014	42
25339418	1956	Qiu M	Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis.	Cancer epidemiology, biomarkers and prevention 	2015	30
25345567	1956	Hagemann IS	Clinical next-generation sequencing in patients with non-small cell lung cancer.	Cancer	2015	29
25349291	1956	Iyengar P	Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer.	Journal of clinical oncology 	2014	23
25349974	1956	D'Incecco A	PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients.	British journal of cancer	2015	69
25394791	1956	Crystal AS	Patient-derived models of acquired resistance can identify effective drug combinations for cancer.	Science	2014	120
25405368	1956	Chiyomaru T	Dual regulation of receptor tyrosine kinase genes EGFR and c-Met by the tumor-suppressive microRNA-23b/27b cluster in bladder cancer.	International journal of oncology	2015	22
25405807	1956	Wang Z	Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC.	PloS one	2014	31
25409146	1956	Cheng CJ	MicroRNA silencing for cancer therapy targeted to the tumour microenvironment.	Nature	2015	97
25444907	1956	Hao C	Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer.	Cancer letters	2015	18
25468140	1956	Kalia M	Biomarkers for personalized oncology: recent advances and future challenges.	Metabolism	2015	32
25468223	1956	Cohen AL	Glioma biology and molecular markers.	Cancer treatment and research	2015	26
25492084	1956	Keck MK	Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes.	Clinical cancer research 	2015	30
25573908	1956	Kopp JB	Clinical Features and Histology of Apolipoprotein L1-Associated Nephropathy in the FSGS Clinical Trial.	Journal of the American Society of Nephrology 	2015	22
25579803	1956	Gustavsson B	A review of the evolution of systemic chemotherapy in the management of colorectal cancer.	Clinical colorectal cancer	2015	29
25583986	1956	Liu Z	A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism.	The Journal of biological chemistry	2015	16
25586468	1956	Schuster J	A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.	Neuro-oncology	2015	54
25589191	1956	Yang JC	Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.	The Lancet. Oncology	2015	173
25589621	1956	Yaeger R	Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.	Clinical cancer research 	2015	39
25593032	1956	Linnekamp JF	Colorectal cancer heterogeneity and targeted therapy: a case for molecular disease subtypes.	Cancer research	2015	21
25593300	1956	Cani AK	Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors.	Molecular cancer research 	2015	18
25605843	1956	Van Cutsem E	Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.	Journal of clinical oncology 	2015	74
25623215	1956	Arena S	Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.	Clinical cancer research 	2015	24
25628445	1956	Morelli MP	Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment.	Annals of oncology 	2015	22
25629630	1956	Fillmore CM	EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors.	Nature	2015	49
25629635	1956	Wu C	High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules.	Journal of thoracic oncology 	2015	16
25639985	1956	Mao C	Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases.	Scientific reports	2015	19
25649416	1956	Stahl P	Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer.	BMC gastroenterology	2015	17
25662388	1956	Kim MY	Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.	Lung cancer	2015	25
25667274	1956	Lopez-Chavez A	Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.	Journal of clinical oncology 	2015	33
25673558	1956	Pietrantonio F	Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.	European journal of cancer	2015	37
25673644	1956	Ahronian LG	Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.	Cancer discovery	2015	46
25678824	1956	Coward JI	New perspectives on targeted therapy in ovarian cancer.	International journal of women's health	2015	16
25682441	1956	Fuse N	Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.	Gastric cancer 	2016	19
25689095	1956	Kumarakulasinghe NB	Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC).	Respirology	2015	16
25714397	1956	Stahlhut C	Combinatorial Action of MicroRNAs let-7 and miR-34 Effectively Synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation.	Cell cycle	2015	21
25738220	1956	Sholl LM	Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience.	Journal of thoracic oncology 	2015	37
25752815	1956	Chen J	Signaling pathways in HPV-associated cancers and therapeutic implications.	Reviews in medical virology	2015	15
25758528	1956	Niederst MJ	RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.	Nature communications	2015	45
25769900	1956	Zhu G	Highly Sensitive Droplet Digital PCR Method for Detection of EGFR-Activating Mutations in Plasma Cell-Free DNA from Patients with Advanced Non-Small Cell Lung Cancer.	The Journal of molecular diagnostics 	2015	22
25789560	1956	Xue M	Chemical methods for the simultaneous quantitation of metabolites and proteins from single cells.	Journal of the American Chemical Society	2015	16
25795635	1956	Burotto M	Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.	The oncologist	2015	20
25805821	1956	Kaszuba K	N-Glycosylation as determinant of epidermal growth factor receptor conformation in membranes.	Proceedings of the National Academy of Sciences of the United States of America	2015	18
25807485	1956	Obenauf AC	Therapy-induced tumour secretomes promote resistance and tumour progression.	Nature	2015	63
25807554	1956	Tang MC	Chloroquine enhances gefitinib cytotoxicity in gefitinib-resistant nonsmall cell lung cancer cells.	PloS one	2015	15
25829397	1956	Mok T	Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy.	Clinical cancer research 	2015	43
25832655	1956	Jie HB	CTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis.	Cancer research	2015	33
25843712	1956	Blakely CM	NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer.	Cell reports	2015	22
25870145	1956	Eberlein CA	Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.	Cancer research	2015	30
25882755	1956	Watanabe M	Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non-Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR.	Clinical cancer research 	2015	37
25892145	1956	Machiels JP	Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head &amp;amp; Neck 1): an open-label, randomised phase 3 trial.	The Lancet. Oncology	2015	39
25895031	1956	Tang Y	The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs.	Oncotarget	2015	32
25897154	1956	Lee CK	Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis.	Journal of clinical oncology 	2015	32
25904751	1956	Rosenthal EL	Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer.	Clinical cancer research 	2015	33
25923549	1956	Jänne PA	AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.	The New England journal of medicine	2015	228
25923550	1956	Sequist LV	Rociletinib in EGFR-mutated non-small-cell lung cancer.	The New England journal of medicine	2015	125
25926053	1956	Medico E	The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.	Nature communications	2015	29
25934077	1956	Piotrowska Z	Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.	Cancer discovery	2015	55
25943888	1956	Aldape K	Glioblastoma: pathology, molecular mechanisms and markers.	Acta neuropathologica	2015	25
25956936	1956	Rizzo S	CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer.	European radiology	2016	12
25961939	1956	Moriarity BS	A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis.	Nature genetics	2015	36
25963091	1956	Thomas A	Refining the treatment of NSCLC according to histological and molecular subtypes.	Nature reviews. Clinical oncology	2015	24
25964297	1956	Niederst MJ	The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.	Clinical cancer research 	2015	41
25964637	1956	Ettinger DS	Non-Small Cell Lung Cancer, Version 6.2015.	Journal of the National Comprehensive Cancer Network 	2015	68
25979833	1956	Brulé SY	Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17.	European journal of cancer	2015	22
25989278	1956	Rowland A	Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.	British journal of cancer	2015	21
26014294	1956	Zhou C	BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.	Journal of clinical oncology 	2015	26
26024796	1956	Cooper WA	PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.	Lung cancer	2015	29
26030179	1956	Siravegna G	Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.	Nature medicine	2015	58
26036643	1956	Tricker EM	Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.	Cancer discovery	2015	28
26045340	1956	Thatcher N	Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.	The Lancet. Oncology	2015	52
26105600	1956	Wu YL	First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.	Annals of oncology 	2015	30
26121317	1956	Stewart RL	Clinical significance of the integrin α6β4 in human malignancies.	Laboratory investigation; a journal of technical methods and pathology	2015	24
26124204	1956	Della Corte CM	SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.	Clinical cancer research 	2015	18
26141208	1956	Zhou C	Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802).	Annals of oncology 	2015	39
26149886	1956	Devarakonda S	Genomic alterations in lung adenocarcinoma.	The Lancet. Oncology	2015	20
26159065	1956	Soria JC	Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.	The Lancet. Oncology	2015	49
26169611	1956	Scagliotti G	Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer.	Journal of clinical oncology 	2015	34
26184520	1956	Tabernero J	Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.	The Lancet. Oncology	2015	37
26206882	1956	Uchida J	Diagnostic Accuracy of Noninvasive Genotyping of EGFR in Lung Cancer Patients by Deep Sequencing of Plasma Cell-Free DNA.	Clinical chemistry	2015	25
26227959	1956	Sun W	Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer.	Journal of hematology and oncology	2015	25
26243863	1956	Kavuri SM	HER2 activating mutations are targets for colorectal cancer treatment.	Cancer discovery	2015	18
26267324	1956	Riquelme I	Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy.	Oncotarget	2015	18
26269204	1956	Planchard D	EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients.	Annals of oncology 	2015	26
26295376	1956	Marchetti A	Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients.	Journal of thoracic oncology 	2015	25
26308162	1956	Russo A	A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives.	Oncotarget	2015	30
26324367	1956	Masters GA	Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.	Journal of clinical oncology 	2015	47
26330164	1956	Caruso HG	Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity.	Cancer research	2015	36
26351341	1956	Sacco AG	Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.	Journal of clinical oncology 	2015	22
26354927	1956	Dubbink HJ	Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.	Neuro-oncology	2016	14
26358176	1956	Dietel M	A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.	Cancer gene therapy	2015	25
26370354	1956	Tan CS	Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer.	The Lancet. Oncology	2015	35
26392303	1956	Misale S	Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers.	Nature communications	2015	17
26392535	1956	Kamburov A	Comprehensive assessment of cancer missense mutation clustering in protein structures.	Proceedings of the National Academy of Sciences of the United States of America	2015	26
26410082	1956	Brastianos PK	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets.	Cancer discovery	2015	51
26416997	1956	Cai W	Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma.	Journal of clinical oncology 	2015	21
26434585	1956	Schneider MR	The EGFR-HER2 module: a stem cell approach to understanding a prime target and driver of solid tumors.	Oncogene	2016	12
26438111	1956	Allegra CJ	Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015.	Journal of clinical oncology 	2016	31
26446944	1956	Sundaresan TK	Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses.	Clinical cancer research 	2016	45
26459174	1956	Paweletz CP	Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients.	Clinical cancer research 	2016	19
26460303	1956	Kopetz S	Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.	Journal of clinical oncology 	2015	41
26477306	1956	Schabath MB	Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma.	Oncogene	2016	11
26494259	1956	Thress KS	EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291.	Lung cancer	2015	39
26525104	1956	Best MG	RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics.	Cancer cell	2015	34
26537995	1956	Minguet J	Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives.	International journal of cancer	2016	19
26577492	1956	Sueoka-Aragane N	Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study.	Cancer science	2016	13
26582655	1956	Xu S	Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patients.	Cancer letters	2016	12
26598545	1956	Gebhart G	Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.	Annals of oncology 	2016	19
26644315	1956	Russo M	Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.	Cancer discovery	2016	23
26646759	1956	Schuler M	Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.	Annals of oncology 	2016	14
26690310	1956	Richman SD	HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials.	The Journal of pathology	2016	11
26724471	1956	Lin JJ	Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.	Journal of thoracic oncology 	2016	12
26727163	1956	Quoix E	TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.	The Lancet. Oncology	2016	17
26729443	1956	Awad MM	MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.	Journal of clinical oncology 	2016	33
26735353	1956	Bournet B	Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.	European journal of cancer	2016	16
26755650	1956	Lee JY	Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02).	Oncotarget	2016	16
26777916	1956	Barlesi F	Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).	Lancet	2016	43
26789630	1956	Yoshida T	ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.	PloS one	2016	13
26799287	1956	Del Re M	Contribution of KRAS mutations and c.2369C &amp;gt; T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA.	Oncotarget	2017	9
26823294	1956	Schuler M	First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.	Journal of thoracic oncology 	2016	12
26824988	1956	de Melo Gagliato D	Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer.	Oncotarget	2016	21
26828195	1956	Hata AN	Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.	Nature medicine	2016	57
26832883	1956	Mukai S	Overexpression of Transmembrane Protein BST2 is Associated with Poor Survival of Patients with Esophageal, Gastric, or Colorectal Cancer.	Annals of surgical oncology	2017	5
26843189	1956	Arena S	MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.	Science translational medicine	2016	11
26844548	1956	Hedner C	Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1 and 3 in Gastric and Esophageal Adenocarcinoma.	PloS one	2016	11
26867973	1956	Zheng D	Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance.	Scientific reports	2016	29
26874901	1956	Chan A	Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.	The Lancet. Oncology	2016	13
26890676	1956	Veitch AM	Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines.	Endoscopy	2016	12
26898616	1956	Tan CS	Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.	Lung cancer	2016	17
26926684	1956	Desmedt C	Genomic Characterization of Primary Invasive Lobular Breast Cancer.	Journal of clinical oncology 	2016	12
26942675	1956	Li X	Mitochondria-Translocated PGK1 Functions as a Protein Kinase to Coordinate Glycolysis and the TCA Cycle in Tumorigenesis.	Molecular cell	2016	14
26968708	1956	Feng K	Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer.	Science China. Life sciences	2016	14
27060149	1956	Lai Z	VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research.	Nucleic acids research	2016	12
27071706	1956	Wang S	Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer.	Journal of hematology and oncology	2016	29
27083334	1956	Park K	Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.	The Lancet. Oncology	2016	46
27117702	1956	Lin S	The m(6)A Methyltransferase METTL3 Promotes Translation in Human Cancer Cells.	Molecular cell	2016	23
27354477	1956	Oxnard GR	Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.	Journal of clinical oncology 	2016	31
27688480	1956	Yip SS	Associations Between Somatic Mutations and Metabolic Imaging Phenotypes in Non-Small Cell Lung Cancer.	Journal of nuclear medicine 	2017	7
27718847	1956	Reck M	Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.	The New England journal of medicine	2016	147
27745820	1956	Langer CJ	Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.	The Lancet. Oncology	2016	29
27836716	1956	Gettinger SN	Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.	The Lancet. Oncology	2016	13
27922044	1956	Punt CJ	From tumour heterogeneity to advances in precision treatment of colorectal cancer.	Nature reviews. Clinical oncology	2017	5
27959700	1956	Mok TS	Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.	The New England journal of medicine	2017	42
9878069	1977	Pyronnet S	Human eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF4E.	The EMBO journal	1999	168
10022874	1977	Waskiewicz AJ	Phosphorylation of the cap-binding protein eukaryotic translation initiation factor 4E by protein kinase Mnk1 in vivo.	Molecular and cellular biology	1999	119
12878853	1977	Huang S	Rapamycins: mechanism of action and cellular resistance.	Cancer biology and therapy	2003	77
12901945	1977	Huang S	Targeting mTOR signaling for cancer therapy.	Current opinion in pharmacology	2003	78
14871980	1977	Noh WC	Determinants of rapamycin sensitivity in breast cancer cells.	Clinical cancer research 	2004	83
15094766	1977	Mamane Y	eIF4E--from translation to transformation.	Oncogene	2004	136
15094768	1977	De Benedetti A	eIF-4E expression and its role in malignancies and metastases.	Oncogene	2004	212
16103051	1977	Sun SY	Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.	Cancer research	2005	264
16740688	1977	Del Bufalo D	Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus.	Cancer research	2006	60
18245460	1977	Graff JR	Targeting the eukaryotic translation initiation factor 4E for cancer therapy.	Cancer research	2008	107
18332469	1977	Tabernero J	Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.	Journal of clinical oncology 	2008	147
19176385	1977	Beevers CS	Curcumin disrupts the Mammalian target of rapamycin-raptor complex.	Cancer research	2009	51
19433856	1977	Assouline S	Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin.	Blood	2009	69
19641186	1977	Gupta M	Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2.	Blood	2009	56
20227039	1977	Hsieh AC	Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E.	Cancer cell	2010	149
20606035	1977	Cho DC	The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma.	Clinical cancer research 	2010	73
21190521	1977	Zhou H	Role of mTOR signaling in tumor cell motility, invasion and metastasis.	Current protein and peptide science	2011	44
21233335	1977	Konicek BW	Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases.	Cancer research	2011	47
21876152	1977	Ilic N	PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis.	Proceedings of the National Academy of Sciences of the United States of America	2011	78
21957010	1977	Topisirovic I	Cap and cap-binding proteins in the control of gene expression.	Wiley interdisciplinary reviews. RNA	2011	85
22071574	1977	Yellen P	High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1.	Cell cycle	2011	38
22408430	1977	Pópulo H	The mTOR signalling pathway in human cancer.	International journal of molecular sciences	2012	109
22797067	1977	Adesso L	Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway.	Oncogene	2013	28
22845486	1977	Barrett D	Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.	Paediatric drugs	2012	31
23624914	1977	Ye Q	ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer.	Oncogene	2014	41
23901100	1977	Feoktistova K	Human eIF4E promotes mRNA restructuring by stimulating eIF4A helicase activity.	Proceedings of the National Academy of Sciences of the United States of America	2013	37
24206664	1977	Morita M	mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation.	Cell metabolism	2013	97
24842883	1977	Lee JM	Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.	Journal of the National Cancer Institute	2014	40
24844205	1977	Tapia O	The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance.	Virchows Archiv 	2014	26
25533957	1977	Bah A	Folding of an intrinsically disordered protein by phosphorylation as a regulatory switch.	Nature	2015	64
25688110	1977	Cargnello M	The expanding role of mTOR in cancer cell growth and proliferation.	Mutagenesis	2015	19
26147685	1977	Su X	Interferon-γ regulates cellular metabolism and mRNA translation to potentiate macrophage activation.	Nature immunology	2015	20
10934146	2034	Talks KL	The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages.	The American journal of pathology	2000	240
16418497	2034	Koukourakis MI	Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial.	Journal of clinical oncology 	2006	63
18182667	2034	Sathornsumetee S	Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.	Journal of clinical oncology 	2008	74
18316553	2034	Camps C	hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer.	Clinical cancer research 	2008	210
19372578	2034	McCord AM	Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro.	Molecular cancer research 	2009	66
19706526	2034	Bertout JA	HIF2alpha inhibition promotes p53 pathway activity, tumor cell death, and radiation responses.	Proceedings of the National Academy of Sciences of the United States of America	2009	57
19920819	2034	Reardon DA	Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study.	British journal of cancer	2009	46
20206201	2034	Ralph SJ	The causes of cancer revisited: "mitochondrial malignancy" and ROS-induced oncogenic transformation - why mitochondria are targets for cancer therapy.	Molecular aspects of medicine	2010	82
21466972	2034	Rohwer N	Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways.	Drug resistance updates 	2011	89
22169972	2034	Keith B	HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression.	Nature reviews. Cancer	2011	351
22642602	2034	Liang D	The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells.	BMC cancer	2012	33
22931260	2034	Zhuang Z	Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia.	The New England journal of medicine	2012	56
23090011	2034	Lorenzo FR	A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma.	Journal of molecular medicine	2013	27
23297826	2034	Agani F	Oxygen-independent regulation of HIF-1: novel involvement of PI3K/AKT/mTOR pathway in cancer.	Current cancer drug targets	2013	32
24997364	2034	Slominski A	The role of melanogenesis in regulation of melanoma behavior: melanogenesis leads to stimulation of HIF-1α expression and HIF-dependent attendant pathways.	Archives of biochemistry and biophysics	2014	31
25417700	2034	Choudhry H	Tumor hypoxia induces nuclear paraspeckle formation through HIF-2α dependent transcriptional activation of NEAT1 leading to cancer cell survival.	Oncogene	2015	26
25456395	2034	Kim Y	Expression of lactate/H⁺ symporters MCT1 and MCT4 and their chaperone CD147 predicts tumor progression in clear cell renal cell carcinoma: immunohistochemical and The Cancer Genome Atlas data analyses.	Human pathology	2015	20
25838542	2034	Kouri FM	miR-182 integrates apoptosis, growth, and differentiation programs in glioblastoma.	Genes and development	2015	33
26409567	2034	Cockle JV	Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling.	Neuro-oncology	2016	13
26992424	2034	Li L	Exosomes Derived from Hypoxic Oral Squamous Cell Carcinoma Cells Deliver miR-21 to Normoxic Cells to Elicit a Prometastatic Phenotype.	Cancer research	2016	14
27001847	2034	Zhang C	Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m⁶A-demethylation of NANOG mRNA.	Proceedings of the National Academy of Sciences of the United States of America	2016	21
27139518	2034	Wigerup C	Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer.	Pharmacology and therapeutics	2016	14
1350088	2064	Carter P	Humanization of an anti-p185HER2 antibody for human cancer therapy.	Proceedings of the National Academy of Sciences of the United States of America	1992	276
2470152	2064	Slamon DJ	Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.	Science	1989	1073
3003577	2064	Yamamoto T	Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor.	Nature	1986	184
7538656	2064	Alimandi M	Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas.	Oncogene	1995	135
7657393	2064	Bellacosa A	Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas.	International journal of cancer	1995	174
9504686	2064	Allred DC	Prognostic and predictive factors in breast cancer by immunohistochemical analysis.	Modern pathology 	1998	386
10029066	2064	Bubendorf L	Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays.	Cancer research	1999	105
10223227	2064	Nakajima M	The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas.	Cancer	1999	113
10713699	2064	Cogswell PC	Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3.	Oncogene	2000	118
11158614	2064	Welsh JB	Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer.	Proceedings of the National Academy of Sciences of the United States of America	2001	125
11248153	2064	Slamon DJ	Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.	The New England journal of medicine	2001	1654
11359907	2064	Laughner E	HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression.	Molecular and cellular biology	2001	252
11406546	2064	Molina MA	Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.	Cancer research	2001	162
11553815	2064	Sørlie T	Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.	Proceedings of the National Academy of Sciences of the United States of America	2001	2523
11694782	2064	Yarden Y	Biology of HER2 and its importance in breast cancer.	Oncology	2001	104
11751413	2064	Moulder SL	Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.	Cancer research	2001	96
11752009	2064	Lu Y	Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).	Journal of the National Cancer Institute	2001	204
11870534	2064	Pérez-Tenorio G	Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients.	British journal of cancer	2002	89
11907566	2064	Izumi Y	Tumour biology: herceptin acts as an anti-angiogenic cocktail.	Nature	2002	117
11948130	2064	Park JW	Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.	Clinical cancer research 	2002	101
12060624	2064	Schindl M	Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer.	Clinical cancer research 	2002	96
12124352	2064	Yakes FM	Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.	Cancer research	2002	158
12147373	2064	Andre F	Malignant effusions and immunogenic tumour-derived exosomes.	Lancet	2002	187
12432043	2064	Keyomarsi K	Cyclin E and survival in patients with breast cancer.	The New England journal of medicine	2002	116
12529347	2064	Konecny G	Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.	Journal of the National Cancer Institute	2003	87
12610629	2064	Cho HS	Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab.	Nature	2003	322
12618500	2064	Osborne CK	Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.	Journal of the National Cancer Institute	2003	176
12627523	2064	Bos R	Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.	Cancer	2003	135
12761490	2064	Knuefermann C	HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.	Oncogene	2003	102
12784331	2064	Bendell JC	Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.	Cancer	2003	119
12829800	2064	Sorlie T	Repeated observation of breast tumor subtypes in independent gene expression data sets.	Proceedings of the National Academy of Sciences of the United States of America	2003	1287
12897328	2064	Ross JS	The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy.	The oncologist	2003	91
14527402	2064	Burgess AW	An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors.	Molecular cell	2003	210
14578209	2064	Lin EY	Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases.	The American journal of pathology	2003	327
14647146	2064	Schlieman MG	Incidence, mechanism and prognostic value of activated AKT in pancreas cancer.	British journal of cancer	2003	76
14967450	2064	Marmor MD	Signal transduction and oncogenesis by ErbB/HER receptors.	International journal of radiation oncology, biology, physics	2004	81
15093539	2064	Franklin MC	Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex.	Cancer cell	2004	233
15150302	2064	Pegram MD	Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.	Journal of the National Cancer Institute	2004	74
15173008	2064	Rabindran SK	Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase.	Cancer research	2004	92
15194824	2064	Meng S	HER-2 gene amplification can be acquired as breast cancer progresses.	Proceedings of the National Academy of Sciences of the United States of America	2004	119
15220474	2064	Biswas DK	NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis.	Proceedings of the National Academy of Sciences of the United States of America	2004	102
15256471	2064	Yu JS	Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.	Cancer research	2004	132
15324695	2064	Nagata Y	PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.	Cancer cell	2004	432
15355889	2064	Gennari R	Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2.	Clinical cancer research 	2004	100
15385631	2064	Austin CD	Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin.	Molecular biology of the cell	2004	113
15455388	2064	Lengyel E	C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu.	International journal of cancer	2005	85
15457249	2064	Stephens P	Lung cancer: intragenic ERBB2 kinase mutations in tumours.	Nature	2004	166
15501983	2064	Mondesire WH	Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells.	Clinical cancer research 	2004	86
15534099	2064	Camp RL	X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization.	Clinical cancer research 	2004	274
15542430	2064	Li YM	Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis.	Cancer cell	2004	144
15545664	2064	Winer EP	American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.	Journal of clinical oncology 	2005	139
15561805	2064	Cianfrocca M	Prognostic and predictive factors in early-stage breast cancer.	The oncologist	2004	94
15641021	2064	Simpson PT	Molecular evolution of breast cancer.	The Journal of pathology	2005	94
15701879	2064	Osborne CK	Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer.	Clinical cancer research 	2005	89
15738535	2064	Buzdar AU	Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.	Journal of clinical oncology 	2005	172
15784621	2064	Misra S	Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2.	The Journal of biological chemistry	2005	65
15818618	2064	Abd El-Rehim DM	High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses.	International journal of cancer	2005	106
15897907	2064	Farmer P	Identification of molecular apocrine breast tumours by microarray analysis.	Oncogene	2005	204
15911866	2064	Marty M	Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.	Journal of clinical oncology 	2005	251
15998903	2064	Smith IE	Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.	Journal of clinical oncology 	2005	84
16000569	2064	De Laurentiis M	A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer.	Clinical cancer research 	2005	73
16019138	2064	Chen DC	Serum adiponectin and leptin levels in Taiwanese breast cancer patients.	Cancer letters	2006	84
16088978	2064	Kirkegaard T	AKT activation predicts outcome in breast cancer patients treated with tamoxifen.	The Journal of pathology	2005	74
16115903	2064	Rouzier R	Breast cancer molecular subtypes respond differently to preoperative chemotherapy.	Clinical cancer research 	2005	346
16148022	2064	Goldhirsch A	Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.	Annals of oncology 	2005	137
16151408	2064	Adams GP	Monoclonal antibody therapy of cancer.	Nature biotechnology	2005	232
16166438	2064	Press MF	Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials.	Clinical cancer research 	2005	69
16192626	2064	Weil RJ	Breast cancer metastasis to the central nervous system.	The American journal of pathology	2005	94
16236737	2064	Piccart-Gebhart MJ	Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.	The New England journal of medicine	2005	819
16236738	2064	Romond EH	Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.	The New England journal of medicine	2005	972
16258083	2064	Tan-Chiu E	Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.	Journal of clinical oncology 	2005	121
16258084	2064	Ewer MS	Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.	Journal of clinical oncology 	2005	94
16322262	2064	Nahta R	Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells.	Cancer research	2005	183
16344916	2064	Salvucci O	The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study.	Breast cancer research and treatment	2006	67
16368942	2064	McCabe A	Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis.	Journal of the National Cancer Institute	2005	77
16404427	2064	Arnould L	Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?	British journal of cancer	2006	109
16458110	2064	Nahta R	Herceptin: mechanisms of action and resistance.	Cancer letters	2006	97
16495393	2064	Joensuu H	Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.	The New England journal of medicine	2006	224
16603601	2064	Pestalozzi BC	Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG).	Annals of oncology 	2006	69
16611412	2064	Ghebeh H	The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.	Neoplasia	2006	129
16618759	2064	Orlova A	Tumor imaging using a picomolar affinity HER2 binding affibody molecule.	Cancer research	2006	90
16643655	2064	Hu Z	The molecular portraits of breast tumors are conserved across microarray platforms.	BMC genomics	2006	426
16682622	2064	Xia W	A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2006	110
16682724	2064	Linden HM	Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer.	Journal of clinical oncology 	2006	65
16683005	2064	Nahta R	Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.	Nature clinical practice. Oncology	2006	220
16707747	2064	Pritchard KI	HER2 and responsiveness of breast cancer to adjuvant chemotherapy.	The New England journal of medicine	2006	100
16782917	2064	Robert N	Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.	Journal of clinical oncology 	2006	94
16809727	2064	Perez EA	HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.	Journal of clinical oncology 	2006	84
16846532	2064	Calza S	Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients.	Breast cancer research 	2006	81
16868082	2064	Kinoshita M	Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption.	Proceedings of the National Academy of Sciences of the United States of America	2006	143
16868827	2064	Park DI	HER-2/neu amplification is an independent prognostic factor in gastric cancer.	Digestive diseases and sciences	2006	70
16899776	2064	Fan C	Concordance among gene-expression-based predictors for breast cancer.	The New England journal of medicine	2006	335
17085646	2064	Filardo EJ	Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression.	Clinical cancer research 	2006	97
17096862	2064	Nahta R	HER2 therapy: molecular mechanisms of trastuzumab resistance.	Breast cancer research 	2006	122
17110380	2064	Scott GK	Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b.	The Journal of biological chemistry	2007	192
17116942	2064	Haffty BG	Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.	Journal of clinical oncology 	2006	205
17157792	2064	Chin K	Genomic and transcriptional aberrations linked to breast cancer pathophysiologies.	Cancer cell	2006	472
17159189	2064	Wolff AC	American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.	Journal of clinical oncology 	2007	714
17159499	2064	Stemmler HJ	Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier.	Anti-cancer drugs	2007	57
17200359	2064	Buzdar AU	Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen.	Clinical cancer research 	2007	85
17208639	2064	Smith I	2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.	Lancet	2007	250
17229773	2064	Valabrega G	Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.	Annals of oncology 	2007	111
17317830	2064	Harris LN	Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer.	Clinical cancer research 	2007	57
17332353	2064	Huang F	Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection.	Cancer research	2007	101
17347129	2064	Chapman C	Autoantibodies in breast cancer: their use as an aid to early diagnosis.	Annals of oncology 	2007	62
17377838	2064	Soerjomataram I	An overview of prognostic factors for long-term survivors of breast cancer.	Breast cancer research and treatment	2008	84
17387718	2064	Bauer KR	Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry.	Cancer	2007	443
17409397	2064	Pick E	High HSP90 expression is associated with decreased survival in breast cancer.	Cancer research	2007	73
17438091	2064	Carey LA	The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.	Clinical cancer research 	2007	429
17440164	2064	Scaltriti M	Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.	Journal of the National Cancer Institute	2007	170
17470737	2064	Arpino G	Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.	Journal of the National Cancer Institute	2007	58
17471238	2064	Moasser MM	The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.	Oncogene	2007	133
17493932	2064	Bourguignon LY	Heregulin-mediated ErbB2-ERK signaling activates hyaluronan synthases leading to CD44-dependent ovarian tumor cell growth and migration.	The Journal of biological chemistry	2007	55
17530017	2064	Nahta R	Trastuzumab: triumphs and tribulations.	Oncogene	2007	77
17578664	2064	Millikan RC	Epidemiology of basal-like breast cancer.	Breast cancer research and treatment	2008	282
17606733	2064	Marangoni E	A new model of patient tumor-derived breast cancer xenografts for preclinical assays.	Clinical cancer research 	2007	106
17620276	2064	Morris GJ	Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database.	Cancer	2007	132
17656355	2064	Kulasingam V	Proteomics analysis of conditioned media from three breast cancer cell lines: a mine for biomarkers and therapeutic targets.	Molecular and cellular proteomics 	2007	61
17671126	2064	Dent R	Triple-negative breast cancer: clinical features and patterns of recurrence.	Clinical cancer research 	2007	677
17675364	2064	Bignell GR	Architectures of somatic genomic rearrangement in human cancer amplicons at sequence-level resolution.	Genome research	2007	77
17675394	2064	Goldhirsch A	Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.	Annals of oncology 	2007	157
17683518	2064	Teschendorff AE	An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer.	Genome biology	2007	168
17686164	2064	Viani GA	Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials.	BMC cancer	2007	74
17687157	2064	Telli ML	Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.	Journal of clinical oncology 	2007	66
17785568	2064	Taylor C	Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy.	Clinical cancer research 	2007	66
17922911	2064	Blenkiron C	MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype.	Genome biology	2007	297
17928597	2064	Hayes DF	HER2 and response to paclitaxel in node-positive breast cancer.	The New England journal of medicine	2007	134
17967430	2064	Ahmed KM	NF-kappa B-mediated adaptive resistance to ionizing radiation.	Free radical biology and medicine	2008	56
17993229	2064	Gonzalez-Angulo AM	Overview of resistance to systemic therapy in patients with breast cancer.	Advances in experimental medicine and biology	2007	179
18037158	2064	Tomsová M	Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma.	Gynecologic oncology	2008	60
18048329	2064	Gupta GP	ID genes mediate tumor reinitiation during breast cancer lung metastasis.	Proceedings of the National Academy of Sciences of the United States of America	2007	89
18048823	2064	Modi S	Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.	Journal of clinical oncology 	2007	93
18089790	2064	Sempere LF	Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer.	Cancer research	2007	204
18159072	2064	Gennari A	HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.	Journal of the National Cancer Institute	2008	68
18171422	2064	Reis-Filho JS	Triple negative tumours: a critical review.	Histopathology	2008	212
18223211	2064	Allred DC	Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution.	Clinical cancer research 	2008	91
18227529	2064	Dowsett M	Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.	Journal of clinical oncology 	2008	80
18250347	2064	Liedtke C	Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.	Journal of clinical oncology 	2008	411
18250349	2064	Perez EA	Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.	Journal of clinical oncology 	2008	96
18285604	2064	Kyndi M	Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.	Journal of clinical oncology 	2008	79
18288997	2064	Petrelli A	From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.	Current medicinal chemistry	2008	67
18297396	2064	Lu X	Predicting features of breast cancer with gene expression patterns.	Breast cancer research and treatment	2008	83
18316611	2064	Shattuck DL	Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells.	Cancer research	2008	112
18339869	2064	Yamaguchi N	NOTCH3 signaling pathway plays crucial roles in the proliferation of ErbB2-negative human breast cancer cells.	Cancer research	2008	54
18375893	2064	Seidman AD	Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.	Journal of clinical oncology 	2008	117
18381409	2064	Chaturvedi P	MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells.	Cancer research	2008	62
18396036	2064	Oldenhuis CN	Prognostic versus predictive value of biomarkers in oncology.	European journal of cancer	2008	57
18398844	2064	Bertucci F	How basal are triple-negative breast cancers?	International journal of cancer	2008	112
18413639	2064	Nguyen PL	Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.	Journal of clinical oncology 	2008	147
18422971	2064	Hofmann M	Assessment of a HER2 scoring system for gastric cancer: results from a validation study.	Histopathology	2008	202
18434311	2064	Najy AJ	The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation.	The Journal of biological chemistry	2008	61
18441328	2064	Gravalos C	HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target.	Annals of oncology 	2008	179
18455127	2064	Stoecklein NH	Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer.	Cancer cell	2008	56
18458039	2064	Gomez HL	Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer.	Journal of clinical oncology 	2008	66
18469855	2064	Osipo C	ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.	Oncogene	2008	59
18487574	2064	Rakha EA	Basal-like breast cancer: a critical review.	Journal of clinical oncology 	2008	213
18505968	2064	Martín M	Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.	Journal of the National Cancer Institute	2008	51
18543098	2064	Dent R	Pattern of metastatic spread in triple-negative breast cancer.	Breast cancer research and treatment	2009	79
18591932	2064	Korkaya H	HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion.	Oncogene	2008	203
18592370	2064	Jones RL	The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer.	Breast cancer research and treatment	2009	49
18625725	2064	Wang SE	Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab.	Molecular and cellular biology	2008	61
18679793	2064	Tewes M	Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies.	Breast cancer research and treatment	2009	49
18720457	2064	Weigelt B	Refinement of breast cancer classification by molecular characterization of histological special types.	The Journal of pathology	2008	100
18726992	2064	Phipps AI	Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer.	Cancer	2008	51
18772890	2064	Cancer Genome Atlas Research Network.	Comprehensive genomic characterization defines human glioblastoma genes and core pathways.	Nature	2008	2168
18841463	2064	Tan AR	Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer?	Breast cancer research and treatment	2009	48
18973228	2064	Ferretti E	MicroRNA profiling in human medulloblastoma.	International journal of cancer	2009	85
18981013	2064	Luu TH	A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study.	Clinical cancer research 	2008	59
19001334	2064	Chia S	Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers.	Journal of clinical oncology 	2008	52
19005469	2064	Hurtado A	Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen.	Nature	2008	96
19008097	2064	Irvin WJ Jr	What is triple-negative breast cancer?	European journal of cancer	2008	77
19010894	2064	Eichhorn PJ	Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.	Cancer research	2008	140
19053305	2064	Devaraj NK	Tetrazine-based cycloadditions: application to pretargeted live cell imaging.	Bioconjugate chemistry	2008	119
19088018	2064	Dowsett M	Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer.	Clinical cancer research 	2008	62
19116383	2064	Sieuwerts AM	Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells.	Journal of the National Cancer Institute	2009	131
19118027	2064	Banerji U	Heat shock protein 90 as a drug target: some like it hot.	Clinical cancer research 	2009	71
19179558	2064	Blackwell KL	Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens.	Annals of oncology 	2009	48
19204201	2064	Jones S	Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.	Journal of clinical oncology 	2009	77
19204204	2064	Parker JS	Supervised risk predictor of breast cancer based on intrinsic subtypes.	Journal of clinical oncology 	2009	856
19204205	2064	Hugh J	Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.	Journal of clinical oncology 	2009	107
19204209	2064	Sauter G	Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations.	Journal of clinical oncology 	2009	106
19218427	2064	Ben-Kasus T	Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis.	Proceedings of the National Academy of Sciences of the United States of America	2009	58
19266279	2064	Chen DT	Proliferative genes dominate malignancy-risk gene signature in histologically-normal breast tissue.	Breast cancer research and treatment	2010	58
19272155	2064	Rody A	T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers.	Breast cancer research 	2009	90
19276287	2064	Magnifico A	Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab.	Clinical cancer research 	2009	78
19276373	2064	Iorio MV	microRNA-205 regulates HER3 in human breast cancer.	Cancer research	2009	112
19289619	2064	von Minckwitz G	Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.	Journal of clinical oncology 	2009	134
19299408	2064	Simmons C	Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?	Annals of oncology 	2009	59
19318484	2064	Wong KK	A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.	Clinical cancer research 	2009	52
19318578	2064	Neal CL	14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival.	Cancer research	2009	55
19320967	2064	Stead LA	Triple-negative breast cancers are increased in black women regardless of age or body mass index.	Breast cancer research 	2009	74
19343511	2064	Trivers KF	The epidemiology of triple-negative breast cancer, including race.	Cancer causes and control 	2009	73
19366799	2064	Elsheikh SE	Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome.	Cancer research	2009	76
19380452	2064	Penault-Llorca F	Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer.	Journal of clinical oncology 	2009	49
19416831	2064	Caldas-Lopes E	Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models.	Proceedings of the National Academy of Sciences of the United States of America	2009	93
19432961	2064	Lowery AJ	MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.	Breast cancer research 	2009	120
19436038	2064	Cheang MC	Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.	Journal of the National Cancer Institute	2009	409
19443585	2064	Dijkers EC	Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging.	Journal of nuclear medicine 	2009	72
19463150	2064	Kwan ML	Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors.	Breast cancer research 	2009	87
19509167	2064	Yao E	Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.	Clinical cancer research 	2009	47
19535820	2064	Goldhirsch A	Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.	Annals of oncology 	2009	245
19548375	2064	Wolff AC	American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.	Archives of pathology and laboratory medicine	2007	283
19562338	2064	Reuschenbach M	A systematic review of humoral immune responses against tumor antigens.	Cancer immunology, immunotherapy 	2009	60
19574486	2064	Onitilo AA	Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival.	Clinical medicine and research	2009	153
19589136	2064	Aktas B	Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients.	Breast cancer research 	2009	184
19596702	2064	Liedtke C	Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer.	Annals of oncology 	2009	69
19597704	2064	Pestrin M	Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients.	Breast cancer research and treatment	2009	56
19617568	2064	Ponzo MG	Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2009	76
19633047	2064	Kataoka Y	Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines.	Annals of oncology 	2010	56
19664291	2064	Fehm T	Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells.	Breast cancer research 	2009	59
19668225	2064	Zhao YH	Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth.	Oncogene	2009	51
19671800	2064	Liu L	Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.	Cancer research	2009	114
19676044	2064	Salnikov AV	CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients.	International journal of cancer	2010	53
19687332	2064	Ellard SL	Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.	Journal of clinical oncology 	2009	55
19701706	2064	Weigelt B	HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment.	Breast cancer research and treatment	2010	94
19704069	2064	Huo D	Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer.	Journal of clinical oncology 	2009	96
19720913	2064	Gray R	Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer.	Journal of clinical oncology 	2009	53
19720923	2064	Disis ML	Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer.	Journal of clinical oncology 	2009	78
19732720	2064	Lu J	14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition.	Cancer cell	2009	70
19735549	2064	Behbod F	An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ.	Breast cancer research 	2009	60
19764994	2064	Parise CA	Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.	The breast journal	2009	68
19766563	2064	Cicalese A	The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells.	Cell	2009	231
19786670	2064	Kaufman B	Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.	Journal of clinical oncology 	2009	136
19858088	2064	Aitken SJ	Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases.	Annals of oncology 	2010	40
19884543	2064	Gonzalez-Angulo AM	High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.	Journal of clinical oncology 	2009	66
19884557	2064	Joensuu H	Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.	Journal of clinical oncology 	2009	85
19887463	2064	Park S	Expression of androgen receptors in primary breast cancer.	Annals of oncology 	2010	67
19901115	2064	Makhija S	Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.	Journal of clinical oncology 	2010	44
19917839	2064	Spielmann M	Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial.	Journal of clinical oncology 	2009	56
19920100	2064	Mittendorf EA	Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes.	Clinical cancer research 	2009	52
19933921	2064	Dawood S	Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review.	Journal of clinical oncology 	2010	128
20068073	2064	Ahmed N	HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors.	Clinical cancer research 	2010	72
20100965	2064	Silver DP	Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.	Journal of clinical oncology 	2010	209
20113825	2064	Gianni L	Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.	Lancet	2010	165
20124182	2064	Baselga J	Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.	Journal of clinical oncology 	2010	135
20124187	2064	Blackwell KL	Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.	Journal of clinical oncology 	2010	176
20142587	2064	Burstein HJ	Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.	Journal of clinical oncology 	2010	92
20181526	2064	Weigelt B	Breast cancer molecular profiling with single sample predictors: a retrospective analysis.	The Lancet. Oncology	2010	97
20208134	2064	Grabsch H	HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series.	Cellular oncology 	2010	63
20231686	2064	Staaf J	Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.	Journal of clinical oncology 	2010	54
20238327	2064	Wagner AD	Chemotherapy for advanced gastric cancer.	The Cochrane database of systematic reviews	2010	130
20308670	2064	Untch M	Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.	Journal of clinical oncology 	2010	88
20339913	2064	Barrios CH	Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer.	Breast cancer research and treatment	2010	50
20348949	2064	Bafna S	Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells.	Oncogene	2010	95
20357763	2064	Dijkers EC	Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer.	Clinical pharmacology and therapeutics	2010	145
20371474	2064	Amin DN	Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.	Science translational medicine	2010	63
20404194	2064	John R	In vivo magnetomotive optical molecular imaging using targeted magnetic nanoprobes.	Proceedings of the National Academy of Sciences of the United States of America	2010	42
20406831	2064	Riethdorf S	Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial.	Clinical cancer research 	2010	104
20410336	2064	Shah MA	Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease.	Journal of the National Comprehensive Cancer Network 	2010	48
20421541	2064	Krop IE	Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.	Journal of clinical oncology 	2010	102
20436504	2064	Schnitt SJ	Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy.	Modern pathology 	2010	66
20453058	2064	O'Brien C	Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.	Clinical cancer research 	2010	82
20484419	2064	Baum RP	Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules.	Journal of nuclear medicine 	2010	57
20498394	2064	Kennecke H	Metastatic behavior of breast cancer subtypes.	Journal of clinical oncology 	2010	290
20498403	2064	Miles DW	Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.	Journal of clinical oncology 	2010	187
20530280	2064	Procter M	Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.	Journal of clinical oncology 	2010	51
20535745	2064	Toullec A	Oxidative stress promotes myofibroblast differentiation and tumour spreading.	EMBO molecular medicine	2010	65
20537966	2064	Podo F	Triple-negative breast cancer: present challenges and new perspectives.	Molecular oncology	2010	61
20576095	2064	Jönsson G	Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics.	Breast cancer research 	2010	65
20581867	2064	Chakrabarty A	H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3.	Oncogene	2010	43
20622894	2064	Meng L	Heat-shock transcription factor HSF1 has a critical role in human epidermal growth factor receptor-2-induced cellular transformation and tumorigenesis.	Oncogene	2010	40
20629078	2064	Stark A	African ancestry and higher prevalence of triple-negative breast cancer: findings from an international study.	Cancer	2010	50
20647302	2064	Weigel MT	Current and emerging biomarkers in breast cancer: prognosis and prediction.	Endocrine-related cancer	2010	89
20664598	2064	Dawson SJ	BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received.	British journal of cancer	2010	54
20665045	2064	Rüschoff J	HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing.	Virchows Archiv 	2010	85
20697801	2064	Huober J	Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study.	Breast cancer research and treatment	2010	44
20711231	2064	Arias-Romero LE	A Rac-Pak signaling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells.	Oncogene	2010	52
20728210	2064	Bang YJ	Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.	Lancet	2010	956
20730488	2064	Junttila TT	Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer.	Breast cancer research and treatment	2011	61
20805300	2064	Junutula JR	Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.	Clinical cancer research 	2010	45
20832293	2064	Dedes KJ	Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer.	European journal of cancer	2011	44
20837693	2064	Nielsen TO	A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer.	Clinical cancer research 	2010	165
20859679	2064	Fehm T	HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial.	Breast cancer research and treatment	2010	74
20861225	2064	Toft DJ	Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies.	Molecular endocrinology	2011	38
20863372	2064	Hoefnagel LD	Receptor conversion in distant breast cancer metastases.	Breast cancer research 	2010	49
20877296	2064	Carey L	Triple-negative breast cancer: disease entity or title of convenience?	Nature reviews. Clinical oncology	2010	180
20920229	2064	Bediaga NG	DNA methylation epigenotypes in breast cancer molecular subtypes.	Breast cancer research 	2010	47
20932292	2064	Sircoulomb F	Genome profiling of ERBB2-amplified breast cancers.	BMC cancer	2010	52
20975068	2064	Andre F	Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab.	Journal of clinical oncology 	2010	49
21050424	2064	Chacón RD	Triple-negative breast cancer.	Breast cancer research 	2010	57
21057787	2064	Groheux D	Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer.	European journal of nuclear medicine and molecular imaging	2011	39
21059212	2064	Thompson AM	Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS).	Breast cancer research 	2010	59
21109570	2064	Tamura K	FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer.	Annals of oncology 	2011	41
21115860	2064	Valero V	Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.	Journal of clinical oncology 	2011	43
21135276	2064	Dave B	Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.	Journal of clinical oncology 	2011	77
21147047	2064	Prat A	Deconstructing the molecular portraits of breast cancer.	Molecular oncology	2011	261
21149659	2064	Andersson M	Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study.	Journal of clinical oncology 	2011	46
21169259	2064	O'Brien KM	Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study.	Clinical cancer research 	2010	94
21172893	2064	Burris HA 3rd	Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.	Journal of clinical oncology 	2011	115
21191116	2064	Iwamoto T	Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer.	Journal of the National Cancer Institute	2011	64
21199797	2064	Persson H	Identification of new microRNAs in paired normal and tumor breast tissue suggests a dual role for the ERBB2/Her2 gene.	Cancer research	2011	61
21204711	2064	Gutierrez C	HER2: biology, detection, and clinical implications.	Archives of pathology and laboratory medicine	2011	50
21264346	2064	Ignatiadis M	HER2-positive circulating tumor cells in breast cancer.	PloS one	2011	50
21278436	2064	Baselga J	Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer.	The oncologist	2011	74
21298334	2064	Raimondi C	Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients.	Breast cancer research and treatment	2011	72
21310941	2064	Al-Ejeh F	Breast cancer stem cells: treatment resistance and therapeutic opportunities.	Carcinogenesis	2011	36
21342044	2064	Gajria D	HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.	Expert review of anticancer therapy	2011	73
21346227	2064	Phipps AI	Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer.	Journal of the National Cancer Institute	2011	65
21354370	2064	Gianni L	Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.	The Lancet. Oncology	2011	107
21356373	2064	Conklin MW	Aligned collagen is a prognostic signature for survival in human breast carcinoma.	The American journal of pathology	2011	192
21364029	2064	Phipps AI	Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer.	Cancer epidemiology, biomarkers and prevention 	2011	54
21368164	2064	Chakrabarty A	Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors.	Proceedings of the National Academy of Sciences of the United States of America	2012	116
21373875	2064	Glück S	TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab.	Breast cancer research and treatment	2012	58
21376385	2064	Cortes J	Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.	Lancet	2011	129
21383283	2064	Robert NJ	RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.	Journal of clinical oncology 	2011	215
21385943	2064	Garrett JT	Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase.	Proceedings of the National Academy of Sciences of the United States of America	2011	152
21387260	2064	Lara-Medina F	Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity.	Cancer	2011	41
21399647	2064	Zhang S	Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways.	Nature medicine	2011	146
21422418	2064	Desmedt C	Multifactorial approach to predicting resistance to anthracyclines.	Journal of clinical oncology 	2011	43
21437909	2064	Ladoire S	In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival.	The Journal of pathology	2011	47
21454582	2064	Aertgeerts K	Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein.	The Journal of biological chemistry	2011	48
21469140	2064	Andreopoulou E	Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system.	International journal of cancer	2012	43
21479927	2064	Ascierto ML	A signature of immune function genes associated with recurrence-free survival in breast cancer patients.	Breast cancer research and treatment	2012	44
21497451	2064	Sperduto PW	Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases.	International journal of radiation oncology, biology, physics	2012	37
21498634	2064	Zhao Y	Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism.	Cancer research	2011	43
21501481	2064	Kao KJ	Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization.	BMC cancer	2011	74
21505063	2064	Sieuwerts AM	mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients.	Clinical cancer research 	2011	59
21509760	2064	Musolino A	Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study.	Cancer	2011	35
21518778	2064	Hartman ZC	HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis.	Cancer research	2011	39
21555689	2064	Ellis MJ	Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.	Journal of clinical oncology 	2011	82
21558407	2064	Modi S	HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.	Clinical cancer research 	2011	100
21558518	2064	Hatzis C	A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.	JAMA	2011	153
21562709	2064	Ono M	Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.	Breast cancer research and treatment	2012	53
21642515	2064	Pierga JY	High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients.	Annals of oncology 	2012	59
21667121	2064	Gaudet MM	Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger.	Breast cancer research and treatment	2011	48
21671017	2064	Harrell JC	Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse.	Breast cancer research and treatment	2012	73
21699723	2064	Giuliano M	Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment.	Breast cancer research 	2011	42
21709140	2064	Goldhirsch A	Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.	Annals of oncology 	2011	560
21709195	2064	Begnami MD	Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.	Journal of clinical oncology 	2011	61
21717105	2064	Liu F	CD8⁺ cytotoxic T cell and FOXP3⁺ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes.	Breast cancer research and treatment	2011	42
21768129	2064	Brufsky AM	Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER.	Clinical cancer research 	2011	52
21768458	2064	Perez EA	Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.	Journal of clinical oncology 	2011	144
21773767	2064	Győrffy B	RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data.	Breast cancer research and treatment	2012	35
21780108	2064	Chua TC	Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes--a systematic review.	International journal of cancer	2012	36
21785460	2064	Guedj M	A refined molecular taxonomy of breast cancer.	Oncogene	2012	67
21788566	2064	Untch M	Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.	Journal of clinical oncology 	2011	65
21795664	2064	Yaghjyan L	Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to tumor characteristics.	Journal of the National Cancer Institute	2011	41
21807638	2064	Filipits M	A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.	Clinical cancer research 	2011	79
21847123	2064	Pandya K	Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence.	British journal of cancer	2011	45
21859480	2064	Li J	A nation-wide multicenter 10-year (1999-2008) retrospective clinical epidemiological study of female breast cancer in China.	BMC cancer	2011	41
21862331	2064	Huober J	Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial.	Breast	2012	31
21862872	2064	Liu B	Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions.	Cell cycle	2011	38
21873240	2064	Wang L	Intersection of FOXO- and RUNX1-mediated gene expression programs in single breast epithelial cells during morphogenesis and tumor progression.	Proceedings of the National Academy of Sciences of the United States of America	2011	41
21884641	2064	Holliday DL	Choosing the right cell line for breast cancer research.	Breast cancer research 	2011	189
21900114	2064	Arvold ND	Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy.	Journal of clinical oncology 	2011	54
21908711	2064	Kristensen VN	Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling.	Proceedings of the National Academy of Sciences of the United States of America	2012	62
21965336	2064	Higgins MJ	Targeted therapies for breast cancer.	The Journal of clinical investigation	2011	89
21965473	2064	Giordano A	Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy.	Annals of oncology 	2012	32
21990397	2064	Brufsky AM	RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.	Journal of clinical oncology 	2011	82
21990413	2064	Cuzick J	Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.	Journal of clinical oncology 	2011	116
21991949	2064	Slamon D	Adjuvant trastuzumab in HER2-positive breast cancer.	The New England journal of medicine	2011	356
21996747	2064	Lo PK	CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFβ signaling.	Oncogene	2012	46
22010023	2064	Miller TW	Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer.	Journal of clinical oncology 	2011	79
22042958	2064	Perez EA	Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer.	Journal of clinical oncology 	2011	55
22049225	2064	Mahmoud SM	Tumour-infiltrating macrophages and clinical outcome in breast cancer.	Journal of clinical pathology	2012	43
22062686	2064	Jhaveri K	Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers.	Biochimica et biophysica acta	2012	108
22081974	2064	Fasching PA	Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment.	BMC cancer	2011	55
22114931	2064	Miller TW	Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.	Breast cancer research 	2011	84
22123186	2064	Wang YC	Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.	Breast cancer research 	2011	52
22124102	2064	Amir E	Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer.	Journal of clinical oncology 	2012	79
22124109	2064	Niikura N	Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors.	Journal of clinical oncology 	2012	67
22124364	2064	Arteaga CL	Treatment of HER2-positive breast cancer: current status and future perspectives.	Nature reviews. Clinical oncology	2011	196
22147079	2064	Lowery AJ	Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype.	Breast cancer research and treatment	2012	47
22149875	2064	Baselga J	Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.	The New England journal of medicine	2012	394
22153890	2064	Gianni L	Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.	The Lancet. Oncology	2012	239
22172323	2064	Jensen JD	PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab.	Annals of oncology 	2012	36
22178456	2064	Amir E	Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies.	Cancer treatment reviews	2012	32
22198468	2064	Esserman LJ	Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).	Breast cancer research and treatment	2012	88
22222640	2064	Rüschoff J	HER2 testing in gastric cancer: a practical approach.	Modern pathology 	2012	80
22248472	2064	McDonagh CF	Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.	Molecular cancer therapeutics	2012	70
22257523	2064	Untch M	Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.	The Lancet. Oncology	2012	65
22257673	2064	Baselga J	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.	Lancet	2012	207
22261811	2064	Azim HA Jr	Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling.	Clinical cancer research 	2012	50
22264265	2064	Kasimir-Bauer S	Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells.	Breast cancer research 	2012	66
22276820	2064	von Minckwitz G	Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.	The New England journal of medicine	2012	94
22276821	2064	Bear HD	Bevacizumab added to neoadjuvant chemotherapy for breast cancer.	The New England journal of medicine	2012	94
22294718	2064	Davies BR	Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.	Molecular cancer therapeutics	2012	62
22325357	2064	De Grève J	Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.	Lung cancer	2012	47
22331459	2064	Stevens KN	19p13.1 is a triple-negative-specific breast cancer susceptibility locus.	Cancer research	2012	44
22331954	2064	Bergh J	First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.	Journal of clinical oncology 	2012	53
22351696	2064	Cheang MC	Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial.	Clinical cancer research 	2012	32
22370716	2064	Jung EJ	Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients.	Cancer	2012	61
22373922	2064	Whale AS	Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation.	Nucleic acids research	2012	57
22377126	2064	Pierga JY	Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study.	The Lancet. Oncology	2012	31
22388088	2064	Aceto N	Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop.	Nature medicine	2012	65
22388760	2064	Seol H	Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance.	Modern pathology 	2012	36
22393084	2064	Cortés J	Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer.	Journal of clinical oncology 	2012	52
22400902	2064	Wu X	De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer.	Journal of translational medicine	2012	46
22407832	2064	García-García C	Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.	Clinical cancer research 	2012	49
22412143	2064	Baselga J	Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.	Journal of clinical oncology 	2012	36
22461643	2064	Stern HM	Improving treatment of HER2-positive cancers: opportunities and challenges.	Science translational medicine	2012	42
22465195	2064	Murray S	Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies.	Cancer treatment reviews	2012	44
22467215	2064	Thiel KW	Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers.	Nucleic acids research	2012	59
22471661	2064	Rexer BN	Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications.	Critical reviews in oncogenesis	2012	67
22493419	2064	Guarneri V	Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.	Journal of clinical oncology 	2012	58
22495314	2064	Shah SP	The clonal and mutational evolution spectrum of primary triple-negative breast cancers.	Nature	2012	499
22508812	2064	von Minckwitz G	Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.	Journal of clinical oncology 	2012	250
22513938	2064	Moja L	Trastuzumab containing regimens for early breast cancer.	The Cochrane database of systematic reviews	2012	73
22517820	2064	Gelmon K	Targeting triple-negative breast cancer: optimising therapeutic outcomes.	Annals of oncology 	2012	41
22517885	2064	Yao YD	Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis.	Science translational medicine	2012	34
22544643	2064	Lin NU	Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network.	Cancer	2012	50
22565002	2064	Bachelot T	Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study.	Journal of clinical oncology 	2012	120
22586653	2064	Bertotti A	A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.	Cancer discovery	2011	125
22649126	2064	Krop IE	A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.	Journal of clinical oncology 	2012	58
22665540	2064	Ebb D	Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group.	Journal of clinical oncology 	2012	41
22677156	2064	Lucci A	Circulating tumour cells in non-metastatic breast cancer: a prospective study.	The Lancet. Oncology	2012	96
22689179	2064	Janjigian YY	Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis.	Annals of oncology 	2012	46
22689798	2064	Chlebowski RT	Diabetes, metformin, and breast cancer in postmenopausal women.	Journal of clinical oncology 	2012	48
22689807	2064	Blackwell KL	Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.	Journal of clinical oncology 	2012	105
22711706	2064	Chia SK	A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen.	Clinical cancer research 	2012	48
22711854	2064	Lindström LS	Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.	Journal of clinical oncology 	2012	73
22738135	2064	Marleau AM	Exosome removal as a therapeutic adjuvant in cancer.	Journal of translational medicine	2012	55
22744937	2064	Sawaya H	Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab.	Circulation. Cardiovascular imaging	2012	66
22761469	2064	Arcila ME	Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.	Clinical cancer research 	2012	53
22773826	2064	Clarke CA	Age-specific incidence of breast cancer subtypes: understanding the black-white crossover.	Journal of the National Cancer Institute	2012	54
22817698	2064	Byrski T	Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer.	Breast cancer research 	2012	36
22884505	2064	Ismael G	Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.	The Lancet. Oncology	2012	40
22894854	2064	Müller V	Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study.	Breast cancer research 	2012	35
22926690	2064	Sparano JA	Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer.	Cancer	2012	41
22956644	2064	Takezawa K	HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.	Cancer discovery	2012	134
22966038	2064	Liby KT	Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease.	Pharmacological reviews	2012	69
22967996	2064	Awada A	Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy.	Annals of oncology 	2013	26
22973057	2064	Giordano A	Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer.	Molecular cancer therapeutics	2012	58
22987084	2064	Romond EH	Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer.	Journal of clinical oncology 	2012	60
22988081	2064	Axup JY	Synthesis of site-specific antibody-drug conjugates using unnatural amino acids.	Proceedings of the National Academy of Sciences of the United States of America	2012	81
23000189	2064	Park EJ	Ultrasound-mediated blood-brain/blood-tumor barrier disruption improves outcomes with trastuzumab in a breast cancer brain metastasis model.	Journal of controlled release 	2012	37
23012306	2064	Boyle P	Triple-negative breast cancer: epidemiological considerations and recommendations.	Annals of oncology 	2012	98
23020162	2064	Verma S	Trastuzumab emtansine for HER2-positive advanced breast cancer.	The New England journal of medicine	2012	381
23034170	2064	Ma C	Tumor-infiltrating γδ T lymphocytes predict clinical outcome in human breast cancer.	Journal of immunology	2012	37
23035151	2064	Dubsky P	EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer.	Annals of oncology 	2013	31
23035882	2064	Bastien RR	PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.	BMC medical genomics	2012	64
23071104	2064	Wu Y	Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells.	Molecular cancer research 	2012	37
23102520	2064	Cervantes A	Current questions for the treatment of advanced gastric cancer.	Cancer treatment reviews	2013	32
23122784	2064	Bachelot T	Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.	The Lancet. Oncology	2013	72
23129208	2064	Bidard FC	Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials.	Cancer metastasis reviews	2013	61
23136233	2064	Eiermann W	The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use.	Annals of oncology 	2013	30
23139264	2064	Warneke VS	Her2/neu testing in gastric cancer: evaluating the risk of sampling errors.	Annals of oncology 	2013	27
23159108	2064	Colomba E	Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing.	The Journal of molecular diagnostics 	2013	36
23173552	2064	Lambert JM	Drug-conjugated antibodies for the treatment of cancer.	British journal of clinical pharmacology	2013	30
23204226	2064	Chakrabarty A	Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors.	Cancer research	2013	31
23220880	2064	Bose R	Activating HER2 mutations in HER2 gene amplification negative breast cancer.	Cancer discovery	2013	135
23224237	2064	Li CI	Reproductive factors and risk of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among women 20-44 years of age.	Breast cancer research and treatment	2013	33
23233704	2064	Prat A	Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer.	Journal of clinical oncology 	2013	87
23246022	2064	Mackey JR	Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.	The Lancet. Oncology	2013	41
23271327	2064	Wallwiener M	The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer.	Breast cancer research and treatment	2013	27
23302230	2064	Alkins R	Focused ultrasound delivers targeted immune cells to metastatic brain tumors.	Cancer research	2013	32
23320171	2064	Mitri Z	The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy.	Chemotherapy research and practice	2012	42
23341518	2064	Loi S	Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.	Journal of clinical oncology 	2013	199
23382472	2064	Hurvitz SA	Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.	Journal of clinical oncology 	2013	69
23396049	2064	Van Laere SJ	Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets.	Clinical cancer research 	2013	28
23404817	2064	Prat A	Molecular characterization of basal-like and non-basal-like triple-negative breast cancer.	The oncologist	2013	98
23422754	2064	Miles DW	Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer.	British journal of cancer	2013	34
23442322	2064	Ithimakin S	HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab.	Cancer research	2013	55
23470965	2064	Yu HA	Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.	Clinical cancer research 	2013	251
23475636	2064	Swain SM	Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study.	The oncologist	2013	28
23519125	2064	Wang S	Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells.	Cell death and disease	2013	26
23532334	2064	Bean GR	PUMA and BIM are required for oncogene inactivation-induced apoptosis.	Science signaling	2013	31
23563986	2064	Boku N	HER2-positive gastric cancer.	Gastric cancer 	2014	26
23569311	2064	Gianni L	AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.	Journal of clinical oncology 	2013	46
23589555	2064	Sleijfer S	Designing transformative clinical trials in the cancer genome era.	Journal of clinical oncology 	2013	35
23593079	2064	Lee HJ	Tumor-associated lymphocytes predict response to neoadjuvant chemotherapy in breast cancer patients.	Journal of breast cancer	2013	26
23602601	2064	Swain SM	Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.	The Lancet. Oncology	2013	145
23610105	2064	Mazières J	Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.	Journal of clinical oncology 	2013	82
23627572	2064	Müller BM	Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer--overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression.	BMC cancer	2013	35
23650412	2064	Perez EA	Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial.	Journal of clinical oncology 	2013	35
23667204	2064	Ajani JA	Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines.	Journal of the National Comprehensive Cancer Network 	2013	103
23704196	2064	Schneeweiss A	Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).	Annals of oncology 	2013	75
23737486	2064	Zhang X	A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models.	Cancer research	2013	71
23738752	2064	Chen WC	Interleukin-17-producing cell infiltration in the breast cancer tumour microenvironment is a poor prognostic factor.	Histopathology	2013	31
23740771	2064	Korkaya H	HER2 and breast cancer stem cells: more than meets the eye.	Cancer research	2013	32
23748853	2064	Eichelser C	Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression.	Clinical chemistry	2013	35
23756627	2064	Muenst S	The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer.	Breast cancer research and treatment	2013	49
23757357	2064	Sessa C	First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors.	Clinical cancer research 	2013	33
23764181	2064	Pivot X	6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.	The Lancet. Oncology	2013	37
23793035	2064	Jiralerspong S	Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients.	Annals of oncology 	2013	32
23807776	2064	Hanna WM	HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity.	Modern pathology 	2014	31
23818604	2064	Gerdes MJ	Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue.	Proceedings of the National Academy of Sciences of the United States of America	2013	60
23847214	2064	Theriault RL	Breast cancer, version 3.2013: featured updates to the NCCN guidelines.	Journal of the National Comprehensive Cancer Network 	2013	48
23852170	2064	Roberts SA	An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers.	Nature genetics	2013	205
23871490	2064	Goldhirsch A	2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.	Lancet	2013	79
23873022	2064	Kim HP	Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer.	Oncogene	2014	26
23901018	2064	Engstrøm MJ	Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients.	Breast cancer research and treatment	2013	32
23913138	2064	Sassoon I	Antibody-drug conjugate (ADC) clinical pipeline: a review.	Methods in molecular biology	2013	27
23917950	2064	Goldhirsch A	Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.	Annals of oncology 	2013	376
23965851	2064	Cufí S	The anti-malarial chloroquine overcomes primary resistance and restores sensitivity to trastuzumab in HER2-positive breast cancer.	Scientific reports	2013	27
23970015	2064	Denkert C	Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial.	Annals of oncology 	2013	28
23989717	2064	Ky B	Emerging paradigms in cardiomyopathies associated with cancer therapies.	Circulation research	2013	30
24002511	2064	von Minckwitz G	Response-guided neoadjuvant chemotherapy for breast cancer.	Journal of clinical oncology 	2013	32
24029656	2064	Tamura K	64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer.	Journal of nuclear medicine 	2013	32
24041156	2064	Singh JK	Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells.	Breast cancer research 	2013	34
24056965	2064	Nair R	c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer.	Oncogene	2014	32
24061039	2064	Wadhwa R	Gastric cancer-molecular and clinical dimensions.	Nature reviews. Clinical oncology	2013	76
24069582	2064	den Hollander P	Targeted therapy for breast cancer prevention.	Frontiers in oncology	2013	33
24080156	2064	Kümler I	A systematic review of dual targeting in HER2-positive breast cancer.	Cancer treatment reviews	2014	33
24095300	2064	Robidoux A	Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.	The Lancet. Oncology	2013	54
24099077	2064	Wolff AC	Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.	Archives of pathology and laboratory medicine	2014	99
24101045	2064	Wolff AC	Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.	Journal of clinical oncology 	2013	434
24127447	2064	Gomez-Martin C	Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab.	Journal of clinical oncology 	2013	32
24130112	2064	Walsh AJ	Optical metabolic imaging identifies glycolytic levels, subtypes, and early-treatment response in breast cancer.	Cancer research	2013	43
24148764	2064	Leivonen SK	High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth.	Molecular oncology	2014	39
24157828	2064	Dubsky P	The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients.	British journal of cancer	2013	35
24162158	2064	Prat A	Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.	Breast cancer research and treatment	2013	48
24206575	2064	Chen M	Systematic review and meta-analysis of tumor biomarkers in predicting prognosis in esophageal cancer.	BMC cancer	2013	28
24220145	2064	Pfefferle AD	Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts.	Genome biology	2013	41
24229395	2064	Meredith RF	Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients.	Cancer biotherapy and radiopharmaceuticals	2014	21
24239210	2064	Buzdar AU	Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial.	The Lancet. Oncology	2013	27
24269135	2064	Aurilio G	A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases.	European journal of cancer	2014	26
24297508	2064	Chung SS	STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits.	International journal of oncology	2014	30
24298071	2064	Lin NU	CNS metastases in breast cancer: old challenge, new frontiers.	Clinical cancer research 	2013	33
24323026	2064	Gandhi L	Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.	Journal of clinical oncology 	2014	37
24337597	2064	Auvinen P	Hyaluronan synthases (HAS1-3) in stromal and malignant cells correlate with breast cancer grade and predict patient survival.	Breast cancer research and treatment	2014	20
24337604	2064	Mortimer JE	Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET.	Journal of nuclear medicine 	2014	28
24360619	2064	Figueroa-Magalhães MC	Treatment of HER2-positive breast cancer.	Breast	2014	21
24398324	2064	Farazi TA	Identification of distinct miRNA target regulation between breast cancer molecular subtypes using AGO2-PAR-CLIP and patient datasets.	Genome biology	2014	22
24410085	2064	Gujrati V	Bioengineered bacterial outer membrane vesicles as cell-specific drug-delivery vehicles for cancer therapy.	ACS nano	2014	25
24443618	2064	Prat A	Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study.	Clinical cancer research 	2014	23
24448237	2064	Almendro V	Genetic and phenotypic diversity in breast tumor metastases.	Cancer research	2014	39
24463450	2064	Santagata S	Taxonomy of breast cancer based on normal cell phenotype predicts outcome.	The Journal of clinical investigation	2014	55
24470511	2064	Saura C	Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy.	Clinical cancer research 	2014	25
24477977	2064	Anderson KN	Reproductive risk factors and breast cancer subtypes: a review of the literature.	Breast cancer research and treatment	2014	47
24480556	2064	Bianchini G	The immune system and response to HER2-targeted treatment in breast cancer.	The Lancet. Oncology	2014	29
24518603	2064	Liu YJ	HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.	British journal of cancer	2014	28
24521995	2064	Sweeney C	Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics.	Cancer epidemiology, biomarkers and prevention 	2014	24
24523301	2064	Gross MI	Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer.	Molecular cancer therapeutics	2014	85
24529560	2064	Cortazar P	Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.	Lancet	2014	220
24532163	2064	Dirican A	Do the derived neutrophil to lymphocyte ratio and the neutrophil to lymphocyte ratio predict prognosis in breast cancer?	International journal of clinical oncology	2015	20
24569463	2064	Yoshida T	Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.	British journal of cancer	2014	36
24587643	2064	Orditura M	Treatment of gastric cancer.	World journal of gastroenterology	2014	63
24608200	2064	Loi S	Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.	Annals of oncology 	2014	129
24657003	2064	Gianni L	Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.	The Lancet. Oncology	2014	35
24665085	2064	Sörensen J	First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule.	Journal of nuclear medicine 	2014	36
24721646	2064	Chittaranjan S	Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer.	Clinical cancer research 	2014	22
24722644	2064	Soussan M	Relationship between tumor heterogeneity measured on FDG-PET/CT and pathological prognostic factors in invasive breast cancer.	PloS one	2014	30
24727284	2064	Geng SQ	Breast cancer stem cells: Multiple capacities in tumor metastasis.	Cancer letters	2014	22
24739973	2064	Godinho SA	Oncogene-like induction of cellular invasion from centrosome amplification.	Nature	2014	60
24742739	2064	André F	Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.	The Lancet. Oncology	2014	76
24777111	2064	Howlader N	US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.	Journal of the National Cancer Institute	2014	73
24793816	2064	Krop IE	Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.	The Lancet. Oncology	2014	59
24794243	2064	von Minckwitz G	Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.	The Lancet. Oncology	2014	77
24799465	2064	Giordano SH	Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.	Journal of clinical oncology 	2014	45
24803582	2064	Silwal-Pandit L	TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance.	Clinical cancer research 	2014	35
24829859	2064	Yadav BS	Systemic treatment strategies for triple-negative breast cancer.	World journal of clinical oncology	2014	24
24842267	2064	Muenst S	Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer.	Breast cancer research and treatment	2014	78
24868024	2064	Satoh T	Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.	Journal of clinical oncology 	2014	79
24887180	2064	Barok M	Trastuzumab emtansine: mechanisms of action and drug resistance.	Breast cancer research 	2014	31
24912899	2064	de Azambuja E	Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01).	Journal of clinical oncology 	2014	31
24915873	2064	Ali HR	Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients.	Annals of oncology 	2014	49
24951027	2064	Maisonneuve P	Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes.	Breast cancer research 	2014	22
24960601	2064	Choi W	Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer.	Nature reviews. Urology	2014	30
24967516	2064	Lambert JM	Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer.	Journal of medicinal chemistry	2014	25
24967588	2064	Ferrari N	Expression of RUNX1 correlates with poor patient prognosis in triple negative breast cancer.	PloS one	2014	20
24970867	2064	Wilkerson MD	Integrated RNA and DNA sequencing improves mutation detection in low purity tumors.	Nucleic acids research	2014	21
25025958	2064	Singh JC	HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development.	British journal of cancer	2014	22
25038874	2064	Van Cutsem E	HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.	Gastric cancer 	2015	23
25049332	2064	Ades F	Luminal B breast cancer: molecular characterization, clinical management, and future perspectives.	Journal of clinical oncology 	2014	51
25086636	2064	Müller V	Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.	Breast cancer research and treatment	2014	25
25129345	2064	Byrski T	Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients.	Breast cancer research and treatment	2014	31
25130998	2064	de Azambuja E	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.	The Lancet. Oncology	2014	44
25185096	2064	Partridge AH	Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline.	Journal of clinical oncology 	2014	33
25185099	2064	Mackey JR	Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer.	Journal of clinical oncology 	2015	17
25224496	2064	Palmer JR	Parity, lactation, and breast cancer subtypes in African American women: results from the AMBER Consortium.	Journal of the National Cancer Institute	2014	34
25231953	2064	Piccart M	Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.	Annals of oncology 	2014	62
25273342	2064	von Minckwitz G	Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.	The Lancet. Oncology	2014	24
25276427	2064	Iqbal N	Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications.	Molecular biology international	2014	35
25303979	2064	Yu HA	Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors.	Clinical cancer research 	2014	27
25332247	2064	Baselga J	Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.	Journal of clinical oncology 	2014	42
25332249	2064	Perez EA	Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.	Journal of clinical oncology 	2014	64
25358515	2064	Polzer B	Molecular profiling of single circulating tumor cells with diagnostic intention.	EMBO molecular medicine	2014	45
25373520	2064	Schönfeld K	Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor.	Molecular therapy 	2015	30
25453096	2064	Samanta D	Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells.	Proceedings of the National Academy of Sciences of the United States of America	2014	57
25559818	2064	Majewski IJ	PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.	Journal of clinical oncology 	2015	38
25564897	2064	Tolaney SM	Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.	The New England journal of medicine	2015	52
25567908	2064	Drilon A	Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.	Clinical cancer research 	2015	30
25587647	2064	Rimawi MF	Targeting HER2 for the treatment of breast cancer.	Annual review of medicine	2015	26
25605838	2064	Pivot X	CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.	Journal of clinical oncology 	2015	19
25605861	2064	Perez EA	Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.	Journal of clinical oncology 	2015	36
25605862	2064	Kaufman PA	Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane.	Journal of clinical oncology 	2015	45
25636205	2064	Groenendijk FH	ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy.	European urology	2016	15
25653541	2064	Tomao F	Triple-negative breast cancer: new perspectives for targeted therapies.	OncoTargets and therapy	2015	18
25682074	2064	Wong-Brown MW	Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer.	Breast cancer research and treatment	2015	17
25684987	2064	Chia S	Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancer.	Current oncology	2015	15
25693012	2064	Swain SM	Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.	The New England journal of medicine	2015	132
25713166	2064	Ng CK	Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights.	Journal of the National Cancer Institute	2015	20
25800760	2064	Ahmed N	Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.	Journal of clinical oncology 	2015	70
25805799	2064	Basu B	First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014.	Clinical cancer research 	2015	21
25825511	2064	Kohler BA	Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State.	Journal of the National Cancer Institute	2015	103
25825707	2064	Tang H	Decreased &lt;i&gt;BECN1&lt;/i&gt; mRNA Expression in Human Breast Cancer is Associated with Estrogen Receptor-Negative Subtypes and Poor Prognosis.	EBioMedicine	2015	19
25847929	2064	Telli ML	Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.	Journal of clinical oncology 	2015	27
25849106	2064	McCart Reed AE	Invasive lobular carcinoma of the breast: morphology, biomarkers and 'omics.	Breast cancer research 	2015	19
25895611	2064	Zardavas D	Clinical management of breast cancer heterogeneity.	Nature reviews. Clinical oncology	2015	34
25896973	2064	Chantrill LA	Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial.	Clinical cancer research 	2015	25
25902832	2064	Toss A	Molecular characterization and targeted therapeutic approaches in breast cancer.	Breast cancer research 	2015	19
25918288	2064	Shah MA	Update on metastatic gastric and esophageal cancers.	Journal of clinical oncology 	2015	19
25939896	2064	Coates AS	Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.	Annals of oncology 	2015	139
25959051	2064	Acerbi I	Human breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration.	Integrative biology 	2015	45
25995301	2064	Dieci MV	Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials.	Annals of oncology 	2015	21
26092818	2064	Hurvitz SA	Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.	The Lancet. Oncology	2015	41
26093818	2064	Mazel M	Frequent expression of PD-L1 on circulating breast cancer cells.	Molecular oncology	2015	23
26181252	2064	Salgado R	Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.	JAMA oncology	2015	37
26211827	2064	Early Breast Cancer Trialists' Collaborative Group (EBCTCG).	Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.	Lancet	2015	34
26253814	2064	Prat A	Clinical implications of the intrinsic molecular subtypes of breast cancer.	Breast	2015	32
26318427	2064	Bronte G	New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?	Oncotarget	2015	16
26387133	2064	Palma G	Triple negative breast cancer: looking for the missing link between biology and treatments.	Oncotarget	2015	25
26412349	2064	Sparano JA	Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.	The New England journal of medicine	2015	89
26422389	2064	Nuciforo P	High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy.	Molecular oncology	2016	11
26444637	2064	Kroemer G	Natural and therapy-induced immunosurveillance in breast cancer.	Nature medicine	2015	31
26449837	2064	Keyaerts M	Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma.	Journal of nuclear medicine 	2016	18
26469139	2064	Perez EA	Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.	JAMA oncology	2016	12
26527775	2064	Carey LA	Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.	Journal of clinical oncology 	2016	16
26530965	2064	Murtaza M	Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer.	Nature communications	2015	33
26549855	2064	Sun J	A potential prognostic long non-coding RNA signature to predict metastasis-free survival of breast cancer patients.	Scientific reports	2015	24
26559813	2064	Suck G	NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy.	Cancer immunology, immunotherapy 	2016	15
26578779	2064	Tolaney SM	Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients.	Proceedings of the National Academy of Sciences of the United States of America	2015	19
26598540	2064	Pruneri G	Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer.	Annals of oncology 	2016	12
26598744	2064	Piccart-Gebhart M	Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.	Journal of clinical oncology 	2016	17
26598746	2064	Levine MN	Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario.	Journal of clinical oncology 	2016	12
26628478	2064	Hecht JR	Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.	Journal of clinical oncology 	2016	58
26656517	2064	Gradishar WJ	NCCN Guidelines Insights Breast Cancer, Version 1.2016.	Journal of the National Comprehensive Cancer Network 	2015	17
26667975	2064	Savas P	Clinical relevance of host immunity in breast cancer: from TILs to the clinic.	Nature reviews. Clinical oncology	2016	32
26855592	2064	Xu H	Enrichment of CD44 in basal-type breast cancer correlates with EMT, cancer stem cell gene profile, and prognosis.	OncoTargets and therapy	2016	12
26858339	2064	Harris LN	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.	Journal of clinical oncology 	2016	34
26869049	2064	Untch M	Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial.	The Lancet. Oncology	2016	17
26874951	2064	Shoda K	Monitoring the HER2 copy number status in circulating tumor DNA by droplet digital PCR in patients with gastric cancer.	Gastric cancer 	2017	6
26928228	2064	Dunning AM	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170.	Nature genetics	2016	12
26995633	2064	Yang SX	New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer.	Cancer treatment reviews	2016	15
27108243	2064	Sartore-Bianchi A	Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.	The Lancet. Oncology	2016	32
27156933	2064	Van Cutsem E	Gastric cancer.	Lancet	2016	35
27269946	2064	Fribbens C	Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.	Journal of clinical oncology 	2016	25
27959613	2064	Finn RS	Palbociclib and Letrozole in Advanced Breast Cancer.	The New England journal of medicine	2016	23
9351836	2067	Evans E	Mechanism of open complex and dual incision formation by human nucleotide excision repair factors.	The EMBO journal	1997	138
10882712	2067	Kuraoka I	Repair of an interstrand DNA cross-link initiated by ERCC1-XPF repair/recombination nuclease.	The Journal of biological chemistry	2000	97
11511374	2067	Volker M	Sequential assembly of the nucleotide excision repair factors in vivo.	Molecular cell	2001	236
11905724	2067	McHugh PJ	Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance.	The Lancet. Oncology	2001	117
12114432	2067	Lord RV	Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.	Clinical cancer research 	2002	106
16195237	2067	Zienolddiny S	Polymorphisms of DNA repair genes and risk of non-small cell lung cancer.	Carcinogenesis	2006	101
16957145	2067	Olaussen KA	DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.	The New England journal of medicine	2006	327
17229776	2067	Bellmunt J	Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.	Annals of oncology 	2007	64
17273966	2067	Jaspers NG	First reported patient with human ERCC1 deficiency has cerebro-oculo-facio-skeletal syndrome with a mild defect in nucleotide excision repair and severe developmental failure.	American journal of human genetics	2007	61
17314339	2067	Zheng Z	DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer.	The New England journal of medicine	2007	112
17401013	2067	Ruzzo A	Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.	Journal of clinical oncology 	2007	68
17602080	2067	Cobo M	Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.	Journal of clinical oncology 	2007	94
18316546	2067	Martin LP	Platinum resistance: the role of DNA repair pathways.	Clinical cancer research 	2008	152
18509181	2067	Braun MS	Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial.	Journal of clinical oncology 	2008	77
18584027	2067	Bennardo N	Alternative-NHEJ is a mechanistically distinct pathway of mammalian chromosome break repair.	PLoS genetics	2008	226
19516334	2067	Tubbs JL	Flipping of alkylated DNA damage bridges base and nucleotide excision repair.	Nature	2009	53
19805513	2067	Bhagwat N	XPF-ERCC1 participates in the Fanconi anemia pathway of cross-link repair.	Molecular and cellular biology	2009	55
19884554	2067	Reynolds C	Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer.	Journal of clinical oncology 	2009	53
21227924	2067	Zhang YW	Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells.	Nucleic acids research	2011	51
21896658	2067	Wang AT	Human SNM1A and XPF-ERCC1 collaborate to initiate DNA interstrand cross-link repair.	Genes and development	2011	53
23514287	2067	Friboulet L	ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.	The New England journal of medicine	2013	79
23690416	2067	Bepler G	Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2013	38
7641693	2099	Cavaillès V	Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor.	The EMBO journal	1995	165
8635462	2099	Migliaccio A	Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells.	The EMBO journal	1996	147
9371488	2099	Clarke RB	Dissociation between steroid receptor expression and cell proliferation in the human breast.	Cancer research	1997	155
9524123	2099	Migliaccio A	Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor.	The EMBO journal	1998	119
9662379	2099	Kononen J	Tissue microarrays for high-throughput molecular profiling of tumor specimens.	Nature medicine	1998	753
11171938	2099	Clarke R	Cellular and molecular pharmacology of antiestrogen action and resistance.	Pharmacological reviews	2001	90
11289127	2099	Roger P	Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors.	Cancer research	2001	91
11438457	2099	Leav I	Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma.	The American journal of pathology	2001	90
11473106	2099	Wijayaratne AL	The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators.	The Journal of biological chemistry	2001	104
11773442	2099	Razandi M	ERs associate with and regulate the production of caveolin: implications for signaling and cellular actions.	Molecular endocrinology	2002	91
11929836	2099	Stabile LP	Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen.	Cancer research	2002	101
12040178	2099	McDonnell DP	Connections and regulation of the human estrogen receptor.	Science	2002	123
12408373	2099	Anderson WF	Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database.	Breast cancer research and treatment	2002	105
12743151	2099	Bardou VJ	Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases.	Journal of clinical oncology 	2003	115
12788802	2099	Liu PY	Androgens and cardiovascular disease.	Endocrine reviews	2003	115
12917485	2099	Sotiriou C	Breast cancer classification and prognosis based on gene expression profiles from a population-based study.	Proceedings of the National Academy of Sciences of the United States of America	2003	462
15001666	2099	Bourdeau V	Genome-wide identification of high-affinity estrogen response elements in human and mouse.	Molecular endocrinology	2004	97
15014181	2099	Coombes RC	A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.	The New England journal of medicine	2004	259
15033914	2099	Stossi F	Transcriptional profiling of estrogen-regulated gene expression via estrogen receptor (ER) alpha or ERbeta in human osteosarcoma cells: distinct and common target genes for these receptors.	Endocrinology	2004	71
15221988	2099	Giordano SH	Breast carcinoma in men: a population-based study.	Cancer	2004	103
15223047	2099	Dontu G	Breast cancer, stem/progenitor cells and the estrogen receptor.	Trends in endocrinology and metabolism	2004	90
15310774	2099	Fink AK	Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor--positive breast cancer.	Journal of clinical oncology 	2004	72
15342389	2099	Kubo M	Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer.	Cancer research	2004	103
15342805	2099	Hughes KS	Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer.	The New England journal of medicine	2004	97
15345050	2099	Lin CY	Discovery of estrogen receptor alpha target genes and response elements in breast tumor cells.	Genome biology	2004	102
15496458	2099	Acconcia F	Palmitoylation-dependent estrogen receptor alpha membrane localization: regulation by 17beta-estradiol.	Molecular biology of the cell	2005	120
15572757	2099	Martino S	Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.	Journal of the National Cancer Institute	2004	93
15583021	2099	Herynk MH	Estrogen receptor mutations in human disease.	Endocrine reviews	2004	78
15591335	2099	Paik S	A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.	The New England journal of medicine	2004	1227
15613444	2099	Ring A	Mechanisms of tamoxifen resistance.	Endocrine-related cancer	2004	131
15897552	2099	Mamounas EP	Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.	Journal of clinical oncology 	2005	98
15899795	2099	Dai H	A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients.	Cancer research	2005	89
16009131	2099	Carroll JS	Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1.	Cell	2005	509
16322319	2099	Normanno N	Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer.	Endocrine-related cancer	2005	70
16427018	2099	Wei X	MUC1 oncoprotein stabilizes and activates estrogen receptor alpha.	Molecular cell	2006	71
16478745	2099	Sotiriou C	Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.	Journal of the National Cancer Institute	2006	534
16511588	2099	Deroo BJ	Estrogen receptors and human disease.	The Journal of clinical investigation	2006	267
16515478	2099	Ariazi EA	Estrogen receptors as therapeutic targets in breast cancer.	Current topics in medicinal chemistry	2006	61
16609087	2099	Berry DA	Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.	JAMA	2006	137
16737553	2099	Habel LA	A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients.	Breast cancer research 	2006	109
16754886	2099	Wang Z	A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling.	Proceedings of the National Academy of Sciences of the United States of America	2006	94
16835357	2099	Vivacqua A	17beta-estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the g protein-coupled receptor GPR30.	Molecular pharmacology	2006	74
16954471	2099	Buyse M	Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.	Journal of the National Cancer Institute	2006	242
16980581	2099	Eeckhoute J	A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer.	Genes and development	2006	100
17113977	2099	Russo J	The role of estrogen in the initiation of breast cancer.	The Journal of steroid biochemistry and molecular biology	2006	72
17135638	2099	Bates GJ	Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse.	Journal of clinical oncology 	2006	214
17169390	2099	Jordan VC	Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.	Steroids	2007	77
17178894	2099	Fan M	Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant.	Cancer research	2006	89
17312270	2099	Adams BD	The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines.	Molecular endocrinology	2007	145
17312304	2099	Cuzick J	Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.	Journal of the National Cancer Institute	2007	93
17312305	2099	Powles TJ	Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.	Journal of the National Cancer Institute	2007	80
17360330	2099	Kwon YS	Sensitive ChIP-DSL technology reveals an extensive estrogen receptor alpha-binding program on human gene promoters.	Proceedings of the National Academy of Sciences of the United States of America	2007	59
17372279	2099	Tworoger SS	A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer.	Journal of clinical oncology 	2007	61
17417639	2099	Holst F	Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer.	Nature genetics	2007	75
17475399	2099	Riggins RB	Pathways to tamoxifen resistance.	Cancer letters	2007	78
17542648	2099	Lin CY	Whole-genome cartography of estrogen receptor alpha binding sites.	PLoS genetics	2007	198
17586727	2099	Sasser AK	Interleukin-6 is a potent growth factor for ER-alpha-positive human breast cancer.	FASEB journal 	2007	60
17616709	2099	Eeckhoute J	Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer.	Cancer research	2007	115
17652280	2099	Glass AG	Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status.	Journal of the National Cancer Institute	2007	93
17660348	2099	Gomez BP	Human X-box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines.	FASEB journal 	2007	61
17679729	2099	Blum W	Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.	Journal of clinical oncology 	2007	88
18071188	2099	Owusu C	Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer.	Journal of clinical oncology 	2008	74
18165639	2099	De Laurentiis M	Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials.	Journal of clinical oncology 	2008	72
18219273	2099	Krum SA	Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival.	The EMBO journal	2008	77
18258689	2099	Chang EC	Estrogen Receptors alpha and beta as determinants of gene expression: influence of ligand, dose, and chromatin binding.	Molecular endocrinology	2008	61
18258979	2099	Sparano JA	Development of the 21-gene assay and its application in clinical practice and clinical trials.	Journal of clinical oncology 	2008	118
18347134	2099	Sun M	Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells.	Molecular cancer therapeutics	2008	104
18443585	2099	Ben-Porath I	An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors.	Nature genetics	2008	775
18498629	2099	Loi S	Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen.	BMC genomics	2008	128
18505969	2099	Setlur SR	Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer.	Journal of the National Cancer Institute	2008	106
18509175	2099	Azim AA	Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study.	Journal of clinical oncology 	2008	72
18515733	2099	Ross JS	Commercialized multigene predictors of clinical outcome for breast cancer.	The oncologist	2008	52
18550773	2099	Park SH	Estrogen regulates Snail and Slug in the down-regulation of E-cadherin and induces metastatic potential of ovarian cancer cells through estrogen receptor alpha.	Molecular endocrinology	2008	53
18574464	2099	Ramsay RG	MYB function in normal and cancer cells.	Nature reviews. Cancer	2008	146
18593897	2099	Kondo N	miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer.	Cancer research	2008	97
18593923	2099	Rizzo P	Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches.	Cancer research	2008	103
18818283	2099	Krum SA	Unique ERalpha cistromes control cell type-specific gene regulation.	Molecular endocrinology	2008	62
19027010	2099	Liu WH	MicroRNA-18a prevents estrogen receptor-alpha expression, promoting proliferation of hepatocellular carcinoma cells.	Gastroenterology	2009	63
19112174	2099	Yamnik RL	S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation.	The Journal of biological chemistry	2009	58
19116762	2099	Toh Y	The role of the MTA family and their encoded proteins in human cancers: molecular functions and clinical implications.	Clinical and experimental metastasis	2009	63
19219042	2099	Zheng W	Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1.	Nature genetics	2009	242
19264808	2099	Wickramasinghe NS	Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells.	Nucleic acids research	2009	104
19317994	2099	Gnerlich JL	Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease.	Journal of the American College of Surgeons	2009	61
19470930	2099	Visvanathan K	American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.	Journal of clinical oncology 	2009	72
19487384	2099	Shi L	Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer.	Journal of clinical oncology 	2009	48
19514831	2099	Vona-Davis L	The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: a review.	Journal of women's health	2009	63
19563758	2099	Hua S	Genomic antagonism between retinoic acid and estrogen signaling in breast cancer.	Cell	2009	107
19567422	2099	Milne RL	Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042.	Journal of the National Cancer Institute	2009	52
19730444	2099	Spizzo R	miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells.	Cell death and differentiation	2010	76
20065188	2099	Mamounas EP	Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20.	Journal of clinical oncology 	2010	67
20080637	2099	Lovén J	MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma.	Proceedings of the National Academy of Sciences of the United States of America	2010	44
20180843	2099	Xiong J	An estrogen receptor alpha suppressor, microRNA-22, is downregulated in estrogen receptor alpha-positive human breast cancer cell lines and clinical samples.	The FEBS journal	2010	45
20181970	2099	Cummings SR	Lasofoxifene in postmenopausal women with osteoporosis.	The New England journal of medicine	2010	57
20411366	2099	Ibrahim EM	Physical activity and survival after breast cancer diagnosis: meta-analysis of published studies.	Medical oncology	2011	84
20427689	2099	Barone I	Estrogen receptor mutations and changes in downstream gene expression and signaling.	Clinical cancer research 	2010	42
20519679	2099	Swain SM	Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.	The New England journal of medicine	2010	57
20535543	2099	Zhao Y	Let-7 family miRNAs regulate estrogen receptor alpha signaling in estrogen receptor positive breast cancer.	Breast cancer research and treatment	2011	40
20547749	2099	Stender JD	Genome-wide analysis of estrogen receptor alpha DNA binding and tethering mechanisms identifies Runx1 as a novel tethering factor in receptor-mediated transcriptional activation.	Molecular and cellular biology	2010	63
20567009	2099	Chlebowski RT	Oral bisphosphonate use and breast cancer incidence in postmenopausal women.	Journal of clinical oncology 	2010	45
20663194	2099	Tuominen VJ	ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67.	Breast cancer research 	2010	123
20805453	2099	Bianchini G	Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.	Journal of clinical oncology 	2010	59
20889718	2099	Lupien M	Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance.	Genes and development	2010	53
20975711	2099	Li J	Identification of high-quality cancer prognostic markers and metastasis network modules.	Nature communications	2010	114
21123450	2099	Rhodes LV	Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer.	Cancer research	2011	55
21124311	2099	Nilsson S	Estrogen receptors: therapies targeted to receptor subtypes.	Clinical pharmacology and therapeutics	2011	69
21149515	2099	Murphy LC	Clinical significance of estrogen receptor phosphorylation.	Endocrine-related cancer	2011	42
21362200	2099	Sanchez CG	Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.	Breast cancer research 	2011	46
21483002	2099	Mahmoud SM	Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer.	Journal of clinical oncology 	2011	251
21502505	2099	Shi L	Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis.	Proceedings of the National Academy of Sciences of the United States of America	2011	68
21689398	2099	Patnaik JL	Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study.	Breast cancer research 	2011	79
21753181	2099	Anderson WF	Incidence of breast cancer in the United States: current and future trends.	Journal of the National Cancer Institute	2011	50
21844186	2099	Stevens KN	Common breast cancer susceptibility loci are associated with triple-negative breast cancer.	Cancer research	2011	46
21844907	2099	Prossnitz ER	The G-protein-coupled estrogen receptor GPER in health and disease.	Nature reviews. Endocrinology	2011	129
21846820	2099	Palmer JR	Parity and lactation in relation to estrogen receptor negative breast cancer in African American women.	Cancer epidemiology, biomarkers and prevention 	2011	50
21878914	2099	Kong SL	Cellular reprogramming by the conjoint action of ERα, FOXA1, and GATA3 to a ligand-inducible growth state.	Molecular systems biology	2011	49
22049316	2099	Miller TW	ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer.	Cancer discovery	2011	64
22115959	2099	Wetendorf M	The progesterone receptor regulates implantation, decidualization, and glandular development via a complex paracrine signaling network.	Molecular and cellular endocrinology	2012	45
22125492	2099	Magnani L	PBX1 genomic pioneer function drives ERα signaling underlying progression in breast cancer.	PLoS genetics	2011	47
22151962	2099	West NR	Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer.	Breast cancer research 	2011	78
22267197	2099	Ghoussaini M	Genome-wide association analysis identifies three new breast cancer susceptibility loci.	Nature genetics	2012	106
22291085	2099	Iwamoto T	Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry.	Journal of clinical oncology 	2012	35
22301780	2099	Baumgarten SC	Minireview: Inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers.	Molecular endocrinology	2012	42
22383897	2099	Long J	Genome-wide association study in east Asians identifies novel susceptibility loci for breast cancer.	PLoS genetics	2012	62
22438791	2099	Anbalagan M	Post-translational modifications of nuclear receptors and human disease.	Nuclear receptor signaling	2012	46
22496456	2099	Asmann YW	Detection of redundant fusion transcripts as biomarkers or disease-specific therapeutic targets in breast cancer.	Cancer research	2012	36
22503553	2099	Klinge CM	miRNAs and estrogen action.	Trends in endocrinology and metabolism	2012	44
22752290	2099	Prat A	PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer.	Breast cancer research and treatment	2012	34
22949852	2099	Singh S	Epigenetic effects of environmental chemicals bisphenol A and phthalates.	International journal of molecular sciences	2012	43
22986741	2099	Jerby L	Metabolic associations of reduced proliferation and oxidative stress in advanced breast cancer.	Cancer research	2012	30
23136140	2099	Palmer JR	Genetic susceptibility loci for subtypes of breast cancer in an African American population.	Cancer epidemiology, biomarkers and prevention 	2013	27
23169515	2099	Azim HA Jr	Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study.	Journal of clinical oncology 	2013	27
23251644	2099	Budczies J	Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization.	PloS one	2012	122
23344024	2099	García-Becerra R	Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance.	International journal of molecular sciences	2012	54
23480168	2099	Kim GH	The role of redox signaling in epigenetics and cardiovascular disease.	Antioxidants and redox signaling	2013	32
23535733	2099	Garcia-Closas M	Genome-wide association studies identify four ER negative-specific breast cancer risk loci.	Nature genetics	2013	151
23535825	2099	Zheng W	Common genetic determinants of breast-cancer risk in East Asian women: a collaborative study of 23 637 breast cancer cases and 25 579 controls.	Human molecular genetics	2013	32
23636943	2099	Hah N	Enhancer transcripts mark active estrogen receptor binding sites.	Genome research	2013	117
23645624	2099	Rosner B	Breast cancer risk prediction with heterogeneous risk profiles according to breast cancer tumor markers.	American journal of epidemiology	2013	29
23690420	2099	Hughes KS	Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343.	Journal of clinical oncology 	2013	65
23728302	2099	Li W	Functional roles of enhancer RNAs for oestrogen-dependent transcriptional activation.	Nature	2013	203
23835710	2099	Visvanathan K	Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline.	Journal of clinical oncology 	2013	72
23845444	2099	Vaillant F	Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer.	Cancer cell	2013	62
23917289	2099	Silber JH	Characteristics associated with differences in survival among black and white women with breast cancer.	JAMA	2013	55
23965901	2099	Gucalp A	Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.	Clinical cancer research 	2013	86
23985562	2099	-	Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society.	Menopause	2013	47
24055055	2099	Li S	Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts.	Cell reports	2013	117
24114568	2099	DeSantis C	Breast cancer statistics, 2013.	CA	2014	357
24185510	2099	Robinson DR	Activating ESR1 mutations in hormone-resistant metastatic breast cancer.	Nature genetics	2013	157
24210818	2099	Wu Q	27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth.	Cell reports	2013	48
24217577	2099	Merenbakh-Lamin K	D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer.	Cancer research	2013	56
24273215	2099	Vera-Badillo FE	Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis.	Journal of the National Cancer Institute	2014	45
24343304	2099	Palmer JR	A collaborative study of the etiology of breast cancer subtypes in African American women: the AMBER consortium.	Cancer causes and control 	2014	24
24398047	2099	Jeselsohn R	Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer.	Clinical cancer research 	2014	76
24451109	2099	Cochrane DR	Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide.	Breast cancer research 	2014	46
24469049	2099	Cyr AR	TFAP2C governs the luminal epithelial phenotype in mammary development and carcinogenesis.	Oncogene	2015	18
24663045	2099	Mayer IA	Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.	Journal of clinical oncology 	2014	41
24858917	2099	Ohba K	In vivo and in vitro studies suggest a possible involvement of HPV infection in the early stage of breast carcinogenesis via APOBEC3B induction.	PloS one	2014	23
24874954	2099	Feng Q	An epigenomic approach to therapy for tamoxifen-resistant breast cancer.	Cell research	2014	38
24971815	2099	Paterni I	Estrogen receptors alpha (ERα) and beta (ERβ): subtype-selective ligands and clinical potential.	Steroids	2014	27
25013076	2099	Yu M	Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility.	Science	2014	133
25123150	2099	Sieuwerts AM	Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers.	Hormones and cancer	2014	24
25168343	2099	Santen RJ	Estrogen metabolites and breast cancer.	Steroids	2015	23
25417601	2099	Schuler KM	Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer.	Cancer medicine	2015	20
25529635	2099	Glubb DM	Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1.	American journal of human genetics	2015	19
25855707	2099	Mavaddat N	Prediction of breast cancer risk based on profiling with common genetic variants.	Journal of the National Cancer Institute	2015	57
25876649	2099	Hill SM	Melatonin: an inhibitor of breast cancer.	Endocrine-related cancer	2015	22
25877889	2099	Bosch A	PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.	Science translational medicine	2015	28
25879485	2099	Lai A	Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.	Journal of medicinal chemistry	2015	24
25979954	2099	Guttery DS	Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer.	Clinical chemistry	2015	22
26122181	2099	Jeselsohn R	ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer.	Nature reviews. Clinical oncology	2015	28
26124144	2099	Honda S	Sex hormone-dependent tRNA halves enhance cell proliferation in breast and prostate cancers.	Proceedings of the National Academy of Sciences of the United States of America	2015	24
26261103	2099	Chu D	ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients.	Clinical cancer research 	2016	22
26303083	2099	Jia M	Estrogen receptor alpha and beta in health and disease.	Best practice and research. Clinical endocrinology and metabolism	2015	21
26317216	2099	Butler TM	Exome Sequencing of Cell-Free DNA from Metastatic Cancer Patients Identifies Clinically Actionable Mutations Distinct from Primary Disease.	PloS one	2015	17
26500237	2099	Wang P	Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients.	Clinical cancer research 	2016	22
26541326	2099	Baptista MZ	Prognostic significance of PD-L1 and PD-L2 in breast cancer.	Human pathology	2016	18
26560360	2099	Schiavon G	Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer.	Science translational medicine	2015	41
26563128	2099	Ma CX	A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.	Clinical cancer research 	2016	13
26751173	2099	Korkmaz G	Functional genetic screens for enhancer elements in the human genome using CRISPR-Cas9.	Nature biotechnology	2016	36
26947176	2099	Sflomos G	A Preclinical Model for ERα-Positive Breast Cancer Points to the Epithelial Microenvironment as Determinant of Luminal Phenotype and Hormone Response.	Cancer cell	2016	14
27513155	2099	Giuliano AE	Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial.	Annals of surgery	2016	14
27532364	2099	Chandarlapaty S	Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.	JAMA oncology	2016	18
12351676	2146	Cao R	Role of histone H3 lysine 27 methylation in Polycomb-group silencing.	Science	2002	936
14500907	2146	Kleer CG	EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells.	Proceedings of the National Academy of Sciences of the United States of America	2003	463
14532106	2146	Bracken AP	EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer.	The EMBO journal	2003	331
15231737	2146	Kirmizis A	Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27.	Genes and development	2004	174
16330673	2146	Bachmann IM	EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast.	Journal of clinical oncology 	2006	183
16618801	2146	Bracken AP	Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions.	Genes and development	2006	468
16734726	2146	Matsukawa Y	Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer.	Cancer science	2006	65
18006806	2146	Yu J	A polycomb repression signature in metastatic prostate cancer predicts cancer outcome.	Cancer research	2007	111
18176935	2146	Wei Y	Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers.	Molecular carcinogenesis	2008	80
18430739	2146	Fujii S	Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation.	The Journal of biological chemistry	2008	66
18723033	2146	Simon JA	Roles of the EZH2 histone methyltransferase in cancer epigenetics.	Mutation research	2008	237
19008416	2146	Varambally S	Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer.	Science	2008	327
19053175	2146	Tiwari VK	PcG proteins, DNA methylation, and gene repression by chromatin looping.	PLoS biology	2008	72
19079346	2146	Gonzalez ME	Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1.	Oncogene	2009	70
19258506	2146	Friedman JM	The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2.	Cancer research	2009	128
19351856	2146	Hussain M	Tobacco smoke induces polycomb-mediated repression of Dickkopf-1 in lung cancer cells.	Cancer research	2009	54
20946108	2146	Orzan F	Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells.	Neuropathology and applied neurobiology	2011	38
20952513	2146	Zhang B	Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer.	Carcinogenesis	2011	63
21078963	2146	Sneeringer CJ	Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas.	Proceedings of the National Academy of Sciences of the United States of America	2010	139
21131960	2146	Wei Y	CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells.	Nature cell biology	2011	107
21216927	2146	Rizzo S	Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2.	Molecular cancer therapeutics	2011	61
21270667	2146	Zhang JG	MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2.	Journal of thoracic oncology 	2011	52
21321380	2146	Smits M	miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis.	Oncotarget	2010	76
21367748	2146	Chase A	Aberrations of EZH2 in cancer.	Clinical cancer research 	2011	141
21368858	2146	Alajez NM	Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98.	Cell death and disease	2010	58
21512140	2146	Cheng AS	EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.	Cancer research	2011	55
21539681	2146	Takawa M	Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker.	Cancer science	2011	44
21572997	2146	So AY	DNA methyltransferase controls stem cell aging by regulating BMI1 and EZH2 through microRNAs.	PloS one	2011	38
21659531	2146	Wu SC	Cyclin-dependent kinase 1 (CDK1)-mediated phosphorylation of enhancer of zeste 2 (Ezh2) regulates its stability.	The Journal of biological chemistry	2011	44
21672940	2146	Zheng F	The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2.	Gut	2012	106
21685935	2146	Tong ZT	EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin.	Oncogene	2012	54
21921040	2146	Guglielmelli P	EZH2 mutational status predicts poor survival in myelofibrosis.	Blood	2011	41
22053108	2146	Score J	Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms.	Blood	2012	40
22086681	2146	Bao B	Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells.	Cancer prevention research	2012	91
22108826	2146	Bao B	Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression.	Cancer research	2012	87
22237151	2146	Ntziachristos P	Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia.	Nature medicine	2012	127
22272343	2146	Shin YJ	The role of EZH2 in the regulation of the activity of matrix metalloproteinases in prostate cancer cells.	PloS one	2012	34
22323599	2146	McCabe MT	Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27).	Proceedings of the National Academy of Sciences of the United States of America	2012	101
22370893	2146	Au SL	Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis.	Hepatology	2012	62
22442719	2146	Kong D	Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM.	PloS one	2012	59
22505648	2146	Ren G	Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.	Cancer research	2012	60
22659877	2146	Guil S	Intronic RNAs mediate EZH2 regulation of epigenetic targets.	Nature structural and molecular biology	2012	59
22930729	2146	Börno ST	Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation.	Cancer discovery	2012	31
22948084	2146	Asangani IA	Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma.	Oncotarget	2012	45
22952749	2146	Bao B	Hypoxia induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF, IL-6 and miRNAs that are attenuated by CDF.	PloS one	2012	42
23354591	2146	Luo M	Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression.	Cancer letters	2013	117
23568486	2146	Ronan JL	From neural development to cognition: unexpected roles for chromatin.	Nature reviews. Genetics	2013	122
24052547	2146	Bödör C	EZH2 mutations are frequent and represent an early event in follicular lymphoma.	Blood	2013	30
24097870	2146	Behrens C	EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma.	Clinical cancer research 	2013	33
24211739	2146	Xu L	MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.	Journal of hepatology	2014	30
24261995	2146	Liu X	Regulation of microRNAs by epigenetics and their interplay involved in cancer.	Journal of experimental and clinical cancer research 	2013	27
24516139	2146	Gonzalez ME	EZH2 expands breast stem cells through activation of NOTCH1 signaling.	Proceedings of the National Academy of Sciences of the United States of America	2014	37
24612432	2146	Liu L	Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma.	BJU international	2016	17
25153722	2146	Konno Y	MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation, invasion and stem cell-like phenotype of aggressive endometrial cancer cells.	Oncotarget	2014	46
25457180	2146	Bradley WD	EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation.	Chemistry and biology	2014	31
25601206	2146	Kim SH	EZH2 protects glioma stem cells from radiation-induced cell death in a MELK/FOXM1-dependent manner.	Stem cell reports	2015	26
25644061	2146	Koumangoye RB	SOX4 interacts with EZH2 and HDAC3 to suppress microRNA-31 in invasive esophageal cancer cells.	Molecular cancer	2015	16
25653233	2146	Toden S	Curcumin mediates chemosensitization to 5-fluorouracil through miRNA-induced suppression of epithelial-to-mesenchymal transition in chemoresistant colorectal cancer.	Carcinogenesis	2015	17
25693145	2146	Zheng F	Systemic delivery of microRNA-101 potently inhibits hepatocellular carcinoma in vivo by repressing multiple targets.	PLoS genetics	2015	19
25762643	2146	Zheng M	Snail and Slug collaborate on EMT and tumor metastasis through miR-101-mediated EZH2 axis in oral tongue squamous cell carcinoma.	Oncotarget	2015	18
26005520	2146	Campbell JE	EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity.	ACS medicinal chemistry letters	2015	17
26501191	2146	Huang L	Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids.	Nature medicine	2015	19
26516927	2146	Wang D	LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer.	Oncotarget	2015	18
26523864	2146	Zhao E	Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction.	Nature immunology	2016	29
26552009	2146	Kim KH	SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2.	Nature medicine	2015	30
26755663	2146	Agarwal P	Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target.	Oncotarget	2016	11
26766588	2146	Serresi M	Polycomb Repressive Complex 2 Is a Barrier to KRAS-Driven Inflammation and Epithelial-Mesenchymal Transition in Non-Small-Cell Lung Cancer.	Cancer cell	2016	15
26908628	2146	Wan L	Long Noncoding RNA PVT1 Promotes Non-Small Cell Lung Cancer Cell Proliferation through Epigenetically Regulating LATS2 Expression.	Molecular cancer therapeutics	2016	19
12183437	2305	Teh MT	FOXM1 is a downstream target of Gli1 in basal cell carcinomas.	Cancer research	2002	106
16585184	2305	Liu M	FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells.	Cancer research	2006	116
17014965	2305	Laoukili J	FoxM1: at the crossroads of ageing and cancer.	Biochimica et biophysica acta	2007	117
17149590	2305	Wang H	MAFA controls genes implicated in insulin biosynthesis and secretion.	Diabetologia	2007	58
17404569	2305	Dai B	Aberrant FoxM1B expression increases matrix metalloproteinase-2 transcription and enhances the invasion of glioma cells.	Oncogene	2007	64
17430594	2305	Chandran UR	Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process.	BMC cancer	2007	154
17804744	2305	Wang Z	Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells.	Cancer research	2007	95
18020943	2305	Wierstra I	FOXM1, a typical proliferation-associated transcription factor.	Biological chemistry	2007	81
18974115	2305	Zhang Y	FoxM1B transcriptionally regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of glioma cells.	Cancer research	2008	73
19276163	2305	McGovern UB	Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer.	Molecular cancer therapeutics	2009	47
19287496	2305	Gemenetzidis E	FOXM1 upregulation is an early event in human squamous cell carcinoma and it is enhanced by nicotine during malignant transformation.	PloS one	2009	50
19351851	2305	Li Q	Critical role and regulation of transcription factor FoxM1 in human gastric cancer angiogenesis and progression.	Cancer research	2009	72
19440351	2305	Bhat UG	Thiazole antibiotics target FoxM1 and induce apoptosis in human cancer cells.	PloS one	2009	84
19672316	2305	Bhat UG	FoxM1 is a general target for proteasome inhibitors.	PloS one	2009	69
19696738	2305	Park HJ	FoxM1, a critical regulator of oxidative stress during oncogenesis.	The EMBO journal	2009	71
19813088	2305	Ahmad A	FoxM1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors.	Breast cancer research and treatment	2010	53
20022709	2305	Wang Z	Forkhead box M1 transcription factor: a novel target for cancer therapy.	Cancer treatment reviews	2010	47
20530690	2305	Carr JR	FoxM1 mediates resistance to herceptin and paclitaxel.	Cancer research	2010	66
21204266	2305	Park HJ	Deregulation of FoxM1b leads to tumour metastasis.	EMBO molecular medicine	2011	42
21503965	2305	Bao B	Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells.	Journal of cellular biochemistry	2011	78
21518729	2305	Millour J	ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance.	Molecular cancer therapeutics	2011	38
21720365	2305	Cancer Genome Atlas Research Network.	Integrated genomic analyses of ovarian carcinoma.	Nature	2011	1665
21860463	2305	Hegde NS	The transcription factor FOXM1 is a cellular target of the natural product thiostrepton.	Nature chemistry	2011	60
21888875	2305	Liu S	MicroRNA-135a contributes to the development of portal vein tumor thrombus by promoting metastasis in hepatocellular carcinoma.	Journal of hepatology	2012	49
22094256	2305	Anders L	A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells.	Cancer cell	2011	101
22194465	2305	Huang C	A novel FoxM1-caveolin signaling pathway promotes pancreatic cancer invasion and metastasis.	Cancer research	2012	50
22613004	2305	Xia L	Upregulated FoxM1 expression induced by hepatitis B virus X protein promotes tumor metastasis and indicates poor prognosis in hepatitis B virus-related hepatocellular carcinoma.	Journal of hepatology	2012	34
22617326	2305	Szabova L	Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer.	Cancer research	2012	34
23103567	2305	Halasi M	Targeting FOXM1 in cancer.	Biochemical pharmacology	2013	35
23297075	2305	Wu Z	Development and evaluation of 18F-TTCO-Cys40-Exendin-4: a PET probe for imaging transplanted islets.	Journal of nuclear medicine 	2013	29
23443798	2305	Halasi M	FOX(M1) news--it is cancer.	Molecular cancer therapeutics	2013	41
23870513	2305	Wierstra I	FOXM1 (Forkhead box M1) in tumorigenesis: overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumor-suppressive properties, and target of anticancer therapy.	Advances in cancer research	2013	30
24141789	2305	Khongkow P	FOXM1 targets NBS1 to regulate DNA damage-induced senescence and epirubicin resistance.	Oncogene	2014	22
24382352	2305	Xue J	Sustained activation of SMAD3/SMAD4 by FOXM1 promotes TGF-β-dependent cancer metastasis.	The Journal of clinical investigation	2014	44
24634381	2305	Cui J	FOXM1 promotes the warburg effect and pancreatic cancer progression via transactivation of LDHA expression.	Clinical cancer research 	2014	24
25387393	2305	Gormally MV	Suppression of the FOXM1 transcriptional programme via novel small molecule inhibition.	Nature communications	2014	22
25686834	2305	Xu X	miR-34a induces cellular senescence via modulation of telomerase activity in human hepatocellular carcinoma by targeting FoxM1/c-Myc pathway.	Oncotarget	2015	20
26148240	2305	Karunarathna U	OTUB1 inhibits the ubiquitination and degradation of FOXM1 in breast cancer and epirubicin resistance.	Oncogene	2016	13
26193342	2305	Gentles AJ	The prognostic landscape of genes and infiltrating immune cells across human cancers.	Nature medicine	2015	118
26877780	2305	Zhang Z	BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1.	Theranostics	2016	10
1279432	2321	Plate KH	Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.	Nature	1992	334
15735759	2321	Fan F	Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells.	Oncogene	2005	71
15937304	2321	Chen W	Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.	Journal of nuclear medicine 	2005	90
17109193	2321	Shibuya M	Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis.	Angiogenesis	2006	68
17138749	2321	Cai W	PET of vascular endothelial growth factor receptor expression.	Journal of nuclear medicine 	2006	80
17550303	2321	Lee TH	Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1.	PLoS medicine	2007	87
18541897	2321	Cohen EE	Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.	Journal of clinical oncology 	2008	149
19029957	2321	Fischer C	FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?	Nature reviews. Cancer	2008	152
19244214	2321	Cao Y	Positive and negative modulation of angiogenesis by VEGFR1 ligands.	Science signaling	2009	77
19597027	2321	Schiller JH	Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.	Journal of clinical oncology 	2009	45
19652060	2321	Rini BI	Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.	Journal of clinical oncology 	2009	81
19826113	2321	Matulonis UA	Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.	Journal of clinical oncology 	2009	55
19834490	2321	Zhang Z	VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2.	Cell death and differentiation	2010	50
20200024	2321	Iwamoto FM	Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).	Neuro-oncology	2010	43
21212411	2321	Frank NY	VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth.	Cancer research	2011	49
21306953	2321	Kindler HL	Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study.	The Lancet. Oncology	2011	95
22159180	2321	Schwarzenberg J	3'-deoxy-3'-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab.	Journal of nuclear medicine 	2012	31
22173549	2321	Vermaat JS	Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment.	Clinical cancer research 	2012	44
22565005	2321	Van Cutsem E	Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial.	Journal of clinical oncology 	2012	93
22753922	2321	Scagliotti GV	International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.	Journal of clinical oncology 	2012	47
23172303	2321	Shibuya M	Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases.	Journal of biochemistry	2013	90
24019545	2321	Motzer RJ	Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.	Journal of clinical oncology 	2013	55
25218906	2321	Liu JF	Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.	The Lancet. Oncology	2014	58
25605928	2321	Heist RS	Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.	Proceedings of the National Academy of Sciences of the United States of America	2015	23
25671254	2321	Schlumberger M	Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.	The New England journal of medicine	2015	87
8946930	2322	Nakao M	Internal tandem duplication of the flt3 gene found in acute myeloid leukemia.	Leukemia	1996	187
10216104	2322	Kiyoi H	Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.	Blood	1999	104
10698507	2322	Hayakawa F	Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines.	Oncogene	2000	92
11290608	2322	Yamamoto Y	Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.	Blood	2001	189
11535508	2322	Kottaridis PD	The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.	Blood	2001	208
11585760	2322	Whitman SP	Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.	Cancer research	2001	113
12036858	2322	Thiede C	Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.	Blood	2002	279
12070009	2322	Schnittger S	Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.	Blood	2002	141
12194988	2322	Kelly LM	Genetics of myeloid leukemias.	Annual review of genomics and human genetics	2002	97
12393388	2322	Fröhling S	Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.	Blood	2002	135
12531805	2322	O'Farrell AM	SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.	Blood	2003	164
12538485	2322	Mendel DB	In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.	Clinical cancer research 	2003	379
12748309	2322	Abrams TJ	SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.	Molecular cancer therapeutics	2003	139
12970773	2322	Levis M	FLT3: ITDoes matter in leukemia.	Leukemia	2003	104
15345597	2322	Stone RM	Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.	Blood	2005	132
15459012	2322	Fiedler W	A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.	Blood	2005	80
15514006	2322	George P	Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.	Blood	2005	74
16150941	2322	Heidel F	Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain.	Blood	2006	63
16857985	2322	Knapper S	A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.	Blood	2006	96
16912228	2322	Meshinchi S	Clinical implications of FLT3 mutations in pediatric AML.	Blood	2006	74
17124058	2322	Small D	FLT3 mutations: biology and treatment.	Hematology. American Society of Hematology. Education Program	2006	60
17940205	2322	Whitman SP	FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.	Blood	2008	68
17957027	2322	Gale RE	The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.	Blood	2008	108
18187662	2322	Garzon R	MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia.	Blood	2008	196
18192505	2322	Sallmyr A	Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML.	Blood	2008	71
18270328	2322	Tomasson MH	Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia.	Blood	2008	67
18450603	2322	Marcucci G	MicroRNA expression in cytogenetically normal acute myeloid leukemia.	The New England journal of medicine	2008	142
18612155	2322	Kulke MH	Activity of sunitinib in patients with advanced neuroendocrine tumors.	Journal of clinical oncology 	2008	106
18716133	2322	Metzeler KH	An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia.	Blood	2008	85
18840713	2322	Kornblau SM	Functional proteomic profiling of AML predicts response and survival.	Blood	2009	91
19029442	2322	Pratz KW	A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response.	Blood	2009	52
19047294	2322	Büchner T	Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.	Journal of clinical oncology 	2009	49
19225113	2322	Hu J	Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia.	Proceedings of the National Academy of Sciences of the United States of America	2009	73
19389879	2322	Metzelder S	Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation.	Blood	2009	64
19549778	2322	Meshinchi S	Structural and functional alterations of FLT3 in acute myeloid leukemia.	Clinical cancer research 	2009	51
19654408	2322	Zarrinkar PP	AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).	Blood	2009	115
19808973	2322	Qian F	Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.	Cancer research	2009	69
19844230	2322	Kumar R	Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors.	British journal of cancer	2009	57
20007803	2322	Pratz KW	FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.	Blood	2010	75
20203261	2322	Swords RT	Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia.	Blood	2010	71
20212254	2322	Ravandi F	Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.	Journal of clinical oncology 	2010	94
20656931	2322	Whitman SP	FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.	Blood	2010	58
20705759	2322	Kindler T	FLT3 as a therapeutic target in AML: still challenging after all these years.	Blood	2010	91
20733134	2322	Fischer T	Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.	Journal of clinical oncology 	2010	89
20952518	2322	Borthakur G	Phase I study of sorafenib in patients with refractory or relapsed acute leukemias.	Haematologica	2011	45
21079133	2322	Schwind S	Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.	Journal of clinical oncology 	2010	48
21127174	2322	Kayser S	The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML.	Blood	2011	45
21148331	2322	Schnittger S	RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis.	Blood	2011	42
21177505	2322	Gentles AJ	Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia.	JAMA	2010	88
21270442	2322	Levis M	Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse.	Blood	2011	102
21926191	2322	Yakes FM	Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.	Molecular cancer therapeutics	2011	149
22291086	2322	Brunet S	Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis.	Journal of clinical oncology 	2012	39
22368270	2322	Man CH	Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.	Blood	2012	59
22504140	2322	Metzelder SK	High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses.	Leukemia	2012	36
22504184	2322	Smith CC	Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.	Nature	2012	146
22566605	2322	Blum W	Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia.	Blood	2012	42
22585696	2322	Garcia-Manero G	Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome.	Journal of clinical oncology 	2012	32
22614177	2322	Swords R	Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia.	Leukemia	2012	37
22627678	2322	Stone RM	Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia.	Leukemia	2012	47
22715121	2322	Iland HJ	All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).	Blood	2012	34
22965964	2322	Younes A	Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes.	Journal of clinical oncology 	2012	47
23071272	2322	Quintás-Cardama A	Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.	Blood	2012	32
23087056	2322	Tyner JW	Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening.	Cancer research	2013	45
23321257	2322	Jourdan E	Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.	Blood	2013	32
23377436	2322	Pratcorona M	Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy.	Blood	2013	29
23430109	2322	Smith CC	Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.	Blood	2013	30
23613521	2322	Ravandi F	Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.	Blood	2013	58
23631653	2322	Kayser S	FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations.	Leukemia and lymphoma	2014	28
23897964	2322	Serve H	Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial.	Journal of clinical oncology 	2013	51
24002496	2322	Cortes JE	Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.	Journal of clinical oncology 	2013	56
24056683	2322	Pemovska T	Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia.	Cancer discovery	2013	44
24227820	2322	Galanis A	Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants.	Blood	2014	32
24319184	2322	Levis M	FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?	Hematology. American Society of Hematology. Education Program	2013	30
25092144	2322	Gerloff D	NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia.	Leukemia	2015	18
25142817	2322	Montalban-Bravo G	Novel drugs for older patients with acute myeloid leukemia.	Leukemia	2015	18
25231999	2322	Konig H	Targeting FLT3 to treat leukemia.	Expert opinion on therapeutic targets	2015	20
25253770	2322	Irving J	Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition.	Blood	2014	39
25270908	2322	Schlenk RF	Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation.	Blood	2014	26
25280219	2322	Li L	SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells.	Cell stem cell	2014	22
25732155	2322	Chen X	Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.	Journal of clinical oncology 	2015	20
25762180	2322	Komrokji RS	Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis.	Blood	2015	17
28017614	2322	Li Z	FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N&lt;sup&gt;6&lt;/sup&gt;-Methyladenosine RNA Demethylase.	Cancer cell	2017	9
9815541	2346	Silver DA	Prostate-specific membrane antigen expression in normal and malignant human tissues.	Clinical cancer research 	1997	161
11753365	2346	Maher J	Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor.	Nature biotechnology	2002	177
12124337	2346	Lupold SE	Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen.	Cancer research	2002	150
15837970	2346	Bander NH	Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.	Journal of clinical oncology 	2005	91
17320151	2346	Perner S	Prostate-specific membrane antigen expression as a predictor of prostate cancer progression.	Human pathology	2007	62
18978032	2346	Dhar S	Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles.	Proceedings of the National Academy of Sciences of the United States of America	2008	168
19138409	2346	Mitchell PJ	Can urinary exosomes act as treatment response markers in prostate cancer?	Journal of translational medicine	2009	62
19706750	2346	Hillier SM	Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.	Cancer research	2009	60
20024046	2346	Gleghorn JP	Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody.	Lab on a chip	2010	91
20127956	2346	Tagawa ST	Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer.	Cancer	2010	42
20660376	2346	Holland JP	89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo.	Journal of nuclear medicine 	2010	109
21555850	2346	Ni X	Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts.	The Journal of clinical investigation	2011	54
21606347	2346	Evans MJ	Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen.	Proceedings of the National Academy of Sciences of the United States of America	2011	52
22491949	2346	Hrkach J	Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile.	Science translational medicine	2012	205
22558290	2346	Kirby BJ	Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device.	PloS one	2012	57
22658884	2346	Osborne JR	Prostate-specific membrane antigen-based imaging.	Urologic oncology	2013	26
23179945	2346	Afshar-Oromieh A	PET imaging with a 68Gagallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.	European journal of nuclear medicine and molecular imaging	2013	76
23203246	2346	Cho SY	Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer.	Journal of nuclear medicine 	2012	58
23242161	2346	Kloss CC	Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells.	Nature biotechnology	2013	137
23303962	2346	Barrett JA	First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer.	Journal of nuclear medicine 	2013	37
23590171	2346	Mease RC	PET imaging in prostate cancer: focus on prostate-specific membrane antigen.	Current topics in medicinal chemistry	2013	28
23714732	2346	Tagawa ST	Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.	Clinical cancer research 	2013	40
24072344	2346	Afshar-Oromieh A	Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer.	European journal of nuclear medicine and molecular imaging	2014	73
24166007	2346	Friedlander TW	Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer.	International journal of cancer	2014	26
24577951	2346	Zechmann CM	Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy.	European journal of nuclear medicine and molecular imaging	2014	31
25411132	2346	Afshar-Oromieh A	The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.	European journal of nuclear medicine and molecular imaging	2015	65
25771365	2346	Vallabhajosula S	Radioimmunotherapy of Metastatic Prostate Cancer with ¹⁷⁷Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody.	Current radiopharmaceuticals	2016	11
25791990	2346	Eiber M	Evaluation of Hybrid ⁶⁸Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy.	Journal of nuclear medicine 	2015	61
25883127	2346	Benešová M	Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.	Journal of nuclear medicine 	2015	19
25896814	2346	Szabo Z	Initial Evaluation of (18)FDCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.	Molecular imaging and biology 	2015	44
25957851	2346	Maurer T	Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer.	European urology	2015	19
25975367	2346	Ceci F	(68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?	European journal of nuclear medicine and molecular imaging	2015	18
26013479	2346	Dietlein M	Comparison of (18)FDCFPyL and  (68)GaGa-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer.	Molecular imaging and biology 	2015	25
26069305	2346	Rowe SP	¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer.	Journal of nuclear medicine 	2015	30
26112024	2346	Morigi JJ	Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.	Journal of nuclear medicine 	2015	30
26116958	2346	Budäus L	Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy.	European urology	2016	18
26175541	2346	Pandit-Taskar N	A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.	Clinical cancer research 	2015	19
26318602	2346	Delker A	Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer.	European journal of nuclear medicine and molecular imaging	2016	13
26493203	2346	Rowe SP	Comparison of Prostate-Specific Membrane Antigen-Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate Cancer.	Journal of nuclear medicine 	2016	12
26682756	2346	Maurer T	Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer.	The Journal of urology	2016	19
26795286	2346	Baum RP	177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.	Journal of nuclear medicine 	2016	23
26902337	2346	Maurer T	Current use of PSMA-PET in prostate cancer management.	Nature reviews. Urology	2016	23
26975008	2346	Bluemel C	68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT.	Clinical nuclear medicine	2016	11
26985056	2346	Kratochwil C	PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617.	Journal of nuclear medicine 	2016	18
27506431	2346	Yadav MP	&lt;sup&gt;177&lt;/sup&gt;Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment.	European journal of nuclear medicine and molecular imaging	2017	6
7822316	2475	Sabers CJ	Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells.	The Journal of biological chemistry	1995	171
10749120	2475	Zhong H	Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.	Cancer research	2000	300
12101249	2475	Peng T	The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation.	Molecular and cellular biology	2002	111
12172553	2475	Inoki K	TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling.	Nature cell biology	2002	791
12242281	2475	Hudson CC	Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.	Molecular and cellular biology	2002	256
15004009	2475	Mayer C	mTOR-dependent activation of the transcription factor TIF-IA links rRNA synthesis to nutrient availability.	Genes and development	2004	126
15028555	2475	Gao N	G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.	American journal of physiology. Cell physiology	2004	73
15136596	2475	Raymond E	Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.	Journal of clinical oncology 	2004	87
15254063	2475	Sansal I	The biology and clinical relevance of the PTEN tumor suppressor pathway.	Journal of clinical oncology 	2004	215
15325584	2475	Meijer AJ	Regulation and role of autophagy in mammalian cells.	The international journal of biochemistry and cell biology	2004	139
15624019	2475	Inoki K	Dysregulation of the TSC-mTOR pathway in human disease.	Nature genetics	2005	284
15659337	2475	Tee AR	mTOR, translational control and human disease.	Seminars in cell and developmental biology	2005	88
15681023	2475	Luo Z	AMPK, the metabolic syndrome and cancer.	Trends in pharmacological sciences	2005	109
15718470	2475	Sarbassov DD	Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.	Science	2005	1945
15728109	2475	Vignot S	mTOR-targeted therapy of cancer with rapamycin derivatives.	Annals of oncology 	2005	123
15797377	2475	Beuvink I	The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.	Cell	2005	139
15866171	2475	Jones RG	AMP-activated protein kinase induces a p53-dependent metabolic checkpoint.	Molecular cell	2005	468
15890640	2475	Ghobrial IM	Targeting apoptosis pathways in cancer therapy.	CA	2005	173
15899889	2475	Chiang GG	Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase.	The Journal of biological chemistry	2005	152
15905173	2475	Holz MK	Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase.	The Journal of biological chemistry	2005	104
15916903	2475	Fuchs BC	Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime?	Seminars in cancer biology	2005	115
15955899	2475	Chan S	Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.	Journal of clinical oncology 	2005	103
15983389	2475	Witzig TE	Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.	Journal of clinical oncology 	2005	115
16002336	2475	Guertin DA	An expanding role for mTOR in cancer.	Trends in molecular medicine	2005	111
16012795	2475	Chang SM	Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.	Investigational new drugs	2005	89
16226444	2475	Sarbassov DD	Growing roles for the mTOR pathway.	Current opinion in cell biology	2005	507
16341243	2475	Thomas GV	Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.	Nature medicine	2006	163
16724053	2475	Shaw RJ	Ras, PI(3)K and mTOR signalling controls tumour cell growth.	Nature	2006	545
16883305	2475	Faivre S	Current development of mTOR inhibitors as anticancer agents.	Nature reviews. Drug discovery	2006	227
16915295	2475	Sabatini DM	mTOR and cancer: insights into a complex relationship.	Nature reviews. Cancer	2006	432
16951235	2475	Yee KW	Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.	Clinical cancer research 	2006	69
17031397	2475	Duran I	A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas.	British journal of cancer	2006	72
17041628	2475	Easton JB	mTOR and cancer therapy.	Oncogene	2006	120
17210675	2475	Foster DA	Regulation of mTOR by phosphatidic acid?	Cancer research	2007	68
17253963	2475	Findlay GM	A MAP4 kinase related to Ste20 is a nutrient-sensitive regulator of mTOR signalling.	The Biochemical journal	2007	96
17275731	2475	Tsang CK	Targeting mammalian target of rapamycin (mTOR) for health and diseases.	Drug discovery today	2007	106
17277121	2475	Zheng Y	A role for mammalian target of rapamycin in regulating T cell activation versus anergy.	Journal of immunology	2007	82
17360675	2475	Urano J	Point mutations in TOR confer Rheb-independent growth in fission yeast and nutrient-independent mammalian TOR signaling in mammalian cells.	Proceedings of the National Academy of Sciences of the United States of America	2007	62
17363738	2475	Chan SM	Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia.	Blood	2007	84
17376031	2475	Proud CG	Signalling to translation: how signal transduction pathways control the protein synthetic machinery.	The Biochemical journal	2007	152
17545512	2475	Abraham RT	The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy.	Clinical cancer research 	2007	60
17546049	2475	Bauer S	KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway.	Oncogene	2007	58
17595159	2475	Chan EY	siRNA screening of the kinome identifies ULK1 as a multidomain modulator of autophagy.	The Journal of biological chemistry	2007	134
17599906	2475	Woo SY	PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling.	The Journal of biological chemistry	2007	75
17613433	2475	Guertin DA	Defining the role of mTOR in cancer.	Cancer cell	2007	887
17680028	2475	Yang Q	Expanding mTOR signaling.	Cell research	2007	154
17684489	2475	Veverka V	Structural characterization of the interaction of mTOR with phosphatidic acid and a novel class of inhibitor: compelling evidence for a central role of the FRB domain in small molecule-mediated regulation of mTOR.	Oncogene	2008	51
17693255	2475	Lee DF	IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway.	Cell	2007	182
17827463	2475	Stupp R	Chemoradiotherapy in malignant glioma: standard of care and future directions.	Journal of clinical oncology 	2007	108
17905659	2475	Chiang GG	Targeting the mTOR signaling network in cancer.	Trends in molecular medicine	2007	90
17911267	2475	Zhou J	Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance.	Proceedings of the National Academy of Sciences of the United States of America	2007	188
18006825	2475	Dowling RJ	Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells.	Cancer research	2007	250
18184959	2475	Bissler JJ	Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.	The New England journal of medicine	2008	278
18215105	2475	Cloughesy TF	Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma.	PLoS medicine	2008	194
18332467	2475	Tanaka C	Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data.	Journal of clinical oncology 	2008	54
18332470	2475	O'Donnell A	Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors.	Journal of clinical oncology 	2008	116
18339839	2475	McDonald PC	Rictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival.	Cancer research	2008	73
18460336	2475	Gulati P	Amino acids activate mTOR complex 1 via Ca2+/CaM signaling to hVps34.	Cell metabolism	2008	120
18559509	2475	Wang L	Kaposi's sarcoma-associated herpesvirus confers a survival advantage to endothelial cells.	Cancer research	2008	59
18653228	2475	Motzer RJ	Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.	Lancet	2008	647
18722871	2475	Curatolo P	Tuberous sclerosis.	Lancet	2008	152
18725988	2475	Carracedo A	Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer.	The Journal of clinical investigation	2008	478
18787170	2475	Mao JH	FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.	Science	2008	130
18846101	2475	Wouters BG	Hypoxia signalling through mTOR and the unfolded protein response in cancer.	Nature reviews. Cancer	2008	232
18848473	2475	Weichhart T	The TSC-mTOR signaling pathway regulates the innate inflammatory response.	Immunity	2008	184
18929564	2475	Villanueva A	Pivotal role of mTOR signaling in hepatocellular carcinoma.	Gastroenterology	2008	182
19114562	2475	Toschi A	Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin.	Molecular and cellular biology	2009	122
19223493	2475	Yu G	Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer.	Clinical cancer research 	2009	47
19234517	2475	Hartman TR	The role of the Birt-Hogg-Dubé protein in mTOR activation and renal tumorigenesis.	Oncogene	2009	59
19244117	2475	Copp J	TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2.	Cancer research	2009	122
19245654	2475	Shaw RJ	LKB1 and AMP-activated protein kinase control of mTOR signalling and growth.	Acta physiologica	2009	139
19258318	2475	Ganley IG	ULK1.ATG13.FIP200 complex mediates mTOR signaling and is essential for autophagy.	The Journal of biological chemistry	2009	325
19264150	2475	Foster DA	Phosphatidic acid signaling to mTOR: signals for the survival of human cancer cells.	Biochimica et biophysica acta	2009	73
19301157	2475	Zhou L	The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma.	Medical oncology	2010	43
19332717	2475	Meric-Bernstam F	Targeting the mTOR signaling network for cancer therapy.	Journal of clinical oncology 	2009	190
19372546	2475	Breuleux M	Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition.	Molecular cancer therapeutics	2009	68
19446321	2475	Peterson TR	DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival.	Cell	2009	333
19501590	2475	Mueller MT	Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer.	Gastroenterology	2009	80
19543393	2475	Strauss L	Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin.	PloS one	2009	56
19553991	2475	Scott KL	GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer.	Nature	2009	96
19771169	2475	Balgi AD	Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling.	PloS one	2009	108
19796751	2475	Rini BI	Resistance to targeted therapy in renal-cell carcinoma.	The Lancet. Oncology	2009	126
19817806	2475	Wong M	Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies.	Epilepsia	2010	59
19822355	2475	Cantrell LA	Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy.	Gynecologic oncology	2010	65
19860903	2475	Yuan R	Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy.	Journal of hematology and oncology	2009	58
19875810	2475	Lieberthal W	The role of the mammalian target of rapamycin (mTOR) in renal disease.	Journal of the American Society of Nephrology 	2009	78
19901542	2475	Shor B	Targeting mTOR globally in cancer: thinking beyond rapamycin.	Cell cycle	2009	62
19945836	2475	Efeyan A	mTOR and cancer: many loops in one pathway.	Current opinion in cell biology	2010	128
19948145	2475	Laplante M	An emerging role of mTOR in lipid biosynthesis.	Current biology 	2009	144
19956179	2475	Menon S	Common corruption of the mTOR signaling network in human tumors.	Oncogene	2008	92
19966861	2475	Pradelli LA	Glycolysis inhibition sensitizes tumor cells to death receptors-induced apoptosis by AMP kinase activation leading to Mcl-1 block in translation.	Oncogene	2010	52
20005306	2475	Dowling RJ	Dissecting the role of mTOR: lessons from mTOR inhibitors.	Biochimica et biophysica acta	2010	110
20022946	2475	Soliman GA	mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action.	The Journal of biological chemistry	2010	79
20034776	2475	Yang Z	Mammalian autophagy: core molecular machinery and signaling regulation.	Current opinion in cell biology	2010	478
20038818	2475	Tsang CK	mTOR binds to the promoters of RNA polymerase I- and III-transcribed genes.	Cell cycle	2010	42
20048174	2475	Wagner AJ	Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.	Journal of clinical oncology 	2010	63
20068094	2475	Manara MC	NVP-BEZ235 as a new therapeutic option for sarcomas.	Clinical cancer research 	2010	50
20081105	2475	Nagaraja AK	A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer.	Molecular endocrinology	2010	76
20139716	2475	Blagosklonny MV	Calorie restriction: decelerating mTOR-driven aging from cells to organisms (including humans).	Cell cycle	2010	81
20152770	2475	Balamuth NJ	Ewing's sarcoma.	The Lancet. Oncology	2010	92
20179189	2475	Workman P	Drugging the PI3 kinome: from chemical tools to drugs in the clinic.	Cancer research	2010	72
20196784	2475	Harhaji-Trajkovic L	AMPK-mediated autophagy inhibits apoptosis in cisplatin-treated tumour cells.	Journal of cellular and molecular medicine	2009	56
20227368	2475	Yan L	PP2A T61 epsilon is an inhibitor of MAP4K3 in nutrient signaling to mTOR.	Molecular cell	2010	46
20229590	2475	Johnston PB	A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma.	American journal of hematology	2010	49
20231677	2475	Doi T	Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer.	Journal of clinical oncology 	2010	53
20234352	2475	Dancey J	mTOR signaling and drug development in cancer.	Nature reviews. Clinical oncology	2010	106
20368560	2475	Hainsworth JD	Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma.	Journal of clinical oncology 	2010	46
20388847	2475	Rozengurt E	Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer.	Clinical cancer research 	2010	71
20418915	2475	Sparks CA	Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy.	Oncogene	2010	95
20457610	2475	Li L	Regulation of mTORC1 by the Rab and Arf GTPases.	The Journal of biological chemistry	2010	46
20472883	2475	Akhavan D	mTOR signaling in glioblastoma: lessons learned from bench to bedside.	Neuro-oncology	2010	46
20479250	2475	Loi S	PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2010	106
20484036	2475	Doghman M	Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors.	Cancer research	2010	64
20491627	2475	Zhou H	The complexes of mammalian target of rapamycin.	Current protein and peptide science	2010	42
20501828	2475	Fornari F	MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells.	Cancer research	2010	120
20530877	2475	Miller TW	Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer.	The Journal of clinical investigation	2010	104
20543138	2475	Kantidakis T	mTOR associates with TFIIIC, is found at tRNA and 5S rRNA genes, and targets their repressor Maf1.	Proceedings of the National Academy of Sciences of the United States of America	2010	60
20606252	2475	Korotchkina LG	The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway.	Aging	2010	160
20656475	2475	Jalving M	Metformin: taking away the candy for cancer?	European journal of cancer	2010	92
20664172	2475	Di Nicolantonio F	Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.	The Journal of clinical investigation	2010	110
20664473	2475	Boudreaux JP	The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum.	Pancreas	2010	53
20668229	2475	Green AS	The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation.	Blood	2010	45
20670887	2475	Düvel K	Activation of a metabolic gene regulatory network downstream of mTOR complex 1.	Molecular cell	2010	385
20681032	2475	Slomovitz BM	A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma.	Cancer	2010	42
20704563	2475	Pearce LR	Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1).	The Biochemical journal	2010	72
20805416	2475	Haidinger M	A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation.	Journal of immunology	2010	57
20810672	2475	Memmott RM	Metformin prevents tobacco carcinogen--induced lung tumorigenesis.	Cancer prevention research	2010	129
20857497	2475	Sunayama J	Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells.	Stem cells	2010	56
20860370	2475	Liu Q	Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzoh1,6naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer.	Journal of medicinal chemistry	2010	63
20870173	2475	Powell JD	The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism.	Immunity	2010	146
21047224	2475	Krueger DA	Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.	The New England journal of medicine	2010	206
21051933	2475	Leontieva OV	Weak p53 permits senescence during cell cycle arrest.	Cell cycle	2010	64
21135857	2475	Witzig TE	A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma.	Leukemia	2011	64
21157483	2475	Zoncu R	mTOR: from growth signal integration to cancer, diabetes and ageing.	Nature reviews. Molecular cell biology	2011	1188
21177764	2475	Quek R	Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors.	Clinical cancer research 	2011	64
21179025	2475	Caron E	A comprehensive map of the mTOR signaling network.	Molecular systems biology	2010	64
21228155	2475	Rieker C	Nucleolar disruption in dopaminergic neurons leads to oxidative damage and parkinsonism through repression of mammalian target of rapamycin signaling.	The Journal of neuroscience 	2011	39
21258367	2475	Kim J	AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1.	Nature cell biology	2011	965
21301797	2475	Yecies JL	mTOR links oncogenic signaling to tumor cell metabolism.	Journal of molecular medicine	2011	55
21306238	2475	Yao JC	Everolimus for advanced pancreatic neuroendocrine tumors.	The New England journal of medicine	2011	417
21317208	2475	Prasad G	Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide.	Neuro-oncology	2011	44
21331075	2475	Evangelisti C	Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia.	Leukemia	2011	35
21333749	2475	Zhang YJ	Targeting the mTOR kinase domain: the second generation of mTOR inhibitors.	Drug discovery today	2011	44
21340684	2475	Maddocks OD	Metabolic regulation by p53.	Journal of molecular medicine	2011	89
21346035	2475	Finley DS	Tumor biology and prognostic factors in renal cell carcinoma.	The oncologist	2011	35
21363918	2475	Falcon BL	Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors.	Cancer research	2011	37
21372221	2475	Santiskulvong C	Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.	Clinical cancer research 	2011	42
21430067	2475	Gulhati P	mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways.	Cancer research	2011	153
21447859	2475	Apontes P	Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture.	Oncotarget	2011	92
21460621	2475	Egan D	The autophagy initiating kinase ULK1 is regulated via opposing phosphorylation by AMPK and mTOR.	Autophagy	2011	86
21460630	2475	Dunlop EA	ULK1 inhibits mTORC1 signaling, promotes multisite Raptor phosphorylation and hinders substrate binding.	Autophagy	2011	38
21460795	2475	Galan-Moya EM	Secreted factors from brain endothelial cells maintain glioblastoma stem-like cell expansion through the mTOR pathway.	EMBO reports	2011	38
21470407	2475	Dowling RJ	Understanding the benefit of metformin use in cancer treatment.	BMC medicine	2011	88
21490404	2475	Wander SA	Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy.	The Journal of clinical investigation	2011	127
21501117	2475	Smith GI	Omega-3 polyunsaturated fatty acids augment the muscle protein anabolic response to hyperinsulinaemia-hyperaminoacidaemia in healthy young and middle-aged men and women.	Clinical science	2011	35
21512002	2475	Narita M	Spatial coupling of mTOR and autophagy augments secretory phenotypes.	Science	2011	115
21622984	2475	Xu L	Phospholipase D mediates nutrient input to mammalian target of rapamycin complex 1 (mTORC1).	The Journal of biological chemistry	2011	39
21655990	2475	Hadad S	Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial.	Breast cancer research and treatment	2011	68
21676631	2475	Liu J	Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft.	Urologic oncology	2013	25
21678117	2475	Mirzoeva OK	Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K-mTOR pathway in pancreatic adenocarcinoma.	Journal of molecular medicine	2011	35
21690594	2475	Taveira-DaSilva AM	Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.	Annals of internal medicine	2011	38
21750201	2475	Naing A	Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer.	Clinical cancer research 	2011	44
21779436	2475	Foster DA	Regulation of G1 Cell Cycle Progression: Distinguishing the Restriction Point from a Nutrient-Sensing Cell Growth Checkpoint(s).	Genes and cancer	2010	50
21840335	2475	Speakman JR	Caloric restriction.	Molecular aspects of medicine	2011	138
21946274	2475	Muellner MK	A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer.	Nature chemical biology	2011	50
21952069	2475	Coppin C	Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.	BJU international	2011	49
21963299	2475	Dazert E	mTOR signaling in disease.	Current opinion in cell biology	2011	134
21975930	2475	Patel V	Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer.	Cancer research	2011	49
21998291	2475	Wallin JJ	GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.	Molecular cancer therapeutics	2011	64
22017684	2475	Inoki K	AMPK and mTOR in cellular energy homeostasis and drug targets.	Annual review of pharmacology and toxicology	2012	138
22037041	2475	Benjamin D	Rapamycin passes the torch: a new generation of mTOR inhibitors.	Nature reviews. Drug discovery	2011	200
22065737	2475	Shin S	Glycogen synthase kinase (GSK)-3 promotes p70 ribosomal protein S6 kinase (p70S6K) activity and cell proliferation.	Proceedings of the National Academy of Sciences of the United States of America	2011	38
22067397	2475	Chawla SP	Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas.	Journal of clinical oncology 	2012	56
22080480	2475	Gupta M	Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies.	Blood	2012	33
22098780	2475	Khan MI	Induction of ROS, mitochondrial damage and autophagy in lung epithelial cancer cells by iron oxide nanoparticles.	Biomaterials	2012	44
22119496	2475	Pavel ME	Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.	Lancet	2011	136
22149876	2475	Baselga J	Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.	The New England journal of medicine	2012	505
22156391	2475	Leontieva OV	Yeast-like chronological senescence in mammalian cells: phenomenon, mechanism and pharmacological suppression.	Aging	2011	69
22171948	2475	Deng W	Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition.	Pigment cell and melanoma research	2012	35
22223645	2475	Liu Q	Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics.	The Journal of biological chemistry	2012	34
22261336	2475	Zaytseva YY	mTOR inhibitors in cancer therapy.	Cancer letters	2012	60
22287548	2475	Chen W	Macrophage-induced tumor angiogenesis is regulated by the TSC2-mTOR pathway.	Cancer research	2012	31
22340590	2475	Pei Y	An animal model of MYC-driven medulloblastoma.	Cancer cell	2012	81
22349822	2475	Wen ZH	Critical role of arachidonic acid-activated mTOR signaling in breast carcinogenesis and angiogenesis.	Oncogene	2013	25
22357447	2475	Markman B	Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors.	Annals of oncology 	2012	40
22367541	2475	Hsieh AC	The translational landscape of mTOR signalling steers cancer initiation and metastasis.	Nature	2012	296
22378068	2475	Shi WY	Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy.	Cell death and disease	2012	50
22397650	2475	Gerlinger M	Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.	The New England journal of medicine	2012	1540
22409888	2475	Molinolo AA	mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas.	Clinical cancer research 	2012	36
22427958	2475	Lou E	Tunneling nanotubes provide a unique conduit for intercellular transfer of cellular contents in human malignant pleural mesothelioma.	PloS one	2012	52
22439642	2475	Vinci M	Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation.	BMC biology	2012	120
22449814	2475	Bakan I	Connecting mTORC1 signaling to SREBP-1 activation.	Current opinion in lipidology	2012	36
22465830	2475	Naing A	Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors.	Clinical cancer research 	2012	54
22500211	2475	Song CW	Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells.	Scientific reports	2012	62
22500797	2475	Laplante M	mTOR signaling in growth control and disease.	Cell	2012	1760
22562464	2475	Luo Z	The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth.	Cancer research	2012	60
22685175	2475	Tasian SK	Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia.	Blood	2012	42
22687819	2475	Jansson T	The emerging role of mTORC1 signaling in placental nutrient-sensing.	Placenta	2012	31
22734070	2475	Payne EM	L-Leucine improves the anemia and developmental defects associated with Diamond-Blackfan anemia and del(5q) MDS by activating the mTOR pathway.	Blood	2012	42
22759480	2475	Tran HT	Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.	The Lancet. Oncology	2012	73
22778315	2475	Busaidy NL	Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway.	Journal of clinical oncology 	2012	40
22834827	2475	Arora S	Honokiol: a novel natural agent for cancer prevention and therapy.	Current molecular medicine	2012	32
22847439	2475	Leontieva OV	Hypoxia suppresses conversion from proliferative arrest to cellular senescence.	Proceedings of the National Academy of Sciences of the United States of America	2012	78
22848625	2475	Bray K	Autophagy suppresses RIP kinase-dependent necrosis enabling survival to mTOR inhibition.	PloS one	2012	43
22889214	2475	Waickman AT	mTOR, metabolism, and the regulation of T-cell differentiation and function.	Immunological reviews	2012	63
22958932	2475	Iglesias-Bartolome R	mTOR inhibition prevents epithelial stem cell senescence and protects from radiation-induced mucositis.	Cell stem cell	2012	75
22980037	2475	Chong ZZ	Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin.	Progress in neurobiology	2012	45
22983984	2475	Iwaya T	Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway.	Carcinogenesis	2012	41
22994652	2475	Welker MW	Recurrent hepatocellular carcinoma after liver transplantation - an emerging clinical challenge.	Transplant international 	2013	29
23012248	2475	Acquaviva J	Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib.	Molecular cancer therapeutics	2012	32
23012305	2475	Crown J	Emerging targeted therapies in triple-negative breast cancer.	Annals of oncology 	2012	47
23061800	2475	Passtoors WM	Gene expression analysis of mTOR pathway: association with human longevity.	Aging cell	2013	32
23158522	2475	Franz DN	Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.	Lancet	2013	113
23233719	2475	Wolff AC	Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.	Journal of clinical oncology 	2013	55
23238015	2475	Britschgi A	JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer.	Cancer cell	2012	60
23246963	2475	Montero JC	Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer.	Oncogene	2014	26
23246968	2475	Beauchamp EM	The evolution of the TOR pathway and its role in cancer.	Oncogene	2013	42
23255238	2475	Gorlick R	Children's Oncology Group's 2013 blueprint for research: bone tumors.	Pediatric blood and cancer	2013	29
23265840	2475	Maiese K	mTOR: on target for novel therapeutic strategies in the nervous system.	Trends in molecular medicine	2013	58
23271044	2475	Chiarini F	A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia.	Oncotarget	2012	33
23272949	2475	Schlicker A	Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines.	BMC medical genomics	2012	37
23312829	2475	Bissler JJ	Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial.	Lancet	2013	119
23454761	2475	Lamming DW	Rapalogs and mTOR inhibitors as anti-aging therapeutics.	The Journal of clinical investigation	2013	104
23460185	2475	Alayev A	mTOR signaling for biological control and cancer.	Journal of cellular physiology	2013	34
23465396	2475	Jewell JL	Nutrient signaling to mTOR and cell growth.	Trends in biochemical sciences	2013	75
23477833	2475	Schwartz GK	Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.	The Lancet. Oncology	2013	42
23532336	2475	Casado P	Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells.	Science signaling	2013	30
23549875	2475	Coffee EM	Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.	Clinical cancer research 	2013	28
23601105	2475	Chang HH	A unique herpesviral transcriptional program in KSHV-infected lymphatic endothelial cells leads to mTORC1 activation and rapamycin sensitivity.	Cell host and microbe	2013	28
23619167	2475	Lui VW	Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.	Cancer discovery	2013	106
23636326	2475	Yang H	mTOR kinase structure, mechanism and regulation.	Nature	2013	129
23641065	2475	Laplante M	Regulation of mTORC1 and its impact on gene expression at a glance.	Journal of cell science	2013	128
23644232	2475	Wong M	Mammalian target of rapamycin (mTOR) pathways in neurological diseases.	Biomedical journal	2013	29
23694989	2475	Kim SG	Nutrient regulation of the mTOR complex 1 signaling pathway.	Molecules and cells	2013	56
23792225	2475	Sun SY	mTOR kinase inhibitors as potential cancer therapeutic drugs.	Cancer letters	2013	43
23818640	2475	Meckes DG Jr	Modulation of B-cell exosome proteins by gamma herpesvirus infection.	Proceedings of the National Academy of Sciences of the United States of America	2013	44
23863154	2475	Howell JJ	A growing role for mTOR in promoting anabolic metabolism.	Biochemical Society transactions	2013	50
23872332	2475	Theodoropoulou M	Somatostatin receptors: from signaling to clinical practice.	Frontiers in neuroendocrinology	2013	31
23911927	2475	Linares JF	K63 polyubiquitination and activation of mTOR by the p62-TRAF6 complex in nutrient-activated cells.	Molecular cell	2013	41
23929677	2475	Sinha RA	Caffeine stimulates hepatic lipid metabolism by the autophagy-lysosomal pathway in mice.	Hepatology	2014	36
24024901	2475	Santulli G	Tailoring mTOR-based therapy: molecular evidence and clinical challenges.	Pharmacogenomics	2013	27
24043745	2475	Ohtsu A	Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.	Journal of clinical oncology 	2013	82
24055054	2475	Villanueva J	Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma.	Cell reports	2013	43
24055102	2475	Lee JH	Sestrins orchestrate cellular metabolism to attenuate aging.	Cell metabolism	2013	53
24185040	2475	Francipane MG	Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1.	Oncotarget	2013	28
24204632	2475	Lonardo E	Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells.	PloS one	2013	41
24231729	2475	Matsubara S	mTOR plays critical roles in pancreatic cancer stem cells through specific and stemness-related functions.	Scientific reports	2013	27
24249672	2475	Bagatell R	Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.	Pediatric blood and cancer	2014	23
24270265	2475	Goncharov DA	Mammalian target of rapamycin complex 2 (mTORC2) coordinates pulmonary artery smooth muscle cell metabolism, proliferation, and survival in pulmonary arterial hypertension.	Circulation	2014	32
24308993	2475	Matter MS	Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends.	Journal of hepatology	2014	36
24336084	2475	Blagosklonny MV	TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists.	Cell death and disease	2013	32
24389102	2475	Martin TD	Ral and Rheb GTPase activating proteins integrate mTOR and GTPase signaling in aging, autophagy, and tumor cell invasion.	Molecular cell	2014	22
24430184	2475	Li H	Inactivation of SAG/RBX2 E3 ubiquitin ligase suppresses KrasG12D-driven lung tumorigenesis.	The Journal of clinical investigation	2014	21
24474794	2475	Liu X	Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK.	Proceedings of the National Academy of Sciences of the United States of America	2014	56
24476679	2475	Carlino MS	Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.	Molecular oncology	2014	24
24508508	2475	Li J	Rapamycin: one drug, many effects.	Cell metabolism	2014	66
24553191	2475	Li X	LIF promotes tumorigenesis and metastasis of breast cancer through the AKT-mTOR pathway.	Oncotarget	2014	21
24556040	2475	Motzer RJ	Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.	The Lancet. Oncology	2014	48
24569374	2475	Ma XH	Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma.	The Journal of clinical investigation	2014	77
24622468	2475	Voss MH	Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy.	Clinical cancer research 	2014	37
24625776	2475	Wagle N	Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.	Cancer discovery	2014	70
24632219	2475	Botter SM	Recent advances in osteosarcoma.	Current opinion in pharmacology	2014	31
24662833	2475	Nguyen HG	Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model.	Oncogene	2014	26
24685370	2475	Kaplan B	Strategies for the management of adverse events associated with mTOR inhibitors.	Transplantation reviews	2014	23
24759575	2475	Edlind MP	PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance.	Asian journal of andrology	2014	34
24789445	2475	Pickard MR	Regulation of apoptosis by long non-coding RNA GAS5 in breast cancer cells: implications for chemotherapy.	Breast cancer research and treatment	2014	30
24810336	2475	Minna E	miR-199a-3p displays tumor suppressor functions in papillary thyroid carcinoma.	Oncotarget	2014	29
24821879	2475	Brugarolas J	Molecular genetics of clear-cell renal cell carcinoma.	Journal of clinical oncology 	2014	37
24889617	2475	Leontieva OV	Contact inhibition and high cell density deactivate the mammalian target of rapamycin pathway, thus suppressing the senescence program.	Proceedings of the National Academy of Sciences of the United States of America	2014	41
24900173	2475	Knight SD	Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin.	ACS medicinal chemistry letters	2010	47
24973821	2475	Marçais A	The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells.	Nature immunology	2014	52
24990952	2475	Foster DA	Phospholipase D and the maintenance of phosphatidic acid levels for regulation of mammalian target of rapamycin (mTOR).	The Journal of biological chemistry	2014	23
24991838	2475	Rangwala R	Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma.	Autophagy	2014	80
25103565	2475	Lehmann BD	PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.	Breast cancer research 	2014	32
25158238	2475	Dunlop EA	mTOR and autophagy: a dynamic relationship governed by nutrients and energy.	Seminars in cell and developmental biology	2014	55
25253086	2475	Jia G	Overnutrition, mTOR signaling, and cardiovascular diseases.	American journal of physiology. Regulatory, integrative and comparative physiology	2014	25
25282103	2475	Wood AR	Defining the role of common variation in the genomic and biological architecture of adult human height.	Nature genetics	2014	268
25295501	2475	Wagle N	Response and acquired resistance to everolimus in anaplastic thyroid cancer.	The New England journal of medicine	2014	61
25326666	2475	Ronan B	A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy.	Nature chemical biology	2014	46
25351205	2475	Scelo G	Variation in genomic landscape of clear cell renal cell carcinoma across Europe.	Nature communications	2014	24
25385035	2475	Favier J	Paraganglioma and phaeochromocytoma: from genetics to personalized medicine.	Nature reviews. Endocrinology	2015	26
25432176	2475	Kolev VN	PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells.	Cancer research	2015	33
25446280	2475	Wagner LM	Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children's Oncology Group.	Pediatric blood and cancer	2015	17
25488966	2475	Hobday TJ	Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors.	Journal of clinical oncology 	2015	17
25497227	2475	Chiarini F	Current treatment strategies for inhibiting mTOR in cancer.	Trends in pharmacological sciences	2015	44
25498219	2475	Grignani G	Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.	The Lancet. Oncology	2015	30
25500094	2475	Ritprajak P	Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma.	Oral oncology	2015	35
25512523	2475	Perry JA	Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma.	Proceedings of the National Academy of Sciences of the United States of America	2014	46
25522665	2475	Pollizzi KN	Regulation of T cells by mTOR: the known knowns and the known unknowns.	Trends in immunology	2015	24
25554914	2475	Albert V	mTOR signaling in cellular and organismal energetics.	Current opinion in cell biology	2015	49
25590164	2475	Morita M	mTOR coordinates protein synthesis, mitochondrial activity and proliferation.	Cell cycle	2015	33
25591831	2475	Curatolo P	Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.	Pediatric neurology	2015	15
25650269	2475	Yacqub-Usman K	Reciprocal regulation of GAS5 lncRNA levels and mTOR inhibitor action in prostate cancer cells.	The Prostate	2015	17
25671304	2475	Lamb R	Targeting tumor-initiating cells: eliminating anabolic cancer stem cells with inhibitors of protein synthesis or by mimicking caloric restriction.	Oncotarget	2015	16
25714620	2475	Guo S	A rapid and high content assay that measures cyto-ID-stained autophagic compartments and estimates autophagy flux with potential clinical applications.	Autophagy	2015	17
25749036	2475	Yang H	FBXW7 suppresses epithelial-mesenchymal transition, stemness and metastatic potential of cholangiocarcinoma cells.	Oncotarget	2015	17
25813405	2475	Wang Y	CRNDE, a long-noncoding RNA, promotes glioma cell growth and invasion through mTOR signaling.	Cancer letters	2015	33
25867026	2475	Sesen J	Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response.	PloS one	2015	18
25913192	2475	Venkatesh HS	Neuronal Activity Promotes Glioma Growth through Neuroligin-3 Secretion.	Cell	2015	38
25956062	2475	Zhang XW	Overexpression of long non-coding RNA PVT1 in gastric cancer cells promotes the development of multidrug resistance.	Biochemical and biophysical research communications	2015	19
25974391	2475	Bennett J	Discovery of a Chemical Tool Inhibitor Targeting the Bromodomains of TRIM24 and BRPF.	Journal of medicinal chemistry	2016	15
26004684	2475	Han B	Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy.	Cancer cell	2015	20
26067126	2475	Curatolo P	Neurological and neuropsychiatric aspects of tuberous sclerosis complex.	The Lancet. Neurology	2015	29
26117819	2475	Yap TA	Drugging PI3K in cancer: refining targets and therapeutic strategies.	Current opinion in pharmacology	2015	30
26156073	2475	Bissler JJ	Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial.	Nephrology, dialysis, transplantation 	2016	17
26190651	2475	Fu X	2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling.	Cell metabolism	2015	15
26277543	2475	Hsieh AL	MYC and metabolism on the path to cancer.	Seminars in cell and developmental biology	2015	25
26293922	2475	Liu P	PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex.	Cancer discovery	2015	30
26310906	2475	Wong PM	Regulation of autophagy by coordinated action of mTORC1 and protein phosphatase 2A.	Nature communications	2015	23
26463117	2475	Arriola Apelo SI	Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system.	Aging cell	2016	12
26482279	2475	Motzer RJ	Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.	The Lancet. Oncology	2015	57
26637667	2475	Lastwika KJ	Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer.	Cancer research	2016	31
26794930	2475	Armstrong AJ	Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.	The Lancet. Oncology	2016	16
26947070	2475	Cárdenas C	Selective Vulnerability of Cancer Cells by Inhibition of Ca(2+) Transfer from Endoplasmic Reticulum to Mitochondria.	Cell reports	2016	16
27134180	2475	Jiménez-Valerio G	Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients.	Cell reports	2016	15
27279227	2475	Rodrik-Outmezguine VS	Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.	Nature	2016	19
27279544	2475	Choueiri TK	Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.	The Lancet. Oncology	2016	35
27613521	2475	French JA	Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study.	Lancet	2016	13
27615548	2475	Hsieh JJ	Overcome tumor heterogeneity-imposed therapeutic barriers through convergent genomic biomarker discovery: A braided cancer river model of kidney cancer.	Seminars in cell and developmental biology	2017	7
27748764	2475	Kim LC	mTORC1 and mTORC2 in cancer and the tumor microenvironment.	Oncogene	2017	10
28283069	2475	Saxton RA	mTOR Signaling in Growth, Metabolism, and Disease.	Cell	2017	27
9216996	2735	Lee J	Gli1 is a target of Sonic hedgehog that induces ventral neural tube development.	Development	1997	145
11719506	2735	Yoon JW	Gene expression profiling leads to identification of GLI1-binding elements in target genes and a role for multiple downstream pathways in GLI1-induced cell transformation.	The Journal of biological chemistry	2002	97
15132968	2735	Fan L	Hedgehog signaling promotes prostate xenograft tumor growth.	Endocrinology	2004	75
15314219	2735	Sanchez P	Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling.	Proceedings of the National Academy of Sciences of the United States of America	2004	145
15520176	2735	Regl G	Activation of the BCL2 promoter in response to Hedgehog/GLI signal transduction is predominantly mediated by GLI2.	Cancer research	2004	72
16294371	2735	Tostar U	Deregulation of the hedgehog signalling pathway: a possible role for the PTCH and SUFU genes in human rhabdomyoma and rhabdomyosarcoma development.	The Journal of pathology	2006	66
16406505	2735	Kasper M	GLI transcription factors: mediators of oncogenic Hedgehog signalling.	European journal of cancer	2006	114
16421275	2735	Huntzicker EG	Dual degradation signals control Gli protein stability and tumor formation.	Genes and development	2006	67
16880536	2735	Kasper M	Selective modulation of Hedgehog/GLI target gene expression by epidermal growth factor signaling in human keratinocytes.	Molecular and cellular biology	2006	66
16909105	2735	Yuan Z	Frequent requirement of hedgehog signaling in non-small cell lung carcinoma.	Oncogene	2007	59
17196391	2735	Clement V	HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity.	Current biology 	2007	283
17332349	2735	Feldmann G	Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers.	Cancer research	2007	236
17494766	2735	Lauth M	Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.	Proceedings of the National Academy of Sciences of the United States of America	2007	196
18756266	2735	Ferretti E	Concerted microRNA control of Hedgehog signalling in cerebellar neuronal progenitor and tumour cells.	The EMBO journal	2008	96
19028702	2735	Liao X	Aberrant activation of hedgehog signaling pathway in ovarian cancers: effect on prognosis, cell invasion and differentiation.	Carcinogenesis	2009	62
19147008	2735	Wong SY	The primary cilium at the crossroads of mammalian hedgehog signaling.	Current topics in developmental biology	2008	75
19214186	2735	Stecca B	A GLI1-p53 inhibitory loop controls neural stem cell and tumour cell numbers.	The EMBO journal	2009	75
19351822	2735	Northcott PA	The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors.	Cancer research	2009	108
20049737	2735	Varnat F	Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion.	EMBO molecular medicine	2009	130
20083481	2735	Stecca B	Context-dependent regulation of the GLI code in cancer by HEDGEHOG and non-HEDGEHOG signals.	Journal of molecular cell biology	2010	89
20581802	2735	Zbinden M	NANOG regulates glioma stem cells and is essential in vivo acting in a cross-functional network with GLI1 and p53.	The EMBO journal	2010	98
21076395	2735	Jagani Z	Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway.	Nature medicine	2010	62
21135115	2735	Mazumdar T	Hedgehog signaling drives cellular survival in human colon carcinoma cells.	Cancer research	2011	53
21169257	2735	Schreck KC	The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: a potential mechanism of therapeutic resistance.	Clinical cancer research 	2010	50
21183792	2735	Beauchamp EM	Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway.	The Journal of clinical investigation	2011	66
21300762	2735	LoRusso PM	Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors.	Clinical cancer research 	2011	131
21796625	2735	Tang SN	Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics.	International journal of cancer	2012	47
21801010	2735	Hui CC	Gli proteins in development and disease.	Annual review of cell and developmental biology	2011	161
22087285	2735	Singh BN	Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: molecular mechanisms.	PloS one	2011	54
22730244	2735	Santini R	Hedgehog-GLI signaling drives self-renewal and tumorigenicity of human melanoma-initiating cells.	Stem cells	2012	40
24493717	2735	Kim DJ	Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma.	Journal of clinical oncology 	2014	38
24523439	2735	Rodon J	A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors.	Clinical cancer research 	2014	37
24852887	2735	Aberger F	Context-dependent signal integration by the GLI code: the oncogenic load, pathways, modifiers and implications for cancer therapy.	Seminars in cell and developmental biology	2014	38
24870236	2735	Zahreddine HA	The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation.	Nature	2014	41
25278454	2735	Kim EJ	Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma.	Clinical cancer research 	2014	31
26053182	2735	Gonnissen A	Targeting the Hedgehog signaling pathway in cancer: beyond Smoothened.	Oncotarget	2015	20
8942985	2956	Acharya S	hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6.	Proceedings of the National Academy of Sciences of the United States of America	1996	142
9428522	2956	Gradia S	The human mismatch recognition complex hMSH2-hMSH6 functions as a novel molecular switch.	Cell	1997	106
10078208	2956	Gradia S	hMSH2-hMSH6 forms a hydrolysis-independent sliding clamp on mismatched DNA.	Molecular cell	1999	109
10544223	2956	Lynch HT	Genetic susceptibility to non-polyposis colorectal cancer.	Journal of medical genetics	1999	131
11048711	2956	Lamers MH	The crystal structure of DNA mismatch repair protein MutS binding to a G x T mismatch.	Nature	2000	199
11257106	2956	Peltomäki P	Deficient DNA mismatch repair: a common etiologic factor for colon cancer.	Human molecular genetics	2001	94
15236168	2956	Hendriks YM	Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance.	Gastroenterology	2004	82
15872200	2956	Hampel H	Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer).	The New England journal of medicine	2005	244
16618716	2956	Hunter C	A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy.	Cancer research	2006	80
16807412	2956	Barnetson RA	Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer.	The New England journal of medicine	2006	85
16885385	2956	Hampel H	Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients.	Cancer research	2006	102
17003396	2956	Chen S	Prediction of germline mutations and cancer risk in the Lynch syndrome.	JAMA	2006	86
17327285	2956	Vasen HF	Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer).	Journal of medical genetics	2007	103
17404084	2956	Cahill DP	Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.	Clinical cancer research 	2007	83
17531815	2956	Warren JJ	Structure of the human MutSalpha DNA lesion recognition complex.	Molecular cell	2007	141
17942460	2956	Imai K	Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics.	Carcinogenesis	2008	71
18556767	2956	Shia J	Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry.	The Journal of molecular diagnostics 	2008	71
19584161	2956	Yip S	MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance.	Clinical cancer research 	2009	75
19622357	2956	Stoffel E	Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome.	Gastroenterology	2009	77
20028993	2956	Baglietto L	Risks of Lynch syndrome cancers for MSH6 mutation carriers.	Journal of the National Cancer Institute	2010	73
20516444	2956	de la Chapelle A	Clinical relevance of microsatellite instability in colorectal cancer.	Journal of clinical oncology 	2010	44
21425258	2956	Felsberg J	Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas.	International journal of cancer	2011	45
21642682	2956	Bonadona V	Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.	JAMA	2011	114
21855803	2956	Zlatanou A	The hMsh2-hMsh6 complex acts in concert with monoubiquitinated PCNA and Pol η in response to oxidative DNA damage in human cells.	Molecular cell	2011	44
22331944	2956	Win AK	Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study.	Journal of clinical oncology 	2012	68
22355048	2956	Beamer LC	Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results.	Journal of clinical oncology 	2012	35
22658618	2956	Pritchard CC	ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing.	The Journal of molecular diagnostics 	2012	54
23091106	2956	Engel C	Risks of less common cancers in proven mutation carriers with lynch syndrome.	Journal of clinical oncology 	2012	32
24323032	2956	Buchanan DD	Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing.	Journal of clinical oncology 	2014	24
24362816	2956	Thompson BA	Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database.	Nature genetics	2014	80
24737826	2956	Wimmer K	Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium 'care for CMMRD' (C4CMMRD).	Journal of medical genetics	2014	23
24844595	2956	Meng B	POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium.	Gynecologic oncology	2014	22
25194673	2956	Haraldsdottir S	Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations.	Gastroenterology	2014	35
25238946	2956	Lancaster JM	Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions.	Gynecologic oncology	2015	24
25305506	2956	Sinicrope FA	Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.	Gastroenterology	2015	42
26031544	2956	Kawakami H	Microsatellite instability testing and its role in the management of colorectal cancer.	Current treatment options in oncology	2015	17
26657901	2956	Møller P	Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database.	Gut	2017	10
26720728	2956	Norquist BM	Inherited Mutations in Women With Ovarian Carcinoma.	JAMA oncology	2016	24
26880610	2956	Dudley JC	Microsatellite Instability as a Biomarker for PD-1 Blockade.	Clinical cancer research 	2016	28
27496117	2956	Provenzale D	Genetic/Familial High-Risk Assessment: Colorectal Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.	Journal of the National Comprehensive Cancer Network 	2016	15
8387214	3091	Wang GL	General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia.	Proceedings of the National Academy of Sciences of the United States of America	1993	255
8756616	3091	Forsythe JA	Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1.	Molecular and cellular biology	1996	763
9861020	3091	Der SD	Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays.	Proceedings of the National Academy of Sciences of the United States of America	1998	512
10582706	3091	Zhong H	Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases.	Cancer research	1999	499
10611972	3091	Semenza GL	Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1.	Annual review of cell and developmental biology	1999	378
10640274	3091	Ravi R	Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha.	Genes and development	2000	212
10950862	3091	Semenza GL	HIF-1 and human disease: one highly involved factor.	Genes and development	2000	189
10987269	3091	Birner P	Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer.	Cancer research	2000	125
11306467	3091	Aebersold DM	Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer.	Cancer research	2001	108
11786564	3091	Bos R	Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography.	Journal of clinical oncology 	2002	86
11943784	3091	Lu H	Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis.	The Journal of biological chemistry	2002	143
12067980	3091	Comerford KM	Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene.	Cancer research	2002	176
12124175	3091	Mandriota SJ	HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron.	Cancer cell	2002	125
12149254	3091	Fukuda R	Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells.	The Journal of biological chemistry	2002	160
12154035	3091	Rapisarda A	Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway.	Cancer research	2002	102
12213597	3091	Semenza G	Signal transduction to hypoxia-inducible factor 1.	Biochemical pharmacology	2002	156
12912907	3091	Berra E	HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia.	The EMBO journal	2003	314
13130303	3091	Semenza GL	Targeting HIF-1 for cancer therapy.	Nature reviews. Cancer	2003	1379
15178764	3091	Thomas DD	Hypoxic inducible factor 1alpha, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide.	Proceedings of the National Academy of Sciences of the United States of America	2004	86
15349906	3091	Lee JS	Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling.	Hepatology	2004	192
15677538	3091	Vleugel MM	Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer.	Journal of clinical pathology	2005	68
15994012	3091	Bárdos JI	Negative and positive regulation of HIF-1: a complex network.	Biochimica et biophysica acta	2005	67
16417408	3091	Chi JT	Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers.	PLoS medicine	2006	190
16510593	3091	Krishnamachary B	Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B.	Cancer research	2006	118
16899602	3091	Generali D	Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer.	Clinical cancer research 	2006	74
17075581	3091	Zagzag D	Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion.	Laboratory investigation; a journal of technical methods and pathology	2006	83
17101781	3091	Pan Y	Multiple factors affecting cellular redox status and energy metabolism modulate hypoxia-inducible factor prolyl hydroxylase activity in vivo and in vitro.	Molecular and cellular biology	2007	96
17118889	3091	Tatum JL	Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy.	International journal of radiation biology	2006	165
17245699	3091	Trastour C	HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome.	International journal of cancer	2007	61
17440684	3091	Vaupel P	Hypoxia in cancer: significance and impact on clinical outcome.	Cancer metastasis reviews	2007	374
17483326	3091	Hiraga T	Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer.	Cancer research	2007	61
17502379	3091	Land SC	Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif.	The Journal of biological chemistry	2007	113
17533374	3091	Maxwell PJ	HIF-1 and NF-kappaB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells.	Oncogene	2007	65
17551816	3091	Semenza GL	HIF-1 mediates the Warburg effect in clear cell renal carcinoma.	Journal of bioenergetics and biomembranes	2007	78
17595539	3091	Airley RE	Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics.	Chemotherapy	2007	63
17624581	3091	Gillies RJ	Adaptive landscapes and emergent phenotypes: why do cancers have high glycolysis?	Journal of bioenergetics and biomembranes	2007	63
17785204	3091	Gao P	HIF-dependent antitumorigenic effect of antioxidants in vivo.	Cancer cell	2007	165
17785433	3091	Kim JW	Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1.	Molecular and cellular biology	2007	148
17933687	3091	Semenza GL	Evaluation of HIF-1 inhibitors as anticancer agents.	Drug discovery today	2007	96
17964232	3091	Jiang BH	PI3K/PTEN signaling in tumorigenesis and angiogenesis.	Biochimica et biophysica acta	2008	69
17998060	3091	Brown JM	Tumor hypoxia in cancer therapy.	Methods in enzymology	2007	56
18083891	3091	Archer SL	Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1alpha-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer.	American journal of physiology. Heart and circulatory physiology	2008	104
18259201	3091	Weidemann A	Biology of HIF-1alpha.	Cell death and differentiation	2008	158
18297062	3091	Yang MH	Direct regulation of TWIST by HIF-1alpha promotes metastasis.	Nature cell biology	2008	316
18343725	3091	Vergis R	Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study.	The Lancet. Oncology	2008	65
18551130	3091	Papandreou I	Hypoxia signals autophagy in tumor cells via AMPK activity, independent of HIF-1, BNIP3, and BNIP3L.	Cell death and differentiation	2008	94
18635960	3091	Yang MH	TWIST activation by hypoxia inducible factor-1 (HIF-1): implications in metastasis and development.	Cell cycle	2008	73
18754863	3091	Kyo S	Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers.	Cancer science	2008	83
19074827	3091	Zhao D	Neural stem cell tropism to glioma: critical role of tumor hypoxia.	Molecular cancer research 	2008	59
19118021	3091	Chiche J	Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH.	Cancer research	2009	110
19291283	3091	Hu Z	A compact VEGF signature associated with distant metastases and poor outcomes.	BMC medicine	2009	61
19359588	3091	Zhao S	Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.	Science	2009	284
19454274	3091	Yalcin A	Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer.	Experimental and molecular pathology	2009	72
19479945	3091	Ruan K	Role of hypoxia in the hallmarks of human cancer.	Journal of cellular biochemistry	2009	92
19671047	3091	Semenza GL	HIF-1 inhibitors for cancer therapy: from gene expression to drug discovery.	Current pharmaceutical design	2009	49
19674190	3091	Onnis B	Development of HIF-1 inhibitors for cancer therapy.	Journal of cellular and molecular medicine	2009	74
19718046	3091	Soeda A	Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha.	Oncogene	2009	157
19727403	3091	Dunn LK	Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment.	PloS one	2009	65
19778933	3091	Hung JJ	Prognostic significance of hypoxia-inducible factor-1alpha, TWIST1 and Snail expression in resectable non-small cell lung cancer.	Thorax	2009	46
19782034	3091	Huang X	Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation.	Molecular cell	2009	181
19946328	3091	Semenza GL	Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics.	Oncogene	2010	414
20176937	3091	Horak P	Negative feedback control of HIF-1 through REDD1-regulated ROS suppresses tumorigenesis.	Proceedings of the National Academy of Sciences of the United States of America	2010	44
20463368	3091	Michelakis ED	Metabolic modulation of glioblastoma with dichloroacetate.	Science translational medicine	2010	188
20515450	3091	Méndez O	Knock down of HIF-1alpha in glioma cells reduces migration in vitro and invasion in vivo and impairs their ability to form tumor spheres.	Molecular cancer	2010	46
20665378	3091	Rosmorduc O	Hypoxia: a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease.	Seminars in liver disease	2010	46
20864819	3091	Chiavarina B	HIF1-alpha functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells: Autophagy drives compartment-specific oncogenesis.	Cell cycle	2010	75
21278237	3091	Kim TH	NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF-1α.	Cancer research	2011	59
21283755	3091	Wei J	Hypoxia potentiates glioma-mediated immunosuppression.	PloS one	2011	41
21321221	3091	Keunen O	Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma.	Proceedings of the National Academy of Sciences of the United States of America	2011	167
21569415	3091	Rademakers SE	Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1α, CAIX, LDH-5, GLUT-1, MCT1 and MCT4.	BMC cancer	2011	42
21576632	3091	Xu CF	Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.	Journal of clinical oncology 	2011	39
21616142	3091	Batinic-Haberle I	Diverse functions of cationic Mn(III) N-substituted pyridylporphyrins, recognized as SOD mimics.	Free radical biology and medicine	2011	47
21637285	3091	Martin SK	The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma.	Leukemia	2011	37
21654190	3091	Lisanti MP	Accelerated aging in the tumor microenvironment: connecting aging, inflammation and cancer metabolism with personalized medicine.	Cell cycle	2011	35
21664268	3091	Traber MG	Vitamins C and E: beneficial effects from a mechanistic perspective.	Free radical biology and medicine	2011	87
21712410	3091	Mathieu J	HIF induces human embryonic stem cell markers in cancer cells.	Cancer research	2011	139
21782234	3091	Szot CS	3D in vitro bioengineered tumors based on collagen I hydrogels.	Biomaterials	2011	39
21840486	3091	Yuan WC	A Cullin3-KLHL20 Ubiquitin ligase-dependent pathway targets PML to potentiate HIF-1 signaling and prostate cancer progression.	Cancer cell	2011	43
21911388	3091	Wong CC	Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation.	Proceedings of the National Academy of Sciences of the United States of America	2011	92
21917858	3091	Xu Q	MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis.	Nucleic acids research	2012	66
21984483	3091	Jing Y	Cadmium increases HIF-1 and VEGF expression through ROS, ERK, and AKT signaling pathways and induces malignant transformation of human bronchial epithelial cells.	Toxicological sciences 	2012	39
21998407	3091	Kryczek I	Human TH17 cells are long-lived effector memory cells.	Science translational medicine	2011	81
22084398	3091	Zhou Y	Intracellular ATP levels are a pivotal determinant of chemoresistance in colon cancer cells.	Cancer research	2012	46
22231744	3091	Wong CC	Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis.	Journal of molecular medicine	2012	61
22305612	3091	Xia Y	Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors.	European journal of medicinal chemistry	2012	54
22446391	3091	Zhou W	HIF1α induced switch from bivalent to exclusively glycolytic metabolism during ESC-to-EpiSC/hESC transition.	The EMBO journal	2012	102
22645176	3091	Carter BZ	Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML.	Blood	2012	32
22937154	3091	Krishnamachary B	Hypoxia regulates CD44 and its variant isoforms through HIF-1α in triple negative breast cancer.	PloS one	2012	37
22951983	3091	Zhao Y	Targeting Cullin-RING ligases by MLN4924 induces autophagy via modulating the HIF1-REDD1-TSC1-mTORC1-DEPTOR axis.	Cell death and disease	2012	36
23012449	3091	Schito L	Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells.	Proceedings of the National Academy of Sciences of the United States of America	2012	41
23082126	3091	De Saedeleer CJ	Lactate activates HIF-1 in oxidative but not in Warburg-phenotype human tumor cells.	PloS one	2012	33
23321518	3091	Fujiwara S	PDK1 inhibition is a novel therapeutic target in multiple myeloma.	British journal of cancer	2013	29
23358852	3091	Zhang Q	Wnt/β-catenin signaling enhances hypoxia-induced epithelial-mesenchymal transition in hepatocellular carcinoma via crosstalk with hif-1α signaling.	Carcinogenesis	2013	35
23378577	3091	Gilkes DM	Procollagen lysyl hydroxylase 2 is essential for hypoxia-induced breast cancer metastasis.	Molecular cancer research 	2013	45
23389731	3091	Yeh YM	MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting SOX4 and HIF-1α.	International journal of cancer	2013	53
23496980	3091	Zhang L	Hypoxia induces epithelial-mesenchymal transition via activation of SNAI1 by hypoxia-inducible factor -1α in hepatocellular carcinoma.	BMC cancer	2013	48
23533994	3091	Capece D	The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages.	BioMed research international	2013	58
23633488	3091	Spivak-Kroizman TR	Hypoxia triggers hedgehog-mediated tumor-stromal interactions in pancreatic cancer.	Cancer research	2013	29
23674815	3091	Clem BF	Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer.	Molecular cancer therapeutics	2013	35
23842546	3091	Chae YC	Landscape of the mitochondrial Hsp90 metabolome in tumours.	Nature communications	2013	33
23935962	3091	Cheng HH	Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia.	PloS one	2013	39
23999440	3091	Semenza GL	HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations.	The Journal of clinical investigation	2013	215
24366912	3091	Chesnelong C	Lactate dehydrogenase A silencing in IDH mutant gliomas.	Neuro-oncology	2014	23
24434214	3091	Li J	Cbx4 governs HIF-1α to potentiate angiogenesis of hepatocellular carcinoma by its SUMO E3 ligase activity.	Cancer cell	2014	24
24486645	3091	Martinez-Outschoorn UE	Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth.	Seminars in cancer biology	2014	45
24550282	3091	Faubert B	Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1α.	Proceedings of the National Academy of Sciences of the United States of America	2014	38
24599125	3091	Zhao X	Hypoxia-inducible factor-1 promotes pancreatic ductal adenocarcinoma invasion and metastasis by activating transcription of the actin-bundling protein fascin.	Cancer research	2014	25
24670641	3091	Chen X	XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway.	Nature	2014	108
24787293	3091	Martinez-Outschoorn U	Tumor microenvironment and metabolic synergy in breast cancers: critical importance of mitochondrial fuels and function.	Seminars in oncology	2014	37
24843020	3091	Wheaton WW	Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis.	eLife	2014	104
24857547	3091	Ferrer CM	O-GlcNAcylation regulates cancer metabolism and survival stress signaling via regulation of the HIF-1 pathway.	Molecular cell	2014	38
24901645	3091	Chen J	HIF-1α inhibition reverses multidrug resistance in colon cancer cells via downregulation of MDR1/P-glycoprotein.	PloS one	2014	21
25186948	3091	Ye J	Serine catabolism regulates mitochondrial redox control during hypoxia.	Cancer discovery	2014	47
25746953	3091	Shalova IN	Human monocytes undergo functional re-programming during sepsis mediated by hypoxia-inducible factor-1α.	Immunity	2015	26
25891797	3091	Zhou J	miR-33a functions as a tumor suppressor in melanoma by targeting HIF-1α.	Cancer biology and therapy	2015	17
25965573	3091	El-Naggar AM	Translational Activation of HIF1α by YB-1 Promotes Sarcoma Metastasis.	Cancer cell	2015	22
26054020	3091	Guo W	MiR-199a-5p is negatively associated with malignancies and regulates glycolysis and lactate production by targeting hexokinase 2 in liver cancer.	Hepatology	2015	16
26365179	3091	Dupuy F	PDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer.	Cell metabolism	2015	31
26512116	3091	Zhang H	HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells.	Proceedings of the National Academy of Sciences of the United States of America	2015	17
26773935	3091	Barron CC	Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment.	Metabolism	2016	13
26837767	3091	Ye LY	Hypoxia-Induced Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma Induces an Immunosuppressive Tumor Microenvironment to Promote Metastasis.	Cancer research	2016	17
27322552	3091	Lu PH	Aqueous Oldenlandia diffusa extracts inhibits colorectal cancer cells via activating AMP-activated protein kinase signalings.	Oncotarget	2016	21
11438563	3164	Eifel P	National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000.	Journal of the National Cancer Institute	2001	116
14980220	3164	Lin B	Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3.	Cell	2004	174
16030102	3164	Loi S	Obesity and outcomes in premenopausal and postmenopausal breast cancer.	Cancer epidemiology, biomarkers and prevention 	2005	72
16120859	3164	Braun S	A pooled analysis of bone marrow micrometastasis in breast cancer.	The New England journal of medicine	2005	247
16170171	3164	Hershman D	Racial disparities in treatment and survival among women with early-stage breast cancer.	Journal of clinical oncology 	2005	88
16505422	3164	Guarneri V	Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.	Journal of clinical oncology 	2006	106
16892086	3164	Moll UM	p53 and Nur77/TR3 - transcription factors that directly target mitochondria for cell death induction.	Oncogene	2006	64
17130515	3164	Walshe JM	Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer.	Journal of clinical oncology 	2006	66
17142309	3164	Hicks J	Novel patterns of genome rearrangement and their association with survival in breast cancer.	Genome research	2006	113
17239243	3164	Dunnwald LK	Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients.	Breast cancer research 	2007	141
17515897	3164	Mullican SE	Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia.	Nature medicine	2007	84
17557947	3164	Pierce JP	Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity.	Journal of clinical oncology 	2007	91
17954804	3164	Ahn J	Adiposity, adult weight change, and postmenopausal breast cancer risk.	Archives of internal medicine	2007	76
18083636	3164	Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group.	Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.	The Lancet. Oncology	2008	217
18420499	3164	Sparano JA	Weekly paclitaxel in the adjuvant treatment of breast cancer.	The New England journal of medicine	2008	125
18487567	3164	Badve SS	Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory.	Journal of clinical oncology 	2008	58
18678838	3164	Goldstein LJ	Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.	Journal of clinical oncology 	2008	65
18695137	3164	Brewster AM	Residual risk of breast cancer recurrence 5 years after adjuvant therapy.	Journal of the National Cancer Institute	2008	89
19692688	3164	BIG 1-98 Collaborative Group.	Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.	The New England journal of medicine	2009	97
20547990	3164	Sestak I	Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.	Journal of clinical oncology 	2010	55
20625130	3164	Burstein HJ	American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.	Journal of clinical oncology 	2010	185
20697084	3164	Perez EA	HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.	Journal of clinical oncology 	2010	51
20842526	3164	Campbell MJ	Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome.	Breast cancer research and treatment	2011	54
21428963	3164	McMorrow JP	Inflammation: a role for NR4A orphan nuclear receptors?	Biochemical Society transactions	2011	42
21802721	3164	Early Breast Cancer Trialists' Collaborative Group (EBCTCG).	Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.	Lancet	2011	359
21922245	3164	Livaudais JC	Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer.	Breast cancer research and treatment	2012	30
21987386	3164	Brufsky AM	Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole.	Cancer	2012	36
22331951	3164	Henry NL	Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer.	Journal of clinical oncology 	2012	54
22585699	3164	Hassett MJ	Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer.	Journal of clinical oncology 	2012	34
22821401	3164	Kabos P	Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.	Breast cancer research and treatment	2012	37
22853014	3164	Mehta RS	Combination anastrozole and fulvestrant in metastatic breast cancer.	The New England journal of medicine	2012	58
23358971	3164	Goss PE	Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.	Journal of clinical oncology 	2013	43
23414585	3164	Robertson JF	Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial.	The Lancet. Oncology	2013	32
23845225	3164	Sieh W	Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.	The Lancet. Oncology	2013	57
24375928	3164	Munsell MF	Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status.	Epidemiologic reviews	2014	27
24868023	3164	Burstein HJ	Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update.	Journal of clinical oncology 	2014	93
25495490	3164	Francis PA	Adjuvant ovarian suppression in premenopausal breast cancer.	The New England journal of medicine	2015	64
26040322	3164	Huo CW	High mammographic density is associated with an increase in stromal collagen and immune cells within the mammary epithelium.	Breast cancer research 	2015	17
26628368	3164	Nguyen D	A Polyadenylation-Dependent 3' End Maturation Pathway Is Required for the Synthesis of the Human Telomerase RNA.	Cell reports	2015	18
26884586	3164	Burstein HJ	Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression.	Journal of clinical oncology 	2016	11
27264120	3164	Goss PE	Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.	The New England journal of medicine	2016	19
2547513	3265	Bos JL	ras oncogenes in human cancer: a review.	Cancer research	1989	956
6298635	3265	Capon DJ	Complete nucleotide sequences of the T24 human bladder carcinoma oncogene and its normal homologue.	Nature	1983	213
9162087	3265	Whyte DB	K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors.	The Journal of biological chemistry	1997	142
9219684	3265	Scheffzek K	The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants.	Science	1997	327
10440377	3265	Hahn WC	Creation of human tumour cells with defined genetic elements.	Nature	1999	555
11175856	3265	D'Cruz CM	c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations.	Nature medicine	2001	132
11884599	3265	Hahn WC	Enumeration of the simian virus 40 early region elements necessary for human cell transformation.	Molecular and cellular biology	2002	198
12727991	3265	Nikiforova MN	RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.	The Journal of clinical endocrinology and metabolism	2003	103
15188009	3265	Bamford S	The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website.	British journal of cancer	2004	351
15840712	3265	Ramanathan A	Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements.	Proceedings of the National Academy of Sciences of the United States of America	2005	109
16170316	3265	Aoki Y	Germline mutations in HRAS proto-oncogene cause Costello syndrome.	Nature genetics	2005	149
17263520	3265	Gorfe AA	Structure and dynamics of the full-length lipid-modified H-Ras protein in a 1,2-dimyristoylglycero-3-phosphocholine bilayer.	Journal of medicinal chemistry	2007	59
17568748	3265	Yagoda N	RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels.	Nature	2007	125
18344980	3265	Lim KH	Tumour maintenance is mediated by eNOS.	Nature	2008	97
21119005	3265	Lock R	Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation.	Molecular biology of the cell	2011	134
21325462	3265	Moura MM	High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.	The Journal of clinical endocrinology and metabolism	2011	37
21779495	3265	Castellano E	Functional specificity of ras isoforms: so similar but so different.	Genes and cancer	2011	47
21779504	3265	Fernández-Medarde A	Ras in cancer and developmental diseases.	Genes and cancer	2011	130
22241789	3265	Hayes DN	Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements.	Clinical cancer research 	2012	36
22589270	3265	Prior IA	A comprehensive survey of Ras mutations in cancer.	Cancer research	2012	192
23245831	3265	Mannava S	Depletion of deoxyribonucleotide pools is an endogenous source of DNA damage in cells undergoing oncogene-induced senescence.	The American journal of pathology	2013	27
23264394	3265	Agrawal N	Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS.	The Journal of clinical endocrinology and metabolism	2013	34
23640968	3265	Crona J	Somatic mutations in H-RAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing.	The Journal of clinical endocrinology and metabolism	2013	25
24695311	3265	Cleary AS	Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers.	Nature	2014	71
24715691	3265	Abd Elmageed ZY	Neoplastic reprogramming of patient-derived adipose stem cells by prostate cancer cell-associated exosomes.	Stem cells	2014	44
25086355	3265	Lee TH	Oncogenic ras-driven cancer cell vesiculation leads to emission of double-stranded DNA capable of interacting with target cells.	Biochemical and biophysical research communications	2014	27
25514803	3265	Lo Iacono M	Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study.	Journal of thoracic oncology 	2015	21
26276366	3265	Nishida T	The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines.	Gastric cancer 	2016	18
26985062	3265	Hobbs GA	RAS isoforms and mutations in cancer at a glance.	Journal of cell science	2016	17
18772396	3417	Parsons DW	An integrated genomic analysis of human glioblastoma multiforme.	Science	2008	1466
19228619	3417	Yan H	IDH1 and IDH2 mutations in gliomas.	The New England journal of medicine	2009	972
19246647	3417	Watanabe T	IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.	The American journal of pathology	2009	185
19378339	3417	Kang MR	Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers.	International journal of cancer	2009	86
19554337	3417	Hartmann C	Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.	Acta neuropathologica	2009	219
19636000	3417	Sanson M	Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.	Journal of clinical oncology 	2009	178
19657110	3417	Mardis ER	Recurring mutations found by sequencing an acute myeloid leukemia genome.	The New England journal of medicine	2009	605
19737147	3417	Ohgaki H	Genetic alterations and signaling pathways in the evolution of gliomas.	Cancer science	2009	99
19755387	3417	Nobusawa S	IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas.	Clinical cancer research 	2009	117
19805672	3417	Weller M	Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.	Journal of clinical oncology 	2009	135
19935646	3417	Dang L	Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.	Nature	2009	672
20097881	3417	Chou WC	Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation.	Blood	2010	56
20127344	3417	Bleeker FE	The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma.	Acta neuropathologica	2010	68
20142433	3417	Gross S	Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.	The Journal of experimental medicine	2010	183
20160062	3417	van den Bent MJ	IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.	Clinical cancer research 	2010	88
20171147	3417	Ward PS	The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.	Cancer cell	2010	426
20368543	3417	Marcucci G	IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.	Journal of clinical oncology 	2010	179
20399149	3417	Noushmehr H	Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.	Cancer cell	2010	587
20410924	3417	Pardanani A	IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms.	Leukemia	2010	41
20427748	3417	Labussière M	All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2.	Neurology	2010	56
20508616	3417	Tefferi A	IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.	Leukemia	2010	72
20513808	3417	Reitman ZJ	Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism.	Journal of the National Cancer Institute	2010	101
20567020	3417	Paschka P	IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.	Journal of clinical oncology 	2010	152
20625116	3417	Boissel N	Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group.	Journal of clinical oncology 	2010	45
20724988	3417	Pardanani A	LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations.	Leukemia	2010	42
20805365	3417	Schnittger S	IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status.	Blood	2010	41
20975057	3417	Houillier C	IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.	Neurology	2010	84
21075857	3417	Kim YH	Molecular classification of low-grade diffuse gliomas.	The American journal of pathology	2010	43
21088844	3417	Hartmann C	Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.	Acta neuropathologica	2010	98
21130701	3417	Figueroa ME	Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.	Cancer cell	2010	586
21163902	3417	Christensen BC	DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma.	Journal of the National Cancer Institute	2011	89
21289278	3417	Reitman ZJ	Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome.	Proceedings of the National Academy of Sciences of the United States of America	2011	143
21326614	3417	Jin G	2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.	PloS one	2011	47
21598255	3417	Amary MF	IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours.	The Journal of pathology	2011	161
22015945	3417	Pope WB	Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.	Journal of neuro-oncology	2012	57
22052461	3417	Jin SG	5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations.	Cancer research	2011	110
22101433	3417	Metallo CM	Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia.	Nature	2011	387
22180306	3417	Borger DR	Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.	The oncologist	2012	126
22238332	3417	Andronesi OC	Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy.	Science translational medicine	2012	78
22238333	3417	Elkhaled A	Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas.	Science translational medicine	2012	50
22270850	3417	Bleeker FE	Recent advances in the molecular understanding of glioblastoma.	Journal of neuro-oncology	2012	36
22281806	3417	Choi C	2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas.	Nature medicine	2012	130
22343889	3417	Turcan S	IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.	Nature	2012	385
22343901	3417	Lu C	IDH mutation impairs histone demethylation and results in a block to cell differentiation.	Nature	2012	379
22391558	3417	Yang H	Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation.	Oncogene	2013	124
22415316	3417	Gorovets D	IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma.	Clinical cancer research 	2012	40
22829908	3417	Orr BA	Decreased 5-hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma.	PloS one	2012	39
22899282	3417	Duncan CG	A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation.	Genome research	2012	48
22990979	3417	Zhang W	Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme.	Cancer	2013	32
23071237	3417	van den Bent MJ	Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.	Journal of clinical oncology 	2013	134
23090983	3417	Yan W	Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group.	Neuro-oncology	2012	46
23095825	3417	Weller M	Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.	Neuro-oncology	2012	31
23115158	3417	Li S	Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.	Neuro-oncology	2013	30
23209033	3417	Ohgaki H	The definition of primary and secondary glioblastoma.	Clinical cancer research 	2013	107
23393090	3417	Losman JA	(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible.	Science	2013	147
23558173	3417	Wang F	Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.	Science	2013	152
23641016	3417	DiNardo CD	Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia.	Blood	2013	35
23793099	3417	Tönjes M	BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1.	Nature medicine	2013	63
23801749	3417	Hughes LA	The CpG island methylator phenotype: what's in a name?	Cancer research	2013	40
23896276	3417	Weller M	Molecular neuro-oncology in clinical practice: a new horizon.	The Lancet. Oncology	2013	30
23954893	3417	Chaturvedi A	Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.	Blood	2013	43
24068788	3417	Wick W	Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.	Neurology	2013	31
24077805	3417	Borodovsky A	5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft.	Oncotarget	2013	31
24333121	3417	Emadi A	Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations.	Experimental hematology	2014	32
24478380	3417	Borger DR	Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.	Clinical cancer research 	2014	23
24516018	3417	Cairncross JG	Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.	Journal of clinical oncology 	2014	50
24722048	3417	Killela PJ	Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas.	Oncotarget	2014	45
24810474	3417	Cai J	ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples samples.	Oncotarget	2014	22
24857658	3417	Mullen AR	Oxidation of alpha-ketoglutarate is required for reductive carboxylation in cancer cells with mitochondrial defects.	Cell reports	2014	54
25043048	3417	Schumacher T	A vaccine targeting mutant IDH1 induces antitumour immunity.	Nature	2014	73
25091696	3417	Tang X	A joint analysis of metabolomics and genetics of breast cancer.	Breast cancer research 	2014	26
25132561	3417	Huang Y	Connections between TET proteins and aberrant DNA modification in cancer.	Trends in genetics 	2014	41
25143301	3417	Sahm F	Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma.	Acta neuropathologica	2014	32
25369307	3417	Rizvi S	Cholangiocarcinoma: molecular pathways and therapeutic opportunities.	Seminars in liver disease	2014	27
25599133	3417	Chan SM	Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.	Nature medicine	2015	41
25701198	3417	Olar A	IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas.	Acta neuropathologica	2015	17
25783747	3417	Weller M	Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.	Acta neuropathologica	2015	26
26061751	3417	Cancer Genome Atlas Research Network.	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.	The New England journal of medicine	2015	209
26212717	3417	Intlekofer AM	Hypoxia Induces Production of L-2-Hydroxyglutarate.	Cell metabolism	2015	41
26534967	3417	Andronesi OC	Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate.	Clinical cancer research 	2016	11
26669865	3417	Emir UE	Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations.	Cancer research	2016	14
26691210	3417	de la Fuente MI	Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma.	Neuro-oncology	2016	18
26901439	3417	Reznik E	Mitochondrial DNA copy number variation across human cancers.	eLife	2016	20
27005468	3417	Dang L	IDH mutations in cancer and progress toward development of targeted therapeutics.	Annals of oncology 	2016	16
27157931	3417	Louis DN	The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.	Acta neuropathologica	2016	233
27270107	3417	Wang J	Clonal evolution of glioblastoma under therapy.	Nature genetics	2016	15
27806376	3417	Tirosh I	Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma.	Nature	2016	17
1907934	3439	Taylor MW	Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism.	FASEB journal 	1991	203
6313211	3439	Zinn K	Identification of two distinct regulatory regions adjacent to the human beta-interferon gene.	Cell	1983	344
11507197	3439	Guo JT	Effect of alpha interferon on the hepatitis C virus replicon.	Journal of virology	2001	159
11927189	3439	Capuron L	Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions.	Neuropsychopharmacology 	2002	150
12766484	3439	Chawla-Sarkar M	Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis.	Apoptosis 	2003	184
14500688	3439	Bharti AC	Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells.	Journal of immunology	2003	117
14573318	3439	Capuron L	Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment.	Biological psychiatry	2003	92
15625368	3439	McDermott DF	Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.	Journal of clinical oncology 	2005	104
15697325	3439	Raison CL	Neuropsychiatric adverse effects of interferon-alpha: recognition and management.	CNS drugs	2005	93
16293610	3439	Ito T	Specialization, kinetics, and repertoire of type 1 interferon responses by human plasmacytoid predendritic cells.	Blood	2006	68
16632604	3439	Herbeuval JP	Differential expression of IFN-alpha and TRAIL/DR5 in lymphoid tissue of progressor versus nonprogressor HIV-1-infected patients.	Proceedings of the National Academy of Sciences of the United States of America	2006	86
17488182	3439	Critchley-Thorne RJ	Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma.	PLoS medicine	2007	56
17678633	3439	Felger JC	Effects of interferon-alpha on rhesus monkeys: a nonhuman primate model of cytokine-induced depression.	Biological psychiatry	2007	58
18424722	3439	Errington F	Reovirus activates human dendritic cells to promote innate antitumor immunity.	Journal of immunology	2008	58
18650451	3439	Kiladjian JJ	Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.	Blood	2008	83
18936475	3439	Rini BI	Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.	Journal of clinical oncology 	2008	202
19171708	3439	Escudier B	Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.	Journal of clinical oncology 	2009	101
19229667	3439	Dutcher JP	Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies.	Medical oncology	2009	53
19451644	3439	Critchley-Thorne RJ	Impaired interferon signaling is a common immune defect in human cancer.	Proceedings of the National Academy of Sciences of the United States of America	2009	64
19487381	3439	Motzer RJ	Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.	Journal of clinical oncology 	2009	413
20178101	3439	Garrido F	"Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy.	International journal of cancer	2010	49
20179267	3439	Mocellin S	Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.	Journal of the National Cancer Institute	2010	83
20368553	3439	Escudier B	Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.	Journal of clinical oncology 	2010	152
20368558	3439	Rini BI	Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.	Journal of clinical oncology 	2010	170
21199525	3439	Yuen MF	Treatment of chronic hepatitis B: Evolution over two decades.	Journal of gastroenterology and hepatology	2011	43
21604071	3439	Mundy-Bosse BL	Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4⁺ T cells from patients with GI malignancy.	Cancer immunology, immunotherapy 	2011	46
22806323	3439	Lai CL	Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy.	Hepatology	2013	35
24297945	3439	Rini BI	Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.	Journal of clinical oncology 	2014	29
11694888	3480	Favelyukis S	Structure and autoregulation of the insulin-like growth factor 1 receptor kinase.	Nature structural biology	2001	91
11782378	3480	Chakravarti A	Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling.	Cancer research	2002	111
14695887	3480	Mitsiades CS	Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications.	Proceedings of the National Academy of Sciences of the United States of America	2004	148
16931767	3480	Samani AA	The role of the IGF system in cancer growth and metastasis: overview and recent insights.	Endocrine reviews	2007	256
17296734	3480	Kim HJ	Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-kappaB and snail.	Molecular and cellular biology	2007	74
17875788	3480	Rowinsky EK	IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor.	Clinical cancer research 	2007	68
18927274	3480	Chitnis MM	The type 1 insulin-like growth factor receptor pathway.	Clinical cancer research 	2008	115
19074892	3480	Law JH	Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival.	Cancer research	2008	112
19649631	3480	Haluska P	Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma.	Cancer chemotherapy and pharmacology	2010	45
19789339	3480	Kurmasheva RT	The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.	Cancer research	2009	56
19806209	3480	Gong Y	High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507).	PloS one	2009	56
20036194	3480	Olmos D	Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study.	The Lancet. Oncology	2010	100
20351332	3480	Dziadziuszko R	Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression.	Journal of clinical oncology 	2010	45
20710042	3480	Aleksic T	Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells.	Cancer research	2010	53
20713879	3480	Reidy DL	Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer.	Journal of clinical oncology 	2010	47
20819078	3480	Jiang L	MicroRNA-7 targets IGF1R (insulin-like growth factor 1 receptor) in tongue squamous cell carcinoma cells.	The Biochemical journal	2010	59
21102589	3480	Gualberto A	Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab.	British journal of cancer	2011	37
21156289	3480	Villanueva J	Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.	Cancer cell	2010	376
21177763	3480	Litzenburger BC	High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy.	Clinical cancer research 	2011	37
21382550	3480	Lehtinen MK	The cerebrospinal fluid provides a proliferative niche for neural progenitor cells.	Neuron	2011	144
21425998	3480	Mulvihill MJ	Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor.	Future medicinal chemistry	2009	69
21595894	3480	Zhang Y	Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes.	Breast cancer research 	2011	41
21807868	3480	Medyouf H	High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling.	The Journal of experimental medicine	2011	43
21840990	3480	Iozzo RV	Decorin antagonizes IGF receptor I (IGF-IR) function by interfering with IGF-IR activity and attenuating downstream signaling.	The Journal of biological chemistry	2011	47
21908557	3480	Fox EM	A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer.	Cancer research	2011	51
22025149	3480	Pappo AS	R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study.	Journal of clinical oncology 	2011	89
22215905	3480	Pollak M	The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology.	Clinical cancer research 	2012	34
22239439	3480	Tognon CE	Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy.	Expert opinion on therapeutic targets	2012	30
22337149	3480	Pollak M	The insulin and insulin-like growth factor receptor family in neoplasia: an update.	Nature reviews. Cancer	2012	240
22416079	3480	Romero I	Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy.	Endocrinology	2012	69
22473773	3480	Shan J	Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma.	Hepatology	2012	67
22508822	3480	Tap WD	Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors.	Journal of clinical oncology 	2012	49
22614005	3480	Zhao X	MicroRNA-7 functions as an anti-metastatic microRNA in gastric cancer by targeting insulin-like growth factor-1 receptor.	Oncogene	2013	69
22700995	3480	Kindler HL	A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer.	Annals of oncology 	2012	50
22710713	3480	Guo ST	MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer.	Oncogene	2013	64
22935141	3480	Xu Q	A regulatory circuit of miR-148a/152 and DNMT1 in modulating cell transformation and tumor angiogenesis through IGF-IR and IRS1.	Journal of molecular cell biology	2013	48
23453369	3480	Luo M	MicroRNA-497 is a potential prognostic marker in human cervical cancer and functions as a tumor suppressor by targeting the insulin-like growth factor 1 receptor.	Surgery	2013	39
24338270	3480	Singh P	Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer.	Medical oncology	2014	39
24439931	3480	Rajan A	Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial.	The Lancet. Oncology	2014	25
24489728	3480	Murakami A	Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor.	PloS one	2014	25
24550888	3480	Malaguarnera R	The emerging role of insulin and insulin-like growth factor signaling in cancer stem cells.	Frontiers in endocrinology	2014	27
24668028	3480	Chen WJ	Cancer-associated fibroblasts regulate the plasticity of lung cancer stemness via paracrine signalling.	Nature communications	2014	37
24797726	3480	Pappo AS	A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study.	Cancer	2014	32
24888810	3480	Langer CJ	Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer.	Journal of clinical oncology 	2014	38
25099143	3480	He M	Integrated immunoisolation and protein analysis of circulating exosomes using microfluidic technology.	Lab on a chip	2014	27
25123819	3480	King H	Can we unlock the potential of IGF-1R inhibition in cancer therapy?	Cancer treatment reviews	2014	34
25795408	3480	Fassnacht M	Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study.	The Lancet. Oncology	2015	29
3264384	3558	Rosenberg SA	Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.	The New England journal of medicine	1988	246
3493432	3558	Rosenberg SA	A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.	The New England journal of medicine	1987	221
6327821	3558	Weiss A	The role of T3 surface molecules in the activation of human T cells: a two-stimulus requirement for IL 2 production reflects events occurring at a pre-translational level.	Journal of immunology	1984	179
7523571	3558	Carson WE	Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor.	The Journal of experimental medicine	1994	200
8011282	3558	Romagnani S	Lymphokine production by human T cells in disease states.	Annual review of immunology	1994	169
8028037	3558	Rosenberg SA	Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.	Journal of the National Cancer Institute	1994	157
8120958	3558	Rosenberg SA	Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.	JAMA	1994	150
9500606	3558	Rosenberg SA	Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.	Nature medicine	1998	274
10358752	3558	Waldmann TA	The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens.	Annual review of immunology	1999	139
10685652	3558	Atkins MB	High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update.	The cancer journal from Scientific American	2000	117
10699311	3558	Sudimack J	Targeted drug delivery via the folate receptor.	Advanced drug delivery reviews	2000	117
10887096	3558	Kunzmann V	Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma.	Blood	2000	98
11022927	3558	Takayama T	Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.	Lancet	2000	135
11357146	3558	Rosenberg SA	Progress in human tumour immunology and immunotherapy.	Nature	2001	236
11565838	3558	Dudley ME	Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma.	Journal of immunotherapy	2001	108
12000866	3558	Dudley ME	A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma.	Journal of immunotherapy	2002	86
12082564	3558	Capuron L	Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy.	Molecular psychiatry	2002	99
12427970	3558	Yee C	Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.	Proceedings of the National Academy of Sciences of the United States of America	2002	320
12623838	3558	Wilhelm M	Gammadelta T cells for immune therapy of patients with lymphoid malignancies.	Blood	2003	109
12843795	3558	Dudley ME	Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients.	Journal of immunotherapy	2003	157
12915604	3558	Yang JC	Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer.	Journal of clinical oncology 	2003	110
14961035	3558	Imai C	Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia.	Leukemia	2004	141
14974943	3558	Opelz G	Lymphomas after solid organ transplantation: a collaborative transplant study report.	American journal of transplantation 	2004	79
15141157	3558	Nakamura K	Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model.	Gene therapy	2004	141
15632206	3558	Miller JS	Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.	Blood	2005	340
15638853	3558	Hayashi T	Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.	British journal of haematology	2005	70
15674877	3558	Coppin C	Immunotherapy for advanced renal cell cancer.	The Cochrane database of systematic reviews	2005	88
15800326	3558	Dudley ME	Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.	Journal of clinical oncology 	2005	443
15897568	3558	Atkins M	Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.	Clinical cancer research 	2005	68
15980149	3558	Klebanoff CA	Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells.	Proceedings of the National Academy of Sciences of the United States of America	2005	231
16121185	3558	Watanabe N	Hassall's corpuscles instruct dendritic cells to induce CD4+CD25+ regulatory T cells in human thymus.	Nature	2005	162
16224276	3558	Attia P	Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.	Journal of immunotherapy	2005	70
16308572	3558	Dannull J	Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.	The Journal of clinical investigation	2005	257
16364519	3558	Farag SS	Human natural killer cell development and biology.	Blood reviews	2006	79
16763205	3558	Banerjee DK	Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients.	Blood	2006	94
17025272	3558	Kreitman RJ	Immunotoxins for targeted cancer therapy.	The AAPS journal	2006	68
17075125	3558	Mackensen A	Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.	Journal of clinical oncology 	2006	92
17108138	3558	Kowolik CM	CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.	Cancer research	2006	155
17671216	3558	Clayton A	Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2.	Cancer research	2007	106
18000167	3558	Lange BJ	Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group.	Blood	2008	73
18281670	3558	Testori A	Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group.	Journal of clinical oncology 	2008	69
18334676	3558	Ferrajoli A	Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.	Blood	2008	105
18457330	3558	Klapper JA	High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006.	Cancer	2008	60
18508251	3558	Curiel TJ	Regulatory T cells and treatment of cancer.	Current opinion in immunology	2008	66
18509084	3558	Till BG	Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.	Blood	2008	185
18559587	3558	Bergmann C	T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease.	Clinical cancer research 	2008	56
18779745	3558	Tran KQ	Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy.	Journal of immunotherapy	2008	61
18809613	3558	Dudley ME	Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.	Journal of clinical oncology 	2008	389
19001327	3558	Atkins MB	Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group.	Journal of clinical oncology 	2008	57
19265131	3558	Castriconi R	NK cells recognize and kill human glioblastoma cells with stem cell-like properties.	Journal of immunology	2009	54
19364969	3558	Sabatino M	Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy.	Journal of clinical oncology 	2009	49
19383914	3558	Fujisaki H	Expansion of highly cytotoxic human natural killer cells for cancer cell therapy.	Cancer research	2009	103
19465693	3558	Chung DJ	Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells.	Blood	2009	83
19544689	3558	Bhatia S	Treatment of metastatic melanoma: an overview.	Oncology	2009	95
19726501	3558	Migueles SA	Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy.	Journal of virology	2009	67
20068175	3558	Schatton T	Modulation of T-cell activation by malignant melanoma initiating cells.	Cancer research	2010	66
20085940	3558	Rubnitz JE	NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.	Journal of clinical oncology 	2010	118
20304086	3558	Jensen MC	Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans.	Biology of blood and marrow transplantation 	2010	119
20406835	3558	Besser MJ	Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.	Clinical cancer research 	2010	105
20439625	3558	Abès R	Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response.	Blood	2010	55
20491785	3558	Meraviglia S	In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients.	Clinical and experimental immunology	2010	57
20557286	3558	Heller LC	Electroporation gene therapy preclinical and clinical trials for melanoma.	Current gene therapy	2010	41
20558731	3558	Mandapathil M	Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells.	The Journal of biological chemistry	2010	47
20651070	3558	Görgün G	Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma.	Blood	2010	47
20668005	3558	Dudley ME	CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma.	Clinical cancer research 	2010	60
20680271	3558	Bachanova V	Allogeneic natural killer cells for refractory lymphoma.	Cancer immunology, immunotherapy 	2010	46
20736326	3558	Jacobs JF	Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients.	Clinical cancer research 	2010	50
20849361	3558	Geller MA	A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer.	Cytotherapy	2011	84
20881001	3558	Amato RJ	Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study.	Clinical cancer research 	2010	44
20921469	3558	Shusterman S	Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.	Journal of clinical oncology 	2010	61
20935224	3558	Delgado DC	Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy.	Cancer research	2010	50
20952687	3558	Brunstein CG	Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics.	Blood	2011	272
20978269	3558	Hsu AK	The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy.	Blood	2011	43
21212434	3558	Garbe C	Systematic review of medical treatment in melanoma: current status and future prospects.	The oncologist	2011	78
21389874	3558	Hernandez-Chacon JA	Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.	Journal of immunotherapy	2011	37
21498393	3558	Rosenberg SA	Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.	Clinical cancer research 	2011	412
21631324	3558	Schwartzentruber DJ	gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.	The New England journal of medicine	2011	208
21771874	3558	Lesterhuis WJ	Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.	Clinical cancer research 	2011	39
21791425	3558	Curti A	Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients.	Blood	2011	69
22129252	3558	Koreth J	Interleukin-2 and regulatory T cells in graft-versus-host disease.	The New England journal of medicine	2011	209
22160384	3558	Kochenderfer JN	B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.	Blood	2012	345
22275504	3558	Liu L	Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma.	Clinical cancer research 	2012	37
22311675	3558	Andersen RS	Dissection of T-cell antigen specificity in human melanoma.	Cancer research	2012	44
22393002	3558	Chapuis AG	Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype.	Proceedings of the National Academy of Sciences of the United States of America	2012	47
22461638	3558	Rosenberg SA	Raising the bar: the curative potential of human cancer immunotherapy.	Science translational medicine	2012	75
22555974	3558	Yao X	Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer.	Blood	2012	44
22674552	3558	Seung SK	Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses.	Science translational medicine	2012	56
23369684	3558	Jang S	Which drug, and when, for patients with BRAF-mutant melanoma?	The Lancet. Oncology	2013	45
23552371	3558	Matsuoka K	Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease.	Science translational medicine	2013	93
23639322	3558	Lippitz BE	Cytokine patterns in patients with cancer: a systematic review.	The Lancet. Oncology	2013	136
23650429	3558	Dudley ME	Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma.	Journal of clinical oncology 	2013	44
23741305	3558	Singh H	Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells.	PloS one	2013	39
23982524	3558	Kaufman HL	The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.	Nature reviews. Clinical oncology	2013	37
24094496	3558	Tonn T	Treatment of patients with advanced cancer with the natural killer cell line NK-92.	Cytotherapy	2013	40
24573552	3558	Kennedy-Nasser AA	Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity.	Clinical cancer research 	2014	32
24577748	3558	Ackerman A	Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors.	Cancer	2014	29
24719405	3558	Bachanova V	Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.	Blood	2014	59
24782509	3558	Xu Y	Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15.	Blood	2014	59
24907378	3558	Rosenberg SA	IL-2: the first effective immunotherapy for human cancer.	Journal of immunology	2014	84
25060490	3558	McDermott D	Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma.	Cancer treatment reviews	2014	37
25415285	3558	Szmania S	Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients.	Journal of immunotherapy	2015	24
25503054	3558	Schuetz A	Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activation.	PLoS pathogens	2014	48
25695689	3558	Zhang L	Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma.	Clinical cancer research 	2015	29
25747273	3558	Lee JH	Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.	Gastroenterology	2015	31
25850950	3558	Katz SC	Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases.	Clinical cancer research 	2015	23
25940712	3558	Ninomiya S	Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs.	Blood	2015	25
27073224	3558	Koreth J	Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease.	Blood	2016	15
8628398	3717	Meydan N	Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor.	Nature	1996	150
11326271	3717	Yoshikawa H	SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity.	Nature genetics	2001	126
15781101	3717	Baxter EJ	Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.	Lancet	2005	632
15793561	3717	James C	A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.	Nature	2005	653
15837627	3717	Levine RL	Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.	Cancer cell	2005	608
15858187	3717	Kralovics R	A gain-of-function mutation of JAK2 in myeloproliferative disorders.	The New England journal of medicine	2005	669
15863514	3717	Zhao R	Identification of an acquired JAK2 mutation in polycythemia vera.	The Journal of biological chemistry	2005	161
16037387	3717	Jelinek J	JAK2 mutation 1849G&amp;gt;T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia.	Blood	2005	73
16081687	3717	Levine RL	The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.	Blood	2005	77
16325696	3717	Campbell PJ	Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.	Lancet	2005	83
16772604	3717	Scott LM	Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia.	Blood	2006	67
17198871	3717	Nussenzveig RH	Polycythemia vera is not initiated by JAK2V617F mutation.	Experimental hematology	2007	69
17267906	3717	Scott LM	JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.	The New England journal of medicine	2007	223
17363731	3717	Theocharides A	Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.	Blood	2007	65
17379742	3717	Vannucchi AM	Clinical profile of homozygous JAK2 617V&amp;gt;F mutation in patients with polycythemia vera or essential thrombocythemia.	Blood	2007	63
17488875	3717	Tefferi A	Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.	Blood	2007	134
17564968	3717	Yamamoto G	Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays.	American journal of human genetics	2007	87
17721432	3717	Levine RL	Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders.	Nature reviews. Cancer	2007	134
17976518	3717	Bruchova H	Regulated expression of microRNAs in normal and polycythemia vera erythropoiesis.	Experimental hematology	2007	64
18160670	3717	Tiedt R	Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice.	Blood	2008	123
18496562	3717	Vannucchi AM	Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.	Leukemia	2008	58
18779404	3717	Levine RL	Myeloproliferative disorders.	Blood	2008	93
18805579	3717	Bercovich D	Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome.	Lancet	2008	91
19118003	3717	Shin DS	Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells.	Cancer research	2009	56
19350687	3717	Gao H	Activation of signal transducers and activators of transcription 3 and focal adhesion kinase by stromal cell-derived factor 1 is required for migration of human mesenchymal stem cells in response to tumor cell-conditioned medium.	Stem cells	2009	48
19474426	3717	Delhommeau F	Mutation in TET2 in myeloid cancers.	The New England journal of medicine	2009	411
19826111	3717	Quintás-Cardama A	Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.	Journal of clinical oncology 	2009	59
19962667	3717	Hedvat M	The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors.	Cancer cell	2009	194
19965641	3717	Hertzberg L	Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group.	Blood	2010	85
20008298	3717	Santos FP	Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.	Blood	2010	61
20008300	3717	Beer PA	Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm.	Blood	2010	63
20061559	3717	Schaub FX	Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms.	Blood	2010	46
20548334	3717	Ding L	MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2.	Cell research	2010	86
20631743	3717	Passamonti F	A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications.	Leukemia	2010	54
21220608	3717	Pardanani A	Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.	Journal of clinical oncology 	2011	111
21283107	3717	Quintás-Cardama A	Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.	Nature reviews. Drug discovery	2011	74
21841788	3717	Ungureanu D	The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling.	Nature structural and molecular biology	2011	55
22319590	3717	Looyenga BD	STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma.	PloS one	2012	35
22385957	3717	Hou Y	Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm.	Cell	2012	160
22820988	3717	Bandaranayake RM	Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F.	Nature structural and molecular biology	2012	38
22869151	3717	Vainchenker W	JAK/STAT signaling in hematological malignancies.	Oncogene	2013	63
23216616	3717	Marchioli R	Cardiovascular events and intensity of treatment in polycythemia vera.	The New England journal of medicine	2013	56
23382536	3717	Hiatt JB	Single molecule molecular inversion probes for targeted, high-accuracy detection of low-frequency variation.	Genome research	2013	68
23823316	3717	Barbui T	Myeloproliferative neoplasms and thrombosis.	Blood	2013	27
23929215	3717	Wyspiańska BS	BET protein inhibition shows efficacy against JAK2V617F-driven neoplasms.	Leukemia	2014	20
24441292	3717	Tefferi A	An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms.	Leukemia	2014	41
24478400	3717	Lundberg P	Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.	Blood	2014	71
24740812	3717	Rampal R	Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.	Blood	2014	55
24786775	3717	Cazzola M	From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms.	Blood	2014	32
24986690	3717	Rumi E	Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.	Blood	2014	32
25037629	3717	Tefferi A	Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.	Blood	2014	35
25418680	3717	Smith C	Efficient and allele-specific genome editing of disease loci in human iPSCs.	Molecular therapy 	2015	31
25572172	3717	Kleppe M	JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.	Cancer discovery	2015	27
25671252	3717	Ortmann CA	Effect of mutation order on myeloproliferative neoplasms.	The New England journal of medicine	2015	55
26332546	3717	Baerlocher GM	Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia.	The New England journal of medicine	2015	16
26817954	3717	Araki M	Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms.	Blood	2016	18
9892193	3791	Fong TA	SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.	Cancer research	1999	145
10022831	3791	Soldi R	Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2.	The EMBO journal	1999	118
10487832	3791	Maniotis AJ	Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry.	The American journal of pathology	1999	309
11781231	3791	Scharenberg CW	The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors.	Blood	2002	150
15082792	3791	Shao R	Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression.	Molecular and cellular biology	2004	85
15172975	3791	Tong RT	Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors.	Cancer research	2004	250
15800227	3791	Stallone G	Sirolimus for Kaposi's sarcoma in renal-transplant recipients.	The New England journal of medicine	2005	140
15899831	3791	Wedge SR	AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.	Cancer research	2005	160
16391297	3791	Wedam SB	Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer.	Journal of clinical oncology 	2006	129
16397235	3791	LaMontagne K	Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization.	Cancer research	2006	74
17473195	3791	Norden-Zfoni A	Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.	Clinical cancer research 	2007	63
17878479	3791	Heymach JV	Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer.	Journal of clinical oncology 	2007	61
18559524	3791	Hilberg F	BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.	Cancer research	2008	123
18818406	3791	Swendeman S	VEGF-A stimulates ADAM17-dependent shedding of VEGFR2 and crosstalk between VEGFR2 and ERK signaling.	Circulation research	2008	58
18977327	3791	Würdinger T	miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells.	Cancer cell	2008	120
19007739	3791	Norden AD	Novel anti-angiogenic therapies for malignant gliomas.	The Lancet. Neurology	2008	50
19587327	3791	Plotkin SR	Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.	The New England journal of medicine	2009	71
19736552	3791	Ivy SP	An overview of small-molecule inhibitors of VEGFR signaling.	Nature reviews. Clinical oncology	2009	68
19935794	3791	Bengala C	Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.	British journal of cancer	2010	47
20048182	3791	Spratlin JL	Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.	Journal of clinical oncology 	2010	102
20351323	3791	Choueiri TK	Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.	Journal of clinical oncology 	2010	60
20368568	3791	Lam ET	Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.	Journal of clinical oncology 	2010	61
20371662	3791	Robinson BG	Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.	The Journal of clinical endocrinology and metabolism	2010	41
20472683	3791	Eder JP	A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.	Clinical cancer research 	2010	56
20488920	3791	Jutooru I	Methyl 2-cyano-3,12-dioxooleana-1,9-dien-28-oate decreases specificity protein transcription factors and inhibits pancreatic tumor growth: role of microRNA-27a.	Molecular pharmacology	2010	41
20872043	3791	Neyns B	Phase II study of sunitinib malate in patients with recurrent high-grade glioma.	Journal of neuro-oncology	2011	39
21882181	3791	Kim JJ	Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib.	Cancer	2012	36
22393126	3791	Hamerlik P	Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth.	The Journal of experimental medicine	2012	92
22654102	3791	Francescone R	Glioblastoma-derived tumor cells induce vasculogenic mimicry through Flk-1 protein activation.	The Journal of biological chemistry	2012	40
23169517	3791	Smith DC	Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.	Journal of clinical oncology 	2013	104
23213094	3791	Choueiri TK	Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.	Journal of clinical oncology 	2013	72
23454747	3791	Chatterjee S	Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer.	The Journal of clinical investigation	2013	42
23516391	3791	Shah MA	Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer.	PloS one	2013	47
23536763	3791	Yao X	Vascular endothelial growth factor receptor 2 (VEGFR-2) plays a key role in vasculogenic mimicry formation, neovascularization and tumor initiation by Glioma stem-like cells.	PloS one	2013	28
23553848	3791	Lee RJ	A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases.	Clinical cancer research 	2013	30
23630200	3791	Kummar S	Cediranib for metastatic alveolar soft part sarcoma.	Journal of clinical oncology 	2013	29
23697367	3791	Vecchione A	A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis.	Proceedings of the National Academy of Sciences of the United States of America	2013	48
23932548	3791	Cameron D	Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.	The Lancet. Oncology	2013	66
24002501	3791	Elisei R	Cabozantinib in progressive medullary thyroid cancer.	Journal of clinical oncology 	2013	116
24094768	3791	Fuchs CS	Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.	Lancet	2014	250
24297950	3791	Hutson TE	Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.	Journal of clinical oncology 	2014	63
24529377	3791	Croci DO	Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors.	Cell	2014	68
24803676	3791	Karajannis MA	Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas.	Neuro-oncology	2014	26
24827131	3791	Choueiri TK	A phase I study of cabozantinib (XL184) in patients with renal cell cancer.	Annals of oncology 	2014	22
24933332	3791	Garon EB	Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.	Lancet	2014	127
25225436	3791	du Bois A	Incorporation of pazopanib in maintenance therapy of ovarian cancer.	Journal of clinical oncology 	2014	37
25225437	3791	Smith MR	Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.	Journal of clinical oncology 	2014	23
25240821	3791	Wilke H	Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.	The Lancet. Oncology	2014	184
26001391	3791	Zhao Y	Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.	The oncologist	2015	35
26406150	3791	Choueiri TK	Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.	The New England journal of medicine	2015	83
26884585	3791	Li J	Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.	Journal of clinical oncology 	2016	44
2448137	3815	Yarden Y	Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand.	The EMBO journal	1987	241
7479840	3815	Nagata H	Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder.	Proceedings of the National Academy of Sciences of the United States of America	1995	129
9140397	3815	Schmidt L	Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.	Nature genetics	1997	271
9438854	3815	Hirota S	Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.	Science	1998	672
11213830	3815	Miettinen M	Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis.	Virchows Archiv 	2001	241
12094370	3815	Fletcher CD	Diagnosis of gastrointestinal stromal tumors: A consensus approach.	Human pathology	2002	490
12181401	3815	Demetri GD	Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.	The New England journal of medicine	2002	651
12424067	3815	Joensuu H	Management of malignant gastrointestinal stromal tumours.	The Lancet. Oncology	2002	83
12522257	3815	Heinrich MC	PDGFRA activating mutations in gastrointestinal stromal tumors.	Science	2003	371
15010069	3815	Debiec-Rychter M	Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group.	European journal of cancer	2004	80
15365079	3815	Corless CL	Biology of gastrointestinal stromal tumors.	Journal of clinical oncology 	2004	170
16027439	3815	Rugo HS	Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results.	Journal of clinical oncology 	2005	83
16045346	3815	Rankin S	Putative DNA quadruplex formation within the human c-kit oncogene.	Journal of the American Chemical Society	2005	120
16616334	3815	Sun L	Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain.	Cancer cell	2006	252
16624552	3815	Debiec-Rychter M	KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.	European journal of cancer	2006	162
16784237	3815	Fernando H	A conserved quadruplex motif located in a transcription activation site of the human c-kit oncogene.	Biochemistry	2006	94
16908931	3815	Curtin JA	Somatic activation of KIT in distinct subtypes of melanoma.	Journal of clinical oncology 	2006	273
16921041	3815	Paschka P	Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study.	Journal of clinical oncology 	2006	105
17090188	3815	Miettinen M	Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis.	Archives of pathology and laboratory medicine	2006	262
17193820	3815	Miettinen M	Gastrointestinal stromal tumors: pathology and prognosis at different sites.	Seminars in diagnostic pathology	2006	236
17325667	3815	Mahadevan D	A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors.	Oncogene	2007	72
17362008	3815	Phan AT	Structure of an unprecedented G-quadruplex scaffold in the human c-kit promoter.	Journal of the American Chemical Society	2007	97
17913750	3815	Patel DJ	Human telomere, oncogenic promoter and 5'-UTR G-quadruplexes: diverse higher order DNA and RNA targets for cancer therapeutics.	Nucleic acids research	2007	176
18076015	3815	Dematteo RP	Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST).	Cancer	2008	96
18223323	3815	Espinosa I	A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors.	The American journal of surgical pathology	2008	84
18235121	3815	Blanke CD	Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.	Journal of clinical oncology 	2008	195
18519691	3815	Zhang S	Identification and characterization of ovarian cancer-initiating cells from primary human tumors.	Cancer research	2008	366
18596272	3815	Sherman SI	Motesanib diphosphate in progressive differentiated thyroid cancer.	The New England journal of medicine	2008	113
18605894	3815	Virant-Klun I	Parthenogenetic embryo-like structures in the human ovarian surface epithelium cell culture in postmenopausal women with no naturally present follicles and oocytes.	Stem cells and development	2009	50
18623623	3815	Liegl B	Heterogeneity of kinase inhibitor resistance mechanisms in GIST.	The Journal of pathology	2008	77
18671239	3815	Kawai O	Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer.	Cancer	2008	78
18980976	3815	Beadling C	KIT gene mutations and copy number in melanoma subtypes.	Clinical cancer research 	2008	104
19303137	3815	Dematteo RP	Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.	Lancet	2009	245
19522824	3815	Stratakis CA	The triad of paragangliomas, gastric stromal tumours and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney-Stratakis syndrome): molecular genetics and clinical implications.	Journal of internal medicine	2009	55
19768731	3815	Haller F	Localization- and mutation-dependent microRNA (miRNA) expression signatures in gastrointestinal stromal tumours (GISTs), with a cluster of co-expressed miRNAs located at 14q32.31.	The Journal of pathology	2010	43
19789626	3815	Dubreuil P	Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.	PloS one	2009	50
19865100	3815	Bodemer C	Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations.	The Journal of investigative dermatology	2010	45
20008644	3815	Hutson TE	Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma.	Journal of clinical oncology 	2010	62
20100962	3815	Sternberg CN	Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.	Journal of clinical oncology 	2010	472
20224986	3815	Liu T	Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1.	Molecular and cellular biochemistry	2010	42
20226456	3815	Mekky MA	Diagnostic utility of EUS-guided FNA in patients with gastric submucosal tumors.	Gastrointestinal endoscopy	2010	49
21399664	3815	Gao XN	MicroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia.	Oncogene	2011	41
21642685	3815	Carvajal RD	KIT as a therapeutic target in metastatic melanoma.	JAMA	2011	114
21690468	3815	Guo J	Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.	Journal of clinical oncology 	2011	91
22797058	3815	Chau WK	c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.	Oncogene	2013	44
23621814	3815	Díaz-Flores L	Telocytes in neuromuscular spindles.	Journal of cellular and molecular medicine	2013	27
23775962	3815	Hodi FS	Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.	Journal of clinical oncology 	2013	46
24009080	3815	Siemens H	Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness.	Oncotarget	2013	47
24379393	3815	Atay S	Oncogenic KIT-containing exosomes increase gastrointestinal stromal tumor cell invasion.	Proceedings of the National Academy of Sciences of the United States of America	2014	33
24638003	3815	Corless CL	Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.	Journal of clinical oncology 	2014	30
25605837	3815	Joensuu H	KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence.	Journal of clinical oncology 	2015	17
26091043	3815	Cancer Genome Atlas Network.	Genomic Classification of Cutaneous Melanoma.	Cell	2015	197
27011036	3815	Boikos SA	Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic.	JAMA oncology	2016	15
2438556	3845	Forrester K	Detection of high incidence of K-ras oncogenes during human colon tumorigenesis.	Nature	1987	165
2453289	3845	Almoguera C	Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes.	Cell	1988	407
3587348	3845	Bos JL	Prevalence of ras gene mutations in human colorectal cancers.	Nature	1987	293
6888561	3845	Schwab M	Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour.	Nature	1983	261
8342602	3845	Hruban RH	K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization.	The American journal of pathology	1993	134
9586664	3845	Andreyev HJ	Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study.	Journal of the National Cancer Institute	1998	155
9727023	3845	Yan J	Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase.	The Journal of biological chemistry	1998	102
9918209	3845	Wang W	The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells.	Clinical cancer research 	1999	146
11097226	3845	Samowitz WS	Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study.	Cancer epidemiology, biomarkers and prevention 	2000	99
11459867	3845	Adjei AA	Blocking oncogenic Ras signaling for cancer therapy.	Journal of the National Cancer Institute	2001	157
11531254	3845	Andreyev HJ	Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study.	British journal of cancer	2001	201
12093899	3845	Smith G	Mutations in APC, Kirsten-ras, and p53--alternative genetic pathways to colorectal cancer.	Proceedings of the National Academy of Sciences of the United States of America	2002	98
12644542	3845	Singer G	Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.	Journal of the National Cancer Institute	2003	164
14706336	3845	Hingorani SR	Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse.	Cancer cell	2003	632
14966562	3845	Chan IT	Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease.	The Journal of clinical investigation	2004	104
15051286	3845	Li D	Pancreatic cancer.	Lancet	2004	442
15494427	3845	Yu JL	Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis.	Blood	2005	108
15597105	3845	Mascaux C	The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis.	British journal of cancer	2005	130
15604253	3845	Kosaka T	Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.	Cancer research	2004	233
15608639	3845	Sweet-Cordero A	An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis.	Nature genetics	2005	159
15720814	3845	Löhr M	Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis.	Neoplasia	2005	69
15998951	3845	Ince WL	Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.	Journal of the National Cancer Institute	2005	69
16618717	3845	Lièvre A	KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.	Cancer research	2006	491
16880785	3845	Eisen T	Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis.	British journal of cancer	2006	142
16931950	3845	Brune K	Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer.	The American journal of surgical pathology	2006	69
17101316	3845	Spring KJ	High prevalence of sessile serrated adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy.	Gastroenterology	2006	82
17184525	3845	Krypuy M	High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer.	BMC cancer	2006	78
17332339	3845	Campbell PM	K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling.	Cancer research	2007	77
17375050	3845	Di Fiore F	Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy.	British journal of cancer	2007	192
17512720	3845	Duffy MJ	Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use.	European journal of cancer	2007	83
17982507	3845	Pasca di Magliano M	Common activation of canonical Wnt signaling in pancreatic adenocarcinoma.	PloS one	2007	71
17998284	3845	De Roock W	KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.	Annals of oncology 	2008	206
18003927	3845	Shen L	Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer.	Proceedings of the National Academy of Sciences of the United States of America	2007	174
18202412	3845	Lièvre A	KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.	Journal of clinical oncology 	2008	336
18224685	3845	Barault L	Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers.	International journal of cancer	2008	84
18316791	3845	Amado RG	Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.	Journal of clinical oncology 	2008	728
18669866	3845	Perrone F	PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients.	Annals of oncology 	2009	112
18794081	3845	Riely GJ	Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.	Clinical cancer research 	2008	131
18804418	3845	Linardou H	Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.	The Lancet. Oncology	2008	184
18922928	3845	Chin LJ	A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk.	Cancer research	2008	216
18946061	3845	Karapetis CS	K-ras mutations and benefit from cetuximab in advanced colorectal cancer.	The New England journal of medicine	2008	797
19001320	3845	Di Nicolantonio F	Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.	Journal of clinical oncology 	2008	416
19033568	3845	Ogino S	A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer.	Journal of the National Cancer Institute	2008	134
19056857	3845	Santini D	High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice.	The oncologist	2008	57
19114683	3845	Bokemeyer C	Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.	Journal of clinical oncology 	2009	369
19124802	3845	Jimeno A	KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection.	Journal of clinical oncology 	2009	58
19196673	3845	Tol J	Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.	The New England journal of medicine	2009	287
19237633	3845	Ogino S	PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer.	Journal of clinical oncology 	2009	111
19273710	3845	Iacobuzio-Donahue CA	DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.	Journal of clinical oncology 	2009	221
19323605	3845	Torrisani J	let-7 MicroRNA transfer in pancreatic cancer-derived cells inhibits in vitro cell proliferation but fails to alter tumor progression.	Human gene therapy	2009	54
19339720	3845	Van Cutsem E	Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.	The New England journal of medicine	2009	786
19349489	3845	Riely GJ	KRAS mutations in non-small cell lung cancer.	Proceedings of the American Thoracic Society	2009	142
19372139	3845	Tsang WP	The miR-18a* microRNA functions as a potential tumor suppressor by targeting on K-Ras.	Carcinogenesis	2009	58
19380522	3845	Christensen BC	A let-7 microRNA-binding site polymorphism in the KRAS 3' UTR is associated with reduced survival in oral cancers.	Carcinogenesis	2009	70
19398573	3845	Loupakis F	PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.	Journal of clinical oncology 	2009	123
19401449	3845	Wee S	PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.	Cancer research	2009	116
19490892	3845	Scholl C	Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.	Cell	2009	189
19561589	3845	DuPage M	Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase.	Nature protocols	2009	159
19595305	3845	Young A	Ras signaling and therapies.	Advances in cancer research	2009	79
19603018	3845	Loupakis F	KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.	British journal of cancer	2009	136
19603024	3845	Souglakos J	Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.	British journal of cancer	2009	76
19661383	3845	Yun J	Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells.	Science	2009	210
19686742	3845	Nosho K	A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers.	Gastroenterology	2009	53
19738126	3845	Jacobs B	Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab.	Journal of clinical oncology 	2009	84
19738166	3845	Siena S	Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.	Journal of the National Cancer Institute	2009	144
19826477	3845	Soh J	Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells.	PloS one	2009	66
19884549	3845	Richman SD	KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.	Journal of clinical oncology 	2009	146
19908233	3845	Zlobec I	Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.	International journal of cancer	2010	58
19934290	3845	Ogino S	KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.	Clinical cancer research 	2009	62
20005451	3845	Oh JS	Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras.	International journal of radiation oncology, biology, physics	2010	59
20022659	3845	Mao C	KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies.	Lung cancer	2010	74
20102720	3845	Goel A	Aberrant DNA methylation in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency.	Gastroenterology	2010	42
20413299	3845	Tol J	Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.	European journal of cancer	2010	61
20495549	3845	Singh M	Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models.	Nature biotechnology	2010	91
20501503	3845	Fariña-Sarasqueta A	The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients.	Annals of oncology 	2010	72
20505728	3845	Lee W	The mutation spectrum revealed by paired genome sequences from a lung cancer patient.	Nature	2010	197
20512148	3845	Lauth M	DYRK1B-dependent autocrine-to-paracrine shift of Hedgehog signaling by mutant RAS.	Nature structural and molecular biology	2010	48
20570890	3845	Janakiraman M	Genomic and biological characterization of exon 4 KRAS mutations in human cancer.	Cancer research	2010	92
20603437	3845	Zhang W	A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy.	Annals of oncology 	2011	37
20607356	3845	Lee ST	Let-7 microRNA inhibits the proliferation of human glioblastoma cells.	Journal of neuro-oncology	2011	41
20610624	3845	Yu S	miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer.	Cancer research	2010	96
20619739	3845	De Roock W	Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.	The Lancet. Oncology	2010	475
20647319	3845	Ratner E	A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.	Cancer research	2010	52
20736745	3845	Irahara N	NRAS mutations are rare in colorectal cancer.	Diagnostic molecular pathology 	2010	43
20814421	3845	Morris JP 4th	KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma.	Nature reviews. Cancer	2010	171
20927778	3845	Nosho K	Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review.	The Journal of pathology	2010	104
20978259	3845	De Roock W	Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.	JAMA	2010	186
21159816	3845	Kent OA	Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway.	Genes and development	2010	102
21167132	3845	Shin KH	miR-181a shows tumor suppressive effect against oral squamous cell carcinoma cells by downregulating K-ras.	Biochemical and biophysical research communications	2011	48
21228335	3845	Bokemeyer C	Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.	Annals of oncology 	2011	163
21239505	3845	Tie J	KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer.	Clinical cancer research 	2011	47
21300795	3845	Kim MJ	Involvement of autophagy in oncogenic K-Ras-induced malignant cell transformation.	The Journal of biological chemistry	2011	71
21305640	3845	Vaughn CP	Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer.	Genes, chromosomes and cancer	2011	59
21364579	3845	Knijn N	KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients.	British journal of cancer	2011	63
21383284	3845	Hutchins G	Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.	Journal of clinical oncology 	2011	125
21435948	3845	Paranjape T	A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis.	The Lancet. Oncology	2011	44
21519026	3845	Bekaii-Saab T	Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers.	Journal of clinical oncology 	2011	60
21543894	3845	Chan E	MicroRNA signatures differentiate melanoma subtypes.	Cell cycle	2011	35
21594292	3845	Pekin D	Quantitative and sensitive detection of rare mutations using droplet-based microfluidics.	Lab on a chip	2011	61
21632860	3845	Molinari F	Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.	Clinical cancer research 	2011	56
21742770	3845	Babij C	STK33 kinase activity is nonessential in KRAS-dependent cancer cells.	Cancer research	2011	39
21826083	3845	Ogino S	Cancer immunology--analysis of host and tumor factors for personalized medicine.	Nature reviews. Clinical oncology	2011	89
21943101	3845	Makrodouli E	BRAF and RAS oncogenes regulate Rho GTPase pathways to mediate migration and invasion properties in human colon cancer cells: a comparative study.	Molecular cancer	2011	36
21985784	3845	Ebi H	Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.	The Journal of clinical investigation	2011	63
22004085	3845	Baines AT	Inhibition of Ras for cancer treatment: the search continues.	Future medicinal chemistry	2011	98
22062357	3845	Ahlquist DA	Next-generation stool DNA test accurately detects colorectal cancer and large adenomas.	Gastroenterology	2012	56
22099597	3845	Krantz SB	Contribution of epithelial-to-mesenchymal transition and cancer stem cells to pancreatic cancer progression.	The Journal of surgical research	2012	30
22185891	3845	Mancias JD	Targeting autophagy addiction in cancer.	Oncotarget	2011	57
22228631	3845	Spindler KL	Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan.	Clinical cancer research 	2012	44
22247021	3845	Ihle NT	Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.	Journal of the National Cancer Institute	2012	83
22282465	3845	Miranda C	KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors.	Clinical cancer research 	2012	38
22314188	3845	Pai RK	BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.	The American journal of surgical pathology	2012	35
22341439	3845	Singh A	TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers.	Cell	2012	84
22446022	3845	Bokemeyer C	Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials.	European journal of cancer	2012	123
22473155	3845	Tveit KM	Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.	Journal of clinical oncology 	2012	106
22473163	3845	Dewdney A	Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).	Journal of clinical oncology 	2012	49
22474202	3845	Alberts SR	Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial.	JAMA	2012	89
22481281	3845	Chang DT	Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features.	Modern pathology 	2012	33
22613949	3845	Steckel M	Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.	Cell research	2012	45
22665543	3845	Vakiani E	Comparative genomic analysis of primary versus metastatic colorectal carcinomas.	Journal of clinical oncology 	2012	67
22753589	3845	Imamura Y	Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers.	Clinical cancer research 	2012	62
22798500	3845	Tian S	A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction.	Gut	2013	26
22898602	3845	Ward AF	Targeting oncogenic Ras signaling in hematologic malignancies.	Blood	2012	50
23017669	3845	Foxtrot Collaborative Group	Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial.	The Lancet. Oncology	2012	40
23122493	3845	Karachaliou N	KRAS mutations in lung cancer.	Clinical lung cancer	2013	31
23178454	3845	Baker R	Site-specific monoubiquitination activates Ras by impeding GTPase-activating protein function.	Nature structural and molecular biology	2013	30
23182985	3845	Peeters M	Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.	Journal of clinical oncology 	2013	63
23200175	3845	Jänne PA	Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.	The Lancet. Oncology	2013	153
23293113	3845	Tougeron D	Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer.	Annals of oncology 	2013	29
23295441	3845	Sia D	Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.	Gastroenterology	2013	61
23334325	3845	Huang H	Oncogenic K-Ras requires activation for enhanced activity.	Oncogene	2014	31
23348904	3845	Rosty C	Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features.	Modern pathology 	2013	47
23374602	3845	Pentheroudakis G	Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.	BMC cancer	2013	33
23419522	3845	Fabbri F	Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs.	Cancer letters	2013	47
23426905	3845	Shiraha H	Human hepatocyte carcinogenesis (review).	International journal of oncology	2013	30
23453624	3845	Eser S	Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer.	Cancer cell	2013	78
23471846	3845	Heitzer E	Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing.	Cancer research	2013	122
23486266	3845	Russell PA	Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients.	Journal of thoracic oncology 	2013	29
23510984	3845	Cohn AL	A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer.	Annals of oncology 	2013	27
23511557	3845	Phipps AI	KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers.	British journal of cancer	2013	40
23535601	3845	Son J	Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway.	Nature	2013	285
23569301	3845	Ye LC	Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases.	Journal of clinical oncology 	2013	47
23614898	3845	Morris EJ	Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.	Cancer discovery	2013	94
23630215	3845	Shepherd FA	Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.	Journal of clinical oncology 	2013	45
23660947	3845	Eklöf V	The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer.	British journal of cancer	2013	38
23690424	3845	Siu LL	Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial.	Journal of clinical oncology 	2013	34
23698361	3845	Zimmermann G	Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling.	Nature	2013	112
23700391	3845	Marisa L	Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value.	PLoS medicine	2013	140
23725851	3845	Seymour MT	Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.	The Lancet. Oncology	2013	65
23792451	3845	Ogino S	Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology.	Oncogene	2014	38
23912084	3845	Murphy SJ	Genetic alterations associated with progression from pancreatic intraepithelial neoplasia to invasive pancreatic tumor.	Gastroenterology	2013	33
23943799	3845	Licciulli S	Notch1 is required for Kras-induced lung adenocarcinoma and controls tumor cell survival via p53.	Cancer research	2013	27
24018645	3845	Vauthey JN	RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.	Annals of surgery	2013	29
24019539	3845	Sinicrope FA	Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.	Journal of clinical oncology 	2013	30
24024839	3845	Douillard JY	Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.	The New England journal of medicine	2013	383
24042191	3845	Mouradov D	Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations.	The American journal of gastroenterology	2013	27
24043732	3845	Piessevaux H	Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab.	Journal of clinical oncology 	2013	28
24256730	3845	Ostrem JM	K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.	Nature	2013	188
24293274	3845	Liao WT	MicroRNA-30b functions as a tumour suppressor in human colorectal cancer by targeting KRAS, PIK3CD and BCL2.	The Journal of pathology	2014	28
24297898	3845	Zorde Khvalevsky E	Mutant KRAS is a druggable target for pancreatic cancer.	Proceedings of the National Academy of Sciences of the United States of America	2013	37
24385213	3845	Tahara T	Fusobacterium in colonic flora and molecular features of colorectal carcinoma.	Cancer research	2014	46
24398677	3845	Kahlert C	Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer.	The Journal of biological chemistry	2014	94
24645800	3845	Imperiale TF	Multitarget stool DNA testing for colorectal-cancer screening.	The New England journal of medicine	2014	144
24658074	3845	Thierry AR	Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA.	Nature medicine	2014	70
24681997	3845	Thege FI	Microfluidic immunocapture of circulating pancreatic cells using parallel EpCAM and MUC1 capture: characterization, optimization and downstream analysis.	Lab on a chip	2014	23
24687927	3845	Yoon HH	KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).	Clinical cancer research 	2014	22
24718886	3845	Douillard JY	Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.	Annals of oncology 	2014	69
24928083	3845	Taieb J	Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.	The Lancet. Oncology	2014	24
24929527	3845	Spiegel J	Small-molecule modulation of Ras signaling.	Nature chemical biology	2014	33
24944469	3845	Binefa G	Colorectal cancer: from prevention to personalized medicine.	World journal of gastroenterology	2014	31
25051912	3845	Zoratto F	Focus on genetic and epigenetic events of colorectal cancer pathogenesis: implications for molecular diagnosis.	Tumour biology 	2014	35
25088940	3845	Heinemann V	FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.	The Lancet. Oncology	2014	184
25280443	3845	Phipps AI	Association between molecular subtypes of colorectal cancer and patient survival.	Gastroenterology	2015	75
25341011	3845	Ciombor KK	Recent therapeutic advances in the treatment of colorectal cancer.	Annual review of medicine	2015	19
25342560	3845	Sun Q	Competition between human cells by entosis.	Cell research	2014	25
25361982	3845	Klingbiel D	Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial.	Annals of oncology 	2015	20
25561545	3845	Tsai FD	K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif.	Proceedings of the National Academy of Sciences of the United States of America	2015	28
25632066	3845	Chen JS	A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer.	Annals of oncology 	2015	17
25644265	3845	Kamphorst JJ	Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein.	Cancer research	2015	67
25706875	3845	Matano M	Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids.	Nature medicine	2015	74
25722381	3845	Blumenschein GR Jr	A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.	Annals of oncology 	2015	18
25823825	3845	Kinugasa H	Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer.	Cancer	2015	26
25877855	3845	Tabernero J	Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.	The Lancet. Oncology	2015	69
25918287	3845	Dienstmann R	Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients.	Journal of clinical oncology 	2015	29
25937522	3845	Bokemeyer C	FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer.	European journal of cancer	2015	24
25961927	3845	Garcia PL	The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models.	Oncogene	2016	23
26080442	3845	Nan X	Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway.	Proceedings of the National Academy of Sciences of the United States of America	2015	29
26084335	3845	Kim KT	Single-cell mRNA sequencing identifies subclonal heterogeneity in anti-cancer drug responses of lung adenocarcinoma cells.	Genome biology	2015	32
26085511	3845	Frenel JS	Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration.	Clinical cancer research 	2015	31
26091037	3845	Dow LE	Apc Restoration Promotes Cellular Differentiation and Reestablishes Crypt Homeostasis in Colorectal Cancer.	Cell	2015	62
26178787	3845	Chiou SH	Pancreatic cancer modeling using retrograde viral vector delivery and in vivo CRISPR/Cas9-mediated somatic genome editing.	Genes and development	2015	28
26216840	3845	Carethers JM	Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer.	Gastroenterology	2015	32
26608120	3845	Johnson DB	Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms.	European journal of cancer	2015	18
26625312	3845	Pécuchet N	Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer.	Oncotarget	2017	5
26627737	3845	Hart T	High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities.	Cell	2015	78
26739882	3845	Patricelli MP	Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.	Cancer discovery	2016	22
27469033	3845	Ostrem JM	Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design.	Nature reviews. Drug discovery	2016	13
10606205	4072	Balzar M	The biology of the 17-1A antigen (Ep-CAM).	Journal of molecular medicine	1999	111
14745734	4072	Went PT	Frequent EpCam protein expression in human carcinomas.	Human pathology	2004	157
15195135	4072	Münz M	The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation.	Oncogene	2004	81
15942643	4072	Rao CG	Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors.	International journal of oncology	2005	86
16404366	4072	Went P	Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers.	British journal of cancer	2006	85
18097410	4072	Nagrath S	Isolation of rare circulating tumour cells in cancer patients by microchip technology.	Nature	2007	681
18316609	4072	Yamashita T	EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma.	Cancer research	2008	174
18781171	4072	Horst D	CD133 expression is an independent prognostic marker for low survival in colorectal cancer.	British journal of cancer	2008	74
19098912	4072	Ligtenberg MJ	Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1.	Nature genetics	2009	137
19136966	4072	Maetzel D	Nuclear signalling by tumour-associated antigen EpCAM.	Nature cell biology	2009	194
19584271	4072	Munz M	The emerging role of EpCAM in cancer and stem cell signaling.	Cancer research	2009	131
19585654	4072	Ji J	Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells.	Hepatology	2009	145
20147742	4072	Coumans FA	All circulating EpCAM+CK+CD45- objects predict overall survival in castration-resistant prostate cancer.	Annals of oncology 	2010	60
20190561	4072	Linke R	Catumaxomab: clinical development and future directions.	mAbs	2010	46
20347527	4072	Seimetz D	Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy.	Cancer treatment reviews	2010	44
20837599	4072	van der Gun BT	EpCAM in carcinogenesis: the good, the bad or the ugly.	Carcinogenesis	2010	85
21261508	4072	Königsberg R	Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients.	Acta oncologica	2011	58
21281402	4072	Shigdar S	RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule.	Cancer science	2011	36
21415054	4072	Spizzo G	EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis.	Journal of clinical pathology	2011	42
21576002	4072	Patriarca C	Epithelial cell adhesion molecule expression (CD326) in cancer: a short review.	Cancer treatment reviews	2012	60
21601258	4072	Rupp AK	Loss of EpCAM expression in breast cancer derived serum exosomes: role of proteolytic cleavage.	Gynecologic oncology	2011	42
21829190	4072	Farace F	A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas.	British journal of cancer	2011	90
22180853	4072	Pecot CV	A novel platform for detection of CK+ and CK- CTCs.	Cancer discovery	2011	48
22825490	4072	Saucedo-Zeni N	A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire.	International journal of oncology	2012	54
23230278	4072	Tauro BJ	Two distinct populations of exosomes are released from LIM1863 colon carcinoma cell-derived organoids.	Molecular and cellular proteomics 	2013	62
23480100	4072	Song Y	Selection of DNA aptamers against epithelial cell adhesion molecule for cancer cell imaging and circulating tumor cell capture.	Analytical chemistry	2013	30
23486470	4072	Wu CJ	Epithelial cell adhesion molecule (EpCAM) regulates claudin dynamics and tight junctions.	The Journal of biological chemistry	2013	28
23609047	4072	Baccelli I	Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay.	Nature biotechnology	2013	185
23616258	4072	Schulze K	Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma.	International journal of cancer	2013	31
23805171	4072	Gupta V	ApoStream(™), a new dielectrophoretic device for antibody independent isolation and recovery of viable cancer cells from blood.	Biomicrofluidics	2012	67
24061411	4072	Sollier E	Size-selective collection of circulating tumor cells using Vortex technology.	Lab on a chip	2014	47
24141784	4072	Driemel C	Context-dependent adaption of EpCAM expression in early systemic esophageal cancer.	Oncogene	2014	21
24763289	4072	LaDuca H	Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients.	Genetics in medicine 	2014	41
25336717	4072	Satelli A	Circulating tumor cell enumeration with a combination of epithelial cell adhesion molecule- and cell-surface vimentin-based methods for monitoring breast cancer therapeutic response.	Clinical chemistry	2015	28
26184843	4072	de Wit S	The detection of EpCAM(+) and EpCAM(-) circulating tumor cells.	Scientific reports	2015	24
7682708	4170	Kozopas KM	MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2.	Proceedings of the National Academy of Sciences of the United States of America	1993	188
9558396	4170	Kitada S	Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses.	Blood	1998	111
11877256	4170	Zhang B	Myeloid cell factor-1 is a critical survival factor for multiple myeloma.	Blood	2002	85
12070027	4170	Derenne S	Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.	Blood	2002	94
14633975	4170	Cuconati A	DNA damage response and MCL-1 destruction initiate apoptosis in adenovirus-infected cells.	Genes and development	2003	107
15469392	4170	Turkson J	STAT proteins as novel targets for cancer drug discovery.	Expert opinion on therapeutic targets	2004	78
15637055	4170	Weng C	Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells.	The Journal of biological chemistry	2005	66
15837920	4170	Nam S	Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells.	Proceedings of the National Academy of Sciences of the United States of America	2005	66
15901672	4170	Willis SN	Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins.	Genes and development	2005	396
15930886	4170	Jing N	Targeting Stat3 in cancer therapy.	Anti-cancer drugs	2005	74
15940637	4170	Kobayashi S	Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells.	Gastroenterology	2005	71
16109713	4170	Rahmani M	Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation.	The Journal of biological chemistry	2005	96
16289418	4170	Sieghart W	Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy.	Journal of hepatology	2006	60
17043651	4170	Iwamaru A	A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo.	Oncogene	2007	97
17173063	4170	Lin X	'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.	Oncogene	2007	102
17227835	4170	Pérez-Galán P	The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak.	Blood	2007	69
17545623	4170	Gomez-Bougie P	Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.	Cancer research	2007	76
17761520	4170	Liu Q	FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma.	Blood	2008	60
18040043	4170	Nguyen M	Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.	Proceedings of the National Academy of Sciences of the United States of America	2007	213
18451169	4170	Konopleva M	Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).	Cancer research	2008	76
18451170	4170	Tse C	ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.	Cancer research	2008	426
18574029	4170	Trachootham D	Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism.	Blood	2008	56
18599795	4170	Pepper C	Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers.	Blood	2008	69
18676833	4170	Ding Q	Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer.	Cancer research	2008	51
18806758	4170	Vogler M	Bcl-2 inhibitors: small molecules with a big impact on cancer therapy.	Cell death and differentiation	2009	106
18836097	4170	Balakrishnan K	AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance.	Blood	2009	58
19099185	4170	Akgul C	Mcl-1 is a potential therapeutic target in multiple types of cancer.	Cellular and molecular life sciences 	2009	81
19372583	4170	Boisvert-Adamo K	Mcl-1 is required for melanoma cell resistance to anoikis.	Molecular cancer research 	2009	51
19503096	4170	Saito Y	Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced microRNA-512-5p with downregulation of Mcl-1 in human gastric cancer cells.	Oncogene	2009	51
19654003	4170	Crawford M	MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer.	Biochemical and biophysical research communications	2009	56
20023629	4170	Schwickart M	Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival.	Nature	2010	194
20164920	4170	Beroukhim R	The landscape of somatic copy-number alteration across human cancers.	Nature	2010	936
20197552	4170	Yecies D	Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1.	Blood	2010	119
20335218	4170	Buchner M	Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.	Blood	2010	60
20562877	4170	Stewart ML	The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer.	Nature chemical biology	2010	115
20587533	4170	Voss V	The pan-Bcl-2 inhibitor (-)-gossypol triggers autophagic cell death in malignant glioma.	Molecular cancer research 	2010	47
20705336	4170	Moore MJ	An alternative splicing network links cell-cycle control to apoptosis.	Cell	2010	108
21345578	4170	Jendrossek V	Targeting apoptosis pathways by Celecoxib in cancer.	Cancer letters	2013	37
21364647	4170	Placzek WJ	A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy.	Cell death and disease	2010	83
21368833	4170	Inuzuka H	SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction.	Nature	2011	177
21368834	4170	Wertz IE	Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7.	Nature	2011	217
21628457	4170	Albershardt TC	Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXA.	The Journal of biological chemistry	2011	42
21636858	4170	Visone R	miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia.	Blood	2011	41
21648427	4170	Wu Y	MicroRNA delivery by cationic lipoplexes for lung cancer therapy.	Molecular pharmaceutics	2011	42
21851287	4170	Quinn BA	Targeting Mcl-1 for the therapy of cancer.	Expert opinion on investigational drugs	2011	45
22064351	4170	Konopleva M	MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.	Leukemia	2012	39
22128299	4170	Tromp JM	Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.	Clinical cancer research 	2012	35
22184378	4170	Roberts AW	Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.	Journal of clinical oncology 	2012	186
22516262	4170	Wei G	Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency.	Cancer cell	2012	54
22544066	4170	Perciavalle RM	Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration.	Nature cell biology	2012	89
22608923	4170	Min SH	Negative regulation of the stability and tumor suppressor function of Fbw7 by the Pin1 prolyl isomerase.	Molecular cell	2012	47
22999885	4170	Cohen NA	A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survival.	Chemistry and biology	2012	39
23026029	4170	Perciavalle RM	Delving deeper: MCL-1's contributions to normal and cancer biology.	Trends in cell biology	2013	51
23756231	4170	Ji F	MicroRNA-133a, downregulated in osteosarcoma, suppresses proliferation and promotes apoptosis by targeting Bcl-xL and Mcl-1.	Bone	2013	30
24019208	4170	Abulwerdi F	A novel small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in vivo.	Molecular cancer therapeutics	2014	44
24095849	4170	Scarfò L	Reprogramming cell death: BCL2 family inhibition in hematological malignancies.	Immunology letters	2013	32
25590800	4170	Leverson JD	Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).	Cell death and disease	2015	70
25679114	4170	Bruncko M	Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity.	Journal of medicinal chemistry	2015	27
25733019	4170	Huskey NE	CDK1 inhibition targets the p53-NOXA-MCL1 axis, selectively kills embryonic stem cells, and prevents teratoma formation.	Stem cell reports	2015	17
25829398	4170	Cervantes-Gomez F	Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.	Clinical cancer research 	2015	25
25936818	4170	Mohammad RM	Broad targeting of resistance to apoptosis in cancer.	Seminars in cancer biology	2015	26
27760111	4170	Kotschy A	The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.	Nature	2016	21
7791904	4193	Xiao ZX	Interaction between the retinoblastoma protein and the oncoprotein MDM2.	Nature	1995	133
9671804	4193	Momand J	The MDM2 gene amplification database.	Nucleic acids research	1998	217
10341712	4193	Prives C	The p53 pathway.	The Journal of pathology	1999	248
10721693	4193	Momand J	MDM2--master regulator of the p53 tumor suppressor protein.	Gene	2000	111
12393500	4193	Hideshima T	Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.	Blood	2003	122
14612427	4193	Zhang Y	Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway.	Molecular and cellular biology	2003	196
14704432	4193	Vassilev LT	In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.	Science	2004	1114
15004525	4193	Vassilev LT	Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics.	Cell cycle	2004	81
15550242	4193	Bond GL	A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.	Cell	2004	335
15644444	4193	Slack A	The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma.	Proceedings of the National Academy of Sciences of the United States of America	2005	73
15652475	4193	Vousden KH	P53 and prognosis: new insights and further complexity.	Cell	2005	67
15720184	4193	Bond GL	MDM2 is a central node in the p53 pathway: 12 years and counting.	Current cancer drug targets	2005	93
16337594	4193	Sdek P	MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein.	Molecular cell	2005	91
16443686	4193	Tovar C	Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.	Proceedings of the National Academy of Sciences of the United States of America	2006	196
16540668	4193	Patton JT	Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3.	Cancer research	2006	64
16707433	4193	Bond GL	MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner.	Cancer research	2006	107
16915296	4193	Sherr CJ	Divorcing ARF and p53: an unsettled case.	Nature reviews. Cancer	2006	204
17116689	4193	Lindström MS	Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation.	Molecular and cellular biology	2007	59
17157787	4193	Courtois-Cox S	A negative feedback signaling network underlies oncogene-induced senescence.	Cancer cell	2006	183
17310983	4193	Chen D	Ribosomal protein S7 as a novel modulator of p53-MDM2 interaction: binding to MDM2, stabilization of p53 protein, and activation of p53 function.	Oncogene	2007	102
17700533	4193	Lau LM	HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.	Oncogene	2008	53
18172499	4193	Colaluca IN	NUMB controls p53 tumour suppressor activity.	Nature	2008	121
18316739	4193	Shangary S	Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition.	Proceedings of the National Academy of Sciences of the United States of America	2008	188
18765522	4193	Shangary S	Targeting the MDM2-p53 interaction for cancer therapy.	Clinical cancer research 	2008	75
19147532	4193	Wade M	Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?	Molecular cancer research 	2009	61
19448627	4193	Wang SP	p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug.	Nature cell biology	2009	92
19776743	4193	Polager S	p53 and E2f: partners in life and death.	Nature reviews. Cancer	2009	149
19935675	4193	Brown CJ	Awakening guardian angels: drugging the p53 pathway.	Nature reviews. Cancer	2009	252
19955655	4193	Araki S	TGF-beta1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer.	The Journal of clinical investigation	2010	43
20080970	4193	Reed D	Identification and characterization of the first small molecule inhibitor of MDMX.	The Journal of biological chemistry	2010	64
20463003	4193	Lane DP	p53-based cancer therapy.	Cold Spring Harbor perspectives in biology	2010	55
20660730	4193	Liu M	D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms.	Proceedings of the National Academy of Sciences of the United States of America	2010	41
20679392	4193	Manfredi JJ	The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor.	Genes and development	2010	101
20975744	4193	Cheok CF	Translating p53 into the clinic.	Nature reviews. Clinical oncology	2011	118
22275381	4193	Xu-Monette ZY	Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies.	Blood	2012	33
22427896	4193	Koes D	Enabling large-scale design, synthesis and validation of small molecule protein-protein antagonists.	PloS one	2012	37
23084521	4193	Ray-Coquard I	Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.	The Lancet. Oncology	2012	111
23262034	4193	Li Q	Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy.	Clinical cancer research 	2013	38
23303139	4193	Wade M	MDM2, MDMX and p53 in oncogenesis and cancer therapy.	Nature reviews. Cancer	2013	193
23400593	4193	Tovar C	MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.	Cancer research	2013	53
23874713	4193	Daftuar L	Ribosomal proteins RPL37, RPS15 and RPS20 regulate the Mdm2-p53-MdmX network.	PloS one	2013	32
23885265	4193	Nag S	The MDM2-p53 pathway revisited.	Journal of biomedical research	2013	43
24356649	4193	Zheng T	Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis.	Nature communications	2013	34
24387333	4193	Hong B	Targeting tumor suppressor p53 for cancer therapy: strategies, challenges and opportunities.	Current drug targets	2014	25
24900694	4193	Vu B	Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development.	ACS medicinal chemistry letters	2013	30
25164622	4193	Wang W	Ribosomal proteins and human diseases: pathogenesis, molecular mechanisms, and therapeutic implications.	Medicinal research reviews	2015	20
25193859	4193	Zhang C	MicroRNA-339-5p inhibits colorectal tumorigenesis through regulation of the MDM2/p53 signaling.	Oncotarget	2014	23
25396320	4193	Zhao Y	Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.	Journal of medicinal chemistry	2015	32
25477334	4193	Meng X	MDM2-p53 pathway in hepatocellular carcinoma.	Cancer research	2014	23
25621662	4193	Macheret M	DNA replication stress as a hallmark of cancer.	Annual review of pathology	2015	55
25961931	4193	Scala F	Direct relationship between the level of p53 stabilization induced by rRNA synthesis-inhibiting drugs and the cell ribosome biogenesis rate.	Oncogene	2016	12
8811177	4255	Wood RD	DNA repair in eukaryotes.	Annual review of biochemistry	1996	133
10029064	4255	Esteller M	Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia.	Cancer research	1999	212
11070098	4255	Esteller M	Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.	The New England journal of medicine	2000	348
15041700	4255	Hegi ME	Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.	Clinical cancer research 	2004	135
15758010	4255	Hegi ME	MGMT gene silencing and benefit from temozolomide in glioblastoma.	The New England journal of medicine	2005	1079
16174854	4255	Shen L	MGMT promoter methylation and field defect in sporadic colorectal cancer.	Journal of the National Cancer Institute	2005	149
16405512	4255	Hermisson M	O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.	Journal of neurochemistry	2006	65
18082451	4255	Gorlia T	Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.	The Lancet. Oncology	2008	85
18445844	4255	Brandes AA	MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.	Journal of clinical oncology 	2008	137
18632623	4255	Beier D	Temozolomide preferentially depletes cancer stem cells in glioblastoma.	Cancer research	2008	81
18757334	4255	Hegi ME	Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.	Journal of clinical oncology 	2008	161
19088037	4255	Pallini R	Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme.	Clinical cancer research 	2008	89
19107440	4255	Ohgaki H	Epidemiology of brain tumors.	Methods in molecular biology	2009	79
19118063	4255	Kulke MH	O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.	Clinical cancer research 	2009	49
19188675	4255	Brandes AA	Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status.	Journal of clinical oncology 	2009	46
19269895	4255	Stupp R	Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.	The Lancet. Oncology	2009	1189
19841865	4255	Karayan-Tapon L	Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods.	Journal of neuro-oncology	2010	48
19997073	4255	Weller M	MGMT promoter methylation in malignant gliomas: ready for personalized medicine?	Nature reviews. Neurology	2010	132
20150378	4255	Rivera AL	MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma.	Neuro-oncology	2010	53
20439646	4255	Stupp R	Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.	Journal of clinical oncology 	2010	95
20551514	4255	Beard BC	Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates.	The Journal of clinical investigation	2010	44
21129061	4255	von Deimling A	The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations.	Brain pathology	2011	41
21135282	4255	Lai A	Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.	Journal of clinical oncology 	2011	132
21330401	4255	Pope WB	Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma.	AJNR. American journal of neuroradiology	2011	41
21339192	4255	Cohen KJ	Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group.	Neuro-oncology	2011	49
21709196	4255	Gállego Pérez-Larraya J	Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.	Journal of clinical oncology 	2011	38
21988793	4255	Beier D	Chemoresistance of glioblastoma cancer stem cells--much more complex than expected.	Molecular cancer	2011	70
22122467	4255	Zhang J	Temozolomide: mechanisms of action, repair and resistance.	Current molecular pharmacology	2012	73
22139906	4255	Reifenberger G	Predictive impact of MGMT promoter methylation in glioblastoma of the elderly.	International journal of cancer	2012	45
22294349	4255	Quillien V	Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients.	Cancer	2012	39
22527250	4255	Ardon H	Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial.	Cancer immunology, immunotherapy 	2012	42
22810491	4255	Bady P	MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status.	Acta neuropathologica	2012	44
22877848	4255	Malmström A	Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.	The Lancet. Oncology	2012	126
23850491	4255	Westphal M	Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial.	The Lancet. Oncology	2013	31
25140036	4255	Simon M	TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas.	Neuro-oncology	2015	22
25163906	4255	Stupp R	Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.	The Lancet. Oncology	2014	104
25411133	4255	Galldiks N	Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-18Ffluoroethyl)-L-tyrosine PET.	European journal of nuclear medicine and molecular imaging	2015	23
25762461	4255	Nabors LB	Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.	Neuro-oncology	2015	24
25959588	4255	Shao H	Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma.	Nature communications	2015	28
7661930	4292	Hamilton SR	The molecular basis of Turcot's syndrome.	The New England journal of medicine	1995	130
8044777	4292	Koi M	Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation.	Cancer research	1994	139
8128251	4292	Papadopoulos N	Mutation of a mutL homolog in hereditary colon cancer.	Science	1994	298
8145827	4292	Bronner CE	Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer.	Nature	1994	303
8895738	4292	Fink D	The role of DNA mismatch repair in platinum drug resistance.	Cancer research	1996	112
9354436	4292	Dietmaier W	Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression.	Cancer research	1997	129
9593786	4292	Aaltonen LA	Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease.	The New England journal of medicine	1998	185
9671741	4292	Veigl ML	Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers.	Proceedings of the National Academy of Sciences of the United States of America	1998	133
9699680	4292	Cunningham JM	Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability.	Cancer research	1998	142
10734209	4292	Eads CA	MethyLight: a high-throughput assay to measure DNA methylation.	Nucleic acids research	2000	343
12499261	4292	Fahrner JA	Dependence of histone modifications and gene expression on DNA hypermethylation in cancer.	Cancer research	2002	85
15000146	4292	Grady WM	Genomic instability and colon cancer.	Cancer metastasis reviews	2004	75
15342696	4292	Domingo E	BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing.	Journal of medical genetics	2004	77
15855432	4292	Piñol V	Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer.	JAMA	2005	99
16873062	4292	Kadyrov FA	Endonucleolytic function of MutLalpha in human mismatch repair.	Cell	2006	211
17301300	4292	Hitchins MP	Inheritance of a cancer-associated MLH1 germ-line epimutation.	The New England journal of medicine	2007	89
19273709	4292	Bertagnolli MM	Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.	Journal of clinical oncology 	2009	103
19360350	4292	Fujii H	Sphere-forming stem-like cell populations with drug resistance in human sarcoma cell lines.	International journal of oncology	2009	49
19659756	4292	Lynch HT	Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications.	Clinical genetics	2009	139
20420947	4292	Boland CR	Microsatellite instability in colorectal cancer.	Gastroenterology	2010	270
21185836	4292	Jover R	5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer.	Gastroenterology	2011	56
22156295	4292	Wang L	Whole-exome sequencing of human pancreatic cancers and characterization of genomic instability caused by MLH1 haploinsufficiency and complete deficiency.	Genome research	2012	33
22302899	4292	Sinicrope FA	Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications.	Clinical cancer research 	2012	50
23049789	4292	Antelo M	A high degree of LINE-1 hypomethylation is a unique feature of early-onset colorectal cancer.	PloS one	2012	36
23354017	4292	Rodríguez-Soler M	Risk of cancer in cases of suspected lynch syndrome without germline mutation.	Gastroenterology	2013	29
23603115	4292	Ghodgaonkar MM	Ribonucleotides misincorporated into DNA act as strand-discrimination signals in eukaryotic mismatch repair.	Molecular cell	2013	59
23821616	4292	Lang GI	Mutation rates, spectra, and genome-wide distribution of spontaneous mutations in mismatch repair deficient yeast.	G3	2013	27
25111183	4292	Lázaro-Ibáñez E	Different gDNA content in the subpopulations of prostate cancer extracellular vesicles: apoptotic bodies, microvesicles, and exosomes.	The Prostate	2014	37
25224212	4292	Billingsley CC	Polymerase ɛ (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing.	Cancer	2015	17
15464450	4297	Hess JL	MLL: a histone methyltransferase disrupted in leukemia.	Trends in molecular medicine	2004	96
17463288	4297	Barabé F	Modeling the initiation and progression of human acute leukemia in mice.	Science	2007	90
17658395	4297	Pieters R	A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial.	Lancet	2007	82
18538732	4297	Wei J	Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia.	Cancer cell	2008	108
18598942	4297	Yokoyama A	Menin critically links MLL proteins with LEDGF on cancer-associated target genes.	Cancer cell	2008	149
18806775	4297	Wang Z	Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy.	Nature	2008	90
19141473	4297	Guenther MG	Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia.	Genes and development	2008	71
19262598	4297	Meyer C	New insights to the MLL recombinome of acute leukemias.	Leukemia	2009	93
19528532	4297	Balgobind BV	Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study.	Blood	2009	58
19535349	4297	Slany RK	The molecular biology of mixed lineage leukemia.	Haematologica	2009	78
20016527	4297	Salzer WL	Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group.	Leukemia	2010	46
20093773	4297	Jin S	c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis.	The Journal of clinical investigation	2010	45
20223594	4297	Eden T	Aetiology of childhood leukaemia.	Cancer treatment reviews	2010	47
21118195	4297	Marschalek R	Mechanisms of leukemogenesis by MLL fusion proteins.	British journal of haematology	2011	37
21518926	4297	Wang QF	MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome.	Blood	2011	40
22017583	4297	Muntean AG	The pathogenesis of mixed-lineage leukemia.	Annual review of pathology	2012	73
22737091	4297	Akalin A	Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia.	PLoS genetics	2012	100
22936661	4297	Shi A	Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia.	Blood	2012	36
23628958	4297	Meyer C	The MLL recombinome of acute leukemias in 2013.	Leukemia	2013	81
25730765	4297	Andersson AK	The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias.	Nature genetics	2015	46
25998713	4297	Rao RC	Hijacked in cancer: the KMT2 (MLL) family of methyltransferases.	Nature reviews. Cancer	2015	36
26154128	4297	Sausen M	Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients.	Nature communications	2015	45
26237430	4297	Lavallée VP	The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias.	Nature genetics	2015	16
26304874	4297	Pui CH	Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration.	Journal of clinical oncology 	2015	33
26331536	4297	Zhu J	Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth.	Nature	2015	51
9539782	4582	Racila E	Detection and characterization of carcinoma cells in the blood.	Proceedings of the National Academy of Sciences of the United States of America	1998	111
14998492	4582	Ren J	Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents.	Cancer cell	2004	108
15710329	4582	Wei X	Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response.	Cancer cell	2005	74
17033037	4582	Khatcheressian JL	American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting.	Journal of clinical oncology 	2006	121
17090543	4582	Yu LG	Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer-associated MUC1 causes increased cancer cell endothelial adhesion.	The Journal of biological chemistry	2007	79
17889671	4582	Ramasamy S	The MUC1 and galectin-3 oncoproteins function in a microRNA-dependent regulatory loop.	Molecular cell	2007	76
17988798	4582	Tarp MA	Mucin-type O-glycosylation and its potential use in drug and vaccine development.	Biochimica et biophysica acta	2008	67
18698038	4582	Tothill RW	Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.	Clinical cancer research 	2008	325
19377061	4582	Yue T	The prevalence and nature of glycan alterations on specific proteins in pancreatic cancer patients revealed using antibody-lectin sandwich arrays.	Molecular and cellular proteomics 	2009	48
19491255	4582	Raina D	Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells.	Cancer research	2009	65
19706766	4582	Ahmad R	MUC1-C oncoprotein functions as a direct activator of the nuclear factor-kappaB p65 transcription factor.	Cancer research	2009	68
19861441	4582	Zwicker JI	Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy.	Clinical cancer research 	2009	76
20124478	4582	Wandall HH	Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes.	Cancer research	2010	69
21421804	4582	Raina D	Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells.	Molecular cancer therapeutics	2011	55
22019520	4582	Quoix E	Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial.	The Lancet. Oncology	2011	68
23129741	4582	Khatcheressian JL	Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update.	Journal of clinical oncology 	2013	82
23248097	4582	Kimura T	MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study.	Cancer prevention research	2013	46
23446997	4582	Remmers N	Aberrant expression of mucin core proteins and o-linked glycans associated with progression of pancreatic cancer.	Clinical cancer research 	2013	37
23484797	4582	Dawson SJ	Analysis of circulating tumor DNA to monitor metastatic breast cancer.	The New England journal of medicine	2013	320
24331154	4582	Butts C	Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.	The Lancet. Oncology	2014	67
24384091	4582	Gnemmi V	MUC1 drives epithelial-mesenchymal transition in renal carcinoma through Wnt/β-catenin pathway and interaction with SNAIL promoter.	Cancer letters	2014	22
24781336	4582	Zhai X	Abnormal expression of EMT-related proteins, S100A4, vimentin and E-cadherin, is correlated with clinicopathological features and prognosis in HCC.	Medical oncology	2014	27
2251503	4609	Blackwell TK	Sequence-specific DNA binding by the c-Myc protein.	Science	1990	260
3520340	4609	Bentley DL	A block to elongation is largely responsible for decreased transcription of c-myc in differentiated HL60 cells.	Nature	1986	257
6414718	4609	Battey J	The human c-myc oncogene: structural consequences of translocation into the IgH locus in Burkitt lymphoma.	Cell	1983	212
6961453	4609	Dalla-Favera R	Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells.	Proceedings of the National Academy of Sciences of the United States of America	1982	338
9927431	4609	Salghetti SE	Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc.	The EMBO journal	1999	112
10360173	4609	Pelengaris S	Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion.	Molecular cell	1999	129
10378696	4609	Nesbit CE	MYC oncogenes and human neoplastic disease.	Oncogene	1999	309
10637317	4609	Kyo S	Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT).	Nucleic acids research	2000	110
10713166	4609	Gregory MA	c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells.	Molecular and cellular biology	2000	117
11139609	4609	Schuhmacher M	The transcriptional program of a human B cell line in response to Myc.	Nucleic acids research	2001	108
11250904	4609	Boon K	N-myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis.	The EMBO journal	2001	95
11426647	4609	Turkson J	STAT proteins: novel molecular targets for cancer drug discovery.	Oncogene	2000	154
11509179	4609	Fuchs M	The p400 complex is an essential E1A transformation target.	Cell	2001	102
11607812	4609	Boxer LM	Translocations involving c-myc and c-myc function.	Oncogene	2001	95
11885563	4609	Oster SK	The myc oncogene: MarvelouslY Complex.	Advances in cancer research	2002	119
12183433	4609	Dimri GP	The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells.	Cancer research	2002	103
12360279	4609	Pelengaris S	c-MYC: more than just a matter of life and death.	Nature reviews. Cancer	2002	285
12676581	4609	Watnick RS	Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis.	Cancer cell	2003	95
12808131	4609	Li Z	A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells.	Proceedings of the National Academy of Sciences of the United States of America	2003	192
12808455	4609	Roix JJ	Spatial proximity of translocation-prone gene loci in human lymphomas.	Nature genetics	2003	105
14502555	4609	Calò V	STAT proteins: from normal control of cellular events to tumorigenesis.	Journal of cellular physiology	2003	132
15048125	4609	Yeh E	A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells.	Nature cell biology	2004	237
15150404	4609	Welcker M	The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation.	Proceedings of the National Academy of Sciences of the United States of America	2004	254
15250723	4609	Phan AT	Propeller-type parallel-stranded G-quadruplexes in the human c-myc promoter.	Journal of the American Chemical Society	2004	131
15498494	4609	Welcker M	A nucleolar isoform of the Fbw7 ubiquitin ligase regulates c-Myc and cell size.	Current biology 	2004	90
15661531	4609	Janssens V	PP2A: the expected tumor suppressor.	Current opinion in genetics and development	2005	114
15723054	4609	Grandori C	c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I.	Nature cell biology	2005	190
15778709	4609	Basso K	Reverse engineering of regulatory networks in human B cells.	Nature genetics	2005	461
15780936	4609	Koshiji M	HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression.	Molecular cell	2005	105
16064138	4609	Adhikary S	Transcriptional regulation and transformation by Myc proteins.	Nature reviews. Molecular cell biology	2005	302
16094360	4609	Hemann MT	Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants.	Nature	2005	152
16408022	4609	Phan AT	Small-molecule interaction with a five-guanine-tract G-quadruplex structure from the human MYC promoter.	Nature chemical biology	2005	76
16760443	4609	Dave SS	Molecular diagnosis of Burkitt's lymphoma.	The New England journal of medicine	2006	179
16904903	4609	Dang CV	The c-Myc target gene network.	Seminars in cancer biology	2006	270
16934487	4609	Vita M	The Myc oncoprotein as a therapeutic target for human cancer.	Seminars in cancer biology	2006	147
17093053	4609	Zeller KI	Global mapping of c-Myc binding sites and target gene networks in human B cells.	Proceedings of the National Academy of Sciences of the United States of America	2006	191
17114293	4609	Palomero T	NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth.	Proceedings of the National Academy of Sciences of the United States of America	2006	254
17558397	4609	Popov N	The ubiquitin-specific protease USP28 is required for MYC stability.	Nature cell biology	2007	97
17597761	4609	Dominguez-Sola D	Non-transcriptional control of DNA replication by c-Myc.	Nature	2007	194
17632056	4609	Junttila MR	CIP2A inhibits PP2A in human malignancies.	Cell	2007	170
17646408	4609	Thompson BJ	The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia.	The Journal of experimental medicine	2007	147
17906636	4609	Soucek L	Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors.	Nature medicine	2007	136
17908964	4609	Guan Y	Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer.	Clinical cancer research 	2007	98
18035408	4609	Takahashi K	Induction of pluripotent stem cells from adult human fibroblasts by defined factors.	Cell	2007	4123
18397753	4609	Wong DJ	Module map of stem cell genes guides creation of epithelial cancer stem cells.	Cell stem cell	2008	251
18567993	4609	Gurel B	Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis.	Modern pathology 	2008	112
18679422	4609	Zhuang D	C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells.	Oncogene	2008	52
18786420	4609	Maherali N	A high-efficiency system for the generation and study of human induced pluripotent stem cells.	Cell stem cell	2008	160
19200803	4609	Marion RM	Telomeres acquire embryonic stem cell characteristics in induced pluripotent stem cells.	Cell stem cell	2009	131
19219026	4609	Gao P	c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism.	Nature	2009	525
19255330	4609	Pfister S	Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci.	Journal of clinical oncology 	2009	77
19299331	4609	Loh YH	Generation of induced pluripotent stem cells from human blood.	Blood	2009	167
19448666	4609	Morrish F	c-Myc activates multiple metabolic networks to generate substrates for cell-cycle entry.	Oncogene	2009	54
19461583	4609	Napoli S	Promoter-specific transcriptional interference and c-myc gene silencing by siRNAs in human cells.	The EMBO journal	2009	51
19470954	4609	Khanna A	MYC-dependent regulation and prognostic role of CIP2A in gastric cancer.	Journal of the National Cancer Institute	2009	56
19549847	4609	Papapetrou EP	Stoichiometric and temporal requirements of Oct4, Sox2, Klf4, and c-Myc expression for efficient human iPSC induction and differentiation.	Proceedings of the National Academy of Sciences of the United States of America	2009	96
19549893	4609	Pomerantz MM	Evaluation of the 8q24 prostate cancer risk locus and MYC expression.	Cancer research	2009	53
19581307	4609	González V	Identification and characterization of nucleolin as a c-myc G-quadruplex-binding protein.	The Journal of biological chemistry	2009	73
19597184	4609	Johnson NA	Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.	Blood	2009	73
19690609	4609	Chandriani S	A core MYC gene expression signature is prominent in basal-like breast cancer but only partially overlaps the core serum response.	PloS one	2009	49
19697349	4609	Zhou W	Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells.	Stem cells	2009	119
19962879	4609	Soucek L	The ups and downs of Myc biology.	Current opinion in genetics and development	2010	60
20041972	4609	Germanguz I	Molecular characterization and functional properties of cardiomyocytes derived from human inducible pluripotent stem cells.	Journal of cellular and molecular medicine	2011	44
20129246	4609	Kim HS	SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress.	Cancer cell	2010	231
20133671	4609	Wolfer A	MYC regulation of a "poor-prognosis" metastatic cancer cell state.	Proceedings of the National Academy of Sciences of the United States of America	2010	62
20208519	4609	Chen D	Transcription-independent ARF regulation in oncogenic stress-mediated p53 responses.	Nature	2010	48
20399964	4609	Albihn A	MYC in oncogenesis and as a target for cancer therapies.	Advances in cancer research	2010	72
20434984	4609	Rahl PB	c-Myc regulates transcriptional pause release.	Cell	2010	492
20498406	4609	Barrans S	Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab.	Journal of clinical oncology 	2010	71
20940416	4609	Herishanu Y	The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.	Blood	2011	189
21059911	4609	Cairo S	Stem cell-like micro-RNA signature driven by Myc in aggressive liver cancer.	Proceedings of the National Academy of Sciences of the United States of America	2010	51
21098324	4609	Cho YJ	Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome.	Journal of clinical oncology 	2011	180
21285958	4609	Balaj L	Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences.	Nature communications	2011	218
21321600	4609	Papp B	Reprogramming to pluripotency: stepwise resetting of the epigenetic landscape.	Cell research	2011	46
21478273	4609	Sodir NM	Endogenous Myc maintains the tumor microenvironment.	Genes and development	2011	50
21692241	4609	Pike LS	Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells.	Biochimica et biophysica acta	2011	73
21949397	4609	Mertz JA	Targeting MYC dependence in cancer by inhibiting BET bromodomains.	Proceedings of the National Academy of Sciences of the United States of America	2011	284
22002575	4609	Li S	B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.	Modern pathology 	2012	34
22037351	4609	Thayanithy V	Perturbation of 14q32 miRNAs-cMYC gene network in osteosarcoma.	Bone	2012	34
22333578	4609	Vazquez-Martin A	Activation of AMP-activated protein kinase (AMPK) provides a metabolic barrier to reprogramming somatic cells into stem cells.	Cell cycle	2012	35
22463982	4609	De Los Angeles A	Accessing naïve human pluripotency.	Current opinion in genetics and development	2012	32
22615405	4609	Liu W	Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC.	Proceedings of the National Academy of Sciences of the United States of America	2012	94
22806891	4609	Holien T	Addiction to c-MYC in multiple myeloma.	Blood	2012	41
22851565	4609	Johnson NA	Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.	Journal of clinical oncology 	2012	96
23001146	4609	Calado DP	The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers.	Nature immunology	2012	53
23021215	4609	Lin CY	Transcriptional amplification in tumor cells with elevated c-Myc.	Cell	2012	375
23176581	4609	Yamada Y	Tumor-suppressive microRNA-135a inhibits cancer cell proliferation by targeting the c-MYC oncogene in renal cell carcinoma.	Cancer science	2013	29
23352430	4609	Barlow JH	Identification of early replicating fragile sites that contribute to genome instability.	Cell	2013	80
23386128	4609	Merling RK	Transgene-free iPSCs generated from small volume peripheral blood nonmobilized CD34+ cells.	Blood	2013	28
23449635	4609	Hu S	MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.	Blood	2013	75
23720054	4609	Itkonen HM	O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells.	Cancer research	2013	46
24002871	4609	Wang L	c-Myc-mediated epigenetic silencing of MicroRNA-101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma.	Hepatology	2014	41
24394663	4609	Roderick JE	c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells.	Blood	2014	28
24591536	4609	Farrell AS	MYC degradation.	Cold Spring Harbor perspectives in medicine	2014	40
24608428	4609	Poortinga G	Targeting RNA polymerase I to treat MYC-driven cancer.	Oncogene	2015	19
24793789	4609	Tsai LH	The MZF1/c-MYC axis mediates lung adenocarcinoma progression caused by wild-type lkb1 loss.	Oncogene	2015	17
24890832	4609	Gabay M	MYC activation is a hallmark of cancer initiation and maintenance.	Cold Spring Harbor perspectives in medicine	2014	69
24927563	4609	Janghorban M	Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2014	25
24933113	4609	Tu WB	Myc and its interactors take shape.	Biochimica et biophysica acta	2015	17
24951766	4609	Ryan JJ	The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure.	Circulation research	2014	27
25009295	4609	Trabucco SE	Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma.	Clinical cancer research 	2015	22
25038584	4609	Wahlström T	Impact of MYC in regulation of tumor cell metabolism.	Biochimica et biophysica acta	2015	33
25043018	4609	Walz S	Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles.	Nature	2014	89
26099045	4609	Yates LR	Subclonal diversification of primary breast cancer revealed by multiregion sequencing.	Nature medicine	2015	74
4047115	4613	Seeger RC	Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas.	The New England journal of medicine	1985	281
6719137	4613	Brodeur GM	Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage.	Science	1984	340
16306521	4613	Attiyeh EF	Chromosome 1p and 11q deletions and outcome in neuroblastoma.	The New England journal of medicine	2005	112
16954472	4613	Asgharzadeh S	Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification.	Journal of the National Cancer Institute	2006	81
17283129	4613	Chen Y	Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis.	Cancer research	2007	119
18463370	4613	Maris JM	Chromosome 6p22 locus associated with clinically aggressive neuroblastoma.	The New England journal of medicine	2008	82
19047291	4613	Cohn SL	The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.	Journal of clinical oncology 	2009	226
19111882	4613	Otto T	Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma.	Cancer cell	2009	116
19171713	4613	Janoueix-Lerosey I	Overall genomic pattern is a predictor of outcome in neuroblastoma.	Journal of clinical oncology 	2009	64
19401703	4613	Ambros PF	International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee.	British journal of cancer	2009	60
19515614	4613	Vermeulen J	Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study.	The Lancet. Oncology	2009	49
19524506	4613	Xu XL	Retinoblastoma has properties of a cone precursor tumor and depends upon cone-specific MDM2 signaling.	Cell	2009	69
19924232	4613	Bray I	Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival.	PloS one	2009	47
20173740	4613	Ma L	miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis.	Nature cell biology	2010	368
20227189	4613	Modak S	Neuroblastoma: Therapeutic strategies for a clinical enigma.	Cancer treatment reviews	2010	42
20961996	4613	Qing G	Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1alpha.	Cancer research	2010	43
21768459	4613	London WB	Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project.	Journal of clinical oncology 	2011	38
22389870	4613	Beltran H	Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.	Cancer discovery	2011	110
23358695	4613	Mosquera JM	Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer.	Neoplasia	2013	44
23430699	4613	Puissant A	Targeting MYCN in neuroblastoma by BET bromodomain inhibition.	Cancer discovery	2013	135
23498719	4613	Rushlow DE	Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies.	The Lancet. Oncology	2013	43
23890779	4613	Kreissman SG	Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.	The Lancet. Oncology	2013	36
24009722	4613	Wyce A	BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.	PloS one	2013	32
25142020	4613	Ren P	ATF4 and N-Myc coordinate glutamine metabolism in MYCN-amplified neuroblastoma cells through ASCT2 activation.	The Journal of pathology	2015	21
25533335	4613	Hill RM	Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease.	Cancer cell	2015	18
26539795	4613	Bosse KR	Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations.	Cancer	2016	14
1694727	4763	Viskochil D	Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus.	Cell	1990	165
2114220	4763	Cawthon RM	A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations.	Cell	1990	171
2116237	4763	Xu GF	The neurofibromatosis type 1 gene encodes a protein related to GAP.	Cell	1990	172
2121371	4763	Ballester R	The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins.	Cell	1990	151
2134734	4763	Wallace MR	Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients.	Science	1990	223
9207339	4763	Gutmann DH	The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2.	JAMA	1997	173
11894862	4763	Ferner RE	International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis.	Cancer research	2002	89
16217056	4763	Hyman SL	The nature and frequency of cognitive deficits in children with neurofibromatosis type 1.	Neurology	2005	76
16330947	4763	Miettinen M	Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases.	The American journal of surgical pathology	2006	69
17283119	4763	Sharma MK	Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin.	Cancer research	2007	59
17387725	4763	Listernick R	Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations.	Annals of neurology	2007	64
19111880	4763	Alcantara Llaguno S	Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model.	Cancer cell	2009	197
19474676	4763	Zou C	Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome.	Annals of surgery	2009	50
19539839	4763	Boyd KP	Neurofibromatosis type 1.	Journal of the American Academy of Dermatology	2009	54
19576851	4763	van Nederveen FH	An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis.	The Lancet. Oncology	2009	69
20027112	4763	Jett K	Clinical and genetic aspects of neurofibromatosis 1.	Genetics in medicine 	2010	59
20821343	4763	Wiemels J	Epidemiology and etiology of meningioma.	Journal of neuro-oncology	2010	83
21262951	4763	Eisenhofer G	Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma.	Clinical chemistry	2011	40
21861229	4763	Stucky CC	Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience.	Annals of surgical oncology	2012	37
22328163	4763	Gimenez-Roqueplo AP	An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes.	Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme	2012	39
22544022	4763	Carter SL	Absolute quantification of somatic DNA alterations in human cancer.	Nature biotechnology	2012	316
23099009	4763	Robertson KA	Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial.	The Lancet. Oncology	2012	33
23288408	4763	Whittaker SR	A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.	Cancer discovery	2013	79
24814062	4763	Maertens O	An expanding role for RAS GTPase activating proteins (RAS GAPs) in cancer.	Advances in biological regulation	2014	22
25049390	4763	Chen PC	Next-generation sequencing identifies rare variants associated with Noonan syndrome.	Proceedings of the National Academy of Sciences of the United States of America	2014	21
25710373	4763	Schwarz RF	Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis.	PLoS medicine	2015	52
25877329	4763	Ratner N	A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.	Nature reviews. Cancer	2015	35
26017449	4763	Patch AM	Whole-genome characterization of chemoresistant ovarian cancer.	Nature	2015	123
26214590	4763	Krauthammer M	Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas.	Nature genetics	2015	40
26580448	4763	Zhang J	Germline Mutations in Predisposition Genes in Pediatric Cancer.	The New England journal of medicine	2015	43
1831692	4851	Ellisen LW	TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms.	Cell	1991	380
10669757	4851	Rand MD	Calcium depletion dissociates and activates heterodimeric notch receptors.	Molecular and cellular biology	2000	110
10801437	4851	Lowell S	Stimulation of human epidermal differentiation by delta-notch signalling at the boundaries of stem-cell clusters.	Current biology 	2000	103
11062542	4851	Varnum-Finney B	Pluripotent, cytokine-dependent, hematopoietic stem cells are immortalized by constitutive Notch1 signaling.	Nature medicine	2000	133
14670925	4851	Nefedova Y	Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines.	Blood	2004	80
15472075	4851	Weng AP	Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.	Science	2004	749
15976178	4851	Delaney C	Dose-dependent effects of the Notch ligand Delta1 on ex vivo differentiation and in vivo marrow repopulating ability of cord blood cells.	Blood	2005	77
16651424	4851	Mungamuri SK	Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53.	Cancer research	2006	67
16738328	4851	Malecki MJ	Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes.	Molecular and cellular biology	2006	88
17173050	4851	Vilimas T	Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia.	Nature medicine	2007	91
17344417	4851	Lefort K	Notch1 is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCK1/2 and MRCKalpha kinases.	Genes and development	2007	105
17575125	4851	Malyukova A	The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling.	Cancer research	2007	57
17804701	4851	Chen Y	Oxygen concentration determines the biological effects of NOTCH-1 signaling in adenocarcinoma of the lung.	Cancer research	2007	66
17873882	4851	Palomero T	Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia.	Nature medicine	2007	277
18039126	4851	Aster JC	Notch signaling in leukemia.	Annual review of pathology	2008	110
18924608	4851	Bedogni B	Notch1 is an effector of Akt and hypoxia in melanoma development.	The Journal of clinical investigation	2008	71
19151708	4851	Rustighi A	The prolyl-isomerase Pin1 is a Notch1 target that enhances Notch1 activation in cancer.	Nature cell biology	2009	53
19491270	4851	Yeh TS	The activated Notch1 signal pathway is associated with gastric cancer progression through cyclooxygenase-2.	Cancer research	2009	52
20007775	4851	Westhoff B	Alterations of the Notch pathway in lung cancer.	Proceedings of the National Academy of Sciences of the United States of America	2009	110
20008221	4851	Ferrando AA	The role of NOTCH1 signaling in T-ALL.	Hematology. American Society of Hematology. Education Program	2009	51
20056578	4851	Tokar EJ	Arsenic exposure transforms human epithelial stem/progenitor cells into a cancer stem-like phenotype.	Environmental health perspectives	2010	41
20190812	4851	Gao MQ	CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells.	Oncogene	2010	83
21139809	4851	Sethi S	Molecular signature of epithelial-mesenchymal transition (EMT) in human prostate cancer bone metastasis.	American journal of translational research	2010	61
21463919	4851	Bao B	Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells.	Cancer letters	2011	104
21798897	4851	Agrawal N	Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1.	Science	2011	496
21948802	4851	Lobry C	Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think.	The Journal of experimental medicine	2011	94
22077063	4851	Rossi D	Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.	Blood	2012	63
22173954	4851	Xie M	Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells.	Journal of cellular biochemistry	2012	41
22207691	4851	Del Giudice I	NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL.	Haematologica	2012	36
22210878	4851	Kridel R	Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma.	Blood	2012	52
22863622	4851	Kim HA	Notch1 counteracts WNT/β-catenin signaling through chromatin modification in colorectal cancer.	The Journal of clinical investigation	2012	30
23135908	4851	Liu YP	Cisplatin selects for multidrug-resistant CD133+ cells in lung adenocarcinoma by activating Notch signaling.	Cancer research	2013	35
23295735	4851	Villamor N	NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome.	Leukemia	2013	26
23825651	4851	Kluk MJ	Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry.	PloS one	2013	28
24401270	4851	Gutierrez A	Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia.	The Journal of clinical investigation	2014	37
24662767	4851	South AP	NOTCH1 mutations occur early during cutaneous squamous cell carcinogenesis.	The Journal of investigative dermatology	2014	30
25104330	4851	Stoeck A	Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.	Cancer discovery	2014	25
25194570	4851	Herranz D	A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia.	Nature medicine	2014	45
25477004	4851	Yuan X	Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application.	Journal of hematology and oncology	2014	34
26681674	4851	San Lucas FA	Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes.	Annals of oncology 	2016	13
15193898	5068	O'Malley AS	The role of trust in use of preventive services among low-income African-American women.	Preventive medicine	2004	84
15870438	5068	Leyden WA	Cervical cancer in women with comprehensive health care access: attributable factors in the screening process.	Journal of the National Cancer Institute	2005	70
16428484	5068	Koopmann J	Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9.	Clinical cancer research 	2006	65
17942872	5068	Naucler P	Human papillomavirus and Papanicolaou tests to screen for cervical cancer.	The New England journal of medicine	2007	158
18802779	5068	Howard M	Accuracy of self-reports of Pap and mammography screening compared to medical record: a meta-analysis.	Cancer causes and control 	2009	48
23519302	5068	Katki HA	Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines.	Journal of lower genital tract disease	2013	31
23618210	5068	Racey CS	Self-collected HPV testing improves participation in cervical cancer screening: a systematic review and meta-analysis.	Canadian journal of public health = Revue canadienne de sante publique	2013	28
24938522	5068	O'Brien DP	Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection.	Clinical cancer research 	2015	20
26687425	5068	Levine JE	A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study.	The Lancet. Haematology	2015	31
1360704	5243	Cole SP	Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line.	Science	1992	341
2432605	5243	Fojo AT	Expression of a multidrug-resistance gene in human tumors and tissues.	Proceedings of the National Academy of Sciences of the United States of America	1987	176
2444983	5243	Thiebaut F	Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.	Proceedings of the National Academy of Sciences of the United States of America	1987	302
2563168	5243	Cordon-Cardo C	Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites.	Proceedings of the National Academy of Sciences of the United States of America	1989	193
2876781	5243	Chen CJ	Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells.	Cell	1986	250
14576852	5243	Ambudkar SV	P-glycoprotein: from genomics to mechanism.	Oncogene	2003	159
15324696	5243	Szakács G	Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells.	Cancer cell	2004	113
15711560	5243	Morizono K	Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection.	Nature medicine	2005	71
17015488	5243	Sarkadi B	Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system.	Physiological reviews	2006	134
17513612	5243	Han W	Shikonin circumvents cancer drug resistance by induction of a necroptotic death.	Molecular cancer therapeutics	2007	74
17942888	5243	Sauna ZE	Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer.	Cancer research	2007	60
17947497	5243	Shen F	Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells.	The Journal of pharmacology and experimental therapeutics	2008	53
18441325	5243	Bourguignon LY	Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells.	The Journal of biological chemistry	2008	109
18713866	5243	Dubikovskaya EA	Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters.	Proceedings of the National Academy of Sciences of the United States of America	2008	55
18829547	5243	Dai CL	Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.	Cancer research	2008	90
19147780	5243	Mita AC	Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors.	Clinical cancer research 	2009	58
19349543	5243	Lara PN Jr	Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.	Journal of clinical oncology 	2009	82
19383919	5243	Dong X	Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP.	Cancer research	2009	50
20388796	5243	Yoo BK	Molecular mechanism of chemoresistance by astrocyte elevated gene-1.	Cancer research	2010	45
20731437	5243	Meng H	Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line.	ACS nano	2010	95
21627074	5243	Xiong XB	Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin.	ACS nano	2011	52
21967057	5243	Sharom FJ	The P-glycoprotein multidrug transporter.	Essays in biochemistry	2011	64
22344233	5243	Chen KG	Molecular pathways: regulation and therapeutic implications of multidrug resistance.	Clinical cancer research 	2012	34
22409994	5243	Shaffer BC	Drug resistance: still a daunting challenge to the successful treatment of AML.	Drug resistance updates 	2012	36
23289892	5243	Meng H	Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo.	ACS nano	2013	57
23721823	5243	Januchowski R	The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance.	Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie	2013	27
24311721	5243	Laszlo GS	Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.	Blood	2014	25
24958102	5243	Wang Y	Long noncoding RNA MRUL promotes ABCB1 expression in multidrug-resistant gastric cancer cell sublines.	Molecular and cellular biology	2014	23
9916799	5290	Shayesteh L	PIK3CA is implicated as an oncogene in ovarian cancer.	Nature genetics	1999	198
15016963	5290	Samuels Y	High frequency of mutations of the PIK3CA gene in human cancers.	Science	2004	909
15467468	5290	Samuels Y	Oncogenic mutations of PIK3CA in human cancers.	Cell cycle	2004	125
15520168	5290	Campbell IG	Mutation of the PIK3CA gene in ovarian and breast cancer.	Cancer research	2004	221
15647370	5290	Kang S	Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.	Proceedings of the National Academy of Sciences of the United States of America	2005	205
15805248	5290	Saal LH	PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.	Cancer research	2005	253
15930273	5290	Ikenoue T	Functional analysis of PIK3CA gene mutations in human colorectal cancer.	Cancer research	2005	96
15950905	5290	Samuels Y	Mutant PIK3CA promotes cell growth and invasion of human cancer cells.	Cancer cell	2005	287
16288007	5290	García-Rostán G	Mutation of the PIK3CA gene in anaplastic thyroid cancer.	Cancer research	2005	81
16322209	5290	Oda K	High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma.	Cancer research	2005	110
16322248	5290	Isakoff SJ	Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells.	Cancer research	2005	167
16339315	5290	Zhao JJ	The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells.	Proceedings of the National Academy of Sciences of the United States of America	2005	119
16357568	5290	Samuels Y	Oncogenic PI3K and its role in cancer.	Current opinion in oncology	2006	127
16432179	5290	Bader AG	Cancer-specific mutations in PIK3CA are oncogenic in vivo.	Proceedings of the National Academy of Sciences of the United States of America	2006	114
16449998	5290	Karakas B	Mutation of the PIK3CA oncogene in human cancers.	British journal of cancer	2006	97
16930767	5290	Kawano O	PIK3CA mutation status in Japanese lung cancer patients.	Lung cancer	2006	72
17060456	5290	Kim JS	Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA.	Molecular and cellular biology	2007	59
17314276	5290	Hollestelle A	Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines.	Molecular cancer research 	2007	106
17575221	5290	Pérez-Tenorio G	PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer.	Clinical cancer research 	2007	91
17936563	5290	Berns K	A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.	Cancer cell	2007	406
18079394	5290	Huang CH	The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations.	Science	2007	144
18754654	5290	Folkes AJ	The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno3,2-dpyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .	Journal of medicinal chemistry	2008	177
18757405	5290	Yamamoto H	PIK3CA mutations and copy number gains in human lung cancers.	Cancer research	2008	140
18794883	5290	Zhao L	Class I PI3K in oncogenic cellular transformation.	Oncogene	2008	155
18829560	5290	Serra V	NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.	Cancer research	2008	251
19223544	5290	Sartore-Bianchi A	PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.	Cancer research	2009	197
19261849	5290	Salvesen HB	Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation.	Proceedings of the National Academy of Sciences of the United States of America	2009	83
19276248	5290	Gonzalez-Angulo AM	Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer.	Clinical cancer research 	2009	67
19349352	5290	Kuo KT	Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma.	The American journal of pathology	2009	89
19573809	5290	Vasudevan KM	AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.	Cancer cell	2009	179
19584227	5290	Raynaud FI	Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941.	Molecular cancer therapeutics	2009	68
19671852	5290	Kalinsky K	PIK3CA mutation associates with improved outcome in breast cancer.	Clinical cancer research 	2009	102
19685490	5290	López-Knowles E	PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality.	International journal of cancer	2010	65
19805105	5290	Mandelker D	A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane.	Proceedings of the National Academy of Sciences of the United States of America	2009	92
20699365	5290	Halilovic E	PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.	Cancer research	2010	49
20813970	5290	Esteva FJ	PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.	The American journal of pathology	2010	94
20940279	5290	Dupont Jensen J	PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer.	Clinical cancer research 	2011	54
21266528	5290	Rudd ML	A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas.	Clinical cancer research 	2011	71
21276610	5290	Anglesio MS	Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010.	Gynecologic oncology	2011	39
21358673	5290	Weigelt B	PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.	Oncogene	2011	65
21474066	5290	Kennedy AL	Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis.	Molecular cell	2011	66
21482677	5290	Meyer DS	Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors.	Cancer research	2011	40
21490305	5290	Gonzalez-Angulo AM	PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.	Molecular cancer therapeutics	2011	71
21594665	5290	Razis E	Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.	Breast cancer research and treatment	2011	67
21676217	5290	Wang L	PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib.	BMC cancer	2011	50
21708979	5290	Yamaguchi H	Phosphoinositide 3-kinase signaling pathway mediated by p110α regulates invadopodia formation.	The Journal of cell biology	2011	45
21822287	5290	Liu P	Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms.	Nature medicine	2011	88
21829508	5290	Janku F	PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.	PloS one	2011	60
22039088	5290	Mao C	PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.	Annals of oncology 	2012	51
22157930	5290	Yamamoto S	Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations.	Modern pathology 	2012	43
22188813	5290	Maira SM	Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.	Molecular cancer therapeutics	2012	118
22252965	5290	Hernandez L	Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection.	The Journal of pathology	2012	40
22271473	5290	Janku F	PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.	Journal of clinical oncology 	2012	145
22285706	5290	Sood A	PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.	Clinical colorectal cancer	2012	33
22330809	5290	Cizkova M	PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups.	Breast cancer research 	2012	41
22357840	5290	Liao X	Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review.	Clinical cancer research 	2012	88
22421194	5290	Higgins MJ	Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood.	Clinical cancer research 	2012	56
22525820	5290	del Carmen MG	Clear cell carcinoma of the ovary: a review of the literature.	Gynecologic oncology	2012	35
22923510	5290	Kuhn E	Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.	Journal of the National Cancer Institute	2012	58
23066039	5290	Janku F	PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.	Cancer research	2013	76
23092874	5290	Chandarlapaty S	Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer.	Clinical cancer research 	2012	43
23094721	5290	Liao X	Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.	The New England journal of medicine	2012	204
23136191	5290	Spoerke JM	Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.	Clinical cancer research 	2012	41
23248156	5290	Janku F	PIK3CA mutations in advanced cancers: characteristics and outcomes.	Oncotarget	2012	30
23532889	5290	Shigaki H	PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma.	Clinical cancer research 	2013	28
23739063	5290	Loi S	Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer.	Journal of the National Cancer Institute	2013	34
23785428	5290	Rosty C	PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival.	PloS one	2013	31
23903756	5290	Elkabets M	mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.	Science translational medicine	2013	68
24062397	5290	Domingo E	Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer.	Journal of clinical oncology 	2013	44
24218517	5290	Karapetis CS	PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17.	Clinical cancer research 	2014	25
24504125	5290	Beaver JA	Detection of cancer DNA in plasma of patients with early-stage breast cancer.	Clinical cancer research 	2014	34
24533074	5290	Wang L	PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.	PloS one	2014	25
24608574	5290	Fritsch C	Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.	Molecular cancer therapeutics	2014	52
24736592	5290	Toschi L	Increased SOX2 gene copy number is associated with FGFR1 and PIK3CA gene gain in non-small cell lung cancer and predicts improved survival in early stage disease.	PloS one	2014	20
24910434	5290	Henderson S	APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development.	Cell reports	2014	55
25099740	5290	Wang Z	mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations.	Journal of the National Cancer Institute	2014	22
25199759	5290	Loibl S	PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.	Journal of clinical oncology 	2014	41
25409150	5290	Juric D	Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor.	Nature	2015	60
25539732	5290	Pestrin M	Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients.	Molecular oncology	2015	22
25847936	5290	Isakoff SJ	TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.	Journal of clinical oncology 	2015	43
26392102	5290	Corcoran RB	Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.	Journal of clinical oncology 	2015	48
27096951	5290	Elwood PC	Aspirin in the Treatment of Cancer: Reductions in Metastatic Spread and in Mortality: A Systematic Review and Meta-Analyses of Published Studies.	PloS one	2016	16
7790358	5347	Golsteyn RM	Cell cycle regulation of the activity and subcellular localization of Plk1, a human protein kinase implicated in mitotic spindle function.	The Journal of cell biology	1995	139
8991084	5347	Lane HA	Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes.	The Journal of cell biology	1996	191
12524548	5347	Jackman M	Active cyclin B1-Cdk1 first appears on centrosomes in prophase.	Nature cell biology	2003	178
12732729	5347	Liu X	Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells.	Proceedings of the National Academy of Sciences of the United States of America	2003	113
14734534	5347	Lindon C	Ordered proteolysis in anaphase inactivates Plk1 to contribute to proper mitotic exit in human cells.	The Journal of cell biology	2004	102
15210710	5347	van Vugt MA	Polo-like kinase-1 is required for bipolar spindle formation but is dispensable for anaphase promoting complex/Cdc20 activation and initiation of cytokinesis.	The Journal of biological chemistry	2004	76
15350223	5347	van Vugt MA	Polo-like kinase-1 controls recovery from a G2 DNA damage-induced arrest in mammalian cells.	Molecular cell	2004	110
15766665	5347	Gumireddy K	ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent.	Cancer cell	2005	79
15838519	5347	van Vugt MA	Getting in and out of mitosis with Polo-like kinase-1.	Oncogene	2005	80
16507989	5347	Liu X	Normal cells, but not cancer cells, survive severe Plk1 depletion.	Molecular and cellular biology	2006	101
17081991	5347	Kang YH	Self-regulated Plk1 recruitment to kinetochores by the Plk1-PBIP1 interaction is critical for proper chromosome segregation.	Molecular cell	2006	98
17291758	5347	Steegmaier M	BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.	Current biology 	2007	230
17671160	5347	Santamaria A	Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis.	Molecular biology of the cell	2007	76
18477449	5347	Petronczki M	Polo on the Rise-from Mitotic Entry to Cytokinesis with Plk1.	Developmental cell	2008	174
18482698	5347	Reindl W	Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions.	Chemistry and biology	2008	58
18662541	5347	Bassermann F	The Cdc14B-Cdh1-Plk1 axis controls the G2 DNA-damage-response checkpoint.	Cell	2008	145
19305416	5347	Archambault V	Polo-like kinases: conservation and divergence in their functions and regulation.	Nature reviews. Molecular cell biology	2009	204
19474163	5347	Schöffski P	Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology.	The oncologist	2009	51
19758559	5347	Tsou MF	Polo kinase and separase regulate the mitotic licensing of centriole duplication in human cells.	Developmental cell	2009	92
20068088	5347	Degenhardt Y	Targeting Polo-like kinase in cancer therapy.	Clinical cancer research 	2010	62
20148280	5347	Park JE	Polo-box domain: a versatile mediator of polo-like kinase function.	Cellular and molecular life sciences 	2010	54
22014944	5347	Zhou J	Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors.	Biomaterials	2012	42
22119200	5347	Schöffski P	A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours.	European journal of cancer	2012	46
23144294	5347	Maire V	Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer.	Cancer research	2013	36
25027517	5347	Gjertsen BT	Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy.	Leukemia	2015	31
25619835	5347	Archambault V	Understanding the Polo Kinase machine.	Oncogene	2015	24
27120157	5347	Zhang S	Molecular mechanism of APC/C activation by mitotic phosphorylation.	Nature	2016	15
17978289	5707	Sakuramoto S	Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.	The New England journal of medicine	2007	334
18282805	5707	Koizumi W	S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.	The Lancet. Oncology	2008	297
19230702	5707	Catalano V	Gastric cancer.	Critical reviews in oncology/hematology	2009	94
20159816	5707	Ajani JA	Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial.	Journal of clinical oncology 	2010	91
24366758	5707	Koizumi W	Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START).	Journal of cancer research and clinical oncology	2014	23
25316259	5707	Yamada Y	Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer.	Annals of oncology 	2015	22
27265347	5707	Uesaka K	Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).	Lancet	2016	12
9072974	5728	Li J	PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.	Science	1997	1013
9090379	5728	Steck PA	Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.	Nature genetics	1997	558
9187108	5728	Li DM	TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta.	Cancer research	1997	175
9307275	5728	Tashiro H	Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies.	Cancer research	1997	127
9443392	5728	Suzuki H	Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues.	Cancer research	1998	100
9467011	5728	Marsh DJ	Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation.	Human molecular genetics	1998	118
9560261	5728	Whang YE	Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression.	Proceedings of the National Academy of Sciences of the United States of America	1998	137
10209156	5728	Leevers SJ	Signalling through phosphoinositide 3-kinases: the lipids take centre stage.	Current opinion in cell biology	1999	126
10555148	5728	Lee JO	Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association.	Cell	1999	274
10564676	5728	Ali IU	Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity.	Journal of the National Cancer Institute	1999	113
11559746	5728	Yamada KM	Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis.	Journal of cell science	2001	100
15077152	5728	Gozuacik D	Autophagy as a cell death and tumor suppressor mechanism.	Oncogene	2004	305
15193142	5728	Leslie NR	PTEN function: how normal cells control it and tumour cells lose it.	The Biochemical journal	2004	104
15766664	5728	Kim RH	DJ-1, a novel regulator of the tumor suppressor PTEN.	Cancer cell	2005	125
15805158	5728	Butler MG	Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations.	Journal of medical genetics	2005	196
15960972	5728	Westbrook TF	A genetic screen for candidate tumor suppressors identifies REST.	Cell	2005	166
16412571	5728	Chow LM	PTEN function in normal and neoplastic growth.	Cancer letters	2006	69
17218261	5728	Trotman LC	Ubiquitination regulates PTEN nuclear import and tumor suppression.	Cell	2007	205
17452630	5728	Saal LH	Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity.	Proceedings of the National Academy of Sciences of the United States of America	2007	178
17560336	5728	Vivanco I	Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN.	Cancer cell	2007	86
17908983	5728	Lu CH	Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency.	Clinical cancer research 	2007	69
17940504	5728	Frattini M	PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients.	British journal of cancer	2007	135
18032782	5728	Tamguney T	New insights into PTEN.	Journal of cell science	2007	83
18066063	5728	Saal LH	Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair.	Nature genetics	2008	128
18500259	5728	Yoshimoto M	Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome.	Modern pathology 	2008	79
18767981	5728	Chalhoub N	PTEN and the PI3-kinase pathway in cancer.	Annual review of pathology	2009	251
18794879	5728	Yin Y	PTEN: a new guardian of the genome.	Oncogene	2008	93
18830414	5728	Silva A	PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability.	The Journal of clinical investigation	2008	110
19055754	5728	Marty B	Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells.	Breast cancer research 	2008	60
19402094	5728	Sircar K	PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer.	The Journal of pathology	2009	70
19458356	5728	Gutierrez A	High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia.	Blood	2009	122
19638581	5728	Faratian D	Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab.	Cancer research	2009	49
19729658	5728	Fine B	Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a.	Science	2009	79
19884659	5728	Song LB	The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells.	The Journal of clinical investigation	2009	122
19962668	5728	Garofalo M	miR-221&amp;amp;222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation.	Cancer cell	2009	222
20516122	5728	Mao X	Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis.	Cancer research	2010	56
20530668	5728	McEllin B	PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors.	Cancer research	2010	73
20533527	5728	McBride KL	Confirmation study of PTEN mutations among individuals with autism or developmental delays/mental retardation and macrocephaly.	Autism research 	2010	61
20600018	5728	Heald B	Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers.	Gastroenterology	2010	42
21194675	5728	Tan MH	A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands.	American journal of human genetics	2011	68
21241890	5728	Song MS	Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner.	Cell	2011	128
21725359	5728	Xing F	Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF.	Oncogene	2012	60
21779461	5728	Koh CM	MYC and Prostate Cancer.	Genes and cancer	2010	46
21828076	5728	Rodríguez-Escudero I	A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.	Human molecular genetics	2011	46
21878536	5728	Lotan TL	PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients.	Clinical cancer research 	2011	73
22047762	5728	Clavien PA	Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report.	The Lancet. Oncology	2012	115
22123976	5728	Markert EK	Molecular classification of prostate cancer using curated expression signatures.	Proceedings of the National Academy of Sciences of the United States of America	2011	68
22252256	5728	Tan MH	Lifetime cancer risks in individuals with germline PTEN mutations.	Clinical cancer research 	2012	93
22465665	5728	Fu X	Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells.	FEBS letters	2012	45
22473468	5728	Song MS	The functions and regulation of the PTEN tumour suppressor.	Nature reviews. Molecular cell biology	2012	431
22628410	5728	Martins FC	Evolutionary pathways in BRCA1-associated breast tumors.	Cancer discovery	2012	41
22674438	5728	Antonarakis ES	An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy.	Cancer	2012	31
22970944	5728	Pal A	PTEN mutations as a cause of constitutive insulin sensitivity and obesity.	The New England journal of medicine	2012	41
23060044	5728	Wu Z	Upregulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer.	The Prostate	2013	29
23335809	5728	Bubien V	High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome.	Journal of medical genetics	2013	30
23613428	5728	Mester J	When overgrowth bumps into cancer: the PTEN-opathies.	American journal of medical genetics. Part C, Seminars in medical genetics	2013	33
23670029	5728	Said R	P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy.	Oncotarget	2013	27
23748611	5728	Yin Z	A screen for morphological complexity identifies regulators of switch-like transitions between discrete cell shapes.	Nature cell biology	2013	47
24026406	5728	Zhang G	MicroRNA-92a functions as an oncogene in colorectal cancer by targeting PTEN.	Digestive diseases and sciences	2014	22
24076665	5728	Filbin MG	Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities.	Nature medicine	2013	33
24080776	5728	Michelotti GA	NAFLD, NASH and liver cancer.	Nature reviews. Gastroenterology and hepatology	2013	108
24135135	5728	Haffner MC	Tracking the clonal origin of lethal prostate cancer.	The Journal of clinical investigation	2013	95
24265155	5728	Shi H	Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.	Cancer discovery	2014	163
24768297	5728	Liang H	PTENα, a PTEN isoform translated through alternative initiation, regulates mitochondrial function and energy metabolism.	Cell metabolism	2014	38
24905788	5728	Worby CA	PTEN.	Annual review of biochemistry	2014	47
24993522	5728	Lotan TL	PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy.	Modern pathology 	2015	19
25117714	5728	Ozawa T	Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma.	Cancer cell	2014	54
25190698	5728	Daly MB	Genetic/familial high-risk assessment: breast and ovarian, version 1.2014.	Journal of the National Comprehensive Cancer Network 	2014	30
25763354	5728	Milella M	PTEN: Multiple Functions in Human Malignant Tumors.	Frontiers in oncology	2015	32
25913390	5728	Boström PJ	Genomic Predictors of Outcome in Prostate Cancer.	European urology	2015	20
26123120	5728	Ross AE	Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer.	Prostate cancer and prostatic diseases	2016	11
26546618	5728	Aparicio AM	Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers.	Clinical cancer research 	2016	11
26615022	5728	Ahearn TU	A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.	Journal of the National Cancer Institute	2016	13
1316611	5925	Chellappan S	Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product.	Proceedings of the National Academy of Sciences of the United States of America	1992	172
1648218	5925	Scheffner M	The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines.	Proceedings of the National Academy of Sciences of the United States of America	1991	178
1825028	5925	Kaelin WG Jr	Identification of cellular proteins that can interact specifically with the T/E1A-binding region of the retinoblastoma gene product.	Cell	1991	182
2157286	5925	Werness BA	Association of human papillomavirus types 16 and 18 E6 proteins with p53.	Science	1990	524
2537532	5925	Dyson N	The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product.	Science	1989	700
2673546	5925	Chen PL	Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation.	Cell	1989	215
6633649	5925	Cavenee WK	Expression of recessive alleles by chromosomal mechanisms in retinoblastoma.	Nature	1983	314
8490963	5925	Dowdy SF	Physical interaction of the retinoblastoma protein with human D cyclins.	Cell	1993	186
11545733	5925	Thomas DM	The retinoblastoma protein acts as a transcriptional coactivator required for osteogenic differentiation.	Molecular cell	2001	117
12445661	5925	Münger K	Human papillomavirus immortalization and transformation functions.	Virus research	2002	168
12853964	5925	Sage J	Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry.	Nature	2003	193
15240783	5925	Braakhuis BJ	Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus.	Journal of the National Cancer Institute	2004	87
16809779	5925	Sakamaki T	Cyclin D1 determines mitochondrial function in vivo.	Molecular and cellular biology	2006	63
17645777	5925	Narisawa-Saito M	Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins.	Cancer science	2007	68
18211953	5925	Dimaras H	Loss of RB1 induces non-proliferative retinoma: increasing genomic instability correlates with progression to retinoblastoma.	Human molecular genetics	2008	58
18583314	5925	Montanaro L	Nucleolus, ribosomes, and cancer.	The American journal of pathology	2008	113
18650841	5925	Burkhart DL	Cellular mechanisms of tumour suppression by the retinoblastoma gene.	Nature reviews. Cancer	2008	271
18782450	5925	Herschkowitz JI	The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas.	Breast cancer research 	2008	86
18805009	5925	Polager S	E2F - at the crossroads of life and death.	Trends in cell biology	2008	94
19851314	5925	Chen HZ	Emerging roles of E2Fs in cancer: an exit from cell cycle control.	Nature reviews. Cancer	2009	247
21295686	5925	Chinnam M	RB1, development, and cancer.	Current topics in developmental biology	2011	45
21397855	5925	Chow LM	Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain.	Cancer cell	2011	84
22033280	5925	Kolb T	Lamin A and lamin C form homodimers and coexist in higher complex forms both in the nucleoplasmic fraction and in the lamina of cultured human cells.	Nucleus	2011	36
22529291	5925	Egan JB	Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides.	Blood	2012	85
23618872	5925	Hilgendorf KI	The retinoblastoma protein induces apoptosis directly at the mitochondria.	Genes and development	2013	41
25252974	5925	Xu XL	Rb suppresses human cone-precursor-derived retinoblastoma tumours.	Nature	2014	24
25614009	5925	Hamamoto R	Critical roles of non-histone protein lysine methylation in human tumorigenesis.	Nature reviews. Cancer	2015	44
25621664	5925	Benavente CA	Genetics and epigenetics of human retinoblastoma.	Annual review of pathology	2015	16
26168399	5925	George J	Comprehensive genomic profiles of small cell lung cancer.	Nature	2015	94
27401552	5925	Dyson NJ	RB1: a prototype tumor suppressor and an enigma.	Genes and development	2016	17
8099202	5979	Mulligan LM	Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.	Nature	1993	182
12000816	5979	Neumann HP	Germ-line mutations in nonsyndromic pheochromocytoma.	The New England journal of medicine	2002	169
12881714	5979	Soares P	BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC.	Oncogene	2003	101
15769183	5979	Cerchia L	Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase.	PLoS biology	2005	67
15982921	5979	Arighi E	RET tyrosine kinase signaling in development and cancer.	Cytokine and growth factor reviews	2005	69
16314641	5979	Amar L	Genetic testing in pheochromocytoma or functional paraganglioma.	Journal of clinical oncology 	2005	92
18073307	5979	Elisei R	Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.	The Journal of clinical endocrinology and metabolism	2008	56
19164557	5979	Gajiwala KS	KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients.	Proceedings of the National Academy of Sciences of the United States of America	2009	73
19318445	5979	Nikiforov YE	Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules.	The Journal of clinical endocrinology and metabolism	2009	103
19469690	5979	American Thyroid Association Guidelines Task Force.	Medullary thyroid cancer: management guidelines of the American Thyroid Association.	Thyroid 	2009	175
19758803	5979	Lai AZ	Crosstalk in Met receptor oncogenesis.	Trends in cell biology	2009	64
20130073	5979	Cantara S	Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology.	The Journal of clinical endocrinology and metabolism	2010	51
21878896	5979	Nikiforov YE	Molecular genetics and diagnosis of thyroid cancer.	Nature reviews. Endocrinology	2011	126
22025146	5979	Wells SA Jr	Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.	Journal of clinical oncology 	2012	186
22327624	5979	Kohno T	KIF5B-RET fusions in lung adenocarcinoma.	Nature medicine	2012	170
23150706	5979	Wang R	RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer.	Journal of clinical oncology 	2012	77
23584301	5979	Gautschi O	A patient with lung adenocarcinoma and RET fusion treated with vandetanib.	Journal of thoracic oncology 	2013	34
24248188	5979	Jung CK	The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations.	The Journal of clinical endocrinology and metabolism	2014	49
12944571	6317	Grossman HB	Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.	The New England journal of medicine	2003	247
18617440	6317	Brantsch KD	Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study.	The Lancet. Oncology	2008	59
18971419	6317	Rizzo JD	Solid cancers after allogeneic hematopoietic cell transplantation.	Blood	2009	71
19949014	6317	Gunderson LL	Revised TN categorization for colon cancer based on national survival outcomes data.	Journal of clinical oncology 	2010	78
20643781	6317	Wilkerson MD	Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types.	Clinical cancer research 	2010	54
22251204	6317	Lomas A	A systematic review of worldwide incidence of nonmelanoma skin cancer.	The British journal of dermatology	2012	120
22370316	6317	Zhang M	Use of tanning beds and incidence of skin cancer.	Journal of clinical oncology 	2012	38
23104323	6317	Van de Velde N	Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis.	Journal of the National Cancer Institute	2012	37
24524818	6317	Lortet-Tieulent J	International trends in lung cancer incidence by histological subtype: adenocarcinoma stabilizing in men but still increasing in women.	Lung cancer	2014	28
9288757	7015	Meyerson M	hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization.	Cell	1997	354
9454332	7015	Bodnar AG	Extension of life-span by introduction of telomerase into normal human cells.	Science	1998	850
9501072	7015	Vaziri H	Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span.	Current biology 	1998	175
9843956	7015	Counter CM	Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization.	Proceedings of the National Academy of Sciences of the United States of America	1998	159
9887342	7015	Cong YS	The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter.	Human molecular genetics	1999	96
9916802	7015	Jiang XR	Telomerase expression in human somatic cells does not induce changes associated with a transformed phenotype.	Nature genetics	1999	116
9973199	7015	Takakura M	Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells.	Cancer research	1999	114
10500096	7015	Zhang X	Telomere shortening and apoptosis in telomerase-inhibited human tumor cells.	Genes and development	1999	116
12193655	7015	Stewart SA	Telomerase contributes to tumorigenesis by a telomere length-independent mechanism.	Proceedings of the National Academy of Sciences of the United States of America	2002	105
12887925	7015	Masutomi K	Telomerase maintains telomere structure in normal human cells.	Cell	2003	142
14507943	7015	Sozzi G	Quantification of free circulating DNA as a diagnostic marker in lung cancer.	Journal of clinical oncology 	2003	80
14998489	7015	Chen W	Identification of specific PP2A complexes involved in human cell transformation.	Cancer cell	2004	94
15189140	7015	Smogorzewska A	Regulation of telomerase by telomeric proteins.	Annual review of biochemistry	2004	243
15735037	7015	Burger AM	The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with telomere targeting and interference with telomerase function.	Cancer research	2005	68
15928077	7015	Masutomi K	The telomerase reverse transcriptase regulates chromatin state and DNA damage responses.	Proceedings of the National Academy of Sciences of the United States of America	2005	76
17570133	7015	Berletch JB	Epigenetic and genetic mechanisms contribute to telomerase inhibition by EGCG.	Journal of cellular biochemistry	2008	61
17909019	7015	Bernardo ME	Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms.	Cancer research	2007	162
18201269	7015	Mitomo S	Downregulation of miR-138 is associated with overexpression of human telomerase reverse transcriptase protein in human anaplastic thyroid carcinoma cell lines.	Cancer science	2008	70
19147845	7015	Calado RT	Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia.	Proceedings of the National Academy of Sciences of the United States of America	2009	65
19935775	7015	Nemunaitis J	A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors.	Molecular therapy 	2010	52
20550519	7015	Liang S	Resistance to experimental tumorigenesis in cells of a long-lived mammal, the naked mole-rat (Heterocephalus glaber).	Aging cell	2010	44
20700438	7015	Hsiung CA	The 5p15.33 locus is associated with risk of lung adenocarcinoma in never-smoking females in Asia.	PLoS genetics	2010	65
21071633	7015	Indran IR	hTERT overexpression alleviates intracellular ROS production, improves mitochondrial function, and inhibits ROS-mediated apoptosis in cancer cells.	Cancer research	2011	45
22037553	7015	Haiman CA	A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer.	Nature genetics	2011	130
22381618	7015	Daniel M	Regulation of the human catalytic subunit of telomerase (hTERT).	Gene	2012	69
22523397	7015	Mocellin S	Telomerase reverse transcriptase locus polymorphisms and cancer risk: a field synopsis and meta-analysis.	Journal of the National Cancer Institute	2012	59
22661914	7015	Aubert G	Collapse of telomere homeostasis in hematopoietic cells caused by heterozygous mutations in telomerase genes.	PLoS genetics	2012	43
22854964	7015	Zhang Y	Human telomerase reverse transcriptase (hTERT) is a novel target of the Wnt/β-catenin pathway in human cancer.	The Journal of biological chemistry	2012	45
22863003	7015	Zhong FL	TPP1 OB-fold domain controls telomere maintenance by recruiting telomerase to chromosome ends.	Cell	2012	89
23348503	7015	Horn S	TERT promoter mutations in familial and sporadic melanoma.	Science	2013	316
23348506	7015	Huang FW	Highly recurrent TERT promoter mutations in human melanoma.	Science	2013	346
23535731	7015	Bojesen SE	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer.	Nature genetics	2013	181
23555636	7015	Lan Q	Longer telomere length in peripheral white blood cells is associated with risk of lung cancer and the rs2736100 (CLPTM1L-TERT) polymorphism in a prospective cohort study among women in China.	PloS one	2013	34
23598174	7015	Castelo-Branco P	Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study.	The Lancet. Oncology	2013	46
23610451	7015	Listerman I	The major reverse transcriptase-incompetent splice variant of the human telomerase protein inhibits telomerase activity but protects from apoptosis.	Cancer research	2013	29
23629941	7015	Pellatt AJ	Telomere length, telomere-related genes, and breast cancer risk: the breast cancer health disparities study.	Genes, chromosomes and cancer	2013	28
23766237	7015	Liu X	Highly prevalent TERT promoter mutations in aggressive thyroid cancers.	Endocrine-related cancer	2013	68
23887589	7015	Vinagre J	Frequency of TERT promoter mutations in human cancers.	Nature communications	2013	120
23901009	7015	Zaug AJ	Many disease-associated variants of hTERT retain high telomerase enzymatic activity.	Nucleic acids research	2013	26
23955565	7015	Nonoguchi N	TERT promoter mutations in primary and secondary glioblastomas.	Acta neuropathologica	2013	40
24018021	7015	Allory Y	Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.	European urology	2014	37
24101484	7015	Rachakonda PS	TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism.	Proceedings of the National Academy of Sciences of the United States of America	2013	55
24121487	7015	Kinde I	TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine.	Cancer research	2013	41
24141777	7015	Liu T	The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.	Oncogene	2014	43
24154961	7015	Koelsche C	Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system.	Acta neuropathologica	2013	36
24174164	7015	Remke M	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma.	Acta neuropathologica	2013	28
24476079	7015	Melo M	TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.	The Journal of clinical endocrinology and metabolism	2014	49
24569790	7015	Heidenreich B	Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma.	Nature communications	2014	24
24657534	7015	Heidenreich B	TERT promoter mutations in cancer development.	Current opinion in genetics and development	2014	61
25217772	7015	Griewank KG	TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.	Journal of the National Cancer Institute	2014	30
25314060	7015	Labussière M	TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations.	British journal of cancer	2014	28
25722414	7015	Borah S	Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer.	Science	2015	59
25843513	7015	Huang DS	Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation.	European journal of cancer	2015	20
25977370	7015	Bell RJ	Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer.	Science	2015	67
26053494	7015	Melton C	Recurrent somatic mutations in regulatory regions of human cancer genomes.	Nature genetics	2015	44
26194807	7015	Chiba K	Cancer-associated TERT promoter mutations abrogate telomerase silencing.	eLife	2015	38
26549025	7015	Lü MH	Long noncoding RNA BC032469, a novel competing endogenous RNA, upregulates hTERT expression by sponging miR-1207-5p and promotes proliferation in gastric cancer.	Oncogene	2016	20
26553065	7015	Xi L	A novel two-step genome editing strategy with CRISPR-Cas9 provides new insights into telomerase action and TERT gene expression.	Genome biology	2015	16
26846696	7015	Akincilar SC	Reactivation of telomerase in cancer.	Cellular and molecular life sciences 	2016	13
27165744	7015	Zheng S	Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma.	Cancer cell	2016	23
18801935	7038	Hoofnagle AN	Quantification of thyroglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry.	Clinical chemistry	2008	76
19773371	7038	Hoftijzer H	Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.	European journal of endocrinology	2009	47
19860577	7038	American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer.	Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.	Thyroid 	2009	970
26462967	7038	Haugen BR	2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.	Thyroid 	2016	328
1323840	7157	Kuerbitz SJ	Wild-type p53 is a cell cycle checkpoint determinant following irradiation.	Proceedings of the National Academy of Sciences of the United States of America	1992	317
1423635	7157	Hupp TR	Regulation of the specific DNA binding function of p53.	Cell	1992	231
1525830	7157	Yin Y	Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles.	Cell	1992	204
1533443	7157	Yew PR	Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein.	Nature	1992	177
1661671	7157	Huibregtse JM	A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18.	The EMBO journal	1991	230
1672732	7157	Bressac B	Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa.	Nature	1991	191
1849234	7157	Hsu IC	Mutational hotspot in the p53 gene in human hepatocellular carcinomas.	Nature	1991	202
1905840	7157	Hollstein M	p53 mutations in human cancers.	Science	1991	1290
1946433	7157	Brash DE	A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma.	Proceedings of the National Academy of Sciences of the United States of America	1991	251
1978757	7157	Malkin D	Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.	Science	1990	522
2046748	7157	Levine AJ	The p53 tumour suppressor gene.	Nature	1991	554
2143698	7157	Michalovitz D	Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53.	Cell	1990	217
2144057	7157	Baker SJ	Suppression of human colorectal carcinoma cell growth by wild-type p53.	Science	1990	393
2175676	7157	Scheffner M	The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53.	Cell	1990	907
2233717	7157	Diller L	p53 functions as a cell cycle control protein in osteosarcomas.	Molecular and cellular biology	1990	175
2253215	7157	Baker SJ	p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis.	Cancer research	1990	157
2259385	7157	Srivastava S	Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome.	Nature	1990	174
2531845	7157	Nigro JM	Mutations in the p53 gene occur in diverse human tumour types.	Nature	1989	402
7937055	7157	Hollstein M	Database of p53 gene somatic mutations in human tumors and cell lines.	Nucleic acids research	1994	185
8023157	7157	Cho Y	Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.	Science	1994	486
8030745	7157	Kim H	Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences.	The American journal of pathology	1994	124
8242748	7157	Lu X	Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes?	Cell	1993	138
8380895	7157	Huibregtse JM	Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53.	Molecular and cellular biology	1993	143
8423624	7157	Allred DC	Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer.	Journal of the National Cancer Institute	1993	132
8832894	7157	Denissenko MF	Preferential formation of benzoapyrene adducts at lung cancer mutational hotspots in P53.	Science	1996	229
8994024	7157	Weinstein JN	An information-intensive approach to the molecular pharmacology of cancer.	Science	1997	198
9176490	7157	Heise C	ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents.	Nature medicine	1997	127
9607760	7157	Storey A	Role of a p53 polymorphism in the development of human papillomavirus-associated cancer.	Nature	1998	122
10446993	7157	Chang BD	A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents.	Cancer research	1999	107
10549356	7157	Hainaut P	p53 and human cancer: the first ten thousand mutations.	Advances in cancer research	2000	197
10623654	7157	Vona G	Isolation by size of epithelial tumor cells : a new method for the immunomorphological and molecular characterization of circulatingtumor cells.	The American journal of pathology	2000	212
10713666	7157	Bullock AN	Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy.	Oncogene	2000	94
10720328	7157	Fliss MS	Facile detection of mitochondrial DNA mutations in tumors and bodily fluids.	Science	2000	182
10728684	7157	Barcellos-Hoff MH	Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells.	Cancer research	2000	151
10766157	7157	Soussi T	p53 Antibodies in the sera of patients with various types of cancer: a review.	Cancer research	2000	117
10793107	7157	Gillison ML	Evidence for a causal association between human papillomavirus and a subset of head and neck cancers.	Journal of the National Cancer Institute	2000	547
11238924	7157	Gaiddon C	A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain.	Molecular and cellular biology	2001	107
11343904	7157	Ryan KM	Regulation and function of the p53 tumor suppressor protein.	Current opinion in cell biology	2001	127
11559745	7157	Chan HM	p300/CBP proteins: HATs for transcriptional bridges and scaffolds.	Journal of cell science	2001	283
11830638	7157	Lingle WL	Centrosome amplification drives chromosomal instability in breast tumor development.	Proceedings of the National Academy of Sciences of the United States of America	2002	150
11859195	7157	Yu JL	Effect of p53 status on tumor response to antiangiogenic therapy.	Science	2002	86
11875500	7157	Bykov VJ	Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.	Nature medicine	2002	198
11900253	7157	Bullock AN	Rescuing the function of mutant p53.	Nature reviews. Cancer	2001	112
11902578	7157	Soussi T	Assessing TP53 status in human tumours to evaluate clinical outcome.	Nature reviews. Cancer	2001	128
11965534	7157	Mirza A	Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway.	Oncogene	2002	130
12007217	7157	Olivier M	The IARC TP53 database: new online mutation analysis and recommendations to users.	Human mutation	2002	267
12058060	7157	Chen X	Gene expression patterns in human liver cancers.	Molecular biology of the cell	2002	189
12077306	7157	Hoh J	The p53MH algorithm and its application in detecting p53-responsive genes.	Proceedings of the National Academy of Sciences of the United States of America	2002	103
12241875	7157	Klein CA	Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer.	Lancet	2002	96
12379884	7157	Pfeifer GP	Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers.	Oncogene	2002	203
12483511	7157	Hanawalt PC	Subpathways of nucleotide excision repair and their regulation.	Oncogene	2002	123
12574499	7157	Yu J	PUMA mediates the apoptotic response to p53 in colorectal cancer cells.	Proceedings of the National Academy of Sciences of the United States of America	2003	171
12649205	7157	Pihan GA	Centrosome abnormalities and chromosome instability occur together in pre-invasive carcinomas.	Cancer research	2003	102
12719720	7157	Oren M	Decision making by p53: life, death and cancer.	Cell death and differentiation	2003	226
12821280	7157	Ichihashi M	UV-induced skin damage.	Toxicology	2003	95
12826609	7157	Kato S	Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.	Proceedings of the National Academy of Sciences of the United States of America	2003	156
12884918	7157	Katayama H	The Aurora kinases: role in cell transformation and tumorigenesis.	Cancer metastasis reviews	2003	98
12941807	7157	Riley RR	Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis.	Cancer research	2003	97
14527293	7157	Moore PS	Kaposi's sarcoma-associated herpesvirus immunoevasion and tumorigenesis: two sides of the same coin?	Annual review of microbiology	2003	79
14612504	7157	Massion PP	Significance of p63 amplification and overexpression in lung cancer development and prognosis.	Cancer research	2003	77
14639602	7157	Pim D	p53 polymorphic variants at codon 72 exert different effects on cell cycle progression.	International journal of cancer	2004	71
15042092	7157	Berns K	A large-scale RNAi screen in human cells identifies new components of the p53 pathway.	Nature	2004	267
15054096	7157	Wang S	Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. intermediacy of H(2)O(2)- and p53-dependent pathways.	The Journal of biological chemistry	2004	88
15095006	7157	Harms K	The common and distinct target genes of the p53 family transcription factors.	Cellular and molecular life sciences 	2004	96
15187189	7157	Longworth MS	Pathogenesis of human papillomaviruses in differentiating epithelia.	Microbiology and molecular biology reviews 	2004	153
15282313	7157	Zhu W	Rereplication by depletion of geminin is seen regardless of p53 status and activates a G2/M checkpoint.	Molecular and cellular biology	2004	110
15351967	7157	Dellaire G	PML nuclear bodies: dynamic sensors of DNA damage and cellular stress.	BioEssays 	2004	117
15685439	7157	Ohgaki H	Epidemiology and etiology of gliomas.	Acta neuropathologica	2005	212
16131611	7157	Bourdon JC	p53 isoforms can regulate p53 transcriptional activity.	Genes and development	2005	222
16141321	7157	Miller LD	An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival.	Proceedings of the National Academy of Sciences of the United States of America	2005	509
16172461	7157	Russo A	The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.	Journal of clinical oncology 	2005	72
16413492	7157	Wei CL	A global map of p53 transcription-factor binding sites in the human genome.	Cell	2006	439
16467102	7157	Antonia SJ	Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer.	Clinical cancer research 	2006	95
16489069	7157	Olivier M	The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.	Clinical cancer research 	2006	119
16597322	7157	Doorbar J	Molecular biology of human papillomavirus infection and cervical cancer.	Clinical science	2006	181
16601753	7157	Murray-Zmijewski F	p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress.	Cell death and differentiation	2006	154
16621243	7157	Sah NK	Structural, functional and therapeutic biology of survivin.	Cancer letters	2006	63
16632889	7157	Stark GR	Control of the G2/M transition.	Molecular biotechnology	2006	72
16793544	7157	Kitayner M	Structural basis of DNA recognition by p53 tetramers.	Molecular cell	2006	108
16824017	7157	Stewart SA	Telomeres: cancer to human aging.	Annual review of cell and developmental biology	2006	91
16897746	7157	Bergamaschi A	Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer.	Genes, chromosomes and cancer	2006	161
16945824	7157	Houtgraaf JH	A concise review of DNA damage checkpoints and repair in mammalian cells.	Cardiovascular revascularization medicine 	2006	65
16951157	7157	Rodriguez J	Chromosomal instability correlates with genome-wide DNA demethylation in human primary colorectal cancers.	Cancer research	2006	82
17030796	7157	Feng Z	Acrolein is a major cigarette-related lung cancer agent: Preferential binding at p53 mutational hotspots and inhibition of DNA repair.	Proceedings of the National Academy of Sciences of the United States of America	2006	96
17189187	7157	Sykes SM	Acetylation of the p53 DNA-binding domain regulates apoptosis induction.	Molecular cell	2006	234
17255760	7157	Kindelberger DW	Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.	The American journal of surgical pathology	2007	194
17311302	7157	Petitjean A	Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.	Human mutation	2007	457
17334395	7157	Deyoung MP	p63 and p73 in human cancer: defining the network.	Oncogene	2007	83
17401424	7157	Petitjean A	TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes.	Oncogene	2007	190
17401431	7157	Li Y	Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function?	Oncogene	2007	57
17401432	7157	Joerger AC	Structure-function-rescue: the diverse nature of common p53 cancer mutants.	Oncogene	2007	108
17417627	7157	Song H	p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.	Nature cell biology	2007	112
17468756	7157	Theodorou V	MMTV insertional mutagenesis identifies genes, gene families and pathways involved in mammary cancer.	Nature genetics	2007	69
17504517	7157	Langerød A	TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer.	Breast cancer research 	2007	93
17517648	7157	Dahl F	Multigene amplification and massively parallel sequencing for cancer mutation discovery.	Proceedings of the National Academy of Sciences of the United States of America	2007	57
17804712	7157	Nakahara T	YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.	Cancer research	2007	113
17936556	7157	Soussi T	Shaping genetic alterations in human cancer: the p53 mutation paradigm.	Cancer cell	2007	102
17942417	7157	Rodier F	Two faces of p53: aging and tumor suppression.	Nucleic acids research	2007	111
18024211	7157	Bonnefoi H	Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.	The Lancet. Oncology	2007	60
18024870	7157	Tsao MS	Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer.	Journal of clinical oncology 	2007	67
18094375	7157	Patocs A	Breast-cancer stromal cells with TP53 mutations and nodal metastases.	The New England journal of medicine	2007	93
18094376	7157	Poeta ML	TP53 mutations and survival in squamous-cell carcinoma of the head and neck.	The New England journal of medicine	2007	160
18193093	7157	Courtois-Cox S	Many roads lead to oncogene-induced senescence.	Oncogene	2008	106
18323444	7157	Halazonetis TD	An oncogene-induced DNA damage model for cancer development.	Science	2008	527
18370854	7157	Strimpakos AS	Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials.	Antioxidants and redox signaling	2008	79
18394899	7157	Birkenfeld J	Cellular functions of GEF-H1, a microtubule-regulated Rho-GEF: is altered GEF-H1 activity a crucial determinant of disease pathogenesis?	Trends in cell biology	2008	66
18431400	7157	Riley T	Transcriptional control of human p53-regulated genes.	Nature reviews. Molecular cell biology	2008	565
18454141	7157	Tasdemir E	Regulation of autophagy by cytoplasmic p53.	Nature cell biology	2008	313
18495520	7157	Ashkenazi A	Targeting the extrinsic apoptosis pathway in cancer.	Cytokine and growth factor reviews	2008	86
18563507	7157	Tang N	Osteosarcoma development and stem cell differentiation.	Clinical orthopaedics and related research	2008	92
18650397	7157	Boeckler FM	Targeted rescue of a destabilized mutant of p53 by an in silico screened drug.	Proceedings of the National Academy of Sciences of the United States of America	2008	86
18685109	7157	Shlien A	Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome.	Proceedings of the National Academy of Sciences of the United States of America	2008	51
18689542	7157	Zenz T	Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up.	Blood	2008	76
18757330	7157	Carlson JW	Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention.	Journal of clinical oncology 	2008	70
18840072	7157	Mitra AP	Molecular pathogenesis and diagnostics of bladder cancer.	Annual review of pathology	2009	52
18955976	7157	Pietsch EC	The p53 family and programmed cell death.	Oncogene	2008	68
19081592	7157	Levine AJ	The common mechanisms of transformation by the small DNA tumor viruses: The inactivation of tumor suppressor gene products: p53.	Virology	2009	59
19081593	7157	Howie HL	Papillomavirus E6 proteins.	Virology	2009	77
19165225	7157	Whibley C	p53 polymorphisms: cancer implications.	Nature reviews. Cancer	2009	125
19188171	7157	Rossi D	The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.	Clinical cancer research 	2009	48
19204208	7157	Gonzalez KD	Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations.	Journal of clinical oncology 	2009	86
19225112	7157	Sur S	A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53.	Proceedings of the National Academy of Sciences of the United States of America	2009	108
19237188	7157	Boren T	MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy.	Gynecologic oncology	2009	49
19276448	7157	Rampias T	E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells.	Journal of the National Cancer Institute	2009	62
19308457	7157	Pfeifer GP	Mutational spectra of human cancer.	Human genetics	2009	69
19349354	7157	Seligson DB	Global levels of histone modifications predict prognosis in different cancers.	The American journal of pathology	2009	109
19377293	7157	Maiuri MC	Stimulation of autophagy by the p53 target gene Sestrin2.	Cell cycle	2009	79
19562738	7157	Zuckerman V	Tumour suppression by p53: the importance of apoptosis and cellular senescence.	The Journal of pathology	2009	49
19626115	7157	Suzuki HI	Modulation of microRNA processing by p53.	Nature	2009	393
19657224	7157	Choong ML	Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy.	Cell cycle	2009	51
19701195	7157	Fujita K	p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence.	Nature cell biology	2009	80
19776744	7157	Levine AJ	The first 30 years of p53: growing ever more complex.	Nature reviews. Cancer	2009	419
19881536	7157	Liu DP	A common gain of function of p53 cancer mutants in inducing genetic instability.	Oncogene	2010	50
19887545	7157	Hirai H	Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents.	Molecular cancer therapeutics	2009	90
20005852	7157	Goodarzi H	Revealing global regulatory perturbations across human cancers.	Molecular cell	2009	63
20038740	7157	De Angelis A	Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function.	Circulation	2010	62
20044243	7157	Maiuri MC	Autophagy regulation by p53.	Current opinion in cell biology	2010	139
20066118	7157	Zilfou JT	Tumor suppressive functions of p53.	Cold Spring Harbor perspectives in biology	2009	96
20107315	7157	Hirai H	MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil.	Cancer biology and therapy	2010	55
20123995	7157	Thompson SL	Proliferation of aneuploid human cells is limited by a p53-dependent mechanism.	The Journal of cell biology	2010	142
20179198	7157	Creighton CJ	Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers.	Cancer research	2010	82
20182602	7157	Olivier M	TP53 mutations in human cancers: origins, consequences, and clinical use.	Cold Spring Harbor perspectives in biology	2010	236
20182618	7157	Oren M	Mutant p53 gain-of-function in cancer.	Cold Spring Harbor perspectives in biology	2010	181
20227041	7157	Stambolsky P	Modulation of the vitamin D3 response by cancer-associated mutant p53.	Cancer cell	2010	71
20229506	7157	Ahmed AA	Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.	The Journal of pathology	2010	149
20336134	7157	Sahin E	Linking functional decline of telomeres, mitochondria and stem cells during ageing.	Nature	2010	191
20431349	7157	Witkiewicz AK	Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers.	Cancer biology and therapy	2010	57
20538793	7157	Lin TT	Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis.	Blood	2010	42
20679336	7157	Beckerman R	Transcriptional regulation by p53.	Cold Spring Harbor perspectives in biology	2010	170
20697090	7157	Zenz T	TP53 mutation and survival in chronic lymphocytic leukemia.	Journal of clinical oncology 	2010	91
20871609	7157	Swarbrick A	miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma.	Nature medicine	2010	52
20937856	7157	Scherz-Shouval R	p53-dependent regulation of autophagy protein LC3 supports cancer cell survival under prolonged starvation.	Proceedings of the National Academy of Sciences of the United States of America	2010	71
20952405	7157	Forbes SA	COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer.	Nucleic acids research	2011	834
20974671	7157	Martinez-Garcia E	The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells.	Blood	2011	94
21205082	7157	Nakahara T	Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models.	Cancer science	2011	43
21205967	7157	Fabbri M	Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.	JAMA	2011	72
21263025	7157	Muller PA	p53 and its mutants in tumor cell migration and invasion.	The Journal of cell biology	2011	118
21315819	7157	Bueno MJ	MicroRNAs and the cell cycle.	Biochimica et biophysica acta	2011	74
21331359	7157	Mogi A	TP53 mutations in nonsmall cell lung cancer.	Journal of biomedicine and biotechnology	2011	45
21336310	7157	Jiang P	p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase.	Nature cell biology	2011	128
21364938	7157	Enerly E	miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors.	PloS one	2011	115
21389100	7157	Rajeshkumar NV	MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.	Clinical cancer research 	2011	63
21399611	7157	Freund A	p38MAPK is a novel DNA damage response-independent regulator of the senescence-associated secretory phenotype.	The EMBO journal	2011	158
21427767	7157	Levine AJ	The p53 family: guardians of maternal reproduction.	Nature reviews. Molecular cell biology	2011	87
21483000	7157	Gonzalez D	Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.	Journal of clinical oncology 	2011	47
21483755	7157	Menendez D	The Toll-like receptor gene family is integrated into human DNA damage and p53 networks.	PLoS genetics	2011	42
21519010	7157	Jädersten M	TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.	Journal of clinical oncology 	2011	69
21530747	7157	Ullman TA	Intestinal inflammation and cancer.	Gastroenterology	2011	197
21601526	7157	Villani A	Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study.	The Lancet. Oncology	2011	46
21747090	7157	Hof J	Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia.	Journal of clinical oncology 	2011	41
21764762	7157	Textor S	Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2.	Cancer research	2011	39
21765642	7157	Suzuki K	Recent advances in p53 research and cancer treatment.	Journal of biomedicine and biotechnology	2011	40
21779513	7157	Khoury MP	p53 Isoforms: An Intracellular Microprocessor?	Genes and cancer	2011	44
21779517	7157	Rufini A	p73 in Cancer.	Genes and cancer	2011	39
21779518	7157	Gudkov AV	Inflammation and p53: A Tale of Two Stresses.	Genes and cancer	2011	47
21799033	7157	Bridges KA	MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.	Clinical cancer research 	2011	50
21941372	7157	Marcel V	Biological functions of p53 isoforms through evolution: lessons from animal and cellular models.	Cell death and differentiation	2011	65
21986946	7157	Mei YP	Small nucleolar RNA 42 acts as an oncogene in lung tumorigenesis.	Oncogene	2012	51
22084170	7157	Kreahling JM	MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells.	Molecular cancer therapeutics	2012	39
22090360	7157	Skinner HD	TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence.	Clinical cancer research 	2012	58
22127205	7157	Botcheva K	Distinct p53 genomic binding patterns in normal and cancer-derived human cells.	Cell cycle	2011	43
22171325	7157	Orth JD	Prolonged mitotic arrest triggers partial activation of apoptosis, resulting in DNA damage and p53 induction.	Molecular biology of the cell	2012	48
22184222	7157	Neumaier T	Evidence for formation of DNA repair centers and dose-response nonlinearity in human cells.	Proceedings of the National Academy of Sciences of the United States of America	2012	52
22186996	7157	Rücker FG	TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome.	Blood	2012	69
22265402	7157	Rausch T	Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations.	Cell	2012	175
22265415	7157	Freed-Pastor WA	Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway.	Cell	2012	163
22266220	7157	O'Dell MR	Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma.	Cancer research	2012	33
22282659	7157	Donati G	Ribosome biogenesis and control of cell proliferation: p53 is not alone.	Cancer research	2012	36
22297721	7157	Pospisilova S	ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia.	Leukemia	2012	38
22351930	7157	Scarlett UK	Ovarian cancer progression is controlled by phenotypic changes in dendritic cells.	The Journal of experimental medicine	2012	78
22357944	7157	De S	RECQL4 is essential for the transport of p53 to mitochondria in normal human cells in the absence of exogenous stress.	Journal of cell science	2012	36
22529099	7157	Thurnher M	Novel aspects of mevalonate pathway inhibitors as antitumor agents.	Clinical cancer research 	2012	42
22533606	7157	ElSharawy A	Genome-wide miRNA signatures of human longevity.	Aging cell	2012	32
22549840	7157	Gerstung M	Reliable detection of subclonal single-nucleotide variants in tumour cell populations.	Nature communications	2012	55
22551203	7157	Intarasunanont P	Effects of arsenic exposure on DNA methylation in cord blood samples from newborn babies and in a human lymphoblast cell line.	Environmental health 	2012	38
22611192	7157	Gully CP	Aurora B kinase phosphorylates and instigates degradation of p53.	Proceedings of the National Academy of Sciences of the United States of America	2012	46
22641689	7157	Liu EY	Autophagy and cancer--issues we need to digest.	Journal of cell science	2012	49
22698402	7157	Davoli T	Telomere-driven tetraploidization occurs in human cells undergoing crisis and promotes transformation of mouse cells.	Cancer cell	2012	58
22715097	7157	Ano Bom AP	Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer.	The Journal of biological chemistry	2012	41
22789538	7157	Bywater MJ	Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.	Cancer cell	2012	107
22822097	7157	Walerych D	The rebel angel: mutant p53 as the driving oncogene in breast cancer.	Carcinogenesis	2012	61
22911014	7157	Mirzayans R	New insights into p53 signaling and cancer cell response to DNA damage: implications for cancer therapy.	Journal of biomedicine and biotechnology	2012	55
22955915	7157	Xu-Monette ZY	Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.	Blood	2012	42
22965953	7157	Lehmann S	Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer.	Journal of clinical oncology 	2012	58
22986101	7157	Zhang K	Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma.	Experimental hematology	2013	45
23114601	7157	Rodig SJ	Improved detection suggests all Merkel cell carcinomas harbor Merkel polyomavirus.	The Journal of clinical investigation	2012	41
23150340	7157	Menendez D	Interactions between the tumor suppressor p53 and immune responses.	Current opinion in oncology	2013	31
23151455	7157	Rodriguez OC	Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy.	Cell cycle	2012	33
23199966	7157	Doorbar J	The biology and life-cycle of human papillomaviruses.	Vaccine	2012	128
23200980	7157	Kanda M	Mutant TP53 in duodenal samples of pancreatic juice from patients with pancreatic cancer or high-grade dysplasia.	Clinical gastroenterology and hepatology 	2013	35
23242140	7157	Maddocks OD	Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells.	Nature	2013	145
23256952	7157	Kastelein F	Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus.	Gut	2013	31
23297687	7157	Kulasekararaj AG	TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis.	British journal of haematology	2013	44
23360998	7157	Wassman CD	Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53.	Nature communications	2013	35
23512991	7157	Batey MA	Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer.	Molecular cancer therapeutics	2013	25
23514892	7157	Cheng J	Merkel cell polyomavirus large T antigen has growth-promoting and inhibitory activities.	Journal of virology	2013	27
23589106	7157	Iclozan C	Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer.	Cancer immunology, immunotherapy 	2013	67
23630207	7157	Vignot S	Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer.	Journal of clinical oncology 	2013	38
23644491	7157	Kadoch C	Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy.	Nature genetics	2013	169
23649806	7157	Kleiblova P	Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint.	The Journal of cell biology	2013	33
23749640	7157	Kimple RJ	Enhanced radiation sensitivity in HPV-positive head and neck cancer.	Cancer research	2013	64
23775793	7157	Menendez D	Diverse stresses dramatically alter genome-wide p53 binding and transactivation landscape in human cancer cells.	Nucleic acids research	2013	52
23835706	7157	Zhukova N	Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma.	Journal of clinical oncology 	2013	43
23880895	7157	Kitagawa M	Cell cycle regulation by long non-coding RNAs.	Cellular and molecular life sciences 	2013	31
23906881	7157	Dang CV	MYC, metabolism, cell growth, and tumorigenesis.	Cold Spring Harbor perspectives in medicine	2013	114
23913924	7157	Vakifahmetoglu-Norberg H	Chaperone-mediated autophagy degrades mutant p53.	Genes and development	2013	30
23918355	7157	Lee MO	Inhibition of pluripotent stem cell-derived teratoma formation by small molecules.	Proceedings of the National Academy of Sciences of the United States of America	2013	42
23954752	7157	Liu JC	High mitochondrial priming sensitizes hESCs to DNA-damage-induced apoptosis.	Cell stem cell	2013	36
23966881	7157	Schlereth K	Characterization of the p53 cistrome--DNA binding cooperativity dissects p53's tumor suppressor functions.	PLoS genetics	2013	31
24138928	7157	Horvath S	DNA methylation age of human tissues and cell types.	Genome biology	2013	377
24296170	7157	Mellman I	Endocytosis and cancer.	Cold Spring Harbor perspectives in biology	2013	51
24327604	7157	Abdi J	Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.	Oncotarget	2013	28
24374014	7157	Liu J	Tumor suppressor p53 and its mutants in cancer metabolism.	Cancer letters	2015	24
24379683	7157	Surget S	Uncovering the role of p53 splice variants in human malignancy: a clinical perspective.	OncoTargets and therapy	2013	39
24469795	7157	Morrison CD	Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer.	Proceedings of the National Academy of Sciences of the United States of America	2014	24
24487586	7157	Arjonen A	Mutant p53-associated myosin-X upregulation promotes breast cancer invasion and metastasis.	The Journal of clinical investigation	2014	36
24501221	7157	Rossi D	Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia.	Blood	2014	50
24577402	7157	Khoo KH	Drugging the p53 pathway: understanding the route to clinical efficacy.	Nature reviews. Drug discovery	2014	151
24603336	7157	Xu J	Unequal prognostic potentials of p53 gain-of-function mutations in human cancers associate with drug-metabolizing activity.	Cell death and disease	2014	21
24615777	7157	Brown JR	Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.	Blood	2014	106
24630730	7157	Supek F	Synonymous mutations frequently act as driver mutations in human cancers.	Cell	2014	76
24642672	7157	McBride KA	Li-Fraumeni syndrome: cancer risk assessment and clinical management.	Nature reviews. Clinical oncology	2014	25
24658082	7157	Powell E	Contribution of p53 to metastasis.	Cancer discovery	2014	38
24665023	7157	Leroy B	TP53 mutations in human cancer: database reassessment and prospects for the next decade.	Human mutation	2014	28
24682512	7157	Saft L	p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).	Haematologica	2014	22
24721780	7157	Zhang A	Role of the lncRNA-p53 regulatory network in cancer.	Journal of molecular cell biology	2014	22
24747423	7157	Golomb L	p53 and ribosome biogenesis stress: the essentials.	FEBS letters	2014	36
24768524	7157	Bykov VJ	Mutant p53 reactivation by small molecules makes its way to the clinic.	FEBS letters	2014	32
24819167	7157	Leotta M	A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells.	Journal of cellular physiology	2014	26
24859455	7157	Miao R	Identification of prognostic biomarkers in hepatitis B virus-related hepatocellular carcinoma and stratification by integrative multi-omics analysis.	Journal of hepatology	2014	30
24882724	7157	Blackinton JG	Post-transcriptional RNA regulons affecting cell cycle and proliferation.	Seminars in cell and developmental biology	2014	26
24921086	7157	Schmeiser HH	Exceptionally long-term persistence of DNA adducts formed by carcinogenic aristolochic acid I in renal tissue from patients with aristolochic acid nephropathy.	International journal of cancer	2014	20
24928860	7157	Wang J	Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells.	Blood	2014	35
25058159	7157	Janky R	iRegulon: from a gene list to a gene regulatory network using large motif and track collections.	PLoS computational biology	2014	77
25086664	7157	Gross AM	Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss.	Nature genetics	2014	32
25092778	7157	Bejar R	Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation.	Journal of clinical oncology 	2014	40
25100830	7157	Kennedy EM	Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR/Cas RNA-guided endonuclease.	Journal of virology	2014	34
25287991	7157	Malcikova J	Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia.	Leukemia	2015	18
25362853	7157	Gao J	miR-34a-5p suppresses colorectal cancer metastasis and predicts recurrence in patients with stage II/III colorectal cancer.	Oncogene	2015	24
25402006	7157	Kotlyar M	In silico prediction of physical protein interactions and characterization of interactome orphans.	Nature methods	2015	22
25524025	7157	Sánchez Y	Genome-wide analysis of the human p53 transcriptional network unveils a lncRNA tumour suppressor signature.	Nature communications	2014	33
25538195	7157	Vieira VC	Human papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase APOBEC3B.	mBio	2014	33
25555420	7157	Farooqui MZ	Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.	The Lancet. Oncology	2015	51
25592647	7157	Ito Y	The RUNX family: developmental regulators in cancer.	Nature reviews. Cancer	2015	42
25634208	7157	Neskey DM	Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer.	Cancer research	2015	19
25689248	7157	Boulter L	WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited.	The Journal of clinical investigation	2015	23
25704383	7157	Span PN	Biology of hypoxia.	Seminars in nuclear medicine	2015	16
25824729	7157	Goldar S	Molecular mechanisms of apoptosis and roles in cancer development and treatment.	Asian Pacific journal of cancer prevention 	2015	19
25827447	7157	Hong MK	Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer.	Nature communications	2015	39
25860607	7157	Lee DF	Modeling familial cancer with induced pluripotent stem cells.	Cell	2015	28
25883152	7157	Younger ST	Integrative genomic analysis reveals widespread enhancer regulation by p53 in response to DNA damage.	Nucleic acids research	2015	23
25894828	7157	Cristescu R	Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes.	Nature medicine	2015	84
26014290	7157	Bougeard G	Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers.	Journal of clinical oncology 	2015	20
26024390	7157	Soussi T	TP53: an oncogene in disguise.	Cell death and differentiation	2015	26
26032560	7157	Amelio I	The p53 family and the hypoxia-inducible factors (HIFs): determinants of cancer progression.	Trends in biochemical sciences	2015	15
26398160	7157	Danilova N	Ribosomopathies: how a common root can cause a tree of pathologies.	Disease models and mechanisms	2015	20
26447779	7157	Abegglen LM	Potential Mechanisms for Cancer Resistance in Elephants and Comparative Cellular Response to DNA Damage in Humans.	JAMA	2015	29
26462838	7157	Gong Z	An integrative transcriptomic analysis reveals p53 regulated miRNA, mRNA, and lncRNA networks in nasopharyngeal carcinoma.	Tumour biology 	2016	16
26605532	7157	Jin W	Genome-wide detection of DNase I hypersensitive sites in single cells and FFPE tissue samples.	Nature	2015	31
26748848	7157	Soragni A	A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas.	Cancer cell	2016	19
26853913	7157	Niopek D	Optogenetic control of nuclear protein export.	Nature communications	2016	11
26918045	7157	Chen X	Survivin and Tumorigenesis: Molecular Mechanisms and Therapeutic Strategies.	Journal of Cancer	2016	19
27009395	7157	Stracquadanio G	The importance of p53 pathway genetics in inherited and somatic cancer genomes.	Nature reviews. Cancer	2016	19
27187358	7157	Mirzayans R	The Growing Complexity of Cancer Cell Response to DNA-Damaging Agents: Caspase 3 Mediates Cell Death or Survival?	International journal of molecular sciences	2016	12
27328919	7157	Bouaoun L	TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data.	Human mutation	2016	12
27377626	7157	Fernandez-Cuesta L	Identification of Circulating Tumor DNA for the Early Detection of Small-cell Lung Cancer.	EBioMedicine	2016	13
7683111	7422	Kim KJ	Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo.	Nature	1993	547
8837607	7422	Gabrilovich DI	Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells.	Nature medicine	1996	271
9012841	7422	Möhle R	Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets.	Proceedings of the National Academy of Sciences of the United States of America	1997	110
9377574	7422	Presta LG	Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.	Cancer research	1997	287
9707121	7422	Flore O	Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirus.	Nature	1998	109
9916127	7422	Benjamin LE	Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal.	The Journal of clinical investigation	1999	225
10662790	7422	Yang TY	Transgenic expression of the chemokine receptor encoded by human herpesvirus 8 induces an angioproliferative disease resembling Kaposi's sarcoma.	The Journal of experimental medicine	2000	94
10688871	7422	Kerbel RS	Tumor angiogenesis: past, present and the near future.	Carcinogenesis	2000	118
11005565	7422	Rubenstein JL	Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption.	Neoplasia	2000	137
11549582	7422	Skobe M	Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma.	The American journal of pathology	2001	99
12177445	7422	Holash J	VEGF-Trap: a VEGF blocker with potent antitumor effects.	Proceedings of the National Academy of Sciences of the United States of America	2002	331
12516033	7422	Ferrara N	Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications.	Seminars in oncology	2002	108
14517187	7422	Morgan B	Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies.	Journal of clinical oncology 	2003	102
14745444	7422	Willett CG	Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.	Nature medicine	2004	378
15166496	7422	Kusumanto YH	Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor.	Angiogenesis	2003	85
15175435	7422	Hurwitz H	Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.	The New England journal of medicine	2004	1840
15585754	7422	Hicklin DJ	Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.	Journal of clinical oncology 	2005	526
15611513	7422	Kim WY	Role of VHL gene mutation in human cancer.	Journal of clinical oncology 	2004	209
15681523	7422	Miller KD	Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.	Journal of clinical oncology 	2005	212
15867200	7422	Kabbinavar FF	Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.	Journal of clinical oncology 	2005	102
15908660	7422	Hurwitz HI	Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.	Journal of clinical oncology 	2005	115
16193288	7422	Perrin RM	Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor.	Diabetologia	2005	70
16258101	7422	Kindler HL	Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.	Journal of clinical oncology 	2005	105
16301830	7422	Carmeliet P	VEGF as a key mediator of angiogenesis in cancer.	Oncology	2005	181
16301831	7422	Ferrara N	VEGF as a therapeutic target in cancer.	Oncology	2005	109
16322226	7422	Mironchik Y	Twist overexpression induces in vivo angiogenesis and correlates with chromosomal instability in breast cancer.	Cancer research	2005	84
16330672	7422	Motzer RJ	Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.	Journal of clinical oncology 	2006	245
16364190	7422	Byrne AM	Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF).	Journal of cellular and molecular medicine	2005	141
16376330	7422	Folkman J	Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action.	Experimental cell research	2006	116
16407877	7422	Jain RK	Lessons from phase III clinical trials on anti-VEGF therapy for cancer.	Nature clinical practice. Oncology	2006	256
16622265	7422	Zhu AX	Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma.	Journal of clinical oncology 	2006	73
16880208	7422	Coppé JP	Secretion of vascular endothelial growth factor by primary human fibroblasts at senescence.	The Journal of biological chemistry	2006	104
16912155	7422	Bao S	Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor.	Cancer research	2006	351
17158546	7422	Motzer RJ	Targeted therapy for metastatic renal cell carcinoma.	Journal of clinical oncology 	2006	64
17167137	7422	Sandler A	Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.	The New England journal of medicine	2006	1175
17212999	7422	Shih T	Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.	Clinical therapeutics	2006	82
17236958	7422	Gonzalez J	Effect of bevacizumab on radiation necrosis of the brain.	International journal of radiation oncology, biology, physics	2007	64
17261421	7422	Zhu X	Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.	American journal of kidney diseases 	2007	124
17559806	7422	Liang Z	CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway.	Biochemical and biophysical research communications	2007	69
17631557	7422	Nagengast WB	In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft.	Journal of nuclear medicine 	2007	63
17634482	7422	Drevs J	Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors.	Journal of clinical oncology 	2007	79
17686822	7422	Scappaticci FA	Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.	Journal of the National Cancer Institute	2007	130
17699863	7422	Fricke I	Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses.	Clinical cancer research 	2007	63
17908997	7422	Rich JN	Cancer stem cells in radiation resistance.	Cancer research	2007	113
17909199	7422	Herbst RS	Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.	Journal of clinical oncology 	2007	90
17947719	7422	Vredenburgh JJ	Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.	Journal of clinical oncology 	2007	325
18000042	7422	Rudge JS	VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade.	Proceedings of the National Academy of Sciences of the United States of America	2007	66
18006827	7422	Xia C	Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor.	Cancer research	2007	118
18024863	7422	Burger RA	Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.	Journal of clinical oncology 	2007	185
18156031	7422	Escudier B	Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.	Lancet	2007	433
18160686	7422	Miller K	Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.	The New England journal of medicine	2007	637
18202416	7422	Glade Bender JL	Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study.	Journal of clinical oncology 	2008	58
18235126	7422	Socinski MA	Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.	Journal of clinical oncology 	2008	81
18263769	7422	Ramalingam S	Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions.	The oncologist	2008	73
18316689	7422	Norden AD	Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.	Neurology	2008	230
18349829	7422	Varey AH	VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy.	British journal of cancer	2008	74
18349830	7422	Maeda S	CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer.	British journal of cancer	2008	54
18452647	7422	Shibuya M	Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis.	BMB reports	2008	52
18467655	7422	Pollard JW	Macrophages define the invasive microenvironment in breast cancer.	Journal of leukocyte biology	2008	128
18565886	7422	Siegel AB	Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma.	Journal of clinical oncology 	2008	98
18596824	7422	Ellis LM	VEGF-targeted therapy: mechanisms of anti-tumour activity.	Nature reviews. Cancer	2008	353
18665180	7422	Beckermann BM	VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma.	British journal of cancer	2008	85
18824714	7422	Schneider BP	Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.	Journal of clinical oncology 	2008	165
18842611	7422	Scartozzi M	Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab.	Annals of oncology 	2009	75
18854571	7422	Grothey A	Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE).	Journal of clinical oncology 	2008	150
18927275	7422	Ellis LM	Pathways mediating resistance to vascular endothelial growth factor-targeted therapy.	Clinical cancer research 	2008	79
19017914	7422	Nalluri SR	Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.	JAMA	2008	145
19074844	7422	Ma J	Combination of antiangiogenesis with chemotherapy for more effective cancer treatment.	Molecular cancer therapeutics	2008	79
19150949	7422	Izzedine H	Management of hypertension in angiogenesis inhibitor-treated patients.	Annals of oncology 	2009	57
19167838	7422	Gutin PH	Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas.	International journal of radiation oncology, biology, physics	2009	73
19188680	7422	Reck M	Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.	Journal of clinical oncology 	2009	300
19224847	7422	Feldman DR	Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.	Journal of clinical oncology 	2009	70
19234476	7422	Augustin HG	Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system.	Nature reviews. Molecular cell biology	2009	292
19305413	7422	Reynolds AR	Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors.	Nature medicine	2009	111
19332770	7422	Quant EC	Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab.	Neuro-oncology	2009	48
19333229	7422	Gerstner ER	VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer.	Nature reviews. Clinical oncology	2009	47
19349600	7422	Nghiemphu PL	Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience.	Neurology	2009	66
19357959	7422	Jensen RL	Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target.	Journal of neuro-oncology	2009	74
19451442	7422	Escudier B	Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.	Journal of clinical oncology 	2009	216
19482548	7422	Hapani S	Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis.	The Lancet. Oncology	2009	55
19549711	7422	Linderholm BK	Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer.	Annals of oncology 	2009	48
19549889	7422	Sorensen AG	A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.	Cancer research	2009	108
19581909	7422	Chen HX	Adverse effects of anticancer agents that target the VEGF pathway.	Nature reviews. Clinical oncology	2009	90
19636328	7422	Grothey A	Targeting angiogenesis: progress with anti-VEGF treatment with large molecules.	Nature reviews. Clinical oncology	2009	101
19671869	7422	Ebos JM	Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy.	Clinical cancer research 	2009	69
19901561	7422	Bayet-Robert M	Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer.	Cancer biology and therapy	2010	46
19949018	7422	Lockhart AC	Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.	Journal of clinical oncology 	2010	69
20005148	7422	Ferrara N	Pathways mediating VEGF-independent tumor angiogenesis.	Cytokine and growth factor reviews	2010	64
20010945	7422	Murukesh N	Biomarkers of angiogenesis and their role in the development of VEGF inhibitors.	British journal of cancer	2010	55
20150572	7422	Reck M	Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL).	Annals of oncology 	2010	129
20156114	7422	Ranpura V	Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials.	Acta oncologica	2010	43
20351338	7422	Maitland ML	Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.	Journal of the National Cancer Institute	2010	53
20406897	7422	Gerstner ER	Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib.	Neuro-oncology	2010	44
20501804	7422	Hammers HJ	Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.	Molecular cancer therapeutics	2010	49
21074201	7422	Choueiri TK	The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.	The Journal of urology	2011	48
21126687	7422	Jubb AM	Biomarkers to predict the clinical efficacy of bevacizumab in cancer.	The Lancet. Oncology	2010	85
21167939	7422	Fidler IJ	The role of the organ microenvironment in brain metastasis.	Seminars in cancer biology	2011	63
21364524	7422	Ebos JM	Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.	Nature reviews. Clinical oncology	2011	164
21386818	7422	Zhu AX	HCC and angiogenesis: possible targets and future directions.	Nature reviews. Clinical oncology	2011	85
21527770	7422	Rini BI	Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.	Journal of the National Cancer Institute	2011	115
21537039	7422	Aghajanian C	Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.	Journal of clinical oncology 	2011	44
21565214	7422	Tugues S	Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer.	Molecular aspects of medicine	2011	49
21593862	7422	Carmeliet P	Molecular mechanisms and clinical applications of angiogenesis.	Nature	2011	810
21680800	7422	Battinelli EM	Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis.	Blood	2011	57
21711246	7422	Koch S	Signal transduction by vascular endothelial growth factor receptors.	The Biochemical journal	2011	189
22035272	7422	Narayana A	A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma.	Journal of neurosurgery	2012	39
22056247	7422	Rini BI	Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.	Lancet	2011	303
22084445	7422	Hirschhaeuser F	Lactate: a metabolic key player in cancer.	Cancer research	2011	125
22204724	7422	Burger RA	Incorporation of bevacizumab in the primary treatment of ovarian cancer.	The New England journal of medicine	2011	312
22204725	7422	Perren TJ	A phase 3 trial of bevacizumab in ovarian cancer.	The New England journal of medicine	2011	299
22222630	7422	Pastuskovas CV	Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model.	Molecular cancer therapeutics	2012	33
22229128	7422	Zhang Y	Positron Emission Tomography and Near-Infrared Fluorescence Imaging of Vascular Endothelial Growth Factor with Dual-Labeled Bevacizumab.	American journal of nuclear medicine and molecular imaging	2012	39
22264790	7422	Van der Veldt AA	Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs.	Cancer cell	2012	87
22330688	7422	Jayson GC	Antiangiogenic therapy--evolving view based on clinical trial results.	Nature reviews. Clinical oncology	2012	45
22498007	7422	McIntyre A	Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy.	Clinical cancer research 	2012	44
22525710	7422	Rapisarda A	Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia.	Nature reviews. Clinical oncology	2012	44
22588059	7422	Rapisarda A	Role of the VEGF/VEGFR axis in cancer biology and therapy.	Advances in cancer research	2012	37
22608783	7422	Lambrechts D	VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials.	The Lancet. Oncology	2012	44
22645052	7422	Nathan P	Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer.	Clinical cancer research 	2012	41
22665541	7422	Kindler HL	Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.	Journal of clinical oncology 	2012	35
22767667	7422	Rosen LS	A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer.	Clinical cancer research 	2012	57
22778320	7422	Chan JA	Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.	Journal of clinical oncology 	2012	33
22909788	7422	Pal S	Alternative transcription and alternative splicing in cancer.	Pharmacology and therapeutics	2012	36
22910841	7422	Agulnik M	An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas.	Annals of oncology 	2013	49
22963562	7422	Moccia F	Store-dependent Ca(2+) entry in endothelial progenitor cells as a perspective tool to enhance cell-based therapy and adverse tumour vascularization.	Current medicinal chemistry	2012	30
22965961	7422	Schmoll HJ	Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).	Journal of clinical oncology 	2012	46
22965962	7422	Ramlau R	Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.	Journal of clinical oncology 	2012	33
22965965	7422	Hoff PM	Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).	Journal of clinical oncology 	2012	35
23108136	7422	Terme M	VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer.	Cancer research	2013	61
23143192	7422	Plate KH	Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited.	Acta neuropathologica	2012	35
23169435	7422	Hegde PS	Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab.	Clinical cancer research 	2013	42
23177514	7422	Grothey A	Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.	Lancet	2013	340
23312463	7422	Heng DY	External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study.	The Lancet. Oncology	2013	71
23358650	7422	Tabernero J	First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement.	Cancer discovery	2013	116
23401453	7422	Lambrechts D	Markers of response for the antiangiogenic agent bevacizumab.	Journal of clinical oncology 	2013	80
23512266	7422	Soda Y	Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme.	Journal of molecular medicine	2013	35
23670728	7422	Finley SD	Effect of tumor microenvironment on tumor VEGF during anti-VEGF treatment: systems biology predictions.	Journal of the National Cancer Institute	2013	27
23846483	7422	Prorok-Hamon M	Colonic mucosa-associated diffusely adherent afaC+ Escherichia coli expressing lpfA and pks are increased in inflammatory bowel disease and colon cancer.	Gut	2014	33
23908119	7422	Welti J	Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer.	The Journal of clinical investigation	2013	102
23940216	7422	Batchelor TT	Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.	Journal of clinical oncology 	2013	80
23980090	7422	Llovet JM	Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.	Journal of clinical oncology 	2013	93
24030704	7422	Smith NR	Tumor stromal architecture can define the intrinsic tumor response to VEGF-targeted therapy.	Clinical cancer research 	2013	27
24097868	7422	Kienast Y	Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy.	Clinical cancer research 	2013	34
24135488	7422	Buczek M	Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: from the patient's bed to molecular mechanisms.	Biochimica et biophysica acta	2014	24
24347168	7422	Pereira ER	Endoplasmic reticulum (ER) stress and hypoxia response pathways interact to potentiate hypoxia-inducible factor 1 (HIF-1) transcriptional activity on targets like vascular endothelial growth factor (VEGF).	The Journal of biological chemistry	2014	30
24552317	7422	Gilbert MR	A randomized trial of bevacizumab for newly diagnosed glioblastoma.	The New England journal of medicine	2014	316
24552320	7422	Tewari KS	Improved survival with bevacizumab in advanced cervical cancer.	The New England journal of medicine	2014	139
24841777	7422	Albiges L	A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer.	European urology	2015	22
24949972	7422	Eswarappa SM	Programmed translational readthrough generates antiangiogenic VEGF-Ax.	Cell	2014	40
24996197	7422	Kudo M	Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial.	Hepatology	2014	28
25117977	7422	Baker GJ	Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy.	Neoplasia	2014	26
25220133	7422	Moja L	Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration.	The Cochrane database of systematic reviews	2014	27
25337750	7422	Loupakis F	Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.	The New England journal of medicine	2014	83
25402324	7422	Hiroshima Y	Efficacy of tumor-targeting Salmonella typhimurium A1-R in combination with anti-angiogenesis therapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX) and cell line mouse models.	Oncotarget	2014	41
25452452	7422	Motzer RJ	Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.	Journal of clinical oncology 	2015	120
25700172	7422	McIntyre A	Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality.	EMBO molecular medicine	2015	25
25713439	7422	Lu-Emerson C	Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.	Journal of clinical oncology 	2015	25
26095784	7422	Zhu AX	Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.	The Lancet. Oncology	2015	42
26167629	7422	Sampaziotis F	Cholangiocytes derived from human induced pluripotent stem cells for disease modeling and drug validation.	Nature biotechnology	2015	24
26179201	7422	Valle JW	Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.	The Lancet. Oncology	2015	20
26321262	7422	Chua MLK	Nasopharyngeal carcinoma.	Lancet	2016	42
26853587	7422	Jayson GC	Antiangiogenic therapy in oncology: current status and future directions.	Lancet	2016	38
16243973	10018	Zhao Y	Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim.	Proceedings of the National Academy of Sciences of the United States of America	2005	77
16888645	10018	Obexer P	FKHRL1-mediated expression of Noxa and Bim induces apoptosis via the mitochondria in neuroblastoma cells.	Cell death and differentiation	2007	62
17283153	10018	Tahir SK	Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.	Cancer research	2007	109
17653091	10018	Anderton E	Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt's lymphoma.	Oncogene	2008	66
17927446	10018	Gong Y	Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas.	PLoS medicine	2007	113
17973572	10018	Costa DB	BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.	PLoS medicine	2007	161
17973573	10018	Cragg MS	Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics.	PLoS medicine	2007	112
18200035	10018	Zhang W	Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway.	Leukemia	2008	55
18381439	10018	Hann CL	Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer.	Cancer research	2008	64
18725989	10018	Kinkade CW	Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model.	The Journal of clinical investigation	2008	151
20647567	10018	Bachmann PS	Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition.	Blood	2010	42
21148306	10018	Kazi A	The BH3 alpha-helical mimic BH3-M6 disrupts Bcl-X(L), Bcl-2, and MCL-1 protein-protein interactions with Bax, Bak, Bad, or Bim and induces apoptosis in a Bax- and Bim-dependent manner.	The Journal of biological chemistry	2011	42
21659544	10018	Morales AA	Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells.	Blood	2011	42
22076535	10018	Zhang H	MiR-25 regulates apoptosis by targeting Bim in human ovarian cancer.	Oncology reports	2012	40
22622039	10018	LaBelle JL	A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers.	The Journal of clinical investigation	2012	54
23243017	10018	Rahmani M	Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.	Cancer research	2013	38
23382048	10018	Nakagawa T	EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.	Cancer research	2013	36
23559152	10018	Lee JK	Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.	Annals of oncology 	2013	29
24362915	10018	Atsumi T	Inflammation amplifier, a new paradigm in cancer biology.	Cancer research	2014	37
24493829	10018	Costa C	The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial.	Clinical cancer research 	2014	48
24871945	10018	Wan L	APC(Cdc20) suppresses apoptosis through targeting Bim for ubiquitination and destruction.	Developmental cell	2014	22
25737542	10018	Faber AC	Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer.	Proceedings of the National Academy of Sciences of the United States of America	2015	21
26575167	10018	Li GQ	Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression.	Oncotarget	2016	12
26579470	10018	Huang L	Mechanisms of resistance to EGFR tyrosine kinase inhibitors.	Acta pharmaceutica Sinica. B	2015	29
9450758	10111	Benson FE	Synergistic actions of Rad51 and Rad52 in recombination and DNA repair.	Nature	1998	124
9590181	10111	Carney JP	The hMre11/hRad50 protein complex and Nijmegen breakage syndrome: linkage of double-strand break repair to the cellular DNA damage response.	Cell	1998	260
10426999	10111	Zhong Q	Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response.	Science	1999	123
10802669	10111	Gatei M	ATM-dependent phosphorylation of nibrin in response to radiation exposure.	Nature genetics	2000	113
10839544	10111	Zhao S	Functional link between ataxia-telangiectasia and Nijmegen breakage syndrome gene products.	Nature	2000	108
12124628	10111	Stracker TH	Adenovirus oncoproteins inactivate the Mre11-Rad50-NBS1 DNA repair complex.	Nature	2002	203
12456786	10111	Symington LS	Role of RAD52 epistasis group genes in homologous recombination and double-strand break repair.	Microbiology and molecular biology reviews 	2002	398
12660252	10111	Furuta T	Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes.	The Journal of biological chemistry	2003	123
15078995	10111	Kawabe T	G2 checkpoint abrogators as anticancer drugs.	Molecular cancer therapeutics	2004	82
15201865	10111	Lukas C	Mdc1 couples DNA double-strand break recognition by Nbs1 with its H2AX-dependent chromatin retention.	The EMBO journal	2004	124
15279769	10111	Stracker TH	The Mre11 complex and the metabolism of chromosome breaks: the importance of communicating and holding things together.	DNA repair	2004	103
16618811	10111	Bekker-Jensen S	Spatial organization of the mammalian genome surveillance machinery in response to DNA strand breaks.	The Journal of cell biology	2006	221
17713585	10111	Williams RS	Mre11-Rad50-Nbs1 is a keystone complex connecting DNA repair machinery, double-strand break signaling, and the chromatin template.	Biochemistry and cell biology = Biochimie et biologie cellulaire	2007	144
18066087	10111	Lavin MF	ATM and the Mre11 complex combine to recognize and signal DNA double-strand breaks.	Oncogene	2007	93
18157161	10111	Shrivastav M	Regulation of DNA double-strand break repair pathway choice.	Cell research	2008	316
18176557	10111	Dupré A	A forward chemical genetic screen reveals an inhibitor of the Mre11-Rad50-Nbs1 complex.	Nature chemical biology	2008	108
18596698	10111	Jazayeri A	Mre11-Rad50-Nbs1-dependent processing of DNA breaks generates oligonucleotides that stimulate ATM activity.	The EMBO journal	2008	52
19092773	10111	Ripperger T	Breast cancer susceptibility: current knowledge and implications for genetic counselling.	European journal of human genetics 	2009	45
21252998	10111	Stracker TH	The MRE11 complex: starting from the ends.	Nature reviews. Molecular cell biology	2011	214
21816818	10111	Della-Maria J	Human Mre11/human Rad50/Nbs1 and DNA ligase IIIalpha/XRCC1 protein complexes act together in an alternative nonhomologous end joining pathway.	The Journal of biological chemistry	2011	42
22006311	10111	Walsh T	Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.	Proceedings of the National Academy of Sciences of the United States of America	2011	149
22048815	10111	Weigman VJ	Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival.	Breast cancer research and treatment	2012	39
22365830	10111	Polo SE	Regulation of DNA-end resection by hnRNPU-like proteins promotes DNA double-strand break signaling and repair.	Molecular cell	2012	51
22705791	10111	Schiller CB	Structure of Mre11-Nbs1 complex yields insights into ataxia-telangiectasia-like disease mutations and DNA damage signaling.	Nature structural and molecular biology	2012	43
22743550	10111	Thompson LH	Recognition, signaling, and repair of DNA double-strand breaks produced by ionizing radiation in mammalian cells: the molecular choreography.	Mutation research	2012	101
22983061	10111	Oplustilova L	Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.	Cell cycle	2012	40
24934408	10111	Al-Ahmadie H	Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy.	Cancer discovery	2014	26
25605897	10111	Poruchynsky MS	Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins.	Proceedings of the National Academy of Sciences of the United States of America	2015	21
25625517	10111	Czarny P	Autophagy in DNA damage response.	International journal of molecular sciences	2015	20
25903499	10111	Spurlock CF 3rd	Expression and functions of long noncoding RNAs during human T helper cell differentiation.	Nature communications	2015	16
9145716	10178	Partin AW	Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update.	JAMA	1997	150
9187198	10178	Mountain CF	Revisions in the International System for Staging Lung Cancer.	Chest	1997	408
9628711	10178	Lannin DR	Influence of socioeconomic and cultural factors on racial differences in late-stage presentation of breast cancer.	JAMA	1998	138
12441925	10178	Frank I	An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score.	The Journal of urology	2002	122
15830281	10178	Llovet JM	Updated treatment approach to hepatocellular carcinoma.	Journal of gastroenterology	2005	121
15837991	10178	Patard JJ	Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience.	Journal of clinical oncology 	2005	86
16034041	10178	von der Maase H	Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.	Journal of clinical oncology 	2005	198
17607115	10178	Rusch VW	The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer.	Journal of thoracic oncology 	2007	58
18230780	10178	Schetter AJ	MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma.	JAMA	2008	505
19025987	10178	Fassnacht M	Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification.	Cancer	2009	61
19063642	10178	Chan EC	Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS).	Journal of proteome research	2009	83
20564099	10178	Rice TW	Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals.	Cancer	2010	109
21245428	10178	Mlecnik B	Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction.	Journal of clinical oncology 	2011	176
21523730	10178	Farges O	AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: By the AFC-IHCC-2009 study group.	Cancer	2011	41
21627863	10178	Wei J	Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer.	Chinese journal of cancer	2011	48
21935600	10178	Beasley JM	Meeting the physical activity guidelines and survival after breast cancer: findings from the after breast cancer pooling project.	Breast cancer research and treatment	2012	34
22525418	10178	Rindi G	TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study.	Journal of the National Cancer Institute	2012	43
22790014	10178	Mitrovic B	Tumor budding in colorectal carcinoma: time to take notice.	Modern pathology 	2012	39
23018875	10178	Karamitopoulou E	Proposal for a 10-high-power-fields scoring method for the assessment of tumor budding in colorectal cancer.	Modern pathology 	2013	32
23104212	10178	Roth AD	Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer.	Journal of the National Cancer Institute	2012	45
23399908	10178	Walters S	Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007.	Thorax	2013	42
23649448	10178	Jett JR	Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.	Chest	2013	36
24183870	10178	Grégoire V	Delineation of the neck node levels for head and neck tumors: a 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines.	Radiotherapy and oncology 	2014	34
24961353	10178	Liu Z	Clinical significance of the low expression of FER1L4 in gastric cancer patients.	Tumour biology 	2014	22
25231913	10178	Zhang H	Infiltration of diametrically polarized macrophages predicts overall survival of patients with gastric cancer after surgical resection.	Gastric cancer 	2015	18
25575264	10178	Park JH	Colorectal Cancer, Systemic Inflammation, and Outcome: Staging the Tumor and Staging the Host.	Annals of surgery	2016	18
25667292	10178	Huang SH	Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas.	Journal of clinical oncology 	2015	32
25689795	10178	Li P	Using circular RNA as a novel type of biomarker in the screening of gastric cancer.	Clinica chimica acta; international journal of clinical chemistry	2015	60
25897338	10178	Zhang J	Circulating MiR-16-5p and MiR-19b-3p as Two Novel Potential Biomarkers to Indicate Progression of Gastric Cancer.	Theranostics	2015	18
25903045	10178	Zheng Q	Aberrant expression of UCA1 in gastric cancer and its clinical significance.	Clinical and translational oncology 	2015	26
25919911	10178	Zhang X	Elevated expression of CCAT2 is associated with poor prognosis in esophageal squamous cell carcinoma.	Journal of surgical oncology	2015	18
26314847	10178	Li Y	NEAT expression is associated with tumor recurrence and unfavorable prognosis in colorectal cancer.	Oncotarget	2015	24
26897166	10178	Sano T	Proposal of a new stage grouping of gastric cancer for TNM classification: International Gastric Cancer Association staging project.	Gastric cancer 	2017	10
27313790	10178	Wang Y	The Long Noncoding RNA MALAT-1 is A Novel Biomarker in Various Cancers: A Meta-analysis Based on the GEO Database and Literature.	Journal of Cancer	2016	15
11103784	10232	Hough CD	Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer.	Cancer research	2000	106
14676194	10232	Rump A	Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion.	The Journal of biological chemistry	2004	125
15217923	10232	Hassan R	Mesothelin: a new target for immunotherapy.	Clinical cancer research 	2004	123
15897581	10232	Ho M	Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients.	Clinical cancer research 	2005	67
16061277	10232	Rosen DG	Potential markers that complement expression of CA125 in epithelial ovarian cancer.	Gynecologic oncology	2005	71
17067392	10232	Gubbels JA	Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors.	Molecular cancer	2006	105
17785569	10232	Hassan R	Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers.	Clinical cancer research 	2007	137
17945478	10232	Hassan R	Mesothelin targeted cancer immunotherapy.	European journal of cancer	2008	88
18088084	10232	Hassan R	Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.	Cancer immunity	2007	60
19053170	10232	Köbel M	Ovarian carcinoma subtypes are different diseases: implications for biomarker studies.	PLoS medicine	2008	184
22147941	10232	Le DT	A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction.	Clinical cancer research 	2012	72
22351743	10232	Kelly RJ	Mesothelin-targeted agents in clinical trials and in preclinical development.	Molecular cancer therapeutics	2012	39
22371455	10232	Servais EL	Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients.	Clinical cancer research 	2012	39
22412141	10232	Hollevoet K	Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.	Journal of clinical oncology 	2012	39
24334761	10232	Kachala SS	Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma.	Clinical cancer research 	2014	29
24824231	10232	Pastan I	Discovery of mesothelin and exploiting it as a target for immunotherapy.	Cancer research	2014	46
24919573	10232	Moon EK	Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors.	Clinical cancer research 	2014	46
24989332	10232	Hassan R	Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.	Cancer	2014	34
26503962	10232	Morello A	Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors.	Cancer discovery	2016	35
12839961	10406	Hellström I	The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma.	Cancer research	2003	133
15161682	10406	Lu KH	Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis.	Clinical cancer research 	2004	109
15781627	10406	Drapkin R	Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas.	Cancer research	2005	104
16343244	10406	Bast RC Jr	New tumor markers: CA125 and beyond.	International journal of gynecological cancer 	2005	102
16607372	10406	Galgano MT	Comprehensive analysis of HE4 expression in normal and malignant human tissues.	Modern pathology 	2006	62
18061248	10406	Moore RG	The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.	Gynecologic oncology	2008	116
18851871	10406	Moore RG	A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.	Gynecologic oncology	2009	117
19337252	10406	Huhtinen K	Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts.	British journal of cancer	2009	49
20042715	10406	Anderson GL	Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study.	Journal of the National Cancer Institute	2010	65
20368574	10406	Yurkovetsky Z	Development of a multimarker assay for early detection of ovarian cancer.	Journal of clinical oncology 	2010	71
20471625	10406	Moore RG	Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass.	American journal of obstetrics and gynecology	2010	53
21304524	10406	Van Gorp T	HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm.	British journal of cancer	2011	48
21372036	10406	Cramer DW	Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens.	Cancer prevention research	2011	72
21881677	10406	Wang S	Integration of cell phone imaging with microchip ELISA to detect ovarian cancer HE4 biomarker in urine at the point-of-care.	Lab on a chip	2011	41
16814713	10413	Zender L	Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach.	Cell	2006	374
16894141	10413	Overholtzer M	Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon.	Proceedings of the National Academy of Sciences of the United States of America	2006	278
17889654	10413	Dong J	Elucidation of a universal size-control mechanism in Drosophila and mammals.	Cell	2007	582
17974916	10413	Zhao B	Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control.	Genes and development	2007	583
17980593	10413	Camargo FD	YAP1 increases organ size and expands undifferentiated progenitor cells.	Current biology 	2007	317
18413746	10413	Zhang J	Negative regulation of YAP by LATS1 underscores evolutionary conservation of the Drosophila Hippo pathway.	Cancer research	2008	88
18703216	10413	Steinhardt AA	Expression of Yes-associated protein in common solid tumors.	Human pathology	2008	172
18955139	10413	Zhao B	The Hippo-YAP pathway: new connections between regulation of organ size and cancer.	Current opinion in cell biology	2008	125
19106601	10413	Bertini E	YAP: at the crossroad between transformation and tumor suppression.	Cell cycle	2009	51
19111660	10413	Lapi E	PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop.	Molecular cell	2008	69
19424602	10413	Katoh M	Transcriptional mechanisms of WNT5A based on NF-kappaB, Hedgehog, TGFbeta, and Notch signaling cascades.	International journal of molecular medicine	2009	53
19551889	10413	Xu MZ	Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma.	Cancer	2009	124
19935651	10413	Zhang J	YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway.	Nature cell biology	2009	131
19952108	10413	Fernandez-L A	YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation.	Genes and development	2009	110
20048001	10413	Zhao B	A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP).	Genes and development	2010	245
20159599	10413	Genevet A	Kibra is a regulator of the Salvador/Warts/Hippo signaling network.	Developmental cell	2010	122
20219076	10413	Wang Y	Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer.	Cancer science	2010	72
20516196	10413	Lian I	The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation.	Genes and development	2010	167
20868367	10413	Oka T	Functional complexes between YAP2 and ZO-2 are PDZ domain-dependent, and regulate YAP2 nuclear localization and signalling.	The Biochemical journal	2010	43
20947521	10413	Hall CA	Hippo pathway effector Yap is an ovarian cancer oncogene.	Cancer research	2010	63
21076472	10413	Xu MZ	AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma.	Oncogene	2011	46
21102585	10413	Avruch J	Mst1/2 signalling to Yap: gatekeeper for liver size and tumour development.	British journal of cancer	2011	41
21112960	10413	Muramatsu T	YAP is a candidate oncogene for esophageal squamous cell carcinoma.	Carcinogenesis	2011	57
21187284	10413	Wang W	Angiomotin-like proteins associate with and negatively regulate YAP1.	The Journal of biological chemistry	2011	80
21267586	10413	Ellison DW	Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups.	Acta neuropathologica	2011	94
21317925	10413	Zhang X	The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene.	Oncogene	2011	75
21346147	10413	Kang W	Yes-associated protein 1 exhibits oncogenic property in gastric cancer and its nuclear accumulation associates with poor prognosis.	Clinical cancer research 	2011	47
21610251	10413	Silvis MR	α-catenin is a tumor suppressor that controls cell accumulation by regulating the localization and activity of the transcriptional coactivator Yap1.	Science signaling	2011	92
22042863	10413	Zhou D	Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance.	Proceedings of the National Academy of Sciences of the United States of America	2011	99
22215811	10413	Zhao B	Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis.	Genes and development	2012	165
22286761	10413	Mizuno T	YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes.	Oncogene	2012	46
22337891	10413	Konsavage WM Jr	Wnt/β-catenin signaling regulates Yes-associated protein (YAP) gene expression in colorectal carcinoma cells.	The Journal of biological chemistry	2012	62
22659496	10413	Hong W	The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway.	Seminars in cell and developmental biology	2012	85
22677547	10413	Liu-Chittenden Y	Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP.	Genes and development	2012	210
22707013	10413	Zhang T	Hepatitis B virus X protein modulates oncogene Yes-associated protein by CREB to promote growth of hepatoma cells.	Hepatology	2012	42
22891335	10413	Lamar JM	The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain.	Proceedings of the National Academy of Sciences of the United States of America	2012	105
23143395	10413	Tumaneng K	YAP mediates crosstalk between the Hippo and PI(3)K–TOR pathways by suppressing PTEN via miR-29.	Nature cell biology	2012	87
23178811	10413	Barry ER	Restriction of intestinal stem cell expansion and the regenerative response by YAP.	Nature	2013	106
23419361	10413	Tschaharganeh DF	Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma.	Gastroenterology	2013	57
23542177	10413	Mao B	SIRT1 regulates YAP2-mediated cell proliferation and chemoresistance in hepatocellular carcinoma.	Oncogene	2014	24
23618389	10413	Cai H	The role of LPA and YAP signaling in long-term migration of human ovarian cancer cells.	Cell communication and signaling 	2013	30
23737213	10413	Antonescu CR	Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma.	Genes, chromosomes and cancer	2013	31
23762387	10413	Wang L	Overexpression of YAP and TAZ is an independent predictor of prognosis in colorectal cancer and related to the proliferation and metastasis of colon cancer cells.	PloS one	2013	55
23985307	10413	Hergovich A	Regulation and functions of mammalian LATS/NDR kinases: looking beyond canonical Hippo signalling.	Cell and bioscience	2013	27
24023255	10413	Sun G	Ajuba family proteins link JNK to Hippo signaling.	Science signaling	2013	38
24268772	10413	Anakk S	Bile acids activate YAP to promote liver carcinogenesis.	Cell reports	2013	25
24323901	10413	Touil Y	Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis.	Clinical cancer research 	2014	32
24362629	10413	Mohseni M	A genetic screen identifies an LKB1-MARK signalling axis controlling the Hippo-YAP pathway.	Nature cell biology	2014	59
24366813	10413	Hauri S	Interaction proteome of human Hippo signaling: modular control of the co-activator YAP1.	Molecular systems biology	2013	28
24468535	10413	Wang J	Mutual inhibition between YAP and SRSF1 maintains long non-coding RNA, Malat1-induced tumourigenesis in liver cancer.	Cellular signalling	2014	21
24581491	10413	Mori M	Hippo signaling regulates microprocessor and links cell-density-dependent miRNA biogenesis to cancer.	Cell	2014	73
24622501	10413	Xia Y	YAP promotes ovarian cancer cell tumorigenesis and is indicative of a poor prognosis for ovarian cancer patients.	PloS one	2014	30
24803537	10413	Zhang W	Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma.	Science signaling	2014	58
24882515	10413	Feng X	Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry.	Cancer cell	2014	73
24882516	10413	Yu FX	Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.	Cancer cell	2014	66
24884509	10413	Tu K	Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma.	Molecular cancer	2014	25
24954536	10413	Shao DD	KRAS and YAP1 converge to regulate EMT and tumor survival.	Cell	2014	119
25010260	10413	Perra A	YAP activation is an early event and a potential therapeutic target in liver cancer development.	Journal of hepatology	2014	40
25087979	10413	Tremblay AM	The Hippo transducer YAP1 transforms activated satellite cells and is a potent effector of embryonal rhabdomyosarcoma formation.	Cancer cell	2014	28
25180228	10413	Hong X	Opposing activities of the Ras and Hippo pathways converge on regulation of YAP protein turnover.	The EMBO journal	2014	22
25195862	10413	Liu G	Kaposi sarcoma-associated herpesvirus promotes tumorigenesis by modulating the Hippo pathway.	Oncogene	2015	18
25266986	10413	Kodaka M	The mammalian Hippo pathway: regulation and function of YAP1 and TAZ.	Cellular and molecular life sciences 	2015	16
25293527	10413	Yu FX	Hippo pathway regulation of gastrointestinal tissues.	Annual review of physiology	2015	15
25388162	10413	Lee KW	Significant association of oncogene YAP1 with poor prognosis and cetuximab resistance in colorectal cancer patients.	Clinical cancer research 	2015	18
25438054	10413	Ma B	Hypoxia regulates Hippo signalling through the SIAH2 ubiquitin E3 ligase.	Nature cell biology	2015	30
25665005	10413	Lin L	The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.	Nature genetics	2015	62
25731159	10413	Taniguchi K	A gp130-Src-YAP module links inflammation to epithelial regeneration.	Nature	2015	61
25739674	10413	Song S	The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer.	Clinical cancer research 	2015	23
25751140	10413	Mo JS	Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway.	Nature cell biology	2015	53
25772357	10413	Fitamant J	YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression.	Cell reports	2015	26
25778702	10413	Porazinski S	YAP is essential for tissue tension to ensure vertebrate 3D body shape.	Nature	2015	26
25796446	10413	Enzo E	Aerobic glycolysis tunes YAP/TAZ transcriptional activity.	The EMBO journal	2015	20
25846731	10413	Deng J	MicroRNA-506 inhibits gastric cancer proliferation and invasion by directly targeting Yap1.	Tumour biology 	2015	19
25893606	10413	Zhou X	Estrogen regulates Hippo signaling via GPER in breast cancer.	The Journal of clinical investigation	2015	18
25915126	10413	Cebola I	TEAD and YAP regulate the enhancer network of human embryonic pancreatic progenitors.	Nature cell biology	2015	25
25943351	10413	Morikawa Y	Actin cytoskeletal remodeling with protrusion formation is essential for heart regeneration in Hippo-deficient mice.	Science signaling	2015	20
25961504	10413	Iglesias-Bartolome R	Inactivation of a Gα(s)-PKA tumour suppressor pathway in skin stem cells initiates basal-cell carcinogenesis.	Nature cell biology	2015	18
25965575	10413	Pajtler KW	Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups.	Cancer cell	2015	42
26058078	10413	Nguyen LT	ERG Activates the YAP1 Transcriptional Program and Induces the Development of Age-Related Prostate Tumors.	Cancer cell	2015	18
26119935	10413	Ciamporcero E	YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage.	Oncogene	2016	12
26121086	10413	Schramm A	Mutational dynamics between primary and relapse neuroblastomas.	Nature genetics	2015	37
26193883	10413	Cai J	β-Catenin destruction complex-independent regulation of Hippo-YAP signaling by APC in intestinal tumorigenesis.	Genes and development	2015	20
26276632	10413	Park HW	Alternative Wnt Signaling Activates YAP/TAZ.	Cell	2015	43
26295846	10413	Stein C	YAP1 Exerts Its Transcriptional Control via TEAD-Mediated Activation of Enhancers.	PLoS genetics	2015	21
26359985	10413	Hugo W	Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance.	Cell	2015	38
26691213	10413	Di Agostino S	YAP enhances the pro-proliferative transcriptional activity of mutant p53 proteins.	EMBO reports	2016	12
26701088	10413	Wang G	Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression.	Cancer discovery	2016	17
26950094	10413	Bonilla X	Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma.	Nature genetics	2016	19
27270433	10413	Selth LA	A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer.	Oncogene	2017	9
27851739	10413	Gjorevski N	Designer matrices for intestinal stem cell and organoid culture.	Nature	2016	15
8649389	10664	Filippova GN	An exceptionally conserved transcriptional repressor, CTCF, employs different combinations of zinc fingers to bind diverged promoter sequences of avian and mammalian c-myc oncogenes.	Molecular and cellular biology	1996	180
11479593	10664	Filippova GN	CTCF-binding sites flank CTG/CAG repeats and form a methylation-sensitive insulator at the DM1 locus.	Nature genetics	2001	95
17382889	10664	Kim TH	Analysis of the vertebrate insulator protein CTCF-binding sites in the human genome.	Cell	2007	446
17512414	10664	Barski A	High-resolution profiling of histone methylations in the human genome.	Cell	2007	2338
17950379	10664	Filippova GN	Genetics and epigenetics of the multifunctional protein CTCF.	Current topics in developmental biology	2008	83
18463634	10664	Guelen L	Domain organization of human chromosomes revealed by mapping of nuclear lamina interactions.	Nature	2008	496
19295514	10664	Heintzman ND	Histone modifications at human enhancers reflect global cell-type-specific gene expression.	Nature	2009	880
20219941	10664	Schmidt D	A CTCF-independent role for cohesin in tissue-specific transcription.	Genome research	2010	150
20625516	10664	Meeran SM	Sulforaphane causes epigenetic repression of hTERT expression in human breast cancer cell lines.	PloS one	2010	85
21281512	10664	Woodfine K	Quantitative analysis of DNA methylation at all human imprinted regions reveals preservation of epigenetic stability in adult somatic tissue.	Epigenetics and chromatin	2011	44
21408204	10664	Euskirchen GM	Diverse roles and interactions of the SWI/SNF chromatin remodeling complex revealed using global approaches.	PLoS genetics	2011	86
21964334	10664	Shukla S	CTCF-promoted RNA polymerase II pausing links DNA methylation to splicing.	Nature	2011	302
22244452	10664	Schmidt D	Waves of retrotransposon expansion remodel genome organization and CTCF binding in multiple mammalian lineages.	Cell	2012	137
22495300	10664	Dixon JR	Topological domains in mammalian genomes identified by analysis of chromatin interactions.	Nature	2012	917
22976956	10664	Dolnik A	Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing.	Blood	2012	35
23010778	10664	Deng Z	A role for CTCF and cohesin in subtelomere chromatin organization, TERRA transcription, and telomere end protection.	The EMBO journal	2012	39
24335803	10664	Zuin J	Cohesin and CTCF differentially affect chromatin architecture and gene expression in human cells.	Proceedings of the National Academy of Sciences of the United States of America	2014	148
24843008	10664	Krawczyk M	p50-associated COX-2 extragenic RNA (PACER) activates COX-2 gene expression by occluding repressive NF-κB complexes.	eLife	2014	33
25580597	10664	Liu M	Genomic discovery of potent chromatin insulators for human gene therapy.	Nature biotechnology	2015	16
25658338	10664	Qin F	Discovery of CTCF-sensitive Cis-spliced fusion RNAs between adjacent genes in human prostate cells.	PLoS genetics	2015	16
26276636	10664	Guo Y	CRISPR Inversion of CTCF Sites Alters Genome Topology and Enhancer/Promoter Function.	Cell	2015	100
26686465	10664	Ji X	3D Chromosome Regulatory Landscape of Human Pluripotent Cells.	Cell stem cell	2016	40
26700815	10664	Flavahan WA	Insulator dysfunction and oncogene activation in IDH mutant gliomas.	Nature	2016	82
10888881	11186	Dammann R	Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3.	Nature genetics	2000	229
11333291	11186	Burbee DG	Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression.	Journal of the National Cancer Institute	2001	133
12024041	11186	Shivakumar L	The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation.	Molecular and cellular biology	2002	81
14633683	11186	Müller HM	DNA methylation in serum of breast cancer patients: an independent prognostic marker.	Cancer research	2003	81
15867337	11186	Agathanggelou A	Role of the Ras-association domain family 1 tumor suppressor gene in human cancers.	Cancer research	2005	108
16618406	11186	Calvisi DF	Ubiquitous activation of Ras and Jak/Stat pathways in human HCC.	Gastroenterology	2006	150
17379520	11186	Guo C	RASSF1A is part of a complex similar to the Drosophila Hippo/Salvador/Lats tumor-suppressor network.	Current biology 	2007	66
17606710	11186	Kwabi-Addo B	Age-related DNA methylation changes in normal human prostate tissues.	Clinical cancer research 	2007	69
17692468	11186	van der Weyden L	The Ras-association domain family (RASSF) members and their role in human tumourigenesis.	Biochimica et biophysica acta	2007	105
17878233	11186	Donninger H	The RASSF1A tumor suppressor.	Journal of cell science	2007	128
17889669	11186	Matallanas D	RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein.	Molecular cell	2007	114
18381931	11186	Wu JM	Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases.	Clinical cancer research 	2008	61
20682973	11186	Cho YH	Aberrant promoter hypermethylation and genomic hypomethylation in tumor, adjacent normal tissues and blood from breast cancer patients.	Anticancer research	2010	46
21146512	11186	Lambert MP	Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake.	Journal of hepatology	2011	46
21352471	11186	Meng F	Functional analysis of microRNAs in human hepatocellular cancer stem cells.	Journal of cellular and molecular medicine	2012	37
22195963	11186	Matallanas D	Mutant K-Ras activation of the proapoptotic MST2 pathway is antagonized by wild-type K-Ras.	Molecular cell	2011	43
22549947	11186	Matei D	Epigenetic resensitization to platinum in ovarian cancer.	Cancer research	2012	78
22999998	11186	Stewart GD	Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study.	The Journal of urology	2013	28
10617473	11200	Bell DW	Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome.	Science	1999	140
10724175	11200	Lee JS	hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response.	Nature	2000	115
11298456	11200	Falck J	The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis.	Nature	2001	247
11967536	11200	Meijers-Heijboer H	Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.	Nature genetics	2002	216
12094328	11200	Vahteristo P	A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer.	American journal of human genetics	2002	86
12598907	11200	Lukas C	Distinct spatiotemporal dynamics of mammalian checkpoint regulators induced by DNA damage.	Nature cell biology	2003	149
15122511	11200	CHEK2 Breast Cancer Case-Control Consortium.	CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies.	American journal of human genetics	2004	107
15604286	11200	Hickson I	Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM.	Cancer research	2004	422
15829956	11200	Bartkova J	DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis.	Nature	2005	819
15829965	11200	Gorgoulis VG	Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions.	Nature	2005	644
16551709	11200	Walsh T	Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.	JAMA	2006	143
16901786	11200	Zhang D	A role for the deubiquitinating enzyme USP28 in control of the DNA-damage response.	Cell	2006	103
17101782	11200	Tan Y	Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate expression of DNA repair genes.	Molecular and cellular biology	2007	87
18004398	11200	Antoni L	CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin?	Nature reviews. Cancer	2007	85
19597488	11200	Rodier F	Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion.	Nature cell biology	2009	416
19879149	11200	Le Guezennec X	WIP1 phosphatase at the crossroads of cancer and aging.	Trends in biochemical sciences	2010	46
20126263	11200	van Vugt MA	A mitotic phosphorylation feedback network connects Cdk1, Plk1, 53BP1, and Chk2 to inactivate the G(2)/M DNA damage checkpoint.	PLoS biology	2010	71
20364141	11200	Stolz A	The CHK2-BRCA1 tumour suppressor pathway ensures chromosomal stability in human somatic cells.	Nature cell biology	2010	52
21147465	11200	Nikitin PA	An ATM/Chk2-mediated DNA damage-responsive signaling pathway suppresses Epstein-Barr virus transformation of primary human B cells.	Cell host and microbe	2010	74
21156285	11200	Squatrito M	Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas.	Cancer cell	2010	56
21960636	11200	Janssen A	Chromosome segregation errors as a cause of DNA damage and structural chromosome aberrations.	Science	2011	143
23400594	11200	Casetti L	Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells.	Cancer research	2013	27
24549055	11200	Castéra L	Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes.	European journal of human genetics 	2014	39
24976383	11200	Ertych N	Increased microtubule assembly rates influence chromosomal instability in colorectal cancer cells.	Nature cell biology	2014	30
25132270	11200	Sarmento LM	CHK1 overexpression in T-cell acute lymphoblastic leukemia is essential for proliferation and survival by preventing excessive replication stress.	Oncogene	2015	17
25186627	11200	Tung N	Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.	Cancer	2015	49
25288723	11200	Kiiski JI	Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2014	22
25613496	11200	Hu L	Up-regulation of long noncoding RNA MALAT1 contributes to proliferation and metastasis in esophageal squamous cell carcinoma.	Journal of experimental and clinical cancer research 	2015	43
26270727	11200	Desmond A	Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.	JAMA oncology	2015	24
26483394	11200	Hu C	Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients.	Cancer epidemiology, biomarkers and prevention 	2016	11
26510020	11200	Mateo J	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.	The New England journal of medicine	2015	128
26976419	11200	Tung N	Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.	Journal of clinical oncology 	2016	10
27433846	11200	Pritchard CC	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.	The New England journal of medicine	2016	29
7542586	22882	Marais R	Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation.	The EMBO journal	1995	138
12183360	22882	Hamad NM	Distinct requirements for Ras oncogenesis in human versus mouse cells.	Genes and development	2002	135
12438234	22882	Yuen ST	Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia.	Cancer research	2002	95
12692057	22882	Tannapfel A	Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma.	Gut	2003	92
12813171	22882	Fu Z	Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis.	Journal of the National Cancer Institute	2003	94
15052340	22882	McDermott M	Phospholipase D.	Biochemistry and cell biology = Biochimie et biologie cellulaire	2004	86
15059882	22882	Wellbrock C	V599EB-RAF is an oncogene in melanocytes.	Cancer research	2004	97
15208680	22882	Karasarides M	B-RAF is a therapeutic target in melanoma.	Oncogene	2004	97
15519853	22882	Repasky GA	Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?	Trends in cell biology	2004	82
15520807	22882	Wellbrock C	The RAF proteins take centre stage.	Nature reviews. Molecular cell biology	2004	279
15781657	22882	Sharma A	Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.	Cancer research	2005	94
16273091	22882	Solit DB	BRAF mutation predicts sensitivity to MEK inhibition.	Nature	2006	370
16364920	22882	Garnett MJ	Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization.	Molecular cell	2005	106
16720434	22882	Kohno M	Targeting the ERK signaling pathway in cancer therapy.	Annals of medicine	2006	97
17188374	22882	Chambard JC	ERK implication in cell cycle regulation.	Biochimica et biophysica acta	2007	150
17208430	22882	Dhomen N	New insight into BRAF mutations in cancer.	Current opinion in genetics and development	2007	67
17470685	22882	Strumberg D	Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.	The oncologist	2007	94
18223206	22882	Friday BB	Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.	Clinical cancer research 	2008	108
18372904	22882	Haigis KM	Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon.	Nature genetics	2008	193
18390968	22882	Adjei AA	Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.	Journal of clinical oncology 	2008	161
18650514	22882	Llovet JM	Sorafenib in advanced hepatocellular carcinoma.	The New England journal of medicine	2008	1938
18725993	22882	Grant S	Cotargeting survival signaling pathways in cancer.	The Journal of clinical investigation	2008	55
18846109	22882	Balmanno K	Tumour cell survival signalling by the ERK1/2 pathway.	Cell death and differentiation	2009	100
18852116	22882	Wilhelm SM	Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.	Molecular cancer therapeutics	2008	277
19117997	22882	Ihle NT	Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance.	Cancer research	2009	110
19915144	22882	Emery CM	MEK1 mutations confer resistance to MEK and B-RAF inhibition.	Proceedings of the National Academy of Sciences of the United States of America	2009	170
20130576	22882	Hatzivassiliou G	RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.	Nature	2010	371
20149254	22882	Frémin C	From basic research to clinical development of MEK1/2 inhibitors for cancer therapy.	Journal of hematology and oncology	2010	57
20538618	22882	Whittaker S	Gatekeeper mutations mediate resistance to BRAF-targeted therapies.	Science translational medicine	2010	59
20818433	22882	Kaplan FM	Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells.	Oncogene	2011	44
21098323	22882	Matei D	Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.	Journal of clinical oncology 	2011	38
21447797	22882	Poulikakos PI	Resistance to MEK inhibitors: should we co-target upstream?	Science signaling	2011	36
21803746	22882	Shi H	Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.	Cancer research	2011	64
21898400	22882	Liu P	miR-520c and miR-373 upregulate MMP9 expression by targeting mTOR and SIRT1, and activate the Ras/Raf/MEK/Erk signaling pathway and NF-κB factor in human fibrosarcoma cells.	Journal of cellular physiology	2012	40
22113612	22882	Poulikakos PI	RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).	Nature	2011	347
22402123	22882	Hatzivassiliou G	ERK inhibition overcomes acquired resistance to MEK inhibitors.	Molecular cancer therapeutics	2012	48
22421192	22882	Mross K	A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors.	Clinical cancer research 	2012	55
22443084	22882	De Luca A	The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches.	Expert opinion on therapeutic targets	2012	116
22451120	22882	Xie B	Sorafenib for treatment of hepatocellular carcinoma: a systematic review.	Digestive diseases and sciences	2012	34
23134356	22882	Callahan MK	Progression of RAS-mutant leukemia during RAF inhibitor treatment.	The New England journal of medicine	2012	57
23489023	22882	Kim KB	Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.	Thyroid 	2013	43
23712190	22882	Gibney GT	Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma.	Nature reviews. Clinical oncology	2013	32
23934108	22882	Hatzivassiliou G	Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.	Nature	2013	55
24108405	22882	Hartsough E	Resistance to RAF inhibitors revisited.	The Journal of investigative dermatology	2014	23
24121058	22882	Neuzillet C	MEK in cancer and cancer therapy.	Pharmacology and therapeutics	2014	32
24158481	22882	Nan X	Single-molecule superresolution imaging allows quantitative analysis of RAF multimer formation and signaling.	Proceedings of the National Academy of Sciences of the United States of America	2013	33
24178622	22882	Jain N	Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.	Clinical cancer research 	2014	27
24202393	22882	Lito P	Tumor adaptation and resistance to RAF inhibitors.	Nature medicine	2013	130
24265153	22882	Van Allen EM	The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.	Cancer discovery	2014	157
24265154	22882	Wagle N	MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.	Cancer discovery	2014	109
24823863	22882	Levy JM	Autophagy inhibition improves chemosensitivity in BRAF(V600E) brain tumors.	Cancer discovery	2014	31
24840079	22882	Zhao Y	The clinical development of MEK inhibitors.	Nature reviews. Clinical oncology	2014	55
24957944	22882	Holderfield M	Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond.	Nature reviews. Cancer	2014	110
25324352	22882	Hyman DM	Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders.	Cancer discovery	2015	27
25355599	22882	Chai J	MicroRNA-455 inhibits proliferation and invasion of colorectal cancer by targeting RAF proto-oncogene serine/threonine-protein kinase.	Tumour biology 	2015	15
25437913	22882	Thevakumaran N	Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation.	Nature structural and molecular biology	2015	21
25878360	22882	McCormick F	KRAS as a Therapeutic Target.	Clinical cancer research 	2015	29
26466569	22882	Zhang C	RAF inhibitors that evade paradoxical MAPK pathway activation.	Nature	2015	28
26566875	22882	Diamond EL	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.	Cancer discovery	2016	21
27104980	22882	Athuluri-Divakar SK	A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling.	Cell	2016	20
16505370	23405	Cummins JM	The colorectal microRNAome.	Proceedings of the National Academy of Sciences of the United States of America	2006	336
16518686	23405	Sevignani C	Mammalian microRNAs: a small world for fine-tuning gene expression.	Mammalian genome 	2006	88
16648842	23405	Marques JT	A structural basis for discriminating between self and nonself double-stranded RNAs in mammalian cells.	Nature biotechnology	2006	96
16754881	23405	Zhang L	microRNAs exhibit high frequency genomic alterations in human cancer.	Proceedings of the National Academy of Sciences of the United States of America	2006	312
18700235	23405	Tokumaru S	let-7 regulates Dicer expression and constitutes a negative feedback loop.	Carcinogenesis	2008	78
19047128	23405	Horikawa Y	Single nucleotide polymorphisms of microRNA machinery genes modify the risk of renal cell carcinoma.	Clinical cancer research 	2008	74
19092150	23405	Merritt WM	Dicer, Drosha, and outcomes in patients with ovarian cancer.	The New England journal of medicine	2008	252
19219043	23405	Melo SA	A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function.	Nature genetics	2009	146
19556464	23405	Hill DA	DICER1 mutations in familial pleuropulmonary blastoma.	Science	2009	118
19672267	23405	Grelier G	Prognostic value of Dicer expression in human breast cancers and association with the mesenchymal phenotype.	British journal of cancer	2009	68
19701182	23405	Maida Y	An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA.	Nature	2009	122
20194440	23405	Klusmann JH	miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia.	Genes and development	2010	77
20459673	23405	Vaz C	Analysis of microRNA transcriptome by deep sequencing of small RNA libraries of peripheral blood.	BMC genomics	2010	57
20603000	23405	Martello G	A MicroRNA targeting dicer for metastasis control.	Cell	2010	203
20739353	23405	Starega-Roslan J	Structural basis of microRNA length variety.	Nucleic acids research	2011	58
20805302	23405	Lin RJ	microRNA signature and expression of Dicer and Drosha can predict prognosis and delineate risk groups in neuroblastoma.	Cancer research	2010	59
20962848	23405	Su X	TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs.	Nature	2010	157
21205968	23405	Rio Frio T	DICER1 mutations in familial multinodular goiter with and without ovarian Sertoli-Leydig cell tumors.	JAMA	2011	43
21266384	23405	Slade I	DICER1 syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome.	Journal of medical genetics	2011	59
21345667	23405	Faber C	Overexpression of Dicer predicts poor survival in colorectal cancer.	European journal of cancer	2011	44
21882293	23405	Foulkes WD	Extending the phenotypes associated with DICER1 mutations.	Human mutation	2011	37
22055188	23405	Suzuki HI	MCPIP1 ribonuclease antagonizes dicer and terminates microRNA biogenesis through precursor microRNA degradation.	Molecular cell	2011	70
22407237	23405	Inoue T	Clinicopathological and prognostic significance of microRNA-107 and its relationship to DICER1 mRNA expression in gastric cancer.	Oncology reports	2012	33
22643892	23405	Blandino G	Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC.	Nature communications	2012	50
23297232	23405	Maute RL	tRNA-derived microRNA modulates proliferation and the DNA damage response and is down-regulated in B cell lymphoma.	Proceedings of the National Academy of Sciences of the United States of America	2013	70
23325850	23405	Castellano L	Deep sequencing of small RNAs identifies canonical and non-canonical miRNA and endogenous siRNAs in mammalian somatic tissues.	Nucleic acids research	2013	30
23620094	23405	Wu MK	Biallelic DICER1 mutations occur in Wilms tumours.	The Journal of pathology	2013	29
25027649	23405	Ha M	Regulation of microRNA biogenesis.	Nature reviews. Molecular cell biology	2014	550
25190313	23405	Rakheja D	Somatic mutations in DROSHA and DICER1 impair microRNA biogenesis through distinct mechanisms in Wilms tumours.	Nature communications	2014	27
25351418	23405	van den Beucken T	Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER.	Nature communications	2014	28
25446899	23405	Melo SA	Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis.	Cancer cell	2014	162
26971015	23405	Gurtner A	Dysregulation of microRNA biogenesis in cancer: the impact of mutant p53 on Drosha complex activity.	Journal of experimental and clinical cancer research 	2016	17
11227921	23411	Wolk A	A prospective study of obesity and cancer risk (Sweden).	Cancer causes and control 	2001	102
11672522	23411	Luo J	Negative control of p53 by Sir2alpha promotes cell survival under stress.	Cell	2001	634
12006491	23411	Langley E	Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence.	The EMBO journal	2002	233
15768047	23411	Bordone L	Calorie restriction, SIRT1 and metabolism: understanding longevity.	Nature reviews. Molecular cell biology	2005	260
16079181	23411	Michishita E	Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins.	Molecular biology of the cell	2005	327
16170353	23411	Ota H	Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells.	Oncogene	2006	116
16596166	23411	Pruitt K	Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation.	PLoS genetics	2006	128
16923962	23411	Fu M	Hormonal control of androgen receptor function through SIRT1.	Molecular and cellular biology	2006	79
17283066	23411	Stankovic-Valentin N	An acetylation/deacetylation-SUMOylation switch through a phylogenetically conserved psiKXEP motif in the tumor suppressor HIC1 regulates transcriptional repression activity.	Molecular and cellular biology	2007	57
17612497	23411	Yuan Z	SIRT1 regulates the function of the Nijmegen breakage syndrome protein.	Molecular cell	2007	101
17638871	23411	Huffman DM	SIRT1 is significantly elevated in mouse and human prostate cancer.	Cancer research	2007	131
17806102	23411	Stünkel W	Function of the SIRT1 protein deacetylase in cancer.	Biotechnology journal	2007	67
18203716	23411	Li K	Regulation of WRN protein cellular localization and enzymatic activities by SIRT1-mediated deacetylation.	The Journal of biological chemistry	2008	53
18235501	23411	Kim JE	DBC1 is a negative regulator of SIRT1.	Nature	2008	207
18235502	23411	Zhao W	Negative regulation of the deacetylase SIRT1 by DBC1.	Nature	2008	186
18414679	23411	Firestein R	The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth.	PloS one	2008	193
18755897	23411	Yamakuchi M	miR-34a repression of SIRT1 regulates apoptosis.	Proceedings of the National Academy of Sciences of the United States of America	2008	348
18805010	23411	Kwon HS	The ups and downs of SIRT1.	Trends in biochemical sciences	2008	75
18835033	23411	Wang RH	Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice.	Cancer cell	2008	247
19060927	23411	Lara E	Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect.	Oncogene	2009	67
19114688	23411	Powles T	Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection.	Journal of clinical oncology 	2009	76
19244112	23411	Liu T	The critical role of the class III histone deacetylase SIRT1 in cancer.	Cancer research	2009	99
19509139	23411	Cha EJ	Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma.	Clinical cancer research 	2009	61
19839049	23411	Tryndyak VP	E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells.	International journal of cancer	2010	62
20078221	23411	Haigis MC	Mammalian sirtuins: biological insights and disease relevance.	Annual review of pathology	2010	460
20409078	23411	Donmez G	Aging and disease: connections to sirtuins.	Aging cell	2010	115
21056897	23411	Lee H	Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma.	Human pathology	2011	55
21149730	23411	Ming M	Regulation of global genome nucleotide excision repair by SIRT1 through xeroderma pigmentosum C.	Proceedings of the National Academy of Sciences of the United States of America	2010	49
21432843	23411	Iyer NG	Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy.	Cancer	2011	40
21527554	23411	Chen J	Sirtuin 1 is upregulated in a subset of hepatocellular carcinomas where it is essential for telomere maintenance and tumor cell growth.	Cancer research	2011	41
21596753	23411	Eades G	miR-200a regulates SIRT1 expression and epithelial to mesenchymal transition (EMT)-like transformation in mammary epithelial cells.	The Journal of biological chemistry	2011	82
22045767	23411	Engels EA	Spectrum of cancer risk among US solid organ transplant recipients.	JAMA	2011	143
22146883	23411	Chen HC	SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma and its expression predicts poor prognosis.	Annals of surgical oncology	2012	37
22190494	23411	Menssen A	The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop.	Proceedings of the National Academy of Sciences of the United States of America	2012	75
22207735	23411	Yuan H	Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis.	Blood	2012	49
22249256	23411	Byles V	SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis.	Oncogene	2012	68
22331558	23411	Zhang Q	A small molecule Inauhzin inhibits SIRT1 activity and suppresses tumour growth through activation of p53.	EMBO molecular medicine	2012	33
22340598	23411	Li L	Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib.	Cancer cell	2012	108
22479251	23411	Yamakuchi M	MicroRNA Regulation of SIRT1.	Frontiers in physiology	2012	38
22553202	23411	Nin V	Role of deleted in breast cancer 1 (DBC1) protein in SIRT1 deacetylase activation induced by protein kinase A and AMP-activated protein kinase.	The Journal of biological chemistry	2012	38
22728651	23411	Lee CW	AMPK promotes p53 acetylation via phosphorylation and inactivation of SIRT1 in liver cancer cells.	Cancer research	2012	50
23728341	23411	Bae HJ	MicroRNA-29c functions as a tumor suppressor by direct targeting oncogenic SIRT1 in hepatocellular carcinoma.	Oncogene	2014	36
24133372	23411	Yuan H	The emerging and diverse roles of sirtuins in cancer: a clinical perspective.	OncoTargets and therapy	2013	47
24160699	23411	Sinclair DA	Small-molecule allosteric activators of sirtuins.	Annual review of pharmacology and toxicology	2014	49
24439680	23411	Hubbard BP	Small molecule SIRT1 activators for the treatment of aging and age-related diseases.	Trends in pharmacological sciences	2014	77
25315298	23411	Kulkarni SS	The molecular targets of resveratrol.	Biochimica et biophysica acta	2015	33
12091876	29126	Dong H	Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.	Nature medicine	2002	813
12538684	29126	Brown JA	Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.	Journal of immunology	2003	194
12704383	29126	Curiel TJ	Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity.	Nature medicine	2003	270
14612546	29126	Wintterle S	Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis.	Cancer research	2003	78
15297412	29126	Konishi J	B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression.	Clinical cancer research 	2004	166
15569934	29126	Thompson RH	Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target.	Proceedings of the National Academy of Sciences of the United States of America	2004	181
15837746	29126	Ohigashi Y	Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer.	Clinical cancer research 	2005	169
16413538	29126	Lee SJ	Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274).	FEBS letters	2006	74
16482562	29126	Blank C	Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro.	International journal of cancer	2006	75
16530813	29126	Wu C	Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance.	Acta histochemica	2006	109
16585157	29126	Thompson RH	Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.	Cancer research	2006	198
16699366	29126	Gajewski TF	Immune suppression in the tumor microenvironment.	Journal of immunotherapy	2006	62
17159987	29126	Parsa AT	Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma.	Nature medicine	2007	281
17186290	29126	Nakanishi J	Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers.	Cancer immunology, immunotherapy 	2007	65
17340590	29126	Inman BA	PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.	Cancer	2007	63
17360651	29126	Hamanishi J	Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer.	Proceedings of the National Academy of Sciences of the United States of America	2007	289
17363736	29126	Liu J	Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway.	Blood	2007	100
17875753	29126	Gajewski TF	Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment.	Clinical cancer research 	2007	82
18223165	29126	Azuma T	B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells.	Blood	2008	91
18268286	29126	Rawstron AC	Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders.	Haematologica	2008	72
19188168	29126	Gao Q	Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma.	Clinical cancer research 	2009	141
19451266	29126	Kuang DM	Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1.	The Journal of experimental medicine	2009	128
19825956	29126	Karim R	Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma.	Clinical cancer research 	2009	62
19826049	29126	Wu K	Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions.	Cancer research	2009	54
20068105	29126	Wei J	Glioma-associated cancer-initiating cells induce immunosuppression.	Clinical cancer research 	2010	68
20143437	29126	Hino R	Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma.	Cancer	2010	128
20308313	29126	Rodrigues JC	Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties.	Neuro-oncology	2010	57
20373055	29126	Mu CY	High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation.	Medical oncology	2011	105
20460501	29126	Benson DM Jr	The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.	Blood	2010	114
20473887	29126	Shi F	PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients.	International journal of cancer	2011	71
21523733	29126	Gadiot J	Overall survival and PD-L1 expression in metastasized malignant melanoma.	Cancer	2011	40
22133721	29126	Amarnath S	The PDL1-PD1 axis converts human TH1 cells into regulatory T cells.	Science translational medicine	2011	74
22271878	29126	Green MR	Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.	Clinical cancer research 	2012	66
22461641	29126	Taube JM	Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape.	Science translational medicine	2012	408
22547582	29126	Ramsay AG	Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer.	Blood	2012	58
22611421	29126	Rozali EN	Programmed death ligand 2 in cancer-induced immune suppression.	Clinical and developmental immunology	2012	48
22658127	29126	Topalian SL	Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.	The New England journal of medicine	2012	2035
22658128	29126	Brahmer JR	Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.	The New England journal of medicine	2012	1346
22828443	29126	Tamura H	Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma.	Leukemia	2013	28
23087408	29126	Chen DS	Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1.	Clinical cancer research 	2012	66
23095323	29126	Jiang X	The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.	Clinical cancer research 	2013	75
23288508	29126	Lyford-Pike S	Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma.	Cancer research	2013	114
23340297	29126	Abiko K	PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction.	Clinical cancer research 	2013	28
23370250	29126	Yao S	Advances in targeting cell surface signalling molecules for immune modulation.	Nature reviews. Drug discovery	2013	51
23389362	29126	Chen YB	Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study.	Tumori	2012	51
23460533	29126	Sznol M	Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.	Clinical cancer research 	2013	103
23613317	29126	Bloch O	Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages.	Clinical cancer research 	2013	71
23674495	29126	Chen BJ	PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.	Clinical cancer research 	2013	95
23785454	29126	Song M	PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer.	PloS one	2013	35
24124529	29126	Shi SJ	B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells.	PloS one	2013	32
24153012	29126	Atanackovic D	Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma.	Leukemia	2014	21
24217091	29126	Velcheti V	Programmed death ligand-1 expression in non-small cell lung cancer.	Laboratory investigation; a journal of technical methods and pathology	2014	145
24270737	29126	Yang H	Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.	Leukemia	2014	47
24297569	29126	Maine CJ	Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer.	Cancer immunology, immunotherapy 	2014	22
24315741	29126	Sideras K	Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies.	Cancer treatment reviews	2014	25
24349382	29126	Kim JR	Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas.	PloS one	2013	48
24403533	29126	Chinnadurai R	IDO-independent suppression of T cell effector function by IFN-γ-licensed human mesenchymal stromal cells.	Journal of immunology	2014	40
24416729	29126	Lipson EJ	PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival.	Cancer immunology research	2013	53
24657498	29126	Hou J	Correlation between infiltration of FOXP3+ regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer.	Experimental and molecular pathology	2014	27
24691993	29126	Lines JL	VISTA is an immune checkpoint molecule for human T cells.	Cancer research	2014	26
24714771	29126	Taube JM	Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.	Clinical cancer research 	2014	326
24804867	29126	Geng Y	Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance.	International journal of clinical oncology	2015	21
24866169	29126	Shen JK	Programmed cell death ligand 1 expression in osteosarcoma.	Cancer immunology research	2014	28
25079100	29126	Menzies AM	Systemic treatment for BRAF-mutant melanoma: where do we go next?	The Lancet. Oncology	2014	21
25193987	29126	Choueiri TK	PD-L1 expression in nonclear-cell renal cell carcinoma.	Annals of oncology 	2014	42
25314639	29126	Berghoff AS	Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases.	Histopathology	2015	21
25337246	29126	Chen L	B7-H1 expression associates with tumor invasion and predicts patient's survival in human esophageal cancer.	International journal of clinical and experimental pathology	2014	24
25348003	29126	Chen L	Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression.	Nature communications	2014	75
25355681	29126	Berghoff AS	Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma.	Neuro-oncology	2015	59
25361008	29126	Fang W	EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy.	Oncotarget	2014	45
25384063	29126	Ishii H	Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer.	Journal of thoracic oncology 	2015	24
25384886	29126	Mahoney KM	Prognostic and predictive markers for the new immunotherapies.	Oncology	2014	24
25399552	29126	Robert C	Nivolumab in previously untreated melanoma without BRAF mutation.	The New England journal of medicine	2015	461
25424850	29126	McDermott DF	The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.	Clinical cancer research 	2015	19
25428503	29126	Powles T	MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.	Nature	2014	345
25428505	29126	Tumeh PC	PD-1 blockade induces responses by inhibiting adaptive immune resistance.	Nature	2014	512
25440090	29126	Ohaegbulam KC	Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.	Trends in molecular medicine	2015	47
25477049	29126	Madore J	PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials.	Pigment cell and melanoma research	2015	25
25482239	29126	Ansell SM	PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.	The New England journal of medicine	2015	397
25527356	29126	Wimberly H	PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer.	Cancer immunology research	2015	41
25538263	29126	Choueiri TK	Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial.	Clinical cancer research 	2015	27
25540867	29126	D'Angelo SP	Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment.	Human pathology	2015	23
25582496	29126	Schultheis AM	PD-L1 expression in small cell neuroendocrine carcinomas.	European journal of cancer	2015	24
25600565	29126	Bellmunt J	Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma.	Annals of oncology 	2015	29
25609202	29126	Mao Y	B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer.	Oncotarget	2015	18
25622193	29126	Woo SR	Innate immune recognition of cancer.	Annual review of immunology	2015	43
25674748	29126	Zhang Y	Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) Expression in epithelial-originated cancer: a meta-analysis.	Medicine	2015	21
25682184	29126	Wang A	The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis.	European journal of surgical oncology 	2015	29
25695955	29126	Patel SP	PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy.	Molecular cancer therapeutics	2015	104
25733810	29126	Qing Y	Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer.	Drug design, development and therapy	2015	25
25736262	29126	Johnson DB	Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies.	Cancer immunology research	2015	21
25751499	29126	Lussier DM	Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions.	Journal of immunotherapy	2015	22
25856776	29126	Homet Moreno B	Anti-programmed cell death protein-1/ligand-1 therapy in different cancers.	British journal of cancer	2015	34
25891174	29126	Garon EB	Pembrolizumab for the treatment of non-small-cell lung cancer.	The New England journal of medicine	2015	470
25897014	29126	Ali HR	PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes.	Annals of oncology 	2015	29
25977331	29126	Heskamp S	Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies.	Cancer research	2015	19
26014098	29126	Boyerinas B	Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.	Cancer immunology research	2015	28
26028407	29126	Brahmer J	Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.	The New England journal of medicine	2015	536
26086854	29126	Carbognin L	Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.	PloS one	2015	54
26114883	29126	Wu P	PD-L1 and Survival in Solid Tumors: A Meta-Analysis.	PloS one	2015	44
26134220	29126	Kerr KM	Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?	Journal of thoracic oncology 	2015	35
26155422	29126	Bellucci R	Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression.	Oncoimmunology	2015	27
26181000	29126	Howitt BE	Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1.	JAMA oncology	2015	35
26210691	29126	Eto S	Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection.	Gastric cancer 	2016	17
26239088	29126	Kiyasu J	Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.	Blood	2015	29
26279307	29126	He J	Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer.	Scientific reports	2015	30
26313362	29126	Schmidt LH	PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.	PloS one	2015	28
26317305	29126	Phillips T	Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer.	Applied immunohistochemistry and molecular morphology 	2015	22
26317899	29126	Barrett MT	Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer.	Oncotarget	2015	19
26320063	29126	Lipson EJ	Antagonists of PD-1 and PD-L1 in Cancer Treatment.	Seminars in oncology	2015	31
26325035	29126	Chen L	Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future.	The Journal of clinical investigation	2015	73
26408403	29126	Vassilakopoulou M	Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma.	Clinical cancer research 	2016	18
26527522	29126	Cimino-Mathews A	PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas.	Human pathology	2016	19
26541606	29126	Sivan A	Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.	Science	2015	114
26573597	29126	Gevensleben H	The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer.	Clinical cancer research 	2016	14
26589760	29126	Meng X	Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.	Cancer treatment reviews	2015	38
26598942	29126	Smyth MJ	Combination cancer immunotherapies tailored to the tumour microenvironment.	Nature reviews. Clinical oncology	2016	43
26602187	29126	Zak KM	Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1.	Structure	2015	26
26681673	29126	Chen J	Regulation of PD-L1: a novel role of pro-survival signalling in cancer.	Annals of oncology 	2016	29
26712084	29126	Herbst RS	Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.	Lancet	2016	207
26761210	29126	Chen MF	The role of PD-L1 in the radiation response and prognosis for esophageal squamous cell carcinoma related to IL-6 and T-cell immunosuppression.	Oncotarget	2016	13
26801886	29126	Thompson ED	Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma.	Gut	2017	21
26822383	29126	Johnson DB	Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.	Nature communications	2016	26
26848870	29126	Chatterjee S	A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors.	Oncotarget	2016	13
26895815	29126	Gandini S	PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis.	Critical reviews in oncology/hematology	2016	27
26915032	29126	Ilie M	Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients.	Virchows Archiv 	2016	17
26936508	29126	Zou W	PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations.	Science translational medicine	2016	85
26977880	29126	Tang H	Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade.	Cancer cell	2016	19
27030389	29126	Georgiou K	Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas.	Blood	2016	11
27069084	29126	Roemer MG	PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.	Journal of clinical oncology 	2016	25
27093365	29126	Nghiem PT	PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.	The New England journal of medicine	2016	56
27138582	29126	Nanda R	Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.	Journal of clinical oncology 	2016	55
27157491	29126	Muro K	Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial.	The Lancet. Oncology	2016	36
27196573	29126	Masugi Y	Tumour CD274 (PD-L1) expression and T cells in colorectal cancer.	Gut	2017	8
27267608	29126	Goldberg SB	Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.	The Lancet. Oncology	2016	29
27269937	29126	Massard C	Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.	Journal of clinical oncology 	2016	31
27269947	29126	Lesokhin AM	Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.	Journal of clinical oncology 	2016	35
27281199	29126	Kataoka K	Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers.	Nature	2016	31
27569912	29126	Daley D	γδ T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation.	Cell	2016	15
27574444	29126	Wang X	PD-L1 expression in human cancers and its association with clinical outcomes.	OncoTargets and therapy	2016	17
27592805	29126	Kaufman HL	Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.	The Lancet. Oncology	2016	20
27646946	29126	Chow LQ	Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.	Journal of clinical oncology 	2016	27
27821490	29126	Wang X	Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy.	Cancer research	2017	9
27827313	29126	Champiat S	Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.	Clinical cancer research 	2017	11
27903500	29126	Shin DS	Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.	Cancer discovery	2017	13
27924752	29126	Gibney GT	Predictive biomarkers for checkpoint inhibitor-based immunotherapy.	The Lancet. Oncology	2016	17
27932067	29126	Hellmann MD	Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.	The Lancet. Oncology	2017	10
28081914	29126	Plimack ER	Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study.	The Lancet. Oncology	2017	7
28131785	29126	Sharma P	Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.	The Lancet. Oncology	2017	16
28212060	29126	Bellmunt J	Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.	The New England journal of medicine	2017	17
28278348	29126	Rimm DL	A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.	JAMA oncology	2017	8
28291584	29126	Alley EW	Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.	The Lancet. Oncology	2017	7
9310469	54474	Maloney DG	IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.	Blood	1997	187
12011122	54474	Witzig TE	Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.	Journal of clinical oncology 	2002	133
14576843	54474	Smith MR	Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.	Oncogene	2003	110
15494430	54474	Marcus R	CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.	Blood	2005	100
15689582	54474	Kaminski MS	131I-tositumomab therapy as initial treatment for follicular lymphoma.	The New England journal of medicine	2005	103
16230395	54474	Fang D	A tumorigenic subpopulation with stem cell properties in melanomas.	Cancer research	2005	346
16502413	54474	Thomas DA	Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.	Cancer	2006	80
16926291	54474	Vera J	T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells.	Blood	2006	92
17200219	54474	Arnold DM	Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura.	Annals of internal medicine	2007	62
18003886	54474	Coiffier B	Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study.	Blood	2008	78
18453625	54474	James SE	Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane.	Journal of immunology	2008	53
18662969	54474	Marcus R	Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.	Journal of clinical oncology 	2008	83
18698040	54474	Al-Shibli KI	Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer.	Clinical cancer research 	2008	89
18854568	54474	Morschhauser F	Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.	Journal of clinical oncology 	2008	69
20194844	54474	Robak T	Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.	Journal of clinical oncology 	2010	69
20194866	54474	Wierda WG	Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.	Journal of clinical oncology 	2010	125
20194898	54474	Mössner E	Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.	Blood	2010	125
20660823	54474	Thomas DA	Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.	Journal of clinical oncology 	2010	47
20660832	54474	Gisselbrecht C	Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.	Journal of clinical oncology 	2010	140
20813259	54474	Chao MP	Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma.	Cell	2010	133
20888994	54474	Hallek M	Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.	Lancet	2010	324
20962266	54474	Nelson BH	CD20+ B cells: the other tumor-infiltrating lymphocytes.	Journal of immunology	2010	68
20980506	54474	Ma SD	A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas.	Journal of virology	2011	60
21289059	54474	Caliskan M	The effects of EBV transformation on gene expression levels and methylation profiles.	Human molecular genetics	2011	49
21378274	54474	Alduaij W	Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.	Blood	2011	66
21856867	54474	Wierda WG	Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study.	Blood	2011	37
22039471	54474	Fluge Ø	Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study.	PloS one	2011	39
22308288	54474	Till BG	CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.	Blood	2012	97
22431570	54474	Salles G	Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients.	Blood	2012	44
22438256	54474	Sehn LH	A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies.	Blood	2012	41
23720127	54474	Hallek M	Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment.	American journal of hematology	2013	37
23775967	54474	Huang YH	Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.	Journal of clinical oncology 	2013	45
23835718	54474	Morschhauser FA	Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study.	Journal of clinical oncology 	2013	26
24401022	54474	Goede V	Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.	The New England journal of medicine	2014	173
24475900	54474	Woo JR	Tumor infiltrating B-cells are increased in prostate cancer tissue.	Journal of translational medicine	2014	24
24817416	54474	Wallace ZS	Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations.	Annals of the rheumatic diseases	2015	31
24881631	54474	Byrd JC	Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.	The New England journal of medicine	2014	171
25049322	54474	Byrd JC	Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.	Journal of clinical oncology 	2014	35
25135992	54474	Nowakowski GS	Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.	Journal of clinical oncology 	2015	32
25344523	54474	Da Roit F	Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.	Haematologica	2015	25
25636338	54474	Castillo JJ	The biology and treatment of plasmablastic lymphoma.	Blood	2015	22
25908509	54474	Hallek M	Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.	American journal of hematology	2015	38
26282650	54474	Sehn LH	Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.	Journal of clinical oncology 	2015	22
27059623	54474	Zah E	T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells.	Cancer immunology research	2016	19
28002688	54474	Montalban X	Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.	The New England journal of medicine	2017	19
6310399	94025	Bast RC Jr	A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.	The New England journal of medicine	1983	227
11369781	94025	Yin BW	Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16.	The Journal of biological chemistry	2001	122
15547181	94025	Vasey PA	Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.	Journal of the National Cancer Institute	2004	84
18414853	94025	Cho H	Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment.	Cancer immunology, immunotherapy 	2009	101
18468571	94025	Nossov V	The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?	American journal of obstetrics and gynecology	2008	61
19282241	94025	Menon U	Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).	The Lancet. Oncology	2009	169
19395008	94025	Chi DS	Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm.	Gynecologic oncology	2009	53
20584542	94025	Friedlander M	A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer.	Gynecologic oncology	2010	41
20888993	94025	Rustin GJ	Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial.	Lancet	2010	72
20959669	94025	Derycke MS	Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarker.	American journal of clinical pathology	2010	41
24081806	94025	Wu XS	Evaluation of two inflammation-based prognostic scores in patients with resectable gallbladder carcinoma.	Annals of surgical oncology	2014	21
24462730	94025	Williams KA	Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer.	Gynecologic oncology	2014	26
25707631	94025	Nick AM	A framework for a personalized surgical approach to ovarian cancer.	Nature reviews. Clinical oncology	2015	24
25964255	94025	Menon U	Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening.	Journal of clinical oncology 	2015	24
19388938	171023	Gelsi-Boyer V	Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia.	British journal of haematology	2009	137
20068184	171023	Abdel-Wahab O	Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.	Cancer research	2010	68
20693432	171023	Chou WC	Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations.	Blood	2010	41
20880116	171023	Gelsi-Boyer V	ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia.	British journal of haematology	2010	46
21576631	171023	Thol F	Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes.	Journal of clinical oncology 	2011	59
22031865	171023	Metzeler KH	ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.	Blood	2011	61
22343920	171023	Damm F	Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.	Blood	2012	47
22489043	171023	Brecqueville M	Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms.	Genes, chromosomes and cancer	2012	39
22897849	171023	Abdel-Wahab O	ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.	Cancer cell	2012	95
22898539	171023	Shih AH	The role of mutations in epigenetic regulators in myeloid malignancies.	Nature reviews. Cancer	2012	186
22915647	171023	Grossmann V	A novel hierarchical prognostic model of AML solely based on molecular mutations.	Blood	2012	37
23018865	171023	Schnittger S	ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.	Leukemia	2013	38
23531518	171023	Patnaik MM	Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes.	Leukemia	2013	29
23690417	171023	Itzykson R	Prognostic score including gene mutations in chronic myelomonocytic leukemia.	Journal of clinical oncology 	2013	70
23782935	171023	Quintás-Cardama A	Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a.	Blood	2013	30
23958953	171023	Schwaab J	Comprehensive mutational profiling in advanced systemic mastocytosis.	Blood	2013	28
24045501	171023	Traina F	Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms.	Leukemia	2014	46
24077845	171023	West RR	Acquired ASXL1 mutations are common in patients with inherited GATA2 mutations and correlate with myeloid transformation.	Haematologica	2014	21
24695057	171023	Patnaik MM	ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients.	Leukemia	2014	25
25139356	171023	Kulasekararaj AG	Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome.	Blood	2014	24
25224413	171023	Bejar R	TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.	Blood	2014	56
25326804	171023	Xie M	Age-related mutations associated with clonal hematopoietic expansion and malignancies.	Nature medicine	2014	168
25426837	171023	Jaiswal S	Age-related clonal hematopoiesis associated with adverse outcomes.	The New England journal of medicine	2014	222
25426838	171023	Genovese G	Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.	The New England journal of medicine	2014	202
25574665	171023	Gerstung M	Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes.	Nature communications	2015	21
26132940	171023	Yoshizato T	Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia.	The New England journal of medicine	2015	30
26182311	171023	Tefferi A	Myeloproliferative Neoplasms: A Contemporary Review.	JAMA oncology	2015	21
26332545	171023	Tefferi A	A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis.	The New England journal of medicine	2015	26
9050879	246100	Chen YT	A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening.	Proceedings of the National Academy of Sciences of the United States of America	1997	211
9432985	246100	Jäger E	Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes.	The Journal of experimental medicine	1998	131
9547346	246100	Stockert E	A survey of the humoral immune response of cancer patients to a panel of human tumor antigens.	The Journal of experimental medicine	1998	150
12445278	246100	Scanlan MJ	Cancer/testis antigens: an expanding family of targets for cancer immunotherapy.	Immunological reviews	2002	177
15252201	246100	Davis ID	Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans.	Proceedings of the National Academy of Sciences of the United States of America	2004	82
16299236	246100	Gure AO	Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer.	Clinical cancer research 	2005	89
16344461	246100	Sato E	Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.	Proceedings of the National Academy of Sciences of the United States of America	2005	479
16860654	246100	Gnjatic S	NY-ESO-1: review of an immunogenic tumor antigen.	Advances in cancer research	2006	80
17517626	246100	Valmori D	Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming.	Proceedings of the National Academy of Sciences of the United States of America	2007	83
17652518	246100	Odunsi K	Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer.	Proceedings of the National Academy of Sciences of the United States of America	2007	64
17947658	246100	Zhao Y	High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines.	Journal of immunology	2007	71
18093940	246100	Vence L	Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma.	Proceedings of the National Academy of Sciences of the United States of America	2007	58
18424733	246100	Robbins PF	Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions.	Journal of immunology	2008	81
18565862	246100	Hunder NN	Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.	The New England journal of medicine	2008	265
18566444	246100	Adams S	Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant.	Journal of immunology	2008	71
19719775	246100	Caballero OL	Cancer/testis (CT) antigens: potential targets for immunotherapy.	Cancer science	2009	147
21149605	246100	Tsuji T	Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity.	Journal of immunology	2011	39
21282551	246100	Robbins PF	Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.	Journal of clinical oncology 	2011	350
22454499	246100	Odunsi K	Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients.	Proceedings of the National Academy of Sciences of the United States of America	2012	46
22549784	246100	Irving M	Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness.	The Journal of biological chemistry	2012	32
22553348	246100	Nielsen JS	CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer.	Clinical cancer research 	2012	61
23032745	246100	Sabbatini P	Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients.	Clinical cancer research 	2012	48
24323899	246100	Weide B	Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells.	Clinical cancer research 	2014	38
24329789	246100	Hinrichs CS	Exploiting the curative potential of adoptive T-cell therapy for cancer.	Immunological reviews	2014	79
24739759	246100	Dhodapkar MV	Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205.	Science translational medicine	2014	53
25538264	246100	Robbins PF	A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response.	Clinical cancer research 	2015	59
26193344	246100	Rapoport AP	NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.	Nature medicine	2015	51
12629218	100133941	Al-Hajj M	Prospective identification of tumorigenic breast cancer cells.	Proceedings of the National Academy of Sciences of the United States of America	2003	2582
15709183	100133941	Abraham BK	Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis.	Clinical cancer research 	2005	128
16778178	100133941	Liu S	Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells.	Cancer research	2006	360
17020963	100133941	Balic M	Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype.	Clinical cancer research 	2006	161
17229949	100133941	Liu R	The prognostic role of a gene signature from tumorigenic breast-cancer cells.	The New England journal of medicine	2007	282
17283135	100133941	Li C	Identification of pancreatic cancer stem cells.	Cancer research	2007	864
17700640	100133941	Keller S	CD24 is a marker of exosomes secreted into urine and amniotic fluid.	Kidney international	2007	70
17900673	100133941	Runz S	Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM.	Gynecologic oncology	2007	64
17975224	100133941	Cho RW	Isolation and molecular characterization of cancer stem cells in MMTV-Wnt-1 murine breast tumors.	Stem cells	2008	108
18241344	100133941	Wright MH	Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics.	Breast cancer research 	2008	177
18268494	100133941	Hurt EM	CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis.	British journal of cancer	2008	118
18366788	100133941	Fillmore CM	Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy.	Breast cancer research 	2008	344
18445819	100133941	Li X	Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.	Journal of the National Cancer Institute	2008	499
18539958	100133941	Lee CJ	Pancreatic cancer stem cells.	Journal of clinical oncology 	2008	112
18559090	100133941	Honeth G	The CD44+/CD24- phenotype is enriched in basal-like breast tumors.	Breast cancer research 	2008	176
18681906	100133941	Croker AK	High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability.	Journal of cellular and molecular medicine	2009	125
18780791	100133941	Bloushtain-Qimron N	Cell type-specific DNA methylation patterns in the human breast.	Proceedings of the National Academy of Sciences of the United States of America	2008	83
19188015	100133941	Keller S	Systemic presence and tumor-growth promoting effect of ovarian carcinoma released exosomes.	Cancer letters	2009	64
19437567	100133941	Choi D	Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma.	World journal of gastroenterology	2009	51
19582426	100133941	Li C	Identification of human pancreatic cancer stem cells.	Methods in molecular biology	2009	57
19619935	100133941	Theodoropoulos PA	Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer.	Cancer letters	2010	71
19666588	100133941	Creighton CJ	Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features.	Proceedings of the National Academy of Sciences of the United States of America	2009	405
20027313	100133941	Hwang-Verslues WW	Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers.	PloS one	2009	70
20103682	100133941	Park SY	Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer.	Clinical cancer research 	2010	113
20176987	100133941	Lian Q	Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice.	Circulation	2010	117
20405247	100133941	Giatromanolaki A	The CD44+/CD24- phenotype relates to 'triple-negative' state and unfavorable prognosis in breast cancer patients.	Medical oncology	2011	41
20521089	100133941	Blick T	Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi/)CD24 (lo/-) stem cell phenotype in human breast cancer.	Journal of mammary gland biology and neoplasia	2010	107
20572012	100133941	Battula VL	Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells.	Stem cells	2010	85
20691079	100133941	Bhat-Nakshatri P	SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24- phenotype.	BMC cancer	2010	61
20937839	100133941	Wu K	Cell fate determination factor Dachshund reprograms breast cancer stem cell function.	The Journal of biological chemistry	2011	35
20964822	100133941	Keller PJ	Mapping the cellular and molecular heterogeneity of normal and malignant breast tissues and cultured cell lines.	Breast cancer research 	2010	65
21067584	100133941	Louie E	Identification of a stem-like cell population by exposing metastatic breast cancer cell lines to repetitive cycles of hypoxia and reoxygenation.	Breast cancer research 	2010	47
21169070	100133941	Kamalakaran S	DNA methylation patterns in luminal breast cancers differ from non-luminal subtypes and can identify relapse risk independent of other clinical variables.	Molecular oncology	2011	44
21281815	100133941	Lindgren D	Isolation and characterization of progenitor-like cells from human renal proximal tubules.	The American journal of pathology	2011	53
21392411	100133941	May CD	Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression.	Breast cancer research 	2011	87
21394208	100133941	Song Z	Sonic hedgehog pathway is essential for maintenance of cancer stem-like cells in human gastric cancer.	PloS one	2011	42
21480217	100133941	Kryczek I	Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells.	International journal of cancer	2012	70
21487112	100133941	Coustan-Smith E	New markers for minimal residual disease detection in acute lymphoblastic leukemia.	Blood	2011	47
21559013	100133941	Lee HE	An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer.	British journal of cancer	2011	45
21633165	100133941	Marotta LL	The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors.	The Journal of clinical investigation	2011	209
21726833	100133941	Lee TK	CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation.	Cell stem cell	2011	139
21835433	100133941	Idowu MO	CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.	Human pathology	2012	46
21882047	100133941	Zhang C	Identification of CD44+CD24+ gastric cancer stem cells.	Journal of cancer research and clinical oncology	2011	35
21953503	100133941	Zhu Y	Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5.	Clinical cancer research 	2011	47
21996751	100133941	Buijs JT	The BMP2/7 heterodimer inhibits the human breast cancer stem cell subpopulation and bone metastases formation.	Oncogene	2012	37
22308459	100133941	Meirelles K	Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance.	Proceedings of the National Academy of Sciences of the United States of America	2012	33
22496457	100133941	Palafox M	RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis.	Cancer research	2012	40
22565037	100133941	Cufi S	Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts.	Oncotarget	2012	61
22610780	100133941	Meng E	CD44+/CD24- ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival.	Clinical and experimental metastasis	2012	37
22692575	100133941	Leth-Larsen R	Functional heterogeneity within the CD44 high human breast cancer stem cell-like compartment reveals a gene signature predictive of distant metastasis.	Molecular medicine	2012	34
23340294	100133941	Schott AF	Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors.	Clinical cancer research 	2013	41
23436798	100133941	Akalay I	Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis.	Cancer research	2013	43
23943797	100133941	Cieply B	Epithelial-mesenchymal transition and tumor suppression are controlled by a reciprocal feedback loop between ZEB1 and Grainyhead-like-2.	Cancer research	2013	32
24129232	100133941	Seo AN	Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer.	British journal of cancer	2013	38
24367507	100133941	Győrffy B	Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer.	PloS one	2013	221
24497554	100133941	Lau AN	Tumor-propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis.	The EMBO journal	2014	38
24752081	100133941	Im H	Label-free detection and molecular profiling of exosomes with a nano-plasmonic sensor.	Nature biotechnology	2014	82
24955581	100133941	Yang CH	Identification of CD24 as a cancer stem cell marker in human nasopharyngeal carcinoma.	PloS one	2014	21
25051962	100133941	Khoder A	Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD.	Blood	2014	41
25086633	100133941	Gwak JM	MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer.	Breast cancer research and treatment	2014	26
25823923	100133941	Qin L	WNT5A promotes stemness characteristics in nasopharyngeal carcinoma cells leading to metastasis and tumorigenesis.	Oncotarget	2015	19
26421710	100133941	Farnie G	High mitochondrial mass identifies a sub-population of stem-like cancer cells that are chemo-resistant.	Oncotarget	2015	22
